PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CLEMENS, JD; FERRECCIO, C; LEVINE, MM; HORWITZ, I; RAO, MR; EDWARDS, KM; FRITZELL, B				CLEMENS, JD; FERRECCIO, C; LEVINE, MM; HORWITZ, I; RAO, MR; EDWARDS, KM; FRITZELL, B			IMPACT OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE-TETANUS PROTEIN CONJUGATE VACCINE ON RESPONSES TO CONCURRENTLY ADMINISTERED DIPHTHERIA-TETANUS-PERTUSSIS VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE; SERUM ANTIBODIES; EFFICACY; CHILDREN; INFANTS; DISEASE; ALASKA	Objective. - To assess whether serum antibody responses to diphtheria-tetanus-pertussis (DTP) vaccine were affected by coadministration of Haemophilus influenzae type b capsular polyribosylribitol phosphate polysaccharide-tetanus protein (PRP-T) conjugate vaccine when given to patients at 2, 4, and 6 months of age. Design. - Randomized, double-blind clinical trial. Setting. - Urban Santiago, Chile. Patients. - Healthy infants assembled from health centers, Two hundred seventy-eight (74%) of 375 eligible infants participated; 222, who complied with the complete protocol, constituted the primary group under analysis. Interventions. - One of three vaccine regimens was given to study participants at 2,4, and 6 months of age, either DTP mixed in the same syringe as PRP-T (group 1); DTP and PRP-T given at separate injection sites (group 2); or DTP without PRP-T (group 3). Primary Outcome Measures. - Titers of serum antidiphtheria toxoid, antitetanus toxoid, and pertussis agglutinin antibodies were measured in blood samples taken from patients 2 months after each dose. Results. - Serum antidiphtheria toxoid and antitetanus toxoid responses showed no important depressions in the patients receiving PRP-T. In contrast, geometric mean titers (GMTs) of pertussis agglutinins, expressed as reciprocal serum dilutions, after both the second and third doses (GMT2, GMT3) were lowest in group 1 (GMT2=89; GMT3=1230), intermediate in group 2 (GMT2 = 123; GMT3 = 1995), and highest in group 3 (GMT2 = 210; GMT3 = 3090; P < .05 for trend group 1 < group 2 < group 3 after each dose). Antipertussis toxin and antipertussis filamentous hemagglutinin antibody titers also were de-pressed in patients who received PRP-T. Follow-up of a subset at 18 months revealed an expected decline of pertussis agglutinin titers to near baseline levels in each group. Conclusions. - Concurrent administration of PRP-T vaccine with DTP vaccine, either in the same syringe or at different sites, interfered with antipertussis responses to a primary series of immunizations. Although the clinical significance of this antagonism is uncertain, these data underscore the caution required in decisions to add new vaccines to existing immunization regimens.	NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,BETHESDA,MD 20892; ROBERTO RIO HOSP,DEPT PEDIAT,SANTIAGO,CHILE; UNIV MARYLAND,SCH MED,CTR VACCINE DEV,BALTIMORE,MD 21201; MINIST CHILE,SANTIAGO,CHILE; VANDERBILT UNIV,MED CTR,SCH MED,DEPT PEDIAT,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universidad de Chile; University System of Maryland; University of Maryland Baltimore; Vanderbilt University								ANDERSON PW, 1990, NEW GENERATION VACCI, P349; ARMITAGE P, 1971, STATISTICAL METHODS; BARRETT DJ, 1985, ADV PEDIATRICS; CLAESSON BA, 1988, J PEDIATR-US, V112, P695, DOI 10.1016/S0022-3476(88)80684-X; COCCHI S, 1986, J PEDIATR, V108, P887; EDWARDS KM, 1989, J INFECT DIS, V160, P832, DOI 10.1093/infdis/160.5.832; FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009; FINE PEM, 1987, REV INFECT DIS, V9, P866; GRANOFF DM, 1980, J INFECT DIS, V141, P40, DOI 10.1093/infdis/141.1.40; GREENWOOD FC, 1969, CLIN SCI, V35, P571; HALSEY N, WHO EPIGEN848; KALLINGS LO, 1988, LANCET, V1, P955; KAYHTY H, 1983, J INFECT DIS, V147, P1100; KAYHTY H, 1988, 28TH INT C ANT AG CH; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; Manclark CR, 1984, BACTERIAL VACCINES, P69; Martin C. N., 1981, CARCINOGENESIS, V2, P307, DOI DOI 10.1093/CARCIN/2.4.307; MURPHY TV, 1987, PEDIATRICS, V79, P173; Orenstein WA, 1983, RECENT ADV IMMUNIZAT, P30; PARKMAN PD, 1983, RECENT ADV IMMUNIZAT, P65; PELTOLA H, 1984, NEW ENGL J MED, V310, P1566; ROTHSTEIN E, 1991, PEDIATR RES, V29, P182; SCHNEERSON R, 1986, INFECT IMMUN, V52, P519, DOI 10.1128/IAI.52.2.519-528.1986; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17; WATEMBERG N, 1991, PEDIATR INFECT DIS J, V10, P758, DOI 10.1097/00006454-199110000-00008; WILKINS J, 1987, VACCINE, V5, P49, DOI 10.1016/0264-410X(87)90009-0; 1956, BMJ, V2, P454	28	101	103	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					673	678		10.1001/jama.267.5.673	http://dx.doi.org/10.1001/jama.267.5.673			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1731134				2022-12-28	WOS:A1992HB35400024
J	SEPPALA, H; NISSINEN, A; JARVINEN, H; HUOVINEN, S; HENRIKSSON, T; HERVA, E; HOLM, SE; JAHKOLA, M; KATILA, ML; KLAUKKA, T; KONTIAINEN, S; LIIMATAINEN, O; OINONEN, S; PASSIMETSOMAA, L; HUOVINEN, P				SEPPALA, H; NISSINEN, A; JARVINEN, H; HUOVINEN, S; HENRIKSSON, T; HERVA, E; HOLM, SE; JAHKOLA, M; KATILA, ML; KLAUKKA, T; KONTIAINEN, S; LIIMATAINEN, O; OINONEN, S; PASSIMETSOMAA, L; HUOVINEN, P			RESISTANCE TO ERYTHROMYCIN IN GROUP-A STREPTOCOCCI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-HEMOLYTIC STREPTOCOCCI; PYOGENES; LINCOSAMIDES; PHARYNGITIS; ANTIBIOTICS; INFECTIONS; PENICILLIN; MACROLIDES; PATTERN; ADULTS	Background. The use of erythromycin in Finland nearly tripled from 1979 to 1989. In 1988, we observed an unusually high frequency of resistance to erythromycin in group A streptococci in one geographic region. Because routine testing does not detect the sensitivity of these organisms to antibiotics, we initiated a national study to evaluate the extent of this resistance. Methods. We studied 272 isolates of group A streptococci obtained from blood cultures from 1988 through 1990. In 1990 we collected from six regional laboratories 3087 consecutive isolates from throat swabs and 1349 isolates from pus samples. Resistance was indicated by growth on blood agar containing 2-mu-g of erythromycin per milliliter after incubation in 5 percent carbon dioxide. We also evaluated the clinical importance of erythromycin resistance in a retrospective study of consecutive patients with pharyngitis. Results. The frequency of resistance to erythromycin in group A streptococci from blood cultures increased from 4 percent in 1988 to 24 percent in 1990. From January to December 1990, the frequency of resistance in isolates from throat swabs increased from 7 percent to 20 percent, and resistance in isolates from pus increased from 11 percent to 31 percent. In four communities within 50 km of each other, the frequency of erythromycin resistance ranged from 2 to 5 percent to 26 to 44 percent. Several distinct DNA restriction profiles and serotypes were found among resistant isolates from the same area, suggesting a multiclonal origin. The treatment of pharyngitis with erythromycin failed in 9 of 19 patients infected with erythromycin-resistant group A streptococci, as compared with 1 of 26 patients with erythromycin-susceptible isolates (47 percent vs. 4 percent, P = 0.008). Conclusions. In Finland since 1988 there has been a rapid and substantial increase in resistance to erythromycin in group A streptococci. The extent of this resistance is particularly serious since there are only a few alternative antibiotics available for peroral treatment of group A streptococcal infections.	NATL INST PUBL HLTH, OULU REG INST, OULU, FINLAND; NATL INST PUBL HLTH, DEPT BACTERIOL, OULU, FINLAND; UMEA UNIV, DEPT CLIN MICROBIOL, S-90187 UMEA, SWEDEN; HLTH CTR, Pargas, FINLAND; HLTH CTR, POYTYA, FINLAND; KUOPIO UNIV HOSP, DEPT CLIN MICROBIOL, KUOPIO, FINLAND; AURORA HOSP, SF-00250 HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; SEINAJOKI CENT HOSP, SEINAJOKI, FINLAND; SOCIAL INSURANCE INST, SOCIAL SECUR RES INST, HELSINKI, FINLAND	Umea University; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; Seinajoki Central Hospital	SEPPALA, H (corresponding author), NATL INST PUBL HLTH, ANTIMICROBIAL RES UNIT, POB 57, SF-20521 TURKU, FINLAND.		Huovinen, Pentti/C-1917-2009					[Anonymous], 1991, LANCET, V337, P651; BORZANI M, 1989, J CHEMOTHERAPY, V1, P35, DOI 10.1080/1120009X.1989.11738861; CLEARY PP, 1988, J INFECT DIS, V158, P1317, DOI 10.1093/infdis/158.6.1317; COL NF, 1987, REV INFECT DIS, V9, pS232; DIXON JMS, 1974, J INFECT DIS, V130, P351, DOI 10.1093/infdis/130.4.351; Fernandes P. B., 1987, Antimicrobic Newsletter, V4, P25, DOI 10.1016/0738-1751(87)90002-5; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; GUNN BA, 1977, J CLIN MICROBIOL, V5, P650; HOLMSTROM L, 1990, SCAND J INFECT DIS, V22, P179, DOI 10.3109/00365549009037900; HORAUD T, 1985, J ANTIMICROB CHEMOTH, V16, P111, DOI 10.1093/jac/16.suppl_A.111; HUOVINEN P, 1989, ANN INTERN MED, V110, P612, DOI 10.7326/0003-4819-110-8-612; ISTRE GR, 1981, ANTIMICROB AGENTS CH, V20, P244, DOI 10.1128/AAC.20.2.244; JARVINEN H, 1989, LANCET, V1, P1022; KAPLAN EL, 1991, EUR J CLIN MICROBIOL, V10, P55, DOI 10.1007/BF01964407; KOMAROFF AL, 1983, SCIENCE, V222, P927, DOI 10.1126/science.6415813; MAKELA PH, 1989, FINN MED J, V44, P419; MALMBORG AS, 1986, J ANTIMICROB CHEMOTH, V18, P293, DOI 10.1093/jac/18.3.293; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MARUYAMA S, 1979, AM J DIS CHILD, V133, P1143, DOI 10.1001/archpedi.1979.02130110051007; MAXTED WR, 1972, STREPTOCOCCI STREPTO, P256; MIYAMOTO Y, 1978, ANTIMICROB AGENTS CH, V13, P399, DOI 10.1128/AAC.13.3.399; PHILLIPS G, 1990, J ANTIMICROB CHEMOTH, V25, P723, DOI 10.1093/jac/25.4.723; SCOTT RJD, 1989, EPIDEMIOL INFECT, V102, P85, DOI 10.1017/S095026880002971X; SKJOLD SA, 1987, J INFECT DIS, V155, P1145, DOI 10.1093/infdis/155.6.1145; SPENCER RC, 1989, LANCET, V1, P168; STINGEMORE N, 1989, MED J AUSTRALIA, V150, P626, DOI 10.5694/j.1326-5377.1989.tb136725.x; TRALLERO EP, 1989, LANCET, V2, P444; WEISBLUM B, 1985, J ANTIMICROB CHEMOTH, V16, P63, DOI 10.1093/jac/16.suppl_A.63; WITTLER RR, 1990, AM J DIS CHILD, V144, P587, DOI 10.1001/archpedi.1990.02150290081033; ZACKRISSON G, 1988, SCAND J INFECT DIS, V20, P419, DOI 10.3109/00365548809032478; 1990, NLN PUBLICATION, V30; 1990, FINNISH STATISTICS M; 1982, NLN PUBLICATION, V8; 1986, NLN PUBLICATION, V14; 1990, ANTIMICROBIAL SUSCEP, V10	35	295	298	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					292	297		10.1056/NEJM199201303260503	http://dx.doi.org/10.1056/NEJM199201303260503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728733				2022-12-28	WOS:A1992HA99100003
J	BURRIS, JF; SCHWARTZ, SL				BURRIS, JF; SCHWARTZ, SL			OCCUPATIONAL EXPOSURE TO FREON - AN ASSOCIATION WITH SEVERE HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BURRIS, JF (corresponding author), GEORGETOWN UNIV,MED CTR,WASHINGTON,DC 20007, USA.							Haynes R. B., 1979, COMPLIANCE HLTH CARE; MORISKY DE, 1983, AM J PUBLIC HEALTH, V73, P153, DOI 10.2105/AJPH.73.2.153; 1988, ARCH INTERN MED, V148, P1023	3	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					569	569		10.1001/jama.267.4.569	http://dx.doi.org/10.1001/jama.267.4.569			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729583				2022-12-28	WOS:A1992GZ43900039
J	WILLIAMS, RB; BAREFOOT, JC; CALIFF, RM; HANEY, TL; SAUNDERS, WB; PRYOR, DB; HLATKY, MA; SIEGLER, IC; MARK, DB				WILLIAMS, RB; BAREFOOT, JC; CALIFF, RM; HANEY, TL; SAUNDERS, WB; PRYOR, DB; HLATKY, MA; SIEGLER, IC; MARK, DB			PROGNOSTIC IMPORTANCE OF SOCIAL AND ECONOMIC-RESOURCES AMONG MEDICALLY TREATED PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; SMOKING CESSATION; HEART-DISEASE; A BEHAVIOR; SUPPORT; MORTALITY; SURVIVAL; STRESS; DEATH; EDUCATION	Objective. - To evaluate the hypothesis that diminished social and economic resources impact adversely on cardiovascular mortality in patients with coronary artery disease. Design. - Inception cohort study of patients undergoing cardiac catheterization from 1974 through 1980 and followed up through 1989. Setting. - Tertiary care university medical center. Patients. - Consecutive sample of 1965 medically treated patients with stenosis 75% or greater of at least one major coronary artery. Five hundred patients were not enrolled due to logistic problems; 33 refused; 64 had missing data on key medical variables. The final study population included 1368 patients, 82% male, with a median age of 52 years. Main Outcome Measure. - Survival time until cardiovascular death. Results. - Independent of all known baseline invasive and noninvasive medical prognostic factors, patients with annual household incomes of $40 000 or more had an unadjusted 5-year survival of 0.91, compared with 0.76 in patients with incomes of $10 000 or less (Cox model adjusted hazard ratio, 1.9; 95% confidence interval, 1.57 to 2.32; P = .002). Similarly, unmarried patients without a confidant had an unadjusted 5-year survival rate of 0.50, compared with 0.82 in patients who were married, had a confidant, or both (adjusted hazard ratio, 3.34; 95% confidence interval, 1.84 to 6.20; P < .0001). Conclusions. - Low levels of social and economic resources identify an important high-risk group among medically treated patients with coronary artery disease, independent of important medical prognostic factors. Additional study will be required to see if interventions to increase these resources improve prognosis.	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,DURHAM,NC 27710	Duke University	WILLIAMS, RB (corresponding author), DUKE UNIV,MED CTR,DEPT PSYCHIAT,BEHAV MED RES CTR,POB 3926,DURHAM,NC 27710, USA.			Hlatky, Mark/0000-0003-4686-9441; Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670, P01HL036587] Funding Source: NIH RePORTER; AHRQ HHS [HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-17670, P01 HL036587, HL-36587] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAREFOOT JC, 1989, AM J CARDIOL, V64, P427, DOI 10.1016/0002-9149(89)90416-5; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLAZER DG, 1982, AM J EPIDEMIOL, V115, P684, DOI 10.1093/oxfordjournals.aje.a113351; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHANDRA V, 1983, AM J EPIDEMIOL, V117, P320, DOI 10.1093/oxfordjournals.aje.a113544; Cohen S., 1985, SOCIAL SUPPORT HLTH, P3; DEAN A, 1977, J NERV MENT DIS, V165, P403, DOI 10.1097/00005053-197712000-00006; DOLISZNY KM, 1989, CIRCULATION, V80, P410; FLEMING R, 1982, J HUM STRESS, V8, P14, DOI 10.1080/0097840X.1982.9936110; FRASURESMITH N, 1985, PSYCHOSOM MED, V47, P431, DOI 10.1097/00006842-198509000-00003; GIANNETTI VJ, 1985, SOC SCI MED, V20, P241, DOI 10.1016/0277-9536(85)90237-0; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRIS PJ, 1980, CIRCULATION, V62, P718, DOI 10.1161/01.CIR.62.4.718; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; House J.S., 1985, SOCIAL SUPPORT HLTH, P83, DOI DOI 10.1016/0883-0355(88)90010-9; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; Kaplan B H, 1977, Med Care, V15, P47, DOI 10.1097/00005650-197705001-00006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; MERMELSTEIN R, 1986, J CONSULT CLIN PSYCH, V54, P447, DOI 10.1037/0022-006X.54.4.447; PRYOR DB, 1984, J CHRON DIS, V37, P521, DOI 10.1016/0021-9681(84)90003-1; PRYOR DB, 1989, CIRCULATION S2, V80, P409; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; RUBERMAN W, 1983, J CHRON DIS, V36, P151, DOI 10.1016/0021-9681(83)90089-9; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; WIKLUND I, 1988, AM J EPIDEMIOL, V128, P786, DOI 10.1093/oxfordjournals.aje.a115032; WILLIAMS CA, 1985, AM J PUBLIC HEALTH, V75, P483, DOI 10.2105/AJPH.75.5.483; WILLIAMS RB, 1988, PSYCHOSOM MED, V50, P139, DOI 10.1097/00006842-198803000-00004	32	408	413	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					520	524		10.1001/jama.267.4.520	http://dx.doi.org/10.1001/jama.267.4.520			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729574				2022-12-28	WOS:A1992GZ43900027
J	BELL, TA; STAMM, WE; WANG, SP; KUO, CC; HOLMES, KK; GRAYSTON, JT				BELL, TA; STAMM, WE; WANG, SP; KUO, CC; HOLMES, KK; GRAYSTON, JT			CHRONIC CHLAMYDIA-TRACHOMATIS INFECTIONS IN INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MONOCLONAL-ANTIBODIES; CONJUNCTIVITIS; CELLS	Objective. - To study the natural history of Chlamydia trachomatis infections in infants. Design. - Bacteriologic and serologic study of an inception cohort. Setting. - University of Washington Medical Center, Seattle. Participants. - Twenty-two infants with C trachomatis infections either not treated early in life or recurring after antimicrobial treatment. Main Outcome Measures. - Persistence of infection in various anatomic sites, antibody responses to specific serovars (serologic variants) of C trachomatis, and serovars of isolates from mothers and infants. Results. - The cumulative proportion of infants still infected at the age of 1 year was 35%. Infection persisted in the conjunctiva, nasopharynx, and oropharynx in one child for as long as 866 days (28.5 months), when she was cured by treatment. In none of the infants did serologic tests suggest acquisition of infection other than at birth. Isolates of C trachomatis from mothers and their respective infants were always of the same serovar. Conclusions. - Many infants infected with C trachomatis at birth remain infected for months or years in the absence of specific antimicrobial therapy. Such infections may be confused with those acquired by sexual abuse.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	BELL, TA (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.		, Holmes/K-6215-2019		NEI NIH HHS [EY-00219] Funding Source: Medline; NIAID NIH HHS [AI-16222, AI-12192] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016222, P01AI012192] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES RC, 1985, J CLIN MICROBIOL, V22, P609, DOI 10.1128/JCM.22.4.609-613.1985; Freedman A, 1966, Trans Ophthalmol Soc U K, V86, P313; FUSTER CD, 1987, PEDIATRICS, V79, P235; HAMMERSCHLAG MR, 1982, PEDIATR INFECT DIS J, V1, P395, DOI 10.1097/00006454-198211000-00007; KUO CC, 1972, J INFECT DIS, V125, P665, DOI 10.1093/infdis/125.6.665; LEE ET, 1980, STATISTICAL METHODS, P127; MARDH PA, 1987, LANCET, V1, P804; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; MORDHORST CH, 1978, JAMA-J AM MED ASSOC, V239, P1765, DOI 10.1001/jama.239.17.1765; MORDHORST CH, 1971, AM J OPHTHALMOL, V71, P861, DOI 10.1016/0002-9394(71)90256-X; REES E, 1977, BRIT J VENER DIS, V53, P173; RETTIG PH, 1985, PEDIATR INFECT DIS, V3, P95; SANDSTROM I, 1988, ACTA PAEDIATR SCAND, V77, P207, DOI 10.1111/j.1651-2227.1988.tb10631.x; SCHACHTER J, 1986, JAMA-J AM MED ASSOC, V255, P3374, DOI 10.1001/jama.255.24.3374; SCHACHTER J, 1987, NEW ENGL J MED, V316, P1023; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STENBERG K, 1986, LANCET, V2, P1278; Wang S., 1977, NONGONOCOCCAL URETHR, P237; WANG SP, 1985, J INFECT DIS, V152, P791, DOI 10.1093/infdis/152.4.791; WENTWORT.BB, 1974, APPL MICROBIOL, V27, P912, DOI 10.1128/AEM.27.5.912-916.1974; YODER BL, 1981, J CLIN MICROBIOL, V13, P1036, DOI 10.1128/JCM.13.6.1036-1039.1981; 1982, MMWR S2, V31, pS33	22	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					400	402		10.1001/jama.267.3.400	http://dx.doi.org/10.1001/jama.267.3.400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727964				2022-12-28	WOS:A1992GY43700039
J	SLATER, AFG; CERAMI, A				SLATER, AFG; CERAMI, A			INHIBITION BY CHLOROQUINE OF A NOVEL HEME POLYMERASE ENZYME-ACTIVITY IN MALARIA TROPHOZOITES	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; FERRIPROTOPORPHYRIN-IX; ANTIMALARIAL ACTIVITY; MECHANISM; HEMOZOIN; PIGMENT; PH	THE incidence of human malaria has increased during the past 20 years; 270 million people are now estimated to be infected with the parasite 1. An important contribution to this increase has been the appearance of malaria organisms resistant to quinoline-containing antimalarials such as chloroquine and quinine 2. These drugs accumulate in the acid food vacuoles of the intraerythrocytic-stage malaria parasite 3-5, although the mechanism of their specific toxicity in this organelle is uncertain. The primary function of the food vacuole is the proteolysis of ingested red cell haemoglobin 6,7 to provide the growing parasite with essential amino acids. Haemoglobin breakdown in the food vacuole releases haem, which if soluble can damage biological membranes 8 and inhibit a variety of enzymes 9-10. Rather than degrading or excreting the haem, the parasite has evolved a novel pathway for its detoxification by incorporating it into an insoluble crystalline material called haemozoin or malaria pigment 11. These crystals form in the food vacuole of the parasite concomitant with haemoglobin degradation, where they remain until the infected red cell bursts. The structure of haemozoin comprises a polymer of haems linked between the central ferric ion of one haem and a carboxylate side-group oxygen of another 12. This structure does not form spontaneously from either free haem or haemoglobin under physiological conditions 12-14, and the biochemistry of its formation is unclear. Here we report the identification and characterization of a haem polymerase enzyme activity from extracts of Plasmodium falciparum trophozoites, and show that this enzyme is inhibited by quinoline-containing drugs such as chloroquine and quinine. This provides a possible explanation for the highly stage-specific anti-malarial properties of these drugs.			SLATER, AFG (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.							ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1987, J BIOL CHEM, V262, P15552; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P757; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; GINSBURG H, 1989, BIOCHEM PHARMACOL, V38, P2645, DOI 10.1016/0006-2952(89)90550-9; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; KROGSTAD DJ, 1986, BIOCHEM PHARMACOL, V35, P547, DOI 10.1016/0006-2952(86)90345-X; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; LEMBERG R, 1949, HEMATIN COMPOUNDS BI; Peters W, 1987, CHEMOTHERAPY DRUG RE; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285, DOI 10.1016/0006-2952(87)90646-0; WARHURST DC, 1987, ANN TROP MED PARASIT, V81, P65, DOI 10.1080/00034983.1987.11812093; WARHURST DC, 1981, BIOCHEM PHARMACOL, V30, P3323, DOI 10.1016/0006-2952(81)90606-7; WHITE NJ, 1981, LANCET, V2, P1069, DOI 10.1016/S0140-6736(81)91275-7; YA Z, 1986, J PARASITOL, V72, P830, DOI 10.2307/3281830; YAMADA KA, 1979, EXP PARASITOL, V48, P61, DOI 10.1016/0014-4894(79)90055-9; YASUHARA T, 1991, BIOCHEM BIOPH RES CO, V178, P95, DOI 10.1016/0006-291X(91)91784-A; YAYON A, 1984, J PROTOZOOL, V31, P367, DOI 10.1111/j.1550-7408.1984.tb02981.x; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; 1990, WHO TECHNICAL REPORT, V805	28	528	534	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					167	169		10.1038/355167a0	http://dx.doi.org/10.1038/355167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729651				2022-12-28	WOS:A1992GY62900060
J	PAMER, EG; HARTY, JT; BEVAN, MJ				PAMER, EG; HARTY, JT; BEVAN, MJ			PRECISE PREDICTION OF A DOMINANT CLASS-I MHC-RESTRICTED EPITOPE OF LISTERIA-MONOCYTOGENES	NATURE			English	Article							LYMPHOCYTES-T; CELLS; HEMOLYSIN; EXPRESSION; IMMUNITY; GROWTH; DETERMINANT; INFECTION; VIRULENCE; PEPTIDE	Listeria monocytogenes is a Gram-positive bacterium which grows in the cytoplasm of eukaryotic cells and can cause severe disease in immunocompromised individuals 1,2. In murine systems CD8+ T lymphocytes have been shown to be important effectors of acquired protective immunity against L. monocytogenes 3-5. Class I MHC restricted CD8+ cytotoxic T lymphocytes (CTL), which lyse J774 macrophage-like targets infected with L. monocytogenes, are induced following in vivo injection of live organisms. Natural peptide epitopes derived from L. monocytogenes can be acid-extracted from heavily infected BALB/c spleens and detected by CTL. A CTL clone, B9, derived from a (BALB/c x C57BL/6)F1 (H-2dxb) mouse, recognizes one of these natural epitopes in an H-2K(d)-restricted fashion. B9 also recognizes P815 (H-2d) mastocytoma cells transfected with the listeriolysin gene. To identify the region of the listeriolysin recognized by CTL we used the H-2K(d) peptide-binding motif described by Rammensee and colleagues 6 to synthesize 11 nonamer peptides. One of these peptides, listeriolysin 91-99, was recognized very efficiently by B9. This represents the first identified class I MHC-restricted epitope of bacteria and demonstrates the utility of the allele-specific motif for predicting CTL epitopes.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	PAMER, EG (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT IMMUNOL, SEATTLE, WA 98195 USA.			Harty, John/0000-0001-7266-2802	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080619, R01AI019335, R01AI039031, R01AI046653] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI046653-05, R01 AI039031-11, R01 AI046653, R01 AI039031, R01 AI019335-19, R01 AI080619, R01 AI019335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BERCHE P, 1987, J IMMUNOL, V139, P3813; BISHOP DK, 1987, J IMMUNOL, V139, P2005; BRUNT LM, 1990, J IMMUNOL, V145, P3540; DELIBERO G, 1986, J IMMUNOL, V137, P2688; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; LUKACS K, 1989, J IMMUNOL, V143, P3731; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; MARGET W, 1988, INFECTION, V16, pS175, DOI 10.1007/BF01639744; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PINE L, 1987, J CLIN MICROBIOL, V25, P2247, DOI 10.1128/JCM.25.11.2247-2251.1987; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAFLEY SA, 1991, J IMMUNOL, V146, P3604; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VANBLEEK GM, 1990, NATURE, V348, P213	26	398	430	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					852	855		10.1038/353852a0	http://dx.doi.org/10.1038/353852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719425	Green Accepted			2022-12-28	WOS:A1991GM73200062
J	CHENG, SH; RICH, DP; MARSHALL, J; GREGORY, RJ; WELSH, MJ; SMITH, AE				CHENG, SH; RICH, DP; MARSHALL, J; GREGORY, RJ; WELSH, MJ; SMITH, AE			PHOSPHORYLATION OF THE R-DOMAIN BY CAMP-DEPENDENT PROTEIN-KINASE REGULATES THE CFTR CHLORIDE CHANNEL	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; AIRWAY EPITHELIA; TRANSPORT; EXPRESSION; IDENTIFICATION; INACTIVATION; MECHANISMS; PP60C-SRC; TYROSINE	CFTR, the protein associated with cystic fibrosis, is phosphorylated on serine residues in response to cAMP agonists. Serines 660, 737, 795, and 813 were identified as in vivo targets for phosphorylation by protein kinase A. The SPQ fluorescence assay revealed that mutagenesis of any one of these sites did not affect Cl- channel activity. Indeed, concomitant mutagenesis of three of the four sites still resulted in cAMP-responsive Cl- channel activity. However, mutagenesis of all four sites abolished the response. One interpretation of these results is that the CFTR Cl- channel is blocked by the R domain and that phosphorylation on serines by protein kinase A electrostatically repels the domain, allowing passage of Cl-. The four phosphorylation events appear to be degenerate: no one site is essential for channel activity, and, at least in the case of serine 660, phosphorylation at one site alone is sufficient for regulation of Cl- channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED & PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa	CHENG, SH (corresponding author), GENZYME CORP,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869; Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BERGER HA, 1991, IN PRESS J CLIN INVE; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1988, MOL CELL BIOL, V6, P1562; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ESPINO PC, 1990, ONCOGENE, V5, P283; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1059; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J, 1989, MOL CLONING LABORATO; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHANG B, 1991, J BIOL CHEM, V266, P990	34	578	587	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					1027	1036		10.1016/0092-8674(91)90446-6	http://dx.doi.org/10.1016/0092-8674(91)90446-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716180				2022-12-28	WOS:A1991GE46000019
J	TABCHARANI, JA; CHANG, XB; RIORDAN, JR; HANRAHAN, JW				TABCHARANI, JA; CHANG, XB; RIORDAN, JR; HANRAHAN, JW			PHOSPHORYLATION-REGULATED CL- CHANNEL IN CHO CELLS STABLY EXPRESSING THE CYSTIC-FIBROSIS GENE	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNEL; CAMP; TOXIN	A CYCLIC AMP-stimulated chloride conductance appears when the cystic fibrosis gene is expressed in non-epithelial cells by infection with recombinant viruses 1,2. Cyclic AMP-stimulated conductance in this system is mediated by the same ohmic, low-conductance Cl- channel as in human secretory epithelia 2-4, but control of this channel by phosphorylation has not been directly demonstrated. Here we report the appearance of the low-conductance Cl- channel in Chinese hamster ovary cells after stable transfection with the cystic fibrosis gene. The channel is regulated on-cell by membrane-permeant analogues of cAMP and off-cell by protein kinases A and C and by alkaline phosphatase. These results are further evidence that the cystic fibrosis transmembrane regulator is a Cl- channel which can be activated by specific phosphorylation events and inactivated by dephosphorylation; they reveal an unsuspected synergism between converging kinase regulatory pathways.	MCGILL UNIV, DEPT PHYSIOL, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA	McGill University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRUM G, 1983, PFLUG ARCH EUR J PHY, V398, P147, DOI 10.1007/BF00581064; CHANG EB, 1985, AM J PHYSIOL, V249, pC356, DOI 10.1152/ajpcell.1985.249.3.C356; COHEN P, 1989, REV BIOCH, V58, P453; FONDACARO JD, 1985, AM J PHYSIOL, V249, pG422, DOI 10.1152/ajpgi.1985.249.3.G422; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HERSCHELER J, 1987, EUR J BIOCHEM, V165, P261; JAHR H, 1988, EUR J BIOCHEM, V178, P535; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LACERDA AE, 1988, NATURE, V335, P245; LEVITAN IB, 1990, ADV SEC MESS PHOSPH, V24, P36; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O	20	528	540	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					628	631		10.1038/352628a0	http://dx.doi.org/10.1038/352628a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1714039				2022-12-28	WOS:A1991GB21100058
J	PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M				PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M			INCREASED RISK OF MYELODYSPLASIA AND LEUKEMIA AFTER ETOPOSIDE, CISPLATIN, AND BLEOMYCIN FOR GERM-CELL TUMORS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; THERAPY-RELATED LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DISSEMINATED TESTICULAR CANCER; NON-HODGKINS LYMPHOMA; ALKYLATING-AGENTS; COMBINATION CHEMOTHERAPY; OVARIAN-CARCINOMA; CYTO-TOXICITY; SOLID TUMORS	Among the cytostatic drugs only the alkylating agents have been firmly established as being leukaemogenic. This report describes 4 cases of acute myeloid leukaemia and 1 of myelodysplasia occurring in a cohort of 212 patients with germ-cell tumours treated with etoposide, cisplatin, and bleomycin. The mean cumulative risk of leukaemic complications was 4.7% (SE 2.3) 5.7 years after start of etoposide-containing chemotherapy, and, compared with the risk in the general population, the relative risk of overt leukaemia was 336 (95% Cl 92-861). No leukaemias were detected in a previous cohort of 127 patients with germ-cell tumours treated with cisplatin, bleomycin, and vinblastine. The increased risk of leukaemia was most probably due to etoposide alone or in combination with cisplatin or bleomycin, since other published work has also not revealed an excess of leukaemias among patients with germ-cell tumours treated with only cisplatin, bleomycin, and vinblastine. The risk of leukaemia was dose related since all 5 patients with leukaemic complications were among the 82 who had received a cumulative dose of more than 2000 mg/m2 etoposide, whereas no leukaemias were observed among 130 patients who had received up to 2000 mg/m2 (p = 0.004). 3 of the leukaemic patients had balanced chromosome translocations affecting bands 11q23 and 21q22. These translocations, and perhaps also other balanced aberrations, seem to be characteristic of myelodysplasia and acute leukaemia occurring after therapy with cytostatic agents acting on DNA-topoisomerase II.	STATE SERUM INST,DEPT BIOSTAT,COPENHAGEN,DENMARK; RIGSHOSP,DEPT ONCOL ONK,DK-2100 COPENHAGEN,DENMARK; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN,DENMARK	Statens Serum Institut; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	PEDERSENBJERGAARD, J (corresponding author), RIGSHOSP,DEPT HAEMATOL L4132,9 BLEGDAMSVEJ,DK-2100 COPENHAGEN,DENMARK.		Daugaard, Gedske/AAD-4009-2019	Daugaard, Gedske/0000-0002-9618-9180				ANDERSSON M, 1990, CANCER, V65, P2460, DOI 10.1002/1097-0142(19900601)65:11<2460::AID-CNCR2820651110>3.0.CO;2-S; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BASSETT WB, 1986, J CLIN ONCOL, V4, P614; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; CHAGANTI RSK, 1989, GENE CHROMOSOME CANC, V1, P83, DOI 10.1002/gcc.2870010113; CHAK LY, 1984, J CLIN ONCOL, V2, P385, DOI 10.1200/JCO.1984.2.5.385; CHAMBERS SK, 1989, CANCER, V64, P2459, DOI 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; EDER JP, 1987, J CLIN INVEST, V79, P1524, DOI 10.1172/JCI112983; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; GREENE MH, 1982, NEW ENGL J MED, V307, P1416, DOI 10.1056/NEJM198212023072302; GREENE MH, 1983, CANCER RES, V43, P1891; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KANTARJIAN HM, 1986, CANCER, V58, P924, DOI 10.1002/1097-0142(19860815)58:4<924::AID-CNCR2820580420>3.0.CO;2-Y; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KAUFMANN SH, 1991, CANCER RES, V51, P1129; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; OZOLS RF, 1988, J CLIN ONCOL, V6, P1031, DOI 10.1200/JCO.1988.6.6.1031; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; PEDERSENBJERGAARD J, 1991, BLOOD, V78, P1147; PEDERSENBJERGAARD J, 1985, BLOOD, V66, P1393; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PEDERSENBJERGAARD J, 1985, ANN INTERN MED, V103, P195, DOI 10.7326/0003-4819-103-2-195; PEDERSENBJERGAARD J, 1980, CANCER-AM CANCER SOC, V45, P19, DOI 10.1002/1097-0142(19800101)45:1<19::AID-CNCR2820450106>3.0.CO;2-L; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; POMMIER Y, 1988, CANCER RES, V48, P512; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; RUBIN CM, 1990, BLOOD, V76, P2594; TAN KB, 1987, P NATL ACAD SCI USA, V84, P7668, DOI 10.1073/pnas.84.21.7668; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VANIMHOFF GW, 1986, CANCER, V57, P984, DOI 10.1002/1097-0142(19860301)57:5<984::AID-CNCR2820570518>3.0.CO;2-H; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302	36	316	318	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					359	363		10.1016/0140-6736(91)90490-G	http://dx.doi.org/10.1016/0140-6736(91)90490-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1713639				2022-12-28	WOS:A1991GA60700015
J	NIGHTINGALE, SL				NIGHTINGALE, SL			IMPRINTING OF ORAL SOLID DOSAGE FORM-DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, FED REG         0515, V56, P22370	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-28	WOS:A1991FU89600003
J	FELLER, DC; DELACRUZ, VF				FELLER, DC; DELACRUZ, VF			IDENTIFYING ANTIGENIC T-CELL SITES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; RECOGNITION; PREDICTION; SEQUENCE				FELLER, DC (corresponding author), MEDLMMUNE INC, 19 FIRSTFIELD RD, GAITHERSBURG, MD 20878 USA.							BERZOFSKY JA, 1988, J CLIN INVEST, V82, P1811, DOI 10.1172/JCI113796; BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; GREY HM, 1985, IMMUNOL TODAY, V6, P101, DOI 10.1016/0167-5699(85)90025-8; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; REYES VE, 1989, J BIOL CHEM, V264, P12854; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHBARD JB, IN PRESS ANN REV IMM; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SPOUGE JL, 1987, J IMMUNOL, V138, P204; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	17	68	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					720	721		10.1038/349720a0	http://dx.doi.org/10.1038/349720a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1705016				2022-12-28	WOS:A1991EY62700056
J	CHAROENVIT, Y; COLLINS, WE; JONES, TR; MILLET, P; YUAN, L; CAMPBELL, GH; BEAUDOIN, RL; BRODERSON, JR; HOFFMAN, SL				CHAROENVIT, Y; COLLINS, WE; JONES, TR; MILLET, P; YUAN, L; CAMPBELL, GH; BEAUDOIN, RL; BRODERSON, JR; HOFFMAN, SL			INABILITY OF MALARIA VACCINE TO INDUCE ANTIBODIES TO A PROTECTIVE EPITOPE WITHIN ITS SEQUENCE	SCIENCE			English	Article							PLASMODIUM-VIVAX; CIRCUMSPOROZOITE PROTEIN; IMMUNODOMINANT EPITOPE; MONOCLONAL-ANTIBODIES; PEPTIDE-SYNTHESIS; FALCIPARUM; ANTIGEN; SPOROZOITES; INFECTION; EFFICACY	Saimiri monkeys immunized with a recombinant protein containing 20 copies of the nine amino acid repeat of the Plasmodium vivax circumsporozoite (CS) protein developed high concentrations of antibodies to the repeat sequence and to sporozoites, but were not protected against challenge. After intravenous injection of an immunoglobulin G3 monoclonal antibody (NVS3) against irradiated P. vivax sporozoites, four of six monkeys were protected against sporozoite-induced malaria, and the remaining two animals took significantly longer to become parasitemic. Epitope mapping demonstrated that NVS3 recognizes only four (AGDR) of the nine amino acids within the repeat region of the P. vivax CS protein. The monkeys immunized with (DRA(D)(A)GQPAG)20 did not produce antibodies to the protective epitope AGDR. Thus, determination of the fine specificity of protective immune responses may be critical to the construction of successful subunit vaccines.	USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD 20889; CTR DIS CONTROL,MALARIA BRANCH,ATLANTA,GA 30333	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								ALVING CR, UNPUB; ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; ARNOT DE, 1988, P NATL ACAD SCI USA, V85, P8102, DOI 10.1073/pnas.85.21.8102; BALLOU WR, 1987, LANCET, V1, P1277; BARR PJ, 1987, J EXP MED, V165, P1160, DOI 10.1084/jem.165.4.1160; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, IN PRESS J IMMUNOL; COLLINS WE, 1989, AM J TROP MED HYG, V40, P455, DOI 10.4269/ajtmh.1989.40.455; COLLINS WE, 1986, AM J TROP MED HYG, V35, P56, DOI 10.4269/ajtmh.1986.35.56; EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GORDON DM, 1990, AM J TROP MED HYG, V42, P527, DOI 10.4269/ajtmh.1990.42.527; HALL T, 1984, J IMMUNOL, V132, P2059; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HJELM H, 1976, IMMUNOADSORBENTS PRO, P51; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLET P, 1988, AM J TROP MED HYG, V38, P340; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; RICKMAN LS, 1990, CLIN RES, V38, pA352; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336	25	88	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					668	671		10.1126/science.1704150	http://dx.doi.org/10.1126/science.1704150			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1704150				2022-12-28	WOS:A1991EW39900044
J	THOMAS, PJ; SHENBAGAMURTHI, P; YSERN, X; PEDERSEN, PL				THOMAS, PJ; SHENBAGAMURTHI, P; YSERN, X; PEDERSEN, PL			CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - NUCLEOTIDE BINDING TO A SYNTHETIC PEPTIDE	SCIENCE			English	Article							BACTERIAL TRANSPORT PROTEINS; MITOCHONDRIAL ATP SYNTHASE; AMINO-ACID-SEQUENCE; ADENYLATE KINASE; SECONDARY-STRUCTURE; BETA-SUBUNIT; ALPHA-3-BETA-3 COMPLEX; MULTIDRUG RESISTANCE; ESCHERICHIA-COLI; F1-ATPASE	Multiple mutations in the gene responsible for cystic fibrosis are located within a region predicted to encode a nucleotide-binding fold in the amino terminal half of the cystic fibrosis transmembrane conductance regulator protein. A 67-amino acid peptide (P-67) that corresponds to the central region of this putative nucleotide binding site was chemically synthesized and purified. This peptide bound adenine nucleotides. The apparent dissociation constants (Kd's) for the trinitrophenyl (TNP) adenine nucleotides, TNP-adenosine triphosphate, TNP-adenosine diphosphate, and TNP-adenosine monophosphate, were 300 nanomolar, 200 nanomolar, and greater than 1 micromolar, respectively. The Kd for adenosine triphosphate was 300 micromolar. Circular dichroism spectroscopy was used to show that P-67 assumes a predominantly beta sheet structure in solution, a finding that is consistent with secondary structure predictions. On the basis of this information, the phenylalanine at position 508, which is deleted in approximately 70 percent of individuals with cystic fibrosis, was localized to a beta strand within the nucleotide binding peptide. Deletion of this residue is predicted to induce a significant structural change in the beta strand and altered nucleotide binding.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LABS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,PROT PEPTIDE FACIL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Thomas, Philip J/F-7115-2012		NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; ARORA KK, 1990, J BIOL CHEM, V265, P5324; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHANDRASEGARAN S, 1990, 2ND ANN NEW ENGL BIO, P106; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DREUSICKE D, 1977, J MOL BIOL, V114, P359; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; ENGER U, 1987, J MOL BIOL, V185, P649; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1987, BIOCHEMISTRY-US, V26, P1645, DOI 10.1021/bi00380a024; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMADA H, 1988, CANCER RES, V48, P4926; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; LEE JH, 1990, J BIOL CHEM, V265, P4664; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; REDFIELD AG, 1990, BIOCHEMISTRY-US, V29, P3509, DOI 10.1021/bi00466a013; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; THOMAS P, UNPUB; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0	42	99	100	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					555	557		10.1126/science.1703660	http://dx.doi.org/10.1126/science.1703660			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1703660				2022-12-28	WOS:A1991EV45900049
J	MCLEAN, S; GANONG, AH; SEEGER, TF; BRYCE, DK; PRATT, KG; REYNOLDS, LS; SIOK, CJ; LOWE, JA; HEYM, J				MCLEAN, S; GANONG, AH; SEEGER, TF; BRYCE, DK; PRATT, KG; REYNOLDS, LS; SIOK, CJ; LOWE, JA; HEYM, J			ACTIVITY AND DISTRIBUTION OF BINDING-SITES IN BRAIN OF A NONPEPTIDE SUBSTANCE-P (NK1) RECEPTOR ANTAGONIST	SCIENCE			English	Article							LOCUS COERULEUS NEURONS; SPINAL-CORD; RAT; RELEASE; EXCITATION; NIGRA	CP-96,345, a nonpeptide substance P antagonist, is selective for the tachykinin NK1 receptor. The compound binds to a single population of sites in guinea pig brain and potently inhibits substance P-induced excitation of locus ceruleus neurons. CP-96,345 should be a useful tool for studying the action of substance P in the central nervous system.			MCLEAN, S (corresponding author), PFIZER INC,CENT RES DIV,DEPT NEUROSCI,GROTON,CT 06340, USA.							BANNON MJ, 1986, BRAIN RES, V381, P393, DOI 10.1016/0006-8993(86)90097-1; CHEESEMAN HJ, 1983, EUR J PHARMACOL, V94, P93, DOI 10.1016/0014-2999(83)90445-4; DAM TV, 1986, PEPTIDES, V7, P855, DOI 10.1016/0196-9781(86)90106-3; DAVIES J, 1976, BRAIN RES, V107, P623, DOI 10.1016/0006-8993(76)90150-5; DEUTCH AY, 1985, PEPTIDES, V6, P113, DOI 10.1016/0196-9781(85)90143-3; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; ELLIOTT PJ, 1986, BRAIN RES, V385, P379, DOI 10.1016/0006-8993(86)91087-5; GRAY EG, 1962, J ANAT, V96, P79; GUYENET PG, 1977, BRAIN RES, V136, P178, DOI 10.1016/0006-8993(77)90144-5; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HENRY JL, 1976, BRAIN RES, V114, P439, DOI 10.1016/0006-8993(76)90965-3; INNIS RB, 1985, BRAIN RES, V335, P381, DOI 10.1016/0006-8993(85)90499-8; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LOWE J, UNPUB; LUNBERG JM, 1984, ACTA PHYSL SCAND, V120, P217; OTSUKA M, 1976, NATURE, V264, P83, DOI 10.1038/264083a0; PAYAN DG, 1989, ANNU REV MED, V40, P341; PERNOW B, 1983, PHARMACOL REV, V35, P85; RANDIC M, 1977, BRAIN RES, V128, P164, DOI 10.1016/0006-8993(77)90245-1; REGOLI D, 1987, LIFE SCI, V40, P109, DOI 10.1016/0024-3205(87)90349-3; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; TAKANO Y, 1985, LIFE SCI, V37, P2507, DOI 10.1016/0024-3205(85)90608-3; TITELER M, 1987, BIOCHEM PHARMACOL, V36, P3265, DOI 10.1016/0006-2952(87)90643-5; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0	25	206	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					437	439		10.1126/science.1703324	http://dx.doi.org/10.1126/science.1703324			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1703324				2022-12-28	WOS:A1991EU50400044
J	REABAN, ME; GRIFFIN, JA				REABAN, ME; GRIFFIN, JA			INDUCTION OF RNA-STABILIZED DNA CONFORMERS BY TRANSCRIPTION OF AN IMMUNOGLOBULIN SWITCH REGION	NATURE			English	Article									BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT MOLEC BIOL,RIDGEFIELD,CT 06877	Boehringer Ingelheim	REABAN, ME (corresponding author), UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294, USA.							COLLIER DA, 1988, J BIOL CHEM, V263, P7397; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; LUTZKER SG, 1989, MOBILE DNA; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; STANTON LW, 1982, NUCLEIC ACIDS RES, V10, P5993, DOI 10.1093/nar/10.19.5993; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	11	205	208	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 22	1990	348	6299					342	344		10.1038/348342a0	http://dx.doi.org/10.1038/348342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ955	1701219				2022-12-28	WOS:A1990EJ95500063
J	SCHALL, TJ; BACON, K; TOY, KJ; GOEDDEL, DV				SCHALL, TJ; BACON, K; TOY, KJ; GOEDDEL, DV			SELECTIVE ATTRACTION OF MONOCYTES AND LYMPHOCYTES-T OF THE MEMORY PHENOTYPE BY CYTOKINE RANTES	NATURE			English	Article									ST THOMAS HOSP,INST DERMATOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	SCHALL, TJ (corresponding author), GENENTECH INC,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							AKBAR AN, 1988, J IMMUNOL, V140, P2171; BACON KB, 1989, BIOCHEM BIOPH RES CO, V165, P349, DOI 10.1016/0006-291X(89)91076-0; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BROWN KD, 1989, J IMMUNOL, V142, P679; BUDD RC, 1987, J IMMUNOL, V138, P3583; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; LARSEN CG, 1989, SCIENCE, V243, P1461; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MERKENSCHLAGER M, 1988, EUR J IMMUNOL, V18, P1653, DOI 10.1002/eji.1830181102; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1989, EUR J IMMUNOL, V19, P803, DOI 10.1002/eji.1830190504; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; UNEMORI EN, 1988, J BIOL CHEM, V263, P16252; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	23	1297	1319	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 18	1990	347	6294					669	671		10.1038/347669a0	http://dx.doi.org/10.1038/347669a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED620	1699135				2022-12-28	WOS:A1990ED62000054
J	BREO, DL				BREO, DL			THE SURE SUPER BOWL BET - INJURED PLAYERS ARE PENALIZED FOR LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		TATUM J, THEY CALL ME ASSASSI	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					706	707		10.1001/jama.267.5.706	http://dx.doi.org/10.1001/jama.267.5.706			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1731141				2022-12-28	WOS:A1992HB35400032
J	OYAIZU, N; CHIRMULE, N; PAHWA, S				OYAIZU, N; CHIRMULE, N; PAHWA, S			VACCINATION WITH GP160 IN HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; INVIVO				OYAIZU, N (corresponding author), CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,MANHASSET,NY 11030, USA.		Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216; /0000-0002-5704-8094				CHIRMULE N, 1990, BLOOD, V75, P152; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DUESBERG PH, 1989, P NATL ACAD SCI USA, V86, P755, DOI 10.1073/pnas.86.3.755; GORONZY J, 1986, J EXP MED, V164, P911, DOI 10.1084/jem.164.3.911; GORONZY JJ, 1989, J IMMUNOL, V142, P4435; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; OYAIZU N, 1990, P NATL ACAD SCI USA, V87, P2379, DOI 10.1073/pnas.87.6.2379; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401	8	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					347	347						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728747				2022-12-28	WOS:A1992HA99100021
J	FUSTER, V; BADIMON, L; BADIMON, JJ; CHESEBRO, JH				FUSTER, V; BADIMON, L; BADIMON, JJ; CHESEBRO, JH			MECHANISMS OF DISEASE - THE PATHOGENESIS OF CORONARY-ARTERY DISEASE AND THE ACUTE CORONARY SYNDROMES .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA-PECTORIS; SMOOTH-MUSCLE CELLS; HUMAN ATHEROSCLEROTIC PLAQUES; LOW-DENSITY LIPOPROTEIN; CHEMOTACTIC FACTOR; ANGIOGRAPHIC MORPHOLOGY; VASCULAR INJURY; CAROTID-ARTERY; TISSUE FACTOR		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Harvard University; Harvard Medical School; Mayo Clinic	FUSTER, V (corresponding author), MASSACHUSETTS GEN HOSP, CARDIAC UNIT, 32 FRUIT ST, BOSTON, MA 02114 USA.		Fuster, Valentin/H-4319-2015; BADIMON, LINA/S-2950-2019; BADIMON, LINA/O-4711-2014	Fuster, Valentin/0000-0002-9043-9986; BADIMON, LINA/0000-0002-9162-2459				AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; AMBROSE JA, 1988, AM J CARDIOL, V61, P244, DOI 10.1016/0002-9149(88)90924-1; AQEL NM, 1984, ATHEROSCLEROSIS, V53, P265, DOI 10.1016/0021-9150(84)90127-8; BARGER AC, 1990, AM J CARDIOL, V66, pG41, DOI 10.1016/0002-9149(90)90394-G; BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BERK BC, 1990, J BIOL CHEM, V265, P17334; BERLINER JA, 1986, ARTERIOSCLEROSIS, V6, P254, DOI 10.1161/01.ATV.6.3.254; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; BOCAN TMA, 1986, AM J PATHOL, V123, P413; BROWN BG, 1986, CIRCULATION, V73, P653, DOI 10.1161/01.CIR.73.4.653; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BRUSCHKE AVG, 1989, AM HEART J, V117, P296, DOI 10.1016/0002-8703(89)90772-2; CHAPMAN I, 1965, ARCH PATHOL, V80, P256; CHESEBRO JH, 1989, CIRCULATION S2, V80, P266; CLOWES AW, 1989, J CARDIOVASC PHARM, V14, pS12, DOI 10.1097/00005344-198906146-00005; COHEN M, 1989, J AM COLL CARDIOL, V13, P297, DOI 10.1016/0735-1097(89)90502-0; COHEN P, 1968, J ATHEROSCLER RES, V8, P389, DOI 10.1016/S0368-1319(68)80096-1; CONSTANT.P, 1966, J ATHEROSCLER RES, V6, P1, DOI 10.1016/S0368-1319(66)80056-X; DAVIES MJ, 1988, BRIT HEART J, V60, P459; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DAVIES SW, 1991, J AM COLL CARDIOL, V18, P669, DOI 10.1016/0735-1097(91)90787-A; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DUGUID JB, 1946, J PATHOL BACTERIOL, V58, P207, DOI 10.1002/path.1700580207; FALK E, 1989, AM J CARDIOL, V63, pE114, DOI 10.1016/0002-9149(89)90242-7; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; FULTON WFM, 1965, CORONARY ARTERIES AR, P230; FUSTER V, 1986, PROG HEMOST THROMB, V8, P159; FUSTER V, 1990, CIRCULATION, V82, P47; FUSTER V, 1982, CIRC RES, V51, P587, DOI 10.1161/01.RES.51.5.587; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; FUSTER V, 1979, CIRCULATION, V59, P1137, DOI 10.1161/01.CIR.59.6.1137; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOWN AM, 1986, AM J PATHOL, V125, P191; HABIB GB, 1991, CIRCULATION, V83, P739, DOI 10.1161/01.CIR.83.3.739; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HATHAWAY DR, 1989, J AM COLL CARDIOL, V13, P265, DOI 10.1016/0735-1097(89)90498-1; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KARINO T, 1987, ANN NY ACAD SCI, V516, P422, DOI 10.1111/j.1749-6632.1987.tb33063.x; KEREIAKES DJ, 1991, J AM COLL CARDIOL, V17, P304, DOI 10.1016/S0735-1097(10)80091-9; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRAGEL AH, 1991, J AM COLL CARDIOL, V18, P801, DOI 10.1016/0735-1097(91)90805-J; LEVIN DC, 1982, CIRCULATION, V66, P316, DOI 10.1161/01.CIR.66.2.316; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LIN CS, 1988, ANGIOLOGY, V39, P535; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LITTLE WC, 1990, AM J CARDIOL, V66, pG44, DOI 10.1016/0002-9149(90)90395-H; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MCPHERSON DD, 1987, NEW ENGL J MED, V316, P304, DOI 10.1056/NEJM198702053160604; MITCHINSON MJ, 1987, LANCET, V2, P146; MOISE A, 1984, AM J CARDIOL, V54, P1176, DOI 10.1016/S0002-9149(84)80063-6; NISSEN SE, 1991, CIRCULATION, V84, P1087, DOI 10.1161/01.CIR.84.3.1087; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V18, P904, DOI 10.1016/0735-1097(91)90745-U; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; PRITCHARD KA, 1991, ARTERIOSCLER THROMB, V11, P1175, DOI 10.1161/01.ATV.11.5.1175; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RENTROP KP, 1989, CIRCULATION, V80, P1166, DOI 10.1161/01.CIR.80.5.1166; RENTROP P, 1981, CIRCULATION, V63, P307, DOI 10.1161/01.CIR.63.2.307; RICHARDSON PD, 1989, LANCET, V2, P941; RIDOLFI RL, 1977, AM HEART J, V93, P468, DOI 10.1016/S0002-8703(77)80410-9; ROBERTS WC, 1972, AM J MED, V52, P425, DOI 10.1016/0002-9343(72)90033-2; ROSS AM, 1992, THROMBOSIS CARDIOVAS, P327; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P1, DOI 10.1002/clc.4960141302; SERRUYS PW, 1987, EUR HEART J, V8, P1172, DOI 10.1093/oxfordjournals.eurheartj.a062189; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; SPURLOCK BO, 1987, SCANNING MICROSCOPY, V1, P1359; SPURLOCK BO, 1988, SCANNING MICROSCOPY, V2, P1214; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; VANLIERDE J, 1990, J AM COLL CARDIOL, V16, P1545, DOI 10.1016/0735-1097(90)90298-4; Virchow R, 1856, GESAMMELTE ABH, P458; VONROKITANSKY C, 1852, MANUAL PATHOLOGICAL, V4, P261; WEBSTER MWI, 1990, J AM COLL CARDIOL S, V15, pS218; WEINBERGER J, 1988, J AM COLL CARDIOL, V12, P1515, DOI 10.1016/S0735-1097(88)80019-6; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WHITE HD, 1990, LANCET, V336, P297, DOI 10.1016/0140-6736(90)91818-U; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WOOLF N, 1992, THROMBOSIS CARDIOVAS, P41; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	100	2711	2823	6	131	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					242	250		10.1056/NEJM199201233260406	http://dx.doi.org/10.1056/NEJM199201233260406			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1727977				2022-12-28	WOS:A1992HA43100006
J	OSBORNE, NG; FEIT, MD				OSBORNE, NG; FEIT, MD			THE USE OF RACE IN MEDICAL-RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; BLOOD-PRESSURE; CHLAMYDIA-TRACHOMATIS; VASCULAR-RESISTANCE; SKIN COLOR; WOMEN; POPULATION; INFECTION; ETHNICITY; MORTALITY		SUNY COLL SYRACUSE,DEPT OBSTET GYNECOL,SYRACUSE,NY; UNIV AKRON,DEPT SOCIAL WORK,AKRON,OH 44325	State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; University System of Ohio; University of Akron								ARAL SO, 1991, SCI AM, V264, P62, DOI 10.1038/scientificamerican0291-62; ARCHER C, 1960, S AFR MED J, V34, P242; ARENSMAN FW, 1989, AM J DIS CHILD, V143, P212, DOI 10.1001/archpedi.1989.02150140106030; BABBOTT D, 1989, ARCH INTERN MED, V149, P576, DOI 10.1001/archinte.149.3.576; BRINK AJ, 1977, S AFR MED J, V51, P493; CARTWRIGHT S, 1851, DEBOWS REV, V11, P64; Cartwright Samuel, 1851, BOWS SO W REV, V11, P64; FROST F, 1980, AM J PUBLIC HEALTH, V70, P974, DOI 10.2105/AJPH.70.9.974; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HAHN RA, 1989, AM J PUBLIC HEALTH, V79, P467, DOI 10.2105/AJPH.79.4.467; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; HARBURG E, 1978, AM J PUBLIC HEALTH, V68, P1177, DOI 10.2105/AJPH.68.12.1177; HARBURG E, 1978, AM J PUBLIC HEALTH, V68, P1184, DOI 10.2105/AJPH.68.12.1184; KALDOR J, 1991, JAMA-J AM MED ASSOC, V265, P975, DOI 10.1001/jama.1991.03460080045019; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KLAG MJ, 1991, JAMA-J AM MED ASSOC, V265, P599, DOI 10.1001/jama.265.5.599; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; LANDMAN GB, 1988, CLIN PEDIATR, V27, P596, DOI 10.1177/000992288802701206; LEE NC, 1991, OBSTET GYNECOL, V77, P425; MARE RD, 1982, AM J PUBLIC HEALTH, V72, P539, DOI 10.2105/AJPH.72.6.539; MCCALLA S, 1991, AM J OBSTET GYNECOL, V164, P625, DOI 10.1016/S0002-9378(11)80036-0; MCCAULEY J, 1986, PEDIATRICS, V78, P1039; MERCY JA, 1989, AM J PUBLIC HEALTH, V79, P595, DOI 10.2105/AJPH.79.5.595; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; MOSCICKI B, 1987, AM J OBSTET GYNECOL, V157, P65, DOI 10.1016/S0002-9378(87)80347-2; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; PARK E, 1991, SMITHSONIAN, V21, P18; RESNICK MB, 1990, AM J OBSTET GYNECOL, V162, P374, DOI 10.1016/0002-9378(90)90389-O; RYAN GM, 1990, AM J OBSTET GYNECOL, V162, P34, DOI 10.1016/0002-9378(90)90815-O; SATIN AJ, 1991, OBSTET GYNECOL, V77, P710; SAVITZ DA, 1991, AM J OBSTET GYNECOL, V164, P467, DOI 10.1016/S0002-9378(11)80001-3; STOWE HB, 1981, UNCLE TOMS CABIN, pCH10; TABOR E, 1990, JAMA-J AM MED ASSOC, V264, P691; TELINDE RW, 1970, OPERATIVE GYNECOLOGY, P323; WARWICK R, 1973, GRAYS ANATOMY, P312; WARWICK R, 1973, GRAYS ANATOMY, P982; WEINSTEIN RS, 1988, NEW ENGL J MED, V319, P1698, DOI 10.1056/NEJM198812293192603; ZEMEL MB, 1990, NEW ENGL J MED, V323, P434, DOI 10.1056/NEJM199008163230702; 1967, VITAL STATISTICS U A, V2, P1; 1990, MMWR, V39, P525; 1989, OB GYN NEWS, V31, P12; 1987, MMWR, V36, P634	43	161	163	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					275	279		10.1001/jama.267.2.275	http://dx.doi.org/10.1001/jama.267.2.275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY046	1727527				2022-12-28	WOS:A1992GY04600034
J	MASSON, RG; RENNKE, HG; GOTTLIEB, MN				MASSON, RG; RENNKE, HG; GOTTLIEB, MN			PULMONARY HEMORRHAGE IN A PATIENT WITH FIBRILLARY GLOMERULONEPHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							GLOMERULOPATHY; DEPOSITS		BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	MASSON, RG (corresponding author), FRAMINGHAM UNION HOSP, DEPT PULM MED, 115 LINCOLN ST, FRAMINGHAM, MA 01701 USA.							ALPERS CE, 1987, KIDNEY INT, V31, P781, DOI 10.1038/ki.1987.66; BYRD RB, 1973, CHEST, V64, P128, DOI 10.1378/chest.64.1.128; DREW WL, 1977, AM REV RESPIR DIS, V116, P215; DUFFY JL, 1983, AM J PATHOL, V113, P279; Goodpasture EW, 1919, AM J MED SCI, V158, P863, DOI 10.1097/00000441-191911000-00012; KORBET SM, 1985, MEDICINE, V64, P228, DOI 10.1097/00005792-198507000-00004; KORBET SM, 1991, AM J KIDNEY DIS, V17, P247, DOI 10.1016/S0272-6386(12)80469-0; LEATHERMAN JW, 1984, MEDICINE, V63, P343, DOI 10.1097/00005792-198411000-00002; LOCKWOOD CM, 1976, LANCET, V1, P711; ROSENMANN E, 1977, NEPHRON, V18, P301, DOI 10.1159/000180846; STURGILL BC, 1985, HUM PATHOL, V16, P220, DOI 10.1016/S0046-8177(85)80005-8; TORRENTE AD, 1975, ANN INTERN MED, V83, P218, DOI 10.7326/0003-4819-83-2-218; 1990, NEW ENGL J MED, V323, P1050; 1989, NEW ENGL J MED, V320, P1677	14	49	50	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					36	39		10.1056/NEJM199201023260106	http://dx.doi.org/10.1056/NEJM199201023260106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1727064				2022-12-28	WOS:A1992GX31500006
J	ZWERLING, C; RYAN, J; ORAV, EJ				ZWERLING, C; RYAN, J; ORAV, EJ			COSTS AND BENEFITS OF PREEMPLOYMENT DRUG SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective. - This study provides a cost-benefit analysis of preemployment drug screening and evaluates the sensitivity of this analysis to variation in its underlying assumptions. Design. - Cost-benefit analysis, based on a cohort analytic study previously reported. Setting. - Employees of the US Postal Service in Boston, Mass. Participants. - Estimates of costs and benefit are based on a cohort of 2533 postal workers in Boston and on average costs for the Postal Service in Boston and nationwide. Results. - Drug screening would have saved the Postal Service $162 per applicant hired. However, these results were sensitive to the assumptions in the model. If the prevalence of drug use in the population screened were 1 % rather than 12%, the program would lose money. Similarly, if the cost per urine sample screened were $95 rather than the $49 assumed, then the program would lose money, even if the prevalence of drug positives was as high as 9%. Conclusions. - Because of the sensitivity of this analysis to changes in its underlying assumptions, any company considering preemployment drug screening should carefully weigh the costs and benefits in its own industry.	E BOSTON NEIGHBORHOOD HLTH CTR,BOSTON,MA; TUFTS UNIV,SCH MED,DEPT COMMUNITY MED,BOSTON,MA 02111; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT MED PROGRAM,BOSTON,MA 02115	Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	ZWERLING, C (corresponding author), UNIV IOWA,COLL MED,INST AGR MED & OCCUPAT HLTH,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242, USA.				PHS HHS [R49 CCR703640 01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DRUMMOND MF, 1987, METHODS EC EVALUATIO, P72; FREUDENHEIM M, 1990, NY TIMES        0205, pA1; HARWOOD HJ, 1984, RT127340001FR RES TR; HAYGHE HV, 1991, MONTHLY LABOR RE APR, P26; LUNDBERG G, 1986, JAMA-J AM MED ASSOC, V256, P3005; NORMAND J, 1990, J APPL PSYCHOL, V75, P629, DOI 10.1037/0021-9010.75.6.629; SEXTON TR, 1988, J POLICY ANAL MANAG, V7, P542, DOI 10.2307/3323731; SPIEHLER VR, 1988, CLIN CHEM, V34, P1535; WARNER KE, 1982, COST BENEFIT COST EF, P93; WELLS VE, 1988, AM J PUBLIC HEALTH, V78, P817, DOI 10.2105/AJPH.78.7.817; ZWERLING C, 1990, JAMA-J AM MED ASSOC, V264, P2639, DOI 10.1001/jama.264.20.2639; 1989, GAOGGD8975 US GEN AC; 1989, NY TIMES        0322, pA1; 1989, 760 US DEP LAB BUR L	14	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					91	93		10.1001/jama.267.1.91	http://dx.doi.org/10.1001/jama.267.1.91			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GW848	1727203				2022-12-28	WOS:A1992GW84800030
J	WHITE, RE; SCHONBRUNN, A; ARMSTRONG, DL				WHITE, RE; SCHONBRUNN, A; ARMSTRONG, DL			SOMATOSTATIN STIMULATES CA2+-ACTIVATED K+ CHANNELS THROUGH PROTEIN DEPHOSPHORYLATION	NATURE			English	Article							PITUITARY CELL-LINE; VASOACTIVE INTESTINAL PEPTIDE; AMP-INDEPENDENT ACTIONS; INTRACELLULAR FREE CALCIUM; PERTUSSIS TOXIN BLOCKS; CYCLIC-AMP; TUMOR-CELLS; GH3 CELLS; POTASSIUM CONDUCTANCE; PROLACTIN SECRETION	THE neuropeptide somatostatin inhibits secretion from electrically excitable cells in the pituitary, pancreas, gut and brain 1. In mammalian pituitary tumour cells somatostatin inhibits secretion through two distinct pertussis toxin-sensitive mechanisms 2-5. One involves inhibition of adenylyl cyclase 6, the other an unidentified cyclic AMP-independent mechanism that reduces Ca2+ influx 7,8 by increasing membrane conductance to potassium 9,10. Here we demonstrate that the predominant electrophysiological effect of somatostatin on metabolically intact pituitary tumour cells is a large, sustained increase in the activity of the large-conductance Ca2+- and voltage-activated K+ channels (BK). This action of somatostatin does not involve direct effects of Ca2+, cAMP or G proteins on the channels. Our results indicate instead that somatostatin stimulates BK channel activity through protein dephosphorylation.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709; UNIV TEXAS,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System								ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1541, DOI 10.1210/endo-113-5-1541; DORFLINGER LJ, 1983, ENDOCRINOLOGY, V113, P1551, DOI 10.1210/endo-113-5-1551; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOCH BD, 1988, J BIOL CHEM, V263, P226; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LECHLEITER JD, 1988, NEURON, V1, P27; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LUINI A, 1986, J NEUROSCI, V6, P3128; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; PATEL YC, 1990, METABOLISM, V39, P1, DOI 10.1016/0026-0495(90)90196-J; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; REINHART PH, IN PRESS J NEUROSCI; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P591, DOI 10.1113/jphysiol.1987.sp016509; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHLEGEL W, 1984, CELL CALCIUM, V5, P223, DOI 10.1016/0143-4160(84)90038-1; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMASHITA N, 1988, P NATL ACAD SCI USA, V85, P4924, DOI 10.1073/pnas.85.13.4924; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	39	257	258	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					570	573		10.1038/351570a0	http://dx.doi.org/10.1038/351570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1710783				2022-12-28	WOS:A1991FR03400060
J	MARTINAC, B; ADLER, J; KUNG, C				MARTINAC, B; ADLER, J; KUNG, C			MECHANOSENSITIVE ION CHANNELS OF ESCHERICHIA-COLI ACTIVATED BY AMPHIPATHS	NATURE			English	Article									UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MARTINAC, B (corresponding author), UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706, USA.		Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082				BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; COOPER KE, 1986, J MEMBRANE BIOL, V93, P259, DOI 10.1007/BF01871180; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; DEUTICKE B, 1968, BIOCHIM BIOPHYS ACTA, V163, P494, DOI 10.1016/0005-2736(68)90078-3; FALKE LC, 1988, FEBS LETT, V237, P141, DOI 10.1016/0014-5793(88)80188-1; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; HUDSPETH AJ, 1986, HEARING RES, V22, P21, DOI 10.1016/0378-5955(86)90070-5; KIRBER MT, 1987, BIOPHYS J, V51, pA252; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; NIKAIDO H, 1987, CELLULAR MOL BIOL, V1, P7; OHMORI H, 1984, J PHYSIOL-LONDON, V350, P561, DOI 10.1113/jphysiol.1984.sp015218; OPSAHL LR, 1990, BIOPHYS J, V57, pA321; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; ROTHMAN JE, 1977, SCIENCE, V195, P743, DOI 10.1126/science.402030; SHEETZ MP, 1976, J CELL BIOL, V70, P193, DOI 10.1083/jcb.70.1.193; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X	24	386	398	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 15	1990	348	6298					261	263		10.1038/348261a0	http://dx.doi.org/10.1038/348261a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700306				2022-12-28	WOS:A1990EH79600066
J	CHESNUT, CH				CHESNUT, CH			OSTEOPOROSIS AND ITS TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POSTMENOPAUSAL OSTEOPOROSIS; CALCITRIOL				CHESNUT, CH (corresponding author), UNIV WASHINGTON,MED CTR,SEATTLE,WA 98195, USA.							ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002-9343(88)90259-8; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; LUFKIN EG, 1990, OSTEOPOROSIS 1990, V3, P1995; MEUNIER PJ, 1991, J BONE MINER RES  S1, V6, pS135; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	9	24	25	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					406	408		10.1056/NEJM199202063260609	http://dx.doi.org/10.1056/NEJM199202063260609			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729625				2022-12-28	WOS:A1992HC38600009
J	WACHTER, RM; LUCE, JM; HOPEWELL, PC				WACHTER, RM; LUCE, JM; HOPEWELL, PC			CRITICAL CARE OF PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MEDICAL INTENSIVE-CARE; IMMUNE-DEFICIENCY SYNDROME; LIFE-SUSTAINING TREATMENT; PLACEBO-CONTROLLED TRIAL; RESPIRATORY-FAILURE; TRIMETHOPRIM-SULFAMETHOXAZOLE; BRONCHOALVEOLAR LAVAGE; FIBEROPTIC BRONCHOSCOPY	Objective. - We sought to review the clinical and ethical issues surrounding critical care for patients with the acquired immunodeficiency syndrome (AIDS). Data Sources. - We reviewed published studies and abstracts dealing with the outcome of critical care for patients with AIDS, decision making about life-sustaining treatments in patients with AIDS, and infection control in the intensive care unit. We also consulted with a number of experts in the field. Study Selection. - We selected outcome studies in which patients with documented AIDS or infection with the human immunodeficiency virus (HIV) were analyzed. We rejected data concerning patients with suspected or presumed AIDS and data concerning presumed cases of Pneumocystis carinii pneumonia (PCP). Data Synthesis. - Most AIDS patients who require critical care do so because of respiratory failure caused by PCP. Although studies early in the epidemic reported survival rates to hospital discharge of 0% to 14%, recent studies demonstrate improved survival rates of 36% to 55%. Treatment for patients with PCP and respiratory failure should include either intravenous trimethoprim-sulfamethoxazole or pentamidine isethionate, as well as adjuvant corticosteroids. Patients with AIDS may require critical care for many other indications, including seizures, sepsis, and hypotension, or reasons unrelated to their immunodeficiency. In general, such patients have a better prognosis than those with respiratory failure. Conclusions. - The provision of critical care for PCP and respiratory failure specifically or AIDS generally cannot be considered futile. Therefore, decisions about the use of critical care should be guided by the particular clinical situation and the patient's preferences. More research is needed to elucidate the reasons for the improving survival for patients with PCP and respiratory failure and the predictors of such survival.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,MED CTR,DIV GEN INTERNAL MED,MED SERV,SAN FRANCISCO,CA 94143, USA.							ALBERTIN.RE, 1974, JAMA-J AM MED ASSOC, V230, P1666, DOI 10.1001/jama.230.12.1666; ALLEGRA CJ, 1987, NEW ENGL J MED, V317, P978, DOI 10.1056/NEJM198710153171602; AMUNDSON DE, 1989, SOUTHERN MED J, V82, P711, DOI 10.1097/00007611-198906000-00009; AMUNDSON DE, 1989, SO MED J, V82, P718; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P3000; AREEN J, 1987, JAMA-J AM MED ASSOC, V258, P229, DOI 10.1001/jama.258.2.229; BAGGOTT L A, 1987, Chest, V92, p132S; BANKS RA, 1985, INTENS CARE MED, V11, P169, DOI 10.1007/BF00272396; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARTLETT RH, 1986, CHEST, V89, P684, DOI 10.1378/chest.89.5.684; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; BECKER MH, 1990, AM J INFECT CONTROL, V18, P232, DOI 10.1016/0196-6553(90)90164-N; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BROADDUS C, 1985, ANN INTERN MED, V102, P747, DOI 10.7326/0003-4819-102-6-747; CAUGHEY G, 1985, CHEST, V88, P659, DOI 10.1378/chest.88.5.659; Chaisson R E, 1989, Semin Respir Infect, V4, P133; CHASSIN MR, 1982, MED CARE, V20, P165, DOI 10.1097/00005650-198202000-00004; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P1; COLEMAN DL, 1984, AM REV RESPIR DIS, V130, P1166; DAVEY RT, 1990, ANTIMICROB AGENTS CH, V34, P499, DOI 10.1128/AAC.34.4.499; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY S, 1986, AM REV RESPIR DIS, V133, pA344; GARAY SM, 1989, CHEST, V95, P769, DOI 10.1378/chest.95.4.769; GILFIX M, 1984, WESTERN J MED, V141, P387; GOLDEN JA, 1986, CHEST, V90, P18, DOI 10.1378/chest.90.1.18; GOODMAN PC, 1986, AM J ROENTGENOL, V147, P29, DOI 10.2214/ajr.147.1.29; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENVIK A, 1983, CRIT CARE MED, V11, P394; HADLEY WK, 1989, AM J HOSP PHARM, V46, pS4, DOI 10.1093/ajhp/46.12_Suppl_3.S4; HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HENDERSON DJ, 1988, NURS CLIN N AM, V23, P767; HOPEWELL PC, 1988, J INFECT DIS, V157, P1115, DOI 10.1093/infdis/157.6.1115; HURST JM, 1989, ARCH SURG-CHICAGO, V124, P1067; Jonsen Albert R., 1998, CLIN ETHICS, V4th; JONSEN AR, 1978, CLIN RES, V26, P55; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KELEN GD, 1989, ANN EMERG MED, V18, P378, DOI 10.1016/S0196-0644(89)80574-8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; KOVACS JA, 1989, J INFECT DIS, V160, P882, DOI 10.1093/infdis/160.5.882; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; LO B, 1987, REV INFECT DIS, V9, P1163; LO B, 1980, ANN INTERN MED, V93, P764, DOI 10.7326/0003-4819-93-5-764; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; MANN JM, 1987, CHEST, V91, P319, DOI 10.1378/chest.91.3.319; MATTHAY MA, 1989, WESTERN J MED, V150, P187; MAXFIELD RA, 1986, CRIT CARE MED, V14, P443, DOI 10.1097/00003246-198605000-00001; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MONTGOMERY AB, 1987, LANCET, V2, P480; MONTGOMERY AB, 1990, 6TH INT C AIDS SAN F, V1, P220; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NG VL, 1990, J CLIN MICROBIOL, V28, P2228, DOI 10.1128/JCM.28.10.2228-2233.1990; OBRIEN RF, 1989, AM REV RESPIR DIS, V139, P1324, DOI 10.1164/ajrccm/139.6.1324; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; PRICE RA, 1974, HUM PATHOL, V5, P737, DOI 10.1016/S0046-8177(74)80043-2; RAFFIN T A, 1989, American Review of Respiratory Disease, V140, pS28; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SAUNDERS C, 1959, NURS TIMES, V55, P960; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHUSTER DP, 1983, AM J MED, V75, P402, DOI 10.1016/0002-9343(83)90340-6; SCITOVSKY AA, 1986, JAMA-J AM MED ASSOC, V256, P3103, DOI 10.1001/jama.256.22.3103; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SHAW RJ, 1988, THORAX, V43, P436, DOI 10.1136/thx.43.6.436; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STEINBROOK R, 1985, ANN INTERN MED, V103, P787, DOI 10.7326/0003-4819-103-5-787; STOKES DC, 1986, BRIT J EXP PATHOL, V67, P383; STOVER DE, 1989, AM REV RESPIR DIS, V139, P1343, DOI 10.1164/ajrccm/139.6.1343; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; TENO J, 1990, J GEN INTERN MED, V5, P490, DOI 10.1007/BF02600877; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WACHTER RM, 1988, ARCH INTERN MED, V148, P149, DOI 10.1001/archinte.148.1.149; WACHTER RM, 1989, CHEST, V95, P647, DOI 10.1378/chest.95.3.647; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WEINKE T, 1990, 6TH INT C AIDS SAN F, V1, P253; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; ZAMAN MK, 1988, AM REV RESPIR DIS, V137, P796, DOI 10.1164/ajrccm/137.4.796; 1990, NEW ENGL J MED, V323, P1500	107	49	49	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					541	547		10.1001/jama.267.4.541	http://dx.doi.org/10.1001/jama.267.4.541			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729577				2022-12-28	WOS:A1992GZ43900032
J	SMITH, GD; SHIPLEY, MJ; MARMOT, MG; ROSE, G				SMITH, GD; SHIPLEY, MJ; MARMOT, MG; ROSE, G			PLASMA-CHOLESTEROL CONCENTRATION AND MORTALITY - THE WHITEHALL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TOTAL SERUM-CHOLESTEROL; FOLLOW-UP; CANCER MORTALITY; RISK-FACTORS; DENSITY-LIPOPROTEIN; COLON CANCER; CARDIOVASCULAR-DISEASE; 7 COUNTRIES; DEATH	Objective. - To examine the relationship between plasma cholesterol concentration and mortality from major causes of death. Design. - Cohort study. Setting. - Civil service offices in London, England. Participants. - There were 17 718 male civil servants aged 40 through 64 years at the time of study entry between 1967 and 1969. Main Outcome Measure. - Mortality from major cause groups. Results. - There were 4022 deaths in the cohort over the 18 years of follow-up. Total mortality increased with cholesterol level, although mortality in the small group with very low cholesterol levels (5% of study population) was nonsignificantly higher (P > .5) than that of the remainder of the lowest quintile cholesterol group. Coronary heart disease mortality increased with increasing cholesterol concentration from the lowest levels (P < .001 for trend). The cancer mortality rate in the group below the fifth centile of the cholesterol distribution was higher than in the remainder of the cohort for lung (P < .001), pancreas (P = .05), liver (P = .09), and all smoking-related cancers (P = .02). Only for lung cancer was there a consistent inverse trend with cholesterol level (P < .01). Rates of mortality due to non-neoplastic respiratory disease were inversely related to cholesterol level (P < .001). Health state at the time of examination and socioeconomic position were related to cholesterol concentration-subjects in lower employment grades, with disease at baseline, with a history of recent unexplained weight loss, or who had been widowed had lower initial cholesterol levels. These associations largely accounted for the relationships between cholesterol level and noncardiovascular mortality. Conclusions. - The inverse associations between plasma cholesterol concentration and mortality from certain causes of death seen in cohort studies could be because the participants with low cholesterol levels possess other characteristics that place them at an elevated risk of death.			SMITH, GD (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Davey Smith, George/A-7407-2013; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAMSON ZH, 1985, BRIT J CANCER, V52, P93, DOI 10.1038/bjc.1985.154; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BASU TK, 1974, INT J VITAM NUTR RES, V44, P14; BOTTIGER LE, 1982, ACTA MED SCAND, V211, P437; BUDD D, 1986, CANCER, V58, P1361, DOI 10.1002/1097-0142(19860915)58:6<1361::AID-CNCR2820580630>3.0.CO;2-S; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; COX DR, 1972, J R STAT SOC B, V34, P187; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P59; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; EBIKRYSTON KL, 1988, J CLIN EPIDEMIOL, V41, P251, DOI 10.1016/0895-4356(88)90129-1; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FISER RH, 1972, J INFECT DIS, V125, P54, DOI 10.1093/infdis/125.1.54; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GERHARDSSON M, 1986, INT J EPIDEMIOL, V15, P155, DOI 10.1093/ije/15.2.155; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; HAMMOND EC, 1966, EPIDEMIOLOGICAL APPR, P127; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JOHANSEN H, 1987, CAN MED ASSOC J, V136, P823; JOHANSSON BW, 1973, EARLY PHASES CORONAR, P314; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KERTTULA Y, 1988, ANN CLIN RES, V20, P184; KEYS A, 1985, AM J EPIDEMIOL, V121, P870, DOI 10.1093/oxfordjournals.aje.a114057; KNEKT P, 1991, BRIT MED J, V302, P90, DOI 10.1136/bmj.302.6768.90; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; MARMOT MG, 1984, LANCET, V1, P1003; MORRIS DL, 1983, CANCER-AM CANCER SOC, V52, P1754, DOI 10.1002/1097-0142(19831101)52:9<1754::AID-CNCR2820520933>3.0.CO;2-J; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; NEATON JD, IN PRESS ARCH INTERN; NEUGUT AI, 1989, INT J EPIDEMIOL, V4, P798; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PERSSON B, 1984, ACTA MED SCAND, V216, P485; PETERSSON B, 1984, AM J MED, V77, P418, DOI 10.1016/0002-9343(84)90096-2; PETERSSON B, 1983, KLIN WOCHENSCHR, V63, P795; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; REID DD, 1974, LANCET, V1, P469; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1980, LANCET, V1, P523; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHATZKIN A, 1987, LANCET, V2, P298; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; SMITH GD, IN PRESS BMJ; SMITH GD, IN PRESS AM J EPIDEM; STEMMERMANN GN, 1981, J NATL CANCER I, V67, P1179; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; THOMAS CB, 1982, JOHNS HOPKINS MED J, V150, P89; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VITOLS S, 1985, LANCET, V2, P1150; WALD NJ, 1989, BRIT J CANCER, V59, P936, DOI 10.1038/bjc.1989.198; WALLACE RB, 1982, J NATL CANCER I, V68, P915; WESTLUND K, 1972, SCAND J CLIN IN S127, V30, P3; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WINAWER SJ, 1990, JAMA-J AM MED ASSOC, V263, P2083, DOI 10.1001/jama.263.15.2083; WINGARD DL, 1984, J CHRON DIS, V37, P401, DOI 10.1016/0021-9681(84)90107-3; YAARI S, 1981, LANCET, V1, P1011; 1982, JAMA-J AM MED ASSOC, V248, P2853	72	255	258	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					70	76		10.1001/jama.267.1.70	http://dx.doi.org/10.1001/jama.267.1.70			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727199				2022-12-28	WOS:A1992GW84800026
J	KUMAR, KN; TILAKARATNE, N; JOHNSON, PS; ALLEN, AE; MICHAELIS, EK				KUMAR, KN; TILAKARATNE, N; JOHNSON, PS; ALLEN, AE; MICHAELIS, EK			CLONING OF CDNA FOR THE GLUTAMATE-BINDING SUBUNIT OF AN NMDA RECEPTOR COMPLEX	NATURE			English	Article							FUNCTIONAL EXPRESSION; PROTEIN; FAMILY; HOMOLOGY; SEQUENCE; BRAIN; SHOWS	THE amino acids L-glutamic and L-aspartic acids form the most widespread excitatory transmitter network in mammalian brain 1,2. The excitation produced by L-glutamic acid is important in the early development of the nervous system 3,4, Synaptic plasticity and memory formation 5-6, seizures 7,8 and neuronal degeneration 9,10. The receptors activated by L-glutamic acid are a target for therapeutic intervention in neurodegenerative diseases, brain ischaemia and epilepsy. There are two types of receptors for the excitatory amino acids, those that lead to the opening of cation-selective channels and those that activate phospholipase C (ref. 11). The receptors activating ion channels are NMDA (N-methyl-D-aspartate) and kainate/AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive receptors. The complementary DNAs for the kainate/AMPA receptor 12,13 and for the metabotropic receptor 14 have been cloned. We report here on the isolation and characterization of a protein complex of four major proteins that represents an intact complex of the NMDA receptor ion channel and on the cloning of the cDNA for one ot the subunits of this receptor complex, the glutamate-binding protein.	UNIV KANSAS,DEPT PHARMACOL & TOXICOL,2099 CONSTANT AVE,W CAMPUS,LAWRENCE,KS 66047; UNIV KANSAS,CTR BIOMED RES,LAWRENCE,KS 66047	University of Kansas; University of Kansas								BALAZS R, 1988, NEUROSCI LETT, V87, P80, DOI 10.1016/0304-3940(88)90149-8; CHAPMAN AG, 1987, EUR J PHARMACOL, V139, P91, DOI 10.1016/0014-2999(87)90501-2; CHEN JW, 1988, J BIOL CHEM, V263, P417; CHOI DW, 1987, J NEUROSCI, V7, P369; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; EATON MJ, 1990, J BIOL CHEM, V265, P16196; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GEAN DW, 1988, NEUROPHARMACOLOGY, V27, P557; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, IN PRESS BRAIN RES; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEYER JM, 1977, BIOCHEMISTRY-US, V16, P1158, DOI 10.1021/bi00625a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WEILOCH T, 1985, SCIENCE, V230, P681	32	153	163	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					70	73		10.1038/354070a0	http://dx.doi.org/10.1038/354070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1719427				2022-12-28	WOS:A1991GN82900060
J	BANCHEREAU, J; ROUSSET, F				BANCHEREAU, J; ROUSSET, F			GROWING HUMAN LYMPHOCYTES-B IN THE CD40 SYSTEM	NATURE			English	Article							CELLS				BANCHEREAU, J (corresponding author), SCHERING PLOUGH CORP, IMMUNOL RES LAB, 27 CHEMIN PEUPLIERS, BP 11, F-69571 DARDILLY, FRANCE.							BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	9	182	192	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1991	353	6345					678	679		10.1038/353678a0	http://dx.doi.org/10.1038/353678a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1717852				2022-12-28	WOS:A1991GK67200077
J	BATES, SE				BATES, SE			CLINICAL-APPLICATIONS OF SERUM TUMOR-MARKERS	ANNALS OF INTERNAL MEDICINE			English	Review						TUMOR MARKERS, BIOLOGICAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ALPHA-FETOPROTEINS; FALSE POSITIVE REACTIONS; FALSE NEGATIVE REACTIONS	PROSTATE-SPECIFIC ANTIGEN; GERM-CELL TUMORS; HUMAN CHORIONIC-GONADOTROPIN; NEURON-SPECIFIC ENOLASE; EPITHELIAL OVARIAN-CANCER; CARCINOMA-ASSOCIATED ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; METASTATIC BREAST-CANCER; NONSEMINOMATOUS TESTICULAR CANCER; GESTATIONAL TROPHOBLASTIC DISEASE	The pursuit of the ideal tumor marker has generated many tests for use in the diagnosis and management of cancer, several of which are now widely available. Tumor markers have five potential uses in patient care: They can be used for screening, for diagnosis, for establishing prognosis, for monitoring treatment, and for detecting relapse. The value of a marker in a given setting depends on two marker-related characteristics-sensitivity and specificity. The value of a marker in a particular malignancy also depends on the effectiveness of therapy for the malignancy. Tumor markers have been used to screen for occult cancer but have proved to be valuable only in selected cancers. As diagnostic tools, tumor markers have limitations: Nearly all markers can be elevated in benign disorders, and most markers are not elevated in the early stages of malignancy. Extreme marker elevation often indicates a poor prognosis and in some malignancies can indicate the need for more aggressive treatment. Tumor markers have their greatest value when used to monitor therapy in patients with widespread cancer. Nearly all markers show some correlation with the clinical course of disease, with marker elevation in any stage declining to normal after a curative intervention. Recurrent disease can be accompanied by increased marker levels, but markers can detect an occult recurrence in only a few diseases, thereby facilitating a second attempt at cure. Although it seems unlikely that an ideal tumor marker will be identified for every malignancy, several workable markers are already available. Increasing our knowledge about the capabilities and limitations of existing markers will enable us to use them judiciously in the treatment of cancer.			BATES, SE (corresponding author), NCI, MED BRANCH, BLDG 10, ROOM 12N226, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Bates, Susan/AFP-9514-2022					AASS N, 1990, RADIOTHER ONCOL, V17, P285, DOI 10.1016/0167-8140(90)90002-E; ALTUG MU, 1987, BRIT J UROL, V59, P458, DOI 10.1111/j.1464-410X.1987.tb04846.x; ANDERSON T, 1979, ANN INTERN MED, V90, P373, DOI 10.7326/0003-4819-90-3-373; ANDRENSANDBERG A, 1989, ACTA CHIR SCAND, P75; ARAI Y, 1990, J UROLOGY, V144, P1415, DOI 10.1016/S0022-5347(17)39757-4; ATACK DB, 1986, AM J OBSTET GYNECOL, V154, P287, DOI 10.1016/0002-9378(86)90657-5; ATTIYEH FF, 1981, CANCER, V47, P2119, DOI 10.1002/1097-0142(19810501)47:9<2119::AID-CNCR2820470903>3.0.CO;2-7; AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E; BAGSHAWE KD, 1976, CANCER, V38, P112, DOI 10.1002/1097-0142(197607)38:1<112::AID-CNCR2820380120>3.0.CO;2-P; BAGSHAWE KD, 1983, CLIN ONCOLOGY, V2, P159; BALLANTYNE GH, 1988, J CLIN GASTROENTEROL, V10, P359; BARAK M, 1990, EUR J CANCER, V26, P577, DOI 10.1016/0277-5379(90)90081-4; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BATES SE, 1987, SEMIN ONCOL, V14, P102; BEARD DB, 1986, AM J MED, V80, P241, DOI 10.1016/0002-9343(86)90015-X; BEATTY JD, 1979, ARCH SURG-CHICAGO, V114, P563; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BENINI L, 1988, PANCREAS, V3, P61, DOI 10.1097/00006676-198802000-00011; BEREK JS, 1986, OBSTET GYNECOL, V67, P685, DOI 10.1097/00006250-198605000-00016; BERETTA E, 1987, CANCER, V60, P2428, DOI 10.1002/1097-0142(19871115)60:10<2428::AID-CNCR2820601013>3.0.CO;2-O; BERGMANN JF, 1987, CANCER-AM CANCER SOC, V59, P213, DOI 10.1002/1097-0142(19870115)59:2<213::AID-CNCR2820590206>3.0.CO;2-I; BIRCH R, 1986, J CLIN ONCOL, V4, P400, DOI 10.1200/JCO.1986.4.3.400; Bjorklund B, 1978, Antibiot Chemother (1971), V22, P16; BOMBARDIERI E, 1989, CANCER, V63, P490, DOI 10.1002/1097-0142(19890201)63:3<490::AID-CNCR2820630317>3.0.CO;2-4; BOSL GJ, 1981, CANCER-AM CANCER SOC, V47, P328, DOI 10.1002/1097-0142(19810115)47:2<328::AID-CNCR2820470220>3.0.CO;2-Z; BOSL GJ, 1991, CANCER, V67, P1299, DOI 10.1002/1097-0142(19910301)67:5<1299::AID-CNCR2820670505>3.0.CO;2-4; BOSL GJ, 1988, SEMIN ONCOL, V15, P339; BOSL GJ, 1988, CANCER RES, V48, P3524; BRIOSCHI PA, 1987, BRIT J OBSTET GYNAEC, V94, P196, DOI 10.1111/j.1471-0528.1987.tb02353.x; BUAMAH PK, 1987, EUR J CANCER CLIN ON, V23, P87, DOI 10.1016/0277-5379(87)90424-X; BUAMAH PK, 1990, J SURG ONCOL, V44, P1, DOI 10.1002/jso.2930440102; BURGHUBER OC, 1990, CANCER, V65, P1386, DOI 10.1002/1097-0142(19900315)65:6<1386::AID-CNCR2820650623>3.0.CO;2-9; CANNEY PA, 1984, BRIT J CANCER, V50, P765, DOI 10.1038/bjc.1984.254; CATALONA WJ, 1979, UROL CLIN N AM, V6, P613; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHEN DS, 1984, GASTROENTEROLOGY, V86, P1404; CHODAK GW, 1990, UROLOGY, V35, P288, DOI 10.1016/0090-4295(90)80147-F; COLOMER R, 1989, BREAST CANCER RES TR, V13, P123, DOI 10.1007/BF01806524; COLOMER R, 1989, CANCER, V64, P1674, DOI 10.1002/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO;2-V; COOPER EH, 1989, BRIT J CANCER, V59, P797, DOI 10.1038/bjc.1989.166; COTTONE M, 1988, HEPATO-GASTROENTEROL, V35, P101; CRUICKSHANK DJ, 1987, BRIT J OBSTET GYNAEC, V94, P692, DOI 10.1111/j.1471-0528.1987.tb03177.x; CULLEN KJ, 1976, AUST NZ J MED, V6, P279, DOI 10.1111/imj.1976.6.4.279; DEJTER SW, 1988, UROLOGY, V32, P288, DOI 10.1016/0090-4295(88)90228-2; DELARUE JC, 1988, BREAST CANCER RES TR, V11, P273, DOI 10.1007/BF01807287; DELFAVERO G, 1986, CANCER, V57, P1576; DENSTMAN F, 1986, CANCER, V58, P2089, DOI 10.1002/1097-0142(19861101)58:9<2089::AID-CNCR2820580921>3.0.CO;2-W; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DUBESHTER B, 1988, GYNECOL ONCOL, V29, P199, DOI 10.1016/0090-8258(88)90214-4; EBARA M, 1986, GASTROENTEROLOGY, V90, P289, DOI 10.1016/0016-5085(86)90923-6; EINHORN LH, 1981, CANCER, V48, P904, DOI 10.1002/1097-0142(19810815)48:4<904::AID-CNCR2820480407>3.0.CO;2-O; EINHORN LH, 1986, EUR J CANCER CLIN ON, V22, P1289, DOI 10.1016/0277-5379(86)90135-5; EINHORN N, 1989, ACTA ONCOL, V28, P655, DOI 10.3109/02841868909092288; EINHORN N, 1986, OBSTET GYNECOL, V67, P414; ERBIL KM, 1985, CANCER, V55, P404, DOI 10.1002/1097-0142(19850115)55:2<404::AID-CNCR2820550219>3.0.CO;2-Q; ERCOLE CJ, 1987, J UROLOGY, V138, P1181, DOI 10.1016/S0022-5347(17)43543-9; ESSCHER T, 1985, THORAX, V40, P85, DOI 10.1136/thx.40.2.85; EVANS JT, 1978, CANCER, V42, P1419, DOI 10.1002/1097-0142(197809)42:3+<1419::AID-CNCR2820420806>3.0.CO;2-L; FERRO MA, 1987, BRIT J UROL, V60, P69, DOI 10.1111/j.1464-410X.1987.tb09137.x; FISKEN J, 1989, DIS MARKERS, V7, P61; FOTI AG, 1977, NEW ENGL J MED, V297, P1357, DOI 10.1056/NEJM197712222972501; FOWLER JE, 1980, J UROLOGY, V124, P365, DOI 10.1016/S0022-5347(17)55451-8; FREEDMAN LS, 1987, LANCET, V2, P294; FUCINI C, 1987, DIS COLON RECTUM, V30, P273, DOI 10.1007/BF02556172; FUJINO N, 1986, JPN J CLIN ONCOL, V16, P335; GADDUCCI A, 1989, J NUCL MED ALLIED S, V33, P32; GANZ PA, 1987, J CLIN ONCOL, V5, P472, DOI 10.1200/JCO.1987.5.3.472; GELDERMAN WAH, 1987, CANCER, V59, P578, DOI 10.1002/1097-0142(19870201)59:3<578::AID-CNCR2820590337>3.0.CO;2-J; GELLER NL, 1989, CANCER-AM CANCER SOC, V63, P440, DOI 10.1002/1097-0142(19890201)63:3<440::AID-CNCR2820630308>3.0.CO;2-7; GERO EJ, 1989, J CLIN LAB ANAL, V3, P360, DOI 10.1002/jcla.1860030609; GIBB I, 1986, CLIN CHEM, V32, P1760; GION M, 1990, TUMORI J, V76, P360, DOI 10.1177/030089169007600411; GION M, 1986, J NUCL MED ALLIED S, V30, P29; GLENN J, 1988, J CLIN ONCOL, V6, P462, DOI 10.1200/JCO.1988.6.3.462; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; GOLDSTEIN DP, 1988, CURR THER HEMATOLONC, V3, P320; GOSLIN R, 1980, ANN SURG, V192, P747, DOI 10.1097/00000658-198012000-00010; GOZDZ SS, 1989, TUMOR BIOL, V10, P103; GREM JL, 1986, J CLIN ONCOL, V4, P41, DOI 10.1200/JCO.1986.4.1.41; GRONOWITZ JS, 1990, CANCER, V66, P722, DOI 10.1002/1097-0142(19900815)66:4<722::AID-CNCR2820660421>3.0.CO;2-J; Gutman AB, 1938, J CLIN INVEST, V17, P473, DOI 10.1172/JCI100974; HAAGENSEN DE, 1978, CANCER, V42, P1512, DOI 10.1002/1097-0142(197809)42:3+<1512::AID-CNCR2820420824>3.0.CO;2-6; HAAPIAINEN RK, 1990, BRIT J UROL, V65, P264, DOI 10.1111/j.1464-410X.1990.tb14723.x; HABUCHI T, 1988, UROL INT, V43, P248, DOI 10.1159/000281348; HAGLUND C, 1986, SCAND J GASTROENTERO, V21, P75, DOI 10.3109/00365528609091898; HAMMOND CB, 1973, AM J OBSTET GYNECOL, V115, P451, DOI 10.1016/0002-9378(73)90389-X; HARDING M, 1990, BRIT J CANCER, V61, P605, DOI 10.1038/bjc.1990.134; HARE WSC, 1988, MED J AUSTRALIA, V149, P402, DOI 10.5694/j.1326-5377.1988.tb120698.x; HARMENBERG U, 1988, CANCER RES, V48, P1985; HAWKINS RE, 1989, BRIT J OBSTET GYNAEC, V96, P1395, DOI 10.1111/j.1471-0528.1989.tb06301.x; HAYES DF, 1986, J CLIN ONCOL, V4, P1542, DOI 10.1200/JCO.1986.4.10.1542; HELLER JE, 1987, J UROLOGY, V137, P1091, DOI 10.1016/S0022-5347(17)44414-4; HEPTNER G, 1989, SCAND J GASTROENTERO, V24, P745, DOI 10.3109/00365528909093116; HERRERA MA, 1976, ANN SURG, V183, P5, DOI 10.1097/00000658-197601000-00002; HEYWARD WL, 1985, JAMA-J AM MED ASSOC, V254, P3052, DOI 10.1001/jama.254.21.3052; HILKENS J, 1986, CANCER RES, V46, P2582; Hogberg T, 1990, ACTA OBSTET GYN SCAN, V69, P423, DOI 10.3109/00016349009013306; HORTIN GL, 1988, J UROLOGY, V139, P762, DOI 10.1016/S0022-5347(17)42627-9; HORWICH A, 1989, EUR J CANCER CLIN ON, V25, P177, DOI 10.1016/0277-5379(89)90005-9; HORWICH A, 1986, CANCER TREAT REP, V70, P1329; HOSKIN P, 1986, J CLIN ONCOL, V4, P1031, DOI 10.1200/JCO.1986.4.7.1031; HOSTETTER RB, 1990, J NATL CANCER I, V82, P380, DOI 10.1093/jnci/82.5.380; HUNTER VJ, 1990, GYNECOL ONCOL, V36, P161, DOI 10.1016/0090-8258(90)90165-H; IAFFAIOLI R V, 1991, International Journal of Biological Markers, V6, P21; JACOBS I, 1989, HUM REPROD, V4, P1; JAGER W, 1988, ARCH GYNECOL OBSTET, V243, P91, DOI 10.1007/BF00932974; JAGER W, 1988, FERTIL STERIL, V50, P223; JALANKO H, 1984, J CLIN PATHOL, V37, P218, DOI 10.1136/jcp.37.2.218; JAVADPOUR N, 1986, J UROLOGY, V135, P879, DOI 10.1016/S0022-5347(17)45881-2; JESSUP JM, 1988, CANCER RES, V48, P1689; JORGENSEN LGM, 1989, EUR J CANCER CLIN ON, V25, P123, DOI 10.1016/0277-5379(89)90059-X; KAYSER K, 1988, PATHOL RES PRACT, V183, P412, DOI 10.1016/S0344-0338(88)80087-6; KERIN MJ, 1989, BRIT J SURG, V76, P838, DOI 10.1002/bjs.1800760826; KHOO SK, 1987, EUR J CANCER CLIN ON, V23, P765, DOI 10.1016/0277-5379(87)90276-8; KILLIAN CS, 1985, CANCER RES, V45, P886; KLEPP O, 1990, J CLIN ONCOL, V8, P509, DOI 10.1200/JCO.1990.8.3.509; KOBAYASHI K, 1985, HEPATOLOGY, V5, P1100, DOI 10.1002/hep.1840050607; KOPROWSKI H, 1981, SCIENCE, V212, P53, DOI 10.1126/science.6163212; KREBS HB, 1986, OBSTET GYNECOL, V67, P473; KRISCHKE W, 1988, CANCER, V62, P1348, DOI 10.1002/1097-0142(19881001)62:7<1348::AID-CNCR2820620718>3.0.CO;2-#; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; KURIYAMA M, 1980, CANCER RES, V40, P4568; KURMAN RJ, 1977, CANCER-AM CANCER SOC, V40, P2136, DOI 10.1002/1097-0142(197711)40:5<2136::AID-CNCR2820400524>3.0.CO;2-D; LABERGE F, 1987, CANCER, V59, P2047, DOI 10.1002/1097-0142(19870615)59:12<2047::AID-CNCR2820591214>3.0.CO;2-9; LAMBERT J, 1987, BRIT J OBSTET GYNAEC, V94, P193, DOI 10.1111/j.1471-0528.1987.tb02352.x; Lange P H, 1977, Urol Clin North Am, V4, P393; LANGE PH, 1980, J UROLOGY, V124, P472, DOI 10.1016/S0022-5347(17)55500-7; LANGE PH, 1990, J UROLOGY, V144, P927, DOI 10.1016/S0022-5347(17)39624-6; LANGE PH, 1989, J UROLOGY, V141, P873; LAURENCE DJ, 1972, BMJ-BRIT MED J, V3, P605, DOI 10.1136/bmj.3.5827.605; LAVIN PT, 1987, OBSTET GYNECOL, V69, P223; LEITENBERGER A, 1990, EUR UROL, V17, P12; LEO ME, 1991, J UROLOGY, V145, P802, DOI 10.1016/S0022-5347(17)38456-2; LI MC, 1956, P SOC EXP BIOL MED, V93, P361; LIAW YF, 1986, GASTROENTEROLOGY, V90, P263, DOI 10.1016/0016-5085(86)90919-4; LIAW YF, 1986, LIVER, V6, P133; LIGHTNER DJ, 1990, J UROLOGY, V144, P921, DOI 10.1016/S0022-5347(17)39623-4; LIPTON A, 1979, CANCER-AM CANCER SOC, V43, P1766, DOI 10.1002/1097-0142(197905)43:5<1766::AID-CNCR2820430528>3.0.CO;2-Q; LOEHRER PJ, 1988, J NATL CANCER I, V80, P1373, DOI 10.1093/jnci/80.17.1373; LOKICH JJ, 1978, ANN INTERN MED, V89, P902, DOI 10.7326/0003-4819-89-6-902; LOMBARDI C, 1990, CHEST, V97, P639, DOI 10.1378/chest.97.3.639; LOPRINZI CL, 1986, ARCH INTERN MED, V146, P2125, DOI 10.1001/archinte.146.11.2125; LOPRINZI CL, 1986, J CLIN ONCOL, V4, P46, DOI 10.1200/JCO.1986.4.1.46; MANNINI D, 1988, UROL RES, V16, P9; MARECHAL F, 1990, ANTICANCER RES, V10, P977; MARTIN EW, 1985, ANN SURG, V202, P310, DOI 10.1097/00000658-198509000-00006; MASSON P, 1990, BRIT J CANCER, V62, P118, DOI 10.1038/bjc.1990.241; MINTON JP, 1985, CANCER, V55, P1284, DOI 10.1002/1097-0142(19850315)55:6<1284::AID-CNCR2820550622>3.0.CO;2-B; MOERTEL CG, 1986, CANCER, V58, P603, DOI 10.1002/1097-0142(19860801)58:3<603::AID-CNCR2820580302>3.0.CO;2-K; MOGENSEN O, 1990, GYNECOL ONCOL, V37, P44, DOI 10.1016/0090-8258(90)90305-5; MOHLER JL, 1987, UROLOGY, V30, P252, DOI 10.1016/0090-4295(87)90247-0; MOLONEY MD, 1989, OBSTET GYNECOL, V73, P767; MORGENSEN O, 1989, EUR J CANCER CLIN ON, V25, P1187; MORROW CP, 1977, AM J OBSTET GYNECOL, V128, P424, DOI 10.1016/0002-9378(77)90562-2; MYERS RE, 1978, CANCER, V42, P1520, DOI 10.1002/1097-0142(197809)42:3+<1520::AID-CNCR2820420825>3.0.CO;2-8; NEWLANDS ES, 1987, MED LAB SCI, V44, P361; NILOFF JM, 1986, AM J OBSTET GYNECOL, V155, P56, DOI 10.1016/0002-9378(86)90077-3; NISSENKORN I, 1982, J UROLOGY, V127, P1122, DOI 10.1016/S0022-5347(17)54260-3; NOU E, 1990, CANCER, V65, P1380, DOI 10.1002/1097-0142(19900315)65:6<1380::AID-CNCR2820650622>3.0.CO;2-U; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; Olt G, 1990, Obstet Gynecol Surv, V45, P570, DOI 10.1097/00006254-199009000-00002; PAGANUZZI M, 1988, CANCER, V61, P2100, DOI 10.1002/1097-0142(19880515)61:10<2100::AID-CNCR2820611028>3.0.CO;2-Z; PANZA N, 1988, CANCER, V61, P76, DOI 10.1002/1097-0142(19880101)61:1<76::AID-CNCR2820610113>3.0.CO;2-G; PATEL PS, 1990, CANCER LETT, V51, P203, DOI 10.1016/0304-3835(90)90103-5; PECKHAM MJ, 1985, LANCET, V1, P8; PERSIJN JP, 1981, J CLIN CHEM CLIN BIO, V19, P1117; PERSSON BE, 1988, EUR J CANCER CLIN ON, V24, P241, DOI 10.1016/0277-5379(88)90260-X; PIANTINO P, 1986, AM J GASTROENTEROL, V81, P436; PICOZZI VJ, 1984, ANN INTERN MED, V100, P183, DOI 10.7326/0003-4819-100-2-183; PINTO MM, 1987, CANCER, V59, P218, DOI 10.1002/1097-0142(19870115)59:2<218::AID-CNCR2820590207>3.0.CO;2-0; PIZZOCARO G, 1986, J CLIN ONCOL, V4, P35, DOI 10.1200/JCO.1986.4.1.35; PLESKOW DK, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-704; PODCZASKI E, 1989, GYNECOL ONCOL, V33, P193, DOI 10.1016/0090-8258(89)90550-7; PONSANICET DMF, 1987, BRIT J CANCER, V55, P567, DOI 10.1038/bjc.1987.115; PRICE P, 1990, EUR J CANCER, V26, P453, DOI 10.1016/0277-5379(90)90015-L; PUTZKI H, 1988, J SURG ONCOL, V37, P133, DOI 10.1002/jso.2930370214; RASMUSON T, 1987, ACTA ONCOL, V26, P261, DOI 10.3109/02841868709089972; ROBLES JM, 1988, EUR UROL, V14, P360; RUBIN SC, 1989, AM J OBSTET GYNECOL, V160, P667, DOI 10.1016/S0002-9378(89)80054-7; RUSTIN GJS, 1989, J CLIN ONCOL, V7, P1667, DOI 10.1200/JCO.1989.7.11.1667; RUSTIN GJS, 1989, J CLIN ONCOL, V7, P900, DOI 10.1200/JCO.1989.7.7.900; SACKS NPM, 1987, BRIT J CANCER, V56, P820, DOI 10.1038/bjc.1987.297; SAFI F, 1990, B CANCER, V77, P83; SAID JW, 1985, HUM PATHOL, V16, P236, DOI 10.1016/S0046-8177(85)80008-3; SALLER B, 1990, CLIN CHEM, V36, P234; SARDI A, 1990, AM SURGEON, V56, P255; SCAMBIA G, 1990, BRIT J CANCER, V62, P147, DOI 10.1038/bjc.1990.248; SCHWARTZ PE, 1989, OBSTET GYNECOL, V73, P339; SECKL MJ, 1990, BRIT J CANCER, V61, P916, DOI 10.1038/bjc.1990.205; SENER SF, 1989, CA-CANCER J CLIN, V39, P50, DOI 10.3322/canjclin.39.1.50; SHINAGAWA T, 1984, GASTROENTEROLOGY, V86, P495; SHINKAI T, 1986, CANCER, V57, P1318, DOI 10.1002/1097-0142(19860401)57:7<1318::AID-CNCR2820570711>3.0.CO;2-2; SILVER HKB, 1991, CANCER RES, V51, P1904; SOPER JT, 1990, OBSTET GYNECOL, V75, P249; SOPER JT, 1988, OBSTET GYNECOL, V71, P338; SOX HC, 1986, ANN INTERN MED, V104, P60, DOI 10.7326/0003-4819-104-1-60; STACKER SA, 1985, J NATL CANCER I, V75, P801, DOI 10.1093/jnci/75.5.801; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1084, DOI 10.1016/S0022-5347(17)41176-1; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STAMEY TA, 1989, J UROLOGY, V141, P1070; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; STEELE G, 1980, AM J SURG, V139, P544, DOI 10.1016/0002-9610(80)90335-9; STEINBERG W, 1990, AM J GASTROENTEROL, V85, P350; STEINBERG WM, 1986, GASTROENTEROLOGY, V90, P343, DOI 10.1016/0016-5085(86)90930-3; STOTER G, 1987, CANCER RES, V47, P2714; SUGARBAKER PH, 1976, CANCER, V38, P2310, DOI 10.1002/1097-0142(197612)38:6<2310::AID-CNCR2820380618>3.0.CO;2-L; SURWIT EA, 1980, OBSTET GYNECOL, V55, P565; TAKASHIMA T, 1982, RADIOLOGY, V145, P635, DOI 10.1148/radiology.145.3.6183708; TALBOT RW, 1989, SURG GYNECOL OBSTET, V168, P407; TANG ZY, 1989, CANCER, V64, P536, DOI 10.1002/1097-0142(19890715)64:2<536::AID-CNCR2820640230>3.0.CO;2-X; TANG ZY, 1985, SUBCLINICAL HEPATOCE, P12; TAPIA FJ, 1981, LANCET, V1, P808; TATSUTA M, 1986, ONCOLOGY, V43, P306, DOI 10.1159/000226388; TAYLOR RE, 1986, EUR J CANCER CLIN ON, V22, P647, DOI 10.1016/0277-5379(86)90161-6; TEELING M, 1989, IRISH J MED SCI, V158, P59, DOI 10.1007/BF02942143; THOMPSON PI, 1988, J CLIN ONCOL, V6, P1597, DOI 10.1200/JCO.1988.6.10.1597; THOR A, 1986, CANCER RES, V46, P3118; TJANDRA JJ, 1988, EUR J CANCER CLIN ON, V24, P1633, DOI 10.1016/0277-5379(88)90056-9; TONDINI C, 1988, CANCER RES, V48, P4107; VANDIEIJENVISSER MP, 1988, CLIN CHIM ACTA, V174, P131; VANZANDWIJK N, 1990, EUR J CANCER, V26, P373, DOI 10.1016/0277-5379(90)90236-M; VASILEV SA, 1988, OBSTET GYNECOL, V71, P751; VERAZIN G, 1990, DIS COLON RECTUM, V33, P139, DOI 10.1007/BF02055544; VERGOTE IB, 1987, AM J OBSTET GYNECOL, V157, P88, DOI 10.1016/S0002-9378(87)80352-6; VOGELZANG NJ, 1982, CANCER RES, V42, P4855; VONEYBEN FE, 1988, J UROLOGY, V140, P986, DOI 10.1016/S0022-5347(17)41906-9; VRBA R, 1976, IMMUNOCHEMISTRY, V13, P87, DOI 10.1016/0019-2791(76)90301-3; WANEBO HJ, 1978, NEW ENGL J MED, V299, P448, DOI 10.1056/NEJM197808312990904; WARNES TW, 1987, BAILLIERE CLIN GASTR, V1, P63, DOI 10.1016/0950-3528(87)90034-0; WIELDERS JPM, 1990, J CLIN CHEM CLIN BIO, V28, P225; WILKING N, 1986, SURG GYNECOL OBSTET, V162, P465; WILLEMSE PHB, 1981, ONCODEV BIOL MED, V2, P129; WILLIAMS MP, 1987, RADIOLOGY, V164, P671, DOI 10.1148/radiology.164.3.2441430; WINKLE D C, 1988, Australian and New Zealand Journal of Surgery, V58, P737, DOI 10.1111/j.1445-2197.1988.tb01106.x; WISHNOW KI, 1989, UROLOGY, V34, P339, DOI 10.1016/0090-4295(89)90436-6; WOLMARK N, 1984, ANN SURG, V199, P375, DOI 10.1097/00000658-198404000-00001; WU JC, 1988, LIVER, V8, P100; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507; ZURAWSKI VR, 1990, GYNECOL ONCOL, V36, P299, DOI 10.1016/0090-8258(90)90130-D; ZURAWSKI VR, 1987, OBSTET GYNECOL, V69, P606	242	201	206	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					623	638		10.7326/0003-4819-115-8-623	http://dx.doi.org/10.7326/0003-4819-115-8-623			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1716430				2022-12-28	WOS:A1991GJ90200008
J	TREZISE, AEO; BUCHWALD, M				TREZISE, AEO; BUCHWALD, M			INVIVO CELL-SPECIFIC EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article							IDENTIFICATION; GENE	CYSTIC fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 1-3. The principal manifestations of CF include increased concentration of Cl- in exocrine gland secretions 4,5, pancreatic insufficiency, chronic lung disease, intestinal blockage and malabsorption of fat 5,6, and male and female infertility 7. Insight into the function of CFTR can be gained by correlating its cell-specific expression with the physiology of those cells and with CF pathology. Determination of CFTR messenger RNA in rat tissues by in situ hybridization shows that it is specifically expressed in the ductal cells of the pancreas and the salivary glands. In the intestine, decreasing gradients of expression of the CFTR gene are observed on both the crypt-villus and the proximal-distal axes. This expression is consistent with CFTR being responsible for bidirectional Cl- transport, secretion in the intestinal crypts 8 and reabsorption in the salivary gland ducts 4, and suggests that in these tissues CFTR functions as a regulated Cl- channel. In the lung, a broad band of hybridization includes the mucosa and submucosa of the bronchi and bronchioles. In the testis, CFTR expression is regulated during the cycle of the seminiferous epithelium. Post-meiotic expression is maximal in the round spermatids of stages VII and VIII, suggesting that CFTR plays a critical role in spermatogenesis and that deficiency of this function contributes to CF male infertility.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BURGMAN SM, 1984, CYSTIC FIBROSIS, P323; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; QUINTON PM, 1990, FASEB J, V4, P1709; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Taussig LM, 1984, CYSTIC FIBROSIS, P338; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054	13	322	329	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					434	437		10.1038/353434a0	http://dx.doi.org/10.1038/353434a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1716739				2022-12-28	WOS:A1991GH60600058
J	COEN, ES; MEYEROWITZ, EM				COEN, ES; MEYEROWITZ, EM			THE WAR OF THE WHORLS - GENETIC INTERACTIONS CONTROLLING FLOWER DEVELOPMENT	NATURE			English	Review							ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; ARABIDOPSIS-THALIANA; FLORAL DEVELOPMENT; MORPHOGENESIS	The analysis of mutations affecting flower structure has led to the identification of some of the genes that direct flower development. Cloning of these genes has allowed the formulation of molecular models of how floral meristem and organ identity may be specified, and has shown that the distantly related flowering plants Arabidopsis thaliana and Antirrhinum majus use homologous mechanisms in floral pattern formation.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; JOHN INNES INST, DEPT GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND	California Institute of Technology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Meyerowitz, Elliot M/A-7118-2009					BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, PLANT MOL CELL BIOL, V5, P57; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT S1, V112, P157; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pruitt RE, 1987, GENETIC REGULATION D, P327; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; Stubbe H, 1966, GENETIK ZYTOLOGIE AN; Weberling F, 1989, MORPHOLOGY FLOWERS I; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	27	2124	2497	28	480	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					31	37		10.1038/353031a0	http://dx.doi.org/10.1038/353031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1715520				2022-12-28	WOS:A1991GD80500048
J	GARRAWAY, WM; COLLINS, GN; LEE, RJ				GARRAWAY, WM; COLLINS, GN; LEE, RJ			HIGH PREVALENCE OF BENIGN PROSTATIC HYPERTROPHY IN THE COMMUNITY	LANCET			English	Article							ELDERLY MALES; UROFLOWMETRY; HYPERPLASIA; SIZE	There is a strong suspicion among urologists that the prevalence of benign prostatic hyperplasia is higher than has been reported in clinical retrospective and necropsy studies. To find out the prevalence in one community all men aged 40-79 years registered with a group general practice were invited to complete a urinary symptom questionnaire and to undergo uroflowmetry. 705 men (77% of those eligible) participated. 214 men (84% of those invited) with signs and symptoms of prostatic dysfunction subsequently underwent transrectal ultrasonography (TRUS) for assessment of the volume (and by inference weight) of their prostates. The prevalence rate of benign prostatic hypertrophy (BPH), defined as enlargement of the prostate gland of equivalent weight > 20 g in the presence of symptoms of urinary dysfunction and/or a urinary peak flow rate < 15 ml/s and without evidence of malignancy, was 253 (95% Cl 221-285) per 1000 men in the community, rising from 138 per 1000 men aged 40-49 years to 430 per 1000 men aged 60-69 years. Thus apparently well men have a much higher frequency of BPH than was previously thought to be the case.	UNIV EDINBURGH,DEPT PUBL HLTH SCI,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; STIRLING ROYAL INFIRM,DEPT UROL,STIRLING,SCOTLAND	University of Edinburgh								ABUYOUSEF MM, 1982, J CLIN ULTRASOUND, V10, P275, DOI 10.1002/jcu.1870100606; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78; GRAVES EJ, 1989, DETAILED DIAGNOSIS P, V13, P295; GRIFFITHS CJ, 1983, BRIT J UROL, V55, P21, DOI 10.1111/j.1464-410X.1983.tb07072.x; JENSEN KME, 1985, UROL RES, V13, P237, DOI 10.1007/BF00261583; JENSEN KME, 1986, SCAND J UROL NEPHROL, V20, P93; MEYHOFF HH, 1978, SCAND J UROL NEPHROL, V12, P219, DOI 10.3109/00365597809179720; ROWAN D, 1977, BRIT J UROL, V49, P285, DOI 10.1111/j.1464-410X.1977.tb04138.x; WATANABE H, 1986, ULTRASOUND MED BIOL, V12, P567, DOI 10.1016/0301-5629(86)90100-6	11	643	676	1	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					469	471		10.1016/0140-6736(91)90543-X	http://dx.doi.org/10.1016/0140-6736(91)90543-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1714529				2022-12-28	WOS:A1991GC15300003
J	RIVIERE, GR; WAGONER, MA; BAKERZANDER, SA; WEISZ, KS; ADAMS, DF; SIMONSON, L; LUKEHART, SA				RIVIERE, GR; WAGONER, MA; BAKERZANDER, SA; WEISZ, KS; ADAMS, DF; SIMONSON, L; LUKEHART, SA			IDENTIFICATION OF SPIROCHETES RELATED TO TREPONEMA-PALLIDUM IN NECROTIZING ULCERATIVE GINGIVITIS AND CHRONIC PERIODONTITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHAGEDENIS BIOTYPE REITER; MONOCLONAL-ANTIBODY; NICHOLS; SERUM; POLYPEPTIDES; DIAGNOSIS; PERTENUE; PROTEINS; DISEASE	Background. Spirochetes are commonly associated with periodontal disease, but it is not known whether these treponemes are pathogenic or merely opportunistic. We sought to determine whether spirochetes present in periodontal disease share antigens thought to be unique to spirochetes that are known pathogens. Methods. We examined dental plaque from 24 healthy subjects, from ulcerative sites in 17 patients with ulcerative gingivitis, and from areas of involvement in 19 patients with chronic periodontitis, using an immunocytochemical technique with monoclonal antibodies against pathogen-specific determinants on 47-kd and 37-kd molecules from Treponema pallidum subspecies pallidum. Serum was tested against T pallidum by immunoblotting and by serologic assays for syphilis. Results. Spirochetes with a pathogen-specific epitope on a 47-kd molecule were not found in plaque samples from any of the 24 healthy subjects, but they were identified in plaque samples from 11 of 17 patients with ulcerative gingivitis (P < 0.001) and from 10 of 19 patients with periodontitis (P < 0.01). Monoclonal antibodies directed against a 37-kd molecule reacted with spirochetes in plaque samples from 1 of 14 controls, from all 11 patients with gingivitis from whom samples could be obtained (P < 0.001), and from 14 of 19 patients with periodontitis (P < 0.001). Five of 18 normal subjects had IgG against 47-kd and 37-kd molecules, but none had IgG against 14-kd or 12-kd molecules from T. pallidum subspecies pallidum. Among 19 patients with ulcerative gingivitis, IgG was identified against 47-kd molecules in 15, against 37-kd molecules in 12, against 14-kd molecules in 4, and against 12-kd molecules in 15. Conclusions. The spirochetes found in dental plaque from patients with ulcerative gingivitis or chronic periodontitis have antigens that are thought to be unique to pathogenic treponemes. This close antigenic relation suggests that T. pallidum or a closely related organism may be involved in the pathogenesis of periodontal disease.	USN,DENT RES INST,GREAT LAKES,IL 60088; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; OREGON HLTH SCI UNIV,SCH DENT,DEPT PERIODONTOL,PORTLAND,OR 97201	United States Department of Defense; United States Navy; University of Washington; University of Washington Seattle; Oregon Health & Science University	RIVIERE, GR (corresponding author), OREGON HLTH SCI UNIV,SCH DENT,DEPT PEDIAT DENT,611 SW CAMPUS DR,PORTLAND,OR 97201, USA.				NIAID NIH HHS [AI-18988] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018988] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKERZANDER SA, 1983, INFECT IMMUN, V42, P634, DOI 10.1128/IAI.42.2.634-638.1983; BAKERZANDER SA, 1985, J INFECT DIS, V15, P264; BARRON SL, 1991, ORAL MICROBIOL IMMUN, V6, P97, DOI 10.1111/j.1399-302X.1991.tb00458.x; BLANCO DR, 1986, J IMMUNOL, V137, P2031; COURTOIS GJ, 1983, J PERIODONTOL, V54, P671, DOI 10.1902/jop.1983.54.11.671; HANFF PA, 1982, J IMMUNOL, V129, P1287; HOOK EW, 1985, J CLIN MICROBIOL, V22, P241, DOI 10.1128/JCM.22.2.241-244.1985; ISAACS RD, 1989, INFECT IMMUN, V57, P3403, DOI 10.1128/IAI.57.11.3403-3411.1989; JACOBS PA, 1982, J MOL CATAL, V17, P145, DOI 10.1016/0304-5102(82)85026-8; JOHNSON BD, 1986, J PERIODONTOL, V57, P141, DOI 10.1902/jop.1986.57.3.141; JONES SA, 1984, J EXP MED, V160, P1404, DOI 10.1084/jem.160.5.1404; KORNMAN KS, 1987, J PERIODONTAL RES, V22, P192, DOI 10.1111/j.1600-0765.1987.tb01566.x; LAI CH, 1986, J CLIN PERIODONTOL, V13, P752, DOI 10.1111/j.1600-051X.1986.tb00878.x; LINDHE J, 1980, J PERIODONTOL, V51, P264, DOI 10.1902/jop.1980.51.5.264; LISTGARTEN M. A., 1965, ARCH ORAL BIOL, V10, P127, DOI 10.1016/0003-9969(65)90064-6; LISTGARTEN MA, 1965, J PERIODONTOL, V36, P328, DOI 10.1902/jop.1965.36.4.328; LISTGARTEN MA, 1976, J PERIODONTOL, V47, P1, DOI 10.1902/jop.1976.47.1.1; LISTGARTEN MA, 1967, J PERIODONTOL, V38, P379, DOI 10.1902/jop.1967.38.5.379; Loesche W J, 1988, Adv Dent Res, V2, P275; LOESCHE WJ, 1981, HOST PARASITE INTERA, P62; LUKEHART SA, 1985, J IMMUNOL, V134, P585; RADOLF JD, 1988, INFECT IMMUN, V56, P1825, DOI 10.1128/IAI.56.7.1825-1828.1988; RADOLF JD, 1986, INFECT IMMUN, V54, P626, DOI 10.1128/IAI.54.3.626-634.1986; TEW JG, 1985, J PERIODONTAL RES, V20, P580, DOI 10.1111/j.1600-0765.1985.tb00842.x; THORNBURG RW, 1983, INFECT IMMUN, V42, P623, DOI 10.1128/IAI.42.2.623-627.1983; Umemoto T, 1988, Adv Dent Res, V2, P292; 1969, MANUAL TESTS SYPHILI, P15	27	66	68	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					539	543		10.1056/NEJM199108223250803	http://dx.doi.org/10.1056/NEJM199108223250803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1713299	Bronze			2022-12-28	WOS:A1991GB44700003
J	BREDT, DS; HWANG, PM; GLATT, CE; LOWENSTEIN, C; REED, RR; SNYDER, SH				BREDT, DS; HWANG, PM; GLATT, CE; LOWENSTEIN, C; REED, RR; SNYDER, SH			CLONED AND EXPRESSED NITRIC-OXIDE SYNTHASE STRUCTURALLY RESEMBLES CYTOCHROME-P-450 REDUCTASE	NATURE			English	Article							ADENINE-DINUCLEOTIDE-PHOSPHATE; RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; NADPH-CYTOCHROME-P450 REDUCTASE; MACROPHAGE OXIDATION; NUCLEOTIDE-SEQUENCE; GUANYLATE-CYCLASE; BRAIN; NEURONS; CELLS	Nitric oxide is a messenger molecule, mediating the effect of endothelium-derived relaxing factor in blood vessels and the cytotoxic actions of macrophages, and playing a part in neuronal communication in the brain. Cloning of a complementary DNA for brain nitric oxide synthase reveals recognition sites for NADPH, FAD, flavin mononucleotide and calmodulin as well as phosphorylation sites, indicating that the synthase is regulated by many different factors. The only known mammalian enzyme with close homology is cytochrome P-450 reductase.	JOHNS HOPKINS MED INST,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University				Lowenstein, Charles/0000-0003-0485-7514				ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DAWSON TM, IN PRESS P NATN ACAD; DAWSON VL, IN PRESS P NATN ACAD; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HAGLUND L, 1984, NATURE, V307, P259, DOI 10.1038/307259a0; HEIMS LF, 1990, BIOCHEM BIOPH RES CO, V168, P809; HIBBS JB, 1987, J IMMUNOL, V138, P550; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KAPITULNIK J, 1987, NEUROSCIENCE, V20, P829, DOI 10.1016/0306-4522(87)90243-0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LU AYH, 1969, J BIOL CHEM, V244, P3714; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MIZUKAWA K, 1989, J COMP NEUROL, V279, P281, DOI 10.1002/cne.902790210; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NAKANE M, 1983, BRAIN RES, V273, P9, DOI 10.1016/0006-8993(83)91088-0; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THOMAS E., 1964, ACTA NEUROPATHOL, V3, P238; VEMURA Y, 1990, ANN NEUROL, V27, P620; WARNER M, 1988, J NEUROCHEM, V50, P1057, DOI 10.1111/j.1471-4159.1988.tb10573.x; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; YUI Y, 1991, J BIOL CHEM, V266, P3369	48	2311	2376	0	81	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					714	718		10.1038/351714a0	http://dx.doi.org/10.1038/351714a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1712077				2022-12-28	WOS:A1991FU20100053
J	VERDOORN, TA; BURNASHEV, N; MONYER, H; SEEBURG, PH; SAKMANN, B				VERDOORN, TA; BURNASHEV, N; MONYER, H; SEEBURG, PH; SAKMANN, B			STRUCTURAL DETERMINANTS OF ION FLOW THROUGH RECOMBINANT GLUTAMATE RECEPTOR CHANNELS	SCIENCE			English	Article								Functional glutamate receptors (GluRs) were transiently expressed in cultured mammalian cells from cloned complementary DNAs encoding GluR-A, -B, -C, or -D polypeptides. The steady-state current-voltage (I-V) relations of glutamate- and kainate-induced currents through homomeric channels fell into two classes: channels composed of either the GluR-A, -C, and -D subunits showed doubly rectifying I-V curves, and channels composed of the GluR-B subunits displayed simple outward rectification. The presence of GluR-B subunits in heteromeric GluRs determined the I-V behavior of the resulting channels. Site-directed mutagenesis identified a single amino acid difference (glutamine to arginine) in the putative transmembrane segment TM2 responsible for subunit-specific I-V relationships. The properties of heteromeric wild-type and mutant GluRs revealed that the dominance of GluR-B is due to the arginine residue in the TM2 region.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, W-6900 HEIDELBERG 1, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749				ADAMS PR, 1975, BRIT J PHARMACOL, V53, P308, DOI 10.1111/j.1476-5381.1975.tb07364.x; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONAS P, IN PRESS J PHYSL LON; JONAS P, UNPUB; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MONGHAN DT, 1989, ANN REV PHARM TOXICO, V21, P165; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NEHER E, 1975, P NATL ACAD SCI USA, V72, P2140, DOI 10.1073/pnas.72.6.2140; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHERIDAN RE, 1975, P NATL ACAD SCI USA, V72, P3496, DOI 10.1073/pnas.72.9.3496; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012	23	718	729	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1715	1718		10.1126/science.1710829	http://dx.doi.org/10.1126/science.1710829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1710829				2022-12-28	WOS:A1991FT11400049
J	BARTOLOMEI, MS; ZEMEL, S; TILGHMAN, SM				BARTOLOMEI, MS; ZEMEL, S; TILGHMAN, SM			PARENTAL IMPRINTING OF THE MOUSE H19 GENE	NATURE			English	Article							EXPRESSION; EVOLUTION; RNA	THE mouse H19 gene encodes one of the most abundant RNAs in the developing mouse embryo 1. It is expressed at the blastocyst stage of development, and accumulates to high levels in tissues of endodermal and mesodermal origin (H. Kim, unpublished result). After birth the gene is repressed in all tissues except skeletal muscle. It lacks a common open reading frame in the 2.5-kilobase RNA, but has considerable nucleotide sequence similarity between the genes of rodents and humans 2,3. Expression of the gene in transgenic mice results in late prenatal lethality, suggesting that the dosage of its gene product is strictly controlled 4. The H19 gene maps to the distal segment of mouse chromosome 7, in a region that is parentally imprinted 5, a process by which genes are differentially expressed on the maternal and paternal chromosomes. We have now used an RNase protection assay that can distinguish between H19 alleles in four subspecies of Mus, to demonstrate that the H19 gene is parentally imprinted, with the active copy derived from the mother. This assay will be of general use in assaying allele-specific gene expression.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	BARTOLOMEI, MS (corresponding author), PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544, USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BONHOMME F, 1984, BIOCHEM GENET, V22, P275, DOI 10.1007/BF00484229; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, IN PRESS GENES DEV; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVISSON MT, 1988, MOUSE NEWS LETT, V81, P12; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HAMMER MF, 1989, P NATL ACAD SCI USA, V86, P3261, DOI 10.1073/pnas.86.9.3261; LYON MF, 1988, AM J HUM GENET, V42, P8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SEARLE AG, 1985, ANEUPLOIDY ETIOLOGY, P363; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	23	971	999	1	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					153	155		10.1038/351153a0	http://dx.doi.org/10.1038/351153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709450				2022-12-28	WOS:A1991FL03500053
J	VALLANCE, P; MONCADA, S				VALLANCE, P; MONCADA, S			HYPERDYNAMIC CIRCULATION IN CIRRHOSIS - A ROLE FOR NITRIC-OXIDE	LANCET			English	Article							L-ARGININE; ENDOTOXIN; INVIVO; BLOOD	Hypotension, low systemic vascular resistance, and a reduced sensitivity to vasoconstrictors are features of cirrhosis. These cardiovascular changes might be the result of increased synthesis of a vasodilator. Nitric oxide (NO), a potent vasodilator, is synthesised in and released from peripheral blood-vessels in man. Studies in animals indicate that bacterial endotoxin and cytokines induce NO synthase expression in vessel walls, with sustained NO release and consequent hypotension. Endotoxaemia is a common feature of cirrhosis; persistent induction of NO synthase may account for the associated haemodynamic changes.	WELLCOME RES LABS, LANGLEY COURT, BECKENHAM BR3 3BS, KENT, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories								AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; BENDTSEN F, 1990, J HEPATOL, V10, P198, DOI 10.1016/0168-8278(90)90052-S; BOSCH J, 1988, KIDNEY LIVER DISEASE, P286; BOURGOIGNIE JJ, 1988, KIDNEY LIVER DISEASE, P486; BURTON GA, 1990, BRIT J PHARMACOL, V99, P364, DOI 10.1111/j.1476-5381.1990.tb14709.x; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; FONG YM, 1990, J CLIN INVEST, V85, P1896, DOI 10.1172/JCI114651; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LINTRUP J, 1966, ACTA MED SCAND, V179, P13; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; MIYASE S, 1990, Gastroenterologia Japonica, V25, P356; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADLOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; SCHRIER RW, 1988, KIDNEY LIVER DISEASE, P265; SHEARMAN DJC, 1989, DISEASES GASTROINTES, P795; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TOLINS JP, 1990, AM J PHYSIOL, V258, pH655, DOI 10.1152/ajpheart.1990.258.3.H655; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1989, LANCET, V2, P997; WYKE RJ, 1989, BAILLIERE CLIN GASTR, V3, P187, DOI 10.1016/0950-3528(89)90052-3; YOMOTA M, 1989, J BIOCHEM BIOPH METH, V18, P97	27	580	603	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	1991	337	8744					776	778		10.1016/0140-6736(91)91384-7	http://dx.doi.org/10.1016/0140-6736(91)91384-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1706450				2022-12-28	WOS:A1991FD88400015
J	GOODALL, J				GOODALL, J			HELPING A CHILD TO UNDERSTAND HER OWN TESTICULAR FEMINIZATION	LANCET			English	Editorial Material								Children do not think as adults do. They would therefore be less worried than adults are about a diagnosis with serious or ominous implications, yet they are commonly left uninformed until someone judges that they are old enough to understand. For most, this means delivery of painful information during the very vulnerable teenage years. A better approach is to unfold the trust stage by stage, matching simple statements to the child's conceptual growth until the personal implication are finally realised as part of a maturing process. Use of this approach for a child with testicular feminisation is described.	N STAFFORDSHIRE HOSP,DEPT PAEDIAT,STOKE ON TRENT,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								BEADLE M, 1972, CHILDS MIND; BRANDON J, 1977, BRIT J SOC WORK, V7, P335; EISER C, 1983, CHILD CARE HLTH DEV, V9, P233, DOI 10.1111/j.1365-2214.1983.tb00320.x; GOODALL J, 1987, J ROY SOC HEALTH, V107, P224, DOI 10.1177/146642408710700606; Goodenough F. L., 1963, GOODENOUGH HARRIS DR; SPINETTA J, 1980, PSYCHOL ASPECTS CHIL	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					33	35		10.1016/0140-6736(91)93344-9	http://dx.doi.org/10.1016/0140-6736(91)93344-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EQ604	1702173				2022-12-28	WOS:A1991EQ60400018
J	MERLUZZI, VJ; HARGRAVE, KD; LABADIA, M; GROZINGER, K; SKOOG, M; WU, JC; SHIH, CK; ECKNER, K; HATTOX, S; ADAMS, J; ROSEHTHAL, AS; FAANES, R; ECKNER, RJ; KOUP, RA; SULLIVAN, JL				MERLUZZI, VJ; HARGRAVE, KD; LABADIA, M; GROZINGER, K; SKOOG, M; WU, JC; SHIH, CK; ECKNER, K; HATTOX, S; ADAMS, J; ROSEHTHAL, AS; FAANES, R; ECKNER, RJ; KOUP, RA; SULLIVAN, JL			INHIBITION OF HIV-1 REPLICATION BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR	SCIENCE			English	Article									UNIV MASSACHUSETTS,SCH MED,DEPT PEDIAT & MED,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	MERLUZZI, VJ (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877, USA.				NHLBI NIH HHS [HB 67027, HL 42257] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042257] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENVENISTE RE, 1975, SCIENCE, V190, P886, DOI 10.1126/science.52892; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HO DD, 1989, NEW ENGL J MED, V321, P1622; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MERLUZZI VJ, UNPUB; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; Moore M., COMMUNICATION; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SARMA PS, 1971, VIROLOGY, V44, P137, DOI 10.1016/0042-6822(71)90160-7; SINGER RH, 1989, BLOOD, V74, P2295; SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STARNES MC, 1989, J BIOL CHEM, V264, P7073; SULLIVAN JM, UNPUB, P61901; TOJI L, 1969, P NATL ACAD SCI USA, V63, P871, DOI 10.1073/pnas.63.3.871; YARCHOAN R, 1986, LANCET, V1, P575	23	788	834	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 7	1990	250	4986					1411	1413		10.1126/science.1701568	http://dx.doi.org/10.1126/science.1701568			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL843	1701568				2022-12-28	WOS:A1990EL84300043
J	GREGORY, RJ; CHENG, SH; RICH, DP; MARSHALL, J; PAUL, S; HEHIR, K; OSTEDGAARD, L; KLINGER, KW; WELSH, MJ; SMITH, AE				GREGORY, RJ; CHENG, SH; RICH, DP; MARSHALL, J; PAUL, S; HEHIR, K; OSTEDGAARD, L; KLINGER, KW; WELSH, MJ; SMITH, AE			EXPRESSION AND CHARACTERIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article									GENZYME CORP,1 MP RD,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; IG LABS INC,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; University of Iowa; Howard Hughes Medical Institute; University of Iowa			Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Marshall, John/0000-0003-1361-2869; Ostedgaard, Lynda/0000-0001-7717-3442				Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; MOLE SE, 1985, J VIROL, V54, P703, DOI 10.1128/JVI.54.3.703-710.1985; Murikami H., 1980, P NATL ACAD SCI USA, V77, P3464; NASH B, 1984, J BIOL CHEM, V259, P678; QUINTON PM, 1989, CLIN CHEM, V35, P726; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J, 1989, MOL CLONING LABORATO; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WURZNER R, 1980, J IMMUN METHS, V126, P231	33	334	361	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					382	386		10.1038/347382a0	http://dx.doi.org/10.1038/347382a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699127				2022-12-28	WOS:A1990EA56400063
J	FLETCHER, AE; BULPITT, CJ				FLETCHER, AE; BULPITT, CJ			CURRENT CONCEPTS - HOW FAR SHOULD BLOOD-PRESSURE BE LOWERED	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; FOLLOW-UP; HYPERTENSION; REDUCTION; MORTALITY				FLETCHER, AE (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH,DEPT MED,DIV GERIATR MED, EPIDEMIOL RES UNIT, DU CANE RD, LONDON W12 0HS, ENGLAND.							ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1990, LANCET, V335, P1092; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1989, BMJ, V298, P694; BEEVERS DG, 1988, BRIT MED J, V297, P1212, DOI 10.1136/bmj.297.6658.1212; BRENNAN PJ, 1988, BRIT HEART J, V59, P364; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1988, J HUM HYPERTENS, V2, P79; COOPE J, 1987, LANCET, V2, P518; COOPER SP, 1988, AM J EPIDEMIOL, V127, P387, DOI 10.1093/oxfordjournals.aje.a114812; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; CRUICKSHANK JM, 1987, J HUM HYPERTENS, V1, P87; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; HANSSON L, 1988, J HYPERTENS, V6, P693; KANNEL WB, 1980, AM J CARDIOL, V45, P326, DOI 10.1016/0002-9149(80)90654-2; KAPLAN NM, 1990, LANCET, V335, P1093; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MIALL WE, 1987, MILD HYPERTENSION IS; PEART WS, 1988, BRIT MED J, V296, P1565; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; SLEIGHT P, 1988, LANCET, V1, P235; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEWART IMG, 1979, LANCET, V1, P861; WALLER PC, 1988, J HUM HYPERTENS, V2, P7; ZANCHETTI A, 1989, J HYPERTENS, V7, pS338, DOI 10.1097/00004872-198900076-00165	28	138	138	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					251	254						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1727978				2022-12-28	WOS:A1992HA43100007
J	STOUT, JE; YU, VL; MURACA, P; JOLY, J; TROUP, N; TOMPKINS, LS				STOUT, JE; YU, VL; MURACA, P; JOLY, J; TROUP, N; TOMPKINS, LS			POTABLE WATER AS A CAUSE OF SPORADIC CASES OF COMMUNITY-ACQUIRED LEGIONNAIRES-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEGIONELLA-PNEUMOPHILA CONTAMINATION; DISTRIBUTION-SYSTEMS; PNEUMONIA; PREVALENCE	Background. The environmental sources of sporadic, community-acquired legionnaires' disease are largely unknown, and culturing of water sources after identification of a case is currently not recommended. We conducted a prospective study of sporadic cases of community-acquired legionnaires' disease to determine whether the environmental reservoirs could be identified. Methods. We cultured samples of potable water obtained from sources to which each of 20 patients with culture-confirmed, community-acquired legionnaires' disease had been exposed during the two weeks before the onset of symptoms. Monoclonal-antibody subtyping and restriction-endonuclease analysis were performed on the legionella isolates recovered from both the patients and the associated environmental cultures. Results. For 8 of the 20 patients, isolates of Legionella pneumophila with identical subtypes were identified in cultures from both the patient and the potable water to which the patient had been exposed. The environmental reservoirs linked to the infections were the water supplies of two private residences, two nursing homes, two hospital outpatient clinics, and an industrial plant. Conclusions. Potable-water supplies that harbor L. pneumophila are an important source of community-acquired legionnaires' disease. Future studies should include attempts to identify the environmental sources of this infection.	VET AFFAIRS MED CTR, INFECT DIS SECT, UNIV DR C, PITTSBURGH, PA 15240 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; UNIV LAVAL, QUEBEC CITY G1K 7P4, QUEBEC, CANADA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Stanford University								[Anonymous], 1985, CAN MED ASSOC J, V132, P160; ARNOW PM, 1985, J INFECT DIS, V152, P145, DOI 10.1093/infdis/152.1.145; AUBERTIN J, 1987, INFECTION, V15, P328, DOI 10.1007/BF01647732; BATES JH, 1989, CHEST, V95, pS194, DOI 10.1378/chest.95.3_Supplement.194S; BEST M, 1983, LANCET, V2, P307; CHERRY WB, 1978, J CLIN MICROBIOL, V8, P329; EZZEDDINE H, 1989, J HOSP INFECT, V13, P121, DOI 10.1016/0195-6701(89)90018-2; FALCO V, 1991, CHEST, V100, P1007, DOI 10.1378/chest.100.4.1007; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FIELDS BS, 1984, APPL ENVIRON MICROB, V47, P467, DOI 10.1128/AEM.47.3.467-471.1984; FISHERHOCH SP, 1981, LANCET, V1, P932; FRIISMOLLER A, 1986, SCAND J INFECT DIS, V18, P321, DOI 10.3109/00365548609032343; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; KLIMEK JJ, 1983, AM J INFECT CONTROL, V11, P79, DOI 10.1016/0196-6553(83)90117-7; LEE TC, 1988, ARCH ENVIRON HEALTH, V43, P59, DOI 10.1080/00039896.1988.9934375; MACFARLANE JT, 1982, LANCET, V2, P255; MUDER RR, 1983, JAMA-J AM MED ASSOC, V249, P3184, DOI 10.1001/jama.249.23.3184; MUDER RR, 1986, ARCH INTERN MED, V146, P1607, DOI 10.1001/archinte.146.8.1607; MURACA PW, 1988, AM IND HYG ASSOC J, V49, P584, DOI 10.1202/0002-8894(1988)049&lt;0584:LDITWE&gt;2.0.CO;2; MURACA PW, 1990, INFECT CONT HOSP EP, V11, P79, DOI 10.1086/646126; REDD SC, 1987, JAMA-J AM MED ASSOC, V257, P1221, DOI 10.1001/jama.257.9.1221; REDD SC, 1987, JAMA-J AM MED ASSOC, V2, P274; RUF B, 1989, LUNG, V167, P11, DOI 10.1007/BF02714926; STOUT JE, 1985, APPL ENVIRON MICROB, V49, P221, DOI 10.1128/AEM.49.1.221-228.1985; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P2595; SYNDER MB, 1990, J INFECT DIS, V162, P127, DOI 10.1093/infdis/162.1.127; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; Vickers R M, 1987, Semin Respir Infect, V2, P274; VICKERS RM, 1987, INFECT CONT HOSP EP, V8, P357, DOI 10.1017/S0195941700067412; VICKERS RM, IN PRESS J CLIN MICR; WADOWSKY RM, 1985, APPL ENVIRON MICROB, V49, P1197, DOI 10.1128/AEM.49.5.1197-1205.1985; WITHERELL LE, 1988, J AM WATER WORKS ASS, V80, P87	32	122	127	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					151	155		10.1056/NEJM199201163260302	http://dx.doi.org/10.1056/NEJM199201163260302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727545				2022-12-28	WOS:A1992GZ21300002
J	SAAG, MS; POWDERLY, WG; CLOUD, GA; ROBINSON, P; GRIECO, MH; SHARKEY, PK; THOMPSON, SE; SUGAR, AM; TUAZON, CU; FISHER, JF; HYSLOP, N; JACOBSON, JM; HAFNER, R; DISMUKES, WE				SAAG, MS; POWDERLY, WG; CLOUD, GA; ROBINSON, P; GRIECO, MH; SHARKEY, PK; THOMPSON, SE; SUGAR, AM; TUAZON, CU; FISHER, JF; HYSLOP, N; JACOBSON, JM; HAFNER, R; DISMUKES, WE			COMPARISON OF AMPHOTERICIN-B WITH FLUCONAZOLE IN THE TREATMENT OF ACUTE AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; FLUCYTOSINE; NEOFORMANS; EXPERIENCE	Background. Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS): Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease. Methods. In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patents, in all of whom the diagnosis had been confirmed by culture, were randomly assigned in a 2:1 ratio to receive either fluconazole (200 mg per day) or amphotericin B. Treatment was considered successful if the patient had had two consecutive negative cerebrospinal fluid cultures by the end of the 10-week treatment period. Results. Of the 194 eligible patients, 131 received fluconazole and 63 received amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in patients with successful treatment and 0.5 mg per kilogram in patients with treatment failure; P = 0.34). Treatment was successful in 25 of the 63 amphotericin B recipients (40 percent; 95 percent confidence interval, 26 percent to 53 percent) and in 44 of the 131 fluconazole recipients (34 percent; 95 percent confidence interval, 25 percent to 42 percent) (P = 0.40). There was no significant difference between the groups in overall mortality due to cryptococcosis (amphotericin vs. fluconazole, 9 of 63 [14 percent] vs. 24 of 131 [18 percent]; P = 0.48); however, mortality during the first two weeks of therapy was higher in the fluconazole group (15 percent vs. 8 percent; P = 0.25). The median length of time to the first negative cerebrospinal fluid culture was 42 days (95 percent confidence interval, 28 to 71) in the amphotericin B group and 64 days (95 percent confidence interval, 53 to 67) in the fluconazole group (P = 0.25). Multivariate analyses identified abnormal mental status (lethargy, somnolence, or obtundation) as the most important predictive factor of a high risk of death during therapy (P < 0.0001). Conclusions. Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS. Single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. The optimal therapy for patients at high risk remains to be determined.	UNIV ALABAMA, SCH MED, DEPT MED, DIV INFECT DIS, BIRMINGHAM, AL 35233 USA; UNIV ALABAMA, SCH MED, CTR COMPREHENS CANC, DIV BIOSTAT, BIRMINGHAM, AL 35233 USA; WASHINGTON UNIV, SCH MED, DIV INFECT DIS, ST LOUIS, MO 63110 USA; ST LOUIS VET AFFAIRS MED CTR, ST LOUIS, MO USA; COLUMBIA UNIV, ST LUKES ROOSEVELT HOSP, SCH MED, NEW YORK, NY 10027 USA; UNIV TEXAS SAN ANTONIO, SAN ANTONIO, TX 78285 USA; AUDIE L MURPHY VET AFFAIRS HOSP, SAN ANTONIO, TX USA; EMORY UNIV, GRADY MEM HOSP, ATLANTA, GA 30322 USA; BOSTON CITY HOSP, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, UNIV HOSP, DEPT MED, BOSTON, MA 02215 USA; GEORGE WASHINGTON UNIV, DEPT MED, WASHINGTON, DC 20052 USA; MED COLL GEORGIA, DEPT MED, AUGUSTA, GA 30912 USA; TULANE UNIV, DEPT MED, NEW ORLEANS, LA 70118 USA; MT SINAI MED CTR, DEPT MED, DIV INFECT DIS, NEW YORK, NY 10029 USA; BRONX VET AFFAIRS MED CTR, BRONX, NY USA; NIAID, DIV AIDS, BETHESDA, MD 20892 USA; NIAID, DIV MICROBIOL & INFECT DIS, BETHESDA, MD 20892 USA; PFIZER INC, CENT RES, GROTON, CT 06340 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); Columbia University; Mount Sinai St. Luke's; Mount Sinai West; University of Texas System; University of Texas at San Antonio (UTSA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Emory University; Boston Medical Center; Boston University; George Washington University; University System of Georgia; Augusta University; Tulane University; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pfizer	SAAG, MS (corresponding author), UNIV ALABAMA, BIRMINGHAM VET AFFAIRS MED CTR, 700 19TH ST S, RM 2B-108, BIRMINGHAM, AL 35233 USA.			Powderly, William/0000-0001-7808-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00032] Funding Source: Medline; NIAID NIH HHS [N01-AI-15082, NIH-NIAID-DMID-91-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT JE, 1979, NEW ENGL J MED, V301, P126, DOI 10.1056/NEJM197907193010303; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; CLARK RA, 1990, REV INFECT DIS, V12, P768; COX DR, 1972, J R STAT SOC B, V34, P187; DEFERNANDEZ EP, 1986, J ANTIMICROB CHEMOTH, V18, P261, DOI 10.1093/jac/18.2.261; DENNING DW, 1989, ARCH INTERN MED, V111, P125; DISMUKES WE, 1987, NEW ENGL J MED, V317, P334, DOI 10.1056/NEJM198708063170602; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; JONES BE, 1991, 7TH P INT C AIDS FLO; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; PERFECT JR, 1990, REV INFECT DIS, V12, pS299; PERFECT JR, 1986, ANTIMICROB AGENTS CH, V29, P579, DOI 10.1128/AAC.29.4.579; PIETROSKI N, 1990, 30TH INT C ANT AG CH; Plum F, 1972, Contemp Neurol Ser, V10, P1; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; Snedecor G.W., 1980, STAT METHODS, V7; SQUIRES K, 1990, 30TH INT C ANT AG CH; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; SUGAR AM, 1990, REV INFECT DIS, V12, pS338; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	25	519	539	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					83	89		10.1056/NEJM199201093260202	http://dx.doi.org/10.1056/NEJM199201093260202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727236				2022-12-28	WOS:A1992GY04500002
J	FRANCIOLI, P; ETIENNE, J; HOIGNE, R; THYS, JP; GERBER, A				FRANCIOLI, P; ETIENNE, J; HOIGNE, R; THYS, JP; GERBER, A			TREATMENT OF STREPTOCOCCAL ENDOCARDITIS WITH A SINGLE DAILY DOSE OF CEFTRIAXONE SODIUM FOR 4 WEEKS - EFFICACY AND OUTPATIENT TREATMENT FEASIBILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; NEUROLOGIC COMPLICATIONS; THERAPY; STREPTOMYCIN; PENICILLIN	Objective. - To evaluate the efficacy and safety of ceftriaxone sodium in the treatment of streptococcal endocarditis. Design. - An open, multicenter, noncomparative study with a follow-up of patients for 4 months to 5 years. Setting. - Internal medicine wards and outpatient clinics of hospitals of various sizes in three European countries. Patients. - Fifty-nine patients with defined criteria for streptococcal endocarditis. Intervention. - Ceftriaxone sodium administered at a once-daily dose of 2 g for 4 weeks. Main Outcome Measures. - Clinical outcome and microbiological cure rate. Results. - Among the 59 patients, 55 completed the treatment and were followed up for 4 months to 5 years. No patients showed evidence of relapse. Treatment was completely uneventful in 42 patients (71%). A cardiac valve was replaced in four patients (7%) receiving antimicrobial therapy and in six patients (10%) who had completed antimicrobial therapy. One of the 10 valves taken for culture at surgery was positive, but only for microorganisms that were different from the microorganism isolated before the treatment. The treatment had to be interrupted in four patients because of drug allergy. Other side effects were mild except for two cases of reversible neutropenia. The treatment was easy to administer: 27 patients (46%) had no permanent intravenous catheter at any time, seven patients (120/o) had such a catheter for less than 4 days. Twenty-three patients (39%) were discharged from the hospital less than 2 weeks after admission. Conclusions. - Ceftriaxone sodium administered at a once-daily dose of 2 g appears to be an effective and safe treatment of streptococcal endocarditis. In hospitals, this agent may be more convenient to administer than penicillin G with or without aminoglycosides. Some patients may even be treated as outpatients.	HOP CARDIOL LOUIS PRADEL LYONS,LYONS,FRANCE; ZIEGLERSPITAL BERN,SERV MED,BERN,SWITZERLAND; HOP ERASME,INFECT DIS CLIN,BRUSSELS,BELGIUM; REG SPITAL,SERV MED,BERGDORF,SWITZERLAND	CHU Lyon; Universite Libre de Bruxelles	FRANCIOLI, P (corresponding author), CHU VAUDOIS,DEPT MED INTERNE,DIV MALAD INFECT,CH-1011 LAUSANNE,SWITZERLAND.		ETIENNE, Jerome/C-5471-2014	ETIENNE, Jerome/0000-0002-3348-3315				BAUMGARTNER JD, 1984, ARCH INTERN MED, V143, P1868; BISNO AL, 1989, JAMA-J AM MED ASSOC, V261, P1471, DOI 10.1001/jama.261.10.1471; BRADLEY JS, 1988, PEDIATR INFECT DIS J, V7, P160, DOI 10.1097/00006454-198803000-00005; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; ETIENNE J, 1989, CHEMOTHERAPY, V35, P355, DOI 10.1159/000238695; GREENBERG BH, 1977, CHEST, V71, P794, DOI 10.1378/chest.71.6.794; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; KARCHMER AW, 1979, JAMA-J AM MED ASSOC, V241, P1801, DOI 10.1001/jama.241.17.1801; MALACOFF RF, 1979, JAMA-J AM MED ASSOC, V241, P1807, DOI 10.1001/jama.241.17.1807; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OLAISON L, 1990, J ANTIMICROB CHEMOTH, V25, P449, DOI 10.1093/jac/25.3.449; PASCHALIS C, 1990, EUR NEUROL, V30, P87, DOI 10.1159/000117317; PATEL IH, 1984, AM J MED, V77, P17; PFEIFER JF, 1976, AM J CARDIOL, V37, P920, DOI 10.1016/0002-9149(76)90119-3; PRUITT AA, 1978, MEDICINE, V57, P329, DOI 10.1097/00005792-197807000-00004; RICHARDS DM, 1984, DRUGS, V27, P469, DOI 10.2165/00003495-198427060-00001; RUSSO TA, 1988, ANTIMICROB AGENTS CH, V32, P1439, DOI 10.1128/AAC.32.9.1439; SALGADO AV, 1989, NEUROLOGY, V39, P173, DOI 10.1212/WNL.39.2.173; STAMBOULIAN D, 1991, REV INFECT DIS S2, V13, P160; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WILSON WR, 1985, AM J MED, V78, P128, DOI 10.1016/0002-9343(85)90375-4; WILSON WR, 1981, JAMA-J AM MED ASSOC, V245, P360, DOI 10.1001/jama.245.4.360; WOLFE JC, 1974, ANN INTERN MED, V81, P178, DOI 10.7326/0003-4819-81-2-178	23	119	120	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					264	267		10.1001/jama.267.2.264	http://dx.doi.org/10.1001/jama.267.2.264			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727524	Green Published			2022-12-28	WOS:A1992GY04600031
J	PEI, D; ULRICH, HD; SCHULTZ, PG				PEI, D; ULRICH, HD; SCHULTZ, PG			A COMBINATORIAL APPROACH TOWARD DNA RECOGNITION	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; SEQUENCE-SPECIFIC CLEAVAGE; SITE-SPECIFIC CLEAVAGE; DUPLEX DNA; PLASMID DNA; LIGANDS; NUCLEASE; POLYMERASE; MOLECULES; INVITRO	A combinatorial approach has been used to identify individual RNA molecules from a large population of sequences that bind a 16-base pair homopurine-homopyrimidine DNA sequence through triple-helix formation. Fourteen of the seventeen clones selected contained stretches of pyrimidines highly homologous to the target DNA sequence (T.AT and C+.GC). In addition, these RNA molecules contained hairpin loops, interior loops, and nonstandard base triplets [C+(or C).AT, U.GC, G.GC, and A.AT] at various positions. Affinity cleavage experiments confirmed the ability of selected sequences to bind specifically to the target DNA. Systematic variation in both the target DNA sequence and buffer components should provide increased insight into the molecular interactions required for triple-helix-mediated recognition of natural DNA.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Pei, Dehua/P-4594-2016	Pei, Dehua/0000-0002-2057-6934; Ulrich, Helle D./0000-0003-0431-2223	NIGMS NIH HHS [R01GM41679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; KAISER R, 1991, NATURE, V350, P656, DOI 10.1038/350656d0; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LIPSETT MN, 1963, BIOCHEM BIOPH RES CO, V11, P224, DOI 10.1016/0006-291X(63)90338-3; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MILLER JH, 1966, P NATL ACAD SCI USA, V55, P1201, DOI 10.1073/pnas.55.5.1201; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MUAIYAMA T, 1968, TETRAHEDRON LETT, V56, P5907; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; PEI DF, UNPUB; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WU TF, 1989, NUCLEIC ACIDS RES, V17, P3501, DOI 10.1093/nar/17.9.3501	40	58	66	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1408	1411		10.1126/science.1716784	http://dx.doi.org/10.1126/science.1716784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716784				2022-12-28	WOS:A1991GF85100038
J	GARDULF, A; HAMMARSTROM, L; SMITH, CIE				GARDULF, A; HAMMARSTROM, L; SMITH, CIE			HOME TREATMENT OF HYPOGAMMAGLOBULINEMIA WITH SUBCUTANEOUS GAMMA-GLOBULIN BY RAPID INFUSION	LANCET			English	Article							IMMUNOGLOBULIN REPLACEMENT THERAPY; IMMUNE SERUM GLOBULIN; INTRAVENOUS IMMUNOGLOBULIN; GAMMA-GLOBULIN; ANTIBODY DEFICIENCY; ADVERSE REACTIONS; SELF-INFUSION; AGAMMAGLOBULINEMIA; IMMUNODEFICIENCY; CORTICOSTEROIDS	Intramuscular and intravenous gammaglobulin treatment for hypogammaglobulinaemia is often associated with systemic adverse reactions in some patients. Subcutaneous infusions of gammaglobulin are usually given at a slow rate. To assess the safety of home treatment with subcutaneous gammaglobulin, rapid infusions (34-40 ml/h) given by small portable pumps were used to treat twenty-five patients with hypogammaglobulinaemia. Fifteen patients had previously had adverse reactions to intramuscular or intravenous gammaglobulin treatment. After the patients had been taught how to use the pumps during 6 months of treatment in hospital, in which they initially received 100 mg of an intramuscular gammaglobulin preparation/kg per week, they went on to use the pumps at home or at work. So far, the patients have given themselves 3232 rapid subcutaneous infusions (2308 in home therapy). A median pre-infusion serum IgG concentration of 8.1 g/l resulted after 6 months of treatment. There were only 30 (0.93%) mild systemic adverse reactions; there were fewer reactions with subcutaneous gammaglobulin than with previously given intramuscular injections (n = 21, p < 0.001) or intravenous infusions (n = 9, p < 0.001) in this group of patients. Overall, the patients spent 0.2 days a year in hospital due to respiratory tract infections. The findings show that the method for subcutaneous administration is very easy to learn and is appreciated by the patients; moreover, the infusions can be given much faster than previously reported without any pronounced local reaction.	KAROLINSKA HOSP,KAROLINSKA INST,DEPT INTERNAL MED,NURSING RES UNIT,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital	GARDULF, A (corresponding author), KAROLINSKA HOSP,KAROLINSKA INST,DEPT CLIN IMMUNOL,F71,S-10401 STOCKHOLM 60,SWEDEN.			SMITH, C. I. Edvard/0000-0003-1907-3392				AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; [Anonymous], 1969, Lancet, V1, P163; ASHIDA ER, 1986, J CLIN IMMUNOL, V6, P306, DOI 10.1007/BF00917331; BAYSTON K, 1985, NZ MED J, P652; BERGER M, 1980, ANN INTERN MED, V93, P55, DOI 10.7326/0003-4819-93-1-55; BJORKANDER J, 1985, INFECTION, V13, P102, DOI 10.1007/BF01642867; BLEEKER WK, 1989, CLIN EXP IMMUNOL, V77, P338; CHAPEL H, 1988, CLIN EXP IMMUNOL, V73, P160; CUNNINGHAMRUNDLES C, 1985, VOX SANG, V49, P8, DOI 10.1111/j.1423-0410.1985.tb01138.x; Effersoe H, 1985, Ugeskr Laeger, V147, P3303; GISLASON D, 1978, VOX SANG, V34, P143, DOI 10.1111/j.1423-0410.1978.tb02456.x; HAMMARSTROM L, 1986, LANCET, V1, P743; HANSON LA, 1980, DHHS FDA809005 US DE, P151; HOLMES S, 1989, INT J NURS STUD, V26, P69, DOI 10.1016/0020-7489(89)90047-3; JORUPRONSTROM C, 1989, INFECTION, V17, P301, DOI 10.1007/BF01650712; KAMME C, 1966, ACTA MED SCAND, V179, P679; KOHLER PF, 1966, NATURE, V210, P1070, DOI 10.1038/2101070a0; LEAHY MF, 1986, LANCET, V2, P48; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEDERMAN HM, 1986, AM J MED, V81, P443, DOI 10.1016/0002-9343(86)90296-2; OCHS HD, 1987, J INFECT DIS, V156, P652, DOI 10.1093/infdis/156.4.652; OCHS HD, 1986, LANCET, V1, P610; POLLACK S, 1986, POSTGRAD MED J, V62, P939, DOI 10.1136/pgmj.62.732.939; ROIFMAN CM, 1987, LANCET, V1, P1075; ROORD JJ, 1982, LANCET, V1, P689; RYAN A, 1988, LANCET, V2, P793; SMITH CIE, 1985, OBSTET GYNECOL, V66, P395; SMITH GN, 1972, LANCET, V1, P1208; UGAZIO AG, 1982, LANCET, V1, P226; 1990, LANCET, V336, P470; 1983, CLIN EXP IMMUNOL, V52, P417	31	178	184	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					162	166						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1712881				2022-12-28	WOS:A1991FX42400014
J	ANDERSON, MP; GREGORY, RJ; THOMPSON, S; SOUZA, DW; PAUL, S; MULLIGAN, RC; SMITH, AE; WELSH, MJ				ANDERSON, MP; GREGORY, RJ; THOMPSON, S; SOUZA, DW; PAUL, S; MULLIGAN, RC; SMITH, AE; WELSH, MJ			DEMONSTRATION THAT CFTR IS A CHLORIDE CHANNEL BY ALTERATION OF ITS ANION SELECTIVITY	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; ION CHANNEL; PATCH-CLAMP; TRANSPORT; IDENTIFICATION; EXPRESSION; CELLS; CAMP	Expression of the cystic fibrosis transmembrane conductance regulator (CFTR) generates adenosine 3',5'-monophosphate (cAMP)-regulated chloride channels, indicating that CFTR is either a chloride channel or a chloride channel regulator. To distinguish between these possibilities, basic amino acids in the putative transmembrane domains were mutated. The sequence of anion selectivity of cAMP-regulated channels in cells containing either endogenous or recombinant CFTR was bromide > chloride > iodide > fluoride. Mutation of the lysines at positions 95 or 335 to acidic amino acids converted the selectivity sequence to iodide > bromide > chloride > fluoride. These data indicate that CFTR is a cAMP-regulated chloride channel and that lysines 95 and 335 determine anion selectivity.	GENZYME CORP,FRAMINGHAM,MA 01701; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Welsh, Michael/0000-0002-1646-6206; Anderson, Matthew/0000-0003-4602-1811				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, IN PRESS P NATL ACAD; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CARSON MR, 1989, AM J PHYSIOL, V257, pL259, DOI 10.1152/ajplung.1989.257.4.L259; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING G, 1991, FASEB J, V5, pA1760; DIAMOND G, 1991, AM ASS CANCER RES A, V33; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRZELCZAK Z, 1990, Journal of Cell Biology, V111, p310A; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; OSTEDGAARD LS, UNPUB; QUINTON PM, 1989, ANN NY ACAD SCI, V574, P438; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	36	990	1007	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					202	205		10.1126/science.1712984	http://dx.doi.org/10.1126/science.1712984			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712984				2022-12-28	WOS:A1991FW16000039
J	MCARDLE, CS; HOLE, D				MCARDLE, CS; HOLE, D			IMPACT OF VARIABILITY AMONG SURGEONS ON POSTOPERATIVE MORBIDITY AND MORTALITY AND ULTIMATE SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article							LARGE-BOWEL-CANCER; LOCAL RECURRENCE	Objective - To assess the differences among surgeons in postoperative complications, postoperative mortality, and survival in patients undergoing surgery for colorectal cancer. Design - Prospective study of patients with colorectal cancer managed by one of 13 consultant surgeons, none of whom had a special interest in colorectal surgery. Setting - Royal Infirmary, Glasgow. Patients - 645 sequential patients with colorectal cancer presenting over the six years from 1974 to 1979. Main outcome measures - Postoperative complications, postoperative mortality (within 30 days), and survival (up to 10 years); predictive factors for postoperative mortality and survival; and relative hazard rate ratios for individual surgeons. Results - The proportion of patients undergoing apparently curative resection varied among surgeons from 40% to 76%; overall postoperative mortality varied from 8% to 30%. After curative resection postoperative mortality varied from 0% to 20%, local recurrence from 0% to 21%, and the rate of anastomotic leak from 0% to 25%. Survival at 10 years in patients who underwent curative resection varied from 20% to 63%, two year survival in those who underwent palliative resection varied from 7% to 32%, and median survival in those who underwent palliative diversion varied from one to eight months. The hazard rate ratios among individual surgeons, taking into account the identified risk factors, varied from 0.56 to 2.03, from 0.17 to 1.92, and from 0.57 to 1.50 for curative resection, palliative resection, and palliative diversion, respectively. Conclusion - There were significant variations in patient outcome among surgeons after surgery for colorectal cancer; such differences compromise survival. A considerable improvement in overall survival might be achieved if such surgery were undertaken by surgeons with a special interest in colorectal surgery or surgical oncology.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20,SCOTLAND		MCARDLE, CS (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT SURG,GLASGOW G31 2ER,SCOTLAND.							AUSOBSKY JR, 1985, ANN ROY COLL SURG, V67, P159; Breslow NE, 1987, SCI PUBLICATION INT, V2; Buck N, 1987, REPORT CONFIDENTIAL; COX DR, 1972, J R STAT SOC B, V34, P187; FIELDING LP, 1980, BRIT MED J, V281, P411, DOI 10.1136/bmj.281.6237.411; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCARDLE CS, 1990, BRIT J SURG, V77, P280, DOI 10.1002/bjs.1800770314; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; SHANDALL A, 1985, BRIT J SURG, V72, P606, DOI 10.1002/bjs.1800720808	10	474	479	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1501	1505		10.1136/bmj.302.6791.1501	http://dx.doi.org/10.1136/bmj.302.6791.1501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1713087	Green Published, Bronze			2022-12-28	WOS:A1991FT50500021
J	PYLE, AM; CECH, TR				PYLE, AM; CECH, TR			RIBOZYME RECOGNITION OF RNA BY TERTIARY INTERACTIONS WITH SPECIFIC RIBOSE 2'-OH GROUPS	NATURE			English	Article							TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; KINETICS; BINDING; TEMPERATURE; SUBSTRATE; SELECTION	SHORTENED forms of the group I intron from Tetrahymena catalyse sequence-specific cleavage of exogenous oligonucleotide substrates 1, 2. The association between RNA enzyme (ribozyme) and substrate is mediated by pairing between an internal guide sequence on the ribozyme and a complementary sequence on the substrate 1, 3, 4. RNA substrates and cleavage products associate with a binding energy greater than that of base-pairing by approximately 4 kcal-mol-1 (at 42-degrees-C), whereas DNA associates with an energy around that expected for base-pairing 5-9. It has been proposed that the difference in binding affinity is due to specific 2'-OH groups on an RNA substrate forming stabilizing tertiary interactions with the core of the ribozxyme, or that the RNA.RNA helix formed upon association of an RNA substrate and the ribozyme might be more stable than an RNA.DNA helix of the same sequence 6. To differentiate between these two models, chimaeric oligonucleotides containing deoxynucleotide residues at successive positions along the chain were synthesized, and their equilibrium binding constants for association with the ribozyme were measured directly by a new gel electrophoresis technique 5. We report here that most of the extra binding energy can be accounted for by discrete RNA-ribozyme interactions, the 2'-OH group on the sugar residue three nucleotides from the cleavage site contributing the most interaction energy. Thus, in addition to the well documented binding of RNA to RNA by base-pairing 10-14, 2'-OH groups within a duplex can also mediate association between RNA molecules.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1987, CELL, V50, P951, DOI 10.1016/0092-8674(87)90522-8; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DIX DB, 1986, J BIOL CHEM, V261, P112; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NELSON JW, 1982, BIOCHEMISTRY-US, V21, P5289, DOI 10.1021/bi00264a026; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WU T, 1989, NUCLEIC ACIDS RES, V9, P3501; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	31	184	189	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					628	631		10.1038/350628a0	http://dx.doi.org/10.1038/350628a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1708111				2022-12-28	WOS:A1991FH11200066
J	OTSU, M; HILES, I; GOUT, I; FRY, MJ; RUIZLARREA, F; PANAYOTOU, G; THOMPSON, A; DHAND, R; HSUAN, J; TOTTY, N; SMITH, AD; MORGAN, SJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD				OTSU, M; HILES, I; GOUT, I; FRY, MJ; RUIZLARREA, F; PANAYOTOU, G; THOMPSON, A; DHAND, R; HSUAN, J; TOTTY, N; SMITH, AD; MORGAN, SJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD			CHARACTERIZATION OF 2 85KD PROTEINS THAT ASSOCIATE WITH RECEPTOR TYROSINE KINASES, MIDDLE-T/PP60C-SRC COMPLEXES, AND PI3-KINASE	CELL			English	Article							MIDDLE-T-ANTIGEN; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-II; PHOSPHATIDYLINOSITOL KINASE; PDGF RECEPTOR; SEQUENCE-ANALYSIS; MESSENGER-RNAS; BOVINE BRAIN; INOSITOL 3-PHOSPHATE; HEMATOPOIETIC-CELLS	Affinity-purified bovine brain phosphatidylinositol 3-kinase (PI3-kinase) contains two major proteins of 85 and 110 kd. Amino acid sequence analysis and cDNA cloning reveals two related 85 kd proteins (p85-alpha and p85-beta), which both contain one SH3 and two SH2 regions (src homology regions). When expressed, these 85 kd proteins bind to and are substrates for tyrosine-phosphorylated receptor kinases and the polyoma virus middle-T antigen/pp60c-src complex, but lack PI3-kinase activity. However, an antiserum raised against p85-beta immunoprecipitates PI3-kinase activity. The active PI3-kinase complex containing p85-alpha or p85-beta and the 110 kd protein binds to PDGF but not EGF receptors. p85-alpha and p85-beta may mediate specific PI3-kinase interactions with a subset of tyrosine kinases.	UNIV COLL & MIDDLX SCH MED,DEPT CHEM PATHOL,LONDON,ENGLAND; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	University of London; University College London; European Molecular Biology Laboratory (EMBL)	OTSU, M (corresponding author), LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON,ENGLAND.		Hsuan, Justin/C-8825-2009; Parker, Peter j/D-5192-2013	Hsuan, Justin/0000-0001-6083-7564; Fry, Michael/0000-0001-8518-1370; parker, peter/0000-0002-6218-2933; Ruiz Larrea, Fernanda/0000-0001-5610-7745				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COHEN B, 1990, MOL CELL BIOL, V87, P4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSTOVA J, 1989, NUCLEIC ACIDS RES, V17, P1427, DOI 10.1093/nar/17.4.1427; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACDONALD ML, 1985, P NATL ACAD SCI USA, V82, P3993, DOI 10.1073/pnas.82.12.3993; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P499, DOI 10.1093/nar/12.1Part2.499; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STOCKWELL PA, 1987, COMPUT APPL BIOSCI, V3, P37; SUGANO S, 1985, MOL CELL BIOL, V5, P2399, DOI 10.1128/MCB.5.9.2399; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; Summers MD, 1987, MANUAL METHODS BACUL; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; ULUG ET, 1990, J VIROL, V64, P3995; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	114	734	824	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					91	104		10.1016/0092-8674(91)90411-Q	http://dx.doi.org/10.1016/0092-8674(91)90411-Q			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707345	Bronze			2022-12-28	WOS:A1991FF77300012
J	MACLEOD, AM; THOMSON, AW				MACLEOD, AM; THOMSON, AW			FK-506 - AN IMMUNOSUPPRESSANT FOR THE 1990S	LANCET			English	Review							PEPTIDYL-PROLYL ISOMERASE; RECEIVING FK-506; DRUG FK-506; FK506; TRANSPLANTATION; RATS; CYCLOSPORINE; COMBINATION; ACTIVATION; INHIBITION	The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.	UNIV ABERDEEN,SCH MED,DEPT PATHOL,IMMUNOPATHOL LAB,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	MACLEOD, AM (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND.							ABUELMAGD K, IN PRESS TRANSPLANTA; ALESSIANI M, IN PRESS TRANSPLANT; ARMITAGE JM, IN PRESS TRANSPLANT; BURKE MD, IN PRESS TRANSPLANTA; CALNE R, 1987, TRANSPLANT P, V19, P63; COLLIER DS, 1987, TRANSPLANT P, V19, P62; FRANCAVILLA A, 1989, LANCET, V2, P1248; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; INAMURA N, 1988, CLIN IMMUNOL IMMUNOP, V46, P82, DOI 10.1016/0090-1229(88)90008-6; JAIN AB, IN PRESS TRANSPLANT; KAHAN BD, 1988, CYCLOSPORINE THERAPE; KAWASHIMA H, 1988, INVEST OPHTH VIS SCI, V29, P1265; KAY JE, 1989, IMMUNOLOGY, V67, P473; KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256; MCCAULEY J, 1990, LANCET, V335, P674, DOI 10.1016/0140-6736(90)90471-G; MIELES L, 1990, TRANSPLANT P, V22, P41; MURASE N, 1987, TRANSPLANT P, V19, P71; MURASE N, 1990, TRANSPLANTATION, V50, P186, DOI 10.1097/00007890-199008000-00002; MURASE N, 1990, LANCET, P373; NAKAJIMA K, 1988, TRANSPLANTATION, V45, P1146, DOI 10.1097/00007890-198806000-00033; NALESNIK MA, 1987, TRANSPLANT P, V19, P89; OCHIAI T, 1987, TRANSPLANT P, V19, P84; OCHIAI T, 1987, TRANSPLANTATION, V44, P729, DOI 10.1097/00007890-198712000-00001; OCHIAI T, 1987, TRANSPLANTATION, V44, P734, DOI 10.1097/00007890-198712000-00002; OHARA K, 1990, TRANSPLANT P, V22, P83; PROPPER DJ, 1990, TRANSPLANTATION, V50, P267, DOI 10.1097/00007890-199008000-00020; PUGHHUMPHREYS RGP, 1990, IMMUNOLOGY, V70, P398; REYES J, IN PRESS TRANSPLANTA; SAKR MF, IN PRESS TRANSPLANT; SHAPIRO R, IN PRESS TRANSPLANT; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, IN PRESS TRANSPLANT; STEPHEN M, 1989, TRANSPLANTATION, V47, P60, DOI 10.1097/00007890-198901000-00014; TAKABAYASHI K, 1989, CLIN IMMUNOL IMMUNOP, V51, P110, DOI 10.1016/0090-1229(89)90211-0; TAMURA K, 1987, TRANSPLANT P, V19, P23; THIRU S, 1989, CYCLOSPORIN MODE ACT, P324; THOMSON AW, 1990, TRANSPLANT P, V22, P100; THOMSON AW, 1990, TRANSPLANT REV, V4, P1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TODO S, 1989, SURGERY, V106, P444; TODO S, 1988, SURGERY, V104, P239; TODO S, IN PRESS TRANSPLANT; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; VENKATARAMANAN R, IN PRESS TRANSPLANT; VONGRAFFENRIED B, 1989, CYCLOSPORIN MODE ACT, P213; WALLISER P, 1989, IMMUNOLOGY, V68, P434; WOO J, 1990, SCAND J IMMUNOL, V31, P297, DOI 10.1111/j.1365-3083.1990.tb02772.x; YOSHIMURA N, 1989, TRANSPLANTATION, V47, P35	49	59	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					25	27		10.1016/0140-6736(91)93341-6	http://dx.doi.org/10.1016/0140-6736(91)93341-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1702172				2022-12-28	WOS:A1991EQ60400015
J	BANCHEREAU, J; DEPAOLI, P; VALLE, A; GARCIA, E; ROUSSET, F				BANCHEREAU, J; DEPAOLI, P; VALLE, A; GARCIA, E; ROUSSET, F			LONG-TERM HUMAN B-CELL LINES DEPENDENT ON INTERLEUKIN-4 AND ANTIBODY TO CD40	SCIENCE			English	Article							ACTIVATION; GROWTH; PROLIFERATION; MONOCYTES; RECEPTOR; ANTIGEN; BP35	CD40 is a 45- to 50-kilodalton transmembrane glycoprotein expressed on B lymphocytes, epithelial cells, and some carcinoma cell lines. Human resting B lymphocytes entered a state of sustained proliferation when incubated with both the mouse fibroblastic Ltk- cell line that had been transfected with the human Fc receptor (Fc-gamma-RII/CDw32) and monoclonal antibodies to CD40. In combination with interleukin-4, factor-dependent long-term normal human B cell lines were generated that were consistently negative for Epstein-Barr viral infection. Thus, cross-linking of CD40 is likely to represent an important phenomenon in the clonal expansion of B cells.			BANCHEREAU, J (corresponding author), SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE.		De Paoli, Paolo/AAG-2586-2021	De Paoli, Paolo/0000-0002-9502-1781				BANCHEREAU J, UNPUB; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DARZYNKIEWICZ Z, 1980, CYTOMETRY, V1, P98, DOI 10.1002/cyto.990010203; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DEFRANCE T, 1990, CYTOKINES B LYMPHOCY, P65; KANEOKA H, 1983, J IMMUNOL, V131, P158; LEFKOVITS I, 1985, LIMITING DILUTION AN, P81; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PELTZ GA, 1988, J IMMUNOL, V141, P1891; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROUSSET F, UNPUB; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPITS H, 1987, J IMMUNOL, V139, P1142; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TAX WJM, 1984, J IMMUNOL, V133, P1185; TISCH R, 1988, IMMUNOL TODAY, V9, P145, DOI 10.1016/0167-5699(88)91202-9; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818	22	620	685	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					70	72		10.1126/science.1702555	http://dx.doi.org/10.1126/science.1702555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1702555				2022-12-28	WOS:A1991EQ60300028
J	KNAPP, HR				KNAPP, HR			REDUCED ALLERGEN-INDUCED NASAL CONGESTION AND LEUKOTRIENE SYNTHESIS WITH AN ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									VANDERBILT UNIV, DEPT MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37240 USA; VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37240 USA	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [HL-35380] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISGAARD H, 1984, PROSTAGLANDINS, V27, P369, DOI 10.1016/0090-6980(84)90196-5; BISGAARD H, 1984, PROSTAGLANDINS, V27, P599, DOI 10.1016/0090-6980(84)90095-9; BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243; BOKOCH GM, 1981, J BIOL CHEM, V256, P5317; CASHMAN J R, 1988, Drugs of Today, V24, P723; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DOLOVICH J, 1970, International Archives of Allergy and Applied Immunology, V38, P337; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FREELAND HS, 1989, J ALLERGY CLIN IMMUN, V83, P634, DOI 10.1016/0091-6749(89)90076-6; FRIEDMAN MM, 1985, J ALLERGY CLIN IMMUN, V76, P70, DOI 10.1016/0091-6749(85)90807-3; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; KNAPP HR, 1989, NEW ENGL J MED, V320, P1037, DOI 10.1056/NEJM198904203201603; KNAPP HR, 1990, PROSTAGLANDINS, V39, P407, DOI 10.1016/0090-6980(90)90122-C; LAURSEN LS, 1990, LANCET, V335, P683; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; MYGIND N, 1983, EUR J RESPIR DIS, V64, P16; PETERS SP, 1987, AM REV RESPIR DIS, V135, pS42; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; REILLY IAG, 1988, J CLIN PATHOL, V41, P1163, DOI 10.1136/jcp.41.11.1163; ROBERTS LJ, 1984, ANAL BIOCHEM, V136, P258, DOI 10.1016/0003-2697(84)90333-6; RUBIN P, 1989, CLIN PHARMACOL THER, V45, P187; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SIEGEL S, 1956, NONPARAMETRIC STAT, P184; SOLOMON WR, 1983, PROVOCATIVE CHALLENG, V1, P134; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TAUBER AI, 1973, J IMMUNOL, V111, P27; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P940, DOI 10.1016/0091-6749(88)90157-1; WASSERMAN SI, 1987, AM REV RESPIR DIS, V135, pS46; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880	39	211	216	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	1990	323	25					1745	1748		10.1056/NEJM199012203232506	http://dx.doi.org/10.1056/NEJM199012203232506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EN375	1701029	Bronze			2022-12-28	WOS:A1990EN37500006
J	GOULD, KL; MORENO, S; TONKS, NK; NURSE, P				GOULD, KL; MORENO, S; TONKS, NK; NURSE, P			COMPLEMENTATION OF THE MITOTIC ACTIVATOR, P80CDC25, BY A HUMAN PROTEIN-TYROSINE PHOSPHATASE	SCIENCE			English	Article									UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GOULD, KL (corresponding author), UNIV OXFORD, DEPT BIOCHEM, MICROBIOL UNIT, IMPERIAL CANC RES FUND, CELL CYCLE GRP, OXFORD OX1 3QU, ENGLAND.		Moreno, Sergio/K-3671-2014	Moreno, Sergio/0000-0002-8039-1413; Gould, Kathleen/0000-0002-3810-4070				COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, IN PRESS P NATL ACAD; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FANTES PA, 1981, J BACTERIOL, V146, P746, DOI 10.1128/JB.146.2.746-754.1981; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, UNPUB; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY CJ, UNPUB; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9	34	188	200	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	1990	250	4987					1573	1576		10.1126/science.1703321	http://dx.doi.org/10.1126/science.1703321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM931	1703321				2022-12-28	WOS:A1990EM93100041
J	SCHULZ, S; GREEN, CK; YUEN, PST; GARBERS, DL				SCHULZ, S; GREEN, CK; YUEN, PST; GARBERS, DL			GUANYLYL CYCLASE IS A HEAT-STABLE ENTEROTOXIN RECEPTOR	CELL			English	Article									VANDERBILT UNIV, MED CTR, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University			ST Yuen, Peter/B-1954-2008	ST Yuen, Peter/0000-0001-9557-3909				ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; BURGESS MN, 1978, INFECT IMMUN, V21, P526, DOI 10.1128/IAI.21.2.526-531.1978; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1989, AM J PHYSIOL, V257, pF874, DOI 10.1152/ajprenal.1989.257.5.F874; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GUANDALINI S, 1982, AM J PHYSIOL, V243, pG36, DOI 10.1152/ajpgi.1982.243.1.G36; GUERRANT RL, 1980, J INFECT DIS, V142, P220, DOI 10.1093/infdis/142.2.220; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; IVENS K, 1990, INFECT IMMUN, V58, P1817, DOI 10.1128/IAI.58.6.1817-1820.1990; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSE WJ, 1990, CELL TISSUE RES, V260, P387, DOI 10.1007/BF00318641; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUNO T, 1986, J BIOL CHEM, V261, P1470; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIMOMURA H, 1986, J BIOL CHEM, V261, P5778; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; THOMPSON MR, 1987, PATHOL IMMUNOPATH R, V6, P103, DOI 10.1159/000157052; THOMPSON MR, 1985, ANAL BIOCHEM, V148, P26, DOI 10.1016/0003-2697(85)90623-2; THOMPSON MR, 1990, J RECEPTOR RES, V10, P97, DOI 10.3109/10799899009064660; THORPE DS, 1989, J BIOL CHEM, V264, P6545; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986; WHITE AA, 1989, BIOCHEM BIOPH RES CO, V159, P363, DOI 10.1016/0006-291X(89)92447-9; YOSHIMURA S, 1985, FEBS LETT, V181, P138, DOI 10.1016/0014-5793(85)81129-7	42	541	566	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	1990	63	5					941	948		10.1016/0092-8674(90)90497-3	http://dx.doi.org/10.1016/0092-8674(90)90497-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EL759	1701694				2022-12-28	WOS:A1990EL75900009
J	WAKUI, M; OSIPCHUK, YV; PETERSEN, OH				WAKUI, M; OSIPCHUK, YV; PETERSEN, OH			RECEPTOR-ACTIVATED CYTOPLASMIC CA2+ SPIKING MEDIATED BY INOSITOL TRISPHOSPHATE IS DUE TO CA2+-INDUCED CA2+ RELEASE	CELL			English	Article									UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAUCH P, 1986, J MEMBRANE BIOL, V94, P99, DOI 10.1007/BF01871191; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; PETERSEN OH, 1989, CELL CALCIUM, V10, P375, DOI 10.1016/0143-4160(89)90063-8; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAYLOR CW, 1986, BIOCHEM J, V238, P765, DOI 10.1042/bj2380765; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	46	258	260	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 30	1990	63	5					1025	1032		10.1016/0092-8674(90)90505-9	http://dx.doi.org/10.1016/0092-8674(90)90505-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EL759	1701691				2022-12-28	WOS:A1990EL75900017
J	RICH, DP; ANDERSON, MP; GREGORY, RJ; CHENG, SH; PAUL, S; JEFFERSON, DM; MCCANN, JD; KLINGER, KW; SMITH, AE; WELSH, MJ				RICH, DP; ANDERSON, MP; GREGORY, RJ; CHENG, SH; PAUL, S; JEFFERSON, DM; MCCANN, JD; KLINGER, KW; SMITH, AE; WELSH, MJ			EXPRESSION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CORRECTS DEFECTIVE CHLORIDE CHANNEL REGULATION IN CYSTIC-FIBROSIS AIRWAY EPITHELIAL-CELLS	NATURE			English	Article									UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701; IG LABS INC,FRAMINGHAM,MA 01701; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; NEW ENGLAND MED CTR,DEPT PEDIAT,BOSTON,MA 02111; NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Sanofi-Aventis; Genzyme Corporation; Tufts University; Tufts Medical Center; Tufts Medical Center			Cheng, Seng H/AAC-6564-2022	Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				BEHM JK, 1987, PEDIATR RES, V22, P271, DOI 10.1203/00006450-198709000-00007; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAO AC, 1990, J MEMBRANE BIOL, V113, P193, DOI 10.1007/BF01870071; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; CLIFF WH, 1989, PED PULM S, V4, P45; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fields BN, 1985, VIROLOGY, P685; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JEFFERSON DM, IN PRESS AM J PHYSL; KEEREM BS, 1989, SCIENCE, V245, P1073; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; LI M, 1990, AM J PHYSIOL, V259, pC295, DOI 10.1152/ajpcell.1990.259.2.C295; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAM SJ, 1989, P NATL ACAD SCI USA, V86, P10166, DOI 10.1073/pnas.86.24.10166; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO K, 1988, J LAB CLIN MED, V111, P511; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; VERKMAN AS, 1989, ANAL BIOCHEM, V178, P355, DOI 10.1016/0003-2697(89)90652-0; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WELSH MJ, 1985, J MEMBRANE BIOL, V88, P149, DOI 10.1007/BF01868429	35	586	623	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					358	363		10.1038/347358a0	http://dx.doi.org/10.1038/347358a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699126				2022-12-28	WOS:A1990EA56400053
J	STEINBROOK, R; LO, B				STEINBROOK, R; LO, B			THE OREGON MEDICAID DEMONSTRATION PROJECT - WILL IT PROVIDE ADEQUATE MEDICAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH				STEINBROOK, R (corresponding author), UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROWN LD, 1991, HEALTH AFFAIR, V10, P28, DOI 10.1377/hlthaff.10.2.28; CALLAHAN D, 1991, HEALTH AFFAIR, V10, P78, DOI 10.1377/hlthaff.10.2.78; CALLAHAN D, 1991, J AM GERIATR SOC, V39, P622, DOI 10.1111/j.1532-5415.1991.tb03605.x; CRAWSHAW R, 1990, WESTERN J MED, V152, P441; DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2232, DOI 10.1001/jama.265.17.2232; DELOZIER JE, 1991, ADV DATA VITAL HLTH, V203; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; DOUGHERTY CJ, 1991, HASTINGS CENT REP, V21, pS1; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2439, DOI 10.1001/jama.266.17.2439; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HADORN DC, 1991, HASTINGS CENT REP, V21, pS11, DOI 10.2307/3563329; LEVIT KR, 1991, HEALTH AFFAIR, V10, P117, DOI 10.1377/hlthaff.10.1.117; POVAR G, 1988, ANN INTERN MED, V109, P419, DOI 10.7326/0003-4819-109-5-419; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; SCHWARTZ WB, 1990, NY TIMES        0709, pA17; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; Thomasma D., 1988, PATIENTS GOOD; WELCH HG, 1989, NEW ENGL J MED, V321, P1261, DOI 10.1056/NEJM198911023211809; 1991, PRIORITIZATION HLTH; 1991, MEDICAID STATE REPOR; 1991, WAIVER APPLICATION O; 1991, OREGON MED BASIC HLT; 1989, 65TH OR LEG ASS, pCH836	26	38	38	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					340	344		10.1056/NEJM199201303260511	http://dx.doi.org/10.1056/NEJM199201303260511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728740				2022-12-28	WOS:A1992HA99100011
J	LEVEY, AS; LAN, SP; CORWIN, HL; KASINATH, BS; LACHIN, J; NEILSON, EG; HUNSICKER, LG; LEWIS, EJ				LEVEY, AS; LAN, SP; CORWIN, HL; KASINATH, BS; LACHIN, J; NEILSON, EG; HUNSICKER, LG; LEWIS, EJ			PROGRESSION AND REMISSION OF RENAL-DISEASE IN THE LUPUS NEPHRITIS COLLABORATIVE STUDY - RESULTS OF TREATMENT WITH PREDNISONE AND SHORT-TERM ORAL CYCLOPHOSPHAMIDE	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; PREDNISONE; CYCLOPHOSPHAMIDE; CREATININE	NON-HODGKINS LYMPHOMA; SYSTEMIC LUPUS; PROGNOSTIC FACTORS; CLINICAL COURSE; GLOMERULONEPHRITIS; ERYTHEMATOSUS; CLASSIFICATION; BLADDER; INJURY; FORMS	Objective: To describe the clinical course of severe lupus nephritis and to identify the risk factors for progression to renal failure among patients treated with prednisone and short-term courses of low-dose oral cyclophosphamide. Design: Ancillary analyses of data from the Lupus Nephritis Collaborative Study (LNCS). Setting: University hospital medical centers (14). Patients: The 86 patients who participated in the LNCS (mean follow-up, 136 weeks [2.6 years]) and a subgroup of 63 patients with follow-up of more than 48 weeks (mean follow-up, 160 weeks [3.1 years]). Measurements: Initial clinical and pathologic features, response to therapy within 48 weeks, and subsequent clinical events, including development of renal failure. Main Results: Renal failure developed in 18 patients (21%). An observed elevation in serum creatinine concentration was the only initial feature predictive of subsequent renal failure. Mean (+/- SD) initial serum creatinine levels were higher in patients who subsequently developed renal failure (244 +/- 134-mu-mol/L [2.76 +/- 1.52 mg/dL] compared with 163 +/- 103-mu-mol/L [1.85 +/- 1.17 mg/dL]; P = 0.007). The risk for renal failure was higher among patients with initial serum creatinine levels greater than 106-mu-mol/L (1.2 mg/dL) (29% compared with 6.5%; P = 0.014). Response to therapy (defined as resolution of initial serum creatinine elevations within 48 weeks) refined the prognosis based on initial serum creatinine determinations. The risk for subsequent renal failure was higher among patients who failed to respond to therapy within 48 weeks (30% compared with 0%; P = 0.015). By comparison, 9% of patients with normal initial serum creatinine levels progressed to renal failure after 48 weeks. Conclusions: Initial serum creatinine levels and responses to initial therapy with prednisone and short-term cyclophosphamide, as used in the LNCS, can guide further therapy. Patients with normal initial serum creatinine levels or resolution of initial serum creatinine elevations within 48 weeks have a low risk for renal failure and may not require long-term treatment with cyclophosphamide.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, ROCKVILLE, MD 20852 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, HANOVER, NH 03756 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, SAN ANTONIO, TX 78284 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV IOWA HOSP & CLIN, DIV NEPHROL, IOWA CITY, IA 52242 USA	George Washington University; Dartmouth College; University of Texas System; University of Texas Health San Antonio; University of Pennsylvania; University of Iowa	LEVEY, AS (corresponding author), NEW ENGLAND MED CTR HOSP, DIV NEPHROL, BOX 784, 750 WASHINGTON ST, BOSTON, MA 02111 USA.			Lachin, John/0000-0001-9838-2841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027770, R01DK027769] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27769, DK27770] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPEL GB, 1978, MEDICINE, V57, P371, DOI 10.1097/00005792-197809000-00001; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALDWIN DS, 1970, ANN INTERN MED, V73, P929, DOI 10.7326/0003-4819-73-6-929; BALDWIN DS, 1977, AM J MED, V62, P12, DOI 10.1016/0002-9343(77)90345-X; CAMERON JS, 1979, Q J MED, V48, P1; CHAGNAC A, 1989, J CLIN INVEST, V84, P922, DOI 10.1172/JCI114254; Churg J, 1982, RENAL DIS CLASSIFICA, P127; Clough J D, 1990, Prog Clin Biol Res, V337, P301; Cochran W.G, 1957, STAT METHODS, V6th ed; COX DR, 1972, J R STAT SOC B, V34, P187; Fleiss JL, 1981, STAT METHODS RATES P; HECHT B, 1976, MEDICINE, V55, P163, DOI 10.1097/00005792-197603000-00005; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KASINATH BS, 1986, AM J KIDNEY DIS, V8, P239, DOI 10.1016/S0272-6386(86)80032-4; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LEWIS E, 1992, IN PRESS N ENGL J ME; MAGIL AB, 1988, KIDNEY INT, V34, P511, DOI 10.1038/ki.1988.211; PEDERSENBJERGAARD J, 1988, NEW ENGL J MED, V318, P1028, DOI 10.1056/NEJM198804213181604; POLLAK VE, 1964, J LAB CLIN MED, V63, P537; POLLAK VE, 1961, J LAB CLIN MED, V57, P495; Randles R, 1979, INTRO THEORY NONPARA; RUSH PJ, 1986, KIDNEY INT, V29, P1066, DOI 10.1038/ki.1986.108; SCHWARTZ MM, 1989, AM J KIDNEY DIS, V13, P273, DOI 10.1016/S0272-6386(89)80033-2; SCHWARTZ MM, 1989, KIDNEY INT, V36, P891, DOI 10.1038/ki.1989.276; SCHWARTZ MM, 1987, KIDNEY INT, V32, P274, DOI 10.1038/ki.1987.203; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TRAVIS LB, 1989, NEW ENGL J MED, V321, P544; WHITINGOKEEFE Q, 1982, ANN INTERN MED, V96, P718, DOI 10.7326/0003-4819-96-6-718; 1985, SAS USERS GUIDE STAT; 1988, BMDP STATISTICAL SOF	32	143	145	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					114	123		10.7326/0003-4819-116-2-114	http://dx.doi.org/10.7326/0003-4819-116-2-114			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727614				2022-12-28	WOS:A1992GZ35600003
J	DAUNNO, T; VAUGHN, TE				DAUNNO, T; VAUGHN, TE			VARIATIONS IN METHADONE TREATMENT PRACTICES - RESULTS FROM A NATIONAL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; MAINTENANCE	Objective. - To examine the extent to which outpatient methadone maintenance treatment units are engaging in treatment practices that previous research indicates are ineffective (eg, inadequate dose levels); to examine factors that may be related to variation in methadone treatment practices. Design. - Survey of unit directors and clinical supervisors. Setting. - The study includes units that vary in terms of ownership (public, private for-profit, or private not-for-profit) and setting (eg, hospital-based, mental health center-based, or free-standing facility). Participants. - A national random sample of 172 units participated, for an 82% response rate; the data were weighted to ensure that they were nationally representative. Main Outcome Measures. - Clients' awareness of and influence on doses; units' use of take-home dosages; upper limits on doses; average dose levels; unit emphasis on decreasing dosages; time when clients are encouraged to detoxify; average length of treatment. Results. - The data indicate that many units have treatment practices such as low average dose levels that are not effective according to the majority of previous studies. Units with higher average dose levels have longer average lengths of time in treatment. Conclusions. - Steps should be taken to monitor and, if necessary, change the treatment practices of methadone units that are providing inadequate dose levels with little client input.			DAUNNO, T (corresponding author), UNIV MICHIGAN,INST SOCIAL RES,SURVEY RES CTR,POB 1248,ANN ARBOR,MI 48106, USA.		D'Aunno, Thomas/P-9320-2019; D'Aunno, Thomas/V-8107-2019					ABDULQUADER AS, 1987, CONTEMP DRUG PROBL, V14, P425; BAKTI SL, 1988, 50TH ANN M COMM PROB; BALL JC, 1988, J HEALTH SOC BEHAV, V29, P214, DOI 10.2307/2137033; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; COOPER JR, 1983, ADM831281 US DEP HLT; DAMANDA C, 1983, ADM831281 US DEP HLT, P637; DOLE VP, 1982, NEW ENGL J MED, V306, P169, DOI 10.1056/NEJM198201213060310; DOLE VP, 1989, JAMA-J AM MED ASSOC, V262, P1681, DOI 10.1001/jama.262.12.1681; DOLE VP, 1988, JAMA-J AM MED ASSOC, V260, P3025, DOI 10.1001/jama.260.20.3025; FLYER P, 1990, SAMPLING WEIGHTING D; HARGREAVES WA, 1983, ADM831281 US DEP HLT, P19; Hubbard RL, 1989, DRUG ABUSE TREATMENT; JARLAIS DCD, 1981, ANN NY ACAD SCI, V362, P231; LIAPPAS JA, 1988, INT J ADDICT, V23, P927, DOI 10.3109/10826088809058849; MCLELLAN TA, 1983, ADM831281 US DEP HLT, P500; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; PRICE RH, 1991, ADM911754 US DEP HLT, P63; ROSENTHAL SN, 1985, INT J NUCL MED BIOL, V12, P375, DOI 10.1016/S0047-0740(85)80007-3; SIMPSON DD, 1978, 7810 TEX CHRIST U I; WATTERS JK, 1986, TREATMENT ENV CLIENT; WOODY GE, 1983, ADM831281 US DEP HLT, P541; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185	22	190	189	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					253	258		10.1001/jama.267.2.253	http://dx.doi.org/10.1001/jama.267.2.253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY046	1727522				2022-12-28	WOS:A1992GY04600029
J	GETHING, MJ; SAMBROOK, J				GETHING, MJ; SAMBROOK, J			PROTEIN FOLDING IN THE CELL	NATURE			English	Review							CHAIN BINDING-PROTEIN; IMMUNOGLOBULIN HEAVY-CHAIN; RIBULOSE BISPHOSPHATE CARBOXYLASE; GLUCOSE-REGULATED PROTEINS; ESCHERICHIA-COLI DNAK; PURIFIED PRECURSOR PROTEIN; CIS-TRANS-ISOMERASE; ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; SACCHAROMYCES-CEREVISIAE	In the cell, as in vitro, the final conformation of a protein is determined by its amino-acid sequence. But whereas some isolated proteins can be denatured and refolded in vitro in the absence of other macromolecular cellular components, folding and assembly of polypeptides in vivo involves other proteins, many of which belong to families that have been highly conserved during evolution.	HOWARD HUGHES MED INST, DALLAS, TX USA	Howard Hughes Medical Institute	GETHING, MJ (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BACHINGER HP, 1991, J CELL BIOCH SG, V15, P188; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BOSTON RS, IN PRESS PL CELL; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1983, MOL CELL BIOL, V4, P2697; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; COLMAN A, 1982, J MOL BIOL, V160, P459, DOI 10.1016/0022-2836(82)90308-4; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; CRAIG EA, 1990, STRESS PROTEINS BIOL, P320; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1989, BIOCHEM SOC SYMP, V55, P45; Dingwall C, 1990, Semin Cell Biol, V1, P11; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FARQUHAR R, IN PRESS GENE; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FONTES EBP, IN PRESS PL CELL; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1989, METHOD CELL BIOL, V32, P185; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; Hallberg R L, 1990, Semin Cell Biol, V1, P37; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; Hemmingsen S M, 1990, Semin Cell Biol, V1, P47; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT L, 1987, IMMUNOL TODAY, V8, P111, DOI 10.1016/0167-5699(87)90861-9; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOCH G, 1986, J CELL SCI, V86, P217; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, IN PRESS PEPTIDES; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE AS, 1984, J BIOL CHEM, V259, P4616; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LORIMER GH, 1991, J CELL BIOCH SG, V15, P160; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MACER DRJ, 1988, J CELL SCI, V91, P61; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; MORIMOTO R I, 1990, P1; MORRISON SL, 1975, J IMMUNOL, V114, P655; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NICHOLSON RC, 1990, P NATL ACAD SCI USA, V87, P1159, DOI 10.1073/pnas.87.3.1159; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; PETTEY CL, 1987, J BIOL CHEM, V262, P4854; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POLAINA J, 1982, MOL GEN GENET, V186, P253, DOI 10.1007/BF00331858; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAMBROOK J, 1989, NATURE, V342, P224, DOI 10.1038/342224a0; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SPIK G, 1991, J BIOL CHEM, V266, P10735; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WILDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	207	3783	3940	9	431	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1992	355	6355					33	45		10.1038/355033a0	http://dx.doi.org/10.1038/355033a0			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1731198				2022-12-28	WOS:A1992GY22800043
J	MITRAKOU, A; KELLEY, D; MOKAN, M; VENEMAN, T; PANGBURN, T; REILLY, J; GERICH, J				MITRAKOU, A; KELLEY, D; MOKAN, M; VENEMAN, T; PANGBURN, T; REILLY, J; GERICH, J			ROLE OF REDUCED SUPPRESSION OF GLUCOSE-PRODUCTION AND DIMINISHED EARLY INSULIN RELEASE IN IMPAIRED GLUCOSE-TOLERANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; ORAL GLUCOSE; POSTPRANDIAL HYPERGLYCEMIA; PIMA-INDIANS; BETA-CELL; SECRETION; RESISTANCE; MUSCLE; PROINSULIN; RECEPTOR	Background. Insulin resistance and impaired insulin secretion both occur in non-insulin-dependent diabetes (NIDDM), but their relative importance is unclear. Hyperglycemia itself has adverse effects on tissue insulin sensitivity and insulin secretion that make it difficult to distinguish between primary and secondary abnormalities. To avoid this problem we studied subjects with postprandial glucose intolerance but not sustained hyperglycemia. Methods. We compared the rate of systemic appearance and disappearance of glucose, the output of endogenous hepatic glucose, splanchnic and muscle uptake of glucose, and plasma insulin and glucagon responses after the ingestion of 1 g of glucose per kilogram of body weight in 15 subjects with impaired glucose tolerance (8 of them nonobese and 7 obese) and in 16 normal subjects (9 nonobese and 7 obese) who were matched for age and weight. Results. After glucose ingestion the mean (+/- SE) rate of total systemic appearance of glucose was significantly higher in both the nonobese subjects (455 +/- 12 mmol per five hours) and the obese subjects (486 +/- 17 mmol per five hours) with impaired glucose tolerance than in the respective normal subjects (411 +/- 11 and 436 +/- 7 mmol per five hours). This difference was fully accounted for by the reduced suppression of endogenous hepatic glucose in the subjects with impaired glucose tolerance (a reduction of about 28 percent, vs. 48 percent in the normal subjects; P < 0.01). Despite late hyperinsulinemia, at 30 minutes the subjects with impaired glucose tolerance had smaller increases in plasma insulin and smaller reductions in plasma glucagon (both P < 0.01). Molar ratios of plasma insulin to plasma glucagon levels correlated inversely (r = -0.62, P < 0.001) with the rates of systemic glucose appearance; the latter correlated positively (r = 0.72, P < 0.0001) with peak plasma glucose concentrations. Conclusions. Impaired glucose tolerance, the precursor of NIDDM, results primarily from reduced suppression of hepatic glucose output due to abnormal pancreatic islet-cell function. The late hyperinsulinemia may be the consequence of an inadequate early beta-cell response rather than of insulin resistance.	UNIV PITTSBURGH,SCH MED,DEPT MED,CLIN RES CTR,3488 PRESBYTERIAN UNIV HOSP,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PHYSIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCRR NIH HHS [5M01 RR00056] Funding Source: Medline; NIDDK NIH HHS [5R37 DK20411] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020411] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES R, 1956, J CLIN INVEST, V35, P671, DOI 10.1172/JCI103324; BLOOM B, 1962, ANAL BIOCHEM, V3, P85, DOI 10.1016/0003-2697(62)90048-9; BRUCE DG, 1988, DIABETES, V37, P736, DOI 10.2337/diabetes.37.6.736; CAMPBELL PJ, 1988, METABOLISM, V37, P15, DOI 10.1016/0026-0495(88)90023-6; CHIASSON JL, 1977, FED PROC, V36, P229; CHILES R, 1970, DIABETES, V19, P458, DOI 10.2337/diab.19.6.458; COOPER KE, 1955, J PHYSIOL-LONDON, V128, P258, DOI 10.1113/jphysiol.1955.sp005304; DeFronzo R A, 1983, Am J Med, V74, P52, DOI 10.1016/0002-9343(83)90654-X; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DILLON RS, 1965, DIABETES, V14, P672, DOI 10.2337/diab.14.10.672; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FELIG P, 1978, DIABETES, V27, P121, DOI 10.2337/diab.27.2.121; FERRANNINI E, 1989, DIABETES METAB REV, V5, P711, DOI 10.1002/dmr.5610050806; FERRANNINI E, 1988, METABOLISM, V37, P79, DOI 10.1016/0026-0495(88)90033-9; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; GERICH JE, 1988, BAILLIERE CLIN ENDOC, V2, P307, DOI 10.1016/S0950-351X(88)80034-X; GREENFIELD ADM, 1963, BRIT MED BULL, V19, P101, DOI 10.1093/oxfordjournals.bmb.a070026; GREENSTEIN BD, 1979, BRIT J PHARMACOL, V66, P317, DOI 10.1111/j.1476-5381.1979.tb13682.x; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HETENYI G, 1974, FED PROC, V33, P1841; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V35, P1192, DOI 10.1093/ajcn/35.5.1192; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KIPNIS D, 1968, ANN INTERN MED, V67, P891; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LUZI L, 1989, AM J PHYSIOL, V257, pE241, DOI 10.1152/ajpendo.1989.257.2.E241; MANDARINO L, 1984, DIABETOLOGIA, V27, P358, DOI 10.1007/BF00304850; MITRAKOU A, 1990, DIABETES, V39, P1381, DOI 10.2337/diabetes.39.11.1381; OHLSON LO, 1988, DIABETOLOGIA, V31, P798; ORAHILLY SP, 1986, LANCET, V2, P360; OSEI K, 1987, PANCREAS, V2, P386, DOI 10.1097/00006676-198707000-00004; PERLEY MJ, 1967, J CLIN INVEST, V46, P1954, DOI 10.1172/JCI105685; PFEIFER MA, 1981, DIABETOLOGIA, V21, P198; PORTE D, 1969, J CLIN INVEST, V48, P2309, DOI 10.1172/JCI106197; RADZIUK J, 1978, METABOLISM, V27, P657, DOI 10.1016/0026-0495(78)90003-3; REAVEN G, 1968, DIABETES, V17, P560, DOI 10.2337/diab.17.9.560; REICHARD GA, 1963, J BIOL CHEM, V238, P495; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; SAAD MF, 1990, J CLIN ENDOCR METAB, V70, P1247, DOI 10.1210/jcem-70-5-1247; SAAD MF, 1989, LANCET, V1, P1356; SACCA L, 1984, J CLIN INVEST, V73, P1683, DOI 10.1172/JCI111375; SAVAGE PJ, 1975, DIABETES, V24, P362, DOI 10.2337/diabetes.24.4.362; STEINER KE, 1982, DIABETES, V31, P964, DOI 10.2337/diacare.31.11.964; TEMPLE RC, 1990, CLIN ENDOCRINOL, V32, P689, DOI 10.1111/j.1365-2265.1990.tb00915.x; UNGER RH, 1985, DIABETOLOGIA, V28, P119; UNGER RH, 1976, PHYSIOL REV, V56, P779; WARD WK, 1987, DIABETOLOGIA, V30, P698, DOI 10.1007/BF00296991; YKIJARVINEN H, 1987, DIABETES, V36, P892, DOI 10.2337/diabetes.36.8.892; YOSHIOKA N, 1988, DIABETOLOGIA, V31, P355, DOI 10.1007/BF02341503; ZIMMET P, 1979, DIABETES, V28, P624, DOI 10.2337/diabetes.28.7.624; 1980, WHO TECH REP SER, V646, P1	53	517	536	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					22	29		10.1056/NEJM199201023260104	http://dx.doi.org/10.1056/NEJM199201023260104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1727062				2022-12-28	WOS:A1992GX31500004
J	REVAH, F; BERTRAND, D; GALZI, JL; DEVILLERSTHIERY, A; MULLE, C; HUSSY, N; BERTRAND, S; BALLIVET, M; CHANGEUX, JP				REVAH, F; BERTRAND, D; GALZI, JL; DEVILLERSTHIERY, A; MULLE, C; HUSSY, N; BERTRAND, S; BALLIVET, M; CHANGEUX, JP			MUTATIONS IN THE CHANNEL DOMAIN ALTER DESENSITIZATION OF A NEURONAL NICOTINIC RECEPTOR	NATURE			English	Article							AFFINITY BINDING-SITE; ACETYLCHOLINE-RECEPTOR; H-3 CHLORPROMAZINE; ION CHANNEL; DELTA-SUBUNIT; NONCOMPETITIVE BLOCKERS; ACTIVATED CHANNELS; AMINO-ACIDS; SUPERFAMILY; TRANSPORT	A VARIETY of ligand-gated ion channels undergo a fast activation process after the rapid application of agonist and also a slower transition towards desensitized or inactivated closed channel states when exposure to agonist is prolonged 1-5. Desensitization involves at least two distinct closed states in the acetylcholine receptor, each with an affinity for agonists higher than those of the resting or active conformations 1-5. Here we investigate how structural elements could be involved in the desensitization of the acetylcholine-gated ion channel from the chick brain alpha-bungarotoxin sensitive homo-oligomeric alpha-7 receptor 6,7, using site-directed mutagenesis and expression in Xenopus oocytes. Mutations of the highly conserved leucine 247 residue 8,9 from the uncharged MII segment of alpha-7 suppress inhibition by the open-channel blocker QX-222 (ref. 10), indicating that this residue, like others from MII (refs 11-22), faces the lumen of the channel. But, unexpectedly, the same mutations decrease the rate of desensitization of the response, increase the apparent affinity for acetylcholine and abolish current rectification. Moreover, unlike wild-type alpha-7, which has channels with a single conductance level, the leucine-to-threonine mutant has an additional conducting state active at low acetylcholine concentrations. It is possible that mutation of Leu 247 renders conductive one of the high-affinity desensitized states of the receptor.	UNIV GENEVA,DEPT BIOCHIM,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,FAC MED,DEPT PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva	REVAH, F (corresponding author), INST PASTEUR,CNRS,UNITE RECH ASSOCIEE D1284,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			Mulle, Christophe/0000-0003-2709-6615				Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P5452, DOI 10.1021/bi00292a029; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P281, DOI 10.1111/j.1432-1033.1979.tb12894.x; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEUBIG RR, 1982, BIOCHEMISTRY-US, V21, P3460, DOI 10.1021/bi00257a032; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; [No title captured]	25	461	474	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					846	849		10.1038/353846a0	http://dx.doi.org/10.1038/353846a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719423				2022-12-28	WOS:A1991GM73200060
J	STEIMER, KS; SCANDELLA, CJ; SKILES, PV; HAIGWOOD, NL				STEIMER, KS; SCANDELLA, CJ; SKILES, PV; HAIGWOOD, NL			NEUTRALIZATION OF DIVERGENT HIV-1 ISOLATES BY CONFORMATION-DEPENDENT HUMAN-ANTIBODIES TO GP120	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; HTLV-III/LAV; CD4 RECEPTOR; CHIMPANZEES; INFECTION; IDENTIFICATION; DETERMINANT; RETROVIRUS; SEQUENCE	The spectrum of human immunodeficiency virus type 1 (HIV-1) isolates neutralized by antibodies from HIV-1-infected humans is broader than the spectrum of isolates neutralized by sera from animals immunized with purified gp120 subunits. This broader neutralization was due, in part, to the presence of antibodies to conserved gp120 conformational epitopes. Purified conformation-dependent gp120-specific human antibodies neutralized a wider range of virus isolates than human antibodies directed to linear determinants in gp120 and were also responsible for the majority of the gp120-specific CD4-blocking activity of HIV-1-infected human sera. A gp120 subunit vaccine that effectively presents these conformation-dependent neutralization epitopes should protect against a broader range of HIV-1 variants than a vaccine that presents exclusively linear determinants.			STEIMER, KS (corresponding author), CHIRON CORP,EMERYVILLE,CA 94608, USA.		Haigwood, Nancy Logan/AAV-7484-2020	Haigwood, Nancy/0000-0002-1477-9575				ARTHUR LO, 1987, P NATL ACAD SCI USA, V84, P8583, DOI 10.1073/pnas.84.23.8583; BARR PJ, 1987, VACCINE, V5, P90, DOI 10.1016/0264-410X(87)90053-3; BARR PJ, 1987, S MOL CELLULAR BIOL, V43, P205; BERKOWER I, 1989, J EXP MED, V170, P1681, DOI 10.1084/jem.170.5.1681; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; GARVEY JS, 1977, METHOD IMMUNOL, P218; GOUDSMIT J, 1989, AIDS, V3, pS119, DOI 10.1097/00002030-198901001-00017; HAIGWOOD NL, 1991, VACCINES, V91, P51; HAIGWOOD NL, 1990, VACCINES, V90, P31; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; Means G.E., 1971, CHEM MODIFICATION PR; MYERS G, 1990, HUMAN RETROVIRUSES A; NARA PL, 1988, J VIROL, V62, P2622, DOI 10.1128/JVI.62.8.2622-2628.1988; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PRINCE AM, 1987, J INFECT DIS, V156, P268, DOI 10.1093/infdis/156.2.268; PROFY AT, 1990, J IMMUNOL, V144, P4641; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3; ROBEY WG, 1986, P NATL ACAD SCI USA, V83, P7023, DOI 10.1073/pnas.83.18.7023; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SARIN PS, 1986, SCIENCE, V232, P1135, DOI 10.1126/science.3010464; SCANDELLA CJ, UNPUB; STEIMER KS, 1988, VACCINES, V88, P347; STEIMER KS, 1987, VACCINES, V87, P236; STEIMER KS, IN PRESS AIDS RES RE, V2; WEISS RA, 1986, NATURE, V324, P572, DOI 10.1038/324572a0	36	253	259	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					105	108		10.1126/science.1718036	http://dx.doi.org/10.1126/science.1718036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718036				2022-12-28	WOS:A1991GH60500039
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			REEXAMINATION OF THE FOLDING OF BPTI - PREDOMINANCE OF NATIVE INTERMEDIATES	SCIENCE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; STRUCTURAL CHARACTERIZATION; DISULFIDE BOND; RIBONUCLEASE-A; CYTOCHROME-C; PROTEIN; NMR; EXCHANGE; PATHWAY; ENERGETICS	Bovine pancreatic trypsin inhibitor (BPTI) continues to be the only protein for which a detailed pathway of folding has been described. Previous studies led to the conclusion that nonnative states are well populated in the oxidative folding of BPTI. This conclusion has broadly influenced efforts to understand protein folding. The population of intermediates present during the folding of BPTI has been reexamined by modern separation techniques. It was found that all well-populated folding intermediates contain only native disulfide bonds. These data emphasize the importance of native protein structure for understanding protein folding.	MIT,DEPT PHYS,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NCRR NIH HHS [RR 05927] Funding Source: Medline; NIGMS NIH HHS [GM 41307] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041307] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CREIGHTON TE, 1974, J MOL BIOL, V87, P603, DOI 10.1016/0022-2836(74)90106-5; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1977, J MOL BIOL, V113, P295, DOI 10.1016/0022-2836(77)90143-7; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; CREIGHTON TE, 1975, J MOL BIOL, V96, P777, DOI 10.1016/0022-2836(75)90152-7; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P3, DOI 10.1016/0959-440X(91)90003-C; DARBY NJ, 1991, FEBS LETT, V279, P61, DOI 10.1016/0014-5793(91)80251-W; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; GOLDENBERG DP, 1985, BIOPOLYMERS, V24, P167, DOI 10.1002/bip.360240114; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIEFHABER T, IN PRESS PROTEINS; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; MCCOY LF, 1980, BIOCHEMISTRY-US, V19, P4738, DOI 10.1021/bi00562a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STALEY JP, UNPUB; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1980, NATURE, V286, P630, DOI 10.1038/286630a0; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JG, UNPUB; WEISSMAN JS, 1982, J MOL BIOL, V155, P347; YAGISAWA S, 1989, BIOCHEM J, V263, P985, DOI 10.1042/bj2630985	46	513	518	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1386	1393		10.1126/science.1716783	http://dx.doi.org/10.1126/science.1716783			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716783				2022-12-28	WOS:A1991GF85100032
J	BARON, S; TYRING, SK; FLEISCHMANN, WR; COPPENHAVER, DH; NIESEL, DW; KLIMPEL, GR; STANTON, GJ; HUGHES, TK				BARON, S; TYRING, SK; FLEISCHMANN, WR; COPPENHAVER, DH; NIESEL, DW; KLIMPEL, GR; STANTON, GJ; HUGHES, TK			THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; TUMOR-NECROSIS-FACTOR; CHRONIC HEPATITIS-B; PHASE-II TRIAL; IMMUNODEFICIENCY-SYNDROME AIDS; RENAL-CELL CARCINOMA; RECOMBINANT LEUKOCYTE INTERFERON; HUMAN-LYMPHOBLASTOID INTERFERON; GAMMA-INTERFERON; IFN-GAMMA	The interferons (IFN) are one of the body's natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (alpha, beta, and gamma), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi's sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs alpha and beta and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.	UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	BARON, S (corresponding author), UNIV TEXAS,MED BRANCH,DEPT MICROBIOL,GALVESTON,TX 77550, USA.							ABBRUZZESE JL, 1990, J BIOL RESP MODIF, V9, P522; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ANTONELLI G, 1991, J INFECT DIS, V163, P882, DOI 10.1093/infdis/163.4.882; ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309; ARNHEITER H, 1990, New Biologist, V2, P851; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BAJETTA E, 1990, AM J CLIN ONCOL-CANC, V13, P405, DOI 10.1097/00000421-199010000-00008; BARON S, 1987, INTERFERON SYSTEM CU; BARON S, 1963, ADV VIRUS RES, P39; BERGLUND O, 1991, J INFECT DIS, V163, P710, DOI 10.1093/infdis/163.4.710; BERGMANN L, 1989, EUR J CANCER CLIN S3, V25, P831; BERMAN B, 1989, J AM ACAD DERMATOL, V21, P694, DOI 10.1016/S0190-9622(89)70239-5; BILLIAU A, 1983, INTERFERONS MOL BIOL, P255; BLACK CM, 1988, INTERFERON NONVIRAL, P237; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BOUTIN C, 1991, CANCER, V67, P2033, DOI 10.1002/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8; BROWN SL, 1989, BLOOD, V73, P651; BRUCKNER H W, 1990, Cancer, V66, P135; BUNN PA, 1989, J INVEST DERMATOL, V93, P545; BYRNE GI, 1988, INTERFERON NONVIRAL, P53; CANNON GW, 1990, J RHEUMATOL, V17, P304; CASATO M, 1989, J INTERFERON RES, V9, pS113; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; CONION KC, 1990, CANCER, V65, P2237; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; COPPENS JP, 1989, LIVER, V9, P307; CORNELL RC, 1990, J AM ACAD DERMATOL, V23, P694, DOI 10.1016/0190-9622(90)70276-N; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DEGRE M, 1988, INTERFERON NONVIRAL, P295; DEWIT R, 1988, LANCET, V2, P1214; DEWIT R, 1991, J INTERN MED, V229, P35; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DOANE LL, 1990, HEMATOL ONCOL CLIN N, V2, P489; DOUGLAS JM, 1990, J INFECT DIS, V162, P52, DOI 10.1093/infdis/162.1.52; DOUGLAS RM, 1986, NEW ENGL J MED, V314, P65, DOI 10.1056/NEJM198601093140201; EDWARDS L, 1990, ARCH DERMATOL, V126, P1029, DOI 10.1001/archderm.126.8.1029; EVERS M, 1991, ANN SURG, V213, P411; FALTYNEK C R, 1988, Biofactors, V1, P227; FATTOVICH G, 1989, J HEPATOL, V9, P331, DOI 10.1016/0168-8278(89)90142-6; FIERLBECK G, 1990, Journal of Interferon Research, V10, pS16; FLEISCHMANN WR, 1984, J BIOL RESP MODIF, V3, P397; FLEISCHMANN WR, 1984, ANTIVIR RES, V4, P221, DOI 10.1016/0166-3542(84)90020-2; FLEISCHMANN WR, 1986, CANCER RES, V46, P1722; FOSSA SD, 1990, CANCER, V65, P2451, DOI 10.1002/1097-0142(19900601)65:11<2451::AID-CNCR2820651108>3.0.CO;2-3; FRIEDLAND GH, 1988, J ACQ IMMUN DEF SYND, V1, P111; FROST L, 1990, BRIT J OBSTET GYNAEC, V97, P626, DOI 10.1111/j.1471-0528.1990.tb02552.x; GALLIN JI, 1991, NEW ENGL J MED, V324, P509; GIACOMINI P, 1990, INT J CANCER, V46, P539, DOI 10.1002/ijc.2910460334; GISSLINGER H, 1989, LANCET, V1, P634, DOI 10.1016/S0140-6736(89)92142-9; GLASHAN RW, 1990, J UROLOGY, V144, P658, DOI 10.1016/S0022-5347(17)39547-2; GOLOMB HM, 1988, J NATL CANCER I, V80, P369, DOI 10.1093/jnci/80.5.369; GRANSTEIN RD, 1990, ARCH DERMATOL, V126, P1295, DOI 10.1001/archderm.126.10.1295; Greenberg S B, 1987, Infect Dis Clin North Am, V1, P383; GROOPMAN JE, 1989, ANN INTERN MED, V110, P335, DOI 10.7326/0003-4819-110-5-335; GUILNOT F, 1987, BLOOD S1, V70, P230; HARMS G, 1989, LANCET, V1, P1287; HEAGY W, 1990, J ACQ IMMUN DEF SYND, V3, P584; HEALY GB, 1988, NEW ENGL J MED, V319, P401, DOI 10.1056/NEJM198808183190704; HESS CB, 1989, MICROB PATHOGENESIS, V7, P111, DOI 10.1016/0882-4010(89)90030-2; HOUGHTON AN, 1984, J EXP MED, V160, P255, DOI 10.1084/jem.160.1.255; HUGHES TK, 1988, ANTIVIR RES, V10, P1, DOI 10.1016/0166-3542(88)90010-1; HUGHES TK, 1987, J INTERFERON RES, V7, P603, DOI 10.1089/jir.1987.7.603; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JACOBSEN H, 1986, ARZNEIMITTEL-FORSCH, V36-1, P512; KAHAN A, 1989, AM J MED, V87, P273; KAKUMU S, 1990, AM J GASTROENTEROL, V85, P655; KINNEY P, 1990, J CLIN ONCOL, V8, P881, DOI 10.1200/JCO.1990.8.5.881; KNOBLER R L, 1990, Journal of Interferon Research, V10, pS115; KOECH D K, 1990, Molecular Biotherapy, V2, P91; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; KOVARIK J, 1988, TRANSPLANTATION, V45, P402, DOI 10.1097/00007890-198802000-00031; KRIGEL RL, 1988, J BIOL RESP MODIF, V7, P359; KRIGEL RL, 1990, J CLIN ONCOL, V8, P460, DOI 10.1200/JCO.1990.8.3.460; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; KURZROCK R, 1986, J CLIN ONCOL, V4, P1677, DOI 10.1200/JCO.1986.4.11.1677; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LE JM, 1986, J IMMUNOL, V136, P4525; LEE KH, 1989, J CLIN ONCOL, V7, P1726, DOI 10.1200/JCO.1989.7.11.1726; LIPPMAN S, 1991, P AN M AM SOC CLIN, V10, P197; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MEYER JL, 1989, PHARMACOL THERAPEUT, V42, P251, DOI 10.1016/0163-7258(89)90038-7; MILES SA, 1990, ANN INTERN MED, V112, P582, DOI 10.7326/0003-4819-112-8-582; MITTELMAN A, 1990, CANCER, V66, P664, DOI 10.1002/1097-0142(19900815)66:4<664::AID-CNCR2820660411>3.0.CO;2-D; Nagai M, 1989, Gan To Kagaku Ryoho, V16, P156; NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NIESEL DW, 1986, INFECT IMMUN, V52, P828, DOI 10.1128/IAI.52.3.828-833.1986; OZER H, 1990, ASCO P, V9, pC21; PANITCH HS, 1986, NEUROLOGY, V36, P285; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PHILIP R, 1986, NATURE, V323, P86, DOI 10.1038/323086a0; PORZSOLT F, 1989, J CANCER RES CLIN, V115, P465, DOI 10.1007/BF00393339; REDMAN BG, 1990, J CLIN ONCOL, V8, P1269, DOI 10.1200/JCO.1990.8.7.1269; REICHMAN RC, 1988, ANN INTERN MED, V108, P675, DOI 10.7326/0003-4819-108-5-675; REICHMAN RC, 1990, J INFECT DIS, V162, P1270, DOI 10.1093/infdis/162.6.1270; ROBINS HI, 1989, CANCER RES, V49, P1609; ROENIGK HH, 1990, J INVEST DERMATOL, V95, pS198, DOI 10.1111/1523-1747.ep12875523; ROSENBERG SA, 1989, J CLIN ONCOL, V7, P1863, DOI 10.1200/JCO.1989.7.12.1863; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SARACCO G, 1989, HEPATOLOGY, V10, P336, DOI 10.1002/hep.1840100315; SCHILLER JH, 1990, CANCER RES, V50, P4588; SCHWARTZ R, 1985, INT J CANCER, V35, P245, DOI 10.1002/ijc.2910350217; SEKAR V, 1983, BIOCHEM BIOPH RES CO, V114, P950, DOI 10.1016/0006-291X(83)90652-6; SPIEGEL RJ, 1989, UROLOGY, V34, P75, DOI 10.1016/0090-4295(89)90238-0; STADLER R, 1990, J INVEST DERMATOL, V95, pS170, DOI 10.1111/1523-1747.ep12875494; SWANSON DA, 1988, SEMIN SURG ONCOL, V4, P174, DOI 10.1002/ssu.2980040307; TAKIGUCHI M, 1985, EUR J IMMUNOL, V15, P809, DOI 10.1002/eji.1830150813; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TALPAZ M, 1990, NOV ANN M INT SOC IN; TAYLOR JL, 1990, VIRUS RES       0115, P1; TEMPERO MA, 1990, J CLIN ONCOL, V8, P2019, DOI 10.1200/JCO.1990.8.12.2019; THESTRUPPEDERSEN K, 1988, BRIT J DERMATOL, V118, P811, DOI 10.1111/j.1365-2133.1988.tb02600.x; THIVOLET J, 1990, BRIT J DERMATOL, V122, P405, DOI 10.1111/j.1365-2133.1990.tb08290.x; TSURUO T, 1982, GANN, V73, P42; TULLI A, 1989, J AM ACAD DERMATOL, V20, P686, DOI 10.1016/S0190-9622(89)80150-1; TYRING SK, 1987, INT J DERMATOL, V26, P549, DOI 10.1111/j.1365-4362.1987.tb02304.x; TYRING SK, 1988, SEMIN ONCOL, V15, P35; TYRING SK, 1987, J INVEST DERMATOL, V89, P136, DOI 10.1111/1523-1747.ep12470547; VANDAMME J, 1987, J IMMUNOL, V139, P1867; VASILYEV R V, 1990, European Journal of Gynaecological Oncology, V11, P313; VOLBERDING P A, 1987, Cancer, V59, P620, DOI 10.1002/1097-0142(19870201)59:3+<620::AID-CNCR2820591309>3.0.CO;2-5; VONSCHEIDT W, 1990, KLIN WOCHENSCHR, V68, P241; WADLER S, 1990, CANCER RES, V50, P3473; WADLER S, 1990, CANCER RES, V50, P2056; WEIGENT DA, 1983, BIOCHEM BIOPH RES CO, V111, P525, DOI 10.1016/0006-291X(83)90338-8; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WHITE CW, 1991, J PEDIATR-US, V118, P59, DOI 10.1016/S0022-3476(05)81844-X; YASUI H, 1986, P NATL ACAD SCI USA, V83, P6622, DOI 10.1073/pnas.83.17.6622; Zabel P, 1990, Pneumologie, V44 Suppl 1, P586; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	132	607	632	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1375	1383		10.1001/jama.266.10.1375	http://dx.doi.org/10.1001/jama.266.10.1375			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1715409				2022-12-28	WOS:A1991GD80700032
J	DEVIVO, DC; TRIFILETTI, RR; JACOBSON, RI; RONEN, GM; BEHMAND, RA; HARIK, SI				DEVIVO, DC; TRIFILETTI, RR; JACOBSON, RI; RONEN, GM; BEHMAND, RA; HARIK, SI			DEFECTIVE GLUCOSE-TRANSPORT ACROSS THE BLOOD-BRAIN-BARRIER AS A CAUSE OF PERSISTENT HYPOGLYCORRHACHIA, SEIZURES, AND DEVELOPMENTAL DELAY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POSITRON EMISSION TOMOGRAPHY; MESSENGER-RNA; GENE; CELLS; RAT; IDENTIFICATION; EXPRESSION; CLONING; PROTEIN; CDNA		MEM UNIV NEWFOUNDLAND,DEPT PEDIAT,PEDIAT NEUROL SECT,ST JOHNS A1C 5S7,NEWFOUNDLAND,CANADA; JANEWAY CHILD HLTH CTR,ST JOHNS,NEWFOUNDLAND,CANADA; UNIV HOSP CLEVELAND,DEPT NEUROL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; COLUMBIA PRESBYTERIAN MED CTR,DEPT PEDIAT,DIV PEDIAT NEUROL,NEW YORK,NY 10032; COLUMBIA PRESBYTERIAN MED CTR,DEPT NEUROL,NEW YORK,NY 10032	Memorial University Newfoundland; Memorial University Newfoundland; University Hospitals of Cleveland; Case Western Reserve University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital			Ronen, Gabriel M/AAS-3048-2021; Ronen, Gabriel M/AAS-5028-2021	Ronen, Gabriel M/0000-0002-7467-0627; Ronen, Gabriel M/0000-0002-7467-0627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON L, 1988, J BIOL CHEM, V263, P11414; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; CREMER JE, 1981, EARLY HUM DEV, V5, P117, DOI 10.1016/0378-3782(81)90043-8; DEVIVO DC, 1978, ANN NEUROL, V3, P331, DOI 10.1002/ana.410030410; DEVIVO DC, 1990, ANN NEUROL, V29, P414; DEVIVO DC, 1980, CEREBRAL METABOLISM, P243; DICK APK, 1986, J NEUROCHEM, V46, P1406, DOI 10.1111/j.1471-4159.1986.tb01755.x; DICK APK, 1984, P NATL ACAD SCI-BIOL, V81, P7233, DOI 10.1073/pnas.81.22.7233; DYVE S, 1991, ACTA NEUROL SCAND, V83, P14; FISHMAN RA, 1980, CEREBROSPINAL FLUID, P212; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657; HARIK S I, 1989, Alzheimer Disease and Associated Disorders, V3, P191, DOI 10.1097/00002093-198903040-00001; HARIK SI, 1990, P NATL ACAD SCI USA, V87, P4261, DOI 10.1073/pnas.87.11.4261; HARIK SI, 1991, J CLIN ENDOCR METAB, V72, P814, DOI 10.1210/jcem-72-4-814; HARIK SI, 1990, J NEUROSCI, V10, P3862, DOI 10.1523/JNEUROSCI.10-12-03862.1990; HASPEL HC, 1988, J BIOL CHEM, V263, P398; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; JONES MN, 1981, BIOCHIM BIOPHYS ACTA, V650, P1, DOI 10.1016/0304-4157(81)90006-X; KALARIA RN, 1989, J NEUROCHEM, V53, P1083, DOI 10.1111/j.1471-4159.1989.tb07399.x; KALARIA RN, 1988, ANN NEUROL, V24, P757, DOI 10.1002/ana.410240610; KASANICKI MA, 1987, BIOCHEM J, V247, P101, DOI 10.1042/bj2470101; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KRAUS H, 1974, H-S Z PHYSIOL CHEM, V355, P164, DOI 10.1515/bchm2.1974.355.1.164; LAMANNA JC, 1985, BRAIN RES, V326, P299, DOI 10.1016/0006-8993(85)90039-3; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; Passonneau OH, 1972, FLEXIBLE SYSTEM ENZY, P68, DOI 10.1016/B978-0-12-457950-7.50007%26%23x2013%3B3; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHOWS TB, 1987, DIABETES, V36, P546, DOI 10.2337/diabetes.36.4.546; Siesjo BK, 1978, BRAIN ENERGY METABOL, P101; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; WEILERGUTTLER H, 1989, BIOL CHEM H-S, V370, P467, DOI 10.1515/bchm3.1989.370.1.467; WERNER H, 1989, MOL ENDOCRINOL, V3, P273, DOI 10.1210/mend-3-2-273; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	41	524	530	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					703	709		10.1056/NEJM199109053251006	http://dx.doi.org/10.1056/NEJM199109053251006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1714544				2022-12-28	WOS:A1991GD49700006
J	COHEN, S; TYRRELL, DAJ; SMITH, AP				COHEN, S; TYRRELL, DAJ; SMITH, AP			PSYCHOLOGICAL STRESS AND SUSCEPTIBILITY TO THE COMMON COLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTEERS; INFECTION	Background. It is not known whether psychological stress suppresses host resistance to infection. To investigate this issue, we prospectively studied the relation between psychological stress and the frequency of documented clinical colds among subjects intentionally exposed to respiratory viruses. Methods. After completing questionnaires assessing degrees of psychological stress, 394 healthy subjects were given nasal drops containing one of five respiratory viruses (rhinovirus type 2, 9, or 14, respiratory syncytial virus, or coronavirus type 229E), and an additional 26 were given saline nasal drops. The subjects were then quarantined and monitored for the development of evidence of infection and symptoms. Clinical colds were defined as clinical symptoms in the presence of an infection verified by the isolation of virus or by an increase in the virus-specific antibody titer. Results. The rates of both respiratory infection (P < 0.005) and clinical colds (P < 0.02) increased in a dose-response manner with increases in the degree of psychological stress. Infection rates ranged from approximately 74 percent to approximately 90 percent, according to levels of psychological stress, and the incidence of clinical colds ranged from approximately 27 percent to 47 percent. These effects were not altered when we controlled for age, sex, education, allergic status, weight, the season, the number of subjects housed together, the infectious status of subjects sharing the same housing, and virus-specific antibody status at base line (before challenge). Moreover, the associations observed were similar for all five challenge viruses. Several potential stress-illness mediators, including smoking, alcohol consumption, exercise, diet, quality of sleep, white-cell counts, and total immunoglobulin levels, did not explain the association between stress and illness. Similarly, controls for personality variables (self-esteem, personal control, and introversion-extraversion) failed to alter our findings. Conclusions. Psychological stress was associated in a dose-response manner with an increased risk of acute infectious respiratory illness, and this risk was attributable to increased rates of infection rather than to an increased frequency of symptoms after infection.	UNIV WALES COLL CARDIFF,HLTH PSYCHOL RES UNIT,CARDIFF CF1 1XL,S GLAM,WALES; MRC,COMMON COLD UNIT,SALISBURY,ENGLAND	Cardiff University	COHEN, S (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Winwood, Peter/A-6363-2008; Smith, Andrew P/B-2192-2010	Smith, Andrew/0000-0001-8805-8028; Cohen, Sheldon/0000-0003-2248-4600	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023072] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23072] Funding Source: Medline; NIMH NIH HHS [MH00721] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ader R., 1981, PSYCHONEUROIMMUNOLOG, V1st ed.; Afifi A.A., 1984, COMPUTER AIDED MULTI; ALEXANDER R W, 1956, Stud Med, V4, P61; BARCLAY WS, 1987, J VIROL METHODS, V15, P53, DOI 10.1016/0166-0934(87)90048-6; BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27; BOYCE WT, 1977, PEDIATRICS, V60, P609; BROADBENT DE, 1984, J PSYCHOSOM RES, V28, P511, DOI 10.1016/0022-3999(84)90085-0; CALABRESE JR, 1987, AM J PSYCHIAT, V144, P1123; CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410; CLUFF LE, 1966, ARCH INTERN MED, V117, P159, DOI 10.1001/archinte.117.2.159; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; COHEN S, 1988, SOCIAL PSYCHOL HLTH, P31; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FELTEN DL, 1985, J IMMUNOL, V135, pS755; FELTEN SY, 1987, J NEUROSCI RES, V18, P37, DOI 10.1002/jnr.490180108; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FLEMING JS, 1980, J PERS SOC PSYCHOL, V39, P921, DOI 10.1037/0022-3514.39.5.921; GRAHAM NMH, 1986, AM J EPIDEMIOL, V124, P389, DOI 10.1093/oxfordjournals.aje.a114409; Henderson, 1981, NEUROSIS SOCIAL ENV; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; KIECOLT-GLASER J K, 1988, Brain Behavior and Immunity, V2, P67, DOI 10.1016/0889-1591(88)90007-4; Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849; Laudenslager ML, 1987, VIRUSES IMMUNITY MEN, P391; Lazarus RS., 1984, STRESS APPRAISAL COP; MEYER RJ, 1962, PEDIATRICS, V29, P539; MORAHAN PS, 1989, NAT IMMUN, P557; PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253; RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279; SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146; TOTMAN R, 1980, J PSYCHOSOM RES, V24, P155, DOI 10.1016/0022-3999(80)90037-9; Tyrrell DAJ, 1988, LAB DIAGNOSIS INFECT, V2, P723; ZEVON MA, 1982, J PERS SOC PSYCHOL, V43, P111, DOI 10.1037/0022-3514.43.1.111	34	1151	1166	4	185	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					606	612		10.1056/NEJM199108293250903	http://dx.doi.org/10.1056/NEJM199108293250903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC328	1713648				2022-12-28	WOS:A1991GC32800003
J	DOORBAR, J; ELY, S; STERLING, J; MCLEAN, C; CRAWFORD, L				DOORBAR, J; ELY, S; STERLING, J; MCLEAN, C; CRAWFORD, L			SPECIFIC INTERACTION BETWEEN HPV-16 E1-E4 AND CYTOKERATINS RESULTS IN COLLAPSE OF THE EPITHELIAL-CELL INTERMEDIATE FILAMENT NETWORK	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; OPEN READING FRAMES; HUMAN KERATINOCYTES; VACCINIA VIRUS; PROTEINS; E4; IDENTIFICATION; TRANSFORMATION; L1; CYTOSKELETON	THE human papillomaviruses (HPV) are associated specifically with epithelial lesions, ranging from benign warts to invasive carcinoma (for review, see refs 1, 2). The virus encodes three late proteins, which are produced only in terminally differentiating keratinocytes, two of which are structural components of the virion 3. The third, E1-E4, is derived primarily from the E4 open reading frame, which represents a region of maximal divergence between different HPV types 4,5. E1-E4 does not seem to be a component of the virus particle or to be needed for transformation in vitro 6,7, but accumulates in the cytoplasm 5,8-10, where in certain benign lesions it can comprise 20-30% of total cell protein 4,10. We show here that expression of the HPV-16 E1-E4 protein in human keratinocytes (the natural host cell for HPV infection) results in the total collapse of the cytokeratin matrix. Tubulin and actin networks are unaffected by E1-E4, as are the nuclear lamins.			DOORBAR, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREITBURD F, 1987, CANCER CELL, V5, P115; Broker T.R., 1986, CANCER CELL, V4, P17; BROWN DR, 1988, VIROLOGY, V165, P262, DOI 10.1016/0042-6822(88)90680-0; BROWNE HM, 1988, J GEN VIROL, V69, P1263, DOI 10.1099/0022-1317-69-6-1263; CRUM CP, 1990, VIROLOGY, V178, P238, DOI 10.1016/0042-6822(90)90399-C; DOORBAR J, 1988, EMBO J, V7, P825, DOI 10.1002/j.1460-2075.1988.tb02881.x; DOORBAR J, 1987, J VIROL, V61, P2793, DOI 10.1128/JVI.61.9.2793-2799.1987; DOORBAR J, 1989, VIROLOGY, V172, P51, DOI 10.1016/0042-6822(89)90106-2; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; Eckert B S, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P403; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HILLER G, 1979, VIROLOGY, V98, P142, DOI 10.1016/0042-6822(79)90533-6; Lane E B, 1990, Semin Cancer Biol, V1, P165; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MACKETT M, 1985, DNA CLONING PRACTICA, V2; MCLEAN CS, 1990, J CLIN PATHOL, V43, P488, DOI 10.1136/jcp.43.6.488; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SHYY TT, 1989, J CELL BIOL, V108, P997, DOI 10.1083/jcb.108.3.997; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; ZURHAUSEN H, 1990, PAPOVAVIRIDAE	27	227	237	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					824	827		10.1038/352824a0	http://dx.doi.org/10.1038/352824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715519				2022-12-28	WOS:A1991GC96400067
J	DAVIS, S; LU, ML; LO, SH; LIN, S; BUTLER, JA; DRUKER, BJ; ROBERTS, TM; AN, Q; CHEN, LB				DAVIS, S; LU, ML; LO, SH; LIN, S; BUTLER, JA; DRUKER, BJ; ROBERTS, TM; AN, Q; CHEN, LB			PRESENCE OF AN SH2 DOMAIN IN THE ACTIN-BINDING PROTEIN TENSIN	SCIENCE			English	Article							SMOOTH-MUSCLE VINCULIN; PHOSPHOLIPASE C-II; TYROSINE KINASES; FOCAL ADHESIONS; ALPHA-ACTININ; SARCOMA-VIRUS; CELLS; PHOSPHORYLATION; SIMILARITY; INVITRO	The molecular cloning of the complementary DNA coding for a 90-kilodalton fragment of tensin, an actin-binding component of focal contacts and other submembraneous cytoskeletal structures, is reported. The derived amino acid sequence revealed the presence of a Src homology 2 (SH2) domain. This domain is shared by a number of signal transduction proteins including nonreceptor tyrosine kinases such as Abl, Fps, Src, and Src family members, the transforming protein Crk, phospholipase C-gamma-l, PI-3 (phosphatidylinositol) kinase, and guanosine triphosphatase-activating protein (GAP). Like the SH2 domain found in Src, Crk, and Abl, the SH2 domain of tensin bound specifically to a number of phosphotyrosine-containing proteins from v-src-transformed cells. Tensin was also found to be phosphorylated on tyrosine residues. These findings suggest that by possessing both actin-binding and phosphotyrosine-binding activities and being itself a target for tyrosine kinases, tensin may link signal transduction pathways with the cytoskeleton.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT BIOPHYS,BALTIMORE,MD 21218	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Johns Hopkins University				Druker, Brian/0000-0001-8331-8206	NIGMS NIH HHS [GM 22289, GM 38318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038318, R01GM022289] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Burridge K, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P587; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTLER JAV, UNPUB; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS RR, 1984, J BIOL CHEM, V259, P3916; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; KELLIE S, 1985, EXP CELL RES, V160, P259, DOI 10.1016/0014-4827(85)90174-0; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P669; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LIN S, 1989, SPRINGER SERIES BIOP, V3, P341; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Marston F. A. O., 1987, DNA CLONING, P59; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OTTO JJ, 1986, CELL MOTIL CYTOSKEL, V6, P48, DOI 10.1002/cm.970060107; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RISINGER M A, 1988, Journal of Cell Biology, V107, p256A; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SMITH DB, 1990, CURRENT PROTOCOLS MO; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; WILKINS JA, 1987, J CELL BIOL, V106, pA130	42	217	218	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					712	715		10.1126/science.1708917	http://dx.doi.org/10.1126/science.1708917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1708917				2022-12-28	WOS:A1991FK18500051
J	SHEN, L; CHEN, ZW; MILLER, MD; STALLARD, V; MAZZARA, GP; PANICALI, DL; LETVIN, NL				SHEN, L; CHEN, ZW; MILLER, MD; STALLARD, V; MAZZARA, GP; PANICALI, DL; LETVIN, NL			RECOMBINANT VIRUS-VACCINE INDUCED SIV-SPECIFIC CD8+ CYTOTOXIC LYMPHOCYTES-T	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; AIDS; CELLS; PROTECTION; INDIVIDUALS; REPLICATION; INFECTION; SEQUENCE; INVITRO; MACAQUE	Evidence indicates that cytotoxic T lymphocytes (CTLs) may be important in containing the spread of the human immunodeficiency virus (HIV) in the infected host. Although the use of recombinant viruses has been proposed as an approach to elicit protective immunity against HIV, the ability of recombinant viral constructs to elicit CD8+ CTL responses in higher primates has never been demonstrated. A live recombinant virus, vaccinia-simian immunodeficiency virus of macaques (SIV(mac)), was used to determine whether such a genetically restricted, T lymphocyte-mediated antiviral response could be generated in a primate. Vaccinia-SIV(mac) vaccination elicited an SIV(mac) Gag-specific, CD8+ CTL response in rhesus monkeys. These CTLs recognized a peptide fragment that spans residues 171 to 195 of the Gag protein. The rhesus monkey major histocompatibility complex (MHC) class I gene product restricting this CTL response was defined. Both the vaccinated and SIV(mac)-infected monkeys that shared this MHC class I gene product developed CTLs with the same Gag epitope specificity. These findings support the use of recombinant virus vaccines for the prevention of HIV infections in humans.	HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772; APPL BIOTECHNOL INC,CAMBRIDGE,MA 02142	Harvard University					NATIONAL CANCER INSTITUTE [R01CA050139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020729, R37AI020729] Funding Source: NIH RePORTER; NCI NIH HHS [CA50139] Funding Source: Medline; NIAID NIH HHS [AI26507, AI20729] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ada GF, 1990, SEMIN VIROL SER, V1, P3; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; EARL PL, 1986, SCIENCE, V234, P728, DOI 10.1126/science.3490689; FRANCHINI G, 1987, NATURE, V328, P539, DOI 10.1038/328539a0; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MAZZARA G, UNPUB; MCLAUGHLINTAYLOR E, 1988, J GEN VIROL, V69, P1731, DOI 10.1099/0022-1317-69-7-1731; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MILLER MD, 1990, J IMMUNOL, V144, P122; MILLER MD, IN PRESS VACCINES 91; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROOK AH, 1987, J IMMUNOL, V138, P1064; Shen L., UNPUB; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WAINHOBSON S, 1989, AIDS, V3, pS13, DOI 10.1097/00002030-198901001-00003; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WATANABE M, 1990, J VIROL, V64, P656, DOI 10.1128/JVI.64.2.656-663.1990; YAMAMOTO H, 1990, J IMMUNOL, V145, P3740; YAMAMOTO H, 1990, J IMMUNOL, V144, P3385; ZAGURY D, 1988, NATURE, V332, P728, DOI 10.1038/332728a0; ZARLING JM, 1987, J IMMUNOL, V139, P988	30	90	94	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					440	443		10.1126/science.1708168	http://dx.doi.org/10.1126/science.1708168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1708168				2022-12-28	WOS:A1991FH10300043
J	ANDERSON, JB; GRANT, JBF				ANDERSON, JB; GRANT, JBF			POSTOPERATIVE RETENTION OF URINE - A PROSPECTIVE URODYNAMIC STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORPHINE; INHIBITION; ANALGESIA; DETRUSOR; NALOXONE; REFLEX	Objective-To investigate the cause of post-operative retention of urine in elderly men. Design-Prospective study. Setting-Northern General Hospital, Sheffield. Patients-32 consecutive men (median age 73, range 55-85) referred to the urology department who were unable to pass urine either within 48 hours after operation and required catheterisation (23) or after removal of a catheter inserted at the initial operation (nine). Intervention-Intermittent self catheterisation. Main outcome measures-Urological investigation by medium fill and voiding cystometry within four weeks after operation, and minimum follow up three months thereafter. Results-6 patients resumed normal voiding before urodynamic assessment, three proceeded straight to prostatectomy, and one was unfit for self catheterisation. Of 22 men who underwent urodynamic investigation, only five had bladder outflow obstruction, who subsequently had successful prostatectomy; 15 showed either a low pressure-low flow system (seven) or complete detrusor failure (eight) and two showed pelvic parasympathetic nerve damage. With intermittent self catheterisation spontaneous voiding returned in all but one man within a median of 8 weeks (range 6-32 weeks). Recovery of bladder function took significantly longer in men with detrusor failure than in those with an underactive bladder (median 10 weeks (range 6-32 weeks) upsilon-median 8 weeks (range 6-8 weeks); p = 0.05). Three months later all patients had re-established their own normal voiding pattern with minimal residual urine on ultrasonography and satisfactory flow rates. Conclusions-Postoperative urinary retention in elderly men is not an indication for prostatectomy; a normal pattern of micturition can be re-established by intermittent self catheterisation in most men.	NO GEN HOSP, DEPT UROL, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	Northern General Hospital								CAMPBELL ED, 1972, DIS COLON RECTUM, V15, P69, DOI 10.1007/BF02587676; Craigen A A, 1969, J R Coll Gen Pract, V18, P226; DOYLE PT, 1976, BRIT J UROL, V48, P329, DOI 10.1111/j.1464-410X.1976.tb06645.x; DRAY A, 1984, J PHARMACOL EXP THER, V231, P254; DRAY A, 1988, ANESTHESIOLOGY, V68, P323, DOI 10.1097/00000542-198803000-00001; DURANT PAC, 1988, ANESTHESIOLOGY, V68, P325, DOI 10.1097/00000542-198803000-00002; ELLIS H, 1987, LECTURE NOTES GENERA, P362; GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78; GOSLING JA, 1977, J UROLOGY, V118, P302, DOI 10.1016/S0022-5347(17)57981-1; HASKELL DL, 1974, ARCH SURG-CHICAGO, V109, P378; HISAMITSU T, 1984, BRAIN RES, V298, P51, DOI 10.1016/0006-8993(84)91146-6; HODSMAN NBA, 1988, BRIT J SURG, V75, P212, DOI 10.1002/bjs.1800750307; LEVENTHAL A, 1978, Surgery Gynecology and Obstetrics, V146, P347; MARSHALL V, 1988, CLIN SCI SURGEONS, P552; MITCHELL JP, 1986, HAMILTON BAILEYS EME, P507; MURRAY KHA, 1982, BRIT J UROL, V54, P638, DOI 10.1111/j.1464-410X.1982.tb13614.x; PETERSEN TK, 1982, BRIT J ANAESTH, V54, P1175, DOI 10.1093/bja/54.11.1175; PETROS JG, 1990, AM J SURG, V159, P374, DOI 10.1016/S0002-9610(05)81274-7; SANDYK R, 1986, UROLOGY, V27, P79, DOI 10.1016/0090-4295(86)90215-3; STALLARD S, 1988, BRIT J SURG, V75, P1141, DOI 10.1002/bjs.1800751128; TAMMELA T, 1986, SCAND J UROL NEPHROL, V20, P197, DOI 10.3109/00365598609024494; TREIGER P, 1950, AM J SURG, V80, P195, DOI 10.1016/0002-9610(50)90529-0; VAIDYANATHAN S, 1981, J UROLOGY, V126, P500, DOI 10.1016/S0022-5347(17)54596-6; VIRTANEN R, 1982, ACTA ANAESTH SCAND, V26, P297, DOI 10.1111/j.1399-6576.1982.tb01770.x; WALTS LF, 1985, CLIN ORTHOP RELAT R, V194, P280; 1990, BR J OBSTET GYNAE S6, V97	26	39	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	1991	302	6781					894	896		10.1136/bmj.302.6781.894	http://dx.doi.org/10.1136/bmj.302.6781.894			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	1709058	Green Published, Bronze			2022-12-28	WOS:A1991FG42100028
J	WEIDNER, N; SEMPLE, JP; WELCH, WR; FOLKMAN, J				WEIDNER, N; SEMPLE, JP; WELCH, WR; FOLKMAN, J			TUMOR ANGIOGENESIS AND METASTASIS - CORRELATION IN INVASIVE BREAST-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRENEOPLASTIC LESIONS; GROWTH-FACTOR; MARKER; NEOVASCULARIZATION; VESSELS; CANCER; CELLS; MELANOMA; MEMBRANE; BIOLOGY	Background. Experimental evidence suggests that the growth of a tumor beyond a certain size requires angiogenesis, which may also permit metastasis. To investigate how tumor angiogenesis correlates with metastases in breast carcinoma, we counted microvessels (capillaries and venules) and graded the density of microvessels within the initial invasive carcinomas of 49 patients (30 with metastases and 19 without). Methods. Using light microscopy, we highlighted the vessels by staining their endothelial cells immunocytochemically for factor VIII. The microvessels were carefully counted (per 200 x field), and their density was graded (1 to 4+), in the most active areas of neovascularization, without knowledge of the outcome in the patient, the presence or absence of metastases, or any other pertinent variable. Results. Both microvessel counts and density grades correlated with metastatic disease. The mean (+/- SD) count and grade in the patients with metastases were 101 +/- 49.3 and 2.95 +/- 1.00 vessels, respectively. The corresponding values in the patients without metastases were significantly lower - 45 +/- 21.1 and 1.38 +/- 0.82 (P = 0.003 and P less-than-or-equal-to 0.001, respectively). For each 10-microvessel increase in the count per 200 x field, there was a 1.59-fold increase in the risk of metastasis (95 percent confidence interval, 1.19 to 2.12; P = 0.003). The microvessel count and density grade also correlated with distant metastases. For each 10-microvessel increase in the vessel count per 200 x field, there was a 1.17-fold increase in the risk of distant metastasis (95 percent confidence interval, 1.02 to 1.34; P = 0.029). Conclusions. The number of microvessels per 200 x field in the areas of most intensive neovascularization in an invasive breast carcinoma may be an independent predictor of metastatic disease either in axillary lymph nodes or at distant sites (or both). Assessment of tumor angiogenesis may therefore prove valuable in selecting patients with early breast carcinoma for aggressive therapy.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	WEIDNER, N (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R37CA037395, R01CA037395] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37395-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO;2-X; BREM SS, 1977, SCIENCE, V195, P880, DOI 10.1126/science.402692; CHODAK GW, 1980, ANN SURG, V192, P762, DOI 10.1097/00000658-198012000-00012; Cox DR., 1970, ANAL BINARY DATA; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Folkman J., 1987, THROMB DIATH HAEMO, P583; FOLKMAN J, 1989, NATURE, P339; HERLYN M, 1987, LAB INVEST, V56, P461; JENSEN HM, 1982, SCIENCE, V218, P293, DOI 10.1126/science.6181563; JENSEN HM, 1987, ANGIOGENESIS MECHANI, P155; LEDOUSSAL V, 1989, CANCER, V64, P1914, DOI 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G; LIOTTA LA, 1974, CANCER RES, V34, P997; LIOTTA LA, 1976, CANCER RES, V36, P889; MOSCATELLI D, 1981, J CELL BIOL, V91, pA201; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; NICHOLSON GL, 1979, SCI AM, V240, P66; PINKUS GS, 1986, AM J CLIN PATHOL, V85, P269, DOI 10.1093/ajcp/85.3.269; POLVERINI PJ, 1984, LAB INVEST, V51, P635; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SMITH SS, 1970, CAN J OPHTHALMOLOGY, V5, P175; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; SRIVASTAVA A, 1986, EUR J CANCER CLIN ON, V22, P1205, DOI 10.1016/0277-5379(86)90322-6; WEISS L, 1976, FUNDAMENTAL ASPECTS, P51; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	29	4985	5621	5	331	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					1	8		10.1056/NEJM199101033240101	http://dx.doi.org/10.1056/NEJM199101033240101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1701519	Bronze			2022-12-28	WOS:A1991EQ50300001
J	MISHIRO, S; HOSHI, Y; TAKEDA, K; YOSHIKAWA, A; GOTANDA, T; TAKAHASHI, K; AKAHANE, Y; YOSHIZAWA, H; OKAMOTO, H; TSUDA, F; PETERSON, DA; MUCHMORE, E				MISHIRO, S; HOSHI, Y; TAKEDA, K; YOSHIKAWA, A; GOTANDA, T; TAKAHASHI, K; AKAHANE, Y; YOSHIZAWA, H; OKAMOTO, H; TSUDA, F; PETERSON, DA; MUCHMORE, E			NON-A, NON-B HEPATITIS SPECIFIC ANTIBODIES DIRECTED AT HOST-DERIVED EPITOPE - IMPLICATION FOR AN AUTOIMMUNE PROCESS	LANCET			English	Article									JAPANESE RED CROSS, CTR BLOOD, SAITAMA, JAPAN; YAMANASHI MED COLL, DEPT INTERNAL MED 1, YAMANASHI, JAPAN; HIROSHIMA UNIV, SCH MED, DEPT HYG, HIROSHIMA 730, JAPAN; JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; ABBOTT LABS, N CHICAGO, IL 60064 USA; KITASATO INST, IMMUNOL SECT, TOKYO 108, JAPAN; HAMAMATSU UNIV, SCH MED, DEPT PUBL HLTH, HAMAMATSU, SHIZUOKA 43131, JAPAN; NYU MED CTR, EXPTL MED & SURG PRIMATES LAB, NEW YORK, NY 10016 USA	Japanese Red Cross Medical Center; University of Yamanashi; Hiroshima University; Jichi Medical University; Abbott Laboratories; Kitasato University; Hamamatsu University School of Medicine; New York University	MISHIRO, S (corresponding author), INST IMMUNOL, KORAKU 1-1-10, BUNKYO KU, TOKYO, JAPAN.		Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; HOFFNAGLE JH, 1973, LANCET, V2, P869; HUYNH TV, 1985, DNA CLONING, V1; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MIYAMURA T, 1990, P NATL ACAD SCI USA, V87, P983, DOI 10.1073/pnas.87.3.983; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; SHIMIZU YK, 1979, SCIENCE, V205, P197, DOI 10.1126/science.451589; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; THEILMANN L, 1990, LANCET, V335, P1345; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIZAWA H, 1980, GASTROENTEROLOGY, V79, P512; 883109225	19	213	217	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	1990	336	8728					1400	1403		10.1016/0140-6736(90)93101-T	http://dx.doi.org/10.1016/0140-6736(90)93101-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL851	1701012				2022-12-28	WOS:A1990EL85100004
J	SULMASY, DP; GELLER, G; FADEN, R; LEVINE, DM				SULMASY, DP; GELLER, G; FADEN, R; LEVINE, DM			THE QUALITY OF MERCY - CARING FOR PATIENTS WITH DO NOT RESUSCITATE ORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY RESUSCITATION; MEDICAL-ETHICS; SURVIVAL	Objective. - To assess (1) the effect of an ethics education intervention for medical house officers on practices surrounding "Do Not Resuscitate" (DNR) orders and (2) the association of DNR care with patient diagnosis and demographic variables. Design. - A 1 -year randomized, controlled trial. Setting. - An urban, university teaching hospital. Participants. - Eighty-eight internal medicine house officers. Intervention. - House officers were arbitrarily assigned to four "firms." One firm was randomized to an extensive ethics education intervention (EI), one to a limited intervention, and two served as controls. Main Outcome Measures. - Charts of patients with DNR orders were reviewed for compliance with the hospital's DNR policy, which instructs that when DNR orders are written there should be (1) an attending signature, (2) documentation of reasons, (3) appropriate consent, and (4) attention to 11 concurrent care concerns (CCCs) (eg, the appropriateness of intubation, tube feedings, hospice). Results. - Thirty-nine charts were reviewed before the intervention and 57 after. The number of CCCs per DNR order fell among patients cared for by controls (1.9 to 1.0, P < .05) and rose among patients cared for by the El group (0.9 to 3.8, P < .05). Compliance with the DNR policy varied among patients with differing diagnoses. "Do Not Resuscitate" orders were signed less frequently (P = .01) for patients with the acquired immunodeficiency syndrome (AIDS) (65%) compared with patients who had other diagnoses (85%) or malignancy (91 %). Similarly, appropriate consent was recorded for 59% of patients with AIDS, 83% of others, and 85% of those with malignancy (P < .05). The number of CCCs per DNR was 0.7 for AIDS, 1.4 for others, and 2.4 for malignancy (P < .05). In multivariate regression analysis, house officer ethics education and patient diagnosis, but not patient gender, age, race, or insurance status, were predictors of the number of CCCs per DNR. Conclusions. - (1) An extensive ethics education intervention can improve care for DNR patients, especially with respect to CCCs. (2) In this setting, quality of care for DNR patients varied systematically with diagnosis. These results have implications for the design and implementation of ethics education programs.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,CTR LAW ETH & HLTH,BALTIMORE,MD 21218; GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,CTR CLIN BIOETH,WASHINGTON,DC 20007; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INTERNAL MED,BALTIMORE,MD 21205	Johns Hopkins University; Georgetown University; Georgetown University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007180] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00035] Funding Source: Medline; NHLBI NIH HHS [T32 HL07180] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BUCHANAN S, 1988, MD MED J, V37, P461; DANS PE, 1985, SOUTHERN MED J, V78, P1174; DEBARD ML, 1981, ANN EMERG MED, V147, P37; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; LAPUMA J, 1988, ARCH INTERN MED, V148, P2193, DOI 10.1001/archinte.148.10.2193; LO B, 1987, REV INFECT DIS, V9, P1163; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; PELLEGRINO ED, 1985, JAMA-J AM MED ASSOC, V253, P49, DOI 10.1001/jama.253.1.49; RAVIGLIONE MC, 1988, ARCH INTERN MED, V148, P2602, DOI 10.1001/archinte.148.12.2602; SULMASY DP, 1990, ARCH INTERN MED, V150, P2509, DOI 10.1001/archinte.150.12.2509; TERRY PB, 1989, CHEST, V96, P1175, DOI 10.1378/chest.96.5.1175; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1987, GUIDELINES TERMINATI, P48; 1988, 73 OPINIONS ATTORNEY; 1991, JAMA-J AM MED ASSOC, V265, P1868	18	43	45	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					682	686						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1731135				2022-12-28	WOS:A1992HB35400026
J	SCHUMAN, EM; MADISON, DV				SCHUMAN, EM; MADISON, DV			A REQUIREMENT FOR THE INTERCELLULAR MESSENGER NITRIC-OXIDE IN LONG-TERM POTENTIATION	SCIENCE			English	Article							RELAXING FACTOR; L-ARGININE; SYNAPTIC TRANSMISSION; HIPPOCAMPAL SLICES; DIVALENT-CATIONS; RAT HIPPOCAMPUS; CENTRAL NEURONS; CA1 NEURONS; ENHANCEMENT; ACTIVATION	Long-term potentiation (LTP) of synaptic transmission is a widely studied model of neuronal plasticity. The induction of LTP is known to require processes in the postsynaptic neuron, while experimental evidence suggests that the expression of LTP may occur in the presynaptic terminal. This has led to speculation that a retrograde messenger travels from the post- to the presynaptic cell during induction of LTP. Extracellular application or postsynaptic injection of two inhibitors of nitric oxide synthase, N-nitro-L-arginine or N(G)-methyl-L-arginine, blocks LTP. Extracellular application of hemoglobin, which binds nitric oxide, also attenuates LTP. These findings suggest that nitric oxide liberated from postsynaptic neurons may travel back to presynaptic terminals to cause LTP expression.	STANFORD UNIV, MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University			Schuman, Erin M/D-6204-2011					ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARINAGA M, 1990, SCIENCE, V248, P1603, DOI 10.1126/science.1973002; BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1990, NATURE, V346, P698, DOI 10.1038/346698a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1989, J BIOL CHEM, V264, P8455; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P19, DOI 10.1113/jphysiol.1983.sp014477; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DOLPHIN AC, 1982, NEUROSCIENCE, V20, P279; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GOH JW, 1989, SCIENCE, V244, P980, DOI 10.1126/science.2543072; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KENNEDY MB, 1988, NATURE, V335, P770, DOI 10.1038/335770a0; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; ODELL TJ, IN PRESS P NATL ACAD; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SCHUMAN E, UNPUB; SCHUMAN E M, 1991, Society for Neuroscience Abstracts, V17, P2; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STEVENS CF, 1988, NATURE, V336, P308, DOI 10.1038/336308a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YUI Y, 1991, J BIOL CHEM, V244, P3714	49	981	1000	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1991	254	5037					1503	1506		10.1126/science.1720572	http://dx.doi.org/10.1126/science.1720572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720572				2022-12-28	WOS:A1991GT90300039
J	WALKER, RM				WALKER, RM			DNR IN THE OR - RESUSCITATION AS AN OPERATIVE RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ETHICAL CHALLENGE; CARDIAC-ARREST; ANESTHESIA; WITNESSES; CARE	Should do-not-resuscitate (DNR) orders be routinely rescinded when terminally ill patients undergo palliative surgery? If so, patients will be forced to balance the benefits of palliative surgery against the risks of unwanted resuscitation. If physicians are required to honor intraoperative DNR orders, they may feel unacceptably restrained from correcting adverse effects for which they feel responsible. This dilemma has been overlooked by DNR policies. This article argues for the permissibility of honoring intraoperative DNR orders. The patient's right to refuse treatment outweighs physicians' concerns about professional scrutiny over intraoperative deaths. Physicians' moral concerns about hastening patient death are important but may be assuaged by (1) emphasizing patients' acceptance of operative mortality risk; (2) viewing matters as analogous to surgery on Jehovah's Witnesses who refuse lifesaving transfusion; (3) viewing the patient's intraoperative death as a double effect, that is, an unintended negative effect that is linked to the performance of a good act (palliation); and (4) distinguishing this from assisted suicide.			WALKER, RM (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV MED ETH & HUMANITIES, 12901 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BENSON KT, 1989, ANESTH ANALG, V69, P647; CANTOR NL, 1987, LEGAL FRONTIERS DEAT; COHEN MM, 1988, JAMA-J AM MED ASSOC, V260, P2859, DOI 10.1001/jama.260.19.2859; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; DIXON JL, 1981, JAMA-J AM MED ASSOC, V246, P2471, DOI 10.1001/jama.246.21.2471; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; FRADER J, 1988, NEONATAL ANESTHESIA, pCH12; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; GILLON R, 1986, BRIT MED J, V292, P193, DOI 10.1136/bmj.292.6514.193; HARRIS TJB, 1983, ANAESTHESIA, V38, P989, DOI 10.1111/j.1365-2044.1983.tb12031.x; Katz J., 1984, SILENT WORLD DOCTOR; KEATS AS, 1983, COMPLICATIONS ANESTH, pCH1; LEDERER DH, 1987, HASTINGS CENT REP, V17, P18, DOI 10.2307/3563178; LONGO WE, 1988, DIS COLON RECTUM, V31, P842, DOI 10.1007/BF02554846; MAY W, 1978, ENCY BIOETHICS, P316; MCGRATH PC, 1989, ANN SURG, V209, P284, DOI 10.1097/00000658-198903000-00006; MEISEL A, 1986, CRIT CARE MED, V14, P239, DOI 10.1097/00003246-198603000-00016; Miles S., 1988, PROTOCOLS ELECTIVE U; MILES SH, 1989, NEW ENGL J MED, V321, P48, DOI 10.1056/NEJM198907063210110; OLSSON GL, 1988, ACTA ANAESTH SCAND, V32, P653, DOI 10.1111/j.1399-6576.1988.tb02804.x; PEATFIELD RC, 1977, LANCET, V1, P1223; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SCOTT NB, 1988, BRIT J SURG, V75, P299; THOMAS JM, 1983, CAN MED ASSOC J, V128, P1153; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1991, ACCREDITATION MANUAL, P77; 1987, GUIDELINES TERMINATI; 1985, CONN MED, V49, P367	30	63	64	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2407	2412		10.1001/jama.266.17.2407	http://dx.doi.org/10.1001/jama.266.17.2407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1717723				2022-12-28	WOS:A1991GM79000028
J	GREENGARD, P; JEN, J; NAIRN, AC; STEVENS, CF				GREENGARD, P; JEN, J; NAIRN, AC; STEVENS, CF			ENHANCEMENT OF THE GLUTAMATE RESPONSE BY CAMP-DEPENDENT PROTEIN-KINASE IN HIPPOCAMPAL-NEURONS	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; RAT HIPPOCAMPUS; RECEPTOR DESENSITIZATION; CHANNELS; MODULATION; QUISQUALATE; FORSKOLIN; KAINATE; CELLS; CONDUCTANCES	Receptor channels activated by glutamate, an excitatory neurotransmitter in the mammalian brain, are involved in processes such as long-term potentiation and excitotoxicity. Studies of glutamate receptor channels expressed in cultured hippocampal pyramidal neurons reveal that these channels are subject to neuromodulatory regulation through the adenylate cyclase cascade. The whole-cell current response to glutamate and kainate [a non-NMDA (N-methyl-D-aspartate) receptor agonist] was enhanced by forskolin, an activator of adenylate cyclase. Single-channel analysis revealed that an adenosine 3',5'-monophosphate-dependent protein kinase (PKA) increases the opening frequency and the mean open time of the non-NMDA-type glutamate receptor channels. Analysis of synaptic events indicated that forskolin, acting through PKA, increased the amplitude and decay time of spontaneous excitatory postsynaptic currents.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; YALE UNIV, NEUROSCI PROGRAM, NEW HAVEN, CT 06510 USA	Salk Institute; Rockefeller University; Yale University				Nairn, Angus/0000-0002-7075-0195				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2100, DOI 10.1021/bi00681a009; CATTERALL WA, 1990, ADV SEC MESS PHOSPH, V24, P30; CHENG HC, 1986, J BIOL CHEM, V261, P989; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; Kaczmarek L. K., 1987, NEUROMODULATION; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; LANDFIELD PW, 1988, LONG TERM POTENTIATI; LEVITAN IB, 1990, ADV SEC MESS PHOSPH, V24, P36; MARKRAM H, 1990, NEUROSCI LETT, V113, P62, DOI 10.1016/0304-3940(90)90495-U; MODY I, 1988, NEUROSCI LETT, V93, P73, DOI 10.1016/0304-3940(88)90015-8; PIN JP, 1989, EUR J PHARM-MOLEC PH, V172, P81, DOI 10.1016/0922-4106(89)90047-3; RASSENDREN FA, 1989, NEUROSCI LETT, V99, P333, DOI 10.1016/0304-3940(89)90469-2; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WATANABE K, 1987, NEUROSCI LETT, V78, P211, DOI 10.1016/0304-3940(87)90635-5; WEINBERG CB, 1979, P NATL ACAD SCI USA, V76, P504, DOI 10.1073/pnas.76.1.504; ZORUMSKI CF, 1988, J NEUROSCI, V8, P4277	25	383	392	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1991	253	5024					1135	1138		10.1126/science.1716001	http://dx.doi.org/10.1126/science.1716001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1716001				2022-12-28	WOS:A1991GD80800031
J	CHAUDHARY, PM; RONINSON, IB				CHAUDHARY, PM; RONINSON, IB			EXPRESSION AND ACTIVITY OF P-GLYCOPROTEIN, A MULTIDRUG EFFLUX PUMP, IN HUMAN HEMATOPOIETIC STEM-CELLS	CELL			English	Article							BONE-MARROW-CELLS; RESISTANCE GENE; ANTIGENIC ANALYSIS; PROGENITOR CELLS; CFU-S; RHODAMINE-123 FLUORESCENCE; MONOCLONAL-ANTIBODY; TUMOR-CELLS; RAT-LIVER; PURIFICATION	Hematopoietic stem cells show reduced staining with a mitochondrial fluorescent dye, rhodamine 123 (Rh123), which was supposed to indicate decreased mitochondrial activity in these cells. Rhl23 and several other fluorescent dyes are substrates for transport mediated by P-glycoprotein (P-gp), an efflux pump responsible for multidrug resistance in tumor cells. We have found that staining of human bone marrow cells with fluorescent dyes is potentiated by P-gp inhibitors and inversely correlated with P-gp expression. P-gp is expressed in practically all hematopoietic progenitor cells, including long-term culture-initiating cells. The highest levels of P-gp among the progenitors are associated with cells displaying characteristics of pluripotent stem cells. These results have implications for stem cell purification and bone marrow resistance to cancer chemotherapy.			CHAUDHARY, PM (corresponding author), UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA.		Chaudhary, Preet/E-1970-2018; Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [CA-40333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333, R01CA040333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERENSON RJ, 1991, BLOOD, V77, P1717; BERTONCELLO I, 1985, EXP HEMATOL, V13, P999; BRANDT J, 1988, J CLIN INVEST, V82, P1017, DOI 10.1172/JCI113658; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; FORD JM, 1990, PHARMACOL REV, V42, P155; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; GELLER RB, 1990, BRIT J HAEMATOL, V76, P340, DOI 10.1111/j.1365-2141.1990.tb06365.x; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAUGHLAND RP, 1989, MOL PROBES HDB FLUOR; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KASTAN MB, 1990, BLOOD, V75, P1947; LALANDE ME, 1981, P NATL ACAD SCI-BIOL, V78, P363, DOI 10.1073/pnas.78.1.363; LAMPIDIS TJ, 1985, CANCER RES, V45, P2626; MCCARTHY KF, 1990, INT J CELL CLONING, V8, P184, DOI 10.1002/stem.5530080305; MULDER AH, 1987, EXP HEMATOL, V15, P99; NEYFAKH AA, 1989, EXP CELL RES, V185, P496, DOI 10.1016/0014-4827(89)90318-2; NEYFAKH AA, 1988, EXP CELL RES, V174, P168, DOI 10.1016/0014-4827(88)90152-8; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PALLAVICINI MG, 1985, EXP HEMATOL, V13, P1173; Pirker R, 1989, Cancer Commun, V1, P141; PLOEMACHER RE, 1988, J CELL PHYSIOL, V136, P531, DOI 10.1002/jcp.1041360320; PLOEMACHER RE, 1989, EXP HEMATOL, V17, P263; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SHUDO N, 1990, CANCER RES, V50, P3055; SKIYSMS D, 1985, DOMSYIV VRLL MOL HRN, V11, P117; SNFTRED TH, 1986, NLOOF, V67, P842; SNFTRED TH, 1986, NLOOF, V68, P1030; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SROUR EF, 1991, CYTOMETRY, V12, P179, DOI 10.1002/cyto.990120213; STRAUSS LC, 1986, EXP HEMATOL, V14, P878; SUGAWARA I, 1988, CANCER RES, V48, P1926; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VANDERSLUIJS JP, 1990, EXP HEMATOL, V18, P893; VISSER JWM, 1990, EXP HEMATOL, V18, P248	47	926	966	0	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					85	94		10.1016/0092-8674(91)90141-K	http://dx.doi.org/10.1016/0092-8674(91)90141-K			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712673				2022-12-28	WOS:A1991FW91300011
J	NIGHTINGALE, SL				NIGHTINGALE, SL			POSSIBILITY OF YERSINIA-ENTEROCOLITICA BACTEREMIA DUE TO TRANSFUSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, MMWR, V40, P176	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-28	WOS:A1991FU89600005
J	PACE, NR				PACE, NR			ORIGIN OF LIFE - FACING UP TO THE PHYSICAL SETTING	CELL			English	Review							EVOLUTION; RNA; ENZYMES				PACE, NR (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.							ANDERS E, 1989, NATURE, V342, P255, DOI 10.1038/342255a0; BAROSS JA, 1985, ORIGINS LIFE EVOL B, V15, P327, DOI 10.1007/BF01808177; BUICK R, 1990, Palaios, V5, P441, DOI 10.2307/3514837; CARINSSMITH AG, 1985, 7 CLUES ORIGIN LIFE; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHANG S, 1983, EARTHS EARLIEST BIOS, P51; CORLISS JB, 1990, NATURE, V347, P624, DOI 10.1038/347624a0; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; GILBERT W, 1986, NATURE, V319, P818; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; MASON TR, 1977, NATURE, V266, P47, DOI 10.1038/266047a0; Miller S. L., 1974, ORIGINS LIFE EARTH; PACE NR, 1986, CELL, V45, P325, DOI 10.1016/0092-8674(86)90315-6; SCHIDLOWSKI M, 1987, ANNU REV EARTH PL SC, V15, P47, DOI 10.1146/annurev.ea.15.050187.000403; Schopf J.W., 1983, P214; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	20	264	275	0	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					531	533		10.1016/0092-8674(91)90082-A	http://dx.doi.org/10.1016/0092-8674(91)90082-A			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709590				2022-12-28	WOS:A1991FM03700002
J	HOLLMANN, M; HARTLEY, M; HEINEMANN, S				HOLLMANN, M; HARTLEY, M; HEINEMANN, S			CA2+ PERMEABILITY OF KA-AMPA GATED GLUTAMATE RECEPTOR CHANNELS DEPENDS ON SUBUNIT COMPOSITION	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; EXCITATORY AMINO-ACIDS; XENOPUS-LAEVIS OOCYTES; ACTIVATED CHANNELS; DIVALENT-CATIONS; STRIATAL NEURONS; CHLORIDE CURRENT; CALCIUM; CULTURE	NMDA (N-methyl-D-aspartate) receptors and non-NMDA receptors represent the two major classes of ion channel-linked glutamate receptors. Unlike the NMDA receptor channels, non-NMDA receptor channels have usually been thought to conduct monovalent cations only. Non-NMDA receptor ion channels that can be gated by kainic acid (KA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) are formed by the glutamate receptor subunits GluR1, GluR2, and GluR3. These subunits were expressed in various combinations in Xenopus oocytes so that their permeability to divalent cations could be studied. At physiological resting potentials, KA and AMPA elicited inward calcium currents in oocytes expressing GluR1, GluR3, and GluR1 plus GluR3. In contrast, oocytes expressing GluR1 plus GluR2 or GluR3 plus GluR2 showed no such permeability. Thus, in neurons expressing certain KA-AMPA receptor subunits, glutamate may trigger calcium-dependent intracellular events by activating non-NMDA receptors.			HOLLMANN, M (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.			Hollmann, Michael/0000-0001-8000-7787	NINDS NIH HHS [NS28709-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, UNPUB; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1987, J NEUROSCI, V7, P3230; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MONAGHAN DT, 1989, ANN REV PHARM TOXICO, V21, P165; MURPHY SN, 1989, J PHARMACOL EXP THER, V249, P184; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1989, J NEUROPHYSIOL, V61, P1097, DOI 10.1152/jn.1989.61.6.1097; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OLNEY JW, 1989, DRUG DEVELOP RES, V17, P299, DOI 10.1002/ddr.430170406; RANDLE JCR, 1988, MOL CELL BIOCHEM, V80, P121; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275	35	1295	1321	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					851	853		10.1126/science.1709304	http://dx.doi.org/10.1126/science.1709304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709304				2022-12-28	WOS:A1991FL12300049
J	ALFA, CE; DUCOMMUN, B; BEACH, D; HYAMS, JS				ALFA, CE; DUCOMMUN, B; BEACH, D; HYAMS, JS			DISTINCT NUCLEAR AND SPINDLE POLE BODY POPULATIONS OF CYCLIN-CDC2 IN FISSION YEAST	NATURE			English	Article									UNIV LONDON UNIV COLL,DEPT BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND; HOWARD HUGHES MED INST,COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of London; University College London; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				Alfa C. E., 1989, J CELL SCI S, V12, P9; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; DAVIDSE LC, 1986, ANNU REV PHYTOPATHOL, V24, P43, DOI 10.1146/annurev.py.24.090186.000355; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, J CELL SCI, V96, P683; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HAGAN IM, 1988, J CELL SCI, V89, P343; HAGAN IM, 1988, THESIS U LONDON; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HYAMS JS, 1978, J CELL BIOL, V78, P401, DOI 10.1083/jcb.78.2.401; KING SM, 1982, CAN J MICROBIOL, V28, P261, DOI 10.1139/m82-036; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; UMESONO K, 1983, CURR GENET, V7, P123, DOI 10.1007/BF00365637; WALKER GM, 1982, J GEN MICROBIOL, V128, P61	21	186	186	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 18	1990	347	6294					680	682		10.1038/347680a0	http://dx.doi.org/10.1038/347680a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED620	1699136				2022-12-28	WOS:A1990ED62000058
J	WALD, ER				WALD, ER			CURRENT CONCEPTS - SINUSITIS IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MAXILLARY SINUSITIS; RESPIRATORY ALLERGY; DOUBLE-BLIND; AMOXICILLIN; RECURRENT; SURGERY; CT; PHENYLPROPANOLAMINE; RADIOGRAPHS; CEFACLOR		CHILDRENS HOSP,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	WALD, ER (corresponding author), UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261, USA.							AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; CAMACHO AE, 1991, 31ST INT C ANT AG CH, P202; Carson J L, 1988, Adv Pediatr, V35, P139; DIAMENT MJ, 1987, J COMPUT ASSIST TOMO, V11, P426, DOI 10.1097/00004728-198705000-00011; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GLASIER CM, 1986, AM J NEURORADIOL, V7, P861; GOHD RS, 1954, NEW ENGL J MED, V250, P687, DOI 10.1056/NEJM195404222501606; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; GROSS CW, 1989, LARYNGOSCOPE, V99, P272; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KOVATCH AL, 1984, PEDIATRICS, V73, P306; LUSK RP, 1989, PEDIATR CLIN N AM, V36, P1411; LUSK RP, 1990, LARYNGOSCOPE, V100, P654; Maresh MM, 1940, AM J DIS CHILD, V60, P841, DOI 10.1001/archpedi.1940.02000040060005; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; MELEN I, 1986, ACTA OTO-LARYNGOL, V102, P99, DOI 10.3109/00016488609108652; MELEN I, 1986, ACTA OTO-LARYNGOL, V101, P494, DOI 10.3109/00016488609108636; MESSERKLINGER W, 1967, ACTA OTO-LARYNGOL, V63, P178; MUNTZ HR, 1990, LARYNGOSCOPE, V100, P643; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; PERRIN JM, 1974, NEW ENGL J MED, V291, P664, DOI 10.1056/NEJM197409262911307; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RODRIQUEZ RS, 1988, 28TH INT C ANT AG CH, P167; SCHELD WM, 1986, ANTIMICROB AGENTS CH, V30, P350, DOI 10.1128/AAC.30.3.350; SHOPFNER CE, 1973, AM J ROENTGENOL, V118, P176, DOI 10.2214/ajr.118.1.176; SYDNOR A, 1989, ARCH OTOLARYNGOL, V115, P1430; SYDNOR TA, 1991, 31ST INT C ANT AG CH, P200; WALD ER, 1989, J PEDIATR-US, V115, P28, DOI 10.1016/S0022-3476(89)80324-5; WALD ER, 1991, PEDIATRICS, V87, P129; WALD ER, 1984, J PEDIATR-US, V104, P297, DOI 10.1016/S0022-3476(84)81018-5; WALD ER, 1986, PEDIATRICS, V77, P795; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WALD ER, 1988, ADV OTOLARYNGOL HEAD, V2, P165; WALD ER, 1984, POSTGRAD MED     SEP, P133	37	133	136	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					319	323						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728736				2022-12-28	WOS:A1992HA99100007
J	FORBES, GB; PORTA, CR; HERR, BE; GRIGGS, RC				FORBES, GB; PORTA, CR; HERR, BE; GRIGGS, RC			SEQUENCE OF CHANGES IN BODY-COMPOSITION INDUCED BY TESTOSTERONE AND REVERSAL OF CHANGES AFTER DRUG IS STOPPED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MASS	Objective. -To study the changes in body composition produced by large doses of testosterone and reversal of changes when the drug is discontinued. Design. - Weekly injections of testosterone enanthate were given to young adult male volunteers for 12 weeks. Repeated assays of lean body mass (LBM) by potassium 40 counting were made during this period and at intervals during the ensuing 5 to 6 months. Participants and Setting. - Subjects who were living on their own, who were known to be free of significant disease, and who volunteered as controls for a study of patients with neuromuscular disease. Assays were done in the Clinical Research Center. Main Outcome Measures. - Changes in body weight, LBM, and (by subtraction) body fat. Results. - Testosterone treatment produced a progressive increase in LBM and a progressive decrease in body fat. Body composition reverted slowly toward normal when the injections were stopped; thus, the effects of testosterone lingered for some time. The magnitude of the observed changes in LBM was in keeping with the change in urinary creatinine excretion reported for these same subjects. Conclusion. - Testosterone is a powerful anabolic agent that also serves to reduce body fat content.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester				Griggs, Robert/0000-0001-7988-4854	NCRR NIH HHS [RR-00044] Funding Source: Medline; NICHD NIH HHS [HD-18454] Funding Source: Medline; NINDS NIH HHS [NS-22099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K06HD018454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022099] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOIA JF, 1981, METABOLISM, V30, P1076, DOI 10.1016/0026-0495(81)90050-0; Forbes G, 1987, HUMAN BODY COMPOSITI; FORBES GB, 1991, J APPL PHYSIOL, V70, P994, DOI 10.1152/jappl.1991.70.3.994; FORBES GB, 1986, BRIT J NUTR, V56, P1, DOI 10.1079/BJN19860080; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; FORBES GB, 1985, FED PROC, V44, P343; FORBES GB, 1982, DIET EXERCISE SYNERG, P75; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; HASSAGER C, 1989, MATURITAS, V4, P305; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC; WELLE S, IN PRESS J CLIN ENDO; WILMORE JH, 1983, MED SCI SPORT EXER, V15, P21	12	84	85	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					397	399		10.1001/jama.267.3.397	http://dx.doi.org/10.1001/jama.267.3.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727963				2022-12-28	WOS:A1992GY43700038
J	GRAHAM, NMH; NELSON, KE; SOLOMON, L; BONDS, M; RIZZO, RT; SCAVOTTO, J; ASTEMBORSKI, J; VLAHOV, D				GRAHAM, NMH; NELSON, KE; SOLOMON, L; BONDS, M; RIZZO, RT; SCAVOTTO, J; ASTEMBORSKI, J; VLAHOV, D			PREVALENCE OF TUBERCULIN POSITIVITY AND SKIN-TEST ANERGY IN HIV-1-SEROPOSITIVE AND HIV-1-SERONEGATIVE INTRAVENOUS-DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS-INFECTION; AIDS	Objectives. - To identify differences in purified protein derivative (PPD) tuberculin positivity and skin test anergy rates by human immunodeficiency virus (HIV) serostatus, CD4+ lymphocyte count, and other risk factors in intravenous drug users (IVDUs); and to evaluate the appropriateness of the Centers for Disease Control (CDC)-recommended definition for a positive PPD tuberculin skin test result in HIV-1-seropositive patients. Design. - Nested case-control and cross-sectional analyses. Setting. - Community-based cohort of IVDUs. Patients. - Two hundred sixty HIV-1-seropositive and -seronegative IVDUs, drawn from an unselected cohort, were skin-tested for sensitivity to PPD tuberculin, mumps, and Candida antigens using the Mantoux method. Outcome Measures. - Positivity to PPD tuberculin, skin test anergy. Results. - Even using the CDC definition of an induration 5 mm or greater in diameter in HIV-1 seropositives, this group was substantially less likely to be PPD tuberculin positive than HIV-1 seronegatives (13.8% vs 25.2%; P = .02). In the HIV-1 seropositives the relative odds of being PPD positive varied depending on whether 10 mm or greater (odds ratio [OR], 0.3; 95% confidence interval [CI], 0.2 to 0.7), 5 mm or greater (OR, 0.5; 95% CI, 0.2 to 0.9), or 2 mm or greater (OR, 0.7; 95% CI, 0.4 to 1.3) was used to define a positive test result. The mean diameter induration in the HIV-1-seropositive group was 2.6 mm vs 5.4 mm in the seronegative group (P =.005). Skin test anergy (to mumps and Candida) appeared to explain the differential. Anergy was substantially higher in the HIV-1 seropositive group and increased as the CD4+ lymphocyte count fell (chi-2 for linear trend, 24.5; P < .0001). An inverse linear trend for PPD positivity and CD4+ lymphocyte count was also observed (chi-2 for trend, 6.1; P = .01). In multivariate analyses, being 35 years of age or older and being HIV-1 seronegative were significantly associated with PPD positivity, while history of previous police arrest was of borderline significance. Only HIV-1 seropositivity was significantly associated with anergy. Conclusions. - These findings show that CDC-recommended definition of an induration 5 mm or greater in diameter for PPD tuberculin positivity in HIV-1 seropositives significantly underestimates the "true" infection rate (using the PPD positivity rate in HIV-1 seronegatives as the criterion standard). A definition of 2 mm or greater would appear to be a better cutoff for reducing misclassification in HIV-1 seropositives. This study also confirms that delayed-type hypersensitivity is seriously depressed in HIV-1 seropositive IVDUs and that anergy testing is mandatory to properly assess a negative PPD test result.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA	Johns Hopkins University	GRAHAM, NMH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 624 N BROADWAY, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04334, DA 05664] Funding Source: Medline; PHS HHS [CCU300466-10] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRX D, 1989, 5TH P INT C AIDS MON; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P638; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; NOLAN CM, 1988, 4TH INT C AIDS STOCK, P313; PITCHENIK AE, 1987, AM REV RESPIR DIS, V135, P875, DOI 10.1164/arrd.1987.135.4.875; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; SELIK RM, 1987, AIDS, V1, P175; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; Vlahov D, 1991, NIDA Res Monogr, V109, P75; 1991, MMWR, V40, P27; 1989, MMWR, V34, P236; 1990, MMWR, V39, P153; 1990, MMWR, V39, P1	19	188	191	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					369	373		10.1001/jama.267.3.369	http://dx.doi.org/10.1001/jama.267.3.369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727959				2022-12-28	WOS:A1992GY43700033
J	HANAUER, SB				HANAUER, SB			RELIEF OF FUNCTIONAL BOWEL OBSTRUCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HANAUER, SB (corresponding author), UNIV CHICAGO,MED CTR,CHICAGO,IL 60637, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					414	414						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727970				2022-12-28	WOS:A1992GY43700044
J	HIRSCHMANN, JV				HIRSCHMANN, JV			NORMAL BODY-TEMPERATURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HIRSCHMANN, JV (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DOWNTON JH, 1987, AGE AGEING, V16, P41, DOI 10.1093/ageing/16.1.41; HORVATH STEVEN M., 1950, JOUR AMER MED ASSOC, V144, P1562; IVY AC, 1945, GASTROENTEROLOGY, V5, P326; MELLETTE HC, 1951, J APPL PHYSIOL, V3, P65; WEIZMAN ED, 1982, NEUROBIOL AGING, V3, P299	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					414	414						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727969				2022-12-28	WOS:A1992GY43700045
J	SULLIVAN, LW				SULLIVAN, LW			THE NEED FOR AFFIRMATIVE-ACTION IN MEDICAL-EDUCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SULLIVAN, LW (corresponding author), US DEPT HHS,OFF PUBL AFFAIRS,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201, USA.							JONAS, 1991, JAMA-J AM MED ASSOC, V266, P913; READY, 1991, ACAD MED, V66, P181	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					343	343						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY437	1727944				2022-12-28	WOS:A1992GY43700010
J	WALDMANN, TA; PASTAN, IH; GANSOW, OA; JUNGHANS, RP				WALDMANN, TA; PASTAN, IH; GANSOW, OA; JUNGHANS, RP			THE MULTICHAIN INTERLEUKIN-2 RECEPTOR - A TARGET FOR IMMUNOTHERAPY	ANNALS OF INTERNAL MEDICINE			English	Discussion						RECEPTORS, INTERLEUKIN-2; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES-T; LYMPHOKINES	T-CELL LEUKEMIA; CARDIAC ALLOGRAFT SURVIVAL; GROWTH-FACTOR RECEPTOR; ANTI-TAC ANTIBODY; MONOCLONAL-ANTIBODY; PSEUDOMONAS EXOTOXIN; IL-2 RECEPTOR; HUMANIZED ANTIBODY; INFECTED-CELLS; FUSION PROTEIN	Activation of resting T-lymphocytes induces synthesis of interleukin-2 (IL-2) and expression of cell surface receptors for this lymphokine. In contrast to resting normal T-cells that do not express high-affinity IL-2 receptors (IL-2R), abnormal T-cells of patients with leukemia-lymphoma, certain autoimmune disorders, and individuals rejecting allografts express this receptor. Exploiting this difference in receptor expression, antibodies to the IL-2 receptor have been used effectively to treat patients with leukemia and lymphoma. One approach is to use monoclonal antibodies produced in mice; the disadvantage is that they are highly immunogenic. In an effort to reduce the immunogenicity of the mouse monoclonal antibodies, monoclonal-antibody-mediated therapy has been revolutionized by generating humanized antibodies produced by genetic engineering in which the molecule is human except for the antigen-combining regions, which are retained from the mouse. Further, to increase its cytotoxic effectiveness, the monoclonal antibody has been armed with toxins or radionuclides. Alternatively, IL-2 itself has been linked to a toxin to kill IL-2 receptor-bearing cells. Thus, IL-2 receptor-directed therapy provides a new method for treating certain neoplastic diseases and autoimmune disorders and for preventing allograft rejection.	NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, RADIAT ONCOL BRANCH, INORGAN & RADIOIMMUNE CHEM SECT, BETHESDA, MD 20892 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	WALDMANN, TA (corresponding author), NCI, METAB BRANCH, BLDG 10, ROOM 4N115, BETHESDA, MD 20892 USA.		pastan, ira/P-9319-2019; Waldmann, Thomas/AAT-5972-2021	pastan, ira/0000-0002-9223-0270; Waldmann, Thomas/0000-0003-4500-6660				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BRECHBIEL MW, 1988, THESIS AM U; BROWN PS, 1991, P NATL ACAD SCI USA, V88, P2663, DOI 10.1073/pnas.88.7.2663; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON J, 1990, P NATL ACAD SCI USA, V87, P7329, DOI 10.1073/pnas.87.18.7329; CASE JP, 1989, P NATL ACAD SCI USA, V86, P287, DOI 10.1073/pnas.86.1.287; CATANE R, 1988, ISRAEL J MED SCI, V24, P471; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; COOPER MM, 1990, TRANSPLANTATION, V50, P760, DOI 10.1097/00007890-199011000-00005; DEPPER JM, 1983, J IMMUNOL, V131, P690; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DIAMANTSTEIN T, 1986, IMMUNOL REV, V92, P5, DOI 10.1111/j.1600-065X.1986.tb01491.x; DIRBAS FM, 1990, SURG FORUM, V41, P415; DURBIN PATRICIA W., 1960, HEALTH PHYS, V2, P225; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; FITZGERALD DJP, 1984, J CLIN INVEST, V74, P966, DOI 10.1172/JCI111516; GANSOW OA, 1984, ACS SYM SER, V241, P215; HALE G, 1988, LANCET, V2, P1394; Hall E. J., 1988, RADIOBIOLOGY RADIOLO, P107; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HERRMANN T, 1987, IMMUNOBIOLOGY, V175, P145, DOI 10.1016/S0171-2985(87)80024-4; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JUNGHANS RP, 1990, CANCER RES, V50, P1495; KIRKMAN RL, 1991, TRANSPLANTATION, V51, P107, DOI 10.1097/00007890-199101000-00016; KIRKMAN RL, 1985, J EXP MED, V162, P358, DOI 10.1084/jem.162.1.358; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO T, 1988, J BIOL CHEM, V263, P9470; KORSMEYER SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4522, DOI 10.1073/pnas.80.14.4522; KOZAK RW, 1986, P NATL ACAD SCI USA, V83, P474, DOI 10.1073/pnas.83.2.474; KOZAK RW, 1989, CANCER RES, V45, P2835; KREJCAREK GE, 1977, BIOCHEM BIOPH RES CO, V77, P581, DOI 10.1016/S0006-291X(77)80018-1; KUZIEL WA, 1990, J INVEST DERMATOL, V94, pS27, DOI 10.1111/1523-1747.ep12875017; KYKER GC, 1962, MINER METABOL, VB, P499; LARSON SM, 1984, CANCER INVEST, V2, P363, DOI 10.3109/07357908409040313; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; LORBERBOUMGALSKI H, 1989, P NATL ACAD SCI USA, V86, P1008, DOI 10.1073/pnas.86.3.1008; Lovchik J C, 1977, Prog Allergy, V22, P1, DOI 10.1159/000314199; MAEDA M, 1987, BLOOD, V70, P1407; O'Brien H. A., 1983, RADIOIMMUNOIMAGING R, P161; OGATA M, 1988, J IMMUNOL, V141, P4224; PARHAM P, 1985, HUM IMMUNOL, V12, P213, DOI 10.1016/0198-8859(85)90337-4; PETERSEN JG, 1974, J BIOL CHEM, V249, P5633; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUEGG CL, 1990, CANCER RES, V50, P4221; SARAGOVI H, 1990, P NATL ACAD SCI USA, V87, P11, DOI 10.1073/pnas.87.1.11; SCHEINBERG DA, 1982, SCIENCE, V215, P1511, DOI 10.1126/science.7199757; SCHWARTING R, 1985, J CLIN PATHOL, V38, P1196, DOI 10.1136/jcp.38.10.1196-b; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHARON M, 1988, J IMMUNOL, V141, P3512; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SMITH KA, 1988, ADV IMMUNOL, V42, P165, DOI 10.1016/S0065-2776(08)60844-5; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEPLEWSKI Z, 1988, P NATL ACAD SCI USA, V85, P4852, DOI 10.1073/pnas.85.13.4852; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P4215, DOI 10.1073/pnas.84.12.4215; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; UCHIYAMA T, 1981, J IMMUNOL, V126, P1398; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WALDMANN TA, 1989, JNCI-J NATL CANCER I, V81, P914, DOI 10.1093/jnci/81.12.914; WALDMANN TA, 1988, BLOOD, V72, P1805; WALDMANN TA, 1984, J CLIN INVEST, V73, P1711, DOI 10.1172/JCI111379; WESSELS BW, 1984, MED PHYS, V11, P638, DOI 10.1118/1.595559; WILLIAMS JM, 1988, IMMUNOL INVEST, V16, P687, DOI 10.3109/08820138709087109; [No title captured]	79	97	101	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					148	160		10.7326/0003-4819-116-2-148	http://dx.doi.org/10.7326/0003-4819-116-2-148			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727619				2022-12-28	WOS:A1992GZ35600008
J	KAMB, ML; MURPHY, JJ; JONES, JL; CASTON, JC; NEDERLOF, K; HORNEY, LF; SWYGERT, LA; FALK, H; KILBOURNE, EM				KAMB, ML; MURPHY, JJ; JONES, JL; CASTON, JC; NEDERLOF, K; HORNEY, LF; SWYGERT, LA; FALK, H; KILBOURNE, EM			EOSINOPHILIA-MYALGIA-SYNDROME IN L-TRYPTOPHAN-EXPOSED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INGESTION	Objectives. - To study the incidence of eosinophilia-myalgia syndrome, the risk factors associated with the syndrome, and the clinical spectrum of illness associated with L-tryptophan use in an exposed population. Design. - Retrospective cohort and nested case-control studies of risk factors for eosinophilia-myalgia syndrome using inpatient and outpatient chart reviews, telephone interviews, and in-person patient interviews. Descriptive study of clinical course of L-tryptophan users. Setting. - Office practice of one psychiatrist based in a small city (population 43 467) in South Carolina. Patients. - Eligible subjects were all patients from the practice who used L-tryptophan during the 1989 study interval. Of these, 418 (87%) were interviewed. Main Outcome Measures. - Clinical spectrum of illness associated with L-tryptophan use, including definite and possible cases of eosinophilia-myalgia syndrome. Results. - Among the 418 interviewed L-tryptophan users, we identified 47 definite cases (11%) and 68 possible cases (16%) of eosinophilia-myalgia syndrome, most of which involved patients who were using one retail brand of L-tryptophan (brand A). Among the 157 brand A users, we identified 45 definite cases (29%) and 36 possible cases (23%) of eosinophilia-myalgia syndrome, and the risk for the syndrome increased as the brand A dose increased. Fifty percent (19 of 38) of those using more than 4000 mg/day developed definite eosinophilia-myalgia syndrome, and 84% (32 of 38) developed either definite or possible eosinophilia-myalgia syndrome. On multivariate analysis, risk for definite eosinophilia-myalgia syndrome was associated with brand A dose and age of the patient; however, gender, race, and use of other medications were not associated with the syndrome. Conclusions. - These results suggest that many people exposed to the agent causing eosinophilia-myalgia syndrome may develop illness, and dose of presumably contaminated L-tryptophan is the single most important predictor of eosinophilia-myalgia syndrome. The broad range of signs and symptoms reported by patients using L-tryptophan illustrates that a strict case definition may identify only about half of those affected.	S CAROLINA DEPT HLTH & ENVIRONM CONTROL, DIV DIS CONTROL & EPIDEMIOL, COLUMBIA, SC USA		KAMB, ML (corresponding author), CTR DIS CONTROL, 1600 CLIFTON RD NE, MAIL STOP E-02, ATLANTA, GA 30333 USA.							BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MIETTINEN OS, 1972, AM J EPIDEMIOL, V96, P168, DOI 10.1093/oxfordjournals.aje.a121443; NORIEGA AR, 1982, LANCET, V2, P697; POOLE L, 1977, SOME COMMON BASIC PR; Rosner B, 1982, FUNDAMENTALS BIOSTAT; SERRANORIOS M, 1984, TOXIC OIL SYNDROME M, P53; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; 1990, PHYSICIANS DESK REFE; 1989, MMWR, V38, P785; 1990, MMWR, V39, P589	19	100	101	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					77	82		10.1001/jama.267.1.77	http://dx.doi.org/10.1001/jama.267.1.77			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727200				2022-12-28	WOS:A1992GW84800027
J	AMAGAI, M; KLAUSKOVTUN, V; STANLEY, JR				AMAGAI, M; KLAUSKOVTUN, V; STANLEY, JR			AUTOANTIBODIES AGAINST A NOVEL EPITHELIAL CADHERIN IN PEMPHIGUS-VULGARIS, A DISEASE OF CELL-ADHESION	CELL			English	Article							NORMAL HUMAN-SKIN; FOLIACEUS AUTOANTIBODIES; DESMOSOMAL GLYCOPROTEIN; PLASMINOGEN-ACTIVATOR; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; PLACENTAL CADHERIN; SEQUENCE-ANALYSIS; PASSIVE TRANSFER; GENE FAMILY	Pemphigus vulgaris (PV) is a life-threatening skin disease in which autoantibodies against a keratinocyte cell surface 130 kd glycoprotein, PV antigen (PVA), cause loss of cell-cell adhesion, with resultant epidermal blisters. We used affinity-purified PV IgG to isolate CDNA, containing the entire coding sequence for PVA, from human keratinocyte expression libraries. Northern blot analysis indicated PV mRNA expression only in stratified squamous epithelia. The deduced amino acid sequence of PVA was unique but showed significant homology with members of the cadherin family of Ca2+-dependent cell adhesion molecules, most markedly to desmoglein I. These findings demonstrate that a novel epithelial cadherin is the target of autoantibodies in PV.			AMAGAI, M (corresponding author), NCI, DERMATOL BRANCH, BETHESDA, MD 20892 USA.		Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052				AMAGAI M, 1991, J INVEST DERMATOL, V97, P249, DOI 10.1111/1523-1747.ep12480358; AMAGAI M, 1990, J INVEST DERMATOL, V95, P252, DOI 10.1111/1523-1747.ep12484863; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; BEUTNER EH, 1968, J INVEST DERMATOL, V51, P63, DOI 10.1038/jid.1968.94; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1984, J CELL SCI, V70, P41; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EYRE RW, 1987, J EXP MED, V165, P1719, DOI 10.1084/jem.165.6.1719; EYRE RW, 1988, J CLIN INVEST, V81, P807, DOI 10.1172/JCI113387; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; GORBSKY G, 1981, J CELL BIOL, V90, P243, DOI 10.1083/jcb.90.1.243; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HASHIMOTO K, 1983, J EXP MED, V157, P259, DOI 10.1084/jem.157.1.259; HASHIMOTO T, 1990, J INVEST DERMATOL, V94, P327, DOI 10.1111/1523-1747.ep12874456; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; JONES JCR, 1986, P NATL ACAD SCI USA, V83, P7282, DOI 10.1073/pnas.83.19.7282; JONES JCR, 1986, J CELL BIOL, V102, P1109, DOI 10.1083/jcb.102.3.1109; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Maniatis T., 1982, MOL CLONING; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MERLOB P, 1986, PEDIATRICS, V78, P1102; MILLER K, 1987, EMBO J, V6, P885, DOI 10.1002/j.1460-2075.1987.tb04834.x; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; MORIOKA S, 1987, J INVEST DERMATOL, V89, P474, DOI 10.1111/1523-1747.ep12460937; MUELLER H, 1983, J MOL BIOL, V163, P647, DOI 10.1016/0022-2836(83)90116-X; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NILLES LA, 1991, J CELL SCI, V99, P809; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; ROCK B, 1990, J CLIN INVEST, V85, P296, DOI 10.1172/JCI114426; ROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362; SABOLINSKI ML, 1987, J INVEST DERMATOL, V88, P545, DOI 10.1111/1523-1747.ep12470131; SAMS WM, 1971, BRIT J DERMATOL, V84, P7; SAMS WM, 1982, J AM ACAD DERMATOL, V6, P431, DOI 10.1016/S0190-9622(82)70036-2; SCHILTZ JR, 1976, J INVEST DERMATOL, V67, P254, DOI 10.1111/1523-1747.ep12513454; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P177; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SHIRAYOSHI Y, 1986, EMBO J, V5, P2485, DOI 10.1002/j.1460-2075.1986.tb04525.x; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; STANLEY JR, 1981, J INVEST DERMATOL, V77, P240, DOI 10.1111/1523-1747.ep12480082; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STANLEY JR, 1982, J CLIN INVEST, V70, P281, DOI 10.1172/JCI110615; STANLEY JR, 1986, J IMMUNOL, V136, P1227; STANLEY JR, 1984, J INVEST DERMATOL, V82, P108, DOI 10.1111/1523-1747.ep12259224; STEINBERG MS, 1987, CIBA F SYMP, V125, P3; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH FS, 1990, J NEUROCHEM, V55, P805, DOI 10.1111/j.1471-4159.1990.tb04563.x; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WOLFF K, 1971, NATURE, V229, P59, DOI 10.1038/229059a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	71	783	823	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					869	877		10.1016/0092-8674(91)90360-B	http://dx.doi.org/10.1016/0092-8674(91)90360-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720352				2022-12-28	WOS:A1991GT75500006
J	POUVELLE, B; SPIEGEL, R; HSIAO, L; HOWARD, RJ; MORRIS, RL; THOMAS, AP; TARASCHI, TF				POUVELLE, B; SPIEGEL, R; HSIAO, L; HOWARD, RJ; MORRIS, RL; THOMAS, AP; TARASCHI, TF			DIRECT ACCESS TO SERUM MACROMOLECULES BY INTRAERYTHROCYTIC MALARIA PARASITES	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; TRANSPORT; MEMBRANE; PROTEIN; CULTURE	TRAFFICKING pathways in malaria-infected erythrocytes are complex because the internal parasite is separated from the serum by the erythrocyte and parasitophorous vacuolar membranes 1. Intraerythrocytic Plasmodium falciparum parasites can endocytose dextrans, protein A and an IgG2a antibody. Here we show that these macromolecules do not cross the erythrocyte or parasitophorous vacuolar membranes, but rather gain direct access to the aqueous space surrounding the parasite through a parasitophorous duct. Evidence for this structure includes visualization of membranes that are continuous between the parasitophorous vacuolar and erythrocyte membranes, and surface labelling of the parasite with fluorescent macromolecules under conditions that block endocytosis. The parasite can internalize by fluid-phase endocytosis macromolecules from the aqueous compartment surrounding it. Thus, surface antigens on trophozoites and schizonts should be considered as targets for antibody-directed parasiticidal agents.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL & CELL BIOL, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA; DNAX RES INST MOLEC & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	Jefferson University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; BARNWELL JW, 1990, BLOOD CELLS, V16, P379; ELFORD BC, 1985, MOL BIOCHEM PARASIT, V16, P43, DOI 10.1016/0166-6851(85)90048-9; GREEN TJ, 1985, AM J TROP MED HYG, V34, P24, DOI 10.4269/ajtmh.1985.34.24; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; HOWARD RJ, 1987, J CELL BIOL, V104, P1269, DOI 10.1083/jcb.104.5.1269; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; HUNTER J A, 1991, Biophysical Journal, V59, p442A; JENSEN JB, 1982, SCIENCE, V216, P1230, DOI 10.1126/science.7043736; JEPSEN S, 1983, SCAND J IMMUNOL, V18, P567, DOI 10.1111/j.1365-3083.1983.tb00893.x; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; RODRIGUEZ MH, 1986, NATURE, V324, P388, DOI 10.1038/324388a0; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAYLOR DW, 1987, MOL BIOCHEM PARASIT, V25, P165, DOI 10.1016/0166-6851(87)90005-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERSCHAFT PH, 1987, BIOCHIM BIOPHYS ACTA, V901, P1, DOI 10.1016/0005-2736(87)90250-1	17	193	194	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					73	75		10.1038/353073a0	http://dx.doi.org/10.1038/353073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1715521				2022-12-28	WOS:A1991GD80500061
J	PENDERGAST, AM; MULLER, AJ; HAVLIK, MH; MARU, Y; WITTE, ON				PENDERGAST, AM; MULLER, AJ; HAVLIK, MH; MARU, Y; WITTE, ON			BCR SEQUENCES ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE BIND TO THE ABL-SH2 REGULATORY DOMAIN IN A NON-PHOSPHOTYROSINE-DEPENDENT MANNER	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; C-ABL; PHILADELPHIA-CHROMOSOME; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEINS; FUSED TRANSCRIPT; PHOSPHOLIPASE-C; LYMPHOID-CELLS	BCR-ABL is a chimeric oncogene implicated in the pathogenesis of Philadelphia chromosome-positive human leukemias. BCR first exon sequences specifically activate the tyrosine kinase and transforming potential of BCR-ABL. We have tested the hypothesis that activation of BCR-ABL may involve direct interaction between BCR sequences and the tyrosine kinase regulatory domains of ABL. Full-length c-BCR as well as BCR sequences retained in BCR-ABL bind specifically to the SH2 domain of ABL. The binding domain has been localized within the first exon of BCR and consists of at least two SH2-binding sites. This domain is essential for BCR-ABL-mediated transformation. Phosphoserine/phosphothreonine but not phosphotyrosine residues on BCR are required for interaction with the ABL SH2 domain. These findings extend the range of potential SH2-protein interactions in growth control pathways and suggest a function for SH2 domains in the activation of the BCR-ABL oncogene as well as a role for BCR in cellular signaling pathways.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	PENDERGAST, AM (corresponding author), UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA.			Pendergast, Ann Marie/0000-0002-1250-6880; Muller, Alexander/0000-0001-7854-6933				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELLIS C, 1991, IN PRESS ONCOGENE; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUO K, 1900, MOL CELL BIOL, V10, P5305; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MOTSN MG, 1990, P NSYL SVSF DVI UD, V87, P8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; Pendergast A M, 1987, Baillieres Clin Haematol, V1, P1001, DOI 10.1016/S0950-3536(87)80036-7; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, IN PRESS P NATL ACAD; QUILLIAM LA, 1990, MOL CELL BIOL, V11, P1804; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; Summers MD, 1987, MANUAL METHODS BACUL; TIMMONS MS, 1989, ONCOGENE, V4, P559; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	55	325	339	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					161	171		10.1016/0092-8674(91)90148-R	http://dx.doi.org/10.1016/0092-8674(91)90148-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712671				2022-12-28	WOS:A1991FW91300018
J	VARADI, G; LORY, P; SCHULTZ, D; VARADI, M; SCHWARTZ, A				VARADI, G; LORY, P; SCHULTZ, D; VARADI, M; SCHWARTZ, A			ACCELERATION OF ACTIVATION AND INACTIVATION BY THE BETA SUBUNIT OF THE SKELETAL-MUSCLE CALCIUM-CHANNEL	NATURE			English	Article							DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; MAMMALIAN-CELLS; MESSENGER-RNA; CDNA CLONING; ALPHA-1-SUBUNIT; RESOLUTION; INDUCTION; EXISTENCE; CURRENTS	THE L-type voltage-dependent calcium channel is an important link in excitation-contraction coupling of muscle cells 1 (reviewed in refs 2 and 3). The channel has two functional characteristics: calcium permeation and receptor sites for calcium antagonists. In skeletal muscle the channel is a complex of five subunits, alpha-1, alpha-2, beta, gamma and delta (ref. 4). Complementary DNAs to these subunits have been cloned and their amino-acid sequences deduced 5-8. The skeletal muscle alpha-1 subunit cDNA expressed in L cells manifests as specific calcium-ion permeation, as well as sensitivity to the three classes of organic calcium-channel blockers 9,10. We report here that coexpression of the alpha-1 subunit with other subunits results in significant changes in dihydropyridine binding and gating properties. The available number of drug receptor sites increases 10-fold with an alpha-1-beta combination, whereas the affinity of the dihydropyridine binding site remains unchanged. Also, the presence of the beta-subunit accelerates activation and inactivation kinetics of the calcium-channel current.	UNIV CINCINNATI,DEPT PHARMACOL & CELL BIOPHYS,231 BETHESDA AVE,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati				LORY, philippe/0000-0002-1638-7604				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CAFFREY JM, 1989, J NEUROSCI, V9, P3443; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; Janis RA, 1987, ADV DRUG RES, V16, P309; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PRAGNELL M, 1985, NATURE, V314, P747; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sambrook J, 1989, MOL CLONING LABORATO; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VAGHY PL, 1988, TRENDS PHARMACOL SCI, V9, P398, DOI 10.1016/0165-6147(88)90066-1	28	270	273	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					159	162		10.1038/352159a0	http://dx.doi.org/10.1038/352159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1712427				2022-12-28	WOS:A1991FW09700058
J	WALLER, DK; LUSTIG, LS; CUNNINGHAM, GC; GOLBUS, MS; HOOK, EB				WALLER, DK; LUSTIG, LS; CUNNINGHAM, GC; GOLBUS, MS; HOOK, EB			2ND-TRIMESTER MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS AND THE RISK OF SUBSEQUENT FETAL DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; PREGNANCIES; OUTCOMES; VALUES	Background. The finding of an elevated level of maternal serum alpha-fetoprotein during the second trimester of pregnancy may indicate that the fetus has died or is about to die. It is uncertain, however, whether the finding is associated with an increased risk of fetal death later in gestation independent of known causes of elevation, such as the presence of neural-tube defects or multiple gestation. Methods. To address this question, we performed a case-control study of 612 women whose pregnancies ended in fetal death and 2501 women who gave birth to live infants, using reports from California vital statistics for 1987. All the women had singleton pregnancies and alpha-fetoprotein screening in the second trimester. Results. Women with elevated levels of serum alpha-fetoprotein in the second trimester of pregnancy had an increased risk of fetal death, and the risk was increased until term. Women with the highest levels of serum alpha-fetoprotein - greater-than-or-equal-to 3.0 times the median value - had a very high risk of fetal death (odds ratio, 10.4; 95 percent confidence interval, 4.9 to 22.0) as compared with women who had normal levels of alpha-fetoprotein. Maternal serum alpha-fetoprotein levels that were 2.0 to 2.9 times the median were also associated with an elevated risk of fetal death (odds ratio, 2.4; 95 percent confidence interval, 1.7 to 3.4). Elevated levels of alpha-fetoprotein were especially likely to be associated with fetal death in cases in which maternal hypertension or placental infarction was also present. Conclusions. An unexplained elevated level of maternal serum alpha-fetoprotein in the second trimester of pregnancy is associated with an increased risk of subsequent fetal death, up to four to five months after alpha-fetoprotein screening.	UNIV CALIF BERKELEY,SCH PUBL HLTH,WARREN HALL,BERKELEY,CA 94720; CALIF DEPT HLTH SERV,GENET DIS BRANCH,CALIF ALPHA FETOPROT SCREENING PROGRAM,BERKELEY,CA 94704; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; California Department of Health Care Services; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Waller, Dorothy/0000-0003-2211-4773				ADAMS MJ, 1984, AM J OBSTET GYNECOL, V148, P241, DOI 10.1016/S0002-9378(84)80062-9; ANDERSON GD, 1986, OBSTETRICS NORMAL PR, P819; Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BAULD R, 1974, ARCH DIS CHILD, V49, P782, DOI 10.1136/adc.49.10.782; BENNETT MJ, 1979, AM J OBSTET GYNECOL, V135, P545, DOI 10.1016/0002-9378(79)90449-6; BERKELEY AS, 1983, AM J OBSTET GYNECOL, V146, P859, DOI 10.1016/0002-9378(83)91091-8; BOYD PA, 1986, PRENATAL DIAG, V6, P369, DOI 10.1002/pd.1970060505; BROCK DJH, 1979, LANCET, V1, P1281; BURTON BK, 1988, OBSTET GYNECOL, V72, P709; BYRNE J, 1986, AM J MED GENET, V25, P327, DOI 10.1002/ajmg.1320250219; CRANDALL BF, 1983, WESTERN J MED, V138, P524; DAVENPORT DM, 1983, AM J OBSTET GYNECOL, V146, P657, DOI 10.1016/0002-9378(83)91008-6; EVANS MI, 1988, OBSTET GYNECOL, V72, P342; FAROOQUI MO, 1973, OBSTET GYNECOL SURV, V28, P144; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MILUNSKY A, 1989, AM J OBSTET GYNECOL, V161, P291, DOI 10.1016/0002-9378(89)90501-2; MOORE TR, 1989, AM J OBSTET GYNECOL, V160, P1075, DOI 10.1016/0002-9378(89)90164-6; NELSON LH, 1987, AM J OBSTET GYNECOL, V157, P572, DOI 10.1016/S0002-9378(87)80009-1; ROBINSON L, 1989, OBSTET GYNECOL, V74, P17; SALAFIA CM, 1988, AM J OBSTET GYNECOL, V158, P1064, DOI 10.1016/0002-9378(88)90220-7; SEPPALA M, 1976, LANCET, V2, P123; SEPPALA M, 1972, BMJ-BRIT MED J, V4, P769, DOI 10.1136/bmj.4.5843.769; SIMPSON JL, 1987, AM J OBSTET GYNECOL, V156, P852, DOI 10.1016/0002-9378(87)90341-3; SIMPSON JL, 1986, OBSTETRICS NORMAL PR, P651; WARBURTON D, 1964, AM J HUM GENET, V16, P1; 1977, LANCET, V1, P1323	27	71	71	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					6	10		10.1056/NEJM199107043250102	http://dx.doi.org/10.1056/NEJM199107043250102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1710779				2022-12-28	WOS:A1991FU34200002
J	ASHBY, M; STOFFELL, B				ASHBY, M; STOFFELL, B			THERAPEUTIC RATIO AND DEFINED PHASES - PROPOSAL OF ETHICAL FRAMEWORK FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS		ROYAL ADELAIDE HOSP,PALLIAT MED,ADELAIDE,SA 5006,AUSTRALIA; FLINDERS UNIV,MED CTR,MED ETH UNIT,BEDFORD PK,SA 5042,AUSTRALIA	Royal Adelaide Hospital; Flinders University South Australia								AHRONHEIM JC, 1990, LANCET, P278; BLACK D, 1990, BRIT MED J, V300, P1321, DOI 10.1136/bmj.300.6735.1321; CASSIDY S, 1986, J ROY SOC MED, V79, P717; GILHOOLY MLM, 1988, PALLIATIVE MED, V2, P64; Glover J, 1977, CAUSING DEATH SAVING; HIGGINSON I, 1989, PALLIATIVE MED, V3, P267; HIRSCHFIELD MJ, 1989, PALLIATIVE MED, V4, P25; JONES A, 1980, CLIN RADIOL, V31, P121, DOI 10.1016/S0009-9260(80)80135-8; KEARSLEY JH, 1986, BMJ-BRIT MED J, V293, P871, DOI 10.1136/bmj.293.6551.871; LUNT B, 1987, PALLIATIVE MED, V1, P136; MITCHELL JRA, 1979, BRIT MED J, V1, P1523, DOI 10.1136/bmj.1.6177.1523; Rachels J, 1986, END LIFE; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SMITH T, 1988, BRIT MED J, V297, P438, DOI 10.1136/bmj.297.6646.438; STOLL BA, 1990, J MED ETHICS, V16, P71, DOI 10.1136/jme.16.2.71; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; TIMOTHY AR, 1988, BRIT MED J, V297, P471, DOI 10.1136/bmj.297.6646.471; 1989, LANCET, V1, P476	18	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1322	1324		10.1136/bmj.302.6788.1322	http://dx.doi.org/10.1136/bmj.302.6788.1322			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1711907	Green Published, Bronze			2022-12-28	WOS:A1991FQ44400024
J	KOCH, CA; ANDERSON, D; MORAN, MF; ELLIS, C; PAWSON, T				KOCH, CA; ANDERSON, D; MORAN, MF; ELLIS, C; PAWSON, T			SH2 AND SH3 DOMAINS - ELEMENTS THAT CONTROL INTERACTIONS OF CYTOPLASMIC SIGNALING PROTEINS	SCIENCE			English	Article							ROUS-SARCOMA VIRUS; GROWTH-FACTOR RECEPTOR; AMINO-TERMINAL DOMAIN; TYROSINE KINASE GENE; PHOSPHOLIPASE-C-GAMMA; PHOSPHATIDYLINOSITOL KINASE; SRC GENE; PDGF RECEPTOR; EGF RECEPTOR; REGULATES INTERACTIONS	Src homology (SH) regions 2 and 3 are noncatalytic domains that are conserved among a series of cytoplasmic signaling proteins regulated by receptor protein-tyrosine kinases, including phospholipase C-gamma, Ras GTPase (guanosine triphosphatase)-activating protein, and Src-like tyrosine kinases. The SH2 domains of these signaling proteins bind tyrosine phosphorylated polypeptides, implicated in normal signaling and cellular transformation. Tyrosine phosphorylation acts as a switch to induce the binding of SH2 domains, thereby mediating the formation of heteromeric protein complexes at or near the plasma membrane. The formation of these complexes is likely to control the activation of signal transduction pathways by tyrosine kinases. The SH3 domain is a distinct motif that, together with SH2, may modulate interactions with the cytoskeleton and membrane. Some signaling and transforming proteins contain SH2 and SH3 domains unattached to any known catalytic element. These noncatalytic proteins may serve as adaptors to link tyrosine kinases to specific target proteins. These observations suggest that SH2 and SH3 domains participate in the control of intracellular responses to growth factor stimulation.	UNIV TORONTO, MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Moran, Michael/GYD-3631-2022; Pawson, Tony J/E-4578-2013					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SK, 1987, J VIROL, V61, P1893, DOI 10.1128/JVI.61.6.1893-1900.1987; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO J, 1988, NATURE, V343, P377; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KANNER SB, COMMUNICATION; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1990, ANNU REV BIOCHEM, V61, P121; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM JW, 1990, J BIOL CHEM, V265, P3940; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH C, UNPUB; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KRIZ R, 1990, CIBA F SYMP, V150, P112; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTSU M, COMMUNICATION; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PELICCI G, COMMUNICATION; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REICHMAN CT, COMMUNICATION; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROTTAPEL R, IN PRESS MOL CELL BI; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	131	1859	1969	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					668	674		10.1126/science.1708916	http://dx.doi.org/10.1126/science.1708916			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1708916				2022-12-28	WOS:A1991FK18500038
J	IRVING, BA; WEISS, A				IRVING, BA; WEISS, A			THE CYTOPLASMIC DOMAIN OF THE T-CELL RECEPTOR ZETA-CHAIN IS SUFFICIENT TO COUPLE TO RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS	CELL			English	Article							NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; LYMPHOCYTE-T; TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHATES; SURFACE MOLECULES; CD3 COMPLEX; ACTIVATION; EXPRESSION; PROTEIN	The function of the T cell antigen receptor (TCR) invariant chains, CD3-gamma, delta, epsilon, and zeta, is poorly understood. Evidence suggests that CD3 couples receptor ligand binding to intracellular signaling events. To examine the role of the CD3-zeta-chain in TCR-mediated signal transduction, a chimeric protein linking the extracellular and transmembrane domains of CD8 to the cytoplasmic domain of the zeta-chain was constructed. The CD8/zeta-chimera is expressed independently of the TCR and is capable of transducing signals that, by criteria of early and late activation, are indistinguishable from those generated by the intact TCR. These data indicate that CD8/zeta can activate the appropriate signal transduction pathways in the absence of CD3-gamma, delta, and epsilon, and suggest that the role of CD3-zeta is to couple the TCR to intracellular signal transduction mechanisms.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	IRVING, BA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; Frank S J, 1990, Semin Immunol, V2, P89; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GOLDSMITH MA, 1988, IMMUNOL TODAY, V9, P220, DOI 10.1016/0167-5699(88)91219-4; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KLAUSNER R D, 1989, New Biologist, V1, P3; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER N, 1986, J ORG CHEM, V51, P263, DOI 10.1021/jo00352a032; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TESTI R, 1989, J IMMUNOL, V142, P1854; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	57	728	795	4	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					891	901		10.1016/0092-8674(91)90314-O	http://dx.doi.org/10.1016/0092-8674(91)90314-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1705867				2022-12-28	WOS:A1991FA94000007
J	COLWILL, JM				COLWILL, JM			WHERE HAVE ALL THE PRIMARY CARE APPLICANTS GONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-SCHOOL ADMISSIONS; UNITED-STATES; HEALTH-CARE; FAMILY PHYSICIANS; CHOICE; SPECIALTY; STUDENTS; EXPENDITURES; PERSPECTIVE; EDUCATION				COLWILL, JM (corresponding author), UNIV MISSOURI,DEPT FAMILY & COMMUNITY MED,M228 MED SCI BLDG,COLUMBIA,MO 65212, USA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; ADKINS RJ, 1987, J MED EDUC, V62, P810; AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; ASTIN AW, 1991, AM FRESHMAN 25 YEAR; BABBOTT D, 1990, JAMA-J AM MED ASSOC, V263, P815; BABBOTT D, 1989, JAMA-J AM MED ASSOC, V261, P2367, DOI 10.1001/jama.261.16.2367; BARER ML, 1991, JAMA-J AM MED ASSOC, V265, P2393, DOI 10.1001/jama.265.18.2393; BARNETT PG, 1989, JAMA-J AM MED ASSOC, V262, P2864, DOI 10.1001/jama.262.20.2864; BLOOM SW, 1988, J HEALTH SOC BEHAV, V29, P294, DOI 10.2307/2136864; Boulger J G, 1991, J Rural Health, V7, P105, DOI 10.1111/j.1748-0361.1991.tb00713.x; BOWMAN MA, 1989, PUBLIC HEALTH REP, V104, P286; Brazeau N K, 1990, Fam Med, V22, P350; CAMPOSOUTCALT D, 1989, ACAD MED, V64, P610, DOI 10.1097/00001888-198910000-00013; Colwill J M, 1988, Fam Med, V20, P250; Colwill J M, 1988, Fam Med, V20, P405; COLWILL JM, 1988, FAM MED, V20, P462; COLWILL JM, 1990, 2ND P HRSA PRIM CAR, P329; COLWILL JM, 1989, I MED PRIMARY CARE P, P76; CROWLEY AE, 1982, JAMA-J AM MED ASSOC, V248, P3271; CULLISON S, 1976, JAMA-J AM MED ASSOC, V235, P502, DOI 10.1001/jama.235.5.502; EBELL MH, 1989, JAMA-J AM MED ASSOC, V262, P1630, DOI 10.1001/jama.1989.03430120080018; EISENBERG J, 1986, DOCTORS DECISIONS CO; ERNEY SL, 1991, ACAD MED, V66, P234, DOI 10.1097/00001888-199104000-00014; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; Funkenstein DH., 1978, MED STUDENTS MED SCH; GARG ML, 1991, ACAD MED, V66, P348, DOI 10.1097/00001888-199106000-00009; GINZBERG E, 1989, ACAD MED, V64, P495, DOI 10.1097/00001888-198909000-00001; GRIFFEN WO, 1990, AM J SURG, V159, P189, DOI 10.1016/S0002-9610(05)80256-9; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; Hynes K, 1990, J Rural Health, V6, P9, DOI 10.1111/j.1748-0361.1990.tb00187.x; IGLEHART JK, 1986, NEW ENGL J MED, V315, P1623, DOI 10.1056/NEJM198612183152531; Karnell L H, 1991, Bull Am Coll Surg, V76, P26; KASSLER WJ, 1991, ACAD MED, V66, P41, DOI 10.1097/00001888-199101000-00012; KAUFMAN A, 1989, ACAD MED, V64, P285, DOI 10.1097/00001888-198906000-00001; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; KLETKE PR, 1991, PRIMARY CARE RES THE, P261; MANN NS, 1987, NEW ENGL J MED, V317, P1416; MCCARTY DJ, 1987, NEW ENGL J MED, V317, P567, DOI 10.1056/NEJM198708273170909; MOWBRAY RM, 1989, AUST NZ J MED, V19, P389, DOI 10.1111/j.1445-5994.1989.tb00286.x; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; NOBLE J, 1988, ASSESSMENT DEV SUPPO; OVERPECK MD, 1970, PUBLIC HEALTH REP, V85, P485, DOI 10.2307/4593887; Park R, 1990, Acad Med, V65, P485, DOI 10.1097/00001888-199007000-00024; PAWLSON LG, 1979, J MED EDUC, V54, P551; PAWLSON LG, 1980, J FAM PRACTICE, V10, P847; PEABODY FW, 1930, DOCTOR PATIENT; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; Rabinowitz H K, 1988, Fam Med, V20, P118; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; REZLER AG, 1989, J FAM PRACTICE, V29, P652; ROBACK G, 1990, PHYSICIAN CHARACTERI; ROSENBLATT RA, 1991, WESTERN J MED, V154, P43; ROSENTHAL MP, 1991, 24TH C SOC TEACH FAM; ROWLEY BD, 1990, JAMA-J AM MED ASSOC, V264, P822, DOI 10.1001/jama.264.7.822; Schmittling G, 1991, Fam Med, V23, P297; Schroeder S A, 1985, Health Aff (Millwood), V4, P22, DOI 10.1377/hlthaff.4.2.22; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; SCHWARTZ RW, 1989, ACAD MED, V64, P606, DOI 10.1097/00001888-198910000-00012; SCHWARTZ WB, 1980, NEW ENGL J MED, V303, P1032, DOI 10.1056/NEJM198010303031803; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; SHULKIN DJ, 1989, JAMA-J AM MED ASSOC, V262, P1630, DOI 10.1001/jama.1989.03430120080019; SINGER AM, 1990, CLASS 83 FOLLOW STUD; STEINWACHS DM, 1986, NEW ENGL J MED, V314, P217, DOI 10.1056/NEJM198601233140406; Stevens Rosemary, 1971, AM MED PUBLIC INTERE; STRATTON TD, 1991, ACAD MED, V66, P101, DOI 10.1097/00001888-199102000-00012; TARDIFF K, 1986, J MED EDUC, V61, P790; VERBY JE, 1991, JAMA-J AM MED ASSOC, V266, P110, DOI 10.1001/jama.266.1.110; WEINER J, 1991, EFFECTS FUTURE HLTH; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WILENSKY GR, 1983, MILBANK FUND Q, V61, P252, DOI 10.2307/3349907; WILSON JL, 1985, J MED EDUC, V60, P56; WOOD AP, 1991, FAM PRACT NEWS, V21, P1; WOOD AP, 1991, FAM PRACT NEWS, V21, P10; 1982, 1982 GRADUATION QUES; 1991, SUPPLYING PHYSICIANS; 1980, GMENAC REPORT; 1991, FUNCTIONS STRUCTURE; 1991, NRMP 1991 RESULTS; 1978, MANPOWER POLICY PRIM; 1989, 1989 GRADUATION QUES; 1986, NRMP 1986 RESULTS; 1988, 1ST REPORT COUNCIL, V1	86	149	150	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					387	393		10.1056/NEJM199202063260606	http://dx.doi.org/10.1056/NEJM199202063260606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729622				2022-12-28	WOS:A1992HC38600006
J	RAFAL, ES; GRIFFITHS, CEM; DITRE, CM; FINKEL, LJ; HAMILTON, TA; ELLIS, CN; VOORHEES, JJ				RAFAL, ES; GRIFFITHS, CEM; DITRE, CM; FINKEL, LJ; HAMILTON, TA; ELLIS, CN; VOORHEES, JJ			TOPICAL TRETINOIN (RETINOIC ACID) TREATMENT FOR LIVER SPOTS ASSOCIATED WITH PHOTODAMAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHOTOAGED SKIN; VITAMIN-A; MELANOMA; THERAPY	Background. The hyperpigmented lesions commonly called liver spots distress patients, in part because such lesions are associated with aging. We investigated their treatment with topical 0.1 percent tretinoin (retinoic acid). Methods. Fifty-eight patients completed a 10-month randomized, double-blind study in which they applied either 0.1 percent tretinoin (n = 28) or vehicle (n = 30) cream daily to the face, upper extremities, or both. Fifteen patients who responded well were then randomly assigned to continue tretinoin therapy or use vehicle alone for six more months. Patients were evaluated by physical examination every month and by analysis of biopsy specimens of lesions obtained at base line and at the end of the 10-month trial. Results. After one month of treatment the patients treated with tretinoin had significant lightening of hyperpigmented lesions as compared with the patients who received vehicle (P < 0.002). After 10 months, 20 (83 percent) of the 24 patients with facial lesions who were treated with tretinoin had lightening of these lesions, as compared with 8 (29 percent) of the 28 patients with facial lesions who received vehicle. The results for lesions of the upper extremities were similar. As compared with vehicle, tretinoin caused a significant decrease in the degree of epidermal pigmentation and increases in the degree of compaction of stratum corneum, thickness of the granular cell layer, and epidermal thickness. Reductions in epidermal pigmentation evident on histologic analysis were significantly correlated with the degree of clinical lightening of lesions (r = -0.53, P < 0.0001). During the 6-month follow-up study, specifically identified lesions that had disappeared during the first 10 months of tretinoin treatment did not return in any patient, and six of seven patients who continued to use tretinoin had further improvement. Conclusions. Topical 0.1 percent tretinoin significantly improves both clinical and microscopical manifestations of liver spots; these lesions do not return for at least six months after therapy is discontinued.	UNIV MICHIGAN,MED CTR,DEPT DERMATOL,DERMATOPHARMACOL UNIT,1910 TAUBMAN CTR,1500 E MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Ellis, Charles/ABA-7264-2021; Griffiths, Christopher E.M./P-5448-2014	Ellis, Charles/0000-0001-9436-7628; Griffiths, Christopher E.M./0000-0001-5371-4427				BHAWAN J, 1991, ARCH DERMATOL, V127, P666, DOI 10.1001/archderm.127.5.666; BOLLAG W, 1970, Agents and Actions, V1, P172, DOI 10.1007/BF01965758; BOLLAG W, 1983, LANCET, V1, P860; CAPUTO R, 1990, BRIT J DERMATOL, V122, P97, DOI 10.1111/j.1365-2133.1990.tb16133.x; ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; GOLDFARB MT, 1989, J AM ACAD DERMATOL, V21, P645, DOI 10.1016/S0190-9622(89)70232-2; HAAS AA, 1986, J AM ACAD DERMATOL, V15, P870, DOI 10.1016/S0190-9622(86)70244-2; HODGSON C, 1963, ARCH DERMATOL, V87, P197, DOI 10.1001/archderm.1963.01590140059010; KLIGMAN AM, 1989, J AM ACAD DERMATOL, V21, P650, DOI 10.1016/S0190-9622(89)70233-4; KLIGMAN AM, 1986, J AM ACAD DERMATOL, V15, P836, DOI 10.1016/S0190-9622(86)70242-9; KURKA M, 1978, HAUTARZT, V1729, P313; LEVINE N, 1980, LANCET, V2, P224; LOBER CW, 1987, J AM ACAD DERMATOL, V17, P109, DOI 10.1016/S0190-9622(87)70181-9; MARKS R, 1990, BRIT J DERMATOL, V122, P93, DOI 10.1111/j.1365-2133.1990.tb16132.x; MEYSKENS FL, 1982, J AM ACAD DERMATOL, V6, P824, DOI 10.1016/S0190-9622(82)70072-6; MEYSKENS FL, 1986, J AM ACAD DERMATOL, V15, P822, DOI 10.1016/S0190-9622(86)70239-9; ORLOW SJ, 1990, J INVEST DERMATOL, V94, P461, DOI 10.1111/1523-1747.ep12874568; PECK GL, 1986, J AM ACAD DERMATOL, V15, P829, DOI 10.1016/S0190-9622(86)70241-7; SILVERMAN AK, 1987, J AM ACAD DERMATOL, V16, P1027, DOI 10.1016/S0190-9622(87)70133-9; WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274	24	114	119	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					368	374		10.1056/NEJM199202063260603	http://dx.doi.org/10.1056/NEJM199202063260603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729619				2022-12-28	WOS:A1992HC38600003
J	DANNEMANN, B; MCCUTCHAN, JA; ISRAELSKI, D; ANTONISKIS, D; LEPORT, C; LUFT, B; NUSSBAUM, J; CLUMECK, N; MORLAT, P; CHIU, J; VILDE, JL; ORELLANA, M; FEIGAL, D; BARTOK, A; HESELTINE, P; LEEDOM, J; REMINGTON, J				DANNEMANN, B; MCCUTCHAN, JA; ISRAELSKI, D; ANTONISKIS, D; LEPORT, C; LUFT, B; NUSSBAUM, J; CLUMECK, N; MORLAT, P; CHIU, J; VILDE, JL; ORELLANA, M; FEIGAL, D; BARTOK, A; HESELTINE, P; LEEDOM, J; REMINGTON, J			TREATMENT OF TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS - A RANDOMIZED TRIAL COMPARING PYRIMETHAMINE PLUS CLINDAMYCIN TO PYRIMETHAMINE PLUS SULFADIAZINE	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; TOXOPLASMOSIS, CEREBRAL; PYRIMETHAMINE; CLINDAMYCIN; SULFADIAZINE	NERVOUS-SYSTEM TOXOPLASMOSIS; IMMUNE-DEFICIENCY-SYNDROME; ACQUIRED IMMUNODEFICIENCY SYNDROME; CEREBRAL TOXOPLASMOSIS; THERAPY; GONDII; COMBINATION; MACROLIDE; EFFICACY; INVITRO	Objective: To compare pyrimethamine plus clindamycin (PC) to pyrimethamine plus sulfadiazine (PS) as a treatment for toxoplasmic encephalitis (TE) in patients with the acquired immunodeficiency syndrome (AIDS). Design: Randomized, unblinded phase II, multicenter trial with provision for crossover for failure or intolerance of the assigned regimen. Setting: University hospitals. Patients: Eighty-four patients with presumptive TE were entered. Thirteen were excluded when they were found to have another diagnosis, and 12 were excluded because they did not meet entry criteria. The baseline characteristics in the remaining 26 patients randomized to PC and 33 randomized to PS were comparable. Interventions: Patients were treated for 6 weeks with pyrimethamine and folinic acid plus either sulfadiazine or clindamycin. Clindamycin was given intravenously during the first 3 weeks. Measurements and Main Results: There was a trend toward greater survival in patients randomized to PS (hazard ratio, 3.25; 95% Cl, 0.63 to 16.8; P = 0.13), but most study deaths were not directly related to TE. In contrast, patients randomized to PC appeared more likely to achieve complete clinical (odds ratio, 0.67; Cl, 0.2 to 1.97; P < 0.2) and radiologic responses (odds ratio, 0.28; Cl, 0.08 to 0.96; P = 0.02). Multivariate analysis revealed drug effects to be largely independent of other variables. Similar efficacy of the treatments was also suggested by a hazard analysis of resolution of abnormal mental status, fever, and headache. Skin rash was the most common adverse event in both treatment arms. Because of toxicity, six patients randomized to PC and 11 patients randomized to PS had to switch to the alternate treatment, but only three were unable to complete therapy after crossover. Conclusions: The results of several end points of efficacy, taken together, suggest that the relative efficacy of PC approximately equals that of PS. PC appears to be an acceptable alternative in patients unable to tolerate PS.	UNIV CALIF SAN DIEGO, MED CTR 8208, CALIF COLLABORAT TREATMENT GRP, 225 DICKINSON ST, SAN DIEGO, CA 92103 USA; STANFORD UNIV, STANFORD, CA 94305 USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; HOP CLAUDE BERNARD, F-75994 PARIS 19, FRANCE; HOP PELLEGRIN, F-33076 BORDEAUX, FRANCE; SUNY STONY BROOK, STONY BROOK, NY 11794 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; FREE UNIV BRUSSELS, B-1050 BRUSSELS, BELGIUM	University of California System; University of California San Diego; Stanford University; University of Southern California; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; CHU Bordeaux; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Irvine; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Luft, Benjamin/0000-0001-9008-7004	NIAID NIH HHS [AI079089, AI04717] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004717, R37AI004717] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEGRA CJ, 1987, J CLIN INVEST, V79, P478, DOI 10.1172/JCI112837; ANTONISKIS D, 1989, 5TH INT C AIDS MONTR, P355; ARAUJO FG, 1988, ANTIMICROB AGENTS CH, V32, P755, DOI 10.1128/AAC.32.5.755; ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; BELLER AJ, 1973, J NEUROL NEUROSUR PS, V36, P757, DOI 10.1136/jnnp.36.5.757; CARRAZANA EJ, 1989, CLIN NEUROL NEUROSUR, V91, P291, DOI 10.1016/0303-8467(89)90004-8; CHANG HR, 1988, J ANTIMICROB CHEMOTH, V22, P359, DOI 10.1093/jac/22.3.359; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DANNEMANN BR, 1988, ARCH INTERN MED, V148, P2477, DOI 10.1001/archinte.148.11.2477; DELAPAZ R, 1988, AIDS NERVOUS SYSTEM, P121; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; HARRIS C, 1988, J INFECT DIS, V157, P14, DOI 10.1093/infdis/157.1.14; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; HOFFLIN JM, 1987, ANTIMICROB AGENTS CH, V31, P346, DOI 10.1128/AAC.31.2.346; HOFFLIN JM, 1987, ANTIMICROB AGENTS CH, V31, P492, DOI 10.1128/AAC.31.4.492; ISRAELSKI DM, 1989, ANTIMICROB AGENTS CH, V33, P30, DOI 10.1128/AAC.33.1.30; ISRAELSKI DM, 1990, MED MANAGEMENT AIDS, P241; LEPORT C, 1986, JAMA-J AM MED ASSOC, V255, P2290, DOI 10.1001/jama.1986.03370170054013; LEPORT C, 1989, J INFECT DIS, V160, P557, DOI 10.1093/infdis/160.3.557; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEPORT C, 1989, 4TH EUR C CLIN MICR, P356; LEPORT C, 1990, 30TH INT C ANT AG CH, P279; LEVY RM, 1986, AM J ROENTGENOL, V147, P977, DOI 10.2214/ajr.147.5.977; LEVY RM, 1984, J NEUROSURG, V61, P9, DOI 10.3171/jns.1984.61.1.0009; LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MASUR H, 1991, 7TH INT C AIDS FLOR, P30; MATTHEWS DE, 1988, USING UNDERSTANDING; NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; POHLE HD, 1987, AIDS FORSCHUNG AIFO, V3, P122; POLLA MA, 1989, CLIN RES, V37, pA437; REMINGTON JS, 1989, INFECT DIS, P89; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROLSTON KVI, 1987, AM J MED, V83, P551, DOI 10.1016/0002-9343(87)90769-8; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; WANKE C, 1987, AM J TROP MED HYG, V36, P509, DOI 10.4269/ajtmh.1987.36.509; WEISS LM, 1988, J INFECT DIS, V157, P580, DOI 10.1093/infdis/157.3.580; WESTBLOM TU, 1988, SCAND J INFECT DIS, V20, P561, DOI 10.3109/00365548809032507; WONG B, 1984, ANN INTERN MED, V100, P36, DOI 10.7326/0003-4819-100-1-36; 1990, STATISTICAL APPLICAT; 1987, MMWR S1, V36, pS3	43	277	291	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					33	43		10.7326/0003-4819-116-1-33	http://dx.doi.org/10.7326/0003-4819-116-1-33			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727093				2022-12-28	WOS:A1992GX15700006
J	NEWMAN, TB; BROWNER, WS; HULLEY, SB				NEWMAN, TB; BROWNER, WS; HULLEY, SB			CHILDHOOD CHOLESTEROL SCREENING - CONTRAINDICATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PREVENTION; MORTALITY; DISEASE; RISK		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	NEWMAN, TB (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,BOX 0314,SAN FRANCISCO,CA 94143, USA.							BROWNER WS, 1991, JAMA-J AM MED ASSOC, V265, P3285, DOI 10.1001/jama.265.24.3285; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FROOM J, 1991, J CLIN EPIDEMIOL, V44, P1127, DOI 10.1016/0895-4356(91)90144-X; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; RESNICOW K, 1991, JAMA-J AM MED ASSOC, V265, P3003, DOI 10.1001/jama.265.22.3003; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; WYNDER EL, 1989, PREV MED, V18, P323, DOI 10.1016/0091-7435(89)90048-0; 1980, LANCET, V2, P379; 1984, JAMA-J AM MED ASSOC, V251, P351; 1991, PHYSICIANS DESK REFE, P1668	14	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					100	101		10.1001/jama.267.1.100	http://dx.doi.org/10.1001/jama.267.1.100			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727176				2022-12-28	WOS:A1992GW84800032
J	COULOMBE, PA; HUTTON, ME; LETAI, A; HEBERT, A; PALLER, AS; FUCHS, E				COULOMBE, PA; HUTTON, ME; LETAI, A; HEBERT, A; PALLER, AS; FUCHS, E			POINT MUTATIONS IN HUMAN KERATIN-14 GENES OF EPIDERMOLYSIS-BULLOSA SIMPLEX PATIENTS - GENETIC AND FUNCTIONAL ANALYSES	CELL			English	Article							INTERMEDIATE FILAMENT PROTEINS; TERMINAL DIFFERENTIATION; CULTURED FIBROBLASTS; EPIDERMAL KERATIN; WEBER-COCKAYNE; LAMIN-A; EXPRESSION; CELLS; DOMINANT; SEQUENCE	Previously we demonstrated that transgenic mice expressing mutant basal epidermal keratin genes exhibited a phenotype resembling a group of autosomal dominant human skin disorders known as epidermolysis bullosa simplex (EBS). EBS diseases affect approximately 1: 50,000 and are of unknown etiology, although all subtypes exhibit blistering arising from basal cell cytolysis. We now demonstrate that two patients with spontaneous cases of Dowling-Meara EBS have point mutations in a critical region in one (K14) of two basal keratin genes. To demonstrate function, we engineered one of these point mutations in a cloned human K14 cDNA, and showed that a K14 with an Arg-125 --> Cys mutation disrupted keratin network formation in transfected keratinocytes and perturbed filament assembly in vitro. Since we had previously shown that keratin network perturbation is an essential component of EBS diseases, these data suggest that the basis for the phenotype in this patients resides in this point mutation.	UNIV TEXAS,DEPT DERMATOL,HOUSTON,TX 77030; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT DERMATOL,CHICAGO,IL 60614	University of Texas System; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	COULOMBE, PA (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BONIFAS JM, 1991, J INVEST DERMATOL, V96, pA550; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, IN PRESS J CELL BIOL; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; FINE JD, 1985, ARCH DERMATOL, V121, P1292, DOI 10.1001/archderm.121.10.1292; FINE JD, 1989, PEDIATR DERMATOL, V6, P1, DOI 10.1111/j.1525-1470.1989.tb00256.x; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1983, P NATL ACAD SCI-BIOL, V80, P5857, DOI 10.1073/pnas.80.19.5857; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; HANEKE E, 1982, J INVEST DERMATOL, V78, P219, DOI 10.1111/1523-1747.ep12506502; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; ITO M, 1991, ARCH DERMATOL, V127, P367, DOI 10.1001/archderm.127.3.367; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PEARSON RW, 1971, DERMATOLOGY GENERAL, P621; QUAXJEUKEN YEFM, 1983, P NATL ACAD SCI-BIOL, V80, P3548, DOI 10.1073/pnas.80.12.3548; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; SANCHEZ G, 1983, J INVEST DERMATOL, V81, P576, DOI 10.1111/1523-1747.ep12523269; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAVOLAINEN ER, 1981, NEW ENGL J MED, V304, P197, DOI 10.1056/NEJM198101223040403; SAVTCHENKO ES, 1988, MOL BIOL EVOL, V5, P97; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUN TT, 1978, J BIOL CHEM, V253, P2053; TOWBIN H, 1979, P NATL ACAD SCI USA, V81, P4683; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; [No title captured]	50	549	556	2	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1301	1311		10.1016/0092-8674(91)90051-Y	http://dx.doi.org/10.1016/0092-8674(91)90051-Y			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717157				2022-12-28	WOS:A1991GG55200023
J	van der Maas, PJ; VANDELDEN, JJM; PIJNENBORG, L; LOOMAN, CWN				van der Maas, PJ; VANDELDEN, JJM; PIJNENBORG, L; LOOMAN, CWN			EUTHANASIA AND OTHER MEDICAL DECISIONS CONCERNING THE END OF LIFE	LANCET			English	Article							NETHERLANDS	This article presents the first results of the Dutch nationwide study on euthanasia and other medical decisions concerning the end of life (MDEL). The study was done at the request of the Dutch government in preparation for a discussion about legislation on euthanasia. Three studies were undertaken: detailed interviews with 405 physicians, the mailing of questionnaires to the physicians of a sample of 7000 deceased persons, and the collecting of information about 2250 deaths by a prospective survey among the respondents to the interviews. The alleviation of pain and symptoms with such high dosages of opioids that the patient's life might be shortened was the most important MDEL in 17.5% of all deaths. In another 17.5% a non-treatment decision was the most important MDEL. Euthanasia by administering lethal drugs at the patient's request seems to have been done in 1.8% of all deaths. Since MDEL were taken in 38% of all deaths (and in 54% of all non-acute deaths) we conclude that these decisions are common medical practice and should get more attention in research, teaching, and public debate.	CENT BUR STATS, THE HAGUE, NETHERLANDS		van der Maas, PJ (corresponding author), ERASMUS UNIV, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; BARTELDS AIM, 1989, DUTCH SENTINEL PRACT, P259; BROWN NK, 1979, NEW ENGL J MED, V300, P1246, DOI 10.1056/NEJM197905313002204; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; Gevers J K M, 1987, Bioethics, V1, P156, DOI 10.1111/j.1467-8519.1987.tb00024.x; KUHSE H, 1987, MED J AUSTRALIA, V147, P394, DOI 10.5694/j.1326-5377.1987.tb133560.x; LEENEN HJJ, 1987, HEALTH POLICY, V8, P197, DOI 10.1016/0168-8510(87)90062-5; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; OLIEMANS AP, 1986, MED CONTACT, V41, P691; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; SCHUDEL WJ, 1987, EPIDEMIOL B GG GD 19; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; VANDERWAL G, 1991, MED CONTACT, V46, P174; VANDERWAL G, 1991, MED DECISIONS END LI; VOS M, 1985, MEDISCH CONTACT, V40, P1059; 1991, MED DECISIONS END LI; 1991, END LIFE MED PRACTIC; 1987, GG GD1986 AM PEILST; 1988, ETHANASIA	19	457	460	2	83	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 14	1991	338	8768					669	674		10.1016/0140-6736(91)91241-L	http://dx.doi.org/10.1016/0140-6736(91)91241-L			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF105	1715962				2022-12-28	WOS:A1991GF10500012
J	LEWIS, M; FAED, MJW; HOWIE, PW				LEWIS, M; FAED, MJW; HOWIE, PW			SCREENING FOR DOWNS-SYNDROME BASED ON INDIVIDUAL RISK	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; CHORIONIC-GONADOTROPIN; PREGNANCY; ABNORMALITIES	Objective - To evaluate the effectiveness of biochemical screening of individual pregnancies for Down's syndrome risk. Design - Retrospective determination of risk. Setting - Obstetric and cytogenetic services in Tayside, Scotland. Subjects - 3436 pregnant women who had screening for neural tube defects in the second trimester during November 1988 to March 1990 and whose pregnancies were dated by ultrasonography. Three women with pregnancies associated with Down's syndrome reported later in 1990. Main outcome measures - Individual risk calculated from age at estimated date of delivery; chorionic gonadotrophin and a fetoprotein concentrations in serum samples obtained at precisely determined gestational ages in second trimester. Results of karyotype determination and outcome of pregnancy. Results - During November 1988 to March 1990 karyotypes were determined for 5% of pregnancies for reasons of maternal age and genetic history and one of the eight affected fetuses was detected. Individual risk could not be calculated for 347 pregnancies, but screening on this basis would have detected five of the cases and required screening in 194 out of 3089 (6.3%) pregnancies; all three affected pregnancies reported later in 1990 would also have been detected, giving a success rate of 73% (95% confidence interval 39% to 94%). The age distribution of women according to individual risk suggests that women over 35 would be screened effectively. Conclusion - Screening based on individual risk would use resources more effectively than screening based on maternal age and genetic history without affecting detection rates in older women.			LEWIS, M (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND.							BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CHRISTIE AD, 1980, THESIS U DUNDEE DUND; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MANCINI G, 1991, PRENATAL DIAG, V11, P245, DOI 10.1002/pd.1970110406; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35; STEVENSON JD, 1987, ANN CLIN BIOCHEM, V24, P411, DOI 10.1177/000456328702400411; SUCHY SF, 1990, OBSTET GYNECOL, V76, P20; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1989, OBSTETRICS, P269; WALKER EM, 1988, BRIT J OBSTET GYNAEC, V95, P659, DOI 10.1111/j.1471-0528.1988.tb06526.x	13	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					551	553		10.1136/bmj.303.6802.551	http://dx.doi.org/10.1136/bmj.303.6802.551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1717087	Bronze, Green Published			2022-12-28	WOS:A1991GE94800022
J	MCKEON, F				MCKEON, F			WHEN WORLDS COLLIDE - IMMUNOSUPPRESSANTS MEET PROTEIN PHOSPHATASES	CELL			English	Review							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; CYCLOSPORIN-A; CYCLOPHILIN; FK506; IMMUNOPHILIN; DISTINCT				MCKEON, F (corresponding author), HARVARD UNIV,BOSTON,MA 02115, USA.							BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1976, IMMUNOLOGY, V31, P631; CYERT MS, 1991, IN PRESS P NATL ACAD; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, IN PRESS NATURE; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, IN PRESS SCIENCE; KE H, 1991, IN PRESS P NATL ACAD; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL MH, 1991, J EXP MED, V173, P619; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1991, IN PRESS J AM CHEM S; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504	28	119	128	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					823	826		10.1016/0092-8674(91)90426-Y	http://dx.doi.org/10.1016/0092-8674(91)90426-Y			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716181				2022-12-28	WOS:A1991GE46000001
J	LINCHAO, S; COHEN, SN				LINCHAO, S; COHEN, SN			THE RATE OF PROCESSING AND DEGRADATION OF ANTISENSE RNAI REGULATES THE REPLICATION OF COIE1-TYPE PLASMIDS INVIVO	CELL			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; PRIMER TRANSCRIPT; RIBONUCLEASE-E; DNA-REPLICATION; COPY-NUMBER; PMB1 REPLICATION; RIBOSOMAL-RNA; GROWTH-RATE; STABILITY	We show that the rate of degradation of RNAI, an antisense repressor of the replication primer RNAII, is a key element of control in the replication of ColE1-type plasmids in vivo. Cleavage of RNAI by RNAase E, a ribosomal RNA-processing enzyme encoded or controlled by the rne (also known as ams) locus, relieves repression by endonucleolytically converting RNAI to a very rapidly decaying product, pRNAl-5. A 5' triphosphate-terminated homolog of pRNAI-5 is degraded slowly and consequently inhibits replication. Nucleotide substitutions within the RNAase E cleavage sequence alter RNAI half-life and plasmid copy number, changing also the incompatibility phenotype. RNAI variants lacking the sequence cleaved by RNAase E are eliminated by growth rate-dependent degradation, resulting in growth-responsive control of plasmid replication and copy number.	STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University; Stanford University	LINCHAO, S (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CABELLO F, 1976, NATURE, V259, P285, DOI 10.1038/259285a0; CESARENI G, 1985, TRENDS BIOCHEM SCI, V10, P303, DOI 10.1016/0968-0004(85)90168-9; CESARENI G, 1984, EMBO J, V3, P1365, DOI 10.1002/j.1460-2075.1984.tb01978.x; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DAVISON J, 1984, GENE, V28, P1, DOI 10.1016/0378-1119(84)90082-9; DOOLEY TP, 1985, J MOL BIOL, V186, P87, DOI 10.1016/0022-2836(85)90259-1; ELBLE RC, 1983, MECHANISMS DNA REPLI, P303; FITZWATER T, 1988, EMBO J, V7, P3289, DOI 10.1002/j.1460-2075.1988.tb03196.x; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; JAURIN B, 1982, EMBO J, V1, P875, DOI 10.1002/j.1460-2075.1982.tb01263.x; KADO CI, 1981, J BACTERIOL, V145, P1365, DOI 10.1128/JB.145.3.1365-1373.1981; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LACATENA RM, 1981, NATURE, V294, P623, DOI 10.1038/294623a0; LACATENA RM, 1984, CELL, V37, P1009, DOI 10.1016/0092-8674(84)90435-5; LACATENA RM, 1983, J MOL BIOL, V170, P635, DOI 10.1016/S0022-2836(83)80125-9; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; Maniatis T., 1982, MOL CLONING; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; MASUKATA H, 1984, CELL, V36, P513, DOI 10.1016/0092-8674(84)90244-7; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MELEFORS O, 1988, CELL, V52, P893, DOI 10.1016/0092-8674(88)90431-X; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; NUGENT ME, 1986, J GEN MICROBIOL, V132, P1021; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; RAY BK, 1982, EUR J BIOCHEM, V125, P283, DOI 10.1111/j.1432-1033.1982.tb06680.x; RESNEKOV O, 1990, P NATL ACAD SCI USA, V87, P8355, DOI 10.1073/pnas.87.21.8355; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SELZER G, 1983, CELL, V32, P119, DOI 10.1016/0092-8674(83)90502-0; SIMONS RW, 1988, GENE, V72, P35, DOI 10.1016/0378-1119(88)90125-4; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SZEBERENYI J, 1983, J MOL BIOL, V168, P525, DOI 10.1016/S0022-2836(83)80300-3; TAMM J, 1985, P NATL ACAD SCI USA, V82, P2257, DOI 10.1073/pnas.82.8.2257; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA JI, 1981, P NATL ACAD SCI-BIOL, V78, P6096, DOI 10.1073/pnas.78.10.6096; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WONG EM, 1985, CELL, V42, P959, DOI 10.1016/0092-8674(85)90292-2	60	188	190	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1233	1242		10.1016/0092-8674(91)90018-T	http://dx.doi.org/10.1016/0092-8674(91)90018-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1712252				2022-12-28	WOS:A1991FU89900015
J	HARTZELL, HC; MERY, PF; FISCHMEISTER, R; SZABO, G				HARTZELL, HC; MERY, PF; FISCHMEISTER, R; SZABO, G			SYMPATHETIC REGULATION OF CARDIAC CALCIUM CURRENT IS DUE EXCLUSIVELY TO CAMP-DEPENDENT PHOSPHORYLATION	NATURE			English	Article							G-PROTEIN; ION CHANNELS; SINGLE CELLS; ACETYLCHOLINE; HEART; STIMULATION; MYOCYTES; MODULATION; KINASE; ANALOG	THE positive inotropic effect of the sympathetic nervous system on the heart is partly mediated by an increase in the voltage-gated Ca2+ current (I(Ca)). This increase is generally attributed to beta-adrenergic receptor-stimulated cyclic AMP-dependent phosphorylation of the Ca2+ channel 1,2. It has been suggested that cAMP-dependent phosphorylation cannot explain all the effects of beta-adrenergic agonists on I(Ca) and that a parallel membrane-delimited pathway involving the 'direct' action of the G protein G(s) also stimulates I(Ca) (refs 3-7). A precedent exists for such a membrane-delimited pathway in the activation of a K+ channel by acetylcholine in heart 1,8. A membrane-delimited pathway for stimulation of I(Ca) might be important in rapid beat-to-beat regulation of contraction by the sympathetic nervous system 9, because isoproterenol may produce a biphasic increase in I(Ca) with the rapid phase (tau = 150 ms) putatively mediated by the direct pathway and the slow phase (tau = 35 s) by cAMP-dependent phosphorylation. Here we report that in frog, rat, and guinea pig ventricular myocytes I(Ca) increases slowly and monophasically in response to isoproterenol. The increase is completely blocked by inhibitors of cAMP-dependent phosphorylation. Furthermore, the time course of the increase in I(Ca) closely parallels the increase in contractile force produced by sympathetic nerve stimulation. These data refute earlier suggestions that regulation of Ca2+ channels by the sympathetic nervous system involves or requires a direct G-protein pathway.	UNIV PARIS 11, INSERM, U241, PHYSIOL CELLULAIRE CARDIAQUE LAB, F-91405 ORSAY, FRANCE; UNIV VIRGINIA, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Virginia	HARTZELL, HC (corresponding author), EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA.		Fischmeister, Rodolphe/L-6061-2018; MERY, Pierre-François/C-5903-2019	Fischmeister, Rodolphe/0000-0003-2086-9865; Mery, Pierre-Francois/0000-0001-6214-5422				BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HARTZELL HC, 1987, MOL PHARMACOL, V32, P639; HARTZELL HC, 1991, BIOPHYS J, V59, P551; HUTTER OF, 1956, J GEN PHYSIOL, V39, P715, DOI 10.1085/jgp.39.5.715; IMOTO Y, 1988, AM J PHYSIOL, V255, pH722, DOI 10.1152/ajpheart.1988.255.4.H722; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; MERY PF, 1991, BIOPHYS J, V59, P551; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MORAD M, 1983, NATURE, V304, P635, DOI 10.1038/304635a0; PELZER S, 1990, AM J PHYSIOL, V259, pH264, DOI 10.1152/ajpheart.1990.259.1.H264; SHUBA YM, 1990, J PHYSIOL-LONDON, V424, P205, DOI 10.1113/jphysiol.1990.sp018063; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; SPEAR JF, 1979, CIRC RES, V44, P75, DOI 10.1161/01.RES.44.1.75; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	22	214	214	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1991	351	6327					573	576		10.1038/351573a0	http://dx.doi.org/10.1038/351573a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1710784				2022-12-28	WOS:A1991FR03400061
J	AMANN, R; SPRINGER, N; LUDWIG, W; GORTZ, HD; SCHLEIFER, KH				AMANN, R; SPRINGER, N; LUDWIG, W; GORTZ, HD; SCHLEIFER, KH			IDENTIFICATION INSITU AND PHYLOGENY OF UNCULTURED BACTERIAL ENDOSYMBIONTS	NATURE			English	Article							PARAMECIUM-CAUDATUM; HOLOSPORA-ELEGANS; OBTUSA; PROBES; FORMS; CELLS; DNA	THE use of Koch's technique to isolate bacteria in pure cultures has enabled thousands of bacterial species to be characterized. But for the many microorganisms that have never been cultivated, DNA amplification in vitro using the polymerase chain reaction is now making their genes accessible 1-3. Here we use this technique to study bacteria of the genus Holospora, which live in ciliates 4 and whose phylogenetic relationship has remained unknown because they are impossible to cultivate. Species of Holospora are highly infectious 5-7 and live in the nuclei of their specific host cells: H. elegans and H. undulata infect micronuclei of Paramecium caudatum 8, whereas H. obtusa infects the macronucleus in other strains of the same host species 9; Holospora species have a common developmental cycle 10-13. We have amplified, cloned and sequenced gene fragments encoding ribosomal RNA of H. obtusa. The phylogenetic position of H. obtusa in the alpha-group of Proteobacteria was determined by 16S rRNA sequence analysis. The sequences were then used to design species- as well as genus-specific rRNA hybridization probes, which enabled us to detect and differentiate individual cells of the endosymbionts in situ. The large amount of rRNA in the cells indicates a high physiological activity of the endosymbionts in the host nuclei.	UNIV MUNSTER,INST ZOOL,W-4400 MUNSTER,GERMANY	University of Munster	AMANN, R (corresponding author), TECH UNIV MUNICH,LEHRSTUHL MIKROBIOL,ARCISSTR 21,W-8000 MUNICH 2,GERMANY.		Amann, Rudolf I/C-6534-2014	Amann, Rudolf I/0000-0002-0846-7372				AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; AMANN RI, 1990, APPL ENVIRON MICROB, V56, P1919, DOI 10.1128/AEM.56.6.1919-1925.1990; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; DRYDEN SC, 1990, NUCLEIC ACIDS RES, V18, P7267, DOI 10.1093/nar/18.24.7267; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; FUJISHIMA M, 1990, ZOOL SCI, V7, P849; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P720, DOI 10.1128/jb.170.2.720-726.1988; GORTZ HD, 1990, J BACTERIOL, V172, P5664; GORTZ HD, 1980, PROTISTOLOGICA, V16, P591; GORTZ HD, 1989, J GEN MICROBIOL, V135, P3079; GORTZ HD, 1986, INT REV CYTOL, V102, P169, DOI 10.1016/S0074-7696(08)61275-9; GROMOV BV, 1981, INT J SYST BACTERIOL, V31, P348, DOI 10.1099/00207713-31-3-348; Hafkine M. -W., 1890, ANN I PASTEUR, V4, P148; Holt, 1984, BERGEYS MANUAL SYSTE, P795; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OSSIPOV D V, 1975, Acta Protozoologica, V14, P263; PREER JR, 1984, INT J SYST BACTERIOL, V32, P140; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHMIDT HJ, 1987, MICROBIOS, V49, P189; SCHMIDT HJ, 1985, MICROBIOS, V4, P165; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P782, DOI 10.1128/AEM.56.3.782-787.1990; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	287	295	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					161	164		10.1038/351161a0	http://dx.doi.org/10.1038/351161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709451				2022-12-28	WOS:A1991FL03500056
J	IWAKI, Y; STARZL, TE; YAGIHASHI, A; TANIWAKI, S; ABUELMAGD, K; TZAKIS, A; FUNG, J; TODO, S				IWAKI, Y; STARZL, TE; YAGIHASHI, A; TANIWAKI, S; ABUELMAGD, K; TZAKIS, A; FUNG, J; TODO, S			REPLACEMENT OF DONOR LYMPHOID-TISSUE IN SMALL-BOWEL TRANSPLANTS	LANCET			English	Note								The presence of recipient lymphocytes in grafts is thought to equate with rejection. Thus, we wished to follow the fate of lymphocytes after transplant of the small bowel. Three complete small-bowel transplants, two with the liver from the same donor also transplanted, were done successfully. Patients were immunosuppressed with FK 506. 5 to 11% of lymphocytes in the recipients' peripheral blood were of donor origin during the early postoperative period when there were no clinical signs of graft-versus-host disease. However, donor cells were no longer detectable after 12 to 54 days. Serial biopsy specimens of the grafted small bowel showed progressive replacement of lymphocytes in the lamina propria by those of the recipient's HLA phenotype. Lymphoid repopulation was complete after 10 to 12 weeks but the epithelial cells of the intestine remained those of the donor. The patients are on enteral alimentation after 5, 6, and 8 months with histopathologically normal or nearly normal intestines. Re-examination of assumptions about the rejection of intestinal grafts and strategies for its prevention are required following these observations.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARK CLI, 1990, TRANSPLANT P, V22, P2460; FUNG JJ, 1989, CLIN TRANSPLANT, V3, P316; FUNG JJ, 1985, HUM IMMUNOL, V14, P287, DOI 10.1016/0198-8859(85)90236-8; GOUW ASH, 1987, TRANSPLANTATION, V43, P291, DOI 10.1097/00007890-198702000-00025; GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A; MARKUS PM, IN PRESS TRANSPLANTA; MONCHIK GJ, 1971, SURGERY, V70, P693; MURASE N, IN PRESS SURGERY; STARZL TE, 1962, AM J SURG, V103, P219, DOI 10.1016/0002-9610(62)90491-9; TZAKIS AG, 1991, TRANSPLANT P, V23, P924	10	156	158	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					818	819		10.1016/0140-6736(91)92517-6	http://dx.doi.org/10.1016/0140-6736(91)92517-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1707470	Green Accepted			2022-12-28	WOS:A1991FF22800005
J	LIOTTA, LA; STEEG, PS; STETLERSTEVENSON, WG				LIOTTA, LA; STEEG, PS; STETLERSTEVENSON, WG			CANCER METASTASIS AND ANGIOGENESIS - AN IMBALANCE OF POSITIVE AND NEGATIVE REGULATION	CELL			English	Review							BASEMENT-MEMBRANE COLLAGEN; NUCLEOSIDE DIPHOSPHATE KINASE; BRONCHIAL EPITHELIAL-CELLS; HUMAN AMNIOTIC MEMBRANE; HUMAN-BREAST TUMORS; NIH 3T3 CELLS; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; IV COLLAGENASE; TISSUE INHIBITOR				LIOTTA, LA (corresponding author), NCI, PATHOL LAB, BETHESDA, MD 20892 USA.		Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808				ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BARSKY SH, 1983, LAB INVEST, V49, P140; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BONFIL RD, 1989, JNCI-J NATL CANCER I, V81, P587, DOI 10.1093/jnci/81.8.587; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN PD, 1990, CANCER RES, V50, P6184; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CLIFF WJ, 1963, PHILOS T ROY SOC B, V246, P305, DOI 10.1098/rstb.1963.0008; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DERRICO A, 1991, IN PRESS MOD PATHOL; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FIELD JK, 1990, ANTICANCER RES, V10, P1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GARBISA S, 1987, CANCER RES, V47, P1523; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gottesman M., 1990, SEMIN CANCER BIOL, V1, P97; GREENBERG AH, 1989, INVAS METAST, V9, P360; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HENDRIX MJC, 1990, CANCER RES, V50, P4121; HENNESSY C, 1991, IN PRESS J NATL CANC; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KIMURA N, 1983, J BIOL CHEM, V258, P2609; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LEVY A, 1991, IN PRESS CANCER RES; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LIOTTA LA, 1974, CANCER RES, V34, P997; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LUNA EJ, 1989, ADV CELL BIOL, V3, P1; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIN W, 1988, CANCER RES, V48, P6262; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; MURPHY G, 1981, BIOCHEM J, V195, P167, DOI 10.1042/bj1950167; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAJIMA M, 1989, CANCER RES, V49, P1698; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1991, IN PRESS J NATL CANC; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NICOLSON GL, 1987, CANCER RES, V47, P1473; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; REICH R, 1988, CANCER RES, V48, P3307; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAPPINO AP, 1987, CANCER RES, V47, P4043; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; TEMPLETON NS, 1990, CANCER RES, V50, P5431; THEODORESCU D, 1991, IN PRESS P NATL ACAD; THORGEIRSSON UP, 1984, INVAS METAST, V4, P73; THORGEIRSSON UP, 1982, J NATL CANCER I, V69, P1049; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TUCK AB, 1991, IN PRESS CLIN EXP ME; TURPEENNIEMIHUJANEN T, 1985, J NATL CANCER I, V75, P99; URA H, 1989, CANCER RES, V49, P4615; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WANG BS, 1980, CANCER RES, V40, P288; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	113	2711	2842	2	201	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					327	336		10.1016/0092-8674(91)90642-C	http://dx.doi.org/10.1016/0092-8674(91)90642-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1703045				2022-12-28	WOS:A1991EV33600010
J	COEN, ES; ROMERO, JM; DOYLE, S; ELLIOTT, R; MURPHY, G; CARPENTER, R				COEN, ES; ROMERO, JM; DOYLE, S; ELLIOTT, R; MURPHY, G; CARPENTER, R			FLORICAULA - A HOMEOTIC GENE REQUIRED FOR FLOWER DEVELOPMENT IN ANTIRRHINUM-MAJUS	CELL			English	Article							TRANSPOSABLE ELEMENT TAM3; ASPERGILLUS-NIDULANS; PATTERN-FORMATION; AMPLIFICATION; MORPHOGENESIS; ARABIDOPSIS; EXPRESSION; DROSOPHILA; PRIMER; DNA	Plants carrying the floricaula (flo) mutation cannot make the transition from inflorescence to floral meristems and have indeterminate shoots in place of flowers. The flo-613 allele carries a Tam3 transposon insertion, which allowed the isolation of the flo locus. The flow gene encodes a putative protein (FLO) containing a proline-rich N-terminus and a highly acidic region. In situ hybridization shows that the flo gene is transiently expressed in the very early stages of flower development. The earliest expression seen is in bract primordia, followed by sepal, petal, and carpal primordia, but no expression is detected in stamen primordia. This pattern of expression has implications for how flo affects phyllotaxis, organ identify, and determinancy. We propose that flo interacts in a sequential manner with other homeotic genes affecting floral organ identity.	UNIV SEVILLA,CSIC,INST BIOQUIM VEGETAL & FOTOSINTESIS,E-41080 SEVILLE,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	COEN, ES (corresponding author), JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Romero, Jose M/D-5183-2009; Ding, Cheng-Qiang/B-6287-2011	Romero, Jose M/0000-0002-4621-5934; 				ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; ALMEIDA J, 1989, GENE DEV, V3, P1758, DOI 10.1101/gad.3.11.1758; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AWASTHI DK, 1984, BOT MAG TOKYO, V97, P13, DOI 10.1007/BF02488143; BAYLY IL, 1962, CAN J GENET CYTOL, V4, P386, DOI 10.1139/g62-049; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; Chittenden RJ, 1928, J GENET, V19, P281, DOI 10.1007/BF02983160; CLUTTERBUCK AJ, 1969, GENETICS, V63, P317; COEN ES, 1988, EMBO J, V7, P877, DOI 10.1002/j.1460-2075.1988.tb02891.x; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; COEN ES, 1989, MOBILE DNA, P413; COEN ES, 1991, IN PRESS ANN REV PLA, V42; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDENBERG J. B., 1965, Bol. genet. Inst. Fitotec. Castelar, P27; HARRISON BJ, 1964, HEREDITY, V19, P237, DOI 10.1038/hdy.1964.28; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HELM J, 1951, ZUCHTER, V21, P54; HUDSON AD, 1990, PLANT MOL BIOL, V14, P835, DOI 10.1007/BF00016516; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JACKSON DP, 1991, IN PRESS MOL PLANT P; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; Mandelbrot B, 1983, FRACTAL GEOMETRY NAT; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYER VG, 1966, BOT REV, V32, P165, DOI 10.1007/BF02858659; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; Morata G, 1990, Semin Cell Biol, V1, P219; MURRAY NE, 1982, LAMBDA 2, P395; PADDOCK ELTON F., 1952, OHIO JOUR SCI, V52, P327; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHWARZSOMMER Z, 1990, IN PRESS SCIENCE; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOMMER H, 1985, MOL GEN GENET, V199, P225, DOI 10.1007/BF00330263; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Weberling F, 1989, MORPHOLOGY FLOWERS I; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YOUNG JPW, 1983, ANN BOT-LONDON, V52, P311, DOI 10.1093/oxfordjournals.aob.a086579	43	682	744	1	63	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1311	1322		10.1016/0092-8674(90)90426-F	http://dx.doi.org/10.1016/0092-8674(90)90426-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	1702033				2022-12-28	WOS:A1990EN92300021
J	BROWN, ER				BROWN, ER			HEALTH USA - A NATIONAL-HEALTH PROGRAM FOR THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROMOTE QUALITY; PHYSICIANS; CARE; INSURANCE; SERVICES; ECONOMY; CANADA; 1990S; PLAN	The Health USA Act of 1991 addresses two fundamental health services financing problems: the more than 30 million uninsured persons and the rising costs for health care and for health insurance. Health USA would provide coverage of the entire resident population for comprehensive medical and preventive health and long-term care services through a universal tax-funded financing system. The federal government would contribute an average of 87% of program costs to each state, which would establish, under federal guidelines, a state health program. Each individual or family may enroll in any health plan approved by the state program, including many private plans, or a plan run by the state program. Through the approved plan of their choice, enrollees would receive covered services and obtain their care from participating physicians and other professional practitioners, hospitals, and other facilities. The state program would pay approved plans a capitation payment for every person enrolled. The plans would pay professional providers fees, as part of an all-payer system of fee schedules and expenditure targets, or capitation payments or salary. Hospitals would be financed through global budgets negotiated by the state program with each hospital. The plan run by the state program would pay the health care costs of any person who does not enroll in an approved plan, making the state plan the payer of last resort and eliminating uncompensated care and cost shifting by providers. Health USA would separate health care coverage from employment, ensuring uninterrupted coverage and eliminating employers' administrative role in providing coverage. Federal and state taxes would replace present methods of financing by private insurance premiums and large out-of-pocket expenditures. Building on the present system of health plans, Health USA would offer all persons a wide choice of competing plans in which to enroll and offer professional providers a wide choice of plans in which to practice. It would control costs by increasing financial accountability of providers and health plans, reducing present reliance on intrusive utilization review and on patient cost sharing. By controlling health care and administrative costs, Health USA would cover the entire population and, according to independent cost estimates, reduce national health expenditures by $11.5 billion in 1991.			BROWN, ER (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.							BLENDON RJ, 1989, HEALTH AFFAIR, V8, P149, DOI 10.1377/hlthaff.8.1.149; BLENDON RJ, 1991, JAMA-J AM MED ASSOC, V265, P2563, DOI 10.1001/jama.265.19.2563; CANTOR JC, 1991, HEALTH AFFAIR, V10, P98, DOI 10.1377/hlthaff.10.1.98; CANTOR JC, 1990, J HEALTH POLIT POLIC, V15, P755, DOI 10.1215/03616878-15-4-755; ECHHOLM E, 1991, NY TIMES        0926, pA1; ECHHOLM E, 1991, NY TIMES        0926, pA12; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FEIN R, 1991, JAMA-J AM MED ASSOC, V265, P2555; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2549, DOI 10.1001/jama.265.19.2549; HAM FL, 1989, BUS HEALTH, V7, P29; Hastings J E, 1986, J Public Health Policy, V7, P239, DOI 10.2307/3342262; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1991, NEW ENGL J MED, V324, P503, DOI 10.1056/NEJM199102143240725; IGLEHART JK, 1991, NEW ENGL J MED, V324, P1750, DOI 10.1056/NEJM199106133242428; JAJICHTOTH C, 1990, HEALTH AFFAIR, V9, P149, DOI 10.1377/hlthaff.9.4.149; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; Lohr K N, 1986, Med Care, V24, pS1; LOMAS J, 1989, HEALTH AFFAIR, V8, P80, DOI 10.1377/hlthaff.8.1.80; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; McDonnell P, 1986, Health Care Financ Rev, V8, P1; MECHANIC D, 1978, NEW ENGL J MED, V298, P249, DOI 10.1056/NEJM197802022980505; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; PEAR R, 1991, NY TIMES        1118, pA1; PEAR R, 1991, NY TIMES        0811, pA10; RACHLIS M, 1989, 2ND OPINION WHATS WR; RICH S, 1991, WASHINGTON POST 0720, pA1; ROSENBLATT RA, 1989, LOS ANGELES TIM 1116, pA20; SHIEBER GJ, 1991, HLTH AFFAIRS, V10, P106; SHORT PF, 1990, PHS903469 DEP HLTH H; SULLIVAN CB, 1991, HEALTH AFFAIR, V10, P104, DOI 10.1377/hlthaff.10.2.104; TODD JS, 1991, JAMA-J AM MED ASSOC, V265, P2503; VALVONA J, 1988, HEALTH SERV RES, V23, P343; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1989, HLTH BENEFITS SIMULA; 1989, GAOHRD8951 US GEN AC; 1991, GAOHRD9190 US GEN AC; 1991, 1991 US IND OUTLOOK; 1990, CALL ACTION FINAP RE; 1991, PATTERN SHMO ENROLLM	44	13	13	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					552	558						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729579				2022-12-28	WOS:A1992GZ43900034
J	ZAUBER, NP; ZAUBER, AG; GORDON, FJ; TILLIS, AC; LEEDS, HC; BERMAN, E; KUDRYK, AB				ZAUBER, NP; ZAUBER, AG; GORDON, FJ; TILLIS, AC; LEEDS, HC; BERMAN, E; KUDRYK, AB			IRON SUPPLEMENTATION AFTER FEMORAL-HEAD REPLACEMENT FOR PATIENTS WITH NORMAL IRON STORES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To assess the efficacy of oral iron therapy in the recovery of patients' hemoglobin levels after major surgery. Design. - Randomized controlled trial. Setting. - Private orthopedic practice confined to one large community hospital. Patients. - One hundred seventy consecutive elderly patients undergoing hip surgery; 75 failed to meet entry hematologic or medical criteria; 95 were randomized, with 16 withdrawn because of complications. Intervention. - Thirty-seven patients received ferrous sulfate orally four times a day for the duration of their hospitalization. Forty-two patients who received no iron supplement served as the control group. Main Outcome Measures. - Changes in hemoglobin levels and reticulocyte counts over the 2- to 3-week follow-up period. Results. - There was no significant difference in mean hemoglobin levels between the treatment and control groups (95% confidence interval [Cl] for difference of - 6.6 to 5.4 g/L). Corrected reticulocyte fractions increased equally in both groups (95% Cl for difference of -9 x 10(3) to 2 x 10(-3). The study was designed to detect a difference in mean hemoglobin levels of 8.5 g/L or greater or a difference in mean reticulocyte fraction of 10 x 10(-3) between the two groups with a power of 0.80 at the .05 (two-sided) level of significance. Conclusion. - The administration of oral iron supplements to elderly, healthy orthopedic patients postoperatively did not hasten the recovery of hemoglobin levels, provided adequate tissue iron stores were present.	ST BARNABAS HOSP, DEPT MED, LIVINGSTON, NJ 07039 USA; ST BARNABAS HOSP, DEPT ORTHOPED SURG, LIVINGSTON, NJ 07039 USA; ST BARNABAS HOSP, DEPT PATHOL, LIVINGSTON, NJ 07039 USA; MEM SLOAN KETTERING CANC CTR, DEPT EPIDEMIOL & BIOSTAT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center								HALLBERG L, 1966, ACTA MED SCAND, VS, P3; HEINRICH HC, 1975, IRON METABOLISM ITS, P34; HILLMAN RS, 1969, J CLIN INVEST, V48, P454, DOI 10.1172/JCI106002; Jacobs A., 1973, Clinics in Haematology, V2, P323; LIPSCHITZ DA, 1984, BLOOD, V63, P502; MARX JJM, 1979, BLOOD, V53, P204; Minot GR, 1932, AM J MED SCI, V183, P110, DOI 10.1097/00000441-193201000-00012; WORWOOD M, 1977, SEMIN HEMATOL, V14, P3; ZAUBER NP, 1987, JAMA-J AM MED ASSOC, V257, P2181, DOI 10.1001/jama.257.16.2181; 1971, STATISTICAL PRINCIPL, P514	10	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					525	527		10.1001/jama.267.4.525	http://dx.doi.org/10.1001/jama.267.4.525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729575				2022-12-28	WOS:A1992GZ43900028
J	BAIM, DS				BAIM, DS			ANGIOPLASTY AS A TREATMENT FOR CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REGISTRY				BAIM, DS (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							BAIM DS, 1988, AM J CARDIOL, V61, pG3, DOI 10.1016/S0002-9149(88)80025-0; DETRE K, 1989, CIRCULATION, V80, P421, DOI 10.1161/01.CIR.80.3.421; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; RYAN T J, 1988, Journal of the American College of Cardiology, V12, P529; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; 1991, CIRCULATION, V83, P1125; 1983, CIRCULATION, V68, P939; 1990, LANCET, V335, P1315	10	8	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					56	58		10.1056/NEJM199201023260110	http://dx.doi.org/10.1056/NEJM199201023260110			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1727066				2022-12-28	WOS:A1992GX31500010
J	WRIGHT, PF; KIMFARLEY, RJ; DEQUADROS, CA; ROBERTSON, SE; SCOTT, RM; WARD, NA; HENDERSON, RH				WRIGHT, PF; KIMFARLEY, RJ; DEQUADROS, CA; ROBERTSON, SE; SCOTT, RM; WARD, NA; HENDERSON, RH			STRATEGIES FOR THE GLOBAL ERADICATION OF POLIOMYELITIS BY THE YEAR 2000	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TYPE-3 POLIOVIRUS; VACCINE STRAIN; VIRUS; EXCRETION; RECEPTOR; WORLD		PAN AMER HLTH ORG, WASHINGTON, DC USA; WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND; WHO, OFF ASSISTANT DIRECTOR GEN, CH-1211 GENEVA 27, SWITZERLAND	Pan American Health Organization; World Health Organization; World Health Organization	WRIGHT, PF (corresponding author), VANDERBILT UNIV, DEPT PEDIAT, DIV INFECT DIS, NASHVILLE, TN 37232 USA.							ALMOND JW, 1987, ANNU REV MICROBIOL, V41, P153; ALMOND JW, 1990, B WORLD HEALTH ORGAN, V68, P545; [Anonymous], 1990, WKLY EPIDEMIOL REC, V65, P5; [Anonymous], 1990, WHOEPICDSPOLIO901; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CHUMAKOV KM, 1991, P NATL ACAD SCI USA, V88, P199, DOI 10.1073/pnas.88.1.199; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; DORVAL BL, 1989, BIOCHEM BIOPH RES CO, V159, P1177, DOI 10.1016/0006-291X(89)92234-1; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; FENNER F, 1988, SMALLPOX ITE ERADICA; HENDERSON RH, 1989, ANN NY ACAD SCI, V569, P69, DOI 10.1111/j.1749-6632.1989.tb27359.x; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; JANSEN RW, 1990, P NATL ACAD SCI USA, V87, P2867, DOI 10.1073/pnas.87.8.2867; KOHARA M, 1988, J VIROL, V62, P2828, DOI 10.1128/JVI.62.8.2828-2835.1988; LEMON SM, 1991, PROG MED VIROL, V38, P42; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MINOR PD, 1986, J GEN VIROL, V67, P693, DOI 10.1099/0022-1317-67-4-693; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; 1991, WKLY B, V6, P38; 1988, WHO WHA4128 RES, P26; 1989, WHO WHA4232 RES, P33; 1985, B PAN AM HLTH ORGAN, V19, P213; 1990, MMWR-MORBID MORTAL W, V39, P557	30	89	90	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1774	1779		10.1056/NEJM199112193252504	http://dx.doi.org/10.1056/NEJM199112193252504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1719418				2022-12-28	WOS:A1991GV73900004
J	KOSLOWSKY, DJ; BHAT, GJ; READ, LK; STUART, K				KOSLOWSKY, DJ; BHAT, GJ; READ, LK; STUART, K			CYCLES OF PROGRESSIVE REALIGNMENT OF GRNA WITH MESSENGER-RNA IN RNA EDITING	CELL			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; KINETOPLASTID MITOCHONDRIA; CYTOCHROME-OXIDASE; SUBUNIT-III; ORGANIZATION; MINICIRCLES; TRANSCRIPT; DOMAINS; REGION	We characterized numerous partially edited NADH dehydrogenase 7 and ATPase 6 cDNAs. Most of these have a stretch of incompletely edited sequence at the junction of mature and unedited sequences. The characteristics of the junctions suggest editing of sites multiple times and that editing within each junction does not proceed precisely 3' to 5'. Analyses of gRNAs and corresponding junction sequences predict a series of progressively more stable, but incompletely base-paired, interactions in the junction region. The predicted interactions suggest that the gRNA is progressively realigned with the mRNA being edited. We suggest that gRNA interactions with the mRNA result in regions of lower thermodynamic stability that are selected for editing, thus driving toward the most stable structure, the complete gRNA/mRNA duplex.			KOSLOWSKY, DJ (corresponding author), SEATTLE BIOMED RES INST,SEATTLE,WA 98109, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014102, R37AI014102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14102] Funding Source: Medline; NIGMS NIH HHS [GM42188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1989, MOL BIOL RNA, P187; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUART KS, 1990, TRENDS BIOL SCI, V16, P68; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	27	80	83	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					537	546		10.1016/0092-8674(91)90528-7	http://dx.doi.org/10.1016/0092-8674(91)90528-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1718605				2022-12-28	WOS:A1991GN66400010
J	SMITH, DB; NEWLANDS, ES; RUSTIN, GJS; BEGENT, RHJ; HOWELLS, N; MCQUADE, B; BAGSHAWE, KD				SMITH, DB; NEWLANDS, ES; RUSTIN, GJS; BEGENT, RHJ; HOWELLS, N; MCQUADE, B; BAGSHAWE, KD			COMPARISON OF ONDANSETRON AND ONDANSETRON PLUS DEXAMETHASONE AS ANTIEMETIC PROPHYLAXIS DURING CISPLATIN-CONTAINING CHEMOTHERAPY	LANCET			English	Article							HIGH-DOSE METOCLOPRAMIDE; ANTI-EMETIC EFFICACY; CYTO-TOXIC DRUGS; INDUCED NAUSEA; INDUCED EMESIS; CANCER-CHEMOTHERAPY; DOUBLE-BLIND; ANTAGONIST; PREVENTION; GR38032F	Ondansetron, a serotonin antagonist, is effective in controlling the emesis associated with cancer chemotherapy; however, emesis in patients receiving high-dose cisplatin is poorly controlled by ondansetron alone. Dexamethasone is an effective antiemetic with no known interaction with serotonin receptors and was thus chosen for study in combination with ondansetron. 31 patients (30 male, 1 female; median age 28.5 years, range 18-49) receiving a 4-day course of a chemotherapy regimen containing cisplatin (100-120 mg/m2) for metastatic germ-cell tumours were entered in a randomised, double-blind, cross-over trial comparing oral ondansetron plus placebo with oral ondansetron plus dexamethasone as antiemetic prophylaxis. Ondansetron (8 mg every 8 h) was given to all patients for 8 days from the start of chemotherapy. Patients were given 8 mg of dexamethasone or placebo every 8 h starting 2 h before cisplatin (on day 4) and continuing for six doses (ie, for 2 days only). A second course of chemotherapy began 14 days after the start of the first, during which patients crossed over to the alternative antiemetic regimen. Results were available from 27 patients. In the 24-48 h after cisplatin 78% of patients taking ondansetron plus dexamethasone reported complete or major control of emesis compared with 30% of those taking ondansetron plus placebo (p = 0.001). Cross-over analysis showed a significant advantage for ondansetron plus dexamethasone in the control of nausea (p = 0.013) and emesis (p < 0.001) over the 8-day study. 24 of 26 patients expressed a preference for the combination therapy (p < 0.001). Ondansetron plus dexamethasone is effective antiemetic prophylaxis for high-dose cisplatin chemotherapy, has few side effects, and is active when given orally.	MT VERNON CANC CTR,NORTHWOOD,MIDDX,ENGLAND; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND	Mount Vernon Cancer Centre; GlaxoSmithKline	SMITH, DB (corresponding author), CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND.		Rustin, Gordon J. S./J-9763-2019					AAPRO MS, 1981, CANCER CHEMOTH PHARM, V7, P11; ALLAN SG, 1984, BRIT MED J, V289, P878, DOI 10.1136/bmj.289.6449.878-a; BATEMAN DN, 1985, BRIT MED J, V291, P920; BLACKWELL SP, 1989, EUR J CLIN ONCOL S1, V25, P21; CASSIDY J, 1988, BRIT J CANCER, V58, P651, DOI 10.1038/bjc.1988.278; COATES A, 1983, EUR J CANCER CLIN ON, V19, P203, DOI 10.1016/0277-5379(83)90418-2; COSTALL B, 1986, NEUROPHARMACOLOGY, V25, P959, DOI 10.1016/0028-3908(86)90030-4; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, LANCET, V1, P1461, DOI 10.1016/S0140-6736(87)92208-2; CUNNINGHAM D, 1989, LANCET, V1, P1323; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; FOZARD JR, 1978, EUR J PHARMACOL, V49, P109, DOI 10.1016/0014-2999(78)90228-5; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; HAWTHORN J, 1988, Q J EXP PHYSIOL CMS, V73, P7, DOI 10.1113/expphysiol.1988.sp003124; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; KRIS MG, 1987, CANCER, V60, P2816, DOI 10.1002/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; NEWLANDS ES, 1986, BRIT J UROL, V58, P307, DOI 10.1111/j.1464-410X.1986.tb09061.x; Prescott R. J., 1981, Applied Statistics, V30, P9, DOI 10.2307/2346652; SMITH DB, 1990, BRIT J CANCER, V61, P323, DOI 10.1038/bjc.1990.62; SMITH DB, 1990, CANCER CHEMOTH PHARM, V25, P291, DOI 10.1007/BF00684888; STRUM SB, 1982, JAMA-J AM MED ASSOC, V247, P2683, DOI 10.1001/jama.247.19.2683	24	226	226	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					487	490		10.1016/0140-6736(91)90555-4	http://dx.doi.org/10.1016/0140-6736(91)90555-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1714532				2022-12-28	WOS:A1991GC15300015
J	JARDIN, A; BENSADOUN, H; DELAUCHECAVALLIER, MC; ATTALI, P				JARDIN, A; BENSADOUN, H; DELAUCHECAVALLIER, MC; ATTALI, P			ALFUZOSIN FOR TREATMENT OF BENIGN PROSTATIC HYPERTROPHY	LANCET			English	Article							BLADDER OUTFLOW OBSTRUCTION; CONTROLLED TRIAL; PHENOXYBENZAMINE; HYPERPLASIA; PRAZOSIN; PROSTATECTOMY; INDORAMIN; RESECTION; EFFICACY; MUSCLE	To assess the long-term efficacy and safety of alfuzosin, a selective alpha-1-adrenergic antagonist, 518 symptomatic patients with benign prostatic hypertrophy (BPH) were randomised to received either alfuzosin (daily dose 7.5-10 mg) or placebo for 6 months. Obstructive and irritative symptoms, assessed according to the Boyarsky scale, significantly improved in the alfuzosin group compared with the placebo group (p = 0.0004). Fewer patients in the alfuzosin group than in the placebo group dropped out due to lack of efficacy (6.8% vs 14.6%, p = 0.004) and the prevalence of spontaneous acute urine retention was lower in the alfuzosin group (0.4% vs 2.6%, p = 0.04). By 6 months, mean urinary flow rates had increased (p < 0.05) and residual volume had decreased (p = 0.017) in the alfuzosin group, although the two groups were broadly similar with respect to increase in peak flow rate. The overall incidence of adverse events was similar in the two groups, which led to the withdrawal of 10.8% and 9.0% of patients, respectively. The findings emphasise the magnitude of the placebo response in symptomatic patients with BPH and show that treatment with alpha-1-adrenergic antagonist drugs provides long-lasting improvement in such patients.	SYNTHELABO LERS,RECH,F-75621 PARIS 13,FRANCE	Sanofi-Aventis; Sanofi France	JARDIN, A (corresponding author), HOP BICETRE,UROL SERV,78 AVE GEN LECLARE,F-94270 LE KREMLIN BICETR,FRANCE.							ABRAMS PH, 1982, BRIT J UROL, V54, P527, DOI 10.1111/j.1464-410X.1982.tb13581.x; AWAD SA, 1977, UROL INT, V32, P192, DOI 10.1159/000280129; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29; BROOKS ME, 1983, UROLOGY, V21, P474, DOI 10.1016/0090-4295(83)90044-4; CAINE M, 1978, BRIT J UROL, V50, P551, DOI 10.1111/j.1464-410X.1978.tb06210.x; CAINE M, 1975, BRIT J UROL, V47, P193, DOI 10.1111/j.1464-410X.1975.tb03947.x; CAINE M, 1981, UROLOGY, V17, P542, DOI 10.1016/0090-4295(81)90071-6; CAINE M, 1986, J UROLOGY, V136, P1; CAVERO I, 1985, British Journal of Pharmacology, V86, p612P; CAVERO I, 1985, British Journal of Pharmacology, V86, p416P; CHEN KK, 1988, CHIN MED J, V41, P127; CHOW W, 1990, BRIT J UROL, V65, P36, DOI 10.1111/j.1464-410X.1990.tb14657.x; CRAMER P, 1989, PARAPLEGIA, V27, P119, DOI 10.1038/sc.1989.18; DUNZENDORFER U, 1988, UROLOGY S, V37, P27; FERRIE BG, 1987, BRIT J UROL, V59, P63, DOI 10.1111/j.1464-410X.1987.tb04581.x; GEORGE NJR, 1986, BRIT J UROL, V58, P290, DOI 10.1111/j.1464-410X.1986.tb09057.x; GERSTENBERG T, 1980, INVEST UROL, V18, P29; HEDLUND H, 1983, J UROLOGY, V130, P275, DOI 10.1016/S0022-5347(17)51106-4; HIEBLE JP, 1985, EUR J PHARMACOL, V107, P111; IACOVOU JW, 1987, BRIT J UROL, V60, P526, DOI 10.1111/j.1464-410X.1987.tb05035.x; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; KITADA S, 1987, J UROLOGY, V138, P158, DOI 10.1016/S0022-5347(17)43034-5; LEPOR H, 1990, J UROLOGY, V143, P533, DOI 10.1016/S0022-5347(17)40012-7; LEPOR H, 1989, INT J CLIN PHARM TH, V27, P392; MARTORANA G, 1984, IRCS MED SCI-BIOCHEM, V12, P11; MCLOUGHLIN J, 1990, BRIT J UROL, V65, P313, DOI 10.1111/j.1464-410X.1990.tb14746.x; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; PERLBERG S, 1982, UROLOGY, V20, P524, DOI 10.1016/0090-4295(82)90127-3; Raezer D M, 1973, Urology, V2, P211, DOI 10.1016/0090-4295(73)90451-2; RAMSAY JWA, 1985, BRIT J UROL, V57, P657, DOI 10.1111/j.1464-410X.1985.tb07026.x; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; STOTT MA, 1989, J UROLOGY, V139, pA464	33	244	248	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1457	1461		10.1016/0140-6736(91)93140-5	http://dx.doi.org/10.1016/0140-6736(91)93140-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1710750				2022-12-28	WOS:A1991FR06000016
J	PIRCHER, H; ROHRER, UH; MOSKOPHIDIS, D; ZINKERNAGEL, RM; HENGARTNER, H				PIRCHER, H; ROHRER, UH; MOSKOPHIDIS, D; ZINKERNAGEL, RM; HENGARTNER, H			LOWER RECEPTOR AVIDITY REQUIRED FOR THYMIC CLONAL DELETION THAN FOR EFFECTOR T-CELL FUNCTION	NATURE			English	Article							BONE-MARROW CHIMERAS; TRANSGENIC MICE; ANTIGEN RECEPTOR; TOLERANCE; SELECTION; ANTIBODY; COMPLEX; ANERGY; GENES	CLONAL deletion in the thymus plays a major part in T-cell tolerance to self antigens 1-3. But the mechanism of negative selection, its fine specificity and the threshold of affinity and avidity remains unknown. We have now examined these aspects of negative selection with mice expressing a transgenic T-cell receptor with specificity for lymphocytic choriomeningitis virus (LCMV) glycoprotein in association with the class I H-2D(b) molecule. These mice were rendered tolerant to LCMV by neonatal infection with mutant LCMVs bearing point mutations in the T-cell epitope recognized by the transgenic T-cell receptor (ref. 4). Variant LCMVs were also tested for their ability to elicit antiviral responses in transgenic mice in vivo and in vitro. Comparison in vivo revealed that a low-avidity receptor interaction, which was unable to induce effector T cells in the periphery, was still sufficient for clonal deletion in the thymus.			PIRCHER, H (corresponding author), UNIV HOSP ZURICH,INST PATHOL,CH-8091 ZURICH,SWITZERLAND.							AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PULLEN AM, 1989, J IMMUNOL, V142, P3033; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83	18	264	269	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					482	485		10.1038/351482a0	http://dx.doi.org/10.1038/351482a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1710780				2022-12-28	WOS:A1991FP75800056
J	ZHU, X; KOMIYA, H; CHIRINO, A; FAHAM, S; FOX, GM; ARAKAWA, T; HSU, BT; REES, DC				ZHU, X; KOMIYA, H; CHIRINO, A; FAHAM, S; FOX, GM; ARAKAWA, T; HSU, BT; REES, DC			3-DIMENSIONAL STRUCTURES OF ACIDIC AND BASIC FIBROBLAST GROWTH-FACTORS	SCIENCE			English	Article							TRYPSIN-INHIBITOR KUNITZ; MACROMOLECULAR CRYSTALLOGRAPHY; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; SEQUENCE; INTERLEUKIN-1-BETA; REFINEMENT; PROGRAMS; SYSTEM; GENE	Members of the fibroblast growth factor (FGF) family of proteins stimulate the proliferation and differentiation of a variety of cell types through receptor-mediated pathways. The three-dimensional structures of two members of this family, bovine acidic FGF and human basic FGF, have been crystallographically determined. These structures contain 12 antiparallel beta-strands organized into a folding pattern with approximate threefold internal symmetry. Topologically equivalent folds have been previously observed for soybean trypsin inhibitor and interleukins-1-beta and -1-alpha. The locations of sequences implicated in receptor and heparin binding by FGF are presented. These sites include beta-sheet strand 10, which is adjacent to the site of an extended sequence insertion in several oncogene proteins of the FGF family, and which shows sequence conservation among the FGF family and interleukin-1-beta.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	California Institute of Technology; Amgen								BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOX GM, 1988, J BIOL CHEM, V263, P18452; FOX GM, UNPUB; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARICS I, 1989, ONCOGENE, V4, P335; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VEERAPANDIAN B, UNPUB; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	39	357	383	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					90	93		10.1126/science.1702556	http://dx.doi.org/10.1126/science.1702556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1702556				2022-12-28	WOS:A1991EQ60300035
J	HNATIUK, OW; DILLARD, TA; OSTER, CN				HNATIUK, OW; DILLARD, TA; OSTER, CN			BLEOMYCIN SCLEROTHERAPY FOR BILATERAL PNEUMOTHORACES IN A PATIENT WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note											HNATIUK, OW (corresponding author), WALTER REED ARMY MED CTR, DEPT CLIN INVEST, WASHINGTON, DC 20307 USA.							BITRAN JD, 1981, J SURG ONCOL, V16, P273, DOI 10.1002/jso.2930160312; DYNER TS, 1989, ANN INTERN MED, V111, P94, DOI 10.7326/0003-4819-111-1-94; ENG RHK, 1987, ARCH INTERN MED, V147, P746, DOI 10.1001/archinte.147.4.746; FLEISHER AG, 1988, ANN THORAC SURG, V45, P21, DOI 10.1016/S0003-4975(10)62388-0; GOLDSZER RC, 1979, JAMA-J AM MED ASSOC, V241, P724, DOI 10.1001/jama.241.7.724; OSTROWSKI MJ, 1989, J SURG ONCOL, P7; SAHN SA, 1981, AM REV RESPIR DIS, V124, P65; SCANNELL KA, 1990, CHEST, V97, P479, DOI 10.1378/chest.97.2.479; SHERMAN M, 1986, CHEST, V90, P609, DOI 10.1378/chest.90.4.609; TASSI GF, 1983, CHEST, V83, P836, DOI 10.1378/chest.83.5.836a	10	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1990	113	12					988	990		10.7326/0003-4819-113-12-988	http://dx.doi.org/10.7326/0003-4819-113-12-988			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM297	1700656				2022-12-28	WOS:A1990EM29700015
J	MARTIN, TW; SEAWORTH, JF; JOHNS, JP; PUPA, LE; CONDOS, WR				MARTIN, TW; SEAWORTH, JF; JOHNS, JP; PUPA, LE; CONDOS, WR			COMPARISON OF ADENOSINE, DIPYRIDAMOLE, AND DOBUTAMINE IN STRESS ECHOCARDIOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Article						ECHOCARDIOGRAPHY; DOBUTAMINE; DIPYRIDAMOLE; ADENOSINE; EXERCISE TEST	CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; EFFORT ANGINA-PECTORIS; PHYSIOLOGIC BASIS; VASCULAR-SURGERY; CARDIAC RISK; EXERCISE; DIAGNOSIS; HYPEREMIA; TL-201	Objective: To compare adenosine, dipyridamole, and dobutamine in stress echocardiography with regard to sensitivity, specificity, accuracy, and side effects. Design: Crossover, blinded comparison, with coronary angiography serving as the criterion standard. Setting: U.S. Army tertiary care hospital. Participants: Forty participants, 25 with coronary disease and 15 without coronary disease. Patients were eligible if they had coronary angiography within 6 weeks of stress testing or if they had a risk for coronary disease of less than 5%. Measurements: Left ventricular wall motion was recorded after dobutamine (0.38 mg/kg body weight), adenosine (0.84 mg/kg body weight), and dipyridamole (0.84 mg/kg body weight) stress testing. Stress echocardiographic evaluation was considered to be abnormal if the patient developed new or progressive wall motion abnormalities. The rate of side effects for the types of echocardiography and the patient preference were recorded. Main Results: The sensitivity of dobutamine stress echocardiography (76%; 95% Cl, 59% to 93%) was significantly higher than that of adenosine echocardiography (40%; Cl, 21% to 59%; P < 0.001) and that of dipyridamole echocardiography (56%; Cl, 37% to 75%; P = 0.019). The specificity of adenosine testing (93%; Cl, 80% to 100%) was significantly higher than that of dobutamine echocardiography (60%; Cl, 35% to 85%; P = 0.008) and that of dipyridamole echocardiography (67%; Cl, 43% to 91 %; P = 0.028). Symptoms were more frequent with adenosine echocardiography (100%) than with dipyridamole (88%; P< 0.001) or dobutamine (80%; P < 0.001) echocardiography. Treatment for persistent symptoms was required in more patients after dipyridamole echocardiography (40%) than after dobutamine (12%; P < 0.001) or adenosine (0%; P < .001) echocardiography. More patients preferred dobutamine (48%) or dipyridamole (40%) echocardiography to adenosine echocardiography (12%; P < .001). Conclusions: Dobutamine stress echocardiography is more sensitive and is better tolerated than adenosine or dipyridamole stress echocardiography. Adenosine echocardiography is more specific than dobutamine or dipyridamole echocardiography and is less likely to cause persistent symptoms.	BROOKE ARMY MED CTR, FT SAM HOUSTON, TX 78234 USA	San Antonio Military Medical Center; United States Department of Defense; United States Army								BELLER GA, 1991, JAMA-J AM MED ASSOC, V265, P633, DOI 10.1001/jama.265.5.633; BERTHE C, 1986, AM J CARDIOL, V58, P1167, DOI 10.1016/0002-9149(86)90376-0; BOLOGNESE L, 1989, J AM COLL CARDIOL, V14, P357, DOI 10.1016/0735-1097(89)90186-1; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; COYNE EP, 1991, J AM COLL CARDIOL, V17, P1289, DOI 10.1016/S0735-1097(10)80137-8; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EDWARDS WD, 1981, MAYO CLIN PROC, V56, P479; FUNG AY, 1987, CIRCULATION, V76, P943, DOI 10.1161/01.CIR.76.4.943; GOULD KL, 1978, AM J CARDIOL, V41, P279, DOI 10.1016/0002-9149(78)90166-2; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; KLABUNDE RE, 1983, EUR J PHARMACOL, V93, P21, DOI 10.1016/0014-2999(83)90026-2; KNABB RM, 1984, AM J PHYSIOL, V247, pH804, DOI 10.1152/ajpheart.1984.247.5.H804; MANNERING D, 1988, BRIT HEART J, V59, P521; MEYER SL, 1976, AM J CARDIOL, V38, P103, DOI 10.1016/0002-9149(76)90070-9; NGUYEN T, 1990, J AM COLL CARDIOL, V16, P1375, DOI 10.1016/0735-1097(90)90379-4; PICANO E, 1985, AM J CARDIOL, V56, P452, DOI 10.1016/0002-9149(85)90884-7; PICANO E, 1991, J AM COLL CARDIOL, V17, P666, DOI 10.1016/S0735-1097(10)80182-2; PICANO E, 1987, AM J CARDIOL, V59, P539, DOI 10.1016/0002-9149(87)91165-9; PICANO E, 1989, EUR HEART J, V10, P365; PICANO E, 1986, J AM COLL CARDIOL, V8, P848, DOI 10.1016/S0735-1097(86)80426-0; PICANO E, 1989, CIRCULATION, V80, P450, DOI 10.1161/01.CIR.80.3.450; PIERARD LA, 1989, EUR HEART J, V10, P783, DOI 10.1093/oxfordjournals.eurheartj.a059571; PREVITALI M, 1991, CIRCULATION, V83, P27; RANHOSKY A, 1990, CIRCULATION, V81, P1205, DOI 10.1161/01.CIR.81.4.1205; SAWADA SG, 1991, CIRCULATION, V83, P1605, DOI 10.1161/01.CIR.83.5.1605; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; VERANI MS, 1990, CIRCULATION, V82, P80, DOI 10.1161/01.CIR.82.1.80; WILSON RF, 1990, CIRCULATION, V82, P1595, DOI 10.1161/01.CIR.82.5.1595; 1988, LANCET, V2, P1347	30	164	165	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					190	196		10.7326/0003-4819-116-3-190	http://dx.doi.org/10.7326/0003-4819-116-3-190			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728203				2022-12-28	WOS:A1992HB35600003
J	LACOMBE, MA				LACOMBE, MA			PLAYING GOD	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ETHICS; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS ROLE; SPOUSE ABUSE; HOMICIDE		How far may a physician go in treating his or her patient? May a physician, for example, lie to a dying patient to calm the fears of that patient? May a physician divulge information told, to him or her in confidence in the interest of helping a patient? Or, how about covering up a felony? Is it ever permissible for a physician to assist his or her patient in a felony in the interests of patient care? Wait. What about the felony in this story?			LACOMBE, MA (corresponding author), OXFORD HILLS MED GRP, 23 WINTER ST, NORWAY, ME 04268 USA.								0	13	13	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					161	162		10.7326/0003-4819-116-2-161	http://dx.doi.org/10.7326/0003-4819-116-2-161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727620				2022-12-28	WOS:A1992GZ35600009
J	WACHTER, RM				WACHTER, RM			AIDS, ACTIVISM, AND THE POLITICS OF HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOVEMENT				WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; Annas George J, 1989, Villanova Law Rev, V34, P771; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Bayer R., 1991, PRIVATE ACTS SOCIAL; BENNETT JT, 1990, HLTH RES CHARITIES I; Blumberg Rhoda Lois, 1984, CIVIL RIGHTS 1960S F; CHASE M, 1989, WALL STREET J   0919, pA3; COLAIACO JA, 1988, ML KING APOSTLE MILI; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; Dowd Maureen, 1991, NEW YORK TIMES  0302, P7; FINTOR L, 1991, J NATL CANCER I, V83, P528, DOI 10.1093/jnci/83.8.528; FOX P, 1989, MILBANK Q, V67, P58, DOI 10.2307/3350070; Fuchs V., 1974, WHO SHALL LIVE; GROSS J, 1991, NY TIMES        0107, pA12; GROSSMAN H, 1990, NY TIMES        0819, V3, P13; HAMILTON PA, 1982, HLTH CARE CONSUMERIS; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; KOLATA G, 1990, NY TIMES, pA1; KOLATA G, 1991, NY TIMES        0716, pB6; KOLATA G, 1991, NY TIMES        0728, P13; KOLATA G, 1990, NY TIMES        0519, pA8; KRAMER L, 1990, OUTWEEK MAGAZIN 0314, P36; KRAMER L, 1989, REPROTS HOLOCAUST MA; KRAUTHAMMER C, 1990, TIME            0625, P80; LEO J, 1990, US NEWS WORLD R 0205, P18; LITTLE M, 1970, BY ANY MEANS NECESSA; MASTERSONALLEN S, 1990, INT J HEALTH SERV, V20, P485, DOI 10.2190/ATLC-AX39-M5EX-BYHF; McIntosh H, 1990, J Natl Cancer Inst, V82, P730, DOI 10.1093/jnci/82.9.730; ROTHMAN DJ, 1990, HEALTH AFFAIR, V9, P123, DOI 10.1377/hlthaff.9.3.123; Salholz E., 1990, NEWSWEEK        0312, P20; Shilts R., 1987, BAND PLAYED POLITICS; SPIERS HR, 1989, HASTINGS CENT REP, V19, P34, DOI 10.2307/3561987; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STRICKAND SP, 1979, POLITICS HLTH, P75; THOMPSON D, 1990, TIME            0122, P24; Wachter Robert M., 1991, FRAGILE COALITION SC; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1991, MMWR, V40, P358; 1990, FED REGISTER, V55, P20856	39	60	61	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					128	133		10.1056/NEJM199201093260209	http://dx.doi.org/10.1056/NEJM199201093260209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY045	1727220				2022-12-28	WOS:A1992GY04500009
J	HAHN, RA				HAHN, RA			THE STATE OF FEDERAL HEALTH-STATISTICS ON RACIAL AND ETHNIC-GROUPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-INDIANS	Objective. - To examine assumptions underlying federal health statistics on racial and ethnic groups in the United States. Data Sources. - Studies conducted by federal agencies and other investigators, and technical appendices of published vital statistics and census reports. Data Synthesis. - Several assumptions underlying federal health statistics on racial and ethnic groups are not well supported. Conceptual (as opposed to operational) definitions of race and ethnicity are not available, and scientific grounds for definition are not considered. Procedures for the ascertainment of race and ethnicity vary within and among data-collection agencies. Miscounting and misclassification may vary by an order of magnitude between whites and other races. The responses of individuals to questions of racial and ethnic identity differ for different indicators, in different surveys, and at different times. As a result, counts, rates, and rate ratios may not be meaningful or accurate. Particularly for Hispanics and for races other than whites or blacks, there are inconsistencies in statistical information that may hinder health research and program development. Conclusions. - Improvement of federal health statistics for racial and ethnic groups requires (1) clarification of goals for classification, (2) adoption of scientific principles for the validation and definition of the categories "race" and "ethnicity," (3) assessment of perceived social identity in the population, and (4) periodic evaluation.			HAHN, RA (corresponding author), CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,C-08,ATLANTA,GA 30333, USA.							DRURY TF, 1980, CLASSIFICATION ISSUE, P5; FARLEY R, 1990, RACE ETHNICITY US CE; FAY R, 1988, PHC80E4 US DEP COMM; FROST F, 1980, AM J PUBLIC HEALTH, V70, P974, DOI 10.2105/AJPH.70.9.974; GOULD SJ, 1977, EVER SINCE DARWIN, P231; Hambright T Z, 1969, Vital Health Stat 2, P1; HEUSER RL, 1989, 117TH ANN M AM PUBL; HOLLMANN FW, 1990, US DEP COMMERCE P25, V1045; JOHNSON CE, 1974, 31 US DEP COMM BUR C; Kleinman J C, 1990, MMWR CDC Surveill Summ, V39, P31; Lewontin R.C., 1972, EVOL BIOL, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; MASSEY J, 1980, P AM STAT ASSOC, P425; MCKENNEY NR, 1988, APR ANN M POP ASS AM; MONTAGU A, 1965, IDEA RACE; PASSEL JS, 1986, SOC BIOL, V33, P163; POE GS, UNPUB COMP STUDY RES; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SIEGEL JS, 1979, CURRENT POPULATI P23, V82; SNIPP CM, 1986, POPUL RES POLICY REV, V5, P237, DOI 10.1007/BF00136786; SUCHMAN L, 1990, J AM STAT ASSOC, V85, P232, DOI 10.2307/2289550; WALLMAN KK, 1978, STAT REPORTER, V78, P148; Wallman KK, 1977, STAT REP, V77-110, P450; 1989, PHS891100 US DEP HLT; 1983, PC80S110 US DEP COMM; 1990, PHS901101 US DEP HLT; 1986, PHC80E2 US DEP COMM; 1990, HLTH US 1989; 1982, PC80S17 US DEP COMM; 1987, PHS871122 US DEP HLT; 1954, VITAL STATISTICS US, V1; 1978, STATISTICAL POLICY H, P37; 1973, PHCE2 US DEP COMM BU; 1983, PC801C US DEP COMM B; 1988, MMWR, V37, P1	34	160	160	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					268	271		10.1001/jama.267.2.268	http://dx.doi.org/10.1001/jama.267.2.268			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY046	1727525				2022-12-28	WOS:A1992GY04600032
J	ANDERSON, DC; ASINGER, RW; NEWBURG, SM; FARMER, CC; WANG, K; BUNDLIE, SR; KOLLER, RL; JAGIELLA, WM; KREHER, S; JORGENSEN, CR; SHARKEY, SW; FLAKER, GC; WEBEL, R; NOLTE, B; STEVENSON, P; BYER, J; WRIGHT, W; CHESEBRO, JH; WIEBERS, DO; HOLLAND, AE; MILLER, DM; BARDSLEY, WT; LITIN, SC; MEISSNER, I; ZERBE, DM; MCANULTY, JH; MARCHANT, C; COULL, BM; FELDMAN, G; HAYWARD, A; GANDARA, E; MACMILLAN, K; BLANK, N; LEONARD, AD; KANTER, MC; ISENSEE, LM; QUIROGA, ES; PRESTI, CH; TEGELER, CH; LOGAN, WR; HAMILTON, WP; GREEN, BJ; BACON, RS; REDD, RM; CADELL, DJ; GOMEZ, CR; JANOSIK, DL; LABOVITZ, AJ; KELLEY, RE; CHAHINE, R; CRISTO, L; PALERMO, M; PEREZ, O; FEINBERG, WM; VOLD, BK; KERN, KB; APPLETON, C; MILLER, VT; HOCKERSMITH, CJ; COHEN, BA; MARTIN, GJ; PAWLOW, AJ; HALPERIN, JL; ROTHLAUF, EB; WEINBERGER, JM; GOLDMAN, ME; FUSTER, V; DITTRICH, HC; ROTHROCK, JF; HAGENHOFF, C; HELGASON, CM; KONDOS, GT; HOFF, J; KAUFMANN, L; RABJOHNS, RR; MCRAE, RP; GHALI, J; ADAMS, HP; THEILEN, EO; BILLER, J; BROWN, DD; MARSH, EE; SIRNA, SJ; MITCHELL, VL; ROTHBART, RM; BAILEY, GH; BURKHARDT, C; BLACKSHEAR, JL; WEAVER, L; LEE, G; LANE, G; RUBINO, F; SAFFORD, R; KRONMAL, RA; MCBRIDE, R; PEARCE, LA; NASCO, E; HART, RG; SHERMAN, CP; SHERMAN, DG; TALBERT, RL; DACY, TL; HEBERLING, PA				ANDERSON, DC; ASINGER, RW; NEWBURG, SM; FARMER, CC; WANG, K; BUNDLIE, SR; KOLLER, RL; JAGIELLA, WM; KREHER, S; JORGENSEN, CR; SHARKEY, SW; FLAKER, GC; WEBEL, R; NOLTE, B; STEVENSON, P; BYER, J; WRIGHT, W; CHESEBRO, JH; WIEBERS, DO; HOLLAND, AE; MILLER, DM; BARDSLEY, WT; LITIN, SC; MEISSNER, I; ZERBE, DM; MCANULTY, JH; MARCHANT, C; COULL, BM; FELDMAN, G; HAYWARD, A; GANDARA, E; MACMILLAN, K; BLANK, N; LEONARD, AD; KANTER, MC; ISENSEE, LM; QUIROGA, ES; PRESTI, CH; TEGELER, CH; LOGAN, WR; HAMILTON, WP; GREEN, BJ; BACON, RS; REDD, RM; CADELL, DJ; GOMEZ, CR; JANOSIK, DL; LABOVITZ, AJ; KELLEY, RE; CHAHINE, R; CRISTO, L; PALERMO, M; PEREZ, O; FEINBERG, WM; VOLD, BK; KERN, KB; APPLETON, C; MILLER, VT; HOCKERSMITH, CJ; COHEN, BA; MARTIN, GJ; PAWLOW, AJ; HALPERIN, JL; ROTHLAUF, EB; WEINBERGER, JM; GOLDMAN, ME; FUSTER, V; DITTRICH, HC; ROTHROCK, JF; HAGENHOFF, C; HELGASON, CM; KONDOS, GT; HOFF, J; KAUFMANN, L; RABJOHNS, RR; MCRAE, RP; GHALI, J; ADAMS, HP; THEILEN, EO; BILLER, J; BROWN, DD; MARSH, EE; SIRNA, SJ; MITCHELL, VL; ROTHBART, RM; BAILEY, GH; BURKHARDT, C; BLACKSHEAR, JL; WEAVER, L; LEE, G; LANE, G; RUBINO, F; SAFFORD, R; KRONMAL, RA; MCBRIDE, R; PEARCE, LA; NASCO, E; HART, RG; SHERMAN, CP; SHERMAN, DG; TALBERT, RL; DACY, TL; HEBERLING, PA			PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .2. ECHOCARDIOGRAPHIC FEATURES OF PATIENTS AT RISK	ANNALS OF INTERNAL MEDICINE			English	Article						THROMBOEMBOLISM; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; HYPERTENSION; HEART FAILURE, CONGESTIVE	LEFT-VENTRICULAR MASS; SYSTEMIC EMBOLIZATION; STROKE; COMPLICATIONS	Objective: To identify echocardiographic predictors of arterial thromboembolism in patients with nonrheumatic atrial fibrillation and to determine whether these add to clinical variables for risk stratification. Design: Cohort study of patients assigned to placebo in a randomized clinical trial. Setting: Five hundred sixty-eight inpatients and outpatients with nonrheumatic atrial fibrillation assigned to placebo therapy at 15 U.S. medical centers from 1987 to 1989 in the Stroke Prevention in Atrial Fibrillation study. Patients were followed for a mean of 1.3 years. Measurements: M-mode and two-dimensional (2-D) echocardiograms performed at study entry and interpreted by local cardiologists. The predictive value of 14 echocardiographic variables for later ischemic stroke or systemic embolism was assessed by multivariate analysis. Main Results: Left ventricular dysfunction from 2-D echocardiograms (P = 0.003) and the size of the left atrium from M-mode echocardiograms (P = 0.02) were the strongest independent predictors of later thromboembolism. Multivariate analysis of these two independent echocardiographic predictors with the three independent clinical predictors of thromboembolism (history of hypertension, recent congestive heart failure, previous thromboembolism) identified 26% of the cohort with a low risk for thromboembolism (1.0% per year; 95% Cl, 0.2% to 4.0%). Compared with risk stratification using clinical variables alone, echocardiographic results altered thromboembolic risk stratification in 18% of the entire cohort and in 38% of those without clinical risk factors. Conclusions: Both left ventricular and left atrial variables are significant predictors of thromboembolism in patients with nonvalvular atrial fibrillation. Our results challenge traditional views of the pathogenesis of ischemic stroke in patients with atrial fibrillation and suggest that standard echocardiography contributes to risk stratification, differentiating the one third of patients without clinical risk factors who are at increased risk for stroke from the remainder who may not need antithrombotic prophylaxis.	STAT & EPIDEMIOL RES CORP,SPAF STAT COORDINAT CTR,1107 NE 45TH ST,SUITE 520,SEATTLE,WA 98105; HENNEPIN CTY MED CTR,MINNEAPOLIS,MN 55415; ABBOTT NW HOSP,MINNEAPOLIS,MN; UNIV MISSOURI,COLUMBIA,MO 65201; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; OREGON HLTH SCI UNIV,PORTLAND,OR 97201; KAISER PERMANENTE,PORTLAND,OR; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284; ST JOHNS MERCY MED CTR,ST LOUIS,MO 63141; ST LOUIS UNIV,MED CTR,ST LOUIS,MO 63103; UNIV MIAMI,SCH MED,MIAMI,FL 33152; UNIV ARIZONA,COLL MED,TUCSON,AZ 85721; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; MT SINAI MED CTR,NEW YORK,NY 10029; UNIV CALIF SAN DIEGO,MED CTR,LA JOLLA,CA 92093; UNIV ILLINOIS,COLL MED,CHICAGO,IL 60680; UNIV ILLINOIS,COLL MED,PEORIA,IL 61656; UNIV IOWA,COLL MED,IOWA CITY,IA 52242; UNIV COLORADO,COLL MED,BOULDER,CO 80309; MAYO CLIN,JACKSONVILLE,FL; UNIV WASHINGTON,SEATTLE,WA 98195; UNIV TEXAS,HLTH SCI CTR,CTR CLIN COORDINAT,SAN ANTONIO,TX 78284	Hennepin County Medical Center; University of Missouri System; University of Missouri Columbia; Mayo Clinic; Oregon Health & Science University; Kaiser Permanente; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Saint Johns Mercy Medical Center; Saint Louis University; University of Miami; University of Arizona; Northwestern University; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Peoria; University of Iowa; University of Colorado System; University of Colorado Boulder; Mayo Clinic; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio			Halperin, Jonathan/AAJ-4721-2020; Fuster, Valentin/H-4319-2015; Tegeler, Charles/R-3623-2019	Halperin, Jonathan/0000-0002-8318-5471; Fuster, Valentin/0000-0002-9043-9986; 	NINDS NIH HHS [R01-NS-24224] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024224] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAPLAN LR, 1986, ANN NEUROL, V19, P158, DOI 10.1002/ana.410190208; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P269; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; Fleiss JL, 1981, STATISTICAL METHODS, P217; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; HALPERIN JL, 1988, STROKE, V19, P937, DOI 10.1161/01.STR.19.8.937; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOPECKY SL, 1989, CIRCULATION S2, V80, P409; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; WIENER I, 1987, AM J CARDIOL, V59, P177, DOI 10.1016/S0002-9149(87)80102-9; 1990, STROKE, V21, P538; 1991, CIRCULATION, V84, P527; 1989, ARCH NEUROL-CHICAGO, V46, P727; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	25	494	504	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					6	12						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727097				2022-12-28	WOS:A1992GX15700002
J	PETROS, A; BENNETT, D; VALLANCE, P				PETROS, A; BENNETT, D; VALLANCE, P			EFFECT OF NITRIC-OXIDE SYNTHASE INHIBITORS ON HYPOTENSION IN PATIENTS WITH SEPTIC SHOCK	LANCET			English	Note							L-ARGININE; ENDOTOXIN; TONE	Hypotension during septic shock, which may reflect increased synthesis of the potent vasodilator nitric oxide (NO), is often refractory to vasoconstrictors. We describe the effects of NO synthase inhibition in two patients with life-threatening septic shock in whom conventional therapy had failed to restore blood pressure. N(G)-monomethyl-L-arginine (L-NMMA) caused dose-dependent increases in blood pressure and systemic vascular resistance in both patients, and a similar effect was observed in the second patient after treatment with N(G)-nitro-L-arginine methyl ester (L-NAME). These findings indicate that NO synthase induction contributes to the pathogenesis of septic shock, and that inhibition of NO synthase may represent a novel therapeutic option.	ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,INTENS THERAPY UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London								GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; JOULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; MONCADA S, 1991, PHARMACOL REV, V43, P109; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; VALLANCE P, 1989, LANCET, V2, P997; WRIGHT CE, IN PRESS CARDIOVASC	10	805	832	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1557	1558		10.1016/0140-6736(91)92376-D	http://dx.doi.org/10.1016/0140-6736(91)92376-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1720856				2022-12-28	WOS:A1991GW03600007
J	KIM, J; CHEONG, C; MOORE, PB				KIM, J; CHEONG, C; MOORE, PB			TETRAMERIZATION OF AN RNA OLIGONUCLEOTIDE CONTAINING A GGGG SEQUENCE	NATURE			English	Article							5'-GUANOSINE MONOPHOSPHATE; FIBER DIFFRACTION; TELOMERIC DNA; X-RAY; MODEL; ACID	POLY rG can form four-stranded helices 1. The Hoogsteen-paired quartets of G residues on which such structures depend are so stable that they will form in 5'-GMP solutions, provided that Na+ or K+ are present (see for example, refs 2-4). Telomeric DNA sequences, which are G-rich, adopt four-stranded antiparallel G-quartet conformations in vitro 5,6, and parallel tetramerization of G-rich sequences may be involved in meiosis 7,8. Here we show that RNAs containing short runs of Gs can also tetramerize. A 19-base oligonucleotide derived from the 5S RNA of Escherichia coli (strand III), 5'GCCGAUGGUAGUGUGGGGU3', forms a K+-stabilized tetrameric aggregate that depends on the G residues at its 3' end. This complex is so stable that it would be surprising if similar structures do not occur in nature.			KIM, J (corresponding author), YALE UNIV, DEPT CHEM, 225 PROSPECT ST, NEW HAVEN, CT 06511 USA.		Cheong, Chaejoon/GWC-3135-2022					BORZO M, 1980, J AM CHEM SOC, V102, P1124, DOI 10.1021/ja00523a032; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; MOORE PB, 1988, METHOD ENZYMOL, V164, P158; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; STUDENCKI AB, 1981, THESIS U ILLINOIS; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZIMMERMAN SB, 1976, J MOL BIOL, V106, P663, DOI 10.1016/0022-2836(76)90257-6; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	12	137	144	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					331	332		10.1038/351331a0	http://dx.doi.org/10.1038/351331a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	1709723				2022-12-28	WOS:A1991FM97600066
J	VANDENVELDE, C; FONDU, P; DUBOISPRIMO, J				VANDENVELDE, C; FONDU, P; DUBOISPRIMO, J			LOW-DOSE APROTININ FOR REDUCTION OF BLOOD-LOSS AFTER CARDIOPULMONARY BYPASS	LANCET			English	Letter							SURGERY		FREE UNIV BRUSSELS,HOSP BRUGMAN,DEPT ANAESTHESIOL,B-1020 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	VANDENVELDE, C (corresponding author), FREE UNIV BRUSSELS,HOSP BRUGMANN,DEPT IMMUNOL TRANSFUS HAEMATOL,B-1020 BRUSSELS,BELGIUM.							CARREL, 1991, LANCET, V337, P673; DIETRICH W, 1989, THORAC CARDIOV SURG, V37, P92, DOI 10.1055/s-2007-1013915; GRAM J, 1990, THROMB HAEMOSTASIS, V63, P241; VANOEVEREN W, 1990, J THORAC CARDIOV SUR, V99, P788; VANOEVEREN W, 1987, ANN THORAC SURG, V44, P640, DOI 10.1016/S0003-4975(10)62153-4	5	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1157	1158		10.1016/0140-6736(91)92821-I	http://dx.doi.org/10.1016/0140-6736(91)92821-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1709248				2022-12-28	WOS:A1991FL12400028
J	BLOOMFIELD, SA				BLOOMFIELD, SA			2 TYPES OF ORIENTATION-SENSITIVE RESPONSES OF AMACRINE CELLS IN THE MAMMALIAN RETINA	NATURE			English	Article							GANGLION-CELLS; RABBIT RETINA; STRUCTURAL BASIS; ORGANIZATION; SELECTIVITY; CORTEX	NEURONS sensitive to the orientation of light stimuli exist throughout the mammalian visual system 1-3, suggesting that this spatial feature is a fundamental cue used by the brain to decipher visual information. The most peripheral neurons known to show orientation sensitivity are the retinal ganglion cells. Considerable morphological 4,5 and pharmacological 6-10 data suggest that the orientation sensitivity of ganglion cells is formed, at least partly, by the amacrine cells, which are laterally oriented interneurons presynaptic to the ganglion cells in the inner plexiform layer. So far there have been few studies of the responses of amacrine cells to oriented visual stimuli and their role in forming orientation-sensitive responses in the retina remains unclear. Here I report the novel finding of a population of amacrine cells in the rabbit retina which are orientation-sensitive. These amacrine cells can be divided into two subtypes, whose orientation sensitivity is manufactured by two distinct mechanisms. The orientation sensitivity of the first subtype of amacrine cell is formed from the interactions of excitatory, centre-receptive field synaptic inputs and inhibitory inputs of opposite polarity, whereas that for cells of the second subtype seems to be the product of a marked asymmetry in their dendritic arbors.			BLOOMFIELD, SA (corresponding author), NYU MED CTR,DEPT OPHTHALMOL,550 1ST AVE,NEW YORK,NY 10016, USA.				NEI NIH HHS [R01 EY007360] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007360] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1969, J NEUROPHYSIOL, V32, P424, DOI 10.1152/jn.1969.32.3.424; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P135, DOI 10.1113/jphysiol.1982.sp014104; BLOOMFIELD SA, 1982, J COMP NEUROL, V208, P288, DOI 10.1002/cne.902080306; BLOOMFIELD SA, 1986, J NEUROSCI, V6, P1; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P257, DOI 10.1113/jphysiol.1978.sp012232; DOWLING JE, 1968, PROC R SOC SER B-BIO, V170, P205, DOI 10.1098/rspb.1968.0034; DUBIN MW, 1970, J COMP NEUROL, V140, P479, DOI 10.1002/cne.901400406; ELIAS SA, 1980, BRAIN RES, V196, P365; FAMGLIETTI EV, 1989, NEUROBIOLOGY INNER R, P169; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; FERSTER D, 1987, TRENDS NEUROSCI, V10, P487, DOI 10.1016/0166-2236(87)90126-3; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Hughes A., 1985, PROGR RETINAL RES, V4, P243; LEVENTHAL AG, 1983, J COMP NEUROL, V220, P465, DOI 10.1002/cne.902200408; LEVICK WR, 1967, J PHYSIOL-LONDON, V188, P285, DOI 10.1113/jphysiol.1967.sp008140; LEVICK WR, 1982, J PHYSIOL-LONDON, V329, P243, DOI 10.1113/jphysiol.1982.sp014301; MARIANI AP, 1982, NATURE, V298, P654, DOI 10.1038/298654a0; MILLER RF, 1983, P NATL ACAD SCI-BIOL, V80, P3069, DOI 10.1073/pnas.80.10.3069; MILLER RF, 1979, NEUROSCIENCES 4TH ST, P227; VIDYASAGAR TR, 1982, EXP BRAIN RES, V46, P157; WYATT HJ, 1976, SCIENCE, V191, P204, DOI 10.1126/science.1857	24	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					347	350		10.1038/350347a0	http://dx.doi.org/10.1038/350347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1706822				2022-12-28	WOS:A1991FD83800095
J	MOULIN, DE; KREEFT, JH; MURRAYPARSONS, N; BOUQUILLON, AI				MOULIN, DE; KREEFT, JH; MURRAYPARSONS, N; BOUQUILLON, AI			COMPARISON OF CONTINUOUS SUBCUTANEOUS AND INTRAVENOUS HYDROMORPHONE INFUSIONS FOR MANAGEMENT OF CANCER PAIN	LANCET			English	Article							TERMINAL MALIGNANCY; MORPHINE	To compare the safety and efficacy of subcutaneous and intravenous infusion of opioid analgesics, a randomised, double-blind, crossover trial was carried out in inpatients. 15 patients with severe cancer pain received two 48 h infusions of hydromorphone- one subcutaneously and one intravenously in randomly allocated order. The study was made double-blind by the use of two infusion pumps throughout; during the active subcutaneous infusion the intravenous pump delivered saline and vice versa. Serial measurements of pain intensity, pain relief, mood, and sedation by means of visual analogue scales showed no clinically or statistically significant difference between the two infusion routes. Side-effects were slight, and the mean number of morphine injections for breakthrough pain did not differ significantly between the routes (4.8 [SD 4.5] for intravenous vs 5.3 [5.6] for subcutaneous). Plasma hydromorphone concentrations measured at 24 h and 48 h of infusion showed stable steady-state pharmacokinetics; the mean bioavailability from subcutaneous infusion was 78% of that with intravenous infusion. Because of the simplicity, technical advantages, and cost-effectiveness of continuous subcutaneous opioid infusion into the chest wall or trunk, intravenous opioid infusion for the management of severe cancer pain should be abandoned.	UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI & ONCOL,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT MED CLIN PHARMACOL,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)								BRUERA E, 1988, J NATL CANCER I, V80, P1152, DOI 10.1093/jnci/80.14.1152; BRUERA E, 1988, CANCER-AM CANCER SOC, V62, P407, DOI 10.1002/1097-0142(19880715)62:2<407::AID-CNCR2820620227>3.0.CO;2-T; CAMPBELL CF, 1983, ANN INTERN MED, V98, P51, DOI 10.7326/0003-4819-98-1-51; CITRON ML, 1984, AM J MED, V77, P199, DOI 10.1016/0002-9343(84)90691-0; FERRIS FD, IN PRESS J CLIN EPID; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; HOUDE RAYMOND W., 1966, INT ENCYCL PHARMACOL THER, V1, P59; JAFFE JH, 1985, GOODMAN GILMANS PHAR, P494; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; MISER AW, 1980, J PEDIATR-US, V96, P930, DOI 10.1016/S0022-3476(80)80585-3; PENN RD, 1984, J NEUROSURG, V61, P302, DOI 10.3171/jns.1984.61.2.0302; PORTENOY RK, 1986, CANCER TREAT REP, V70, P575; SAWE J, 1981, CLIN PHARMACOL THER, V30, P629; SAWE J, 1983, BRIT J CLIN PHARMACO, V16, P85, DOI 10.1111/j.1365-2125.1983.tb02148.x; SVENSSON JO, 1986, J CHROMATOGR, V375, P174, DOI 10.1016/S0378-4347(00)83707-X; URQUHART ML, 1988, ANESTHESIOLOGY, V69, P428, DOI 10.1097/00000542-198809000-00029; VALLNER JJ, 1981, J CLIN PHARMACOL, V21, P152, DOI 10.1002/j.1552-4604.1981.tb05693.x; WALDMANN CS, 1984, ANAESTHESIA, V39, P768, DOI 10.1111/j.1365-2044.1984.tb06520.x; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	22	83	85	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					465	468		10.1016/0140-6736(91)93401-T	http://dx.doi.org/10.1016/0140-6736(91)93401-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1704089				2022-12-28	WOS:A1991EY88700012
J	PARRY, N; FOX, G; ROWLANDS, D; BROWN, F; FRY, E; ACHARYA, R; LOGAN, D; STUART, D				PARRY, N; FOX, G; ROWLANDS, D; BROWN, F; FRY, E; ACHARYA, R; LOGAN, D; STUART, D			STRUCTURAL AND SEROLOGICAL EVIDENCE FOR A NOVEL MECHANISM OF ANTIGENIC VARIATION IN FOOT-AND-MOUTH-DISEASE VIRUS	NATURE			English	Article									LAB MOLEC BIOPHYS,REX RICHARDS BLDG,S PARKS RD,OXFORD OX1 3QU,ENGLAND; WELLCOME BIOTECH,DEPT VIROL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Oxford; GlaxoSmithKline			Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019	Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Stuart, David/0000-0002-3426-4210; Fry, Elizabeth/0000-0001-9754-5303				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BADGER J, 1988, P NATL ACAD SCI USA, V85, P3304, DOI 10.1073/pnas.85.10.3304; BARNETT PV, 1989, J GEN VIROL, V70, P1483, DOI 10.1099/0022-1317-70-6-1483; BAXT B, 1980, VIROLOGY, V104, P42, DOI 10.1016/0042-6822(80)90364-5; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; BOLWELL C, 1989, J GEN VIROL, V70, P59, DOI 10.1099/0022-1317-70-1-59; BOLWELL C, 1989, J GEN VIROL, V70, P45, DOI 10.1099/0022-1317-70-1-45; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; FOX G, 1987, J MOL BIOL, V196, P591, DOI 10.1016/0022-2836(87)90035-0; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MATEU MG, 1987, VIRUS RES, V8, P261, DOI 10.1016/0168-1702(87)90020-7; MCCAHON D, 1989, J GEN VIROL, V70, P639, DOI 10.1099/0022-1317-70-3-639; MCCULLOUGH KC, 1985, J IMMUNOL METHODS, V82, P91, DOI 10.1016/0022-1759(85)90228-5; MONOD J, 1965, BIOCHEMISTRY-US, V5, P365; OULDRIDGE EJ, 1984, J GEN VIROL, V65, P203, DOI 10.1099/0022-1317-65-1-203; PARRY NR, 1989, J GEN VIROL, V70, P1493, DOI 10.1099/0022-1317-70-6-1493; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; SUROVOI AY, 1989, J BIOORGANIC CHEM, V14, P527; THOMAS AAM, 1988, J VIROL, V62, P2782, DOI 10.1128/JVI.62.8.2782-2789.1988	26	189	197	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 11	1990	347	6293					569	572		10.1038/347569a0	http://dx.doi.org/10.1038/347569a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC454	1699132				2022-12-28	WOS:A1990EC45400058
J	DOBLIN, BH; GELBERG, L; FREEMAN, HE				DOBLIN, BH; GELBERG, L; FREEMAN, HE			CARING FOR THE UNINSURED AND UNDERINSURED - PATIENT-CARE AND PROFESSIONAL STAFFING PATTERNS IN MCKINNEY-ACT CLINICS PROVIDING PRIMARY CARE TO THE HOMELESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH	Objective. - To describe the patient care and staffing patterns of the 157 clinics that receive federal funding to provide health care to the homeless. Data Sources. - Telephone interviews with clinic medical directors. Results. - Clinics treated a mean of 96 homeless patients per week, approximately 50% of the estimated homeless population. Three quarters treated homeless patients only, the others integrated homeless patients into an existing setting. One third of the clinics had no physician more than 5 hours per week, 10% had no physician staff at all, and 80% employed a nurse practitioner. The proportion of patients initially examined by a nurse practitioner and the proportion subsequently referred to a physician ranged between 10% and 100%. Clinic directors reported that in over 50% of clinics, physician recruitment was hampered by poor working conditions, inadequate salaries, physician biases against working with the homeless, and the lack of respect this work receives from the medical profession. Conclusions. - Current financial constraints may be impeding the ability of clinics serving the homeless to ensure adequate access to high quality care. Additional research should evaluate the impact various staffing patterns have on access and quality of care and develop methods to improve physician recruitment.	UNIV CALIF LOS ANGELES,DEPT MED,DIV FAMILY MED,50-071 CHS,10833 LE CONTE AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,DIV GEN INTERNAL MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT SOCIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BRICKNER PW, 1985, HLTH CARE HOMELESS P; BRICKNER PW, 1990, SAFETY NET HLTH SOCI; BURT MR, 1989, 893 URB I REP; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; REULER JB, 1989, AM J PUBLIC HEALTH, V79, P1033, DOI 10.2105/AJPH.79.8.1033; SACKETT DL, 1974, ANN INTERN MED, V80, P137, DOI 10.7326/0003-4819-80-2-137; SPITZER WO, 1973, ONTARIO MED REV, V40, P96; Wood D, 1989, J Pediatr Health Care, V3, P194, DOI 10.1016/0891-5245(89)90083-7; WRIGHT JD, 1987, HOMELESSNESS HLTH; 1990, GAORCED9052 US GEN A; 1990, GAORCED9129 US GEN A; 1988, HOMELESSNESS HLTH HL; 1990, NATIONAL DIRECTORY H	13	16	16	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					698	701		10.1001/jama.267.5.698	http://dx.doi.org/10.1001/jama.267.5.698			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1731139				2022-12-28	WOS:A1992HB35400030
J	FRANZUSOFF, A; LAUZE, E; HOWELL, KE				FRANZUSOFF, A; LAUZE, E; HOWELL, KE			IMMUNOISOLATION OF SEC7P-COATED TRANSPORT VESICLES FROM THE YEAST SECRETORY PATHWAY	NATURE			English	Article							PROTEIN-TRANSPORT; VESICULAR INTERMEDIATE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; MEMBRANE; RECONSTITUTION; COMPLEX; EVENTS; STACK	THE transport of proteins destined for post-endoplasmic reticulum locations in the secretory pathway is Mediated by small vesicuLar carriers 1-3. Transport vesicles have been generated in cell-free assays from the yeast Saccharomyces cerevisiae, and mammalian systems 4-14. Yeast genes encoding cytosolic components that participate in vesicular traffic were first identified from the collection of conditional-lethal sec (secretory) mutants 15-17. Mutations in the yeast SEC7 gene disrupt protein transport in the secretory pathway at the nonpermissive temperature 18. The SEC7 gene product is a phosphoprotein of relative molecular mass 230,000 that functions from the cytoplasmic aspect of intracellular membranes 19,20. We report that in a yeast cell-free transport assay, the introduction of antibodies to Sec7 protein (Sec7p) results in the accumulation of transport vesicles. These vesicles are retrieved with Sec7p-specific antibodies by immuno-isolation for biochemical and electron microscopic characterization. Sec7p on the surface of the accumulated transport vesicles, in combination with previous genetic and biochemical studies 18,20, implicate Sec7p as part of a (non-clathrin) vesicle coat. This Sec7p-containing coat structure is proposed to be essential for vesicle budding at multiple stages in the yeast secretory pathway.			FRANZUSOFF, A (corresponding author), UNIV COLORADO, SCH MED, DEPT CELLULAR & STRUCT BIOL, BOX B-111, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HOWELL KE, 1989, METHOD CELL BIOL, V31, P265; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1991, TRENDS CELL BIOL, V114, P219; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PAULIK M, 1988, J BIOL CHEM, V263, P17738; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WARREN G, 1990, NATURE, V345, P382, DOI 10.1038/345382a0; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	27	53	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1992	355	6356					173	175		10.1038/355173a0	http://dx.doi.org/10.1038/355173a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729652				2022-12-28	WOS:A1992GY62900062
J	GIBSON, AL; WAGNER, LM; COLLINS, FS; OXENDER, DL				GIBSON, AL; WAGNER, LM; COLLINS, FS; OXENDER, DL			A BACTERIAL SYSTEM FOR INVESTIGATING TRANSPORT EFFECTS OF CYSTIC-FIBROSIS ASSOCIATED MUTATIONS	SCIENCE			English	Article							NUCLEOTIDE-BINDING FOLD; ESCHERICHIA-COLI; ADENYLATE KINASE; ATP HYDROLYSIS; MULTIDRUG RESISTANCE; GENE; IDENTIFICATION; PROTEINS; SEQUENCE; SITE	LIV-I, a high-affinity system that transports neutral, branched-chain amino acids into Escherichia coli, has two components, LivG and LivF, that are homologous to the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). CF-associated mutations of human CFTR were introduced into corresponding regions of LivG, and their effects on leucine transport could be grouped into three classes. Mutations were found that (i) abolished LIV-I-directed transport, (ii) retained about a quarter of wild-type activity at the Michaelis-Menten constant (K(M)), and (iii) had minimal activity at the K(M). A mutation equivalent to a benign polymorphism had no effect on transport. The correlation of these mutational phenotypes in LivG and CFTR suggests that the LIV-I prokaryotic transporter is functionally similar to the CF protein and that this similarity can be exploited to clarify the properties of the nucleotide-binding fold in this superfamily of proteins.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS RES DIV,DEPT BIOTECHNOL,ANN ARBOR,MI 48106; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								ADAMS MD, 1990, J BIOL CHEM, V265, P11436; AMES GF, 1988, J BIOENERG BIOMEMBR, V20, P1, DOI 10.1007/BF00762135; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CUPPENS H, 1990, PEDIATR PULM S, V5, P203; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DAVIES K, 1990, NATURE, V348, P110, DOI 10.1038/348110a0; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOOSSENS M, COMMUNICATION; GROSSMAN AD, 1991, CELL, V65, P5, DOI 10.1016/0092-8674(91)90353-Z; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KOBAYASHI K, 1990, AM J HUM GENET, V47, P611; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NAZOS PM, 1985, J BACTERIOL, V163, P1196, DOI 10.1128/JB.163.3.1196-1202.1985; OSBORNE L, 1991, AM J HUM GENET, V48, P608; PARSONAGE D, 1988, FEBS LETT, V232, P111, DOI 10.1016/0014-5793(88)80397-1; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAHMANIAN M, 1973, J BACTERIOL, V116, P1258, DOI 10.1128/JB.116.3.1258-1266.1973; RAO NN, 1990, MOL MICROBIOL, V4, P1083, DOI 10.1111/j.1365-2958.1990.tb00682.x; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS L, 1990, SCIENCE, V247, P1296, DOI 10.1126/science.2315698; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRONG TV, UNPUB; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	53	18	18	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					109	111		10.1126/science.1718037	http://dx.doi.org/10.1126/science.1718037			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718037				2022-12-28	WOS:A1991GH60500040
J	WOLFSON, D; LEE, S				WOLFSON, D; LEE, S			COCCIDIOIDOMYCOSIS DIAGNOSED FROM BONE-MARROW SMEAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CEDARS SINAI MED CTR, DEPT PATHOL & LAB MED, 8700 BEVERLY BLVD, ROOM 4533, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center								DRUTZ DJ, 1983, J INFECT DIS, V147, P372, DOI 10.1093/infdis/147.3.372; Knoper S R, 1988, Infect Dis Clin North Am, V2, P861; RIPPON JW, 1988, MED MYCOLOGY PATHOGE, P433; STEVENS DA, 1980, COCCIDIOIDOMYCOSIS T	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1991	266	5					707	707		10.1001/jama.266.5.707	http://dx.doi.org/10.1001/jama.266.5.707			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ140	1712866				2022-12-28	WOS:A1991FZ14000033
J	NOEBELS, JL; MARCOM, PK; JALILIANTEHRANI, MH				NOEBELS, JL; MARCOM, PK; JALILIANTEHRANI, MH			SODIUM-CHANNEL DENSITY IN HYPOMYELINATED BRAIN INCREASED BY MYELIN BASIC-PROTEIN GENE DELETION	NATURE			English	Article							ACTION-POTENTIAL CONDUCTION; DYSMYELINATING MUTANT MICE; CENTRAL NERVOUS-SYSTEM; SHIVERER MOUSE; OPTIC-NERVE; RAT; EXPRESSION; DIFFERENTIATION; GLYCOPROTEIN; DEFICIENT	TROPHIC control over the expression and membrane distribution of voltage-dependent ion channels is one of the principal organizing events underlying the maturation of excitable cells. The myelin sheath is a major structural determinant of regional ion channel topography in central axons 1,2, but the exact molecular signals that mediate local interactions between the oligodendrocyte and axolemma are not known. We have found that large caliber fibre pathways in the brain of the mutant mouse shiverer (shi, gene on chromosome 18), whose developmental fate of myelination is averted by deletion of five exons in the myelin basic protein gene 3-5, have a striking excess of sodium channels. As cytoplasmic membranes of shiverer oligodendroglia still adhere to axons 6-8, the evidence indicates that myelin basic protein or a myelin basic protein-dependent glial transmembrane signal associated with compact myelin formation, rather than a simple glial-axon contact inhibition or an intrinsic genetic program of neuronal differentiation, could be critical in downregulating sodium channel density in axons. Here we use the shiverer mutant to show that mature central nervous system projection neurons with large caliber unmyelinated fibres sustain functional excitability by increasing sodium channel density. This axon plasticity, triggered by the absence of a single glial protein, contributes to the unexpectedly mild degree of neurological impairment in the mutant brain without myelin, and may be a potentially inducible mechanism determining the recovery of function from dysmyelinating disease.	BAYLOR UNIV,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor University	NOEBELS, JL (corresponding author), BAYLOR UNIV,INST MOLEC GENET,DEPT NEUROL,DIV NEUROSCI,NEUROPHYSIOL SECT,DEV NEUROGENET LAB,HOUSTON,TX 77030, USA.		Marcom, Paul/M-4516-2019; Marcom, Paul/AAE-4761-2020	Marcom, Paul/0000-0001-5302-6368; Noebels, Jeffrey/0000-0002-2887-0839				BARRES BA, 1989, NEURON, V2, P1375, DOI 10.1016/0896-6273(89)90076-7; BIRD TD, 1978, J NEUROCHEM, V31, P387, DOI 10.1111/j.1471-4159.1978.tb12479.x; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHIU SY, 1987, J PHYSIOL-LONDON, V391, P631, DOI 10.1113/jphysiol.1987.sp016760; FRAIL DE, 1985, J NEUROCHEM, V45, P1071, DOI 10.1111/j.1471-4159.1985.tb05525.x; HODGKIN A, 1975, PHILOS T ROY SOC B, V270, P297, DOI 10.1098/rstb.1975.0010; INOUE Y, 1981, BRAIN RES, V219, P85, DOI 10.1016/0006-8993(81)90269-9; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LIDOW MS, 1988, BRAIN RES, V459, P105, DOI 10.1016/0006-8993(88)90290-9; MOLINEAUX SM, 1986, P NATL ACAD SCI USA, V83, P7542, DOI 10.1073/pnas.83.19.7542; MOURRE C, 1988, BRAIN RES, V448, P128, DOI 10.1016/0006-8993(88)91109-2; OFFARD J, 1989, NEURON, V2, P1447; PRIVAT AC, 1979, NEUROSCI LETT, V142, P107; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROSENBLUTH J, 1980, J COMP NEUROL, V194, P639, DOI 10.1002/cne.901940310; ROSENBLUTH J, 1988, INT J DEV NEUROSCI, V6, P3, DOI 10.1016/0736-5748(88)90025-1; ROSENBLUTH J, 1981, BRAIN RES, V208, P283, DOI 10.1016/0006-8993(81)90558-8; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P1060; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; SHEEDLO HJ, 1987, BRAIN RES, V415, P105, DOI 10.1016/0006-8993(87)90273-3; SMITH KJ, 1980, NATURE, V286, P154, DOI 10.1038/286154a0; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; SORG BA, 1987, J NEUROCHEM, V49, P1146, DOI 10.1111/j.1471-4159.1987.tb10005.x; STUMER W, 1987, EUR BIOPHYS J, V14, P131; WAXMAN SG, 1990, J NEUROCYTOL, V19, P11, DOI 10.1007/BF01188436; WAXMAN SG, 1989, P NATL ACAD SCI USA, V86, P1406, DOI 10.1073/pnas.86.4.1406; Waxman SG, 1987, PROG BRAIN RES <D>, V71, P121; WISNIEWSKI HM, 1976, J NEUROPATH EXP NEUR, V35, P327, DOI 10.1097/00005072-197605000-00063	30	55	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					431	434		10.1038/352431a0	http://dx.doi.org/10.1038/352431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1713650				2022-12-28	WOS:A1991FZ34600065
J	SOLDATI, T; PERRIARD, JC				SOLDATI, T; PERRIARD, JC			INTRACOMPARTMENTAL SORTING OF ESSENTIAL MYOSIN LIGHT-CHAINS - MOLECULAR DISSECTION AND INVIVO MONITORING BY EPITOPE TAGGING	CELL			English	Article							SMOOTH MUSCLE ACTIN; FUNCTIONAL DOMAINS; CELL-SURFACE; LIVING CELLS; ER PROTEINS; FIBROBLASTS; EXPRESSION; ANTIBODIES; TRANSPORT; DIFFERENTIATION	The isoprotein-specific intracompartmental sorting of the three essential myosin light chains (LCs), the skeletal muscle LC-1f and LC-3f and the nonmuscle LC-3nm, was investigated. Epitope tagging was used to monitor the intracellular localization to different cytoskeletal structures of the exogenously introduced constructs in adult rat cardiomyocytes (ARCs), which exhibit both stress fibers and regenerating myofibrils. LC-1f and LC-3f bind almost exclusively to the sarcomeric myosin heavy chain (MHC) with high affinity, while the LC-3nm interacts with stress fibers and sarcomeres equally well. Sorting appears to be directed by a hierarchical order of different affinities. Domain mapping by deletion and by construction of a LC-1f/3nm chimera suggests that the LCs are composed of three functionally distinct domains: a basal MHC binding site in the C-terminus; the central part, modulating the preferential interaction with MHC isoforms; and the isoprotein-specific N-terminus of the essential LC, which is probably not involved in the sorting process.	SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			SOLDATI, Thierry/U-6494-2019; SOLDATI, Thierry/A-2902-2009	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; EPPENBERGER ME, 1988, DEV BIOL, V130, P1, DOI 10.1016/0012-1606(88)90408-3; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GAUTHIER GF, 1990, J CELL BIOL, V110, P693, DOI 10.1083/jcb.110.3.693; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KREIS TE, 1980, CELL, V22, P555, DOI 10.1016/0092-8674(80)90365-7; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAMSON G, 1989, DEV BIOL, V132, P62, DOI 10.1016/0012-1606(89)90204-2; LENNETTE DA, 1978, AM J CLIN PATHOL, V69, P647; MCKENNA N, 1985, J CELL BIOL, V100, P292, DOI 10.1083/jcb.100.1.292; MITTAL B, 1987, J CELL BIOL, V105, P1753, DOI 10.1083/jcb.105.4.1753; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NGAI J, 1990, CELL, V60, P415, DOI 10.1016/0092-8674(90)90593-4; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; SANGER JM, 1986, J CELL BIOL, V102, P2053, DOI 10.1083/jcb.102.6.2053; SANGER JW, 1984, J CELL BIOL, V98, P825, DOI 10.1083/jcb.98.3.825; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; YEE JK, 1987, GENE, V53, P97, DOI 10.1016/0378-1119(87)90096-5	37	80	81	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					277	289		10.1016/0092-8674(91)90618-9	http://dx.doi.org/10.1016/0092-8674(91)90618-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713129	Green Published			2022-12-28	WOS:A1991FY71200009
J	BROOKS, SA; LEATHEM, AJC				BROOKS, SA; LEATHEM, AJC			PREDICTION OF LYMPH-NODE INVOLVEMENT IN BREAST-CANCER BY DETECTION OF ALTERED GLYCOSYLATION IN THE PRIMARY TUMOR	LANCET			English	Article							LECTIN-BINDING; HELIX-POMATIA; CARBOHYDRATE EXPRESSION; WHEAT-GERM; CARCINOMA; TN; ANTIGEN; AGGLUTININ; SURVIVAL; MUTANTS	Axillary lymph node metastases at the time of diagnosis of breast cancer is the most accurate predictor of long-term prognosis. However, in patients treated by conservative surgery lymph node status often remains unknown. We have investigated the relation between changes in glycosylation of primary breast cancer cells, as judged by lectin binding, and the presence of axillary lymph node metastases. In a 24-year retrospective study, paraffin-embedded sections of 373 primary breast cancers were stained for the binding of Helix pomatia lectin (HPA). There was a strong association between HPA binding and presence of lymph node metastases, but no association with tumour size, histological grade, S-phase fraction, or patient age at diagnosis. This relation was confirmed by multiple regression analysis (in both survival and relapse free survival models) in which the prognostic significance of HPA binding was lost once nodal status had been introduced into the models. Life tables calculated for lymph-node positive versus lymph-node negative and HPA staining versus non-staining patients were almost identical over 15 years of follow-up. We propose that HPA recognises a glycoprotein that is associated with metastasis (to axillary lymph nodes and elsewhere) and poor prognosis in breast cancer. HPA binding to paraffin sections of primary tumour could aid difficult treatment decisions by providing an additional assessment of staging and likely long-term patient prognosis.	UNIV COLL & MIDDLESEX SCH MED,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND	University of London; University College London	BROOKS, SA (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT HISTOPATHOL,RIDING HOUSE ST,LONDON W1P 7PN,ENGLAND.							ALAM SM, 1990, BRIT J CANCER, V62, P238, DOI 10.1038/bjc.1990.267; BAISCH H, 1975, RADIAT ENVIRON BIOPH, V12, P31, DOI 10.1007/BF02339807; BAKER DA, 1983, BIOCHEMISTRY-US, V22, P2741, DOI 10.1021/bi00280a023; BROOKS SA, 1990, THESIS U LONDON, P88; COOS JS, 1985, CANCER, V56, P797; DANSEY R, 1988, ONCOLOGY, V45, P300, DOI 10.1159/000226627; DENNIS JW, 1986, EUR J BIOCHEM, V161, P359, DOI 10.1111/j.1432-1033.1986.tb10455.x; FENLON S, 1987, J PATHOL, V152, P169, DOI 10.1002/path.1711520305; FENTIMAN IS, 1991, LANCET, V337, P221, DOI 10.1016/0140-6736(91)92172-X; FUKUTOMI T, 1989, JPN J CLIN ONCOL, V19, P127; HAMMARST.S, 1969, BIOCHEMISTRY-US, V8, P2696, DOI 10.1021/bi00835a002; ISHIKAWA M, 1988, CANCER RES, V48, P665; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEATHEM A, 1985, J PATHOL, V145, pA73; LEATHEM A, 1984, J PATHOL, V142, pA32; LEATHEM AJ, 1987, LANCET, V1, P1054; LOUIS CJ, 1983, CANCER, V52, P1244, DOI 10.1002/1097-0142(19831001)52:7<1244::AID-CNCR2820520719>3.0.CO;2-U; MASTERS JRW, 1987, BRIT J CANCER, V55, P455, DOI 10.1038/bjc.1987.89; NISHIYAMA T, 1987, JNCI-J NATL CANCER I, V78, P1113; Sampson Handley W, 1904, ARCH MIDDLESEX HOSP, V3, P27; SPRINGER GF, 1985, CANCER, V55, P561, DOI 10.1002/1097-0142(19850201)55:3<561::AID-CNCR2820550315>3.0.CO;2-1; SPRINGER GF, 1975, J NATL CANCER I, V54, P335; SPRINGER GF, 1989, MOL IMMUNOL, V26, P1, DOI 10.1016/0161-5890(89)90013-8; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450	24	120	122	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					71	74		10.1016/0140-6736(91)90071-V	http://dx.doi.org/10.1016/0140-6736(91)90071-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1712062				2022-12-28	WOS:A1991FW16100002
J	SQUINTO, SP; STITT, TN; ALDRICH, TH; DAVIS, S; BIANCO, SM; RADZIEJEWSKI, C; GLASS, DJ; MASIAKOWSKI, P; FURTH, ME; VALENZUELA, DM; DISTEFANO, PS; YANCOPOULOS, GD				SQUINTO, SP; STITT, TN; ALDRICH, TH; DAVIS, S; BIANCO, SM; RADZIEJEWSKI, C; GLASS, DJ; MASIAKOWSKI, P; FURTH, ME; VALENZUELA, DM; DISTEFANO, PS; YANCOPOULOS, GD			TRKB ENCODES A FUNCTIONAL RECEPTOR FOR BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3 BUT NOT NERVE GROWTH-FACTOR	CELL			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; GENE-TRANSFER; PROTO-ONCOGENE; FACTOR FAMILY; EXPRESSION; IDENTIFICATION; GANGLIA; DIFFERENTIATION	A variety of findings seem to functionally link brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), while distinguishing both of these factors from the third member of the neurotrophin family, nerve growth factor (NGF). Here we demonstrate that all three of these neuronal survival molecules bind similarly to the low affinity NGF receptor, but that BDNF and NT-3, unlike NGF, do not act via the high affinity NGF receptor. However, both BDNF and NT-3, but not NGF, bind to full-length and truncated forms of a receptor-like tyrosine kinase, trkB, for which no ligand had previously been identified. In addition to binding BDNF and NT-3, trkB can mediate functional responses to both of these neurotrophins when it is expressed in PC12 cells, although BDNF appears to be the more effective ligand. Thus trkB encodes an essential component of a functional receptor for BDNF and NT-3, but not for NGF. Further evidence predicts the existence of additional functional receptors for the neurotrophins.			SQUINTO, SP (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P63; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MAISONPIERRE PC, 1991, IN PRESS GENOMICS; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1991, IN PRESS P NATL ACAD; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMANN A, 1978, J SUPRAMOL STR CELL, V9, P351, DOI 10.1002/jss.400090306	48	772	801	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					885	893		10.1016/0092-8674(91)90395-F	http://dx.doi.org/10.1016/0092-8674(91)90395-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710174				2022-12-28	WOS:A1991FP51600018
J	SCHUMACHER, TNM; DEBRUIJN, MLH; VERNIE, LN; KAST, WM; MELIEF, CJM; NEEFJES, JJ; PLOEGH, HL				SCHUMACHER, TNM; DEBRUIJN, MLH; VERNIE, LN; KAST, WM; MELIEF, CJM; NEEFJES, JJ; PLOEGH, HL			PEPTIDE SELECTION BY MHC CLASS-I MOLECULES	NATURE			English	Article							TOXIC LYMPHOCYTES-T; H-2-DEFICIENT LYMPHOMA VARIANTS; ASSOCIATION; DETERMINANT; RECOGNIZE; PROTEINS; CELLS; HLA	SYNTHETIC peptides have been used to sensitize target cells and thereby screen for epitopes recognized by T cells 1-7. Most epitopes of cytotoxic T lymphocytes can be mimicked by synthetic peptides of 12-15 amino acids 8. Although in specific cases, truncations of peptides improves sensitization of target cells 8,9, no optimum length for binding to major histocompatibility complex (MHC) class I molecules has been defined. We have now analysed synthetic peptide captured by empty MHC class I molecules of the mutant cell line RMA-S. We found that class I molecules preferentially bound short peptides (nine amino acids) and selectively bound these peptides even when they were a minor component in a mixture of longer peptides. These results may help to explain the difference in size restriction of T-cell epitopes between experiments with synthetic peptides and those with naturally processed peptides 10-12.	NETHERLANDS CANC INST,DEPT IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	SCHUMACHER, TNM (corresponding author), NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Schumacher, Ton/Y-2432-2019; Neefjes, Jacques J.C./H-8780-2017	Schumacher, Ton/0000-0003-0517-8804; Neefjes, Jacques J.C./0000-0001-6763-2211; Kast, W Martin/0000-0003-2321-3159				BJORKMAN PJ, 1990, REV BIOCH, V59, P253; ELLIOTT T, 1990, NATURE, V348, P195, DOI 10.1038/348195a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOTCH F, 1988, J EXP MED, V186, P2057; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KAST WM, IN PRESS P NATN ACAD; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PHILLIPS DR, 1970, BIOCHEM BIOPH RES CO, V40, P284, DOI 10.1016/0006-291X(70)91007-7; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213	26	276	305	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					703	706		10.1038/350703a0	http://dx.doi.org/10.1038/350703a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1708852				2022-12-28	WOS:A1991FJ13000059
J	FUSTER, V; BADIMON, L; BADIMON, JJ; CHESEBRO, JH				FUSTER, V; BADIMON, L; BADIMON, JJ; CHESEBRO, JH			MECHANISMS OF DISEASE - THE PATHOGENESIS OF CORONARY-ARTERY DISEASE AND THE ACUTE CORONARY SYNDROMES .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR INHIBITOR; MIDDLE-AGED MEN; VASCULAR ENDOTHELIAL-CELLS; GENERAL-POPULATION SAMPLE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; PRIMARY-PREVENTION; RISK-FACTORS; FAMILIAL HYPERCHOLESTEROLEMIA		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MAYO CLIN & MAYO GRAD SCH MED, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Harvard University; Harvard Medical School; Mayo Clinic; Mayo Clinic	FUSTER, V (corresponding author), MASSACHUSETTS GEN HOSP, CARDIAC UNIT, 32 FRUIT ST, BOSTON, MA 02114 USA.		BADIMON, LINA/O-4711-2014; BADIMON, LINA/S-2950-2019; Fuster, Valentin/H-4319-2015	BADIMON, LINA/0000-0002-9162-2459; Fuster, Valentin/0000-0002-9043-9986				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; ARAKI H, 1990, CIRC RES, V67, P312, DOI 10.1161/01.RES.67.2.312; AZNAR J, 1988, BRIT HEART J, V59, P535; BADIMON JJ, 1991, ARTERIOSCLER THROMB, V11, P395, DOI 10.1161/01.ATV.11.2.395; BADIMON JJ, 1989, LAB INVEST, V60, P455; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BADIMON L, 1989, J CLIN INVEST, V84, P1134, DOI 10.1172/JCI114277; BADIMON L, 1990, Journal of the American College of Cardiology, V15, p181A; BADIMON L, 1988, CIRCULATION, V78, P1431, DOI 10.1161/01.CIR.78.6.1431; BADIMON L, 1991, THROMB HAEMOST S, V65, P321; BLANKENHORN DH, 1990, JAMA-J AM MED ASSOC, V263, P1646, DOI 10.1001/jama.263.12.1646; BLANKENHORN DH, 1988, JAMA-J AM MED ASSOC, V259, P2698; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUHLER FR, 1988, AM HEART J, V115, P282, DOI 10.1016/0002-8703(88)90651-5; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CAPONE G, 1985, AM J CARDIOL, V56, P403, DOI 10.1016/0002-9149(85)90875-6; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; CULLEN JW, 1986, CHEST, V89, pS206, DOI 10.1378/chest.89.4.206S; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAVIES SW, 1990, J AM COLL CARDIOL, V16, P1079, DOI 10.1016/0735-1097(90)90535-W; EISENBERG PR, 1987, J AM COLL CARDIOL, V10, P527, DOI 10.1016/S0735-1097(87)80194-8; ELTAMIMI H, 1991, CIRCULATION, V84, P1198, DOI 10.1161/01.CIR.84.3.1198; FISCHELL TA, 1988, CIRCULATION, V78, P1323, DOI 10.1161/01.CIR.78.6.1323; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FRANCIS CW, 1983, J LAB CLIN MED, V102, P220; FRANK SL, 1988, HUM GENET, V79, P352; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURLONG B, 1987, BRIT J PHARMACOL, V90, P687, DOI 10.1111/j.1476-5381.1987.tb11221.x; FUSTER V, 1981, CIRCULATION, V63, P546, DOI 10.1161/01.CIR.63.3.546; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; GOLD HK, 1991, CIRCULATION, V83, P26; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GRIGNANI G, 1991, CIRCULATION, V83, P128; GULBA DC, 1991, CIRCULATION, V83, P937, DOI 10.1161/01.CIR.83.3.937; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAMSTEN A, 1987, LANCET, V2, P3; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HUNT BJ, 1990, CURR OPIN CARDIOL, V5, P758, DOI 10.1097/00001573-199012000-00007; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KARADI I, 1988, BIOCHIM BIOPHYS ACTA, V960, P91, DOI 10.1016/0005-2760(88)90013-6; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LASSILA R, 1990, ARTERIOSCLEROSIS, V10, P306, DOI 10.1161/01.ATV.10.2.306; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; MASERI A, 1978, NEW ENGL J MED, V299, P1271, DOI 10.1056/NEJM197812072992303; MCGILL DA, 1990, CORONARY ARTERY DIS, V1, P557, DOI 10.1097/00019501-199009000-00007; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCLENACHAN JM, 1991, CIRCULATION, V84, P1273, DOI 10.1161/01.CIR.84.3.1273; MCLENACHAN JM, 1990, CIRCULATION, V82, P1169, DOI 10.1161/01.CIR.82.4.1169; MEADE TW, 1980, LANCET, V1, P1050; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; OLOFSSON BO, 1989, EUR HEART J, V10, P77; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; OSBORNE JA, 1989, J CLIN INVEST, V83, P465, DOI 10.1172/JCI113905; OSEROFF A, 1989, J LAB CLIN MED, V113, P88; OWEN J, 1988, BLOOD, V72, P616; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PAUL O, 1989, CIRCULATION, V80, P206, DOI 10.1161/01.CIR.80.1.206; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCARABIN PY, 1990, THROMB RES, V57, P227, DOI 10.1016/0049-3848(90)90322-4; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SIMIONESCU N, 1990, ANN NY ACAD SCI, V598, P1, DOI 10.1111/j.1749-6632.1990.tb42271.x; SMITH P, 1992, THROMBOSIS CARDIOVAS, P343; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STEIN B, 1992, THROMBOSIS CARDIOVAS, P99; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TOYOOKA T, 1991, CIRCULATION, V83, P476, DOI 10.1161/01.CIR.83.2.476; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VERSTRAETE M, 1992, THROMBOSIS CARDIOVAS, P529; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILLERSON JT, 1991, P NATL ACAD SCI USA, V88, P10624, DOI 10.1073/pnas.88.23.10624; WILLERSON JT, 1986, J AM COLL CARDIOL, V8, P245, DOI 10.1016/S0735-1097(86)80121-8; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; 1991, LANCET, V337, P79	101	1479	1519	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					310	318						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728735				2022-12-28	WOS:A1992HA99100006
J	CASE, RB; MOSS, AJ; CASE, N; MCDERMOTT, M; EBERLY, S				CASE, RB; MOSS, AJ; CASE, N; MCDERMOTT, M; EBERLY, S			LIVING ALONE AFTER MYOCARDIAL-INFARCTION - IMPACT ON PROGNOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; SOCIAL RELATIONSHIPS; RISK-FACTORS; FOLLOW-UP; MORTALITY; SURVIVAL; RECOVERY; DEATH; HOSPITALIZATION; PREDICTION	Objective. - To determine if the presence of a disrupted marriage or living alone would be an independent prognostic risk factor for a subsequent major cardiac event following an initial myocardial infarction. Design. - Prospective evaluation in the placebo wing of a randomized, double-blind drug trial in patients with an enzyme-documented acute myocardial infarction who were admitted to a coronary care facility. Data for living alone and/or a marital disruption were entered into a Cox proportional hazards model constructed from important physiologic and nonphysiologic factors in the same database. Setting. - Multicenter trial in a mixture of community and academic hospitals in the United States and Canada. Patients. - All consenting patients who were 25 to 75 years of age and without other serious diseases were enrolled (placebo, N = 1234) within 3 to 15 days of the index infarction and followed for a period of 1 to 4 years (mean, 2.1 years). Nine hundred sixty-seven patients were followed for 1.1 years and 530 for 2.2 years. Primary Outcome Measure. - Recurrent major cardiac event (either recurrent nonfatal infarction or cardiac death). Results. - Living alone was an independent risk factor, with a hazard ratio of 1.54 (95% confidence interval, 1.04 to 2.29; P < .03). Using the Kaplan-Meier statistical method for calculation, the recurrent cardiac event rate at 6 months was 15.8% in the group living alone vs 8.8% in the group not living alone. Risk remained significant throughout the follow-up period (P = .001). A disrupted marriage was not an independent risk factor. Conclusion. - Living alone but not a disrupted marriage is an independent risk factor for prognosis after myocardial infarction when compared with all other known risk factors.	CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, DEPT PSYCHIAT, MANHASSET, NY 11030 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT PREVENT COMMUNITY MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DIV BIOSTAT, ROCHESTER, NY 14642 USA	Cornell University; Northwell Health; North Shore University Hospital; Columbia University; University of Rochester; University of Rochester; University of Rochester	CASE, RB (corresponding author), ST LUKES ROOSEVELT HOSP, DEPT MED, AMSTERDAM AVE & 114TH ST, NEW YORK, NY 10025 USA.							BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BRACKETT CD, 1988, AM J CARDIOL, V61, P979, DOI 10.1016/0002-9149(88)90110-5; Cohen S, 1985, SOCIAL SUPPORT HLTH; COX DR, 1972, J R STAT SOC B, V34, P187; HELSING KJ, 1981, AM J PUBLIC HEALTH, V71, P802, DOI 10.2105/AJPH.71.8.802; HERLITZ J, 1984, AM J CARDIOL, V53, pD9; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; LURIA MH, 1979, AM J MED, V67, P7, DOI 10.1016/0002-9343(79)90062-7; MADSEN EB, 1984, AM J CARDIOL, V53, P47, DOI 10.1016/0002-9149(84)90682-9; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NIITANI H, 1967, Japanese Circulation Journal, V31, P1575; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; NORRIS RM, 1974, BRIT HEART J, V36, P786; PARDAENS J, 1985, AM J EPIDEMIOL, V122, P805, DOI 10.1093/oxfordjournals.aje.a114164; PARKES CM, 1969, BMJ-BRIT MED J, V1, P740, DOI 10.1136/bmj.1.5646.740; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PEEL AAF, 1962, BRIT HEART J, V24, P745; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIERARD LA, 1989, CLIN CARDIOL, V12, P500; POHJOLA S, 1980, BRIT HEART J, V43, P176, DOI 10.1136/hrt.43.2.176; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SEEMAN TE, 1987, PSYCHOSOM MED, V49, P341, DOI 10.1097/00006842-198707000-00003; THOITS PA, 1982, J HEALTH SOC BEHAV, V23, P145, DOI 10.2307/2136511; TYROLER HA, 1987, CIRCULATION, V76, P139; WELIN L, 1985, LANCET, V1, P915; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; [No title captured]	32	349	351	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					515	519		10.1001/jama.267.4.515	http://dx.doi.org/10.1001/jama.267.4.515			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729573				2022-12-28	WOS:A1992GZ43900026
J	CONTI, VR; KRONENBERG, MW				CONTI, VR; KRONENBERG, MW			FOLLOW-UP AFTER CORONARY-ARTERY BYPASS-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CONTI, VR (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550, USA.							WEINER DA, 1991, J AM COLL CARDIOL, V18, P343, DOI 10.1016/0735-1097(91)90584-V	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					568	569						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729582				2022-12-28	WOS:A1992GZ43900038
J	NIGHTINGALE, ST				NIGHTINGALE, ST			3 ADDITIONAL DRUGS AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, ST (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2022-12-28	WOS:A1992GY43700004
J	VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA				VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA			CASE AND SURVIVAL DEFINITIONS IN OUT-OF-HOSPITAL CARDIAC-ARREST - EFFECT ON SURVIVAL RATE CALCULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESUSCITATION; DEATH	Objective. - To determine the effect of different case and survival definitions of out-of-hospital cardiac arrest on survival rate calculations. Design. - A 22-month case series of nontraumatic, out-of-hospital cardiac arrests. Setting. - Southwestern city (population, 400000; area, 390 km2) with a two-tiered emergency response system consisting of emergency medical technicians and paramedics. Patients. - A consecutive sample of 372 patients found without palpable pulse or spontaneous respiration. Main Outcome Measures. - Survival rate after cardiac arrest was calculated using three case definitions of arrest and two definitions of survival. Results. - Twenty percent of all patients survived to hospital admission and 6% survived to hospital discharge. Twenty-six percent of adults whose collapse was witnessed survived to hospital admission, and 10% survived to hospital discharge. Patients whose collapse was witnessed and who experienced initial ventricular fibrillation survived to hospital admission in 38% and to hospital discharge in 15% of cases. Conclusions. - The survival rate after out-of-hospital cardiac arrest varies widely depending on the case and survival definitions selected. To facilitate intersystem comparison and assessment of interventions designed to improve outcome, the Utstein Consensus Conference recommended that case and survival definitions should be adopted by all prehospital emergency systems.	ARIZONA EMERGENCY MED RES CTR,TUCSON,AZ; UNIV ARIZONA,COLL MED,CARDIOL SECT,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MATH,TUCSON,AZ 85721	University of Arizona; University of Arizona				Spaite, Daniel/0000-0003-2601-6476				COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; Colton T., 1974, STAT MED, P128; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DAWSONSAUNDERS E, 1990, BASIC CLIN BIOSTATIS, P148; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; HUNT RC, 1989, AM J EMERG MED, V7, P68, DOI 10.1016/0735-6757(89)90089-2; PANTRIDG.JF, 1967, LANCET, V2, P271; VALENZUELA TD, 1989, ANN EMERG MED, V18, P573, DOI 10.1016/S0196-0644(89)80847-9; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1	12	52	52	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					272	274		10.1001/jama.267.2.272	http://dx.doi.org/10.1001/jama.267.2.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727526				2022-12-28	WOS:A1992GY04600033
J	JOSEPH, AM; ONEIL, PJ				JOSEPH, AM; ONEIL, PJ			THE DEPARTMENT-OF-VETERANS-AFFAIRS SMOKE-FREE POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHIATRIC UNIT; NURSES; ATTITUDES; BEHAVIOR; HEALTH; PREVALENCE; DEPENDENCE; HOSPITALS; BAN		CORP HLTH POLICIES GRP INC,WASHINGTON,DC; DEPT VET AFFAIRS,VET HLTH SERV & RES ADM SMOKE FREE INIAT,WASHINGTON,DC		JOSEPH, AM (corresponding author), UNIV MINNESOTA,DEPT MED,VET AFFAIRS MED CTR,GEN INTERNAL MED SECT 1110,1 VET DR,MINNEAPOLIS,MN 55417, USA.			Joseph, Anne/0000-0002-3440-2679				ALLEN A, 1989, VA PRACT, V6, P15; BECKER DM, 1986, AM J PUBLIC HEALTH, V76, P1449, DOI 10.2105/AJPH.76.12.1449; BECKER DM, 1989, JAMA-J AM MED ASSOC, V262, P79; BIENER L, 1989, AM J PUBLIC HEALTH, V79, P192, DOI 10.2105/AJPH.79.2.192; DALTON J, 1983, AM J NURS, V83, P1149, DOI 10.2307/3463438; DAWLEY HH, 1989, INT J ADDICT, V24, P941, DOI 10.3109/10826088909047321; GARFINKEL L, 1986, CA-CANCER J CLIN, V36, P2, DOI 10.3322/canjclin.36.1.2; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAGEY A, 1989, NEW YORK STATE J MED, V89, P42; HOLLAND RP, 1988, JCAHO2165 AM LUNG AS; HOLLINGSWORTH JW, 1990, NEW ENGL J MED, V322, P1851, DOI 10.1056/NEJM199006283222605; HUDZINSKI LG, 1990, CHEST, V97, P1198, DOI 10.1378/chest.97.5.1198; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; HURT RD, 1989, JAMA-J AM MED ASSOC, V261, P95, DOI 10.1001/jama.261.1.95; JOSEPH A, 1988, JAMA-J AM MED ASSOC, V260, P1551, DOI 10.1001/jama.1988.03410110059012; JOSEPH AM, 1990, JAMA-J AM MED ASSOC, V263, P3043; KNAPP JM, 1991, ARCH INTERN MED, V151, P32, DOI 10.1001/archinte.151.1.32; KOTTKE TE, 1985, MINN MED, V68, P53; KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898; MYERS AH, 1987, AM J PUBLIC HEALTH, V77, P628, DOI 10.2105/AJPH.77.5.628; RESNICK MP, 1989, HOSP COMMUNITY PSYCH, V40, P525; RIGOTTI NA, 1986, CLIN RES, V34, pA833; ROSENSTOCK IM, 1986, AM J PUBLIC HEALTH, V76, P1014, DOI 10.2105/AJPH.76.8.1014; RYAN JJ, 1989, VA PRACT, V6, P21; SCHENKENBERG T, 1989, VA PRACT, V6, P15; SCHENKENBERG T, 1988, VA PRACT, V5, P39; SIROTA AD, 1987, VA PRACTITIONER, V4, P11; SMITH WR, 1989, HOSP COMMUNITY PSYCH, V40, P497; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; THORWARD SR, 1989, GEN HOSP PSYCHIAT, V11, P63, DOI 10.1016/0163-8343(89)90028-5; WELTY TK, 1987, JAMA-J AM MED ASSOC, V258, P185; 1989, 1989 US DEP VET AFF; 1990, 1090142 US DEP VET A; 1988, SMOKING CESSATION RE; 1990, 1090141 US DEP VET A; 1986, HLTH CONSEQUENCES IN; 1986, ENV TOBACCO SMOKE; 1989, 108963 US DEP VET AF	38	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					87	90						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GW848	1727202				2022-12-28	WOS:A1992GW84800029
J	PHILLIPS, RE; ROWLANDJONES, S; NIXON, DF; GOTCH, FM; EDWARDS, JP; OGUNLESI, AO; ELVIN, JG; ROTHBARD, JA; BANGHAM, CRM; RIZZA, CR; MCMICHAEL, AJ				PHILLIPS, RE; ROWLANDJONES, S; NIXON, DF; GOTCH, FM; EDWARDS, JP; OGUNLESI, AO; ELVIN, JG; ROTHBARD, JA; BANGHAM, CRM; RIZZA, CR; MCMICHAEL, AJ			HUMAN-IMMUNODEFICIENCY-VIRUS GENETIC-VARIATION THAT CAN ESCAPE CYTOTOXIC T-CELL RECOGNITION	NATURE			English	Article							TOXIC LYMPHOCYTES-T; PERIPHERAL-BLOOD; INFECTED INDIVIDUALS; SEROPOSITIVE INDIVIDUALS; REVERSE-TRANSCRIPTASE; SYNTHETIC PEPTIDES; HOMOSEXUAL MEN; HIV-1; REPLICATION; SELECTION	In a longitudinal study of HIV seropositive patients, there were fluctuations in the specificity of cytotoxic T cells for the virus. This was matched by variability in proviral gag DNA epitope sequences in the lymphocytes of these patients. Some of these viral variants are not recognized by autologous T cells. Accumulation of such mutations in T-cell antigenic targets would provide a mechanism for immune escape.	IMMULOGIC, PALO ALTO, CA 94304 USA; CHURCHILL HOSP, OXFORD HAEMOPHILIA CTR, OXFORD OX3 7LV, ENGLAND		PHILLIPS, RE (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.		Nixon, Douglas/AAU-5734-2020	Nixon, Douglas/0000-0002-2801-1786; Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BOLOGNESI DP, 1989, AIDS, V3, pS111, DOI 10.1097/00002030-198901001-00016; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BROLIDEN PA, 1989, CLIN EXP IMMUNOL, V76, P216; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOSMALIN A, 1990, P NATL ACAD SCI USA, V87, P2344, DOI 10.1073/pnas.87.6.2344; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JOLY P, 1989, J IMMUNOL, V143, P2193; KABAT E, 1979, NIH802008 DHEW PUBL; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOUP RA, 1989, BLOOD, V73, P1909; Maniatis T., 1982, MOL CLONING; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MEYERHANS A, 1991, EUR J IMMUNOL, V21, P2637, DOI 10.1002/eji.1830211051; MYERS G, 1990, HUMAN RETROVIRUSES A; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHEARER GM, 1984, J CLIN INVEST, V74, P496, DOI 10.1172/JCI111447; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STEEL CM, 1988, LANCET, V1, P1185; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7	43	960	973	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					453	459		10.1038/354453a0	http://dx.doi.org/10.1038/354453a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1721107	Bronze			2022-12-28	WOS:A1991GV07800051
J	SOMMER, L; HAGENBUCHLE, O; WELLAUER, PK; STRUBIN, M				SOMMER, L; HAGENBUCHLE, O; WELLAUER, PK; STRUBIN, M			NUCLEAR TARGETING OF THE TRANSCRIPTION FACTOR PTF1 IS MEDIATED BY A PROTEIN SUBUNIT THAT DOES NOT BIND TO THE PTF1 COGNATE SEQUENCE	CELL			English	Article							NF-KAPPA-B; DNA-BINDING; GLUCOCORTICOID RECEPTOR; XENOPUS OOCYTES; DORSAL PROTEIN; ACTIVATION; GENES; TRANSACTIVATOR; LOCALIZATION; POLYMERASE	The pancreas-specific transcription factor PTF1 is a heterooligomer that exists as two variants, alpha and beta, both of which bind DNA. The nucleus contains exclusively alpha while the cytoplasm contains both forms. alpha and beta differ in protein composition. Reconstitution of alpha in vitro requires, in addition to the DNA-binding subunits common to both forms, a 75 kd glycosylated protein that apparently does not bind DNA. Here we show that this protein is essential for targeting PTF1 to the nucleus. Upon injection into frog oocytes, alpha is translocated quantitatively to the nucleus while beta remains in the Cytoplasm. However, if beta is coinjected with purified 75 kd protein or a particular size fraction of pancreatic MRNA, it can be converted to alpha and imported into the nucleus.			SOMMER, L (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PETRUCCO S, 1990, MOL CELL BIOL, V10, P254, DOI 10.1128/MCB.10.1.254; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH PJ, 1988, ANAL BIOCHEM, V169, P390, DOI 10.1016/0003-2697(88)90301-6; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	35	51	52	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					987	994		10.1016/0092-8674(91)90371-5	http://dx.doi.org/10.1016/0092-8674(91)90371-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720355				2022-12-28	WOS:A1991GT75500017
J	STCLAIR, MH; MARTIN, JL; TUDORWILLIAMS, G; BACH, MC; VAVRO, CL; KING, DM; KELLAM, P; KEMP, SD; LARDER, BA				STCLAIR, MH; MARTIN, JL; TUDORWILLIAMS, G; BACH, MC; VAVRO, CL; KING, DM; KELLAM, P; KEMP, SD; LARDER, BA			RESISTANCE TO DDI AND SENSITIVITY TO AZT INDUCED BY A MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE AZT; THERAPY; DNA; SUSCEPTIBILITIES; MUTAGENESIS; TYPE-1; AGENTS; AIDS	Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis of the reverse transcriptase coding region revealed a mutation associated with reduced sensitivity to ddI. When this mutation was present in the same genome as a mutation known to confer AZT resistance, the isolates showed increased sensitivity to AZT. Analysis of HIV-1 variants confirmed that the ddI resistance mutation alone conferred ddI and 2',3'-dideoxycytidine resistance, and suppressed the effect of the AZT resistance mutation. The use of combination therapy for HIV-1 disease may prevent drug-resistant isolates from emerging.	DUKE UNIV,MED CTR,DURHAM,NC 27710; MAINE MED CTR,PORTLAND,ME 04102; WELLCOME RES LABS,DIV MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND	Duke University; Maine Medical Center; GlaxoSmithKline; Wellcome Research Laboratories	STCLAIR, MH (corresponding author), BURROUGHS WELLCOME CO,DIV VIROL,RES TRIANGLE PK,NC 27709, USA.		Larder, Brendan/AAB-3106-2020	Kellam, Paul/0000-0003-3166-4734				BACH MC, 1990, NEW ENGL J MED, V323, P275; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CANN AJ, 1988, ONCOGENE, V3, P123; DORNSIFE RE, 1991, ANTIMICROB AGENTS CH, V35, P322, DOI 10.1128/AAC.35.2.322; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; KELLAM P, UNPUB; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROCOANCOURT D, 1990, J VIROL, V64, P2660; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	25	718	737	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1991	253	5027					1557	1559		10.1126/science.1716788	http://dx.doi.org/10.1126/science.1716788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1716788				2022-12-28	WOS:A1991GG65100046
J	LOCATELLI, A; MAURELLI, M; BIANCHI, T; CHIAUDANI, G; CERIANA, P; BERTOLLO, D; MAZZA, MP; PAGNIN, A				LOCATELLI, A; MAURELLI, M; BIANCHI, T; CHIAUDANI, G; CERIANA, P; BERTOLLO, D; MAZZA, MP; PAGNIN, A			APROTININ IN CARDIAC-SURGERY	LANCET			English	Letter											LOCATELLI, A (corresponding author), POLICLIN SAN MATTEO,IST RICOVERO & CURO CARATTERE SCI,ANAESTHESIA & RESUSCITAT SERV 1,I-27100 PAVIA,ITALY.		ceriana, Piero/AAB-9668-2020	ceriana, Piero/0000-0002-4186-4257				CARREL, 1991, LANCET, V337, P673	1	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					254	254		10.1016/0140-6736(91)90394-5	http://dx.doi.org/10.1016/0140-6736(91)90394-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1712418				2022-12-28	WOS:A1991FY50400039
J	VEEN, S; ENSDOKKUM, MH; SCHREUDER, AM; VERLOOVEVANHORICK, SP; BRAND, R; RUYS, JH				VEEN, S; ENSDOKKUM, MH; SCHREUDER, AM; VERLOOVEVANHORICK, SP; BRAND, R; RUYS, JH			IMPAIRMENTS, DISABILITIES, AND HANDICAPS OF VERY PRETERM AND VERY-LOW-BIRTH-WEIGHT INFANTS AT 5 YEARS OF AGE	LANCET			English	Article							BIRTH-WEIGHT INFANTS; NEONATAL INTENSIVE-CARE; PERIVENTRICULAR-INTRAVENTRICULAR HEMORRHAGE; NATIONAL COLLABORATIVE SURVEY; FOLLOW-UP; GESTATIONAL-AGE; NETHERLANDS; MORTALITY; MORBIDITY; RESIDENTS	The Project On Preterm and Small for gestational age infants (POPS) was started in the Netherlands in 1983 to investigate the relation between prenatal/perinatal factors and mortality/morbidity in very preterm and very-low-birthweight infants. Of the 1338 liveborn infants (< 32 weeks and/or < 1500 g) 966 were enrolled in the five-year (chronological age) follow-up programme; 96% of these children were assessed during a home visit. The overall outcome was expressed as impairments, disabilities, and handicaps according to World Health Organisation criteria. Of the assessed children, 13% had a disability and 14% were handicapped, which are much higher frequencies than those found in the general population. Handicaps were due mainly to abnormalities of neuromotor function, mental development, or language and speech development. Compared with the handicap frequency in the same cohort at two years of age, a more favourable outcome at five years of age was seen in 10%, and a less favourable outcome in 7% of the children. The findings show that most of those high-risk children survived without handicap or serious disability at preschool age.	UNIV HOSP LEIDEN, DEPT PAEDIAT, NEONATAL UNIT, POB 9600, 2300 RC LEIDEN, NETHERLANDS; TNO, INST PREVENT HLTH CARE, 2313 AD LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC								AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; BAUCHNER H, 1988, PEDIATR CLIN N AM, V35, P1207; BEGANOVIC N, 1988, ARCH DIS CHILD, V63, P66, DOI 10.1136/adc.63.1.66; DENOUDEN L, 1990, NEUROPEDIATRICS, V21, P66, DOI 10.1055/s-2008-1071463; EHRENHAFT PM, 1989, OBSTET GYNECOL, V74, P528; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HORWOOD SP, 1982, PEDIATRICS, V69, P613; HUNT JV, 1988, PEDIATRICS, V82, P596; JOHNSON M A, 1987, Canadian Medical Association Journal, V136, P1157; KITCHEN WH, 1987, J PEDIATR-US, V110, P283, DOI 10.1016/S0022-3476(87)80174-9; KITCHEN WH, 1982, SEMIN PERINATOL, V6, P373; KOLLEE LAA, 1988, OBSTET GYNECOL, V72, P729; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; PIEKKALA P, 1988, NEUROPEDIATRICS, V19, P33, DOI 10.1055/s-2008-1052398; POWELL TG, 1986, LANCET, V1, P539; ROSS G, 1985, PEDIATRICS, V76, P885; SAIGAL S, 1982, J PEDIATR-US, V100, P606, DOI 10.1016/S0022-3476(82)80767-1; TOUWEN BCL, 1986, EUR J PEDIATR, V145, P460, DOI 10.1007/BF02429042; van de Bor M, 1988, Paediatr Perinat Epidemiol, V2, P328; VANDEBOR M, 1987, J PERINAT MED, V15, P333, DOI 10.1515/jpme.1987.15.4.333; VANDEBOR M, 1988, NEUROPEDIATRICS, V19, P183, DOI 10.1055/s-2008-1052442; VANDEBOR M, 1989, PEDIATRICS, V83, P915; VANDERAA DMC, 1989, THESIS STATE U LEIDE, P185; VANDERAA DMV, 1991, EUR J OBSTET GYN R B, V39, P87, DOI 10.1016/0028-2243(91)90069-W; VANDERAA DMV, 1991, PAEDIATR PERINAT EP, V5, P11; VANDERAA DMZ, 1990, NEUROPEDIATRICS, V21, P62; VANDERAA TMZ, 1989, LANCET, V1, P253; VERLOOVEVANHORICK SP, 1988, PEDIATRICS, V81, P404; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VERLOOVEVANHORICK SP, 1989, EUR J PEDIATR, V149, P197, DOI 10.1007/BF01958281; Walther F J, 1989, Paediatr Perinat Epidemiol, V3, P53, DOI 10.1111/j.1365-3016.1989.tb00369.x; WIERENGA H, 1990, EARLY HUM DEV, V23, P15, DOI 10.1016/0378-3782(90)90125-3; 1990, LICHAMELIJKE BEPERKI, P67; 1990, MANAGEMENT GROUP OXF, P15; 1980, INT CLASSIFICATION I, P207	35	177	178	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					33	36		10.1016/0140-6736(91)90015-H	http://dx.doi.org/10.1016/0140-6736(91)90015-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1711644				2022-12-28	WOS:A1991FV29600014
J	FAUSTMAN, D; COE, C				FAUSTMAN, D; COE, C			PREVENTION OF XENOGRAFT REJECTION BY MASKING DONOR HLA CLASS-I ANTIGENS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ISLET ALLOGRAFT SURVIVAL; T-CELL RECEPTORS; AUTOIMMUNE ENCEPHALOMYELITIS; MONOCLONAL-ANTIBODY; RENAL-ALLOGRAFTS; ADHESION; INVIVO; MICE; PROLONGATION	Destruction of target cells by cytotoxic T lymphocytes requires the presence of HLA (human lymphocyte antigen) class I antigens on the target cells for adhesion as well as for triggering of the antigen-specific T cell receptor. Rejection of xenogeneic human pancreatic islets and liver was circumvented by masking, before transplantation, donor antigens with F(ab')2 antibody fragments to HLA class I or tissue-specific epitopes. This strategy eliminated the need for recipient immunosuppression and allowed islet xenograft survival beyond 200 days, as demonstrated functionally by C peptide secretion as well as by histology. These in vivo observations are consistent with the importance of donor HLA class I in eliciting graft rejection and have potential applicability to the successful transplantation of other HLA class I-bearing donor tissues.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital								ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOITARD C, 1988, P NATL ACAD SCI USA, V85, P9719, DOI 10.1073/pnas.85.24.9719; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CAMPBELL IL, 1989, P NATL ACAD SCI USA, V86, P4282, DOI 10.1073/pnas.86.11.4282; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; FABRE JW, 1975, TRANSPLANTATION, V20, P269; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FAUSTMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P3864, DOI 10.1073/pnas.81.12.3864; FRENCH ME, 1972, TRANSPLANT REV-DENMA, V13, P115; GOODFELLOW PN, 1976, TRANSPLANTATION, V22, P595, DOI 10.1097/00007890-197612000-00009; KRENSKY AM, 1983, J IMMUNOL, V131, P611; LACY PE, 1979, SCIENCE, V204, P312, DOI 10.1126/science.107588; LAFFERTY KJ, 1975, SCIENCE, V188, P259, DOI 10.1126/science.1118726; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MARON R, 1983, J IMMUNOL, V131, P2316; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; VIVES M, 1990, IMMUNOLOGY DIABETES, P5; Wang Y, 1987, DIABETES, V36, P535, DOI 10.2337/diabetes.36.4.535; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	26	107	146	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1700	1702		10.1126/science.1710828	http://dx.doi.org/10.1126/science.1710828			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1710828				2022-12-28	WOS:A1991FT11400044
J	DAVIES, JF; HOSTOMSKA, Z; HOSTOMSKY, Z; JORDAN, SR; MATTHEWS, DA				DAVIES, JF; HOSTOMSKA, Z; HOSTOMSKY, Z; JORDAN, SR; MATTHEWS, DA			CRYSTAL-STRUCTURE OF THE RIBONUCLEASE-H DOMAIN OF HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							RNASE-H; ESCHERICHIA-COLI; DNA-REPLICATION; REFINEMENT; RETROVIRUS; RESOLUTION; PROTEINS; MUTANTS; BINDING	The crystal structure of the ribonuclease (RNase) H domain of HIV-1 reverse transcriptase (RT) has been determined at a resolution of 2.4 angstrom and refined to a crystallographic R factor of 0.20. The protein folds into a five-stranded mixed beta sheet flanked by an asymmetric distribution of four alpha helices. Two divalent metal cations bind in the active site surrounded by a cluster of four conserved acidic amino acid residues. The overall structure is similar in most respects to the RNase H from Escherichia coli. Structural features characteristic of the retroviral protein suggest how it may interface with the DNA polymerase domain of p66 in the mature RT heterodimer. These features also offer insights into why the isolated RNase H domain is catalytically inactive but when combined in vitro with the isolated p51 domain of RT RNase H activity can be reconstituted. Surprisingly, the peptide bond cleaved by HIV-1 protease near the polymerase-RNase H junction of p66 is completely inaccessible to solvent in the structure reported here. This suggests that the homodimeric p66-p66 precursor of mature RT is asymmetric with one of the two RNase H domains at least partially unfolded.	AGOURON PHARMACEUT INC,11025 N TORREY PINES RD,LA JOLLA,CA 92037	Pfizer					NIGMS NIH HHS [GM 39599] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039599] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; GILBOA E, 1979, CELL, V18, P91; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; GUPTA AP, 1984, BIOCHEMISTRY-US, V23, P5874, DOI 10.1021/bi00319a029; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; HENDRICKSON W, COMMUNICATION; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HORIUCHI T, 1984, MOL GEN GENET, V195, P17, DOI 10.1007/BF00332717; HOSTOMSKA Z, UNPUB; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TANASE N, 1988, P NATL ACAD SCI USA, V85, P1777; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TISDALE M, 1990, J CELL BIOCHEM     S, V14, P179; TORREY TA, 1984, MOL GEN GENET, V196, P350, DOI 10.1007/BF00328070; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	44	550	566	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					88	95		10.1126/science.1707186	http://dx.doi.org/10.1126/science.1707186			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1707186				2022-12-28	WOS:A1991FE95200038
J	CHOI, YW; KAPPLER, JW; MARRACK, P				CHOI, YW; KAPPLER, JW; MARRACK, P			A SUPERANTIGEN ENCODED IN THE OPEN READING FRAME OF THE 3' LONG TERMINAL REPEAT OF MOUSE MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECOGNITION; GENE-PRODUCTS; MLS-LOCUS; REGION; EXPRESSION; RECEPTOR; SEQUENCE; TOLERANCE; ANTIGENS	Mice express a collection of superantigens, which bind to class II major histocompatibility proteins and interact with T cells bearing particular V-beta chains as part of their alpha-beta-receptors. These superantigens have been suggested to be encoded by exogenous or endogenous mouse mammary tumour viruses. One such superantigen is now shown to be encoded in the open reading frame of the long terminal repeat of a mammary tumour virus, a gene of previously unknown function.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHOI, YW (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DEPT MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687				ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CARBONE AM, 1988, J IMMUNOL, V141, P1369; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CROUSE CA, 1989, VIRUS RES, V12, P123, DOI 10.1016/0168-1702(89)90059-2; DICKSON C, 1981, NATURE, V291, P511, DOI 10.1038/291511a0; DONEHOWER LA, 1983, J VIROL, V45, P941, DOI 10.1128/JVI.45.3.941-949.1983; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1977, IMMUNOGENETICS, V5, P357, DOI 10.1007/BF01570493; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KING LB, 1990, J IMMUNOL, V144, P3218; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; Maniatis T, 1989, DECONTAMINATION DILU; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARTINEZ C, 1964, NATURE, V203, P1199; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; RACEVSKIS J, 1984, J VIROL, V51, P604, DOI 10.1128/JVI.51.3.604-610.1984; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SQUARTINI F, 1970, CANCER RES, V30, P2069; TOMONARI K, IN PRESS IMMUNOGENET; TSUBURA A, 1988, CANCER RES, V48, P6555; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVEREN P, 1988, J VIROL, V62, P4410, DOI 10.1128/JVI.62.11.4410-4413.1988; WEISS R, 1985, RNA TUMOR VIRUSES, P582; WHITE J, 1989, J IMMUNOL, V143, P1822; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	52	414	419	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					203	207		10.1038/350203a0	http://dx.doi.org/10.1038/350203a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706480				2022-12-28	WOS:A1991FC77900046
J	ANDERSON, MP; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ				ANDERSON, MP; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ			GENERATION OF CAMP-ACTIVATED CHLORIDE CURRENTS BY EXPRESSION OF CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS HETEROZYGOTES; RECOMBINANT VACCINIA VIRUS; DEPENDENT PROTEIN-KINASE; ATP SYNTHASE; AIRWAY CELLS; CHANNELS; IDENTIFICATION; EPITHELIUM; TRANSPORT; SYSTEM	Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis. In order to evaluate its function, CFTR was expressed in HeLa, Chinese hamster ovary (CHO), and NIH 3T3 fibroblast cells, and anion permeability was assessed with a fluorescence microscopic assay and the whole-cell patch-clamp technique. Adenosine 3',5'-monophosphate (cAMP) increased anion permeability and chloride currents in cells expressing CFTR, but not in cells expressing a mutant CFTR (DELTA-F508) or in nontransfected cells. The simplest interpretation of these observations is that CFTR is itself a cAMP-activated chloride channel. The alternative interpretation, that CFTR directly or indirectly regulates chloride channels, requires that these cells have endogenous cryptic, chloride channels that are stimulated by cAMP only in the presence of CFTR.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation				Welsh, Michael/0000-0002-1646-6206; Anderson, Matthew/0000-0003-4602-1811				ANDERSON M P, 1990, Journal of Cell Biology, V111, p63A; ANDERSON MW, UNPUB; BEHM JK, 1987, PEDIATR RES, V22, P271, DOI 10.1203/00006450-198709000-00007; BOAT TF, 1989, METABOLIC BASIS INHE; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAO AC, 1990, J MEMBRANE BIOL, V113, P193, DOI 10.1007/BF01870071; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CRYSTAL RA, 1990, PEDIATR PULM S, V5, P59; CULLEN JJ, 1987, J CLIN INVEST, V79, P73, DOI 10.1172/JCI112811; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ERLICH HA, 1989, PRC TECHNOLOGY PRINC; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANRAHAN JW, 1989, BICARBONATE CHLORIDE; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JEFFERSON DM, 1990, AM J PHYSIOL, V249, pL496; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN PY, 1987, J BIOL CHEM, V262, P15345; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; MASTROCOLA T, 1990, LIFE SCI, V46, P1661, DOI 10.1016/0024-3205(90)90381-Z; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCCANN JL, UNPUB; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROMMENS JM, 1989, SCIENCE, V245, P1073; SATO K, 1988, J LAB CLIN MED, V111, P511; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; WAGNER R, 1989, EMBO J, V8, P2827, DOI 10.1002/j.1460-2075.1989.tb08429.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	43	536	546	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					679	682		10.1126/science.1704151	http://dx.doi.org/10.1126/science.1704151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	EW399	1704151				2022-12-28	WOS:A1991EW39900047
J	NISHIBE, S; WAHL, MI; HERNANDEZSOTOMAYOR, SMT; TONKS, NK; RHEE, SG; CARPENTER, G				NISHIBE, S; WAHL, MI; HERNANDEZSOTOMAYOR, SMT; TONKS, NK; RHEE, SG; CARPENTER, G			INCREASE OF THE CATALYTIC ACTIVITY OF PHOSPHOLIPASE C-GAMMA-1 BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article									VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL CANCER INSTITUTE [P01CA043720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720] Funding Source: Medline; NIGMS NIH HHS [GMO7347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; HERNANDEZSOTOMA.SM, UNPUB; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, UNPUB; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RYU SH, 1987, J BIOL CHEM, V262, P12511; SUH PG, 1988, J BIOL CHEM, V263, P14497; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, CANCER CELL-MON REV, V1, P101; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0	25	663	679	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 30	1990	250	4985					1253	1256		10.1126/science.1700866	http://dx.doi.org/10.1126/science.1700866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK723	1700866				2022-12-28	WOS:A1990EK72300036
J	PORITZ, MA; BERNSTEIN, HD; STRUB, K; ZOPF, D; WILHELM, H; WALTER, P				PORITZ, MA; BERNSTEIN, HD; STRUB, K; ZOPF, D; WILHELM, H; WALTER, P			AN ESCHERICHIA-COLI RIBONUCLEOPROTEIN CONTAINING 4.5S RNA RESEMBLES MAMMALIAN SIGNAL RECOGNITION PARTICLE	SCIENCE			English	Article											PORITZ, MA (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Poritz, Mark/AAH-4426-2021	Poritz, Mark/0000-0002-5060-0560				ALTMAN E, COMMUNICATION; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HN, UNPUB; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOURGAIZE DB, 1990, J BACTERIOL, V172, P1151, DOI 10.1128/jb.172.2.1151-1154.1990; BOURGAIZE DB, 1987, NATURE, V325, P281, DOI 10.1038/325281a0; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; BRYSTROM AS, 1983, EMBO J, V2, P899; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COGGESHALL RE, 1979, ANAT REC, V194, P201, DOI 10.1002/ar.1091940203; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GILL DR, 1990, MOL MICROBIOL, V4, P575; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOODMAN HM, 1970, EUR J BIOCHEM, V13, P461, DOI 10.1111/j.1432-1033.1970.tb00950.x; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; ITO K, 1986, J BACTERIOL, V167, P201, DOI 10.1128/jb.167.1.201-204.1986; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MAJESKI AJ, 1988, FASEB J, V2, pA1348; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MEYER DI, 1988, TRENDS BIOCHEM SCI, V13, P471, DOI 10.1016/0968-0004(88)90233-2; MILLER JA, UNPUB; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PHILIPS G, COMMUNICATION; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, UNPUB; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, IN PRESS CELL; RIGGS PD, 1988, GENETICS, V118, P571; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHLOSS P, 1988, EMBO J, V7, P2889, DOI 10.1002/j.1460-2075.1988.tb03146.x; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON F, 1988, VECTORS SURVEY MOL C; STRAUCH KL, 1986, J BACTERIOL, V166, P505, DOI 10.1128/jb.166.2.505-512.1986; STRUB K, UNPUB; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TOBE T, 1984, MOL GEN GENET, V195, P10, DOI 10.1007/BF00332716; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WALTER P, UNPUB; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; ZOPF D, IN PRESS EMBO J	66	253	257	2	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	1990	250	4984					1111	1117		10.1126/science.1701272	http://dx.doi.org/10.1126/science.1701272			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701272				2022-12-28	WOS:A1990EJ58100029
J	MATSUI, Y; ZSEBO, KM; HOGAN, BLM				MATSUI, Y; ZSEBO, KM; HOGAN, BLM			EMBRYONIC EXPRESSION OF A HEMATOPOIETIC GROWTH-FACTOR ENCODED BY THE SI LOCUS AND THE LIGAND FOR C-KIT	NATURE			English	Article									VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Vanderbilt University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREEN MC, 1989, GENETICS VARIANTS ST, P333; JESSELL TM, 1989, CIBA F SYMP, V144, P255; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PELTON RW, 1989, DEVELOPMENT, V106, P759; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; Silvers W.K., 1979, COAT COLORS MICE, P206; SZEBO KM, 1990, CELL, V63, P195; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	19	491	497	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 18	1990	347	6294					667	669		10.1038/347667a0	http://dx.doi.org/10.1038/347667a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED620	1699134				2022-12-28	WOS:A1990ED62000053
J	GULATI, SC; BENNETT, CL				GULATI, SC; BENNETT, CL			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS ADJUNCT THERAPY IN RELAPSED HODGKIN DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HODGKINS DISEASE; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; NEUTROPENIA	BONE-MARROW TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; ACQUIRED IMMUNODEFICIENCY SYNDROME; MULTIVARIATE PREDICTION MODEL; HEMATOPOIETIC RECONSTITUTION; HOSPITAL CHARGES; RAPID ESTIMATION; CYCLOPHOSPHAMIDE; MALIGNANCIES; MORTALITY	Objective: To determine the clinical and economic effects of granulocyte macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed or refractory Hodgkin disease. Design: A randomized, double-blind, phase III clinical trial. Setting: A tertiary referral center. Patients: Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation. Main Results: The 12 patients treated with GM-CSF, when compared with placebo recipients, had shorter periods of neutropenia (median duration of an absolute neutrophil count of less than 1000 cells/mm3, 16 days compared with 27 days; P = 0.02), shorter periods of platelet-transfusion dependency (median duration, 13.5 days compared with 21 days; P = 0.03), and shorter hospitalizations (median hospital stay, 32 days compared with 40.5 days; P = 0.004). Other clinical outcomes, such as frequency and severity of toxicities, development of pneumonia or infection, in-hospital death, and response rate were similar in the two groups. Actuarial long-term disease-free survival was 64% for patients treated with GM-CSF and 58% for patients who received placebo after 32 months of follow-up (P = 0.1 5). The group treated with GM-CSF had lower total charges after infusion of autologous marrow than the placebo group (median in-hospital charges, $39800 compared with $62500; P = 0.005) because of lower post-infusion charges for room and board, antibiotic therapy, transfusions, laboratory tests, and physical therapy visits. Conclusions: Administration of GM-CSF was associated with acceleration of myeloid and platelet recovery and was cost effective in the treatment of patients with relapsed Hodgkin disease who received intensive chemotherapy.	VET AFFAIRS HOSP, DURHAM, NC USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA; RAND CORP, SANTA MONICA, CA 90406 USA	Memorial Sloan Kettering Cancer Center; Duke University; RAND Corporation			Bennett, Charles L/C-2050-2008					ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ARMITAGE JO, 1989, AM J MED, V86, P203, DOI 10.1016/0002-9343(89)90270-2; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; CHESON BD, 1989, ANN INTERN MED, V110, P51, DOI 10.7326/0003-4819-110-1-51; COLLINS C, 1989, CANCER, V63, P228, DOI 10.1002/1097-0142(19890115)63:2<228::AID-CNCR2820630204>3.0.CO;2-3; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DEMETRI GD, 1990, J CLIN ONCOL, V8, P761, DOI 10.1200/JCO.1990.8.5.761; DEVITA VT, 1990, MONOGR NCI, V10, P19; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GIANNI AM, 1989, HEMATOL ONCOL, V7, P139, DOI 10.1002/hon.2900070205; GIANNI AM, 1990, J CLIN ONCOL, V8, P768, DOI 10.1200/JCO.1990.8.5.768; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; GULATI SC, 1991, ANN ONCOL, V2, P51, DOI 10.1093/annonc/2.suppl_1.51; GULATI SC, 1991, CURR PROB CANCER, V15, P5; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; JACOBS J, 1987, DRUG INTEL CLIN PHAR, V21, P373, DOI 10.1177/106002808702100415; JAGANNATH S, 1989, J CLIN ONCOL, V7, P179, DOI 10.1200/JCO.1989.7.2.179; JONES RJ, 1990, J CLIN ONCOL, V8, P527, DOI 10.1200/JCO.1990.8.3.527; KLINGEMANN HG, 1991, EXP HEMATOL, V19, P558; KUKULL WA, 1986, MED CARE, V24, P961, DOI 10.1097/00005650-198610000-00009; MCCUE JD, 1985, REV INFECT DIS, V7, P643; MORTSYN G, 1988, LANCET, V1, P667; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEMUNAITIS J, 1988, BLOOD, V72, P834; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PHILLIPS GL, 1989, BLOOD, V73, P2086; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; WELCH HG, 1989, MED CARE, V27, P900, DOI 10.1097/00005650-198909000-00005; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; 1990, REDBOOK 1990; 1991, MED LETT DRUGS THER, V33, P61	34	172	172	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					177	182		10.7326/0003-4819-116-3-177	http://dx.doi.org/10.7326/0003-4819-116-3-177			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728202				2022-12-28	WOS:A1992HB35600001
J	KRONE, RJ				KRONE, RJ			THE ROLE OF RISK STRATIFICATION IN THE EARLY MANAGEMENT OF A MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; RISK STRATIFICATION; THROMBOLYTIC THERAPY; MYOCARDIAL REPERFUSION; ELECTROCARDIOGRAPHY	NON-Q-WAVE; ST-SEGMENT DEPRESSION; TISSUE PLASMINOGEN-ACTIVATOR; LUMINAL CORONARY ANGIOPLASTY; LEFT-VENTRICULAR FUNCTION; HEART-RATE-VARIABILITY; SIGNAL-AVERAGED ELECTROCARDIOGRAM; THROMBOLYTIC THERAPY; PROGNOSTIC-SIGNIFICANCE; EJECTION FRACTION	Objective: To review the literature on early management of myocardial infarction. Data Sources: Papers published or referenced in major English-language cardiology journals for the last 15 years. Study Selection: Large recent multicenter studies and the guidelines for early management of patients with acute myocardial infarction (American College of Cardiology/American Heart Association Task Force) were emphasized. Data Synthesis: A strategy for risk stratification was developed from information available in the emergency department, from the first days of the hospitalization, and before discharge to identify patients in whom intervention might improve prognosis. Conclusions: Treatment of myocardial infarction requires establishing patency of the infarct-related artery, usually with thrombolysis. Risk stratification begins in the emergency department (phase 1) using clinical (primarily the electrocardiogram) and historical data to identify patients at risk for massive infarction. For patients at highest risk, the efficacy of thrombolytic therapy must be assured and, if not effective, emergency angiography and mechanical reperfusion should be considered. During days 2 to 5, (phase 2), patients with large amounts of ischemic myocardium, postinfarction angina, "flash" pulmonary edema, or anterior non-Q infarctions are identified and studied. Predischarge (phase 3) stratification identifies those patients at risk for early death. A previous infarction, an ejection fraction less than 0.40, pulmonary congestion during the hospitalization, delayed afterpotentials on signal-averaged electrocardiography, symptomatic ventricular ectopic beats, decreased heart rate variability, limited exercise tolerance, or ischemia on exercise testing identifies patients at high risk. Patients with jeopardized myocardium must be identified for revascularization to try to improve survival. More data are needed to determine whether angioplasty or bypass surgery will improve prognosis in these patients.	WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	KRONE, RJ (corresponding author), JEWISH HOSP ST LOUIS, DEPT CARDIOL, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA.							ABBOTTSMITH CW, 1990, J AM COLL CARDIOL, V16, P770, DOI 10.1016/S0735-1097(10)80320-1; ALDRICH HR, 1988, AM J CARDIOL, V61, P749, DOI 10.1016/0002-9149(88)91060-0; [Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1986, Lancet, V2, P57; [Anonymous], 1990, CIRCULATION, V82, P664; BADGER RS, 1987, AM J CARDIOL, V59, P519, DOI 10.1016/0002-9149(87)91160-X; BAIM DS, 1990, J AM COLL CARDIOL, V15, P1188, DOI 10.1016/0735-1097(90)90263-O; BAR FW, 1987, AM J CARDIOL, V59, P6, DOI 10.1016/S0002-9149(87)80060-7; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BEAUCHAMP GD, 1990, AM HEART J, V120, P237, DOI 10.1016/0002-8703(90)90064-5; BELENKIE I, 1991, AM HEART J, V121, P407, DOI 10.1016/0002-8703(91)90706-N; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P1201, DOI 10.1016/S0735-1097(10)80001-4; BENHORIN J, 1988, AM J CARDIOL, V62, P679, DOI 10.1016/0002-9149(88)91202-7; BERGER PB, 1990, CIRCULATION, V81, P401, DOI 10.1161/01.CIR.81.2.401; BIGGER JT, 1978, AM J CARDIOL, V42, P202, DOI 10.1016/0002-9149(78)90901-3; BLANKE H, 1984, AM J CARDIOL, V54, P249, DOI 10.1016/0002-9149(84)90176-0; BODEN WE, 1991, AM J CARDIOL, V67, P335, DOI 10.1016/0002-9149(91)90038-M; BODEN WE, 1988, CARDIOL, P108; BOSCH X, 1987, CIRCULATION, V75, P988, DOI 10.1161/01.CIR.75.5.988; BOURKE JP, 1990, J AM COLL CARDIOL, V16, P1703, DOI 10.1016/0735-1097(90)90323-H; BRODIE BR, 1991, AM J CARDIOL, V67, P7, DOI 10.1016/0002-9149(91)90090-8; BROWN KA, 1987, AM J CARDIOL, V60, P15, DOI 10.1016/0002-9149(87)90975-1; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1985, J AM COLL CARDIOL, V5, P1055, DOI 10.1016/S0735-1097(85)80005-X; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CALIFF RM, 1988, CIRCULATION, V77, P1090, DOI 10.1161/01.CIR.77.5.1090; CHAITMAN BR, 1989, J AM COLL CARDIOL, V14, P1159, DOI 10.1016/0735-1097(89)90410-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHEW EW, 1990, BRIT HEART J, V64, P5; CRIPPS T, 1988, AM J CARDIOL, V62, P995, DOI 10.1016/0002-9149(88)90536-X; DEBUSK RF, 1986, NEW ENGL J MED, V314, P161, DOI 10.1056/NEJM198601163140307; DEBUSK RF, 1989, ANN INTERN MED, V110, P470, DOI 10.7326/0003-4819-110-6-470; DEFEYTER PJ, 1986, CIRCULATION, V74, P1365, DOI 10.1161/01.CIR.74.6.1365; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; DEWOOD MA, 1989, J AM COLL CARDIOL, V14, P78, DOI 10.1016/0735-1097(89)90056-9; DEWOOD MA, 1989, J AM COLL CARDIOL, V14, P65, DOI 10.1016/0735-1097(89)90055-7; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; DWYER EM, 1989, AM J CARDIOL, V63, P1423, DOI 10.1016/0002-9149(89)90001-5; DWYER EM, 1984, J AM COLL CARDIOL, V4, P695, DOI 10.1016/S0735-1097(84)80395-2; DWYER EM, 1986, AM J CARDIOL, V58, P900, DOI 10.1016/S0002-9149(86)80007-8; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLIS SG, 1989, J AM COLL CARDIOL, V13, P1251, DOI 10.1016/0735-1097(89)90296-9; ELLIS SG, 1991, J AM COLL CARDIOL, V17, P752, DOI 10.1016/S0735-1097(10)80195-0; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; ELSHERIF N, 1989, AM HEART J, V118, P256, DOI 10.1016/0002-8703(89)90183-X; FEIT F, 1990, J AM COLL CARDIOL, V16, P1529, DOI 10.1016/0735-1097(90)90295-Z; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FORTIN DF, 1990, AM J MED, V88, pN9; FREEMAN WK, 1991, J AM COLL CARDIOL, V18, P29, DOI 10.1016/S0735-1097(10)80212-8; FROELICHER VF, 1987, AM J MED, V83, P1045, DOI 10.1016/0002-9343(87)90940-5; GACIOCH GM, 1989, J AM COLL CARDIOL, V14, P1202, DOI 10.1016/0735-1097(89)90418-X; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; GANZ W, 1991, CIRCULATION, V83, P1818, DOI 10.1161/01.CIR.83.5.1818; GELMAN JS, 1982, BRIT HEART J, V48, P560; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; GIBSON RS, 1987, AM J CARDIOL, V60, P203, DOI 10.1016/0002-9149(87)90214-1; GIMPLE LW, 1989, AM J CARDIOL, V64, P1243, DOI 10.1016/0002-9149(89)90561-4; GOMES JA, 1989, J AM COLL CARDIOL, V13, P377, DOI 10.1016/0735-1097(89)90515-9; GREENBERG H, 1987, AM J CARDIOL, V59, P1057, DOI 10.1016/0002-9149(87)90848-4; GRINES CL, 1989, J AM COLL CARDIOL, V14, P573, DOI 10.1016/0735-1097(89)90095-8; GURBEL PA, 1990, AM J CARDIOL, V66, P1021, DOI 10.1016/0002-9149(90)90945-W; HACKWORTHY RA, 1986, AM HEART J, V112, P279, DOI 10.1016/0002-8703(86)90262-0; HACKWORTHY RA, 1986, BRIT HEART J, V56, P222; HAKKI AH, 1987, J AM COLL CARDIOL, V10, P25, DOI 10.1016/S0735-1097(87)80155-9; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HARRIS PJ, 1980, CIRCULATION, V62, P718, DOI 10.1161/01.CIR.62.4.718; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HERLITZ J, 1987, CLIN CARDIOL, V10, P529, DOI 10.1002/clc.4960100914; HERLITZ J, 1986, CARDIOLOGY, V73, P13, DOI 10.1159/000173979; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; HJALMARSON A, 1985, AM J CARDIOL, V56, pG1; HLATKY MA, 1985, AM J CARDIOL, V55, P325, DOI 10.1016/0002-9149(85)90369-8; HOCHBERG MS, 1984, J THORAC CARDIOV SUR, V88, P914; HOHNLOSER SH, 1991, J AM COLL CARDIOL, V18, P44, DOI 10.1016/S0735-1097(10)80215-3; HOROWITZ RS, 1982, CIRCULATION, V65, P323, DOI 10.1161/01.CIR.65.2.323; JAARSMA W, 1990, AM J CARDIOL, V66, P551; JACKMAN JD, 1991, AM J CARDIOL, V68, P116, DOI 10.1016/0002-9149(91)90724-Y; JAIN A, 1990, AM HEART J, V120, P839, DOI 10.1016/0002-8703(90)90199-8; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; KAO W, 1989, AM J CARDIOL, V64, P1236, DOI 10.1016/0002-9149(89)90560-2; KARLSON BW, 1990, CIRCULATION, V82, P1140, DOI 10.1161/01.CIR.82.4.1140; KEREIAKES DJ, 1988, J AM COLL CARDIOL, V11, P899, DOI 10.1016/S0735-1097(98)90043-2; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KOWALCHUK GJ, 1990, AM J CARDIOL, V66, P1319, DOI 10.1016/0002-9149(90)91161-X; KRONE RJ, 1983, AM J CARDIOL, V52, P234, DOI 10.1016/0002-9149(83)90114-5; KRONE RJ, 1985, CIRCULATION, V71, P80, DOI 10.1161/01.CIR.71.1.80; KRONE RJ, 1989, J AM COLL CARDIOL, V14, P31, DOI 10.1016/0735-1097(89)90049-1; KUCHAR DL, 1987, J AM COLL CARDIOL, V9, P531, DOI 10.1016/S0735-1097(87)80045-1; KULICK DL, 1991, AM HEART J, V121, P641, DOI 10.1016/0002-8703(91)90747-6; KWON K, 1991, AM J CARDIOL, V67, P109, DOI 10.1016/0002-9149(91)90430-S; LANGE RA, 1990, AM J CARDIOL, V65, P554, DOI 10.1016/0002-9149(90)91030-A; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS BS, 1988, AM J CARDIOL, V62, P20, DOI 10.1016/0002-9149(88)91358-6; LOMBARDI F, 1987, AM J CARDIOL, V60, P1239, DOI 10.1016/0002-9149(87)90601-1; MADSEN EB, 1984, AM J CARDIOL, V53, P47, DOI 10.1016/0002-9149(84)90682-9; MAISEL AS, 1985, CIRCULATION, V71, P211, DOI 10.1161/01.CIR.71.2.211; MALIK M, 1990, CLIN CARDIOL, V13, P570, DOI 10.1002/clc.4960130811; MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7; MASSEL D, 1990, CLIN CARDIOL, V13, P591, DOI 10.1002/clc.4960130904; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; MCQUEEN MJ, 1983, AM HEART J, V105, P258, DOI 10.1016/0002-8703(83)90524-0; MEIER B, 1990, CIRCULATION, V82, P2243, DOI 10.1161/01.CIR.82.6.2243; MONTAGUE NT, 1985, ANN THORAC SURG, V39, P552, DOI 10.1016/S0003-4975(10)61997-2; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSS AJ, 1976, CIRCULATION, V54, P58, DOI 10.1161/01.CIR.54.1.58; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; NICOD P, 1988, AM J CARDIOL, V61, P1165, DOI 10.1016/0002-9149(88)91148-4; NIELSEN BL, 1973, CIRCULATION, V48, P338, DOI 10.1161/01.CIR.48.2.338; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; OUYANG P, 1990, AM J CARDIOL, V65, P267, DOI 10.1016/0002-9149(90)90285-9; PIERARD LA, 1989, AM J CARDIOL, V63, P792, DOI 10.1016/0002-9149(89)90044-1; PRUITT RD, 1963, PROG CARDIOVASC DIS, V6, P85, DOI 10.1016/S0033-0620(63)80023-7; RANHOSKY A, 1990, CIRCULATION, V81, P1205, DOI 10.1161/01.CIR.81.4.1205; RAPAPORT E, 1991, J MYOCARD ISCHEM, V3, P25; RAUNIO H, 1982, AM HEART J, V103, P32, DOI 10.1016/0002-8703(82)90525-7; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; RIVERS JT, 1990, J AM COLL CARDIOL, V16, P340, DOI 10.1016/0735-1097(90)90583-B; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROGERS WJ, 1991, J AM COLL CARDIOL, V17, P1007, DOI 10.1016/0735-1097(91)90823-R; ROGERS WJ, 1980, CIRCULATION, V62, P67; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROSS J, 1989, CIRCULATION, V79, P292, DOI 10.1161/01.CIR.79.2.292; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; ROUBIN GS, 1983, J AM COLL CARDIOL, V2, P38, DOI 10.1016/S0735-1097(83)80374-X; RUDDY TD, 1986, AM HEART J, V112, P1210, DOI 10.1016/0002-8703(86)90350-9; RYAN TJ, 1990, CIRCULATION, V82, P110; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; SCHRODER R, 1989, AM J CARDIOL, V64, P878, DOI 10.1016/0002-9149(89)90835-7; SCHULMAN SP, 1988, J AM COLL CARDIOL, V11, P1164, DOI 10.1016/0735-1097(88)90277-X; SCHUSTER EH, 1981, AM J CARDIOL, V47, P1189, DOI 10.1016/0002-9149(81)90246-0; SCHWEITZER P, 1990, AM HEART J, V119, P642, DOI 10.1016/S0002-8703(05)80288-1; SCLAROVSKY S, 1988, AM HEART J, V116, P933, DOI 10.1016/0002-8703(88)90143-3; SCLAROVSKY S, 1987, AM HEART J, V113, P1085, DOI 10.1016/0002-8703(87)90916-1; SERRUYS PW, 1983, BRIT HEART J, V50, P257; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; SIA STB, 1986, AM J CARDIOL, V57, P738, DOI 10.1016/0002-9149(86)90605-3; SIMOONS M L, 1988, Lancet, V1, P197; SINGH AK, 1985, J AM COLL CARDIOL, V6, P1121, DOI 10.1016/S0735-1097(85)80318-1; SLATER DK, 1987, AM J CARDIOL, V60, P766, DOI 10.1016/0002-9149(87)91020-4; SMALLING RW, 1990, J AM COLL CARDIOL, V15, P915, DOI 10.1016/0735-1097(90)90216-C; STERLING RP, 1984, J THORAC CARDIOV SUR, V87, P487; STONE GW, 1991, AM J CARDIOL, V67, P37, DOI 10.1016/0002-9149(91)90095-3; STONE GW, 1990, J AM COLL CARDIOL, V15, P534, DOI 10.1016/0735-1097(90)90621-U; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TIBBITS PA, 1987, AM J CARDIOL, V60, P451, DOI 10.1016/0002-9149(87)90284-0; TILKEMEIER PL, 1990, AM J CARDIOL, V66, P1203, DOI 10.1016/0002-9149(90)91100-K; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TURNER JD, 1980, CIRCULATION, V61, P729, DOI 10.1161/01.CIR.61.4.729; VATTEROTT PJ, 1991, J AM COLL CARDIOL, V17, P330, DOI 10.1016/S0735-1097(10)80095-6; VERANI MS, 1990, CIRCULATION, P8280; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; WALLER BF, 1987, J AM COLL CARDIOL, V9, P785, DOI 10.1016/S0735-1097(87)80234-6; WARNOWICZ MA, 1983, CIRCULATION, V67, P330, DOI 10.1161/01.CIR.67.2.330; WASSERMAN AG, 1982, CIRCULATION, V65, P1451, DOI 10.1161/01.CIR.65.7.1451; WHITE CW, 1989, CIRCULATION, V80, P1482, DOI 10.1161/01.CIR.80.5.1482; WHITE LJ, 1989, ANN INTERN MED, V110, P485; WILCOX RG, 1988, LANCET, V2, P525; WILLEMS JL, 1990, CIRCULATION, V82, P1147, DOI 10.1161/01.CIR.82.4.1147; WILLICH SN, 1987, AM HEART J, V114, P1110, DOI 10.1016/0002-8703(87)90186-4; YOUNIS LT, 1989, AM J CARDIOL, V64, P161, DOI 10.1016/0002-9149(89)90450-5; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; 1990, LANCET, P71	176	46	48	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					223	237		10.7326/0003-4819-116-3-223	http://dx.doi.org/10.7326/0003-4819-116-3-223			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728206				2022-12-28	WOS:A1992HB35600009
J	MELAMED, Y; SHUPAK, A; BITTERMAN, H				MELAMED, Y; SHUPAK, A; BITTERMAN, H			CURRENT CONCEPTS - MEDICAL PROBLEMS ASSOCIATED WITH UNDERWATER DIVING	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DECOMPRESSION-SICKNESS; PATHO-PHYSIOLOGY; SINUS BAROTRAUMA; DIVERS; ACCIDENTS; EMBOLISM; BUBBLES; LESIONS				MELAMED, Y (corresponding author), ISRAELI NAVAL MED INST, POB 8040, HAIFA, ISRAEL.							ADKISSON GH, 1989, LANCET, V2, P119; ARTHUR DC, 1987, ANN EMERG MED, V16, P689, DOI 10.1016/S0196-0644(87)80075-6; BELLINI MJ, 1987, J LARYNGOL OTOL, V101, P386; Bennett P, 1976, DIVING MED, P157; BENNETT PB, 1975, MOL MECHANISMS ANEST, P367; Bennett PB, 1982, PHYSL MED DIVING, P239; BOETTGER ML, 1983, ANN EMERG MED, V12, P563, DOI 10.1016/S0196-0644(83)80300-X; BOVE AA, 1982, UNDERSEA BIOMED RES, V9, P91; BUTLER BD, 1985, J APPL PHYSIOL, V59, P543, DOI 10.1152/jappl.1985.59.2.543; DUTKA AJ, 1985, UNDERSEA BIOMED RES, V12, P403; EDMONDS C, 1972, MED J AUSTRALIA, V2, P1300, DOI 10.5694/j.1326-5377.1972.tb47589.x; EIDSVIK S, 1985, UNDERSEA BIOMED RES, V12, P459; EVANS A, 1972, AEROSPACE MED, V43, P1095; EVANS DE, 1977, ARTERIAL AIR EMBOLIS, P20; FAGAN P, 1976, ANN OTO RHINOL LARYN, V85, P61, DOI 10.1177/000348947608500110; FARMER JC, 1976, LARYNGOSCOPE, V86, P1315, DOI 10.1288/00005537-197609000-00003; FARMER JC, 1985, ANN OTOL RHINOL LA S, V120, P45; FARMER JC, 1982, PHYSL MED DIVING, P507; GOLDING F C, 1960, Br J Ind Med, V17, P167; GREENE KM, 1977, ARTERIAL AIR EMBOLIS, P8; HALPERN P, 1982, BRIT MED J, V284, P1014, DOI 10.1136/bmj.284.6321.1014; HILLS BA, 1991, UNDERSEA BIOMED RES, V18, P111; Hills BA, 1977, DECOMPRESSION SICKNE, V1; HYLDEGAARD O, 1989, UNDERSEA BIOMED RES, V16, P185; KELLER A P Jr, 1958, Laryngoscope, V68, P2015; Kizer K W, 1981, Phys Sportsmed, V9, P84, DOI 10.1080/00913847.1981.11711012; LANDOLT JP, 1980, J APPL PHYSIOL, V49, P1070, DOI 10.1152/jappl.1980.49.6.1070; LEITCH DR, 1984, UNDERSEA BIOMED RES, V11, P221; MELAMED Y, 1981, AVIAT SPACE ENVIR MD, V52, P480; MELAMED Y, 1980, PARAPLEGIA, V18, P127, DOI 10.1038/sc.1980.21; MELAMED Y, 1991, DESCRIBING DECOMPRES, P23; MILLER JM, 1981, ANN OTO RHINOL LARYN, V90, P281, DOI 10.1177/000348948109000318; MOLVAER OI, 1988, UNDERSEA BIOMED RES, V15, P271; MOON RE, 1989, LANCET, V1, P513; NAKASHIMA T, 1988, ANN OTO RHINOL LARYN, V97, P146, DOI 10.1177/000348948809700211; NEBLETT LM, 1985, ANN OTO RHINOL LARYN, V94, P2, DOI 10.1177/00034894850940S101; PALMER AC, 1978, UNDERSEA BIOMED RES, V5, P275; PALMER AC, 1987, LANCET, V2, P1365; PARELL GJ, 1985, OTOLARYNG HEAD NECK, V93, P393, DOI 10.1177/019459988509300320; PAULEV P, 1965, J APPL PHYSIOL, V20, P1028, DOI 10.1152/jappl.1965.20.5.1028; POLKINGHORNE PJ, 1988, LANCET, V2, P1381; SHUPAK A, 1991, LARYNGOSCOPE, V101, P173; Spencer MP, 1968, B MASON CLIN, V22, P26; VANRENSSELAER H, 1891, MED REC, V40, P141; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003; 1985, NAVSEA0994LP0019010; 1987, ROYAL NAVY DIVING MA; 1988, DIVERS ALERT NETWORK; 1983, DIVING SUBAQUATIC ME, P93; 1983, DIVING SUBAQUATIC ME, P129; 1958, NAVSHIPS250538 DEP N	51	149	151	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					30	35						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1727063				2022-12-28	WOS:A1992GX31500005
J	DALEMANS, W; BARBRY, P; CHAMPIGNY, G; JALLAT, S; DOTT, K; DREYER, D; CRYSTAL, RG; PAVIRANI, A; LECOCQ, JP; LAZDUNSKI, M				DALEMANS, W; BARBRY, P; CHAMPIGNY, G; JALLAT, S; DOTT, K; DREYER, D; CRYSTAL, RG; PAVIRANI, A; LECOCQ, JP; LAZDUNSKI, M			ALTERED CHLORIDE-ION CHANNEL KINETICS ASSOCIATED WITH THE DELTA-F508 CYSTIC-FIBROSIS MUTATION	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; EXPRESSION; GENE; CL; IDENTIFICATION; TRANSPORT; MEMBRANE	CYSTIC fibrosis is associated with a defect in epithelial chloride ion transport (reviewed in refs 1, 2) which is caused by mutations in a membrane protein called CFTR (cystic fibrosis transmembrane conductance regulator) 3. Heterologous expression of CFTR produces cyclicAMP-sensitive Cl--channel activity 4-7. Deletion of phenylalanine at amino-acid position 508 in CFTR (DELTA-F508 CFTR) is the most common mutation in cystic fibrosis 8. It has been proposed that this mutation prevents glycoprotein maturation and its transport to its normal cellular location 9. We have expressed both CFIR and DELTA-F508 CFTR in Vero cells using recombinant vaccinia virus. Although far less DELTA-F508 CFTR reached the plasma membrane than normal CFTR, sufficient DELTA-F508 CFTR was expressed at the plasma membrane to permit functional analysis. DELTA-F508 CFIR expression induced a reduced activity of the cAMP-activated Cl- channel, with conductance, anion selectivity and open-time kinetics similar to those of CFIR, but with much greater closed times, resulting in a large decrease of open probability. The DELTA-F508 mutation thus seems to have two major consequences, an abnormal translocation of the CFTR protein which limits membrane insertion, and an abnormal function in mediating Cl- transport.	INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE; NHLBI,PULM BRANCH,BETHESDA,MD 20892	Transgene SA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; CHAMPIGNY G, 1990, FEBS LETT, V259, P263, DOI 10.1016/0014-5793(90)80024-D; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DREINHOFER J, 1988, BIOCHIM BIOPHYS ACTA, V946, P135, DOI 10.1016/0005-2736(88)90466-X; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EDWARDS G, 1990, TRENDS PHARMACOL SCI, V11, P417, DOI 10.1016/0165-6147(90)90149-3; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAZDUNSKI M, 1982, ANNU REV PHYSIOL, V44, P463, DOI 10.1146/annurev.ph.44.030182.002335; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P673; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	23	595	672	1	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					526	528		10.1038/354526a0	http://dx.doi.org/10.1038/354526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1722027	Bronze			2022-12-28	WOS:A1991GW75100015
J	BONTEMS, F; ROUMESTAND, C; GILQUIN, B; MENEZ, A; TOMA, F				BONTEMS, F; ROUMESTAND, C; GILQUIN, B; MENEZ, A; TOMA, F			REFINED STRUCTURE OF CHARYBDOTOXIN - COMMON MOTIFS IN SCORPION TOXINS AND INSECT DEFENSINS	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURE; SOLUTION CONFORMATION; SARCOPHAGA-PEREGRINA; INHIBITOR; CHANNELS; PURIFICATION; SEQUENCE; PROTEIN; SAPECIN	Conflicting three-dimensional structures of charybdotoxin (Chtx), a blocker of K+ channels, have been previously reported. A high-resolution model depicting the tertiary structure of Chtx has been obtained by DIANA and X-PLOR calculations from new proton nuclear magnetic resonance (NMR) data. The protein possesses a small triple-stranded antiparallel beta-sheet linked to a short helix by two disulfides and to an extended fragment by one disulfide, respectively. This motif also exists in all known structures of scorpion toxins, irrespective of their size, sequence, and function. Strikingly, antibacterial insect defensins also adopt this folding pattern.			BONTEMS, F (corresponding author), CENS,DEPT INGN & ETUD PROT,F-91191 GIF SUR YVETTE,FRANCE.			ROUMESTAND, Christian/0000-0002-4082-3293				ARSENIEV AS, 1984, FEBS LETT, V165, P57, DOI 10.1016/0014-5793(84)80014-9; BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; BRUNGER AT, 1988, XPLOR MANUAL; DARBON H, 1991, BIOCHEMISTRY-US, V30, P1836, DOI 10.1021/bi00221a016; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; FUJIWARA S, 1989, J BIOL CHEM, V265, P11333; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HANZAWA H, 1990, FEBS LETT, V269, P413, DOI 10.1016/0014-5793(90)81206-4; KUZUHARA T, 1990, J BIOCHEM-TOKYO, V107, P514, DOI 10.1093/oxfordjournals.jbchem.a123077; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; MARTINS JC, 1990, FEBS LETT, V260, P249, DOI 10.1016/0014-5793(90)80115-Y; MASSEFSKI W, 1990, SCIENCE, V249, P521, DOI 10.1126/science.1696395; MASSEFSKI W, 1991, SCIENCE, V252, P631, DOI 10.1126/science.252.5006.631.b; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; PASHKOV VS, 1988, BIOPHYS CHEM, V31, P121, DOI 10.1016/0301-4622(88)80016-4; SIMARD M, 1990, BIOL SCORPION, P415; TAKASHIMA H, 1991, PEPTIDES 1990, P557	20	349	357	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1521	1523		10.1126/science.1720574	http://dx.doi.org/10.1126/science.1720574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720574				2022-12-28	WOS:A1991GT90300045
J	HOUGHTEN, RA; PINILLA, C; BLONDELLE, SE; APPEL, JR; DOOLEY, CT; CUERVO, JH				HOUGHTEN, RA; PINILLA, C; BLONDELLE, SE; APPEL, JR; DOOLEY, CT; CUERVO, JH			GENERATION AND USE OF SYNTHETIC PEPTIDE COMBINATORIAL LIBRARIES FOR BASIC RESEARCH AND DRUG DISCOVERY	NATURE			English	Article							SOLID-PHASE SYNTHESIS; ANTIGENIC DETERMINANT; LIGANDS; PROTEIN; ACID	EXISTING methods for the synthesis and screening of large numbers of peptides are limited by their inability to generate and screen the requisite number (millions) of individual peptides 1-4 and/or their inability to generate unmodified free peptides in quantities able to interact in solution 4-8. We have circumvented these limitations by developing synthetic peptide combinatorial libraries composed of mixtures of free peptides in quantities which can be used directly in virtually all existing assay systems. The screening of these heterogeneous libraries, along with an iterative selection and synthesis process, permits the systematic identification of optimal peptide ligands. Starting with a library composed of more than 34 million hexa-peptides, we present here the precise identification of an antigenic determinant recognized by a monoclonal antibody as well as the straightforward development of new potent antimicrobial peptides.			HOUGHTEN, RA (corresponding author), TORREY PINES INST MOLEC STUDIES,3550 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.		Abrams, William R/A-5782-2008					APPEL JR, 1990, J IMMUNOL, V144, P976; BLONDELLE S E, 1991, Peptide Research, V4, P12; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; Cuervo J H, 1988, Pept Res, V1, P81; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GISIN BF, 1972, ANAL CHIM ACTA, V58, P248, DOI 10.1016/S0003-2670(00)86882-8; HOUGHTEN R, 1986, Patent No. 4631211; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOUGHTEN RA, 1988, VACCINES 88, P9; HOUGHTEN RA, 1987, PEPTIDE CHEM, P769; HOUGHTEN RA, 1986, VACCINES 86 NEW APPR, P21; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PINILLA C, 1991, PEPTIDES 1990, P860; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	25	1122	1448	4	104	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					84	86		10.1038/354084a0	http://dx.doi.org/10.1038/354084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1719428				2022-12-28	WOS:A1991GN82900065
J	FLANAGAN, WM; CORTHESY, B; BRAM, RJ; CRABTREE, GR				FLANAGAN, WM; CORTHESY, B; BRAM, RJ; CRABTREE, GR			NUCLEAR-ASSOCIATION OF A T-CELL TRANSCRIPTION FACTOR BLOCKED BY FK-506 AND CYCLOSPORINE-A	NATURE			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; GEL-ELECTROPHORESIS; NEUROSPORA-CRASSA; MACROLIDES FK-506; CYCLOPHILIN; ACTIVATION	CYCLOSPORIN A and FK506 inhibit T- and B-cell activation and other processes essential to an effective immune response 1-3. In T lymphocytes these drugs disrupt an unknown step in the transmission of signals from the T-cell antigen receptor to cytokine genes that coordinate the immune response 4-6. The putative intracellular receptors for FK506 and cyclosporin are cis-trans prolyl isomerases 7-11. Binding of the drug inhibits isomerase activity 8,10,11, but studies with other prolyl isomerase inhibitors 12 and analysis of cyclosporin-resistant mutants in yeast suggest that the effects of the drug result from the formation of an inhibitory complex between the drug and isomerase 13,14, and not from inhibition of isomerase activity. A transcription factor, NF-AT, which is essential for early T-cell gene activation, seems to be a specific target of cyclosporin A and FK506 action because transcription directed by this protein is blocked in T cells treated with these drugs, with little or no effect on other transcription factors such as AP-1 and NF-kappa-B (refs 15-17). Here we demonstrate that NF-AT is formed when a signal from the antigen receptor induces a pre-existing cytoplasmic subunit to translocate to the nucleus and combine with a newly synthesized nuclear subunit of NF-AT. FK506 and cyclosporin A block translocation of the cytoplasmic component without affecting synthesis of the nuclear subunit.			FLANAGAN, WM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305, USA.							BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1985, BIOCHIM BIOPHYS ACTA, V828, P39, DOI 10.1016/0167-4838(85)90006-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HOHMAN R J, 1990, New Biologist, V2, P663; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	34	1030	1063	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					803	807		10.1038/352803a0	http://dx.doi.org/10.1038/352803a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715516				2022-12-28	WOS:A1991GC96400060
J	ITOH, N; YONEHARA, S; ISHII, A; YONEHARA, M; MIZUSHIMA, S; SAMESHIMA, M; HASE, A; SETO, Y; NAGATA, S				ITOH, N; YONEHARA, S; ISHII, A; YONEHARA, M; MIZUSHIMA, S; SAMESHIMA, M; HASE, A; SETO, Y; NAGATA, S			THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS	CELL			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; MOLECULAR-CLONING; ACTIVATION MOLECULE; MAMMALIAN-CELLS; LYMPHOCYTES-T; FACTOR-ALPHA; FACTOR TNF	Mouse anti-Fas monoclonal antibody has a cytolytic activity on human cells that express the antigen. Complementary DNAs encoding the cell surface antigen Fas were isolated from a cDNA library of human T cell lymphoma KT-3 cells. The nucleotide sequence of the cDNAs revealed that the molecule coding for the Fas antigen determinant is a 319 amino acid polypeptide (M(r) 36,000) with a single transmembrane domain. The extracellular domain is rich in cysteine residue, and shows a similarity to that of human tumor necrosis factor receptors, human nerve growth factor receptor, and human B cell antigen CD40. Murine WR19L cells or L929 cells transformed with the human Fas antigen cDNA were killed by the anti-Fas antibody in the process known as apoptosis.	TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN; OSAKA CITY INST PUBL HLTH & ENVIRONM SCI,TENNOJI KU,OSAKA 543,JAPAN	Tokyo Metropolitan Institute of Medical Science	ITOH, N (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1984, J IMMUNOL, V132, P38; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P9620, DOI 10.1073/pnas.87.24.9620; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; ORTALDO JR, 1986, J IMMUNOL, V137, P2857; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RANSOM JH, 1985, CANCER RES, V45, P851; RUBIN BY, 1988, CANCER RES, V48, P6006; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J, 1989, MOL CLONING LABORATO; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMIZU S, 1988, BLOOD, V71, P196; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WATERFIELD MD, 1989, BRIT MED BULL, V45, P541, DOI 10.1093/oxfordjournals.bmb.a072341; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	49	2704	2887	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					233	243		10.1016/0092-8674(91)90614-5	http://dx.doi.org/10.1016/0092-8674(91)90614-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713127				2022-12-28	WOS:A1991FY71200005
J	GEERTS, H; DEBRABANDER, M; NUYDENS, R				GEERTS, H; DEBRABANDER, M; NUYDENS, R			NANOVID MICROSCOPY	NATURE			English	Article							CONTRAST; CELLS; GOLD				GEERTS, H (corresponding author), JANSSEN RES FDN,DEPT PHYSIOL LIFE SCI,BEERSE,BELGIUM.							ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P275, DOI 10.1002/cm.970010302; CORNELISSEN F, 1990, J NEUROSCI METH, V35, P79, DOI 10.1016/0165-0270(90)90097-Y; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; DEBRABANDER M, 1986, CELL MOTIL CYTOSKEL, V6, P105, DOI 10.1002/cm.970060207; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; GEERTS H, 1987, BIOPHYS J, V52, P775, DOI 10.1016/S0006-3495(87)83271-X; INOUE S, 1981, J CELL BIOL, V89, P346, DOI 10.1083/jcb.89.2.346; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0	8	29	42	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					765	765		10.1038/351765a0	http://dx.doi.org/10.1038/351765a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1712078				2022-12-28	WOS:A1991FU20100071
J	BANDARA, LR; LATHANGUE, NB				BANDARA, LR; LATHANGUE, NB			ADENOVIRUS-E1A PREVENTS THE RETINOBLASTOMA GENE-PRODUCT FROM COMPLEXING WITH A CELLULAR TRANSCRIPTION FACTOR	NATURE			English	Article							E1A PROTEINS; DIFFERENTIATION; DOMAINS	THE transforming proteins of several DNA tumour viruses, including adenovirus E1a and simian virus 40 large T antigen, complex with the retinoblastoma (Rb) tumour-suppressor gene product 1,2. This requires regions in these viral proteins necessary for transformation and is thought to inactivate the growth-suppressing properties of the Rb protein by disrupting its interaction with cellular targets 3. Indeed, regions of Rb required to form a complex with E1a and large T antigen are often mutated in transformed cells 4. The level at which the Rb protein regulates proliferation is unknown, although one possibility is transcription. We have previously characterized a sequence-specific transcription factor, DRTF1, the activity of which is downregulated as embryonal carcinoma stem cells differentiate. DRTF1 is found in several discrete protein complexes (a, b and c) which are of different sizes but have the same DNA specificity 5,6. We now show that one of these also contains the Rb protein and, further, that the adenovirus E1a protein causes the dissociation of the Rb protein from this complex. This requires conserved regions 1 and 2 of E1a that are known to be required for efficient transformation 7. These results demonstrate that the Rb protein forms a complex with a DNA-bound transcription factor, and suggests that the Rb protein might act by regulating transcription.			BANDARA, LR (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.							DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1984, EMBO J, V3, P267, DOI 10.1002/j.1460-2075.1984.tb01796.x; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; TASSIOS P T, 1990, New Biologist, V2, P1123; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	13	426	438	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					494	497		10.1038/351494a0	http://dx.doi.org/10.1038/351494a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1710781				2022-12-28	WOS:A1991FP75800060
J	WIECHEN, K; PLENDL, H; GROTE, W				WIECHEN, K; PLENDL, H; GROTE, W			ISOELECTRIC-FOCUSING OF AMNIOTIC-FLUID ALPHA-FETOPROTEIN TO IMPROVE DIAGNOSIS OF NEURAL-TUBE DEFECTS	LANCET			English	Letter											WIECHEN, K (corresponding author), CAU KIEL,KLINIKUM,DEPT HUMAN GENET,W-2300 KIEL 1,GERMANY.							HINDERSSON P, 1979, LANCET, V2, P906; NOERGAARDPEDERS.B, 1980, CLIN GENET, V17, P355	2	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					674	674		10.1016/0140-6736(91)92488-N	http://dx.doi.org/10.1016/0140-6736(91)92488-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1705650				2022-12-28	WOS:A1991FB73000033
J	VACHER, J; TILGHMAN, SM				VACHER, J; TILGHMAN, SM			DOMINANT NEGATIVE REGULATION OF THE MOUSE ALPHA-FETOPROTEIN GENE IN ADULT LIVER	SCIENCE			English	Article											VACHER, J (corresponding author), PRINCETON UNIV, DEPT BIOL, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA.				NATIONAL CANCER INSTITUTE [R37CA044976] Funding Source: NIH RePORTER; NCI NIH HHS [CA44976] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; MARIANI BD, 1988, P NATL ACAD SCI USA, V85, P3029, DOI 10.1073/pnas.85.9.3029; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; OLSSON M, 1977, J EXP MED, V145, P819, DOI 10.1084/jem.145.4.819; OTSURU A, 1988, CANCER, V62, P1105, DOI 10.1002/1097-0142(19880915)62:6<1105::AID-CNCR2820620613>3.0.CO;2-Z; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLIARD AM, 1986, J CELL BIOL, V103, P777, DOI 10.1083/jcb.103.3.777; SCOTT RW, 1983, MOL CELL BIOL, V3, P1295, DOI 10.1128/MCB.3.7.1295; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; VACHER J, UNPUB; VOGT TF, 1987, SCIENCE, V236, P301, DOI 10.1126/science.2436297; WATANABE K, 1987, J BIOL CHEM, V262, P4812; WIDEN SG, 1986, P NATL ACAD SCI USA, V83, P8196, DOI 10.1073/pnas.83.21.8196; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	32	125	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1732	1735		10.1126/science.1702902	http://dx.doi.org/10.1126/science.1702902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	1702902				2022-12-28	WOS:A1990EN92000048
J	BENTLEY, GA; BOULOT, G; RIOTTOT, MM; POLJAK, RJ				BENTLEY, GA; BOULOT, G; RIOTTOT, MM; POLJAK, RJ			3-DIMENSIONAL STRUCTURE OF AN IDIOTOPE ANTI-IDIOTOPE COMPLEX	NATURE			English	Article											BENTLEY, GA (corresponding author), INST PASTEUR, DEPT IMMUNOL, CNRS, URA 359, UNITE IMMUNOL STRUCT, F-75724 PARIS 15, FRANCE.		Bentley, Graham/B-3623-2011					AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BOULOT G, 1987, J MOL BIOL, V194, P577, DOI 10.1016/0022-2836(87)90685-1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; COLMAN PM, 1976, CRYSTALLOGRAPHIC COM, P248; ERLANGER BF, 1989, IMMUNOL TODAY, V10, P151, DOI 10.1016/0167-5699(89)90170-9; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; HARPER M, 1987, MOL IMMUNOL, V24, P97, DOI 10.1016/0161-5890(87)90081-2; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABAT EA, 1984, BIOL IDIOTYPES, P3; LOHSS F, 1953, Z NATURFORSCH B, V8, P625; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; OUDIN J, 1963, CR HEBD ACAD SCI, V257, P805; ROITT IM, 1981, LANCET, V1, P1041; SACKS DL, 1983, SPRINGER SEMIN IMMUN, V6, P79, DOI 10.1007/BF01857368; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SLATER RJ, 1955, J EXP MED, V101, P85, DOI 10.1084/jem.101.1.85; SOBOTTKA SE, 1984, NUCL INSTRUM METH A, V220, P575, DOI 10.1016/0167-5087(84)90325-9; SOUCHON H, 1990, J MOL IMMUN, V27, P429; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TULIP WR, 1989, COLD SPRING HARB SYM, V54, P257; Urbain J, 1981, Contemp Top Mol Immunol, V8, P113; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287	29	250	254	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	1990	348	6298					254	257		10.1038/348254a0	http://dx.doi.org/10.1038/348254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700305				2022-12-28	WOS:A1990EH79600064
J	WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; COFFMAN, GA; HEEREN, T; CUPPLES, LA				WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; COFFMAN, GA; HEEREN, T; CUPPLES, LA			THE IMPACT OF A PHYSICIANS WARNING ON RECOVERY AFTER ALCOHOLISM-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE; PREVALENCE; DRINKING; IDENTIFICATION; INTERVENTION; RECOGNITION	Objective. - To study whether alcoholic workers had seen physicians during the year they were identified by their company, whether they recalled physicians' warnings about drinking, and whether such warnings affected outcomes 2 years later. Design. - Workers were interviewed at intake and 2 years later: subgroups who did and did not see physicians and who did and did not recall warnings were compared. Setting. - A company-union employee assistance program. Participants. - Two hundred problem drinkers, newly identified on the job, predominantly male, blue-collar workers. Outcomes. - Drinking, drunkenness, average daily alcohol consumption, and impairment score. Results. - Among the 200 participants, 74% saw physicians in the index year; only 22% recalled warnings. Recall of a warning was associated with liver disease' continued drinking while ill, supervisors' job warnings, older age, and marijuana use. Two years later, those warned were more likely to be abstaining, and sober, and were less impaired. Conclusions. - Recalling a physician's warning at intake into alcoholism treatment was associated with better prognosis 2 years later. However, among this group of employees whose drinking was serious enough to be identified on the job, fewer than a quarter recalled physicians' warnings, even though more than three quarters had seen physicians in the year preceding intake.	BOSTON UNIV,SCH PUBL HLTH,DEPT SOCIAL & BEHAV SCI,BOSTON,MA 02215; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215	Boston University; Boston University	WALSH, DC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Coffman, Gerald/0000-0002-0044-6219; Levenson, Suzette/0000-0002-1979-2373; Heeren, Timothy/0000-0001-5643-3559	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006461] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA06461] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Armor D. J., 1976, ALCOHOLISM TREATMENT; BELL J, 1988, MED J AUSTRALIA, V149, P351, DOI 10.5694/j.1326-5377.1988.tb120666.x; BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BOWEN OR, 1988, JAMA-J AM MED ASSOC, V260, P2267, DOI 10.1001/jama.260.15.2267; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CLARK WD, 1981, AM J MED, V71, P275, DOI 10.1016/0002-9343(81)90129-7; CLEARY PD, 1988, AM J MED, V85, P466; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; GREEN J R, 1965, Med J Aust, V1, P465; HINGSON R, 1982, J STUD ALCOHOL, V43, P273, DOI 10.15288/jsa.1982.43.273; KAMEROW DB, 1986, JAMA-J AM MED ASSOC, V255, P2054, DOI 10.1001/jama.255.15.2054; KISSIN B, 1977, TREATMENT REHABILITA, P53; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; LEWIS DC, 1983, B NEW YORK ACAD MED, V59, P181; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MULFORD HA, 1977, J STUD ALCOHOL, V38, P21; PRICE J, 1988, MED J AUSTRALIA, V149, P345, DOI 10.5694/j.1326-5377.1988.tb120663.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROHMAN ME, 1987, AM J DRUG ALCOHOL AB, V131, P199; ROLLNICK S, 1987, AUST DRUG ALCOHOL RE, V6, P341; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; TRICE HM, 1973, ALCOHOLISM PROGR RES, P359; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WEST LJ, 1984, ANN INTERN MED, V100, P405, DOI 10.7326/0003-4819-100-3-405; 1980, DIAGNOSTIC STATISTIC; 1987, PHS6TH ALC DRUG AB M	29	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					663	667		10.1001/jama.267.5.663	http://dx.doi.org/10.1001/jama.267.5.663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731132				2022-12-28	WOS:A1992HB35400022
J	AMARENCO, P; DUYCKAERTS, C; TZOURIO, C; HENIN, D; BOUSSER, MG; HAUW, JJ				AMARENCO, P; DUYCKAERTS, C; TZOURIO, C; HENIN, D; BOUSSER, MG; HAUW, JJ			THE PREVALENCE OF ULCERATED PLAQUES IN THE AORTIC-ARCH IN PATIENTS WITH STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACKS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; INFARCTION; COMPLICATION; EMBOLISM; BYPASS	Background and Methods. The cause of cerebral infarction is obscure in up to 40 percent of patients with this disorder who are studied prospectively. In this investigation, we determined the frequency of ulcerated plaques in the aortic arch and explored the part they may play in the formation of cerebral emboli. Using an autopsy data bank, we studied the prevalence of ulcerated plaques in the aortic arch in 500 consecutive patients with cerebrovascular and other neurologic diseases who were studied at autopsy. Results. Ulcerated plaques were present in 26 percent of the 239 patients with cerebrovascular disease but in only 5 percent of the 261 patients with other neurologic diseases (P < 0.001). After we controlled for age and heart weight, the adjusted rates were 16.9 percent and 5.1 percent, respectively (adjusted odds ratio, 4.0; 95 percent confidence interval, 2.1 to 7.8; P < 0.001). Among the patients with cerebrovascular disease, the prevalence of ulcerated plaques in the aortic arch was 28 percent in the 183 patients with cerebral infarcts and 20 percent in the 56 patients with brain hemorrhage. The prevalence of ulcerated plaques was 61 percent among the 28 patients with no known cause of cerebral infarction, as compared with 22 percent among the 155 patients with a known cause of cerebral infarction (P < 0.001). After adjustment for covariates, the prevalence was 57.8 percent among patients with no known cause of cerebral infarction and 20.2 percent among those with a known cause (adjusted odds ratio, 5.7; 95 percent confidence interval, 2.4 to 13.6; P < 0.001). The presence of ulcerated plaques in the aortic arch was not correlated with the presence of extracranial internal-carotid-artery stenosis, suggesting that these were two independent risk factors for stroke. Conclusions. Ulcerated plaques in the aortic arch may play a part in causing cerebral infarction, especially in patients in whom cerebral infarction has no known cause.	HOP LA PITIE SALPETRIERE, NEUROPATHOL R ESCOUROLLE LAB, F-75651 PARIS 13, FRANCE; UNIV PARIS 06, F-75230 PARIS 05, FRANCE; INSERM, U169, F-94800 VILLEJUIF, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	AMARENCO, P (corresponding author), HOP ST ANTOINE, SERV NEUROL, 184 RUE FAUBOURG ST ANTOINE, F-75571 PARIS 12, FRANCE.		Tzourio, christophe/B-4015-2009; Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; 				BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CAPLAN LR, 1978, NEUROLOGY, V28, P1206, DOI 10.1212/WNL.28.12.1206; CASTLEMA B, 1967, NEW ENGL J MED, V276, P1368, DOI 10.1056/NEJM196706152762410; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1557, DOI 10.1056/NEJM199011293232209; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; ESCOUROLLE R, 1976, J NEUROL SCI, V28, P103, DOI 10.1016/0022-510X(76)90051-4; ESCOUROLLE R, 1966, REV PRATICIEN, V16, P749; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; FISHER CM, 1965, J NEUROPATH EXP NEUR, V24, P455, DOI 10.1097/00005072-196507000-00007; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; LHERMITTE F, 1966, REV NEUROL-FRANCE, V115, P641; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; MILLIKAN C, 1990, STROKE, V21, P1251, DOI 10.1161/01.STR.21.9.1251; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; OSTER P, 1979, JAMA-J AM MED ASSOC, V242, P2070, DOI 10.1001/jama.242.19.2070; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; RUSSELL RWR, 1983, VASCULAR DISEASE CEN, P368; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WINTER WJ, 1957, ARCH PATHOL, V64, P137; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; 1972, NEW ENGL J MED, V286, P1146; 1990, SAS USERS GUIDE STAT, V1	34	450	461	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					221	225		10.1056/NEJM199201233260402	http://dx.doi.org/10.1056/NEJM199201233260402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1727976				2022-12-28	WOS:A1992HA43100002
J	RUTTIMANN, S; CLEMENCON, D; DUBACH, UC				RUTTIMANN, S; CLEMENCON, D; DUBACH, UC			USEFULNESS OF COMPLETE BLOOD COUNTS AS A CASE-FINDING TOOL IN MEDICAL OUTPATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD CELL COUNT; AMBULATORY CARE; DIAGNOSTIC TESTS, ROUTINE; COST-BENEFIT ANALYSIS; PATIENT CARE MANAGEMENT		Objective: To determine the usefulness of routine complete blood counts as a case-finding tool in medical outpatients. Design: Prospective evaluation in a consecutive, unselected cohort. Setting: A university-based outpatient clinic providing primary and referral care in general internal medicine. Patients: A total of 595 patients (mean age [+/- SD], 40 +/- 15 years) making their initial clinic visit. Intervention: A complete blood count was done in all patients. Components of the complete blood count that were not indicated for diagnostic or management purposes at the initial visit were classified as routine tests. Main Outcome Measures: The number and nature of new diagnoses leading to new patient management; the number of additional visits and diagnostic tests precipitated by positive results. Main Results: Of the 2378 tests done, 1540 (65%) were routine tests. The percentages of abnormal test results for the four hematologic test components were as follows: leukocyte count, 7.6%; hemoglobin, 5.8%; mean corpuscular volume (MCV) of red blood cells, 7.9%; and platelet count, 4.5%. In only three patients (0.5%) was a new diagnosis made that led to a new management strategy (treatment of iron deficiency). Further work-up was unprofitable in 14 patients (2.4%). Two additional visits were necessary because of abnormal results on routine tests. No abnormality-associated clinical disease developed during a 15-month follow-up period in patients with unexplained abnormal results on routine hematologic tests. Conclusions: The routine complete blood count has limited usefulness as a case-finding tool and has a minimal effect on care in middle-aged medical outpatients.			RUTTIMANN, S (corresponding author), KANTONSSPITAL,DEPT INTERNAL MED,CH-4031 BASEL,SWITZERLAND.							DELAHUNT B, 1980, NEW ZEAL MED J, V92, P431; FRYE EB, 1987, J GEN INTERN MED, V2, P373, DOI 10.1007/BF02596360; KAPLAN EB, 1985, JAMA-J AM MED ASSOC, V253, P3576, DOI 10.1001/jama.253.24.3576; PANZER RJ, 1987, J GEN INTERN MED, V2, P365, DOI 10.1007/BF02596179; RICH EC, 1983, JAMA-J AM MED ASSOC, V249, P633; SACKETT DL, 1975, LANCET, V2, P357; SCHNEIDERMAN LJ, 1972, ARCH INTERN MED, V129, P88, DOI 10.1001/archinte.129.1.88; SHAPIRO MF, 1987, ANN INTERN MED, V106, P65, DOI 10.7326/0003-4819-106-1-65	8	20	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					44	50						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727094				2022-12-28	WOS:A1992GX15700007
J	MEISER, BM; BILLINGHAM, ME; MORRIS, RE				MEISER, BM; BILLINGHAM, ME; MORRIS, RE			EFFECTS OF CYCLOSPORINE, FK506, AND RAPAMYCIN ON GRAFT-VESSEL DISEASE	LANCET			English	Note							VASCULAR CHANGES; TRANSPLANTATION	Graft-vessel disease (GVD) limits the long-term survival of heart-transplant patients, and this effect has not been altered by use of cyclosporin for immunosuppression. We compared the effects of the immunosuppressants cyclosporin, FK506, and rapamycin on GVD in a rat-heart transplantation model. Allografted hearts from rats treated with 1 mg/kg FK506 for 50 days showed the same degree of myocardial rejection but a significantly worse (p < 0.05) grade of GVD compared with grafted hearts from rats treated with 1.5 mg/kg cyclosporin for the same time. 2 mg/kg FK506 for 50 days prevented cellular rejection but GVD was as severe as that found with 1 mg/kg FK506. Moderate GVD was present in two of five allografted hearts after treatment with 4 mg/kg FK506. 1-5 mg/kg rapamycin for 50 days was an effective inhibitor of rejection and GVD. Based on our results in rats, the possibility that GVD may occur in human heart-transplant recipients treated with FK506 cannot be excluded.	STANFORD UNIV,MED CTR,SCH MED,DEPT CARDIOTHORAC SURG,TRANSPLANTAT IMMUNOL LAB,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University; Stanford University								BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; CALNE RY, 1989, LANCET, V2, P227; HESS ML, 1987, TRANSPLANT P, V19, P71; JONASSON L, 1988, P NATL ACAD SCI USA, V85, P2303, DOI 10.1073/pnas.85.7.2303; LADEN AM, 1973, TRANSPL P, V5, P737; LIBBY P, 1989, TRANSPLANT P, V21, P3677; MEISER BM, 1991, TRANSPLANTATION, V51, P690, DOI 10.1097/00007890-199103000-00028; MORRIS RE, 1991, TRANSPL P, V23, P521; OCHIAI T, 1989, TRANSPLANTATION, V48, P193, DOI 10.1097/00007890-198908000-00003; TOCCI MJ, 1989, J IMMUNOL, V143, P718	10	123	130	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1991	338	8778					1297	1298		10.1016/0140-6736(91)92594-R	http://dx.doi.org/10.1016/0140-6736(91)92594-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1719321				2022-12-28	WOS:A1991GR02300006
J	CLEVELAND, DW; HOFFMAN, PN				CLEVELAND, DW; HOFFMAN, PN			SLOW AXONAL-TRANSPORT MODELS COME FULL CIRCLE - EVIDENCE THAT MICROTUBULE SLIDING MEDIATES AXON ELONGATION AND TUBULIN TRANSPORT	CELL			English	Review							PC12 CELLS; STABILITY; NEURONS		JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	CLEVELAND, DW (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BAAS PW, 1990, J CELL BIOL, V111, P495, DOI 10.1083/jcb.111.2.495; BAMBURG JR, 1986, NATURE, V321, P788, DOI 10.1038/321788a0; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; KEITH CH, 1987, SCIENCE, V235, P337, DOI 10.1126/science.2432662; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; LASEK RJ, 1986, J CELL SCI S, V5, P161; LIM SS, 1989, J CELL BIOL, V109, P253, DOI 10.1083/jcb.109.1.253; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PAPASOZOMENOS SC, 1981, J CELL BIOL, V91, P866, DOI 10.1083/jcb.91.3.866; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TSUKITA S, 1981, BIOMED RES-TOKYO, V2, P424, DOI 10.2220/biomedres.2.424	18	33	34	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					453	456		10.1016/0092-8674(91)90518-4	http://dx.doi.org/10.1016/0092-8674(91)90518-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1718604	hybrid			2022-12-28	WOS:A1991GN66400002
J	STAMENKOVIC, I; SGROI, D; ARUFFO, A; SY, MS; ANDERSON, T				STAMENKOVIC, I; SGROI, D; ARUFFO, A; SY, MS; ANDERSON, T			THE LYMPHOCYTE-B ADHESION MOLECULE CD22 INTERACTS WITH LEUKOCYTE COMMON ANTIGEN CD45RO ON T-CELLS AND ALPHA-2-6 SIALYLTRANSFERASE, CD75, ON B-CELLS	CELL			English	Article							MONOCLONAL-ANTIBODIES; COGNATE INTERACTIONS; MEMBRANE-PROTEIN; IMMUNE-SYSTEM; SIALYL-LEX; RECEPTOR; ACTIVATION; CDNA; DIFFERENTIATION; EXPRESSION	Functional maturation of B lymphocytes correlates with expression of the B lineage-specific cell surface glycoprotein CD22. Two CD22 polypeptides have been characterized and suggested to play a role in B cell-B cell interaction as well as in B cell adhesion to monocytes. In this work we provide evidence that CD22 is directly involved in the cognate interaction between B and T cells. One of the two CD22 polypeptides, CD22-beta, interacts with a specific ligand on a subpopulation of CD4+ T cells. Our results suggest that the T cell ligand of CD22 is CD45RO, an isoform of the leukocyte common antigen class of phosphotyrosine phosphatases associated with the helper T cell phenotype. We further demonstrate that CD22 recognizes a second ligand, CD75, expressed predominantly on activated B cells and shown to be a cell surface alpha-2-6 sialytransferase.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP E, BOSTON, MA 02129 USA; BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Harvard University; Harvard Medical School; Bristol-Myers Squibb	STAMENKOVIC, I (corresponding author), MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA.		Sgroi, Dennis/AAV-2487-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], PROG IMMUNOL, DOI DOI 10.1016/B978-0-12-057550-3.50033-8; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARSOUMIAN EL, 1989, LEUKOCYTE TYPING 4, P75; BARTLETT WC, 1990, J IMMUNOL, V145, P3956; BARTLETT WC, 1989, J IMMUNOL, V143, P1745; BOUE DR, 1988, J IMMUNOL, V140, P192; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSTEIN BK, 1989, LEUKOCYTE TYPING 4, P110; GOLAY JT, 1985, J IMMUNOL, V135, P3795; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPLAN HA, 1983, J BIOL CHEM, V258, P1505; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; KISHIMOTO T, 1985, ANNU REV IMMUNOL, V3, P133, DOI 10.1146/annurev.iy.03.040185.001025; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1986, P NATL ACAD SCI USA, V83, P6080, DOI 10.1073/pnas.83.16.6080; LAMMERS G, 1988, J BIOCH, V256, P623; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MORIMOTO C, 1986, J IMMUNOL, V137, P3247; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PULIDO R, 1989, J IMMUNOL, V143, P1930; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SANDERS VM, 1986, J IMMUNOL, V137, P2395; SCHIMPL A, 1972, NATURE-NEW BIOL, V237, P15, DOI 10.1038/newbio237015a0; SCHWARTZALBIEZ R, 1989, LEUKOCYTE TYPING 4, P65; SCHWINZER R, 1989, LEUKOCYTE TYPING, V4, P628; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SMITH SH, 1986, IMMUNOLOGY, V58, P63; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; STROSS WP, 1989, LEUKOCYTE TYPING, V4, P615; SWAIN SL, 1987, IMMUNOL REV, V99, P263, DOI 10.1111/j.1600-065X.1987.tb01180.x; TAIARA S, 1986, J IMMUNOL, V137, P2448; TEDDER TF, 1985, J IMMUNOL, V135, P973; TERRY LA, 1988, IMMUNOLOGY, V64, P331; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VITETTA ES, 1987, IMMUNOL REV, V99, P193, DOI 10.1111/j.1600-065X.1987.tb01178.x; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WHALEN BJ, 1988, J IMMUNOL, V141, P2230; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WONG JT, 1989, J IMMUNOL, V143, P3404; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313	60	370	400	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1133	1144		10.1016/0092-8674(91)90036-X	http://dx.doi.org/10.1016/0092-8674(91)90036-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717156				2022-12-28	WOS:A1991GG55200008
J	COBB, N; ETZEL, RA				COBB, N; ETZEL, RA			UNINTENTIONAL CARBON-MONOXIDE RELATED DEATHS IN THE UNITED-STATES, 1979 THROUGH 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MORTALITY; ARRHYTHMIAS; EXPOSURE; ANGINA	Objective.-To describe the epidemiology of recent unintentional carbon monoxide poisoning deaths in the United States. Design.-Descriptive analysis of carbon monoxide-related deaths in the United States from 1979 through 1988, based on death certificate reports compiled by the National Center for Health Statistics. Population Studied.-All US deaths, 1979 through 1988. Results.-We reviewed data from 56 133 death certificates that contained codes implicating carbon monoxide as a contributing cause of death. Of these, 25 889 were suicides, 21 0 were homicides, 15 523 were associated with severe burns or house fires, and 11 547 were classified as unintentional. The number of unintentional deaths decreased steadily by about 63 deaths per year, from 1513 in 1979 to 878 in 1988. The highest death rates occurred in winter and among males, blacks, the elderly, and residents of northern states. Motor vehicle exhaust gas caused 6552 (57%) of the unintentional deaths; 5432 (83%) of these were associated with stationary automobiles. Conclusions.-The rate of unintentional death from carbon monoxide poisoning is decreasing. This may be attributable to improvements in automobile pollution control systems and improved safety of cooking and heating appliances. Prevention programs should target young drivers, males, and the elderly.			COBB, N (corresponding author), CTR DIS CONTROL, CTR ENVIRONM HLTH & INJURY CONTROL, ATLANTA, GA 30333 USA.		Etzel, Ruth A./N-5700-2019	Etzel, Ruth A./0000-0002-5236-3976				ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; ANDERSON EW, 1973, ANN INTERN MED, V79, P46, DOI 10.7326/0003-4819-79-1-46; DAVIES DM, 1980, ENVIRON RES, V21, P197, DOI 10.1016/0013-9351(80)90022-5; GITTELSOHN A, 1979, AM J PUBLIC HEALTH, V69, P680, DOI 10.2105/AJPH.69.7.680; GLASSER JH, 1981, AM J PUBLIC HEALTH, V71, P231, DOI 10.2105/AJPH.71.3.231; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOODMAN RA, 1982, JAMA-J AM MED ASSOC, V247, P793, DOI 10.1001/jama.247.6.793; QUARLES J, 1990, NEW CLEAN AIR ACT GU; SCHAPLOWSKY AF, 1974, J ENV HLTH, V36, P569; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; STERN FB, 1988, AM J EPIDEMIOL, V128, P1276, DOI 10.1093/oxfordjournals.aje.a115081; THOM SR, 1989, J TOXICOL-CLIN TOXIC, V27, P141; WALDEN SM, 1990, ANN INTERN MED, V113, P337, DOI 10.7326/0003-4819-113-5-337; 1980, PHS801260 US DEP HLT; 1989, ASHRAE621989 AM SOC; 1979, UNDERLYING CAUSE DEA; 1991, MMWR, V40, P154; 1991, EPA450491004 PUBL	18	218	222	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1991	266	5					659	663		10.1001/jama.266.5.659	http://dx.doi.org/10.1001/jama.266.5.659			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ140	1712865				2022-12-28	WOS:A1991FZ14000023
J	STJOHNSTON, D; BEUCHLE, D; NUSSLEINVOLHARD, C				STJOHNSTON, D; BEUCHLE, D; NUSSLEINVOLHARD, C			STAUFEN, A GENE REQUIRED TO LOCALIZE MATERNAL RNAS IN THE DROSOPHILA EGG	CELL			English	Article							POLAR GRANULES; EFFECT MUTATIONS; ANTEROPOSTERIOR POLARITY; BICOID PROTEIN; EMBRYO; PATTERN; MELANOGASTER; SEGMENTATION; VASA; EXPRESSION	The posterior group gene staufen is required both for the localization of maternal determinants to the posterior pole of the Drosophila egg and for bicoid RNA to localize correctly to the anterior pole. We report the cloning and sequencing of staufen and show that staufen protein is one of the first molecules to localize to the posterior pole of the oocyte, perhaps in association with oskar RNA. Once localized, staufen is found in the polar granules and is required to hold other polar granule components at the posterior pole. By the time the egg is laid, staufen protein is also concentrated at the anterior pole, in the same region as bicoid RNA.	MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,W-7400 TUBINGEN,GERMANY	Max Planck Society			St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301				AKAM M, 1987, DEVELOPMENT, V101, P1; BERG CA, 1991, GENETICS, V127, P515; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COUNCE SJ, 1963, J MORPHOL, V112, P129, DOI 10.1002/jmor.1051120203; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUNCAN IM, 1982, GENETICS, V102, P49; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King R. C., 1970, OVARIAN DEV DROSOPHI; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEHMANN R, 1991, IN PRESS DEVELOPMENT; LEPTIN M, 1990, DEVELOPMENT, V110, P73; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; RAFF JW, 1990, DEVELOPMENT, V110, P1249; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9	49	524	529	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					51	63		10.1016/0092-8674(91)90138-O	http://dx.doi.org/10.1016/0092-8674(91)90138-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712672				2022-12-28	WOS:A1991FW91300008
J	YOUNG, LS; DUNSTAN, HM; WITTE, PR; SMITH, TP; OTTONELLO, S; SPRAGUE, KU				YOUNG, LS; DUNSTAN, HM; WITTE, PR; SMITH, TP; OTTONELLO, S; SPRAGUE, KU			A CLASS-III TRANSCRIPTION FACTOR COMPOSED OF RNA	SCIENCE			English	Article							POLYMERASE-III; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; PURIFICATION; RECOGNITION; COMPLEXES; SEQUENCES; REQUIRES; REGION; SIGNAL	It is generally assumed that the machinery that transcribes genes is composed entirely of polypeptides. However, in vitro transcription by silkworm RNA polymerase III requires a transcription factor that is not a polypeptide. This component, TFIIIR, is distinct from the previously identified transcription components: RNA polymerase III, and the accessory factors TFIIIA, TFIIIB, TFIIIC, and TFIIID. The newly discovered TFIIIR is a macromolecule that appears to be composed of RNA. It is resistant to heat, detergent, phenol, protease, and deoxyribonuclease, but it is sensitive to alkali and ribonuclease.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA; UNIV PARMA, INST SCI BIOCHIM, I-43100 PARMA, ITALY	University of Oregon; University of Oregon; University of Oregon; University of Parma					NIGMS NIH HHS [GM 32851, GM 07413, GM 25388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025388, R01GM032851] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CIECHANOVER A, 1985, P NATL ACAD SCI USA, V82, P1341, DOI 10.1073/pnas.82.5.1341; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DUNSTAN H, UNPUB; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HEINS JN, 1967, J BIOL CHEM, V242, P1016; HUANG DD, 1984, SCIENCE, V225, P1482, DOI 10.1126/science.6206568; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KLEKAMP MS, 1987, J BIOL CHEM, V262, P7878; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; MORTON DG, 1982, MOL CELL BIOL, V2, P1524, DOI 10.1128/MCB.2.12.1524; MOWRY KL, 1988, TRENDS BIOCHEM SCI, V13, P447, DOI 10.1016/0968-0004(88)90220-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PACE NR, 1987, MOL BIOL RNA NEW PER, P17; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROMANIUK PJ, 1988, MOL BIOL RNA, P123; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SMITH TW, UNPUB; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; SPRAGUE KU, 1987, RNA POLYM REGULATION, P195; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUZUKI Y, 1974, J MOL BIOL, V88, P393, DOI 10.1016/0022-2836(74)90490-2; TANIUCHI H, 1966, J BIOL CHEM, V241, P4366; TOMIZAWA J, 1987, MOL BIOL RNA NEW PER, P249; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WILSON ET, 1988, MOL CELL BIOL, V8, P624, DOI 10.1128/MCB.8.2.624; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	43	48	48	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					542	546		10.1126/science.1708526	http://dx.doi.org/10.1126/science.1708526			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1708526				2022-12-28	WOS:A1991FJ12700039
J	BAGRODIA, S; CHACKALAPARAMPIL, I; KMIECIK, TE; SHALLOWAY, D				BAGRODIA, S; CHACKALAPARAMPIL, I; KMIECIK, TE; SHALLOWAY, D			ALTERED TYROSINE-527 PHOSPHORYLATION AND MITOTIC ACTIVATION OF P60C-SRC	NATURE			English	Article							OVEREXPRESSED PP60C-SRC; PROTEIN-KINASE; MITOSIS; TRANSFORMATION; SITES; ENTRY	The tyrosine kinase activity of p60c-src, the protein of the c-src gene, increase during mitosis 1,2; this may be important in initiating at least some of the cellular changes that occur during this phase of the cell cycle. Although there is evidence that p60c-src is phosphorylated at several sites during mitosis, phosphorylation in vitro does not increase its kinase activity 2,3. We now report that this kinase activity of a p60c-src mutant with residue tyrosine 527 changed to phenylanine does not change during the cell cycle, suggesting that changes in the phosphorylation state of this residue may be responsible for the activation of p60c-src at mitosis. Although changes in phosphorylation at Tyr527 cannot be detected with the wild-type protein we find that phosphorylation at Tyr527 of a mutant with reduced kinase activity decreased threefold during mitosis. On the basis of these results we suggest that activation of p60c-src at mitosis results from decreased phosphorylation on Tyr 527, and that p60c-src may be or may activate the kinase that phosphorylates Tyr 527.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; CORNELL UNIV,DEPT PATHOL,ITHACA,NY 14853	Cornell University; Cornell University				Kmiecik, Thomas/0000-0002-1367-443X				CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; 1987, TP007 MILL INT; 1987, TP006 MILL INT	17	121	122	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					172	175		10.1038/349172a0	http://dx.doi.org/10.1038/349172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1702522				2022-12-28	WOS:A1991ER41800064
J	KALINKE, U; ARNOLD, B; HAMMERLING, GJ				KALINKE, U; ARNOLD, B; HAMMERLING, GJ			STRONG XENOGENEIC HLA RESPONSE IN TRANSGENIC MICE AFTER INTRODUCING AN ALPHA-3 DOMAIN INTO HLA-B27	NATURE			English	Article											KALINKE, U (corresponding author), GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.			Kalinke, Ulrich/0000-0003-0503-9564				ALTER BJ, 1990, J EXP MED, V171, P333, DOI 10.1084/jem.171.1.333; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; ARNOLD B, 1984, NUCLEIC ACIDS RES, V12, P9473, DOI 10.1093/nar/12.24.9473; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; COPPIN HL, 1986, J IMMUNOL, V137, P2168; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DILL O, 1988, P NATL ACAD SCI USA, V85, P5664, DOI 10.1073/pnas.85.15.5664; DUTTON RW, 1978, IMMUNOL REV, V42, P20, DOI 10.1111/j.1600-065X.1978.tb00257.x; ENGELHARD VH, 1978, P NATL ACAD SCI USA, V75, P5688, DOI 10.1073/pnas.75.11.5688; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HAMMERLING GJ, 1989, EUR J IMMUNOL, V19, P599, DOI 10.1002/eji.1830190404; HINES DL, 1976, TRANSPLANTATION, V21, P375, DOI 10.1097/00007890-197605000-00003; IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091; KIEVITS F, 1989, P NATL ACAD SCI USA, V86, P617, DOI 10.1073/pnas.86.2.617; KOLLER BH, 1985, J IMMUNOL, V134, P2727; KRIMPENFORT P, 1987, EMBO J, V6, P1673, DOI 10.1002/j.1460-2075.1987.tb02416.x; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAZIARZ RT, 1988, J IMMUNOL, V140, P4372; OZATO K, 1983, P NATL ACAD SCI-BIOL, V80, P2040, DOI 10.1073/pnas.80.7.2040; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; REBAI N, 1983, TISSUE ANTIGENS, V22, P107; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAMBERG NL, 1989, EUR J IMMUNOL, V19, P2349, DOI 10.1002/eji.1830191225; SHIMONKEVITZ R, 1985, J IMMUNOL, V135, P892; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; WIDMER MB, 1972, J EXP MED, V135, P1204, DOI 10.1084/jem.135.5.1204; WILSON DB, 1971, J EXP MED, V134, P857, DOI 10.1084/jem.134.4.857	29	97	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 13	1990	348	6302					642	644		10.1038/348642a0	http://dx.doi.org/10.1038/348642a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM760	1701221				2022-12-28	WOS:A1990EM76000063
J	GLINIAK, BC; ROHRSCHNEIDER, LR				GLINIAK, BC; ROHRSCHNEIDER, LR			EXPRESSION OF THE M-CSF RECEPTOR IS CONTROLLED POSTTRANSCRIPTIONALLY BY THE DOMINANT ACTIONS OF GM-CSF OR MULTI-CSF	CELL			English	Article											GLINIAK, BC (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA020551, R01CA040987] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40987, CA 20551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; BURGESS AW, 1980, INT J CANCER, V26, P647, DOI 10.1002/ijc.2910260517; BURGESS AW, 1977, EXPT HEMATOLOGY TODA, P135; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DEXTER TM, 1980, J EXP MED, V152, P1026; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DONAHUE RE, 1986, NATURE, V321, P872, DOI 10.1038/321872a0; ETTENSOHN CA, 1990, SCIENCE, V248, P1115, DOI 10.1126/science.2188366; ETTENSOHN CA, 1988, DEV BIOL, V125, P396, DOI 10.1016/0012-1606(88)90220-5; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HAPEL AJ, 1984, BLOOD, V64, P786; HOLMES KL, 1988, IMMUNOL TODAY, V9, P344, DOI 10.1016/0167-5699(88)91335-7; IKEBUCHI K, 1988, P NATL ACAD SCI USA, V85, P3445, DOI 10.1073/pnas.85.10.3445; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOIKE K, 1986, BLOOD, V67, P859; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; Maniatis T., 1982, MOL CLONING; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1984, HEMOPOIETIC COLONIES; METCALF D, 1989, MOL CONTROL BLOOD CE; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; OGAWA M, 1983, BLOOD, V61, P823; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P5883, DOI 10.1021/bi00566a034; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SXHULER GD, 1988, CELL, V55, P1115; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WILLIAMS DE, 1987, EXP HEMATOL, V15, P243; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	52	124	125	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 30	1990	63	5					1073	1083		10.1016/0092-8674(90)90510-L	http://dx.doi.org/10.1016/0092-8674(90)90510-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EL759	1701692				2022-12-28	WOS:A1990EL75900022
J	GARRY, RF; FERMIN, CD; HART, DJ; ALEXANDER, SS; DONEHOWER, LA; HONG, LZ				GARRY, RF; FERMIN, CD; HART, DJ; ALEXANDER, SS; DONEHOWER, LA; HONG, LZ			DETECTION OF A HUMAN INTRACISTERNAL A-TYPE RETROVIRAL PARTICLE ANTIGENICALLY RELATED TO HIV	SCIENCE			English	Article									CAMBRIDGE BIOTECH CORP,ROCKVILLE,MD 20850; TULANE UNIV,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112; BAYLOR UNIV,DIV MOLEC VIROL,HOUSTON,TX 77030	Tulane University; Baylor University	GARRY, RF (corresponding author), TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NEW ORLEANS,LA 70112, USA.			Garry, Robert/0000-0002-5683-3250	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022720, R01AI028048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000712] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22720, AI 28048] Funding Source: Medline; NIDCD NIH HHS [DC 00712] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALEXANDER S, UNPUB; CALARCO PG, 1973, NATURE-NEW BIOL, V243, P91; CIAMPOLILLO A, 1989, LANCET, V1, P1096; CRAWFORD TB, 1980, SCIENCE, V207, P997, DOI 10.1126/science.6153243; DUVIC M, 1987, J AM ACAD DERMATOL, V17, P656, DOI 10.1016/S0190-9622(87)70252-7; FERMIN CD, UNPUB; GARRY RF, UNPUB; GOTTLIEB A A, 1979, Wakayama Medical Reports, V21, P107; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HART DT, UNPUB; HERMANN M, 1989, MOL CELLULAR MECHANI; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; KOWALSKI M, 1989, P NATL ACAD SCI USA, V86, P3346, DOI 10.1073/pnas.86.9.3346; KRIEG AM, 1988, VIROLOGY, V162, P274, DOI 10.1016/0042-6822(88)90422-9; KUFF EL, 1968, CANCER RES, V28, P2137; KUFF EL, 1988, ADV CANCER RES, V51, P184; LEITER EH, 1986, J EXP MED, V163, P87, DOI 10.1084/jem.163.1.87; LEVY JA, 1975, J VIROL, V16, P844, DOI 10.1128/JVI.16.4.844-853.1975; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; RASHEED S, 1986, VIROLOGY, V154, P395, DOI 10.1016/0042-6822(86)90465-4; ROBERTSON DL, 1975, J VIROL, V15, P407, DOI 10.1128/JVI.15.2.407-415.1975; RUCHETON M, 1985, VIROLOGY, V144, P468, DOI 10.1016/0042-6822(85)90287-9; SARNGADHARAN MG, 1978, BIOCHIM BIOPHYS ACTA, V516, P419, DOI 10.1016/0304-419X(78)90019-7; SCHIODT M, 1989, AIDS, V3, P819, DOI 10.1097/00002030-198912000-00006; STRICKER RB, 1987, NATURE, V327, P710, DOI 10.1038/327710a0; STRICKER RB, 1985, NEW ENGL J MED, V313, P1375, DOI 10.1056/NEJM198511283132202; TALAL N, 1990, ARTHRITIS RHEUM, V33, P774, DOI 10.1002/art.1780330603; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; WAITE MRF, 1975, J VIROL, V16, P872, DOI 10.1128/JVI.16.4.872-879.1975; WILSON SH, 1972, P NATL ACAD SCI USA, V69, P1531, DOI 10.1073/pnas.69.6.1531; WONGSTAAL F, 1975, J VIROL, V16, P887, DOI 10.1128/JVI.16.4.887-896.1975; YANG SS, 1973, J VIROL, V11, P287, DOI 10.1128/JVI.11.2.287-298.1973; ZIEGLER JL, 1986, CLIN IMMUNOL IMMUNOP, V41, P305, DOI 10.1016/0090-1229(86)90001-2	35	224	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 23	1990	250	4984					1127	1129		10.1126/science.1701273	http://dx.doi.org/10.1126/science.1701273			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701273				2022-12-28	WOS:A1990EJ58100033
J	WEHR, TA				WEHR, TA			IMPROVEMENT OF DEPRESSION AND TRIGGERING OF MANIA BY SLEEP-DEPRIVATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIDEPRESSANT RESPONSE; PHASE ADVANCE; WAKE CYCLE; POTENTIATION; PREDICTION; SECRETION; STATES; TSH				WEHR, TA (corresponding author), NIMH,CLIN PSYCHOBIOL BRANCH,BLDG 10,ROOM 4S-239,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							EARLE BV, 1970, AM J PSYCHIAT, V126, P1667, DOI 10.1176/ajp.126.11.1667; ELSENGA A, 1988, SLEEP 1986, P448; ELSENGA S, 1987, J PSYCHIAT RES, V21, P151; Gershon ES, 1987, PSYCHOPHARMACOLOGY 3, P481; GOETZE U, 1981, PSYCHIAT CLIN, V14, P129, DOI 10.1159/000283910; GOODWIN FK, 1982, AM J PSYCHIAT, V139, P34; HAUG HJ, 1990, PSYCHIATRY TODAY ACC, P500; KASCHKA WP, 1989, PSYCHIAT RES, V29, P231, DOI 10.1016/0165-1781(89)90038-3; KASPER S, 1988, BIOL PSYCHIAT, V24, P631, DOI 10.1016/0006-3223(88)90137-0; KUHS H, 1990, PSYCHIATRY TODAY ACC, P484; LEIBENLUFT E, 1991, AM J PSYCHIAT, V149, P159; PRANGE AJ, 1969, AM J PSYCHIAT, V126, P457, DOI 10.1176/ajp.126.4.457; REININK E, 1990, PSYCHIAT RES, V32, P113, DOI 10.1016/0165-1781(90)90077-I; RIEMANN D, 1991, SLEEP RES, V20, P276; ROBERTSON GM, 1921, MANIC DEPRESSIVE INS; SACK DA, 1988, ACTA PSYCHIAT SCAND, V77, P219, DOI 10.1111/j.1600-0447.1988.tb05104.x; SACK DA, 1988, PSYCHIAT RES, V23, P179, DOI 10.1016/0165-1781(88)90008-X; SACK DA, 1985, AM J PSYCHIAT, V142, P606; SOUETRE E, 1987, J AFFECT DISORDERS, V12, P41, DOI 10.1016/0165-0327(87)90059-0; STYRON W, 1988, DARKNESS VISIBLE MEM, V18, P141; VOGEL GW, 1980, ARCH GEN PSYCHIAT, V37, P247; WEHR TA, 1985, ACTA PSYCHIAT SCAND, V72, P161, DOI 10.1111/j.1600-0447.1985.tb02589.x; WEHR TA, 1989, J CLIN PSYCHIAT, V50, P8; WEHR TA, 1990, PSYCHIATRY TODAY ACC, P467; Wehr TA., 1990, SLEEP BIOL RHYTHMS, P42; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WIEGAND M, IN PRESS INTEGRATIVE; WU JC, 1990, AM J PSYCHIAT, V147, P14	28	40	41	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					548	551		10.1001/jama.267.4.548	http://dx.doi.org/10.1001/jama.267.4.548			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729578				2022-12-28	WOS:A1992GZ43900033
J	LINDEN, DJ; CONNOR, JA				LINDEN, DJ; CONNOR, JA			PARTICIPATION OF POSTSYNAPTIC PKC IN CEREBELLAR LONG-TERM DEPRESSION IN CULTURE	SCIENCE			English	Article							PROTEIN KINASE-C; PURKINJE-CELL DENDRITES; EXCITATORY AMINO-ACIDS; CLIMBING FIBER; GRANULE CELL; GLUTAMATE SENSITIVITY; CALCIUM; INDUCTION; INVITRO; POTENTIATION	Long-term depression (LTD) in the intact cerebellum is a decrease in the efficacy of the parallel fiber-Purkinje neuron synapse induced by coactivation of climbing fiber and parallel fiber inputs. In cultured Purkinje neurons, a similar depression can be induced by iontophoretic glutamate pulses and Purkinje neuron depolarization. This form of LTD is expressed as a depression of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-mediated current, and its induction is dependent on activation of metabotropic quisqualate receptors. The effect of inhibitors of protein kinase C (PKC) on LTD induction was studied. Inhibitors of PKC blocked LTD induction, while phorbol-12,13-diacetate (PDA), a PKC activator, mimicked LTD. These results suggest that PKC activation is necessary for the induction of cerebellar LTD.			LINDEN, DJ (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,NUTLEY,NJ 07110, USA.							AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DUPONT JL, 1987, DEV BRAIN RES, V34, P59, DOI 10.1016/0165-3806(87)90195-7; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; EKEROT CF, 1981, J PHYSIOL-LONDON, V318, P207; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEBB DO, 1949, ORG BEHAVIOR; HIRANO T, 1990, NEUROSCI LETT, V119, P141, DOI 10.1016/0304-3940(90)90818-T; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KNOPFEL T, 1991, EUR J NEUROSCI, V3, P343, DOI 10.1111/j.1460-9568.1991.tb00821.x; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LINDEN DJ, UNPUB; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SANGAMESWARAN L, 1989, P NATL ACAD SCI USA, V86, P5651, DOI 10.1073/pnas.86.14.5651; SCHILLING K, IN PRESS NEURON; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; THOMASSET M, 1984, DEV PHARMACOL THERAP, V7, P6, DOI 10.1159/000457220; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519	38	266	272	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1656	1659		10.1126/science.1721243	http://dx.doi.org/10.1126/science.1721243			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721243				2022-12-28	WOS:A1991GV07300049
J	SMITH, B; SELBY, P; SOUTHGATE, J; PITTMAN, K; BRADLEY, C; BLAIR, GE				SMITH, B; SELBY, P; SOUTHGATE, J; PITTMAN, K; BRADLEY, C; BLAIR, GE			DETECTION OF MELANOMA-CELLS IN PERIPHERAL-BLOOD BY MEANS OF REVERSE-TRANSCRIPTASE AND POLYMERASE CHAIN-REACTION	LANCET			English	Article							HUMAN MALIGNANT-MELANOMA; GENE; AMPLIFICATION; TYROSINASE; INSERTION; SEQUENCE; DNA	Only small numbers of cells from solid tumours are needed for haematogenous metastasis. Detection is difficult because existing techniques are not sensitive enough. We have used reverse transcriptase to make complementary DNA from peripheral blood messenger RNA, and the polymerase chain reaction (PCR) to amplify cDNA specific for a gene actively transcribed only in the tumour tissue type. We prepared cDNA from peripheral blood of seven patients with malignant melanoma, four patients with other metastatic cancers, and four healthy subjects, as well as from several melanoma-derived cell lines. PCR was used to amplify the gene for tyrosinase, a tissue-specific gene in melanocytes. Since normal melanocytes are not thought to circulate in peripheral blood, detection of tyrosinase transcription in peripheral blood should indicate the presence of circulating cancer cells. The method was highly sensitive and could detect a single melanoma cell from a cell line in 2 ml normal blood. Blood samples from four of the seven patients with malignant melanoma gave positive results, whereas all eight control subjects gave negative results. This method does not depend on the characterisation of cancer-specific genetic abnormalities and can be applied to any cancer for which tissue-specific genes can be identified, including epithelial cancers. It could prove useful in the diagnosis of primary or metastatic cancers, in assessing prognosis, and in detecting residual disease after treatment.	ST JAMES UNIV HOSP,INST CANC STUDIES,YORKSHIRE CANC RES CAMPAIGN,BECKETT ST,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	Saint James's University Hospital; University of Leeds			Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X				CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LIAO SK, 1975, J NATL CANCER I, V54, P1037; LO YMD, 1989, LANCET, V2, P1363; LYONS J, 1990, PCR PROTOCOLS GUIDE, P386; MOSS TJ, 1990, J CLIN ONCOL, V8, P736, DOI 10.1200/JCO.1990.8.4.736; NAITO H, 1991, EUR J CANCER, V27, P762, DOI 10.1016/0277-5379(91)90184-F; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; TARIN D, 1984, BRIT MED J, V288, P749, DOI 10.1136/bmj.288.6419.749; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563	15	583	629	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1991	338	8777					1227	1229		10.1016/0140-6736(91)92100-G	http://dx.doi.org/10.1016/0140-6736(91)92100-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1719320				2022-12-28	WOS:A1991GQ16600002
J	HOKKENKOELEGA, ACS; STIJNEN, T; KEIZERSCHRAMA, SMPFD; WIT, JM; WOLFF, ED; DEJONG, MCJW; DONCKERWOLCKE, RA; ABBAD, NCB; BOT, A; BLUM, WF; DROP, SLS				HOKKENKOELEGA, ACS; STIJNEN, T; KEIZERSCHRAMA, SMPFD; WIT, JM; WOLFF, ED; DEJONG, MCJW; DONCKERWOLCKE, RA; ABBAD, NCB; BOT, A; BLUM, WF; DROP, SLS			PLACEBO-CONTROLLED, DOUBLE-BLIND, CROSS-OVER TRIAL OF GROWTH-HORMONE TREATMENT IN PREPUBERTAL CHILDREN WITH CHRONIC-RENAL-FAILURE	LANCET			English	Article							SOMATOMEDIN-BINDING PROTEIN; FACTOR-I; ADULTS; INSUFFICIENCY	Stunted growth is a serious problem for children with chronic renal failure (CRF) despite normal endogenous growth hormone secretion and normal or elevated plasma concentrations of insulin-like growth factors (IGF) I and II. Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preceded or followed by 6 months of placebo injection. The patients had a full examination every 3 months. Sixteen children completed the study. Height velocity improved significantly with GH therapy (p < 0.0001) and placebo (p < 0.04), but the GH-induced height-velocity increase exceeded that of placebo by 2.9 cm per 6 months. There was a positive relationship between prestudy height velocity and height-velocity increase. Bone maturation was not affected. GH caused a significant increase in IGF-I and a moderate increase in IGF-II plasma concentrations. The pretreatment elevation of IGF-binding protein-1 decreased by almost 50% during GH therapy, while IGF-binding protein-3 increased significantly in concentration, although this increase was significantly smaller than the GH-induced increase in IGF-I. Fructosamine, lipid, and parathyroid concentrations remained constant. Renal function deterioration did not accelerate. Impressive height-velocity increase can be achieved with GH therapy in children with CRF and growth retardation without changes in renal function. Bone maturation appears unaffected suggesting improved final height. Treatment is best started before growth retardation becomes considerable.	ERASMUS UNIV, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV, DEPT ENDOCRINOL GROWTH & REPROD, 3000 DR ROTTERDAM, NETHERLANDS; STATE UNIV UTRECHT, WILHELMINA CHILDRENS HOSP, DEPT PEDIAT, DIV ENDOCRINOL, UTRECHT, NETHERLANDS; STATE UNIV UTRECHT, WILHELMINA CHILDRENS HOSP, DEPT PEDIAT, DIV NEPHROL, UTRECHT, NETHERLANDS; ERASMUS UNIV, SOPHIA CHILDRENS HOSP, DEPT PEDIAT, DIV NEPHROL, 3000 LL ROTTERDAM, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, RADBOUD HOSP, DIV NEPHROL, NIJMEGEN, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT PEDIAT, DIV NEPHROL, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV TUBINGEN, CHILDRENS HOSP, W-7400 TUBINGEN 1, GERMANY	Erasmus University Rotterdam; Erasmus University Rotterdam; Utrecht University; Wilhelmina Kinderziekenhuis; Utrecht University; Wilhelmina Kinderziekenhuis; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL	HOKKENKOELEGA, ACS (corresponding author), ERASMUS UNIV, SOPHIA CHILDRENS HOSP, DEPT PEDIAT, DIV ENDOCRINOL, POB 70029, 3000 LL ROTTERDAM, NETHERLANDS.							ACKLAND FM, 1990, ACTA PAEDIATR SCAND, P32; ALBERTSSONWIKLAND K, 1988, ACTA PAEDIATR SCAND, P77; ALBERTSSONWIKLAND K, 1989, ACTA PAEDIATR SCAND, P35; ARMITAGE P, 1987, STATISTICAL METHODS; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; BLUM WF, 1989, P WORKSHOP IGF BINDI; BOHN H, 1980, ARCH GYNECOL, V229, P279, DOI 10.1007/BF02108579; COWELL CT, 1990, ACTA PAEDIATR SCAND, P29; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P908, DOI 10.1210/jcem-59-5-908; HACKENG WHL, 1986, J CLIN ENDOCR METAB, V63, P447, DOI 10.1210/jcem-63-2-447; HOKKENKOELEGA ACS, 1990, J CLIN ENDOCR METAB, V71, P688, DOI 10.1210/jcem-71-3-688; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; JONES B, 1988, DESIGN ANAL CROSSOVE; KARLBERG J, 1989, ACTA PAEDIATR SCAND, P26; KOCH VH, 1989, J PEDIATR-US, V115, P365, DOI 10.1016/S0022-3476(89)80833-9; MEHLS O, 1988, KIDNEY INT, V33, P45, DOI 10.1038/ki.1988.7; MEHLS O, 1983, KIDNEY INT, V24, pS53; NISHIYAMA S, 1989, ACTA PAEDIATR SC   S, V356, P141; PHILLIPS LS, 1984, J CLIN ENDOCR METAB, V59, P764, DOI 10.1210/jcem-59-4-764; PHILLIPS LS, 1981, METABOLISM, V30, P1091, DOI 10.1016/0026-0495(81)90053-6; POWELL DR, 1986, J CLIN ENDOCR METAB, V63, P1186; RAMIREZ G, 1978, ARCH INTERN MED, V138, P267, DOI 10.1001/archinte.138.2.267; REES L, 1989, ARCH DIS CHILD, V64, P573, DOI 10.1136/adc.64.4.573; RIZZONI G, 1984, KIDNEY INT, V26, P52, DOI 10.1038/ki.1984.133; ROEDE MJ, 1985, TIJDSCHR SOC GEZON S, V63, P1, DOI DOI 10.1007/978-1-4471-1721-6_10; RUTANEN EM, 1988, BIOCHEM BIOPH RES CO, V152, P208, DOI 10.1016/S0006-291X(88)80701-0; SCHWALBE SL, 1977, BMJ-BRIT MED J, V1, P679, DOI 10.1136/bmj.1.6062.679; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Tanner JM., 1983, ASSESSMENT SKELETAL; TONSHOFF B, 1990, J PEDIATR-US, V116, P561, DOI 10.1016/S0022-3476(05)81603-8; VANDIEMENSTEENVOORDE R, 1987, J PEDIATR-US, V110, P351, DOI 10.1016/S0022-3476(87)80493-6; VANSTIPHOUT WAHJ, 1985, PREV MED, V14, P169, DOI 10.1016/0091-7435(85)90032-5; WIT JM, 1989, ACTA PAEDIATR SCAND, V78, P426, DOI 10.1111/j.1651-2227.1989.tb11103.x	34	177	180	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	1991	338	8767					585	590		10.1016/0140-6736(91)90604-N	http://dx.doi.org/10.1016/0140-6736(91)90604-N			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1715501				2022-12-28	WOS:A1991GD80900001
J	DOLCI, S; WILLIAMS, DE; ERNST, MK; RESNICK, JL; BRANNAN, CI; LOCK, LF; LYMAN, SD; BOSWELL, HS; DONOVAN, PJ				DOLCI, S; WILLIAMS, DE; ERNST, MK; RESNICK, JL; BRANNAN, CI; LOCK, LF; LYMAN, SD; BOSWELL, HS; DONOVAN, PJ			REQUIREMENT FOR MAST-CELL GROWTH-FACTOR FOR PRIMORDIAL GERM-CELL SURVIVAL IN CULTURE	NATURE			English	Article							RECEPTOR TYROSINE KINASES; C-KIT; SI-LOCUS; LIGAND; MOUSE; IDENTIFICATION; PROGENITORS; EXPRESSION; CLONING; RAT	MAST-CELL growth factor (MGF) is encoded by the murine steel (Sl) locus and is a ligand for the tyrosine kinase receptor protein encoded by the proto-oncogene c-kit at the murine dominant white spotting (W) locus. Mutations at both these loci affect mast cells, primordial germ cells (PGCs), haemopoietic stem cells and melanocytes. In many Sl and W mutants, the rapid proliferation of PGC that normally occurs between day 7 and 13.5 of embryonic development fails to occur. As c-kit is expressed in PGCs 1,2 while MGF is expressed in the surrounding mesenchyme 2,3, MGF might promote the proliferation of PGCs. Here we report that MGF is essential for PGC survival in culture, but does not stimulate PGC proliferation. Moreover, whereas both the transmembrane and soluble proteolytic cleavage forms of MGF stimulate mast-cell proliferation, soluble MGF has a relatively limited ability to support survival of PGCs in culture, thus explaining the sterility in mice carrying the steel-dickie (Sl(d)) mutation, which encodes only a soluble form of MGF, and providing a functional role for a transmembrane growth factor.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC MECHANISMS CARCINOGENESIS LAB,FREDERICK,MD 21702; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; UNIV ROME TOR VERGATA 2,DIPARTIMENTO SANITA PUBBL & BIOL CELLULARE,I-00173 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Immunex Corporation; Immunex Corporation; Indiana University System; Indiana University-Purdue University Indianapolis; University of Rome Tor Vergata			dolci, susanna/B-8363-2013	dolci, susanna/0000-0002-6864-3673				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BOSWELL HS, 1987, EXP HEMATOL, V15, P46; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CAIRNS L, 1987, THESIS U LOND; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KESHET E, IN PRESS EMBO J; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCCOSHEN JA, 1975, EXPERIENTIA, V31, P589, DOI 10.1007/BF01932475; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORR UA, 1990, DEVELOPMENT, V109, P911; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	26	437	448	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					809	811		10.1038/352809a0	http://dx.doi.org/10.1038/352809a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715518				2022-12-28	WOS:A1991GC96400062
J	LIU, J; FARMER, JD; LANE, WS; FRIEDMAN, J; WEISSMAN, I; SCHREIBER, SL				LIU, J; FARMER, JD; LANE, WS; FRIEDMAN, J; WEISSMAN, I; SCHREIBER, SL			CALCINEURIN IS A COMMON TARGET OF CYCLOPHILIN-CYCLOSPORINE-A AND FKBP-FK506 COMPLEXES	CELL			English	Article							T-CELL ACTIVATION; DEPENDENT PROTEIN PHOSPHATASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; LIMITED PROTEOLYSIS; MACROLIDES FK-506; CALCIUM-BINDING; CALMODULIN	Although the immediate receptors (immunophilins) of the immunosuppressants cyclosporin A (CsA) and FK506 are distinct, their similar mechanisms of inhibition of cell signaling suggest that their associated immunophilin complexes interact with a common target. We report here that the complexes cyclophilin-CsA and FKBP-FK506 (but not cyclophilin, FKBP, FKBP-rapamycin, or FKBP-506BD) competitively bind to and inhibit the Ca2+- and calmodulin-dependent phosphatase calcineurin, although the binding and inhibition of calcineurin do not require calmodulin. These results suggest that calcineurin is involved in a common step associated with T cell receptor and IgE receptor signaling pathways and that cyclophilin and FKBP mediate the actions of CsA and FK506, respectively, by forming drug-dependent complexes with and altering the activity of calcineurin-calmodulin.	STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,STANFORD,CA 94305; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Harvard University; Howard Hughes Medical Institute; Stanford University	LIU, J (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.				NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, P01GM040660, R37GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA 09302] Funding Source: Medline; NIGMS NIH HHS [GM-40660, GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; FRIEDMAN J, 1991, CELL, V66; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, IN PRESS SCIENCE; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JOHANSSON A, 1990, TRANSPLANTATION, V50, P1001, DOI 10.1097/00007890-199012000-00021; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	43	3630	3852	13	240	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					807	815		10.1016/0092-8674(91)90124-H	http://dx.doi.org/10.1016/0092-8674(91)90124-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1715244				2022-12-28	WOS:A1991GC74500019
J	BARASCH, J; KISS, B; PRINCE, A; SAIMAN, L; GRUENERT, D; ALAWQATI, Q				BARASCH, J; KISS, B; PRINCE, A; SAIMAN, L; GRUENERT, D; ALAWQATI, Q			DEFECTIVE ACIDIFICATION OF INTRACELLULAR ORGANELLES IN CYSTIC-FIBROSIS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CONDUCTANCE; GOLGI-APPARATUS; RAT-LIVER; GLYCOPROTEINS; GANGLIOSIDES; BIOSYNTHESIS; FIBROBLASTS; EPITHELIUM; CHANNELS	THE phenotype of cystic fibrosis (CF) includes abnormalities in transepithelial transport of Cl- (refs 1-5), decreased sialylation and increased sulphation and fucosylation of glycoproteins 6-9, and lung colonization with Pseudomonas. It is not apparent how these abnormalities are interrelated, nor how they result from loss of function of the CF gene-encoded transmembrane regulator (CFTR) 10. We have previously shown that that the pH of a secretory granule is regulated by the vesicular conductance for Cl- (ref. 11). Here we find defective acidification in CF cells of the trans-Golgi/trans-Golgi network, of prelysosomes and of endosomes as a result of diminished Cl- conductance. Sialylation of proteins and lipids is reduced and ligand traffic altered. These abnormalities can result from defective acidification because vacuolar pH regulates glycoprotein processing and ligand transport. The CF phenotype is similar to that of alkalinized cells 12 and acidification-defective mutatants 13.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,SAN FRANCISCO,CA 94143	Columbia University; Columbia University; University of California System; University of California San Francisco	BARASCH, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BOAT TF, 1974, AM REV RESPIR DIS, V110, P428; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DICKSON RB, 1981, J CELL BIOL, V89, P29, DOI 10.1083/jcb.89.1.29; FISHMAN PH, 1976, J BIOL CHEM, V251, P4490; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FRATES RC, 1983, PEDIATR RES, V17, P30, DOI 10.1203/00006450-198301000-00006; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; Roseman S., 1966, METHOD ENZYMOL, V8, P354; ROSNER H, 1973, J NEUROCHEM, V21, P655, DOI 10.1111/j.1471-4159.1973.tb06010.x; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TAATJES DJ, 1986, EUR J CELL BIOL, V42, P344; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WESLEY A, 1983, PEDIATR RES, V17, P65, DOI 10.1203/00006450-198301000-00013; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	36	466	469	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					70	73		10.1038/352070a0	http://dx.doi.org/10.1038/352070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1712081				2022-12-28	WOS:A1991FV17800073
J	VAN DE VELDE, H; VONHOEGEN, I; LUO, W; PARNES, JR; THIELEMANS, K				VAN DE VELDE, H; VONHOEGEN, I; LUO, W; PARNES, JR; THIELEMANS, K			THE B-CELL SURFACE PROTEIN CD72/LYB-2 IS THE LIGAND FOR CD5	NATURE			English	Article							T-CELLS; DIFFERENTIATION ANTIGEN; LYMPHOCYTES-T; RECEPTORS; ACTIVATION; ADHESION; ANTIBODY; SYSTEM; IDENTIFICATION; EXPRESSION	THE glycoprotein CD5 is expressed on the surface membrane of all mature T cells 1 and a small proportion of B lymphocytes 1, 2. Its exact role in immune interactions is still unknown. Studies 3-10 indicate that CD5 functions both in mice and humans as a receptor, delivering co-stimulatory signals to T cells in a manner similar to CD2 (ref. 11) and CD28 (ref. 12). Anti-CD5 antibodies stimulate both T-cell proliferation mediated by CD3 in association with the T-cell receptor and secretion of interleukin-2 and expression of its receptor, as well as inducing an increase in intracellular Ca2+ concentration (refs 5-10). To identify the ligand for CD5 we purified the human CD5 protein, labelled it with biotin and used it as a probe. Here we report that CD5 specifically interacts with the cell-surface protein CD72 exclusive to B cells. This interaction is blocked by anti-CD72 antibodies, but not by any other anti-B-cell antibodies. Moreover, non-B cells (mouse L-cell fibroblasts and human Jurkat T cells) expressing a transfected human CD72 complementary DNA could bind to the CD5-biotin conjugate. The results demonstrate that the B-cell surface protein CD72 (Lyb-2 in mice) is the ligand for CD5.	VRIJE UNIV BRUSSELS, SCH MED, DIV HAEMATOL IMMUNOL, B-1090 BRUSSELS, BELGIUM; STANFORD UNIV, MED CTR, DEPT IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Stanford University								CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P15; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDIN JA, 1990, CELL IMMUNOL, V126, P304, DOI 10.1016/0008-8749(90)90323-J; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KAMAL M, IN PRESS EUR J IMMUN; KAWAMURA N, 1986, J CLIN INVEST, V78, P1331, DOI 10.1172/JCI112719; KURZINGER K, 1982, J BIOL CHEM, V257, P2412; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCMICHAEL AJ, 1987, LEUCOCYTE TYPING, V3, P31; NAKAYAMA E, 1989, P NATL ACAD SCI USA, V86, P1352, DOI 10.1073/pnas.86.4.1352; NISHIMURA Y, 1988, EUR J IMMUNOL, V18, P747, DOI 10.1002/eji.1830180514; PEZZUTTO A, 1989, LEUCOCYTE TYPING, V4, P178; SCHWARTING R, 1989, LEUCOCYTE TYPING, V4, P100; SNOW EC, 1986, J IMMUNOL, V137, P1793; SPERTINI F, 1991, J IMMUNOL, V146, P47; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUBBARAO B, 1984, CURR TOP MICROBIOL, V113, P72; SUBBARAO B, 1983, J IMMUNOL, V130, P2033; SUBBARAO B, 1988, CELL IMMUNOL, V112, P329, DOI 10.1016/0008-8749(88)90302-4; Subbarao B, 1982, Immunol Rev, V69, P81; TAKI S, 1989, J IMMUNOL METHODS, V122, P33, DOI 10.1016/0022-1759(89)90331-1; VANDENBERGHE P, 1991, EUR J IMMUNOL, V21, P251, DOI 10.1002/eji.1830210203; VERWILGHEN J, 1990, CELL IMMUNOL, V131, P109, DOI 10.1016/0008-8749(90)90238-M; VONHOEGEN I, 1990, J IMMUNOL, V144, P4870; VONHOEGEN I, IN PRESS EUR J IMMUN; WANG CY, 1980, J EXP MED, V151, P1539, DOI 10.1084/jem.151.6.1539; YAKURA H, 1981, J EXP MED, V153, P129, DOI 10.1084/jem.153.1.129	32	311	315	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1991	351	6328					662	665						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1711157				2022-12-28	WOS:A1991FT11200070
J	EISEN, JS				EISEN, JS			DETERMINATION OF PRIMARY MOTONEURON IDENTITY IN DEVELOPING ZEBRAFISH EMBRYOS	SCIENCE			English	Article							GROWTH CONES; LINEAGE	The developmental determination of primary motoneurons was investigated by transplanting identified motoneurons in embryonic zebrafish to new spinal cord positions. Some cells moved from the new positions in which they were placed back to their original positions, thus it was difficult to evaluate whether they were determined. Among cells that remained in their new positions, those transplanted about 1 hour before axogenesis developed axonal trajectories that were appropriate for their original soma positions, whereas those transplanted 2 to 3 hours before axogenesis developed morphologies appropriate for their new soma positions. These results suggest that motoneuronal identity is determined before axogenesis.			EISEN, JS (corresponding author), UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403, USA.				NICHD NIH HHS [HD22486] Funding Source: Medline; NINDS NIH HHS [NS23915] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023915, R01NS023915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVEREZ IS, IN PRESS DEVELOPMENT; EISEN J, UNPUB; EISEN JS, 1990, J NEUROSCI, V10, P34; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; HANNEMAN E, 1988, DEVELOPMENT, V103, P49; HATTA K, 1990, Society for Neuroscience Abstracts, V16, P310; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; KANDEL ER, 1976, CELLULAR BASIS BEHAV, P211; Kimble J., 1979, Cell lineage, stem cells and cell determination. (Proc. Internat. Workshop on cell lineage, stem cells and cell determination, Seillac, France, 20-24 May 1979. - Inserm Symposium No.10), P59; KIMMEL CB, 1990, MOL APPROACHES SUPRA, P137; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; PIKE SH, 1990, J NEUROSCI, V10, P44; SANES DH, 1989, NEURON, V2, P1237, DOI 10.1016/0896-6273(89)90308-5; STENT GS, 1985, PHILOS T R SOC B, V312, P3, DOI 10.1098/rstb.1985.0174; WESTERFIELD M, 1988, MESSAGE MIND, P110	17	106	107	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					569	572		10.1126/science.1708527	http://dx.doi.org/10.1126/science.1708527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1708527				2022-12-28	WOS:A1991FJ12700048
J	ROBERTS, RG				ROBERTS, RG			CORRECTION	LANCET			English	Correction, Addition													Roberts, Roland G/C-3596-2009					ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					504	504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1704092				2022-12-28	WOS:A1991EY88700071
J	PHILLIPS, ML; NUDELMAN, E; GAETA, FCA; PEREZ, M; SINGHAL, AK; HAKOMORI, SI; PAULSON, JC				PHILLIPS, ML; NUDELMAN, E; GAETA, FCA; PEREZ, M; SINGHAL, AK; HAKOMORI, SI; PAULSON, JC			ELAM-1 MEDIATES CELL-ADHESION BY RECOGNITION OF A CARBOHYDRATE LIGAND, SIALYL-LEX	SCIENCE			English	Article									CYTEL CORP, 11099 N TORREY PINES RD, LA JOLLA, CA 92037 USA; BIOMEMBRANE INST, SEATTLE, WA 98119 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV WASHINGTON, DEPT PATHOBIOL & MICROBIOL, SEATTLE, WA 98195 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute			Paulson, James/AAG-3565-2019					ASADA M, IN PRESS BIOCHEMISTR; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; CYBULSKY MI, 1988, LAB INVEST, V58, P365; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HARLAN JM, 1987, ACTA MED SCAND, P123; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HOFF SD, 1989, CANCER RES, V49, P6883; HOFF SD, 1990, ARCH SURG-CHICAGO, V125, P206; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACHER BA, 1990, LEUKEMIA RES, V14, P119, DOI 10.1016/0145-2126(90)90040-G; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; MIYAKE M, 1988, CANCER RES, V48, P7150; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; OHMORI K, 1989, BLOOD, V74, P255; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POBER JS, 1986, J IMMUNOL, V136, P1680; POTVIN B, 1990, J BIOL CHEM, V265, P1615; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SAKAMOTO J, 1989, CANCER RES, V49, P745; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SINGHAL A, UNPUB; SINGHAL AK, 1990, CANCER RES, V50, P1375; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANLEY P, 1988, J BIOL CHEM, V263, P11374; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TAKI T, 1988, J BIOCHEM-TOKYO, V103, P998, DOI 10.1093/oxfordjournals.jbchem.a122400; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	54	1440	1526	4	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	1990	250	4984					1130	1132		10.1126/science.1701274	http://dx.doi.org/10.1126/science.1701274			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701274				2022-12-28	WOS:A1990EJ58100034
J	WICTORIN, K; BRUNDIN, P; GUSTAVII, B; LINDVALL, O; BJORKLUND, A				WICTORIN, K; BRUNDIN, P; GUSTAVII, B; LINDVALL, O; BJORKLUND, A			REFORMATION OF LONG AXON PATHWAYS IN ADULT-RAT CENTRAL-NERVOUS-SYSTEM BY HUMAN FOREBRAIN NEUROBLASTS	NATURE			English	Article									UNIV LUND HOSP, DEPT OBSTET & GYNECOL, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT NEUROL, S-22185 LUND, SWEDEN	Lund University; Skane University Hospital; Lund University; Skane University Hospital	WICTORIN, K (corresponding author), UNIV LUND, DEPT MED CELL RES, BISKOPSGATAN 5, S-22362 LUND, SWEDEN.		Björklund, Anders/ABA-1326-2020	Bjorklund, Anders/0000-0002-5676-6203				ALFONSI F, 1984, ROLE CELL INTERACTIO, P157; [Anonymous], 1959, DEGENERATION REGENER; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P1; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P9; BJORKLUND A, 1976, NATURE, V262, P787, DOI 10.1038/262787a0; BRUNDIN P, 1985, EXP BRAIN RES, V60, P204; CARBONETTO S, 1987, J NEUROSCI, V7, P610; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; CRUTCHER KA, 1989, EXP NEUROL, V104, P39, DOI 10.1016/0014-4886(89)90007-1; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DOUCET G, 1989, EXP NEUROL, V106, P1, DOI 10.1016/0014-4886(89)90139-8; FOSTER GA, 1985, EXP BRAIN RES, V60, P427; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; MCLOON LK, 1985, NEURAL GRAFTING MAMM, P267; NORNES H, 1983, CELL TISSUE RES, V230, P15; OUIMET CC, 1984, J NEUROSCI, V4, P111; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205; SOTELO C, 1987, NEUROSCIENCE, V20, P1, DOI 10.1016/0306-4522(87)90002-9; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WICTORIN K, 1989, NEUROSCIENCE, V30, P313, DOI 10.1016/0306-4522(89)90256-X; WICTORIN K, 1989, EUR J NEUROSCI, V1, P690, DOI 10.1111/j.1460-9568.1989.tb00375.x; ZHOU CF, 1989, NEUROSCIENCE, V32, P349, DOI 10.1016/0306-4522(89)90083-3	27	233	239	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 11	1990	347	6293					556	558		10.1038/347556a0	http://dx.doi.org/10.1038/347556a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC454	1699131				2022-12-28	WOS:A1990EC45400053
J	MURRAY, RH; RUBEL, AJ				MURRAY, RH; RUBEL, AJ			PHYSICIANS AND HEALERS - UNWITTING PARTNERS IN HEALTH-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICINE; CANCER; PRACTITIONERS; SURVIVAL; TRIAL		UNIV CALIF IRVINE,IRVINE,CA 92717	University of California System; University of California Irvine	MURRAY, RH (corresponding author), MICHIGAN STATE UNIV,E LANSING,MI 48824, USA.							CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHLEBOWSKI RT, 1990, J CLIN ONCOL, V8, P9, DOI 10.1200/JCO.1990.8.1.9; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; FULDER SJ, 1985, LANCET, V2, P542; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; McGuire Meredith, 1988, RITUAL HEALING SUBUR; SHEKELLE PG, 1991, RAND R40252CCRFLER; SHIPLEY M, 1983, LANCET, V1, P97; SPIEGEL D, 1989, LANCET, V2, P888; WATT J, 1988, TALKING HLTH CONVENT; 1981, ALTERNATIVE MED NETH; 1986, ALTERNATIVE THERAPY; 1987, N Z MED J, V100, P110; 1986, AM MED NEWS     0411, P46; 1990, OTAH405 OFF TECHN AS; 1987, ENCY MED ORG AGENCIE, P93	19	104	105	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					61	64		10.1056/NEJM199201023260113	http://dx.doi.org/10.1056/NEJM199201023260113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX315	1727068				2022-12-28	WOS:A1992GX31500013
J	PAPO, T; MARCELLIN, P; BERNUAU, J; DURAND, F; POYNARD, T; BENHAMOU, JP				PAPO, T; MARCELLIN, P; BERNUAU, J; DURAND, F; POYNARD, T; BENHAMOU, JP			AUTOIMMUNE CHRONIC HEPATITIS EXACERBATED BY ALPHA-INTERFERON	ANNALS OF INTERNAL MEDICINE			English	Note						HEPATITIS-C; AUTOIMMUNE DISEASES; INTERFERON-ALPHA; PREDNISONE; LIVER DISEASES		We describe three patients with type-1 autoimmune chronic hepatitis whose liver disease was exacerbated by alpha-interferon. In all cases, chronic hepatitis was initially considered to be caused by infection with hepatitis C virus (HCV), exacerbation of disease occurred 4 to 8 weeks after alpha-interferon therapy was begun. Infection with HCV was not confirmed by second-generation specific tests. Elevated titers of antinuclear and anti-smoth-muscle antibodies were diagnostic of type-1 autoimmune chronic hepatitis. All patients showed improvement after cessation of alpha-interferon and administration of corticosteroids. Exacerbation of chronic hepatitis after treatment with alpha-interferon has practical implications. It provides a clue to the diagnosis of autoimmune chronic hepatitis, and it should prompt the cessation of alpha-interferon and the administration of corticosteroids.	HOP BEAUJON, SERV HEPATOL, F-92118 CLICHY, FRANCE; HOP ANTOINE BECLERE, F-92140 CLAMART, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP			Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Durand, Francois/0000-0002-0357-1090; Poynard, Thierry/0000-0002-2050-640X				BOTTAZZO GF, 1983, LANCET, V2, P1115; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; MARCELLIN P, 1991, LANCET, V337, P551, DOI 10.1016/0140-6736(91)91335-R; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; RONNBLOM LE, 1991, ANN INTERN MED, V115, P178, DOI 10.7326/0003-4819-115-3-178; VENTO S, 1989, LANCET, V2, P926	10	163	164	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					51	53		10.7326/0003-4819-116-1-51	http://dx.doi.org/10.7326/0003-4819-116-1-51			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727095				2022-12-28	WOS:A1992GX15700008
J	BONIFAS, JM; ROTHMAN, AL; EPSTEIN, EH				BONIFAS, JM; ROTHMAN, AL; EPSTEIN, EH			EPIDERMOLYSIS-BULLOSA SIMPLEX - EVIDENCE IN 2 FAMILIES FOR KERATIN GENE ABNORMALITIES	SCIENCE			English	Article							HUMAN TYPE-I; INTERMEDIATE FILAMENTS; SEQUENCE; EXPRESSION; LINKAGE; CYTOKERATIN-18; CHROMOSOME-12Q; MARKERS; CELLS	Epidermolysis bullosa simplex (EBS) is characterized by skin blistering due to basal keratinocyte fragility. In one family studied, inheritance of EBS is linked to the gene encoding keratin 14, and a thymine to cytosine mutation in exon 6 of keratin 14 has introduced a proline in the middle of an alpha-helical region. In a second family, inheritance of EBS is linked to loci that map near the keratin 5 gene. These data indicate that abnormalities of either of the components of the keratin intermediate filament heterodipolymer can impair the mechanical stability of these epithelial cells.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT DERMATOL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NIAMS NIH HHS [R01-AR39953, R01-AR28069] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR028069] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BASAZS I, 1984, HUM GENET, V68, P57; BONIFAS JM, 1991, J INVEST DERMATOL, V96, P550; BONIFAS JM, UNPUB; CHIN S S M, 1990, Journal of Cell Biology, V111, p176A; FINE JD, 1988, ARCH DERMATOL, V124, P523, DOI 10.1001/archderm.124.4.523; HEATH P, 1990, HUM GENET, V85, P669; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUMPHRIES MM, 1990, GENOMICS, V7, P377, DOI 10.1016/0888-7543(90)90171-P; ITO M, 1991, ARCH DERMATOL, V127, P367, DOI 10.1001/archderm.127.3.367; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KUPPUSWAMY MN, 1991, P NATL ACAD SCI USA, V88, P1143, DOI 10.1073/pnas.88.4.1143; LATHROP GM, 1988, GENOMICS, V3, P361; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; MANN W, 1989, NUCLEIC ACIDS RES, V17, P5410, DOI 10.1093/nar/17.13.5410; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MARTIN C, 1988, NUCLEIC ACIDS RES, V16, P3596, DOI 10.1093/nar/16.8.3596; MUTHA S, 1991, J INVEST DERMATOL, V97, P383, DOI 10.1111/1523-1747.ep12480948; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P779, DOI 10.1093/nar/16.2.779; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5223, DOI 10.1093/nar/16.11.5223; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P778, DOI 10.1093/nar/16.2.778; O'CONNELL P, 1987, Genomics, V1, P93, DOI 10.1016/0888-7543(87)90110-8; OLAISEN B, 1973, HUM HERED, V23, P189, DOI 10.1159/000152573; OTT J, 1985, ANAL HUMAN GENETIC L; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; Sambrook J, 1989, MOL CLONING LABORATO; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SYKES B, 1986, LANCET, V2, P69; TSUI LC, 1989, CYTOGENET CELL GENET, V51, P166, DOI 10.1159/000132791; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WASSEEM A, 1990, GENOMICS, V7, P188; WEAVER EJ, 1989, CYTOGENET CELL GENET, V54, P1103	35	338	347	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1202	1205		10.1126/science.1720261	http://dx.doi.org/10.1126/science.1720261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1720261				2022-12-28	WOS:A1991GQ83400047
J	MATSUI, Y; TOKSOZ, D; NISHIKAWA, S; NISHIKAWA, SI; WILLIAMS, D; ZSEBO, K; HOGAN, BLM				MATSUI, Y; TOKSOZ, D; NISHIKAWA, S; NISHIKAWA, SI; WILLIAMS, D; ZSEBO, K; HOGAN, BLM			EFFECT OF STEEL FACTOR AND LEUKEMIA INHIBITORY FACTOR ON MURINE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT; GROWTH-FACTOR; W-LOCUS; SI-LOCUS; PROTO-ONCOGENE; MOUSE; LIGAND; EXPRESSION; IDENTIFICATION	DESPITE the importance of germ cells to the survival of species, surprisingly little is known about their embryological origin, proliferation, migration and entry into mitotic arrest or meiosis 1-5. Mutations in the murine Dominant White Spotting (W) and Steel genes, which respectively encode the c-kit tyrosine kinase receptor and the c-kit ligand (or Steel factor), impair the development of primordial germ cells (PGCs) in vivo, as well as haematopoietic stem cells and neural crest-derived melanoblast 3,6-16. Here we use a monoclonal antibody against c-kit tyrosine kinase receptor and recombinant Steel factor to study the c-kit receptor-ligand system in cultured PGCs. In addition, we show that leukaemia inhibitory factor (also known as differentiation inhibitory activity) 17,18, a factor secreted by STO fibroblasts, can stimulate proliferation of primordial germ cells in vitro.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; KUMAMOTO UNIV,INST MED IMMUNOL,DEPT PATHOL,KUMAMOTO 860,JAPAN; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Kumamoto University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS L, 1988, NATURE, V336, P688; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	28	393	416	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					750	752		10.1038/353750a0	http://dx.doi.org/10.1038/353750a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1719421				2022-12-28	WOS:A1991GL69600067
J	TURNLEY, AM; MORAHAN, G; OKANO, H; BERNARD, O; MIKOSHIBA, K; ALLISON, J; BARTLETT, PF; MILLER, JFAP				TURNLEY, AM; MORAHAN, G; OKANO, H; BERNARD, O; MIKOSHIBA, K; ALLISON, J; BARTLETT, PF; MILLER, JFAP			DYSMYELINATION IN TRANSGENIC MICE RESULTING FROM EXPRESSION OF CLASS-I HISTOCOMPATIBILITY MOLECULES IN OLIGODENDROCYTES	NATURE			English	Article							PANCREATIC BETA-CELLS; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; MHC MOLECULES; SCHWANN-CELLS; ANTIGENS; TOLERANCE; GENE; TRANSCRIPTION; INTERFERON	MAJOR histocompatibility complex (MHC) molecules are not normally expressed in the central nervous system (CNS) 1-3. However, aberrant expression has been observed in multiple sclerosis lesions and could contribute to the destruction of myelin or the myelinating cells known as oligodendrocytes 4,5. The mechanism of cell damage associated with aberrant MHC molecule expression is unclear: for example, overexpression of class I (ref. 6) and class II (refs 7, 8) MHC molecules in pancreatic beta-cells in transgenic mice leads to nonimmune destruction of the cells and insulin-dependent diabetes mellitus. We have generated transgenic mice that express class I H-2K(b) MHC molecules, under the control of the myelin basic protein promoter, specifically in oligodendrocytes. Homozygous transgenic mice have a shivering phenotype, develop tonic seizures and die at 15-22 days. This phenotype, which we term 'wonky', is due to hypomyelination in the CNS, and not to involvement of the immune system. The primary defect appears to be a shortage of myelinating oligodendrocytes resulting from overexpression of the class I MHC molecules.	OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN	Osaka University	TURNLEY, AM (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA.		Bartlett, Perry/F-3813-2012; Okano, Hideyuki/I-7584-2019; Turnley, Ann/A-8125-2010; Morahan, Grant/T-7501-2019; Mikoshiba, Katsuhiko/N-7943-2015	Turnley, Ann/0000-0002-8442-127X				ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BARTLETT PF, 1983, J CLIN LAB IMMUNOL, V11, P1; BARTLETT PF, 1989, TRANSPLANT P, V21, P3166; DEROSBO NK, 1984, NEUROCHEM RES, V9, P1359, DOI 10.1007/BF00964663; GILFILLAN S, 1990, P NATL ACAD SCI USA, V87, P7319, DOI 10.1073/pnas.87.18.7319; GOULD RM, 1977, J CELL BIOL, V75, P326, DOI 10.1083/jcb.75.2.326; JONESYOUNGBLOOD SL, 1990, J IMMUNOL, V144, P1187; KIDD GJ, 1990, J NEUROSCI RES, V26, P409, DOI 10.1002/jnr.490260403; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILLER J, 1990, J IMMUNOL, V144, P334; MITCHELL LS, 1990, J NEUROSCI RES, V27, P125, DOI 10.1002/jnr.490270202; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OKANO H, 1988, EMBO J, V7, P77, DOI 10.1002/j.1460-2075.1988.tb02785.x; PANITCH HS, 1987, LANCET, V1, P893; PERIER O, 1965, BRAIN, V88, P937, DOI 10.1093/brain/88.5.937; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHEN HZ, 1989, J NEUROSCI RES, V23, P425; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TRAUGOTT U, 1987, J NEUROIMMUNOL, V16, P283, DOI 10.1016/0165-5728(87)90082-8; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0	26	107	107	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					566	569		10.1038/353566a0	http://dx.doi.org/10.1038/353566a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1717849				2022-12-28	WOS:A1991GJ64300070
J	KANDEL, J; BOSSYWETZEL, E; RADVANYI, F; KLAGSBRUN, M; FOLKMAN, J; HANAHAN, D				KANDEL, J; BOSSYWETZEL, E; RADVANYI, F; KLAGSBRUN, M; FOLKMAN, J; HANAHAN, D			NEOVASCULARIZATION IS ASSOCIATED WITH A SWITCH TO THE EXPORT OF BFGF IN THE MULTISTEP DEVELOPMENT OF FIBROSARCOMA	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CELL-GROWTH; TRANSGENIC MICE; ENDOTHELIAL-CELLS; HEPARIN AFFINITY; TRANSFORMING GENE; PURIFICATION; ANGIOGENESIS; SEQUENCE; PROTEIN	In a transgenic mouse model, dermal fibrosarcomas develop in a pathway comprised of at least three stages: mild fibromatosis, aggressive fibromatosis, and fibrosarcoma. The latter two stages are highly vascularized when compared with both the normal dermis and the initial mild lesion. Analysis of cell cultures derived from biopsies of these lesions has revealed that basic fibroblast growth factor (bFGF) is synthesized in all three stages and in normal dermal fibroblasts derived from the same mice. Unexpectedly, there is a change in the localization of bFGF from its normal cell-associated state to extracellular release in the latter two stages, which is concomitant both with the neovascularization seen in vivo and with the tumorigenicity of these cell lines. Thus, in this multistep tumorigenesis pathway there appears to be a discrete switch to the angiogenic phenotype that correlates with the export of bFGF, a known angiogenic factor.	HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, HORMONE RES INST, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	KANDEL, J (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA.			Radvanyi, Francois/0000-0002-5696-6424	NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37392, CA 70118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1986, J CELL BIOCHEM, V30, P79, DOI 10.1002/jcb.240300109; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IBERG N, 1989, J BIOL CHEM, V264, P19951; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLAGSBRUN M, 1977, EXP CELL RES, V105, P99, DOI 10.1016/0014-4827(77)90155-0; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025; LOBB R, 1986, J BIOL CHEM, V261, P1924; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; MARICS I, 1989, ONCOGENE, V4, P335; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; SENGER DR, 1990, CANCER RES, V50, P1774; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	48	501	527	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1095	1104		10.1016/0092-8674(91)90033-U	http://dx.doi.org/10.1016/0092-8674(91)90033-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717155				2022-12-28	WOS:A1991GG55200005
J	YU, XM; HALL, ZW				YU, XM; HALL, ZW			EXTRACELLULAR DOMAINS MEDIATING EPSILON SUBUNIT INTERACTIONS OF MUSCLE ACETYLCHOLINE-RECEPTOR	NATURE			English	Article							ENDOPLASMIC-RETICULUM; ION CHANNELS; TRANSMEMBRANE; MUTAGENESIS; BINDING; CELLS	LIGAND-gated ion channels, a major class of cell-surface proteins, have a pseudosymmetric structure with five highly homologous subunits arranged around a central ion pore 1. The correct assembly of each channel, whose subunit composition varies with cell type and stage of development, requires specific recognition between the subunits 2-4. Assembly of the pentameric form of the acetylcholine receptor from adult muscle (AChR; alpha-2-beta-epsilon-delta) proceeds by a stepwise pathway starting with the formation of the heterodimers, alpha-epsilon and alpha-delta. The heterodimers then associate with the beta-subunit and with each other to form the complete receptor 5-7,21. We have now determined which parts of the subunits mediate the interactions during assembly of the adult form of the receptor from mouse muscle by using a chimaeric subunit in which the N-terminal and C-terminal extracellular domains are derived from the E subunit with the remainder from the beta-subunit. The epsilon and beta-subunits were chosen because the epsilon-subunit forms a heterodimer with the alpha-subunit in the pathway for assembly of the receptor, whereas the beta-subunit does not. The epsilon-beta chimaera can substitute for the epsilon but not the beta-subunit in the oligomeric receptor, indicating that the alpha-subunit specifically recognizes an extracellular domain of the epsilon-subunit.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; GU Y, IN PRESS NEURON; GU Y, IN PRESS J CELL BIOL; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	21	80	80	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					64	67		10.1038/352064a0	http://dx.doi.org/10.1038/352064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1712080				2022-12-28	WOS:A1991FV17800071
J	PASSAMANI, E				PASSAMANI, E			CLINICAL-TRIALS - ARE THEY ETHICAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION				PASSAMANI, E (corresponding author), NHLBI, BETHESDA, MD 20892 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1948, BMJ, V2, P769; BEAUCHAMP TL, 1979, PRINCIPLES BIOMEDICA, P287; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BRAHAMS D, 1988, LANCET, V2, P1033; BURKHARDT R, 1978, LANCET, V2, P1356; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Friedman LM., 1981, FUNDAMENTALS CLIN TR; GIFFORD F, 1986, J MED PHILOS, V11, P347, DOI 10.1093/jmp/11.4.347; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; MARQUIS D, 1983, HASTINGS CENT REP, V13, P40, DOI 10.2307/3561721; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; 1978, DHEW05780012 NAT COM	14	112	112	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1589	1592		10.1056/NEJM199105303242209	http://dx.doi.org/10.1056/NEJM199105303242209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	1709257				2022-12-28	WOS:A1991FN05100009
J	FALK, K; ROTZSCHKE, O; STEVANOVIC, S; JUNG, G; RAMMENSEE, HG				FALK, K; ROTZSCHKE, O; STEVANOVIC, S; JUNG, G; RAMMENSEE, HG			ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES	NATURE			English	Article							TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; SYNTHETIC PEPTIDES; CIRCUMSPOROZOITE PROTEIN; INFLUENZA NUCLEOPROTEIN; MONOCLONAL-ANTIBODIES; IMMUNOGENIC PEPTIDES; CELL RECOGNITION; FINE SPECIFICITY	The crystal structures of major histocompatibility complex (MHC) molecules contain a groove occupied by heterogeneous material thought to represent peptides central to immune recognition, although until now relatively little characterization of the peptides has been possible. Exact information about the contents of MHC grooves is now provided. Moreover, each MHC class I allele has its individual rules to which peptides presented in the grove adhere.	UNIV TUBINGEN, INST ORGAN CHEM, W-7400 TUBINGEN 1, GERMANY	Eberhard Karls University of Tubingen	RAMMENSEE, HG (corresponding author), MAX PLANCK INST BIOL, IMMUNOGENET ABT, CORRENSSTR 42, W-7400 TUBINGEN, GERMANY.		Roetzschke, Olaf/GXH-0012-2022					BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BRACIALE TJ, 1989, P NATL ACAD SCI USA, V86, P277, DOI 10.1073/pnas.86.1.277; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLAVERIE JM, 1988, EUR J IMMUNOL, V18, P1547, DOI 10.1002/eji.1830181012; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; ELLIOTT T, 1990, NATURE, V348, P195, DOI 10.1038/348195a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, IN PRESS J EXP MED; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH F, 1988, J EXP MED, V168, P2045, DOI 10.1084/jem.168.6.2045; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KUWANO K, 1988, FASEB J, V2, pA679; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; MARYANSKI JL, 1988, J EXP MED, V167, P1391, DOI 10.1084/jem.167.4.1391; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUSCH E, 1983, TRANSPLANT P, V15, P2093; SANTOSAGUADO J, 1989, P NATL ACAD SCI USA, V86, P8936, DOI 10.1073/pnas.86.22.8936; SCHILD H, 1990, SCIENCE, V247, P1587, DOI 10.1126/science.2321019; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TEVETHIA SS, 1990, J VIROL, V64, P1192, DOI 10.1128/JVI.64.3.1192-1200.1990; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	47	2298	2539	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					290	296		10.1038/351290a0	http://dx.doi.org/10.1038/351290a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	1709722	Bronze			2022-12-28	WOS:A1991FM97600050
J	LAVORGNA, G; UEDA, H; CLOS, J; WU, C				LAVORGNA, G; UEDA, H; CLOS, J; WU, C			FTZ-F1, A STEROID-HORMONE RECEPTOR LIKE PROTEIN IMPLICATED IN THE ACTIVATION OF FUSHI-TARAZU	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; ESTROGEN-RECEPTOR; AMINO-ACIDS; GENE KNIRPS; SUPERFAMILY; DNA; SEGMENTATION; SEQUENCE; MEMBER; IDENTIFICATION	The Drosophila homeobox segmentation gene fushi tarazu (ftz) is expressed in a seven-stripe pattern during early embryogenesis. This characteristic pattern is largely specified by the zebra element located immediately upstream of the ftz transcriptional start site. The FTZ-F1 protein, one of multiple DNA binding factors that interacts with the zebra element, is implicated in the activation of ftz transcription, especially in stripes 1, 2, 3, and 6. An FTZ-F1 complementary DNA has been cloned by recognition site screening of a Drosophila expression library. The identity of the FTZ-F1 complementary DNA clone was confirmed by immunological cross-reaction with antibodies to FTZ-F1 and by sequence analysis of peptides from purified FTZ-F1 protein. The predicted amino acid sequence of FTZ-F1 revealed that the protein is a member of the nuclear hormone receptor superfamily. This finding raises the possibility that a hormonal ligand affects the expression of a homeobox segmentation gene early in embryonic development.	NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	LAVORGNA, G (corresponding author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA.		UEDA, Hitoshi/B-1455-2011; Lavorgna, Giovanni/AAN-2575-2020					AKAM M, 1987, DEVELOPMENT, V101, P1; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOLLENBERG SM, 1985, NATURE, V318, P670; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LAVORGNA G, UNPUB; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SEAGRAVES WA, 1990, GENE DEV, V4, P204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	49	265	271	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					848	851		10.1126/science.1709303	http://dx.doi.org/10.1126/science.1709303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709303				2022-12-28	WOS:A1991FL12300048
J	DOUDNA, JA; COUTURE, S; SZOSTAK, JW				DOUDNA, JA; COUTURE, S; SZOSTAK, JW			A MULTISUBUNIT RIBOZYME THAT IS A CATALYST OF AND TEMPLATE FOR COMPLEMENTARY STRAND RNA-SYNTHESIS	SCIENCE			English	Article							GROUP-I INTRONS; DIRECTED SYNTHESIS; POLYMERASE; CONSERVATION; TETRAHYMENA; EVOLUTION	Derivatives of the sunY self-splicing intron efficiently catalyzed the synthesis of complementary strand RNA by template-directed assembly of oligonucleotides. These ribozymes were separated into three short RNA fragments that formed active catalytic complexes. One of the multisubunit sunY derivatives catalyzed the synthesis of a strand of RNA complementary to one of its own subunits. These results suggest that prebiotically synthesized oligonucleotides might have been able to assemble into a complex capable of self-replication.			DOUDNA, JA (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MICHEL F, IN PRESS J MOL BIOL; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; USMAN N, 1988, P NATL ACAD SCI USA, V85, P5764; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	21	102	105	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1605	1608		10.1126/science.1707185	http://dx.doi.org/10.1126/science.1707185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1707185				2022-12-28	WOS:A1991FD89000036
J	NEUGEBAUER, KM; REICHARDT, LF				NEUGEBAUER, KM; REICHARDT, LF			CELL-SURFACE REGULATION OF BETA-1-INTEGRIN ACTIVITY ON DEVELOPING RETINAL NEURONS	NATURE			English	Article							GLYCOPROTEIN; PROTEINS; COMPLEX; LAMININ; CSAT	INTEGRINS are a family of alpha-beta-heterodimeric receptors that mediate cell-cell and cell-substratum interactions. Integrin binding to extracellular ligands regulates cell adhesion, shape, motility, intracellular signalling and gene expression 1-3. Mechanisms that regulate integrin function are, therefore, central to the participation of integrins in a diverse set of cellular events. Here we report the identification of TASC, a monoclonal antibody to a novel epitope on the integrin beta-1 subunit, which inhibits cell adhesion to vitronectin but promotes adhesion to laminin and collagen types I and IV. We show that developing retinal neurons that have lost responsiveness to laminin 4 regain the ability to bind laminin in the presence of TASC. Thus, beta-1-class integrins are likely to occupy multiple affinity states that can be modulated at the cell surface.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS019090, R01 NS019090-14] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; COHEN J, 1989, DEVELOPMENT, V107, P381; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1990, J BIOL CHEM, V265, P9575; HALL DE, 1987, J CELL BIOL, V104, P623, DOI 10.1083/jcb.104.3.623; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ AF, 1984, MONOCLONAL ANTIBODIE, P103; KEIZER GD, 1988, J IMMUNOL, V140, P1393; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; NEUGEBAUER KM, IN PRESS NEURON; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REICHARDT LF, 1991, REV NEUROSCI, V14, P531; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	25	181	184	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					68	71		10.1038/350068a0	http://dx.doi.org/10.1038/350068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706071	Green Accepted			2022-12-28	WOS:A1991FA69300067
J	KARTNER, N; HANRAHAN, JW; JENSEN, TJ; NAISMITH, AL; SUN, SZ; ACKERLEY, CA; REYES, EF; TSUI, LC; ROMMENS, JM; BEAR, CE; RIORDAN, JR				KARTNER, N; HANRAHAN, JW; JENSEN, TJ; NAISMITH, AL; SUN, SZ; ACKERLEY, CA; REYES, EF; TSUI, LC; ROMMENS, JM; BEAR, CE; RIORDAN, JR			EXPRESSION OF THE CYSTIC-FIBROSIS GENE IN NONEPITHELIAL INVERTEBRATE CELLS PRODUCES A REGULATED ANION CONDUCTANCE	CELL			English	Article							HIGH-LEVEL EXPRESSION; INSECT CELLS; BACULOVIRUS VECTOR; COMPLEMENTARY-DNA; FOREIGN GENES; GLYCOPROTEIN; RECEPTOR; MEMBRANE; PROTEINS; CHANNEL	The nature of involvement of the cystic fibrosis gene product (CFTR) in epithelial anion transport is not yet understood. We have expressed CFTR in Sf9 insect cells using the baculovirus expression vector system. Reactivity with antibodies against 12 different epitopes spanning the entire sequence suggested that the complete polypeptide chain was synthesized. Immunogold labeling showed localization to both cell-surface and intracellular membranes. Concomitant with CFTR expression, these cells exhibited a new cAMP-stimulated anion permeability. This conductance, monitored both by radioiodide efflux and patch clamping, strongly resembled that present in several CFTR-expressing human epithelial cells. These findings demonstrate that CFTR can function in heterologous nonepithelial cells and lend support to the possibility that CFTR may itself be a regulated anion channel.	UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	University of Toronto; University of Toronto; University of Toronto; McGill University	KARTNER, N (corresponding author), HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA.		Tsui, Lap-chee/A-1081-2010; Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSENO, 1989, PFLUGERS ARCH, V415, P37; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1990, BIOPHYS J, V57, pA88; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON PW, 1989, GENE, V77, P287, DOI 10.1016/0378-1119(89)90076-0; KALIBER K, 1990, NEURON, V5, P221; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; POSSEE RD, 1986, VIRUS RES, V5, P43, DOI 10.1016/0168-1702(86)90064-X; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1990, IDENTIFICATION CF CY; RIORDAN JR, 1991, J PHARM THERAPEUT, V28, P51; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIERHOF YD, 1986, J ULTRA MOL STRUCT R, V97, P187, DOI 10.1016/S0889-1605(86)80017-9; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	40	517	533	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					681	691		10.1016/0092-8674(91)90498-N	http://dx.doi.org/10.1016/0092-8674(91)90498-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1705179				2022-12-28	WOS:A1991EZ47800004
J	HU, WS; TEMIN, HM				HU, WS; TEMIN, HM			RETROVIRAL RECOMBINATION AND REVERSE TRANSCRIPTION	SCIENCE			English	Article											HU, WS (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022443] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22443, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; JORGENSEN RA, 1979, MOL GEN GENET, V177, P65, DOI 10.1007/BF00267254; KAWAI S, 1972, VIROLOGY, V49, P37, DOI 10.1016/S0042-6822(72)80005-9; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; LINIAL M, 1979, J VIROL, V31, P257, DOI 10.1128/JVI.31.1.257-260.1979; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; RIGGS JL, 1974, J GEN VIROL, V25, P21, DOI 10.1099/0022-1317-25-1-21; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAHL FW, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0287-90; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TEMIN HM, IN PRESS TRENDS GENE; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; VOGT PK, 1971, VIROLOGY, V46, P947, DOI 10.1016/0042-6822(71)90093-6; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; Weiss R, 1982, RNA TUMOR VIRUSES; WEISS RA, 1973, VIROLOGY, V52, P535, DOI 10.1016/0042-6822(73)90349-8; WYKE JA, 1979, J GEN VIROL, V43, P349, DOI 10.1099/0022-1317-43-2-349; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; YANG ST, UNPUB	27	522	533	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 30	1990	250	4985					1227	1233		10.1126/science.1700865	http://dx.doi.org/10.1126/science.1700865			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK723	1700865				2022-12-28	WOS:A1990EK72300029
J	BACSKAI, BJ; FRIEDMAN, PA				BACSKAI, BJ; FRIEDMAN, PA			ACTIVATION OF LATENT CA-2+ CHANNELS IN RENAL EPITHELIAL-CELLS BY PARATHYROID-HORMONE	NATURE			English	Article									DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756; DARTMOUTH COLL,THAYER SCH ENGN,HANOVER,NH 03755	Dartmouth College; Dartmouth College			Bacskai, Brian/AAE-9583-2021					ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; BORKE JL, 1990, SEMIN NEPHROL, V10, P15; BORKE JL, 1989, BRAIN RES, V489, P355, DOI 10.1016/0006-8993(89)90870-6; BORKE JL, 1989, AM J PHYSIOL, V257, pC341, DOI 10.1152/ajpcell.1989.257.2.C341; BRONNER F, 1989, AM J PHYSIOL, V257, pF707, DOI 10.1152/ajprenal.1989.257.5.F707; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; CANNON C, 1985, NATURE, V314, P443, DOI 10.1038/314443a0; EXTON JH, 1987, CALCIUM BINDING PROT, P137; FRIEDMAN PA, 1988, AM J PHYSIOL, V254, pF62, DOI 10.1152/ajprenal.1988.254.1.F62; FRIEDMAN PA, 1988, NEWS PHYSIOL SCI, V3, P17, DOI 10.1152/physiologyonline.1988.3.1.17; FRIEDMAN PA, 1982, J GEN PHYSIOL, V80, P683, DOI 10.1085/jgp.80.5.683; FRIEDMAN PA, 1989, J BONE MINER RES, V4, pS346; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GOLIGORSKY MS, 1986, AM J PHYSIOL, V251, pF938, DOI 10.1152/ajprenal.1986.251.5.F938; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANDLER JS, 1983, J EXP BIOL, V106, P55; HEBERT SC, 1984, J MEMBRANE BIOL, V80, P201, DOI 10.1007/BF01868439; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HRUSKA KA, 1987, J CLIN INVEST, V79, P230, DOI 10.1172/JCI112788; HURWITZ L, 1986, ANNU REV PHARMACOL, V26, P225; MARGOLIS RL, 1977, P NATL ACAD SCI USA, V74, P3466, DOI 10.1073/pnas.74.8.3466; MCKENNA E, 1990, BIOCHEM PHARMACOL, V39, P1145, DOI 10.1016/0006-2952(90)90255-J; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PFALLER W, 1989, RENAL PHYSIOL BIOCH, V12, P328; PUTNEY JW, 1987, TRENDS PHARMACOL SCI, V8, P481, DOI 10.1016/0165-6147(87)90043-5; Taylor A., 1985, KIDNEY PHYSL PATHOPH, P1297; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; van Os C H, 1988, Prog Clin Biol Res, V252, P223; VILLEREAL ML, 1989, ANNU REV NUTR, V9, P347, DOI 10.1146/annurev.nu.09.070189.002023; WADE JB, 1980, CURR TOP MEMBR TRANS, V13, P123; Wasserman R H, 1989, Adv Exp Med Biol, V249, P45; YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711; ZEIDEL ML, 1988, J CLIN INVEST, V82, P1067, DOI 10.1172/JCI113663	36	142	142	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					388	391		10.1038/347388a0	http://dx.doi.org/10.1038/347388a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699128				2022-12-28	WOS:A1990EA56400065
J	SHIPP, MA; STEFANO, GB; DADAMIO, L; SWITZER, SN; HOWARD, FD; SINISTERRA, J; SCHARRER, B; REINHERZ, EL				SHIPP, MA; STEFANO, GB; DADAMIO, L; SWITZER, SN; HOWARD, FD; SINISTERRA, J; SCHARRER, B; REINHERZ, EL			DOWN-REGULATION OF ENKEPHALIN-MEDIATED INFLAMMATORY RESPONSES BY CD10 NEUTRAL ENDOPEPTIDASE 24.11	NATURE			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; SUNY COLL OLD WESTBURY,MULTIDISCIPLINARY CTR STUDY AGING,OLD WESTBURY,NY 11568; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; State University of New York (SUNY) System; SUNY Old Westbury; Yeshiva University; Albert Einstein College of Medicine	SHIPP, MA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA 02115, USA.		Stefano, George Bogdan/ABD-9152-2021	Stefano, George Bogdan/0000-0002-8146-0740; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN G, 1975, NATURE, V258, P454, DOI 10.1038/258454a0; COSSMAN J, 1983, J EXP MED, V157, P1064, DOI 10.1084/jem.157.3.1064; GREAVES MF, 1983, BLOOD, V61, P628; KENNY AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1503; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; KERR MA, 1974, BIOCHEM J, V137, P489, DOI 10.1042/bj1370489; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MARTINS MA, 1990, J CLIN INVEST, V85, P170, DOI 10.1172/JCI114408; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; Meglitsch P. A., 1967, INVERTEBRATE ZOOLOGY, P961; METZGAR RS, 1981, J EXP MED, V154, P1249, DOI 10.1084/jem.154.4.1249; PAINTER RG, 1988, J BIOL CHEM, V263, P9456; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P626, DOI 10.1073/pnas.86.2.626; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P6307, DOI 10.1073/pnas.86.16.6307; UMENO E, 1989, J APPL PHYSIOL, V66, P2647, DOI 10.1152/jappl.1989.66.6.2647; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	25	179	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					394	396		10.1038/347394a0	http://dx.doi.org/10.1038/347394a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699130				2022-12-28	WOS:A1990EA56400067
J	SIGURGEIRSSON, B; LINDELOF, B; EDHAG, O; ALLANDER, E				SIGURGEIRSSON, B; LINDELOF, B; EDHAG, O; ALLANDER, E			RISK OF CANCER IN PATIENTS WITH DERMATOMYOSITIS OR POLYMYOSITIS - A POPULATION-BASED STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANCY; DISEASE	Background. An association between polymyositis and cancer was first proposed in 1916, but the existence of the association has been disputed. An association between dermatomyositis and cancer is better accepted, but its magnitude is not known. Methods. We undertook a study to provide accurate estimates of the risk of cancer in patients with dermatomyositis or polymyositis. We studied the incidence of cancer and the rate of mortality from cancer in a population-based cohort of 788 patients with dermatomyositis or polymyositis in Sweden from 1963 through 1983. The results were compared with those for the general population. Results. Among the 396 patients with polymyositis, 42 cancers were diagnosed at the same time or after polymyositis was diagnosed in 37 patients (9 percent). The relative risk of cancer was 1.8 (95 percent confidence interval, 1.1 to 2.7) in the male patients and 1.7 (95 percent confidence interval, 1.0 to 2.5) in the female patients. Eighty-four males and 85 females died, and in 24 of these cases (14 percent) cancer was the principal cause of death. The mortality ratio (the rate of mortality from cancer in these patients as compared with that in the general population) was 0.90 (95 percent confidence interval, 0.6 to 1.4). Among the 392 patients with dermatomyositis, 61 cancers were diagnosed at the same time or after dermatomyositis was diagnosed in 59 patients (15 percent). The relative risk of cancer was 2.4 (95 percent confidence interval, 1.6 to 3.6) in the male patients and 3.4 (95 percent confidence interval, 2.4 to 4.7) in the female patients. Fifty-seven males and 110 females died, and in 67 of these cases (40 percent) cancer was the principal cause of death (mortality ratio, 3.8; 95 percent confidence interval, 2.9 to 4.8). Conclusions. The risk of cancer is increased in patients with polymyositis or dermatomyositis. In patients with dermatomyositis there is also a higher rate of mortality from cancer.	HUDDINGE HOSP,DEPT SOCIAL MED,S-14186 HUDDINGE,SWEDEN; NATL BOARD HLTH & WELF,STOCKHOLM,SWEDEN	National Board of Health & Welfare	SIGURGEIRSSON, B (corresponding author), KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM 60,SWEDEN.		Sigurgeirsson, Bardur/AAP-7755-2020; Sigurgeirsson, Bárður/B-6130-2011	Sigurgeirsson, Bardur/0000-0002-9733-9742				BASSETSEGUIN N, 1990, ARCH DERMATOL, V126, P633, DOI 10.1001/archderm.126.5.633; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; BONNETBLANC JM, 1990, DERMATOLOGICA, V180, P212, DOI 10.1159/000248032; CALLEN JP, 1980, ARCH DERMATOL, V116, P295, DOI 10.1001/archderm.116.3.295; CARO I, 1989, MED CLIN N AM, V73, P1181; COX NH, 1990, ARCH DERMATOL, V126, P61, DOI 10.1001/archderm.126.1.61; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; Goh C L, 1983, Ann Acad Med Singap, V12, P6; HENRIKSSON KG, 1982, ACTA NEUROL SCAND, V65, P280, DOI 10.1111/j.1600-0404.1982.tb03087.x; HIDANO A, 1986, Journal of Dermatology (Tokyo), V13, P233; HOFFMAN GS, 1983, AM J MED, V75, P433, DOI 10.1016/0002-9343(83)90344-3; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; MANCHUL LA, 1985, ARCH INTERN MED, V145, P1835, DOI 10.1001/archinte.145.10.1835; MATTSSON B, 1984, THESIS KAROLINSKA I; RICHARDSON JB, 1989, MED CLIN N AM, V73, P1211, DOI 10.1016/S0025-7125(16)30629-0; SIGURGEIRSSON B, 1991, COMPUT METH PROG BIO, V35, P193, DOI 10.1016/0169-2607(91)90121-9; Stertz G., 1916, BERL KLIN WOCHENSCHR, V53, P489; TYMMS KE, 1985, J RHEUMATOL, V12, P1140; VESTERAGER L, 1980, CLIN EXP DERMATOL, V5, P31, DOI 10.1111/j.1365-2230.1980.tb01661.x; 1960, CANCER INCIDENCE SWE; 1964, CAUSES DEATH SWEDEN	23	552	576	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					363	367		10.1056/NEJM199202063260602	http://dx.doi.org/10.1056/NEJM199202063260602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729618	Bronze			2022-12-28	WOS:A1992HC38600002
J	WEISS, J; AXELROD, L; WHITCOMB, RW; HARRIS, PE; CROWLEY, WF; JAMESON, JL				WEISS, J; AXELROD, L; WHITCOMB, RW; HARRIS, PE; CROWLEY, WF; JAMESON, JL			HYPOGONADISM CAUSED BY A SINGLE AMINO-ACID SUBSTITUTION IN THE BETA SUBUNIT OF LUTEINIZING-HORMONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN CHORIONIC-GONADOTROPIN; MOLECULAR-BIOLOGY; DNA; CELLS; INFERTILITY; GENE		MASSACHUSETTS GEN HOSP,DEPT MED,THYROID UNIT,JACKSON 1021,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,REPROD ENDOCRINOL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,NATL CTR INFERTIL RES,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028138, R01HD015788] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023519, U54HD029164, U01HD044417] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD015788, HD 29164, HD 23519, U54 HD028138, U01 HD044417] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AXELROD L, 1979, J CLIN ENDOCR METAB, V48, P279, DOI 10.1210/jcem-48-2-279; BEITINS IZ, 1981, J CLIN ENDOCR METAB, V52, P1143, DOI 10.1210/jcem-52-6-1143; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAYASHIZAKI Y, 1989, EMBO J, V8, P3542; HUHTANIEMI IT, 1990, TRENDS ENDOCRIN MET, V1, P356, DOI 10.1016/1043-2760(90)90084-G; JAMESON JL, 1990, J CLIN ENDOCR METAB, V70, P301, DOI 10.1210/jcem-70-2-301; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; JAMESON JL, 1986, J CLIN ENDOCR METAB, V64, P319; MARCHBANKS PA, 1989, AM J EPIDEMIOL, V130, P259, DOI 10.1093/oxfordjournals.aje.a115332; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P713; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; SWERDLOFF RS, 1985, ANN INTERN MED, V103, P906, DOI 10.7326/0003-4819-103-6-906; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TAYLOR AE, 1991, NEUROENDOCRINE RES M, P955; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V71, P591, DOI 10.1210/jcem-71-3-591	21	279	290	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					179	183		10.1056/NEJM199201163260306	http://dx.doi.org/10.1056/NEJM199201163260306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727547				2022-12-28	WOS:A1992GZ21300006
J	DRUMM, ML; WILKINSON, DJ; SMIT, LS; WORRELL, RT; STRONG, TV; FRIZZELL, RA; DAWSON, DC; COLLINS, FS				DRUMM, ML; WILKINSON, DJ; SMIT, LS; WORRELL, RT; STRONG, TV; FRIZZELL, RA; DAWSON, DC; COLLINS, FS			CHLORIDE CONDUCTANCE EXPRESSED BY DELTA-F508 AND OTHER MUTANT CFTRS IN XENOPUS OOCYTES	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; IDENTIFICATION; REGULATOR; MUTATIONS	The cystic fibrosis transmembrane conductance regulator (CFTR) is associated with expression of a chloride conductance that is defective in cystic fibrosis (CF). Xenopus oocytes injected with RNA coding for CFTR that contained mutations in the first nucleotide binding fold (NBF1) expressed chloride currents in response to raising adenosine 3',5'-monophosphate (cAMP) with forskolin and 3-isobutyl-1-methylxanthine (IBMX). The mutant CFTRs were less sensitive than wild-type CFTR to this activating stimulus, and the reduction in sensitivity correlated with the severity of cystic fibrosis in patients carrying the corresponding mutations. This demonstration provides the basis for detailed analyses of NBF1 function and suggests potential pharmacologic treatments for cystic fibrosis.	UNIV MICHIGAN, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	DRUMM, ML (corresponding author), UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA.		Strong, Theresa/GSM-6652-2022	Strong, Theresa/0000-0001-6783-8703	NIDDK NIH HHS [DK29786, DK39690, DK42718] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042718, R01DK039690, R01DK029786] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CUNNINGHAM SA, IN PRESS AM J PHYSL; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; IANNUZZI MC, 1991, AM J HUM GENET, V48, P227; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KOBAYASHI K, 1990, AM J HUM GENET, V47, P611; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; OSBORNE L, 1991, AM J HUM GENET, V48, P608; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SARKADI B, IN PRESS J BIOL CHEM; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; STRONG TV, 1991, EMBO J, V10, P1355; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tsui L C, 1991, Adv Hum Genet, V20, P153; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; ZEITLIN PL, IN PRESS P NATL ACAD	32	450	465	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1797	1799		10.1126/science.1722350	http://dx.doi.org/10.1126/science.1722350			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722350				2022-12-28	WOS:A1991GW31600045
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - AIR-POLLUTION .2. ROAD TRAFFIC AND MODERN INDUSTRY	BRITISH MEDICAL JOURNAL			English	Article							DIESEL EXHAUST EXPOSURE; PARENTAL OCCUPATION; ASTHMATIC SUBJECTS; RAILROAD WORKERS; CHILDHOOD-CANCER; BLADDER-CANCER; LUNG-CANCER; ASSOCIATION; DIOXIDE											ANDERSON HR, 1987, ARCH DIS CHILD, V53, P295; AVOL EL, 1985, AM REV RESPIR DIS, V132, P619; BERCIANO FA, 1989, ANN ALLERGY, V62, P135; BLUMER M, 1977, ENVIRON SCI TECHNOL, V11, P1082, DOI 10.1021/es60135a002; BROWN LR, 1990, STATE WORLD 1990, P103; FERGUSSON M, 1989, ATMOSPHERIC EMISSION, V1; GARSHICK E, 1987, AM REV RESPIR DIS, V135, P1242; GARSHICK E, 1988, AM REV RESPIR DIS, V137, P820, DOI 10.1164/ajrccm/137.4.820; GILKS JML, 1989, CONCAWE889 REP; GUNNER G, 1991, Journal of Allergy and Clinical Immunology, V87, P185, DOI 10.1016/0091-6749(91)91469-A; HEMMINKI K, 1981, J EPIDEMIOL COMMUN H, V35, P11, DOI 10.1136/jech.35.1.11; HOLMAN C, 1990, ROUTE AHEAD VEHICLE; HOWARD D, 1990, ENERGY TRANSPORT ENV; HUBER TE, 1954, AMA ARCH IND HYG OCC, V10, P399; JENSEN OM, 1987, SCAND J WORK ENV HEA, V13, P129, DOI 10.5271/sjweh.2070; KAPLAN I, 1959, JAMA-J AM MED ASSOC, V171, P97; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377, DOI 10.1164/ajrccm/141.2.377; KWA SL, 1980, J OCCUP ENVIRON MED, V22, P792, DOI 10.1097/00043764-198012000-00012; LINN WS, 1983, AM REV RESPIR DIS, V127, P234; MOHSENIN V, 1987, J TOXICOL ENV HEALTH, V22, P371, DOI 10.1080/15287398709531080; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; READ C, 1991, AIR POLLUTION CHILD; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360, DOI 10.5271/sjweh.1848; STEENLAND K, 1987, AM J EPIDEMIOL, V126, P247, DOI 10.1093/aje/126.2.247; VANDEHOUT KD, 1986, DIESEL EXHAUST AIR P; WILLIAMS RR, 1977, J NATL CANCER I, V59, P1147, DOI 10.1093/jnci/59.4.1147; 1988, TRANSPORT ENV; 1987, AIR QUALITY GUIDELIN; 1988, IARC MONOGRAPHS EVAL, V46; 1991, SOCIAL TRENDS, V20, P147; 1982, IARC MONOGRAPHS EVAL, V29; 1987, ENERGY CLEANER AIR C; 1984, REPORT SCI REV PANEL	33	17	17	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1539	1543		10.1136/bmj.303.6816.1539	http://dx.doi.org/10.1136/bmj.303.6816.1539			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1723637	Green Published, Bronze			2022-12-28	WOS:A1991GV47600035
J	VAESSIN, H; GRELL, E; WOLFF, E; BIER, E; JAN, LY; JAN, YN				VAESSIN, H; GRELL, E; WOLFF, E; BIER, E; JAN, LY; JAN, YN			PROSPERO IS EXPRESSED IN NEURONAL PRECURSORS AND ENCODES A NUCLEAR-PROTEIN THAT IS INVOLVED IN THE CONTROL OF AXONAL OUTGROWTH IN DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; TRANSCRIPTION FACTOR; ZESTE GENE; ACTIVATION; EMBRYOS; LOCUS; MELANOGASTER; SEQUENCE; PRODUCT	Neurogenesis in Drosophila begins with the formation of neuronal precursors, which give rise to neurons of individual identity. To find out whether there are genes that are expressed in most or all neuronal precursors and are involved in controlling particular aspects of neuronal differentiation, we used the enhancer-trap method to screen for such "neuronal precursor genes." One gene of this group is prospero. Our mutant analysis indicates that prospero regulates other neuronal precursor genes and is essential for the axonal outgrowth and pathfinding of numerous central and peripheral neurons. prospero encodes a large nuclear protein with multiple homopolymeric amino acid stretches and is expressed in neuronal precursors early during their formation. It is probably generally required for proper neuronal differentiation.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VAESSIN, H (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1991, INT REV CYTOL, V124, P1; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FROHMAN MA, 1990, RACE RAPID AMPLIFICA, P28; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANSUKHANI A, 1988, MOL CELL BIOL, V8, P615, DOI 10.1128/MCB.8.2.615; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; POLLACK JA, 1985, CAL TECH BIOL ANN RE, V203; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; ROBERTSON HM, 1988, GENETICS, V118, P461; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	57	324	328	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					941	953		10.1016/0092-8674(91)90367-8	http://dx.doi.org/10.1016/0092-8674(91)90367-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720353				2022-12-28	WOS:A1991GT75500013
J	ZHOU, XL; STUMPF, MA; HOCH, HC; KUNG, C				ZHOU, XL; STUMPF, MA; HOCH, HC; KUNG, C			A MECHANOSENSITIVE CHANNEL IN WHOLE CELLS AND IN MEMBRANE PATCHES OF THE FUNGUS UROMYCES	SCIENCE			English	Article							ACTIVATED ION CHANNELS; ESCHERICHIA-COLI; RUST FUNGUS; K+ CHANNEL; MUSCLE	Bean leaf stomata provide a topographical signal that induces germlings of the phytopathogen Uromyces appendiculatus to develop specialized infection structures. Protoplasts from germ tubes of this fungus, when examined with patch-clamp electrodes, displayed the Activities of a 600-picosiemen mechanosensitive ion channel. This channel passes a variety of cations, including Ca2+, and is blocked by Gd3+ at 50 micromolar. This channel could transduce the membrane stress induced by the leaf topography into an influx of ions, including Ca2+, that may trigger differentiation.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; CORNELL UNIV,NEW YORK STATE AGR EXPT STN,DEPT PLANT PATHOL,GENEVA,NY 14456	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cornell University								ALLEN EA, 1991, PHYTOPATHOLOGY, V81, P323, DOI 10.1094/Phyto-81-323; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; COLE GT, 1991, FUNGAL SPORE DISEASE, P25; EMMETT RW, 1975, ANNU REV PHYTOPATHOL, V13, P147, DOI 10.1146/annurev.py.13.090175.001051; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HOCH HC, 1987, ANNU REV PHYTOPATHOL, V25, P231, DOI 10.1146/annurev.py.25.090187.001311; HOCH HC, 1987, SCIENCE, V235, P1659, DOI 10.1126/science.235.4796.1659; HUANG D, 1990, PHYTOPATHOLOGY, V80, P81, DOI 10.1094/Phyto-80-81; KWON Y, IN PRESS CAN J BOT; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MORRIS CE, 1991, SCIENCE, V251, P246; Sachs F., 1986, P181; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; Spangler S G, 1972, Ala J Med Sci, V9, P218; STUMPF MPH, UNPUB; WYNN WK, 1976, PHYTOPATHOLOGY, V66, P136, DOI 10.1094/Phyto-66-136; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	21	151	153	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1415	1417		10.1126/science.1716786	http://dx.doi.org/10.1126/science.1716786			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716786				2022-12-28	WOS:A1991GF85100040
J	GOMEZ, N; COHEN, P				GOMEZ, N; COHEN, P			DISSECTION OF THE PROTEIN-KINASE CASCADE BY WHICH NERVE GROWTH-FACTOR ACTIVATES MAP KINASES	NATURE			English	Article							MYELIN BASIC-PROTEIN; OKADAIC ACID; PHOSPHORYLATION; INSULIN; CELLS; IDENTIFICATION; PHOSPHATASE-2A; LINE	MITOGEN activated protein (MAP) kinases (MAPKs) are a family of protein-serine/threonine kinases activated as an early intracellular response to a variety of hormones and growth factors 1-4. They are unique in requiring both serine/threonine and tyrosine phosphorylation to become active 5 and are the only examples of protein-serine/threonine kinases activated by tyrosine phosphorylation. Nerve growth factor (NGF) promotes differentiation of phaeochromocytoma (PC12) cells, which respond by conversion within hours from a chromaffin-like to a sympathetic neuron-like phenotype 6,7. NGF stimulation of PC12 cells increases the activity of two protein kinases by > 20-fold within minutes 8, both strikingly similar to MAPKs. They are inactivated by either protein-tyrosine phosphatases or the protein-serine/threonine phosphatase termed protein phosphatase 2A (ref. 8), they activate protein S6 kinase-II (refs 9, 10), and they phosphorylate identical threonine residues on myelin basic protein (our unpublished results) to those phosphorylated by other MAPKs 11,12. Immunological data 13 indicate that these protein kinases, termed peak-I and peak-II (Fig. 1a) are probably ERK2 and ERK1, respectively, two widely expressed MAPK isoforms 13. Here we identify the 'MAP kinase kinases' (MAPKKs) in PC12 cells which are activated by NGF and report that MAPKKs are dependent on serine/threonine phosphorylation for activity and promote phosphorylation of serine/threonine and tyrosine residues on MAPKs.			GOMEZ, N (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND.		Gomez, Nestor/I-2522-2015	Gomez, Nestor/0000-0002-1348-2737				AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; STREULI M, 1988, J EXP MED, V168, P1553; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001	30	564	571	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					170	173		10.1038/353170a0	http://dx.doi.org/10.1038/353170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1716348				2022-12-28	WOS:A1991GE73100055
J	MUCENSKI, ML; MCLAIN, K; KIER, AB; SWERDLOW, SH; SCHREINER, CM; MILLER, TA; PIETRYGA, DW; SCOTT, WJ; POTTER, SS				MUCENSKI, ML; MCLAIN, K; KIER, AB; SWERDLOW, SH; SCHREINER, CM; MILLER, TA; PIETRYGA, DW; SCOTT, WJ; POTTER, SS			A FUNCTIONAL C-MYB GENE IS REQUIRED FOR NORMAL MURINE FETAL HEPATIC HEMATOPOIESIS	CELL			English	Article							EMBRYONIC STEM-CELLS; DNA-BINDING DOMAIN; MOUSE ERYTHROLEUKEMIA-CELLS; AVIAN-MYELOBLASTOSIS VIRUS; HOMOLOGOUS RECOMBINATION; PROTO-ONCOGENE; LEUKEMIA-VIRUS; V-MYB; NUCLEOTIDE-SEQUENCE; INSERTIONAL MUTAGENESIS	The c-myb proto-oncogene encodes a sequence-specific DNA-binding protein. To better understand its normal biological function, we have altered the c-myb gene by homologous recombination in mouse embryonic stem cells. Resulting homozygous c-myb mutant mice displayed an interesting phenotype. At day 13 of gestation these mice appeared normal, suggesting that c-myb is not essential for early development. By day 15, however, the mutant mice were severely anemic. Analysis indicated that embryonic erythropoiesis, which occurs in the yolk sac, was not impaired by the c-myb alteration. Adult-type erythropoiesis, which first takes place in the fetal liver, was greatly diminished in c-myb mutants, however. Additional hematopoietic lineages were similarly affected. These results are compatible with a role for c-myb in maintaining the proliferative state of hematopoietic progenitor cells.	UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT HEMATOL ONCOL,CINCINNATI,OH 45229	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	MUCENSKI, ML (corresponding author), UNIV CINCINNATI,CHILDRENS HOSP,COLL MED,RES FDN,CINCINNATI,OH 45229, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024517] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P60HL015996] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496, HL15996] Funding Source: Medline; NICHD NIH HHS [HD24517] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE RJ, 1966, J EMBRYOL EXP MORPH, V15, P245; COLLINS MD, 1989, AM J PHYSIOL, V257, P542; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CRAIG ML, 1964, DEV BIOL, V10, P191, DOI 10.1016/0012-1606(64)90040-5; CRAIG RW, 1984, CANCER RES, V44, P442; CUDENNEC LA, 1981, P NATL ACAD SCI USA, V78, P2412; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DYSON PJ, 1989, DIFFERENTIATION, V42, P24, DOI 10.1111/j.1432-0436.1989.tb00603.x; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FANTONI A, 1967, SCIENCE, V157, P1327, DOI 10.1126/science.157.3794.1327; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; HENRY JB, 1979, TS DAVIDSOHN CLIN DI; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUANG E, 1990, CELL, V63, P255; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOVACH JS, 1967, J MOL BIOL, V25, P131, DOI 10.1016/0022-2836(67)90284-7; KRAKOWSKY JM, 1989, DNA-J MOLEC CELL BIO, V8, P715, DOI 10.1089/dna.1989.8.715; KUCZUK MH, 1984, TERATOLOGY, V29, P427, DOI 10.1002/tera.1420290314; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P115; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SHEHEE WR, 1989, J MOL BIOL, V205, P41, DOI 10.1016/0022-2836(89)90363-X; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SIRACUSA LD, 1987, GENETICS, V117, P85; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; Tavassoli M, 1983, BONE MARROW STRUCTUR; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WAHLS WP, 1990, MOL CELL BIOL, V10, P794, DOI 10.1128/MCB.10.2.794; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wilson J.G., 1965, TERATOLOGY PRINCIPLE, P251; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	100	924	951	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					677	689		10.1016/0092-8674(91)90099-K	http://dx.doi.org/10.1016/0092-8674(91)90099-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709592				2022-12-28	WOS:A1991FM03700017
J	ADACHI, N; HASHIYAMA, M; MATSUDA, I				ADACHI, N; HASHIYAMA, M; MATSUDA, I			RHG-CSF AND AZTREONAM AS PROPHYLAXIS AGAINST INFECTION IN NEUTROPENIC CHILDREN	LANCET			English	Letter											ADACHI, N (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT PAEDIAT,KUMAMOTO 860,JAPAN.							BODEY GP, 1978, CANCER, V41, P1610, DOI 10.1002/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B; PHILLIPS I, 1981, J ANTIMICROB CHEM SE, V3, P103; SHERIDAN WP, 1989, LANCET, V2, P891; VANDERWAAIJ D, 1971, J HYG-CAMB, V69, P405, DOI 10.1017/S0022172400021653	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1174	1174		10.1016/0140-6736(91)92854-U	http://dx.doi.org/10.1016/0140-6736(91)92854-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1709249				2022-12-28	WOS:A1991FL12400071
J	ARTIGAS, J; ARASTEH, K; AVERDUNK, R; BACHLER, B; HORNSCHEIDT, M; GROSSE, G; LAGE, M; NIEDOBITEK, F				ARTIGAS, J; ARASTEH, K; AVERDUNK, R; BACHLER, B; HORNSCHEIDT, M; GROSSE, G; LAGE, M; NIEDOBITEK, F			HYALINE GLOBULES REACTING POSITIVELY WITH ZIDOVUDINE ANTIBODY IN BRAIN AND SPINAL-CORD OF AIDS PATIENTS	LANCET			English	Note							3'-AZIDO-3'-DEOXYTHYMIDINE; DIDEOXYNUCLEOSIDES	Histology of the central nervous system in nine AIDS patients who had been treated with zidovudine showed extracellular hyaline globules in the white matter of the brain and the spinal cord. In immunohistochemical studies with a battery of antibodies, the only positive reaction of these globules was with an antibody to zidovudine. High-performance liquid chromatography showed the presence of a zidovudine isomer in eluates of brain tissue from these patients.	AUGUSTE VIKTORIA KRANKENHAUS, DEPT MED, W-1000 BERLIN 41, GERMANY; AUGUSTE VIKTORIA KRANKENHAUS, DEPT CLIN BIOCHEM, W-1000 BERLIN 41, GERMANY		ARTIGAS, J (corresponding author), AUGUSTE VIKTORIA KRANKENHAUS, INST PATHOL, RUBENSTR 125, W-1000 BERLIN 41, GERMANY.							DAVTYAN DG, 1987, LANCET, V1, P919; ELLISON S, 1988, CLIN RES, V36, pA117; HAGLER DN, 1986, LANCET, V2, P1392; HARRIS PJ, 1988, NEW ENGL J MED, V318, P250, DOI 10.1056/NEJM198801283180412; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; SPEAR JB, 1988, ANN INTERN MED, V109, P76, DOI 10.7326/0003-4819-109-1-76; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; 1991, BIOCH ORGANIC COMPOU, P1204	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1991	337	8750					1127	1128		10.1016/0140-6736(91)92790-9	http://dx.doi.org/10.1016/0140-6736(91)92790-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1709247				2022-12-28	WOS:A1991FL12400007
J	AHARONI, R; TEITELBAUM, D; ARNON, R; PURI, J				AHARONI, R; TEITELBAUM, D; ARNON, R; PURI, J			IMMUNOMODULATION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY ANTIBODIES TO THE ANTIGEN-IA COMPLEX	NATURE			English	Article							MYELIN BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; CLASS-II; T-CELLS; HISTOCOMPATIBILITY MOLECULES; IMMUNE-RESPONSE; PEPTIDE; BINDING; VACCINATION; RECOGNITION	AUTOIMMUNE diseases occur when T lymphocytes become activated on recognizing self antigen linked to the autologous class II molecule of the major histocompatibility complex (MHC) 1,2. The resulting complex of antigen MHC T-cell receptor could be a target for treatment of autoimmune diseases. Studies in which each component is blocked separately 3-10 might be limited by interference in non-relevant immune responses that either use the same set of T-cell-receptor V gene segments or are linked to the same MHC. We report here an attack by a specific antibody on the unique antigenic site formed by the binding of two components of the trimolecular complex, the autoantigen bound to the self MHC 11-14. We tested its effect in experimental allergic encephalomyelitis, an acute neurological autoimmune disease which is widely regarded as a model for autoimmune disorders 15-17 and which is mediated by CD4+ T cells recognizing myelin basic protein (BP), or its peptides, in association with self Ia 18,19. We made monoclonal antibodies which bound only the complex of BP and I-A(s). These antibodies blocked the proliferative response in vitro to the encephalitogenic determinant of BP and reduced the response to intact BP, without affecting the response to a nonrelevant antigen-purified protein derivative of tuberculin presented on syngeneic macrophages. They also inhibited experimental allergic encephalomyelitis in H-2s mice. Hence, antibodies directed specifically to the autoantigen-Ia complex, may offer a highly selective and effective treatment in autoimmune diseases.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; DEMOTZ S, 1989, 7TH P INT C IMM, P60; ESHHAR Z, 1980, J IMMUNOL, V124, P775; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FRITZ RB, 1985, J IMMUNOL, V134, P2328; HIRSHFELD H, 1970, FEBS LETT, V7, P317, DOI 10.1016/0014-5793(70)80193-4; HOHFELD R, 1989, ANN NEUROL, V25, P532; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; OFFNER H, 1986, CELL IMMUNOL, V100, P364, DOI 10.1016/0008-8749(86)90036-5; PATERSON PY, 1977, AUTOIMMUNITY, P644; PURI J, 1980, EUR J IMMUNOL, V10, P273, DOI 10.1002/eji.1830100410; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SRIRAM S, 1987, J IMMUNOL, V139, P1485; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; URBAN JL, 1989, CELL, V59, P257, DOI 10.1016/0092-8674(89)90288-2; URBAN JL, 1980, CELL, V10, P273; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	25	90	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					147	150		10.1038/351147a0	http://dx.doi.org/10.1038/351147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709449				2022-12-28	WOS:A1991FL03500051
J	CATALONA, WJ; SMITH, DS; RATLIFF, TL; DODDS, KM; COPLEN, DE; YUAN, JJJ; PETROS, JA; ANDRIOLE, GL				CATALONA, WJ; SMITH, DS; RATLIFF, TL; DODDS, KM; COPLEN, DE; YUAN, JJJ; PETROS, JA; ANDRIOLE, GL			MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADICAL PROSTATECTOMY; ULTRASOUND; MARKER	Background. Prostate-specific antigen (PSA) is secreted exclusively by prostatic epithelial cells, and its serum concentration is increased in men with prostatic disease, including cancer. We evaluated its usefulness in the detection and staging of prostate cancer. Methods. We measured serum PSA concentrations in 1653 healthy men 50 or more years old. Those with PSA values greater-than-or-equal-to 4.0-mu-g per liter then underwent rectal examination and prostatic ultrasonography. Ultrasound-directed prostatic needle biopsies were performed in the men with abnormal findings on rectal examination, ultrasonography, or both. The results were compared with those in 300 consecutively studied men 50 or more years old who underwent ultrasound-directed biopsy because of symptoms or abnormal findings on rectal examination. Results. Serum PSA levels ranged from 4.0 to 9.9-mu-g per liter in 6.5 percent of the 1653 men (107). Nineteen of the 85 men in this group (22 percent) who had prostatic biopsies had prostate cancer. Serum PSA levels were 10.0-mu-g per liter or higher in 1.8 percent of the 1653 men (30). Eighteen of the 27 men in this group (67 percent) who had prostatic biopsies had cancer. If rectal examination alone had been used to screen the men who had biopsies, 12 of the 37 cancers (32 percent) would have been missed. If ultrasonography alone had been used to screen these men, 16 of the 37 cancers (43 percent) would have been missed. Serum PSA measurement had the lowest error rate of the tests, and PSA measurement plus rectal examination had the lowest error rate of the two-test combinations. Conclusions. The combination of measurement of the serum PSA concentration and rectal examination, with ultrasonography performed in patients with abnormal findings, provides a better method of detecting prostate cancer than rectal examination alone.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOSTAT,ST LOUIS,MO 63110; BARNES HOSP,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; CATALONA WJ, 1990, J UROLOGY, V143, P538, DOI 10.1016/S0022-5347(17)40013-9; CHODAK GW, 1989, WORLD J SURG, V13, P60, DOI 10.1007/BF01671155; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; FEIG SA, 1988, RADIOLOGY, V167, P659, DOI 10.1148/radiology.167.3.3283836; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; HODGE KK, 1989, J UROLOGY, V142, P71, DOI 10.1016/S0022-5347(17)38664-0; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; KILLIAN CS, 1986, J NATL CANCER I, V76, P179; LANGE PH, 1989, J UROLOGY, V141, P873; LEE F, 1985, PROSTATE, V7, P117, DOI 10.1002/pros.2990070202; NADJI M, 1981, CANCER, V48, P1229, DOI 10.1002/1097-0142(19810901)48:5<1229::AID-CNCR2820480529>3.0.CO;2-L; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501	15	1781	1853	1	122	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1156	1161		10.1056/NEJM199104253241702	http://dx.doi.org/10.1056/NEJM199104253241702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	1707140				2022-12-28	WOS:A1991FH57200002
J	GREGORY, CD; DIVE, C; HENDERSON, S; SMITH, CA; WILLIAMS, GT; GORDON, J; RICKINSON, AB				GREGORY, CD; DIVE, C; HENDERSON, S; SMITH, CA; WILLIAMS, GT; GORDON, J; RICKINSON, AB			ACTIVATION OF EPSTEIN-BARR-VIRUS LATENT GENES PROTECTS HUMAN B-CELLS FROM DEATH BY APOPTOSIS	NATURE			English	Article							ENDEMIC BURKITTS-LYMPHOMA; DEPENDENCE; EXPRESSION; PHENOTYPE; LINES; EBV	EPSTEIN-Barr virus (EBV), a human herpesvirus, establishes a persistent asymptomatic infection of the circulating B-lymphocyte pool 1-3. The mechanism of virus persistence is not understood but, given the limited lifespan of most B cells in vivo, it seems most likely that EBV-infected cells must gain access to the long-lived memory B-cell pool. Here we show in an in vitro system that EBV, through expression of the full set of eight virus-coded 'latent' proteins, can protect human B cells from programmed cell death (apoptosis), the deletion mechanism which normally restricts entry into memory 4. We have found that EBV-positive Burkitt's lymphoma (BL) cell clones 5 retaining the original tumour cell phenotype and expressing only one of the virus latent proteins, the nuclear antigen EBNA 1, are extremely sensitive to apoptosis; in this respect they resemble the tumour's normal cell of origin found in the germinal centres of lymphoid tissue. By contrast, isogenic BL cell clones which have activated expression of all eight EBV latent proteins are resistant to the induction of apoptosis. The EBV latent proteins should therefore be seen not just as activators of B-cell proliferation but, perhaps more importantly, as mediators of enhanced B-cell survival.	UNIV BIRMINGHAM, SCH MED, DEPT CANC STUDIES, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BIRMINGHAM, DEPT ANAT, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV ASTON, INST PHARMACEUT SCI, BIRMINGHAM B4 7ET, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham; Aston University	GREGORY, CD (corresponding author), UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.			Hope, Sheila/0000-0002-3608-4379; Williams, Gwyn/0000-0003-4556-9930; Dive, Caroline/0000-0002-1726-8850				ARENDS MJ, 1990, AM J PATHOL, V136, P593; Berard C W, 1985, IARC Sci Publ, P31; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; PENNELL CA, 1986, EUR J IMMUNOL, V16, P1577, DOI 10.1002/eji.1830161217; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	23	510	525	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					612	614		10.1038/349612a0	http://dx.doi.org/10.1038/349612a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1705663				2022-12-28	WOS:A1991EX57000060
J	TAYLOR, R; LOVELOCK, L; TUNBRIDGE, WMG; ALBERTI, KGMM; BRACKENRIDGE, RG; STEPHENSON, P; YOUNG, E				TAYLOR, R; LOVELOCK, L; TUNBRIDGE, WMG; ALBERTI, KGMM; BRACKENRIDGE, RG; STEPHENSON, P; YOUNG, E			COMPARISON OF NONMYDRIATIC RETINAL PHOTOGRAPHY WITH OPHTHALMOSCOPY IN 2159 PATIENTS - MOBILE RETINAL CAMERA STUDY	BRITISH MEDICAL JOURNAL			English	Article									FREEMAN RD HOSP,NEWCASTLE TYNE NE7 7ON,ENGLAND; HEXHAM GEN HOSP,HEXHAM NE46 1GJ,NORTHD,ENGLAND; QUEEN ELIZABETH HOSP,GATESHEAD NE9 6SX,TYNE & WEAR,ENGLAND; ASHINGTON GEN HOSP,ASHINGTON NE63 0SA,NORTHD,ENGLAND; ROYAL VICTORIA INFIRM,MED,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle General Hospital								ARMITAGE P, 1987, STATISTICAL METHODS; BURNSCOX CJ, 1985, BMJ-BRIT MED J, V290, P1052, DOI 10.1136/bmj.290.6474.1052; GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746; MOHAN R, 1988, BRIT J OPHTHALMOL, V72, P841, DOI 10.1136/bjo.72.11.841; ROGERS D, 1990, DIABETIC MED, V7, P165, DOI 10.1111/j.1464-5491.1990.tb01353.x; ROSEN ES, 1987, SEMIN OPHTHALMOL, V2, P37; RYDER REJ, 1985, BRIT MED J, V291, P1256, DOI 10.1136/bmj.291.6504.1256; SCOBIE IN, 1981, LANCET, V2, P520; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; TAYLOR R, 1988, BRIT MED J, V296, P1602, DOI 10.1136/bmj.296.6636.1602; TAYLOR R, 1987, DIABETIC MED, V4, pA576; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; 1979, 129 DEP HLTH SOC SEC	15	106	107	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 1	1990	301	6763					1243	1247		10.1136/bmj.301.6763.1243	http://dx.doi.org/10.1136/bmj.301.6763.1243			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM284	1703024	Green Published, Bronze			2022-12-28	WOS:A1990EM28400019
J	DUFFY, TP				DUFFY, TP			THE MANY PITFALLS IN THE DIAGNOSIS OF MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											DUFFY, TP (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,HEMATOL SECT,WWW4,POB 3333,NEW HAVEN,CT 06510, USA.							FISCHHOFF B, 1975, J EXP PSYCHOL HUMAN, V1, P288, DOI 10.1037/0096-1523.1.3.288; GINSBURG C, 1983, SIGN 3 DUPIN HOLMES, P81; LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; WOOD G, 1978, J EXP PSYCHOL HUMAN, V4, P345, DOI 10.1037/0096-1523.4.2.345	5	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					394	396		10.1056/NEJM199202063260607	http://dx.doi.org/10.1056/NEJM199202063260607			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729623				2022-12-28	WOS:A1992HC38600007
J	TILYARD, MW; SPEARS, GFS; THOMSON, J; DOVEY, S				TILYARD, MW; SPEARS, GFS; THOMSON, J; DOVEY, S			TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH CALCITRIOL OR CALCIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POST-MENOPAUSAL OSTEOPOROSIS; VITAMIN-D METABOLITES; SERUM 1,25-DIHYDROXYVITAMIN-D; 25-HYDROXYVITAMIN-D3 THERAPY; BONE TURNOVER; ABSORPTION; WOMEN; ESTROGEN; PATHOGENESIS; INDEXES	Background and Methods. osteoporosis is a common problem whose management is controversial. To evaluate the efficacy and safety of calcitriol (1,25-dihydroxyvitamin D3) in the treatment of postmenopausal osteoporosis, we conducted a three-year prospective, multicenter, single-blind study in 622 women who had one or more vertebral compression fractures. The women were randomly assigned to receive treatment with calcitriol (0.25-mu-g twice a day) or supplemental calcium (1 g of elemental calcium daily) for three years. New vertebral fractures were detected by means of lateral roentgenography of the spine each year, and calcium absorption was measured in 392 of the women. Results. The women who received calcitriol had a significant reduction in the rate of new vertebral fractures during the second and third years of treatment, as compared with the women who received calcium (second year, 9.3 vs. 25.0 fractures per 100 patient-years; third year, 9.9 vs. 31.5 fractures per 100 patient-years; P < 0.001). This effect was evident only in women who had had five or fewer vertebral fractures at base line (second year, 5.2 vs. 25.3 fractures per 100 patient-years; third year, 4.2 vs. 31.0 fractures per 100 patient-years; P < 0.0001). The groups also differed significantly in the number of peripheral fractures; 11 such fractures occurred in 11 women in the calcitriol group, whereas 24 occurred in 22 women in the calcium group (P < 0.05). There was no significant difference between the groups in the incidence of side effects requiring withdrawal of treatment (8.6 percent in the calcitriol group vs. 6.5 percent in the calcium group). Conclusions. Continuous treatment of postmenopausal osteoporosis with calcitriol for three years is safe and significantly reduces the rate of new vertebral fractures in women with this disorder.	UNIV OTAGO, DEPT PREVENT & SOCIAL MED, DUNEDIN, NEW ZEALAND	University of Otago	TILYARD, MW (corresponding author), UNIV OTAGO, SCH MED, DEPT GEN PRACTICE, RNZCGP RES UNIT, POB 913, DUNEDIN, NEW ZEALAND.							ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002-9343(88)90259-8; ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BIRKBECK JA, 1977, NZ THEIR DIET REPORT; CANIGGIA A, 1984, J ENDOCRINOL INVEST, V7, P373, DOI 10.1007/BF03351019; CHESNEY RW, 1980, AM J DIS CHILD, V134, P135, DOI 10.1001/archpedi.1980.02130140009004; CRILLY RG, 1981, CURR MED RES OPIN, V7, P337, DOI 10.1185/03007998109114277; DELUCA HF, 1990, METABOLISM, V39, P3, DOI 10.1016/0026-0495(90)90263-C; DELUCA HF, 1976, J LAB CLIN MED, V87, P7; GALLAGHER JC, 1980, J CLIN ENDOCR METAB, V51, P1359, DOI 10.1210/jcem-51-6-1359; GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; JENSEN GF, 1982, CLIN ENDOCRINOL, V16, P515, DOI 10.1111/j.1365-2265.1982.tb02769.x; Jensen GF, 1985, CLIN ORTHOP RELAT R, V192, P215; KUMAR R, 1979, J CLIN INVEST, V63, P342, DOI 10.1172/JCI109308; LAWOYIN S, 1980, J CLIN ENDOCR METAB, V50, P593, DOI 10.1210/jcem-50-3-593; LORE F, 1984, HORM METAB RES, V16, P58, DOI 10.1055/s-2007-1014696; LUND B, 1982, HORM METAB RES, V14, P271, DOI 10.1055/s-2007-1018990; NEED AG, 1985, MINER ELECTROL METAB, V11, P35; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; RECKER RR, 1984, CLIN RES, V32, pA406; RIGGS BL, 1985, J CLIN ENDOCR METAB, V61, P457, DOI 10.1210/jcem-61-3-457; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1981, J CLIN ENDOCR METAB, V53, P833, DOI 10.1210/jcem-53-4-833; RIGGS BL, 1978, MAYO CLIN PROC, V53, P701; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SLOVIK DM, 1981, NEW ENGL J MED, V305, P372, DOI 10.1056/NEJM198108133050704; SORENSEN OH, 1982, J CLIN ENDOCR METAB, V54, P1258, DOI 10.1210/jcem-54-6-1258; TILYARD M, 1990, METABOLISM, V39, P50, DOI 10.1016/0026-0495(90)90273-F; TJELLESEN L, 1984, ACTA MED SCAND, V215, P411; TSAI KS, 1984, CLIN RES, V32, pA411; ZERWEKH JE, 1983, J CLIN ENDOCR METAB, V56, P410, DOI 10.1210/jcem-56-2-410	32	492	505	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					357	362		10.1056/NEJM199202063260601	http://dx.doi.org/10.1056/NEJM199202063260601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729617				2022-12-28	WOS:A1992HC38600001
J	FLACK, MR; OLDFIELD, EH; CUTLER, GB; ZWEIG, MH; MALLEY, JD; CHROUSOS, GP; LORIAUX, DL; NIEMAN, LK				FLACK, MR; OLDFIELD, EH; CUTLER, GB; ZWEIG, MH; MALLEY, JD; CHROUSOS, GP; LORIAUX, DL; NIEMAN, LK			URINE FREE CORTISOL IN THE HIGH-DOSE DEXAMETHASONE SUPPRESSION TEST FOR THE DIFFERENTIAL-DIAGNOSIS OF THE CUSHING SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						DIAGNOSIS, DIFFERENTIAL; CUSHING SYNDROME; PITUITARY DISEASE; DEXAMETHASONE; HYDROCORTISONE	LABORATORY TESTS; UPDATE	Objective: To develop criteria for interpreting the high-dose dexamethasone suppression test using urine free cortisol as an end point for the differential diagnosis of the Cushing syndrome. Design: Retrospective review. Setting: Inpatient research ward. Patients: Patients (118) with surgically confirmed causes of the Cushing syndrome: 94 with pituitary disease, 14 with primary adrenal disease, and 10 with ectopic adrenocorticotropic hormone (ACTH) secretion. Main Outcome Measures: The sensitivity, specificity, and diagnostic accuracy were determined for the high-dose dexamethasone suppression test using urine free cortisol and using 17-hydroxysteroid excretion. For each analysis, patients with pituitary disease were considered to be "diseased" and patients with nonpituitary disease were considered to be "non-diseased". The level of suppression that gave 100% specificity was determined for each steroid. Results: The accuracy of urine free cortisol when used as an end point in the high-dose dexamethasone suppression test was equivalent to that of 17-hydroxysteroid excretion. At all levels of sensitivity and specificity, however, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease was greater than that of 17-hydroxysteroid excretion. The likelihood ratios for pituitary disease based on urine free cortisol suppression of > 50%, of > 80%, and of > 90% were 4.2, 10.1, and "infinite," respectively. Suppression of urine free cortisol greater than 90% or suppression of 17-hydroxysteroid excretion greater than 64% was associated with 100% specificity. When these criteria were combined, the percentage of correct predictions (102 of 118 [86%; 95% Cl, 78% to 92%]) was higher than that obtained using either steroid alone (89 of 118 [75%; Cl, 65% to 83%]) (P = 0.009) and higher than that obtained using the traditional criterion of 50% suppression for 17-hydroxysteroid excretion (95 of 118 [80%; Cl, 71% to 87%]) (P = 0.016). Conclusions: In the high-dose dexamethasone suppression test, the degree of suppression of urine free cortisol used for the diagnosis of pituitary disease is greater than that traditionally used for 17-hydroxysteroid excretion. The diagnostic performance of the test is improved by measuring both urine free cortisol and 17-hydroxysteroid excretion and by requiring greater suppression of both steroids.			FLACK, MR (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLD 10, ROOM 10N262, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							BEARDWELL CG, 1968, J ENDOCRINOL, V42, P79, DOI 10.1677/joe.0.0420079; BEISEL WR, 1964, J CLIN ENDOCR METAB, V24, P887, DOI 10.1210/jcem-24-9-887; BORUSHEK S, 1964, CLIN CHEM, V10, P41; BROWN RD, 1973, J CLIN ENDOCR METAB, V36, P445; BROWNLEE KA, 1965, STATISTICAL THEORY M, P262; BURKE CW, 1973, Q J MED, V42, P175; CARPENTER PC, 1986, MAYO CLIN PROC, V61, P49, DOI 10.1016/S0025-6196(12)61398-6; COPE CL, 1959, BR MED J        1128, P1117; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; EDDY RL, 1973, AM J MED, V55, P621, DOI 10.1016/0002-9343(73)90184-8; FORMAN DT, 1978, MANUAL PROCEDURES SE, P135; GOLD EM, 1979, ANN INTERN MED, V90, P829, DOI 10.7326/0003-4819-90-5-829; HANKIN ME, 1977, CLIN ENDOCRINOL, V6, P185, DOI 10.1111/j.1365-2265.1977.tb03314.x; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LORIAUX DL, 1986, CLIN ENDOCRINOL, P167; MARTIN MM, 1966, J CLIN ENDOCR METAB, V26, P257, DOI 10.1210/jcem-26-3-257; MORRISON DF, 1984, MULTIVARIATE STATIST, P34; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NICHOLS T, 1968, AM J MED, V45, P116, DOI 10.1016/0002-9343(68)90013-2; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; OLDFIELD EH, 1985, NEW ENGL J MED, V312, P1457; SHEELER LR, 1988, CLEV CLIN J MED, V55, P329, DOI 10.3949/ccjm.55.4.329; SILBER RH, 1950, J BIOL CHEM, V185, P923; SILBER RH, 1954, J BIOL CHEM, V21, P262; SINDLER BH, 1983, AM J MED, V74, P657, DOI 10.1016/0002-9343(83)91024-0; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; YOUNG DS, 1975, CLIN CHEM, V21, pD1; 1983, CAN MED ASSOC J, V129, P947	31	128	137	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					211	217		10.7326/0003-4819-116-3-211	http://dx.doi.org/10.7326/0003-4819-116-3-211			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728204				2022-12-28	WOS:A1992HB35600006
J	SCHAPIRO, BL; NEWBURGER, PE; KLEMPNER, MS; DINAUER, MC				SCHAPIRO, BL; NEWBURGER, PE; KLEMPNER, MS; DINAUER, MC			CHRONIC GRANULOMATOUS-DISEASE PRESENTING IN A 69-YEAR-OLD MAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							NEUTROPHIL CYTOCHROME-B; RESPIRATORY BURST OXIDASE; 2 CYTOSOLIC COMPONENTS; INTERFERON-GAMMA; PLASMA-MEMBRANE; CHAIN; ACTIVATION; ABSENCE; DEFICIENCIES; DIAGNOSIS		TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; UNIV MASSACHUSETTS, SCH MED, DEPT PEDIAT, WORCESTER, MA 01605 USA; CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Tufts University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	SCHAPIRO, BL (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOG MED & INFECT DIS, 750 WASHINGTON ST, BOX 067, BOSTON, MA 02111 USA.			Newburger, Peter/0000-0002-8615-673X	NCI NIH HHS [CA-38325] Funding Source: Medline; NHLBI NIH HHS [HL02253, HL45635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038325] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, K08HL002253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BAEHNER R L, 1990, Pediatric Pathology, V10, P143; BOLSCHER BGJM, 1991, BLOOD, V77, P2482; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DING AH, 1988, ANAL BIOCHEM, V175, P22, DOI 10.1016/0003-2697(88)90355-7; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305; GEORGILIS K, 1987, J IMMUNOL, V138, P3403; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HURST JK, 1991, J BIOL CHEM, V266, P1627; KLEINBERG ME, 1991, CLIN RES, V39, pA175; LOMAX KJ, 1989, BLOOD REV, V3, P94, DOI 10.1016/0268-960X(89)90004-0; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NATHAN CF, 1989, BLOOD, V73, P301; NERURKAR LS, 1987, SOUTHERN MED J, V80, P1296, DOI 10.1097/00007611-198710000-00022; NEWBURGER PE, 1979, NEW ENGL J MED, V300, P178, DOI 10.1056/NEJM197901253000406; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; POKORA BR, 1986, NATURE, V322, P32; POKORA BR, 1986, COLD SPRING HARB SYM, V51, P177; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMITH RM, 1991, BLOOD, V77, P673; SPITZNAGEL JK, 1990, J CLIN INVEST, V86, P1381, DOI 10.1172/JCI114851; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	42	93	97	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1786	1790		10.1056/NEJM199112193252506	http://dx.doi.org/10.1056/NEJM199112193252506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1719419				2022-12-28	WOS:A1991GV73900006
J	RICAURTE, GA; MOLLIVER, ME; MARTELLO, MB; KATZ, JL; WILSON, MA; MARTELLO, AL				RICAURTE, GA; MOLLIVER, ME; MARTELLO, MB; KATZ, JL; WILSON, MA; MARTELLO, AL			DEXFENFLURAMINE NEUROTOXICITY IN BRAINS OF NONHUMAN-PRIMATES	LANCET			English	Note							RAT-BRAIN; FENFLURAMINE	Dexfenfluramine, a drug prescribed for appetite suppression, was evaluated in non-human primates for its potential to produce toxic effects on brain serotonin (5-HT) neurons. Squirrel monkeys received dexfenfluramine subcutaneously twice daily for four days at doses of 1.25 or 5.00 mg/kg. Two weeks later, a dose-related depletion of 5-HT and 5-hydroxyindoleacetic acid was found, together with a reduced number of 5-HT uptake sites. Morphological studies showed acute pathological changes in 5-HT axons, followed by a persistent decrease in 5-HT axon density. Our findings indicate that dexfenfluramine damages central 5-HT neurons in monkeys and raise concern about the potential neurotoxicity of this drug in man.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; NIDA,ADDICT RES CTR,BALTIMORE,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	RICAURTE, GA (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,DEPT NEUROL,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.			Katz, Jonathan/0000-0002-1068-1159	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005707, R01DA004431, R29DA005707] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05707, DA04431] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALPHIN RS, 1969, TOXICOL APPL PHARM, V14, P182, DOI 10.1016/0041-008X(69)90178-1; CACCIA S, 1982, ARCH INT PHARMACOD T, V258, P15; CAMPBELL DB, 1986, DEV DRUGS MODERN MED, P298; GARATTINI S, 1987, BODY WEIGHT CONTROL, P261; GUYGRAND B, 1989, LANCET, V2, P1142; KLEVEN MS, 1989, BRAIN RES, V505, P351, DOI 10.1016/0006-8993(89)91467-4; MOLLIVER DC, 1990, BRAIN RES, V511, P165, DOI 10.1016/0006-8993(90)90237-6; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; SANDLER M, 1991, 5 HYDROXYTRYPTAMINE; ZACZEK R, 1990, J PHARMACOL EXP THER, V253, P104	10	76	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1487	1488		10.1016/0140-6736(91)92301-H	http://dx.doi.org/10.1016/0140-6736(91)92301-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1720853	hybrid			2022-12-28	WOS:A1991GV07700005
J	SETO, E; SHI, Y; SHENK, T				SETO, E; SHI, Y; SHENK, T			YY1 IS AN INITIATOR SEQUENCE-BINDING PROTEIN THAT DIRECTS AND ACTIVATES TRANSCRIPTION INVITRO	NATURE			English	Article							MAMMARY-TUMOR VIRUS; MAJOR LATE PROMOTER; LONG-TERMINAL REPEAT; RNA POLYMERASE-II; CONTROL REGION; GENE; BOX; TATA; IDENTIFICATION; PURIFICATION	REGULATION of eukaryotic messenger RNA transcription is governed by DNA sequence elements that serve as binding sites for sequence-specific transcription factors 1-3. These include upstream and downstream promoter-proximal elements, enhancers, repressors, and silencers, which modulate the rate of specific initiation by RNA polymerase II. In addition, the promoter-proximal region between -45 and +30 (relative to the start of initiation) contains two highly conserved motifs, the TATA sequence at around -30 and CA at +1 (ref. 4). Although the TATA element-binding factor TFIID has been purified and cloned from several organisms and has provided invaluable insight into the process of transcription initiation and its regulation, little is known about factors that interact at the +1 region. We have recently shown that the adeno-associated virus type 2 P5 promoter +1 region (P5 + 1 element) binds transcription factor YY1 (ref. 5). We report here that this sequence is necessary and sufficient for accurate basal transcription. Further, partially purified YY1 can restore basal level transcription from a P5 + 1 element in a HeLa extract depleted for YY1 or a Drosophila embryo extract devoid of YY1 activity, whereas a YY1-specific antibody can block the reactivation. Finally, using electrophoretic mobility shift assay, we have identified YY1-related factors that bind to two other transcription initiators in cellular genes.	PRINCETON UNIV,DEPT MOLEC BIOL,HOWARD HUGHES MED INST,PRINCETON,NJ 08544	Howard Hughes Medical Institute; Princeton University								BOYER TG, 1990, J BIOL CHEM, V265, P20524; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FLANAGAN JR, IN PRESS P NATN ACAD; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HARIHARAN N, IN PRESS P NATN ACAD; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; PARK K, IN PRESS P NATN ACAD; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; ULLRICH A, 1982, J MOL BIOL, V156, P467, DOI 10.1016/0022-2836(82)90261-3; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	34	393	402	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					241	245		10.1038/354241a0	http://dx.doi.org/10.1038/354241a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1720509				2022-12-28	WOS:A1991GQ94800053
J	BALK, SP; EBERT, EC; BLUMENTHAL, RL; MCDERMOTT, FV; WUCHERPFENNIG, KW; LANDAU, SB; BLUMBERG, RS				BALK, SP; EBERT, EC; BLUMENTHAL, RL; MCDERMOTT, FV; WUCHERPFENNIG, KW; LANDAU, SB; BLUMBERG, RS			OLIGOCLONAL EXPANSION AND CD1 RECOGNITION BY HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTES	SCIENCE			English	Article							T-CELL RECEPTOR; INTRA-THYMIC DIFFERENTIATION; VARIABLE REGION GENES; GAMMA-DELTA-CELLS; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; LEUKEMIC LYMPHOBLASTS; NORMAL THYMOCYTES; DISCRETE STAGES	A human intestinal intraepithelial lymphocyte (IEL) T cell line was established from jejunum to characterize the structure and function of the alpha-beta T cell antigen receptors (TCRs) expressed by this population. Single-sided polymerase chain reaction (PCR) amplification cloning and quantitative PCR amplification of the TCR chains from the cell line and from fresh IELs demonstrated that IELs were oligoclonal. The IEL T cell line exhibited CD1-specific cytotoxicity and a dominant IEL T cell clone was CD1c-specific. Thus, human jejunal intraepithelial lymphocytes are oligoclonal and recognize members of the CD1 gene family.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GASTROENTEROL,MED RES BLDG,ROOM 013B,BOSTON,MA 02115; UNIV MED & DENT NEW JERSEY,DIV EBERT GASTROENTEROL,NEW BRUNSWICK,NJ 08903; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [K11CA001310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042166, K08DK001886] Funding Source: NIH RePORTER; NCI NIH HHS [CA-01310] Funding Source: Medline; NIDDK NIH HHS [5 KO8 DK01886, DK42166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; AMIOT M, 1986, J IMMUNOL, V136, P1752; ARUFFO A, 1989, J IMMUNOL, V143, P1723; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, UNPUB; BAND H, 1987, SCIENCE, V238, P682, DOI 10.1126/science.3672118; BENEDITA R, 1991, J EXP MED, V173, P483; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BLUMBERG RS, IN PRESS J IMMUNOL; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BRANDTZAEG P, 1989, SCAND J IMMUNOL, V30, P123, DOI 10.1111/j.1365-3083.1989.tb01196.x; BROD SA, 1990, CELL IMMUNOL, V125, P426, DOI 10.1016/0008-8749(90)90096-A; BUCY RP, 1989, J IMMUNOL, V142, P3045; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; DRENO B, 1987, ACTA DERM-VENEREOL, V76, P406; DRIJKONINGEN M, 1986, BRIT J DERMATOL, V115, P511, DOI 10.1111/j.1365-2133.1986.tb06248.x; EBERT EC, 1989, GASTROENTEROLOGY, V97, P1372, DOI 10.1016/0016-5085(89)90379-X; ERNST PB, 1985, IMMUNOL TODAY, V6, P50, DOI 10.1016/0167-5699(85)90047-7; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GROH V, 1989, P NATL ACAD SCI USA, V86, P5059, DOI 10.1073/pnas.86.13.5059; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAHNPERLES B, 1985, J IMMUNOL, V134, P1759; KIMURA N, 1986, J EXP MED, V164, P739, DOI 10.1084/jem.164.3.739; KLEIN MH, 1987, P NATL ACAD SCI USA, V84, P6884, DOI 10.1073/pnas.84.19.6884; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TREJDOSIEWICZ LK, 1989, IMMUNOLOGY, V68, P7; VINEY JL, 1989, IMMUNOLOGY, V66, P583; WALSH LJ, 1988, J INVEST DERMATOL, V90, P13, DOI 10.1111/1523-1747.ep12462413; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	54	236	237	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1411	1415		10.1126/science.1716785	http://dx.doi.org/10.1126/science.1716785			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716785				2022-12-28	WOS:A1991GF85100039
J	PICKER, LJ; WARNOCK, RA; BURNS, AR; DOERSCHUK, CM; BERG, EL; BUTCHER, EC				PICKER, LJ; WARNOCK, RA; BURNS, AR; DOERSCHUK, CM; BERG, EL; BUTCHER, EC			THE NEUTROPHIL SELECTIN LECAM-1 PRESENTS CARBOHYDRATE LIGANDS TO THE VASCULAR SELECTINS ELAM-1 AND GMP-140	CELL			English	Article							NODE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; CELL-ADHESION; MONOCLONAL-ANTIBODY; INTERACTION DOMAINS; SIALYL-LEX; ENDOTHELIUM; EXPRESSION; PROTEINS; RECOGNITION	LECAM-1 (leukocyte-endothelial cell adhesion molecule 1), the lymphocyte lectin ("selectin") homing receptor for peripheral lymph nodes (PLNs), participates in the earliest interactions of polymorphonuclear neutrophilic leukocytes (PMNs) with inflamed venules. Here, we present evidence that LECAM-1 mediates this function through a novel mechanism - presentation of oligosaccharide ligands to the inducible vascular selectins endothelial-leukocyte adhesion molecule (ELAM-1) and granule membrane protein 140 (GMP-140). PMN, but not lymphocyte, LECAM-1 is modified with the vascular selectin ligand sialyl Lewis x (sLex) and specifically binds ELAM-1-transfected cells. Although only a small fraction of total cell surface sLex, LECAM-1-associated sLex appears to play a prominent role in PMN interactions with cell-associated ELAM-1 and GMP-140, as anti-LECAM-1 monoclonal antibodies or selective removal of cell surface LECAM-1 inhibits PMN binding to vascular selectin transfectants by up to 70%. The enhanced function of LECAM-1-associated sLex may reflect the striking concentration, shown here, of LECAM-1 on PMN surface microvilli, the site of initial cellular contact.	STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL & MED, PALO ALTO, CA 94304 USA; UNIV BRITISH COLUMBIA, ST PAULS HOSP, PULM RES LAB, VANCOUVER V6Z 1Y6, BC, CANADA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); St. Paul's Hospital; University of British Columbia; University of Saskatchewan	PICKER, LJ (corresponding author), UNIV TEXAS, DEPT PATHOL, MOLEC PATHOL LAB, SW MED CTR, DALLAS, TX 75235 USA.		Berg, Ellen/T-8827-2019; Berg, Ellen/D-9076-2014	Berg, Ellen/0000-0001-5149-6665	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041965, R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19957] Funding Source: Medline; NIGMS NIH HHS [GM37734, GM41965] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARFORS KE, 1987, BLOOD, V69, P338; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BEESLEY JE, 1978, J CELL SCI, V33, P85; BEESLEY JE, 1979, J CELL SCI, V38, P237; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, IN PRESS J BIOL CHEM; BERG M, 1990, BLOOD, V76, P2381; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARLOS T, 1991, BLOOD, V77, P2266; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; EWIJK WV, 1980, CIBA F S, V71, P21; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1991, BLOOD, V78, P805; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MULLIGAN RC, 1981, MOL CELL BIOL, V1, P449, DOI 10.1128/MCB.1.5.449; MUNRO JM, 1989, AM J PATHOL, V135, P121; ORD DC, 1990, J BIOL CHEM, V265, P7760; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Richardson P D, 1980, Ciba Found Symp, V71, P313, DOI 10.1002/9780470720547.ch17; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Staehelin T, 1981, Methods Enzymol, V79, P589; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TOKUYASU KT, 1983, J HISTOCHEM CYTOCHEM, V31, P164, DOI 10.1177/31.1A_Suppl.6186722; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, IN PRESS P NATL ACAD; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WOOD GS, 1984, AM J CLIN PATHOL, V81, P176, DOI 10.1093/ajcp/81.2.176	65	579	612	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					921	933		10.1016/0092-8674(91)90438-5	http://dx.doi.org/10.1016/0092-8674(91)90438-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716182				2022-12-28	WOS:A1991GE46000011
J	WILSON, KH; BLITCHINGTON, R; FROTHINGHAM, R; WILSON, JAP				WILSON, KH; BLITCHINGTON, R; FROTHINGHAM, R; WILSON, JAP			PHYLOGENY OF THE WHIPPLES-DISEASE-ASSOCIATED BACTERIUM	LANCET			English	Note								Efforts to culture and identify the intracellular bacteria associated with Whipple's disease have been unsuccessful. Nucleotide sequencing and amplification by the polymerase chain reaction was done on the bacterial 16 S ribosomal DNA present in a small-bowel biopsy specimen taken from a patient with Whipple's disease. A search by computer for similar rRNA sequences filed in databases showed the Whipple's-associated organism to be most similar to bacteria of the Rhodococcus, Streptomyces, and Arthrobacter genera, and more weakly related to mycobacteria. The biopsy specimen was estimated to contain around 10(7) cells of the organism. The probable aetiological agent for our patient's illness has not been identified previously in a patient with Whipple's disease.	DUKE UNIV,MED CTR,DIV INFECT DIS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV GASTROENTEROL,DURHAM,NC 27710	Duke University; Duke University	WILSON, KH (corresponding author), VET AFFAIRS MED CTR,INFECT DIS SECT,508 FULTON ST,DURHAM,NC 27705, USA.							VANETTA LL, 1983, REV INFECT DIS, V5, P1012; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WILSON KH, 1990, J CLIN MICROBIOL, V28, P1842; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	4	254	264	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					474	475		10.1016/0140-6736(91)90545-Z	http://dx.doi.org/10.1016/0140-6736(91)90545-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1714530				2022-12-28	WOS:A1991GC15300005
J	SANDGREN, EP; PALMITER, RD; HECKEL, JL; DAUGHERTY, CC; BRINSTER, RL; DEGEN, JL				SANDGREN, EP; PALMITER, RD; HECKEL, JL; DAUGHERTY, CC; BRINSTER, RL; DEGEN, JL			COMPLETE HEPATIC REGENERATION AFTER SOMATIC DELETION OF AN ALBUMIN-PLASMINOGEN ACTIVATOR TRANSGENE	CELL			English	Article							GROWTH-HORMONE; MOLECULAR-GENETICS; LIVER NEOPLASIA; MAMMARY-GLAND; FUSION GENES; MOUSE MODEL; TGF-ALPHA; MICE; EXPRESSION; CELL	We previously demonstrated that expression of an albumin-urokinase-type plasminogen activator (Alb-uPA) fusion construct in transgenic mice resulted in elevated plasma uPA concentration, hypofibrinogenemia, and neonatal hemorrhaging. Two lines of Alb-uPA mice were established in which only one half of the transgenic pups died at birth; surprisingly, plasma uPA concentrations in survivors gradually returned to normal by 2 months of age. The basis for this phenomenon is DNA rearrangement within hepatocytes that affects the transgene tandem array and abolishes transgene expression. Transgene-deficient cells selectively proliferate relative to surrounding liver, and this process culminates in replacement of the entire liver by clonal hepatic nodules derived from transgene-deficient progenitor cells. In some cases as few as two nodules can reconstitute over 90% of liver mass, highlighting the remarkable regenerative capacity of individual liver cells.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	SANDGREN, EP (corresponding author), UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104, USA.			Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA044611, R01CA038635] Funding Source: NIH RePORTER; NCI NIH HHS [CA38635, CA44611] Funding Source: Medline; NICHD NIH HHS [HD09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; COLLEN D, 1987, MOL BASIS BLOOD DISE, P662; DANO K, 1985, ADV CANCER RES, V44, P149; DARRAS BT, 1987, NATURE, V329, P556, DOI 10.1038/329556a0; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; HAMMER RE, 1985, COLD SPRING HARB SYM, V50, P379, DOI 10.1101/SQB.1985.050.01.048; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HETHCOTE HW, 1978, P NATL ACAD SCI USA, V75, P2453, DOI 10.1073/pnas.75.5.2453; HIGGS DR, 1989, BLOOD, V73, P1081; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1984, CELL, V36, P869, DOI 10.1016/0092-8674(84)90036-9; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SELL S, 1990, CANCER RES, V50, P3811; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SODA R, 1984, BLOOD, V63, P270; STOLZ A, 1990, HEPATOLOGY TXB LIVER, P637; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; VNENCAKJONES CL, 1990, SCIENCE, V250, P1745, DOI 10.1126/science.1980158; WILKIE TM, 1987, MOL CELL BIOL, V7, P1646, DOI 10.1128/MCB.7.5.1646; WILKIE TM, 1991, GENE DEV, V5, P38, DOI 10.1101/gad.5.1.38; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	46	306	325	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					245	256		10.1016/0092-8674(91)90615-6	http://dx.doi.org/10.1016/0092-8674(91)90615-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1713128				2022-12-28	WOS:A1991FY71200006
J	NIGG, EA; BAEUERLE, PA; LUHRMANN, R				NIGG, EA; BAEUERLE, PA; LUHRMANN, R			NUCLEAR IMPORT-EXPORT - IN SEARCH OF SIGNALS AND MECHANISMS	CELL			English	Review							PORE COMPLEX; PROTEIN; TRANSPORT; TRANSLOCATION; OOCYTES; RNA; COMPONENT; BINDING; DOMAIN; STEPS		LUDWIG MAXIMILIANS UNIV,GENZENTRUM,W-8033 MARTINSRIED,GERMANY; UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,W-3550 MARBURG,GERMANY	University of Munich; Philipps University Marburg	NIGG, EA (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.			nigg, erich/0000-0003-4835-5719				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1991, IN PRESS NUCLEAR TRA; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DABAUVALLE MC, 1991, J CELL BIOL, V112, P1073, DOI 10.1083/jcb.112.6.1073; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MUCHAUD N, 1991, J CELL BIOL, V112, P215; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHNEIDER J, 1988, CELL, V54, P117, DOI 10.1016/0092-8674(88)90185-7; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; WOANIAK RW, 1989, J CELL BIOL, V8, P2083	35	229	231	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					15	22		10.1016/0092-8674(91)90135-L	http://dx.doi.org/10.1016/0092-8674(91)90135-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1712670				2022-12-28	WOS:A1991FW91300005
J	NADA, S; OKADA, M; MACAULEY, A; COOPER, JA; NAKAGAWA, H				NADA, S; OKADA, M; MACAULEY, A; COOPER, JA; NAKAGAWA, H			CLONING OF A COMPLEMENTARY-DNA FOR A PROTEIN-TYROSINE KINASE THAT SPECIFICALLY PHOSPHORYLATES A NEGATIVE REGULATORY SITE OF P60C-SRC	NATURE			English	Article							PHOSPHOLIPASE-C; RAT-BRAIN; PP60C-SRC; GENE; BINDING; VIRUS; SEQUENCE; DEPHOSPHORYLATION; SIMILARITY; DOMAINS	THE protein-tyrosine kinase activity of the proto-oncogene product p60c-src is negatively regulated by the phosphorylation of a tyrosine residue close to the C terminus, tyrosine 527 (refs 1-11). The phosphorylation might be catalysed by a so-far-unidentified tyrosine kinase, distinct from p60c-src (ref. 7). Recently we purified a protein-tyrosine kinase that specifically phosphorylates tyrosine 527 of p60c-src from neonatal rat brain 8,12,13. We have now confirmed the specificity of this enzyme by using a mutant p60c-src that has a phenylalanine instead of tyrosine 527, and cloned a complementary DNA that encodes the enzyme. The enzyme is similar to kinases of the src family in that it has two conserved regions, Src-homology regions 2 and 3, upstream of a tyrosine kinase domain. The amino-acid identity of each region is no more than 47%, however, and the enzyme lacks phosphorylation sites corresponding to tyrosines 416 and 527 of p60c-src and has no myristylation signal. These results suggest that this protein-tyrosine kinase, which might negatively regulate p60c-src, represents a new type of tyrosine kinase.	OSAKA UNIV,INST PROT RES,DIV PROT METAB,3-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Osaka University; Fred Hutchinson Cancer Center								CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KIMIECIK TE, 1987, CELL, V49, P65; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	32	598	617	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					69	72		10.1038/351069a0	http://dx.doi.org/10.1038/351069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1709258				2022-12-28	WOS:A1991FK19300062
J	TAYLOR, SJ; CHAE, HZ; RHEE, SG; EXTON, JH				TAYLOR, SJ; CHAE, HZ; RHEE, SG; EXTON, JH			ACTIVATION OF THE BETA-1 ISOZYME OF PHOSPHOLIPASE-C BY ALPHA-SUBUNITS OF THE GQ CLASS OF G-PROTEINS	NATURE			English	Article							BOVINE BRAIN; TYROSINE PHOSPHORYLATION	MANY hormones, neurotransmitters and growth factors, on binding to G protein-coupled receptors or receptors possessing tyrosine kinase activity, increase intracellular levels of the second messengers inositol 1,4,5-trisphophate and 1,2-diacylglycerol. This is due to activation of phosphoinositide-specific phospholipase(s) C (PLC), the isozymes of which are classified into groups, alpha, beta, gamma and delta (refs 1, 2). The beta, gamma and delta-groups themselves contain PLC isozymes which have both common and unique structural domains 3. Only the gamma-1 isozyme has been implicated in a signal transduction mechanism 4. This involves association with, and tyrosine phosphorylation by, the ligand-bound epidermal growth factor and platelet-derived growth factor receptors 5-7, probably by means of the PLC-gamma-1-specific src homology (SH2) domain 8. Because EGF receptor-mediated tyrosine phosphorylation of PLC-gamma-1 stimulates catalytic activity in vitro 9 and G proteins have been implicated in the activation of PLC 10, we investigated which PLC isozymes are subject to G protein regulation. We have purified 11 an activated G protein alpha-subunit that stimulates partially purified phospholipase C and now report that this G protein specifically activates the beta-1 isozyme, but not the gamma-1 and delta-1 isozymes of phospholipase C. We also show that this protein is related to the G(q) class of G protein alpha-subunits 12.	VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; KRIZ R, 1990, CIBA F SYMP, V150, P112; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; RATH HM, 1990, J BIOL CHEM, V265, P3080; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; ULLRICH A, 1990, J CELL, V61, P203; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568	30	762	766	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					516	518		10.1038/350516a0	http://dx.doi.org/10.1038/350516a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1707501				2022-12-28	WOS:A1991FG14300056
J	FLANAGAN, JG; CHAN, DC; LEDER, P				FLANAGAN, JG; CHAN, DC; LEDER, P			TRANSMEMBRANE FORM OF THE KIT LIGAND GROWTH-FACTOR IS DETERMINED BY ALTERNATIVE SPLICING AND IS MISSING IN THE SI(D) MUTANT	CELL			English	Article							MOUSE AGGREGATION CHIMERAS; ANEMIC MICE; INVITRO DUPLICATION; PROTO-ONCOGENE; W-LOCUS; FIBROBLASTS; RECEPTOR; KINASE; CELLS; CURE	The ligand (KL) for the c-kit receptor is a growth factor encoded at the mouse steel (SI) locus. KL exists in both cell surface and soluble forms, though little is known of the regulation and functional significance of these forms. We show here that tissue-specific alternative splicing gives two types of KL mRNA. Both encode a transmembrane domain, but in transfected cells one produced the soluble form of KL at relatively high levels, whereas the other preferentially gave the cell surface form. Cell surface KL not only stimulated proliferation, but also mediated cell-cell adhesion. The SI(d) allele, which impairs development of hematopoietic cells, melanocytes, and germ cells, has a deletion in the KL gene removing the transmembrane and intracellular domains. Expression of a corresponding cDNA gave a soluble protein that stimulated cellular proliferation but was not associated with the cell surface. These results provide evidence that cell surface KL has a critical role in the intact organism.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	FLANAGAN, JG (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Chan, Doris/O-1227-2014; Flanagan, John/AAM-2995-2020	Chan, Doris/0000-0002-4990-986X; 				ALTUS MS, 1971, P SOC EXP BIOL MED, V138, P985; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; LANDRETH KS, 1984, J IMMUNOL, V132, P2724; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISONGRAHAM K, 1989, TRENDS GENET, V5, P116, DOI 10.1016/0168-9525(89)90042-5; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NAKAYAMA H, 1988, DEVELOPMENT, V102, P107; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STANLEY ER, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P165; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	723	739	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1025	1035		10.1016/0092-8674(91)90326-T	http://dx.doi.org/10.1016/0092-8674(91)90326-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1705866				2022-12-28	WOS:A1991FA94000019
J	YAMANASHI, Y; KAKIUCHI, T; MIZUGUCHI, J; YAMAMOTO, T; TOYOSHIMA, K				YAMANASHI, Y; KAKIUCHI, T; MIZUGUCHI, J; YAMAMOTO, T; TOYOSHIMA, K			ASSOCIATION OF B-CELL ANTIGEN RECEPTOR WITH PROTEIN TYROSINE KINASE LYN	SCIENCE			English	Article							IMMUNOGLOBULIN GAMMA-CHAINS; LYMPHOCYTES-B; MEMBRANE IGM; CD4 RECEPTOR; P56LCK; GENE; INVOLVEMENT; ACTIVATION; HYDROLYSIS; EXPRESSION	Antigen is thought to cross-link membrane-bound immunoglobulins (Igs) of B cells, causing proliferation and differentiation or the inhibition of growth. Protein tyrosine kinases are probably involved in signal transduction for cell proliferation and differentiation. The Src-like protein tyrosine kinase Lyn is expressed preferentially in B cells. The Lyn protein and its kinase activity could be coimmunoprecipitated with IgM from detergent lysates. Cross-linking of membrane-bound IgM induced a rapid increase in tyrosine phosphorylation of at least ten distinct proteins of B cells. Thus, Lyn is physically associated with membrane-bound IgM, and is suggested to participate in antigen-mediated signal transduction.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; NATL INST HLTH,DEPT APPL IMMUNOL,SHINAGAWA KU,TOKYO 141,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ALLERGOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo								BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOYD AW, 1981, J IMMUNOL, V126, P2466; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GOLD MR, 1987, J IMMUNOL, V139, P3604; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, ANNU REV IMMUNOL, V342, P385; GRUBER MF, 1989, J IMMUNOL, V142, P1444; GRUPP SA, 1985, J IMMUNOL, V134, P4087; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HARNETT MM, 1988, J IMMUNOL, V140, P3135; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KIM KJ, 1979, J IMMUNOL, V122, P549; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MONROE JG, 1989, BIOCHIM BIOPHYS ACTA, V1013, P273, DOI 10.1016/0167-4889(89)90146-8; NOSSAL GJV, 1989, ANNU REV IMMUNOL, V342, P340; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEMBA K, 1990, GENES CANCER, P73; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8697; TYLER BM, 1982, P NATL ACAD SCI-BIOL, V79, P2008, DOI 10.1073/pnas.79.6.2008; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VASILOV RG, 1982, EUR J IMMUNOL, V12, P804, DOI 10.1002/eji.1830121003; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, UNPUB; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	39	479	484	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					192	194		10.1126/science.1702903	http://dx.doi.org/10.1126/science.1702903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1702903				2022-12-28	WOS:A1991ET17300039
J	BAE, HR; VERKMAN, AS				BAE, HR; VERKMAN, AS			PROTEIN KINASE-A REGULATES CHLORIDE CONDUCTANCE IN ENDOCYTIC VESICLES FROM PROXIMAL TUBULE	NATURE			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARTHELSON R, 1987, J CLIN INVEST, V80, P1799, DOI 10.1172/JCI113274; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; DEMAREST JR, 1989, SCIENCE, V245, P402, DOI 10.1126/science.2474200; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; HOPKINS CR, 1990, NATURE, V5346, P335; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MARUNAKA Y, 1990, J GEN PHYSIOL, V95, P773, DOI 10.1085/jgp.95.5.773; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; OGRADY SM, 1988, AM J PHYSIOL, V254, pC115, DOI 10.1152/ajpcell.1988.254.1.C115; PEARCE D, 1989, BIOPHYS J, V55, P1251, DOI 10.1016/S0006-3495(89)82920-0; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SABOLIC I, 1985, AM J PHYSIOL, V248, pF835, DOI 10.1152/ajprenal.1985.248.6.F835; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SHI LB, 1989, J GEN PHYSIOL, V94, P1101, DOI 10.1085/jgp.94.6.1101; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1990, AM J PHYSIOL, V259, pC375, DOI 10.1152/ajpcell.1990.259.3.C375; YE R, 1989, J GEN PHYSIOL, V93, P885, DOI 10.1085/jgp.93.5.885	24	118	118	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 13	1990	348	6302					637	639		10.1038/348637a0	http://dx.doi.org/10.1038/348637a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM760	1701220				2022-12-28	WOS:A1990EM76000061
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FINAL RULE ELIMINATES USE OF 111 WEIGHT-CONTROL INGREDIENTS FROM OVER-THE-COUNTER DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0808, V56, P37792	1	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2022-12-28	WOS:A1992GY43700009
J	CHAN, AML; RUBIN, JS; BOTTARO, DP; HIRSCHFIELD, DW; CHEDID, M; AARONSON, SA				CHAN, AML; RUBIN, JS; BOTTARO, DP; HIRSCHFIELD, DW; CHEDID, M; AARONSON, SA			IDENTIFICATION OF A COMPETITIVE HGF ANTAGONIST ENCODED BY AN ALTERNATIVE TRANSCRIPT	SCIENCE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HEPATOCYTE GROWTH-FACTOR; MOLECULAR-CLONING; EPITHELIAL-CELLS; BIOLOGICAL CHARACTERIZATION; SCATTER FACTOR; PURIFICATION; EXPRESSION; PROTEIN; CDNA	We identified a naturally occurring hepatocyte growth factor (HGF) variant, whose predicted sequence extends only through the second kringle domain of this plasminogen-related molecule. This smaller molecule, derived from an alternative HGF transcript, lacked mitogenic activity but specifically inhibited HGF-induced mitogenesis. Cross-linking studies demonstrated that the truncated molecule competes with HGF for binding to the HGF receptor, which has been identified as the c-met proto-oncogene product. Thus, the same gene encodes both a growth factor and its direct antagonist.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Bottaro, Donald P/AAF-3853-2020; Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/F-8550-2010	Chan, Andrew Man-Lok/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOPINATH E, 1989, P NATL ACAD SCI USA, V86, P3045; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Maniatis T., 1982, MOL CLONING; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; ROSEN EM, 1990, EXP CELL RES, V186, P22, DOI 10.1016/0014-4827(90)90205-O; RUBIN J, UNPUB; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314	37	209	239	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1382	1385		10.1126/science.1720571	http://dx.doi.org/10.1126/science.1720571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720571				2022-12-28	WOS:A1991GR77700058
J	WHARTON, RP; STRUHL, G				WHARTON, RP; STRUHL, G			RNA REGULATORY ELEMENTS MEDIATE CONTROL OF DROSOPHILA BODY PATTERN BY THE POSTERIOR MORPHOGEN NANOS	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; MATERNAL-EFFECT MUTATIONS; RECEPTOR TYROSINE KINASE; BICOID MESSENGER-RNA; ABDOMINAL SEGMENTATION; UNTRANSLATED REGION; SECONDARY STRUCTURE; ANTERIOR PATTERN; EMBRYO; PROTEIN	In Drosophila embryos, graded activity of the posterior determinant nanos (nos) generates abdominal segmentation by blocking protein expression from maternal transcripts of the hunchback (hb) gene. When active inappropriately at the anterior pole, nos can also block expression of the anterior determinant bicoid (bcd). We show that both regulatory interactions are mediated by similar sequences in the 3' untranslated region of each transcript. These nos response elements (NREs) are both necessary and sufficient to confer nos-dependent regulation, the degree of regulation determined by the number and quality of the elements and the level of nos in vivo. Based on these and other results, we argue that nos acts as a morphogen, controlling hb expression (and hence abdominal pattern) as a function of its concentration-dependent interaction with the NREs.			WHARTON, RP (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.							BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHLER J, 1986, GENETICS, V112, P803; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1989, CIBA F SYMP, V144, P65; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	46	331	332	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					955	967		10.1016/0092-8674(91)90368-9	http://dx.doi.org/10.1016/0092-8674(91)90368-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1720354				2022-12-28	WOS:A1991GT75500014
J	AMMALA, C; LARSSON, O; BERGGREN, PO; BOKVIST, K; JUNTTIBERGGREN, L; KINDMARK, H; RORSMAN, P				AMMALA, C; LARSSON, O; BERGGREN, PO; BOKVIST, K; JUNTTIBERGGREN, L; KINDMARK, H; RORSMAN, P			INOSITOL TRISPHOSPHATE-DEPENDENT PERIODIC ACTIVATION OF A CA2+ - ACTIVATED K+ CONDUCTANCE IN GLUCOSE-STIMULATED PANCREATIC BETA-CELLS	NATURE			English	Article							B-CELLS; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; CHANNELS; SECRETION; CURRENTS; TOLBUTAMIDE; CALCIUM; APAMIN; SMOOTH	GLUCOSE-STIMULATED insulin secretion is associated with the appearance of electrical activity in the pancreatic beta-cell. At intermediate glucose concentrations, beta-cell electrical activity follows a characteristic pattern of slow oscillations in membrane potential on which bursts of action potentials are superimposed 1. The electrophysiological background of the bursting pattern remains unestablished. Activation of Ca2+-activated large-conductance K+ channels (K(Ca) channel 12) has been implicated in this process 3 but seems unlikely in view of recent evidence demonstrating that the beta-cell electrical activity is unaffected by the specific K(Ca) channel blocker charybdotoxin 4. Another hypothesis postulates that the bursting arises as a consequence of two components of Ca2+-current inactivation 5. Here we show that activation of a novel Ca2+-dependent K+ current in glucose-stimulated-beta-cells produces a transient membrane repolarization. This interrupts action potential firing so that action potentials appear in bursts. Spontaneous activity of this current was seen only rarely but could be induced by addition of compounds functionally related to hormones and neurotransmitters present in the intact pancreatic islet. K+ currents of the same type could be evoked by intracellular application of GTP, the effect of which was mediated by mobilization of Ca2+ from inositol 1,4,5-trisphosphate (InsP3)-sensitive intracellular Ca2+ stores. These observations suggest that oscillatory glucose-stimulated electrical activity, which is correlated with pulsatile release of insulin 6, results from the interaction between the beta-cell and intraislet hormones and neurotransmitters. Our data also provide evidence for a close interplay between ion channels in the plasma membrane and InsP3-induced mobilization of intracellular Ca2+ in an excitable cell.	GOTHENBURG UNIV,DEPT MED PHYS,BOX 33031,S-40033 GOTHENBURG,SWEDEN; KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN	University of Gothenburg; Karolinska Institutet			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; COOK DL, 1989, DIABETES, V38, P416, DOI 10.2337/diabetes.38.4.416; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HENQUIN JC, 1988, BIOCHEM BIOPH RES CO, V156, P769, DOI 10.1016/S0006-291X(88)80910-0; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; KUKULJAN M, 1991, J MEMBRANE BIOL, V119, P187, DOI 10.1007/BF01871418; LEBRUN P, 1983, FEBS LETT, V161, P41, DOI 10.1016/0014-5793(83)80726-1; LUND PE, 1991, BIOCHEM BIOPH RES CO, V177, P777, DOI 10.1016/0006-291X(91)91856-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NUSSINOVITCH I, 1988, J PHYSIOL-LONDON, V395, P303, DOI 10.1113/jphysiol.1988.sp016920; PENNER R, 1988, J EXP BIOL, V139, P329; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; ROSARIO LM, 1987, ADV EXP MED BIOL, V211, P413; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0	31	125	126	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					849	852		10.1038/353849a0	http://dx.doi.org/10.1038/353849a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719424				2022-12-28	WOS:A1991GM73200061
J	SINGER, D; BIEL, M; LOTAN, I; FLOCKERZI, V; HOFMANN, F; DASCAL, N				SINGER, D; BIEL, M; LOTAN, I; FLOCKERZI, V; HOFMANN, F; DASCAL, N			THE ROLES OF THE SUBUNITS IN THE FUNCTION OF THE CALCIUM-CHANNEL	SCIENCE			English	Article							SKELETAL-MUSCLE; XENOPUS OOCYTES; DIHYDROPYRIDINE RECEPTOR; GAMMA-SUBUNIT; MESSENGER-RNA; ION CHANNELS; HEART-CELLS; RAT-HEART; EXPRESSION; INACTIVATION	Dihydropyridine-sensitive voltage-dependent L-type calcium channels are critical to excitation-secretion and excitation-contraction coupling. The channel molecule is a complex of the main, pore-forming subunit alpha-1 and four additional subunits: alpha-2, delta, beta, and gamma (alpha-2 and delta are encoded by a single messenger RNA). The alpha-1 subunit messenger RNA alone directs expression of functional calcium channels in Xenopus oocytes, and coexpression of the alpha-2/delta and beta-subunits enhances the amplitude of the current. The alpha-2, delta, and gamma-subunits also have pronounced effects on its macroscopic characteristics, such as kinetics, voltage dependence of activation and inactivation, and enhancement by a dihydropyridine agonist. In some cases, specific modulatory functions can be assigned to individual subunits, whereas in other cases the different subunits appear to act in concert to modulate the properties of the channel.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL; TECH UNIV MUNICH, INST PHARMACOL & TOXIKOL, W-8000 MUNICH 40, GERMANY; UNIV SAARLAND, INST MED BIOCHEM, W-6650 HOMBURG, GERMANY	Tel Aviv University; Sackler Faculty of Medicine; Technical University of Munich; Saarland University			Dascal, Nathan/O-3915-2015; Biel, Martin/G-1175-2014; Tuluc, Petronel/C-2527-2011	Dascal, Nathan/0000-0002-5397-4146; Biel, Martin/0000-0002-9974-3052; 				AARONSON PI, 1988, J PHYSIOL-LONDON, V405, P57, DOI 10.1113/jphysiol.1988.sp017321; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BIEL M, UNPUB; BIEL M, IN PRESS EUR J BIOCH; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BROWN AM, 1986, J PHYSIOL-LONDON, V379, P495, DOI 10.1113/jphysiol.1986.sp016266; CAMPBELL DL, 1988, J PHYSIOL-LONDON, V403, P287, DOI 10.1113/jphysiol.1988.sp017250; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANG FC, 1988, J BIOL CHEM, V263, P18929; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; DASCAL N, UNPUB; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DONALDSON PL, 1983, J GEN PHYSIOL, V82, P449, DOI 10.1085/jgp.82.4.449; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERING S, 1989, PFLUG ARCH EUR J PHY, V414, P690, DOI 10.1007/BF00582137; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KASS RS, 1987, J GEN PHYSIOL, V89, P629, DOI 10.1085/jgp.89.4.629; KASS RS, 1984, J GEN PHYSIOL, V84, P705, DOI 10.1085/jgp.84.5.705; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; LEE KS, 1985, J PHYSIOL-LONDON, V364, P395, DOI 10.1113/jphysiol.1985.sp015752; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; LOTAN I, 1989, SCIENCE, V243, P666, DOI 10.1126/science.2464853; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANCHEZ JA, 1983, J PHYSIOL-LONDON, V337, P1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; UMBACH JA, 1987, P NATL ACAD SCI USA, V84, P5464, DOI 10.1073/pnas.84.15.5464; WALSH KB, 1989, J GEN PHYSIOL, V93, P841, DOI 10.1085/jgp.93.5.841	43	470	482	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1553	1557		10.1126/science.1716787	http://dx.doi.org/10.1126/science.1716787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1716787	Green Submitted			2022-12-28	WOS:A1991GG65100045
J	MAJOR, F; TURCOTTE, M; GAUTHERET, D; LAPALME, G; FILLION, E; CEDERGREN, R				MAJOR, F; TURCOTTE, M; GAUTHERET, D; LAPALME, G; FILLION, E; CEDERGREN, R			THE COMBINATION OF SYMBOLIC AND NUMERICAL COMPUTATION FOR 3-DIMENSIONAL MODELING OF RNA	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; HAMMERHEAD RNA; PREDICTION; PROTEIN; LOOP; CONFORMATION; SIMULATIONS; PSEUDOKNOTS; RESOLUTION; SEQUENCE	Three-dimensional (3-D) structural models of RNA are essential for understanding of the cellular roles played by RNA. Such models have been obtained by a technique based on a constraint satisfaction algorithm that allows for the facile incorporation of secondary and other structural information. The program generates 3-D structures of RNA with atomic-level resolution that can be refined by numerical techniques such as energy minimization. The precision of this technique was evaluated by comparing predicted transfer RNA loop and RNA pseudoknot structures with known or consensus structures. The root-mean-square deviation (2.0 to 3.0 angstroms before minimization) between predicted and control structures reveal this system to be an effective method in modeling RNA.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, QUEBEC, CANADA; UNIV MONTREAL, DEPT INFORMAT & RECH OPERAT, MONTREAL H3C 3J7, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal			Turcotte, Marcel/AAB-5397-2019	Turcotte, Marcel/0000-0002-4877-1029; Gautheret, Daniel/0000-0002-1508-8469				ABELSON H, 1989, COMMUN ACM, V32, P546, DOI 10.1145/63485.63486; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FASMAN GD, 1989, TRENDS BIOCHEM SCI, V14, P295, DOI 10.1016/0968-0004(89)90068-6; FULLER W, 1967, NATURE, V215, P817, DOI 10.1038/215817a0; HANEEF I, 1989, J MOL GRAPHICS, V7, P186, DOI 10.1016/0263-7855(89)80001-3; HARALICK RM, 1980, ARTIF INTELL, V14, P263, DOI 10.1016/0004-3702(80)90051-X; HEUS HA, 1990, NUCLEIC ACIDS RES, V18, P1103, DOI 10.1093/nar/18.5.1103; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0; Major F., 1991, Journal of Functional Programming, V1, P213; MALHOTRA A, 1990, P NATL ACAD SCI USA, V87, P1950, DOI 10.1073/pnas.87.5.1950; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MUTTER M, 1988, TRENDS BIOCHEM SCI, V13, P260, DOI 10.1016/0968-0004(88)90159-4; NILSSON L, 1990, BIOCHEMISTRY-US, V29, P10317, DOI 10.1021/bi00497a005; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHERAGA HA, 1968, ADV PHYS ORG CHEM, V6, P103; SKOLNICK J, 1990, SCIENCE, V250, P1121, DOI 10.1126/science.250.4984.1121; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TURNER DA, 1985, P FUNCTIONAL PROGRAM; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P	31	153	157	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1255	1260		10.1126/science.1716375	http://dx.doi.org/10.1126/science.1716375			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1716375				2022-12-28	WOS:A1991GE68900033
J	CYGLER, M; ROSE, DR; BUNDLE, DR				CYGLER, M; ROSE, DR; BUNDLE, DR			RECOGNITION OF A CELL-SURFACE OLIGOSACCHARIDE OF PATHOGENIC SALMONELLA BY AN ANTIBODY FAB FRAGMENT	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; COMBINING SITES; ANTIGEN COMPLEX; SEROGROUP-A; BINDING; PROTEINS; CONFORMATION; SPECIFICITY; LYSOZYME	The 2.05 angstrom (angstrom) resolution crystal structure of a dodecasaccharide-Fab complex revealed an unusual carbohydrate recognition site, defined by aromatic amino acids and a structured water molecule, rather than the carboxylic acid and amide side chains that are features of transport and other carbohydrate binding proteins. A trisaccharide epitope of a branched bacterial lipopolysaccharide fills this hydrophobic pocket (8 angstrom deep by 7 angstrom wide) in an entropy-assisted association (association constant = 2.05 x 10(5) liters per mole, enthalpy = -20.5 +/- 1.7 kilojoules per mole, and temperature times entropy = +10.0 +/- 2.9 kilojoules per mole). The requirement for the complementarity of van der Waals surfaces and the requirements of saccharide-saccharide and protein-saccharide hydrogen-bonding networks determine the antigen conformation adopted in the bound state.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA	National Research Council Canada	CYGLER, M (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA.							AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANAND NN, IN PRESS GENE; ANAND NN, UNPUB J BIOL CHEM; BOCK K, 1984, CARBOHYD RES, V130, P35, DOI 10.1016/0008-6215(84)85268-4; BOCK K, 1984, CARBOHYD RES, V130, P23, DOI 10.1016/0008-6215(84)85267-2; BRUNGER AT, 1990, XPLOR SYSTEM CRYSTAL; BUNDLE DR, 1990, TOP CURR CHEM, V154, P1; BUNDLE DR, UNPUB; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; GLAUDEMANS CPJ, 1987, MOL IMMUNOL, V24, P371, DOI 10.1016/0161-5890(87)90179-9; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JONES AT, 1978, J APPL CRYSTALLOGR, V11, P614; Kauffmann F, 1966, BACTERIOLOGY ENTEROB; Lemieux R. U., 1979, ACS SYM SER, V87, P17, DOI DOI 10.1021/BK-1979-0087.CH002; LEMIEUX RU, 1988, CAN J CHEM, V66, P3083, DOI 10.1139/v88-477; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; NASHED EM, 1990, J BIOL CHEM, V265, P20699; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1988, P NATL ACAD SCI USA, V85, P6885, DOI 10.1073/pnas.85.18.6885; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PEREZ S, 1978, CARBOHYD RES, V65, P114, DOI 10.1016/S0008-6215(00)84218-4; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; ROBBINS JB, 1978, IMMUNOCHEMISTRY, V15, P839, DOI 10.1016/0161-5890(78)90117-7; ROSE DR, 1990, J MOL BIOL, V215, P489, DOI 10.1016/S0022-2836(05)80161-5; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; THURIN J, 1988, CURR TOP MICROBIOL, V139, P59	33	258	264	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					442	445		10.1126/science.1713710	http://dx.doi.org/10.1126/science.1713710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1713710				2022-12-28	WOS:A1991FY28800039
J	INOUYE, S; SUNSHINE, MG; SIX, EW; INOUYE, M				INOUYE, S; SUNSHINE, MG; SIX, EW; INOUYE, M			RETRONPHAGE-PHI-R73 - AN ESCHERICHIA-COLI PHAGE THAT CONTAINS A RETROELEMENT AND INTEGRATES INTO A TRANSFER-RNA GENE	SCIENCE			English	Article							SATELLITE BACTERIOPHAGE-P4; MUTANTS; DNA	Some strains of Escherichia coli contain retroelements (retrons) that encode genes for reverse transcriptase and branched, multicopy, single-stranded DNA (msDNA) linked to RNA. However, the origin of retrons is unknown. A P4-like cryptic prophage was found that contains a retroelement (retron Ec73) for msDNA-Ec73 in an E. coli clinical strain. The entire genome of this prophage, named phi-R73, is 12.7 kilobase pairs and is flanked by 29-base pair direct repeats derived from the 3' end of the selenocystyl transfer RNA gene (selC). P2 bacteriophage caused excision of the phi-R73 prophage and acted as a helper to package phi-R73 DNA into an infectious virion. The newly formed phi-R73 closely resembled P4 as a virion and in its lytic growth. Retronphage phi-R73 lysogenized a new host strain, reintegrating its genome into the selC gene of the host chromosome and enabling the newly formed lysogens to produce msDNA-Ec73. Hence, retron Ec73 can be transferred intercellularly as part of the genome of a helper-dependent retronphage.	RUTGERS STATE UNIV,UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa			Inouye, Sharon/R-7216-2019		NIAID NIH HHS [AI04043] Funding Source: Medline; NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertani LE, 1988, BACTERIOPHAGES, V2, P73; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; GIBBS W, 1973, VIROLOGY, V53, P24, DOI 10.1016/0042-6822(73)90462-5; INOUYE M, 1991, TRENDS BIOCHEM SCI, V16, P18, DOI 10.1016/0968-0004(91)90010-S; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; SIX EW, 1975, VIROLOGY, V67, P249, DOI 10.1016/0042-6822(75)90422-5; SUN J, IN PRESS J BACTERIOL; WALKER JT, 1983, J VIROL, V45, P1118, DOI 10.1128/JVI.45.3.1118-1139.1983	8	77	79	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					969	971		10.1126/science.1709758	http://dx.doi.org/10.1126/science.1709758			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1709758				2022-12-28	WOS:A1991FM04000037
J	SHIMIZU, Y; SHAW, S; GRABER, N; GOPAL, TV; HORGAN, KJ; VANSEVENTER, GA; NEWMAN, W				SHIMIZU, Y; SHAW, S; GRABER, N; GOPAL, TV; HORGAN, KJ; VANSEVENTER, GA; NEWMAN, W			ACTIVATION-INDEPENDENT BINDING OF HUMAN-MEMORY T-CELLS TO ADHESION MOLECULE ELAM-1	NATURE			English	Article							HELPER-INDUCER; ENDOTHELIAL-CELLS; LYMPHOCYTES; RECEPTOR; PROTEINS; LFA-1; ADHESIVENESS; ICAM-1	THE induction of an ensemble of adhesion molecules on endothelial cells by inflammatory cytokines is likely to be crucial to the differential migration of T-lymphocyte subsets into inflammatory sites. Two molecular pathways involving the VLA-4 and LFA-1 integrins are known to mediate T-cell adhesion to activated endothelium 1-4. Here we show that a third pathway involving the rapidly inducible endothelial cell-surface adhesion molecule ELAM-1 (refs 5, 6) contributes to the binding of resting CD4+ T cells to IL-1-induced human endothelial cells. All three pathways contribute to the greater adhesion to endothelium of memory T cells than naive T cells. There are two unique features of T-cell adhesion to purified ELAM-1: first, ELAM-1 exclusively mediates adhesion of memory T cells; second, memory T-cell binding to ELAM-1 is independent of acute activation events that regulate integrin-mediated adhesion 7,8. Thus, ELAM-1 may be of primary importance in the initial attachment of memory T cells to inflamed endothelium in vivo and to the preferential migration of memory T cells into tissue and inflammatory sites.	OTSUKA AMER PHARMACEUT INC,DEPT IMMUNOL,ROCKVILLE,MD 20850; OTSUKA AMER PHARMACEUT INC,DEPT MOLEC BIOL,ROCKVILLE,MD 20850		SHIMIZU, Y (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.			Shimizu, Yoji/0000-0001-9760-0288; Horgan, Kevin/0000-0003-0647-9078				BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CAVENDER DE, 1988, CELL IMMUNOL, V117, P111, DOI 10.1016/0008-8749(88)90081-0; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DAMLE NK, 1990, J IMMUNOL, V144, P1233; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GRABER N, 1990, J IMMUNOL, V145, P819; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HORGAN KJ, 1990, EUR J IMMUNOL, V20, P1111, DOI 10.1002/eji.1830200525; JAMES SP, 1986, GASTROENTEROLOGY, V91, P1483, DOI 10.1016/0016-5085(86)90205-2; JANOSSY G, 1989, IMMUNOLOGY, V66, P517; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUNG TM, 1990, J IMMUNOL, V144, P3130; KINGSLEY G, 1988, SCAND J IMMUNOL, V28, P225, DOI 10.1111/j.1365-3083.1988.tb02435.x; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PITZALIS C, 1988, EUR J IMMUNOL, V18, P1397, DOI 10.1002/eji.1830180915; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TEDDER TF, 1985, J IMMUNOL, V134, P2989; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	34	395	406	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					799	802		10.1038/349799a0	http://dx.doi.org/10.1038/349799a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705667				2022-12-28	WOS:A1991EZ66600059
J	FORTHAL, DN				FORTHAL, DN			INOSINE PRANOBEX FOR PREVENTING AIDS IN PATIENTS WITH HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											FORTHAL, DN (corresponding author), UNIV CALIF IRVINE,COLL MED,IRVINE,CA 92717, USA.							GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; PEDERSEN C, 1990, NEW ENGL J MED, V322, P1757, DOI 10.1056/NEJM199006213222501	2	1	4	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	1991	324	7					491	491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX363	1703281				2022-12-28	WOS:A1991EX36300015
J	CHENG, SH; GREGORY, RJ; MARSHALL, J; PAUL, S; SOUZA, DW; WHITE, GA; ORIORDAN, CR; SMITH, AE				CHENG, SH; GREGORY, RJ; MARSHALL, J; PAUL, S; SOUZA, DW; WHITE, GA; ORIORDAN, CR; SMITH, AE			DEFECTIVE INTRACELLULAR-TRANSPORT AND PROCESSING OF CFTR IS THE MOLECULAR-BASIS OF MOST CYSTIC-FIBROSIS	CELL			English	Article											CHENG, SH (corresponding author), GENZYME CORP,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869				Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, AM J HUM GENET, V47, P213; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER PS, 1989, METABOLIC BASIS INHE, P2869; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P377; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; QUINTON PM, 1989, CLIN CHEM, V35, P726; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Sambrook J, 1989, MOL CLONING LABORATO; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2281; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085	32	1469	1524	8	268	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 16	1990	63	4					827	834		10.1016/0092-8674(90)90148-8	http://dx.doi.org/10.1016/0092-8674(90)90148-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EJ590	1699669				2022-12-28	WOS:A1990EJ59000018
J	WARNER, KE; GOLDENHAR, LM; MCLAUGHLIN, CG				WARNER, KE; GOLDENHAR, LM; MCLAUGHLIN, CG			CIGARETTE ADVERTISING AND MAGAZINE COVERAGE OF THE HAZARDS OF SMOKING - A STATISTICAL-ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; BAN	Background. Health professionals have charged that magazines that depend on revenues from cigarette advertising are less likely to publish articles on the dangers of smoking for fear of off ending cigarette manufacturers. Special concern has focused on magazines directed to women. Restricted coverage of smoking hazards could lead readers to underestimate the risks of smoking in relation to other health risks. Methods. Using logistic-regression analysis of a sample of 99 U.S. magazines published during 25 years (1959 through 1969 and 1973 through 1986), we analyzed the probability that the magazines would publish articles on the risks of smoking in relation to whether they carried advertisements for cigarettes and in relation to the proportion of their advertising revenues derived from cigarette advertisements. We controlled for other factors that might influence coverage. Results. The probability of publishing an article on the risks of smoking in a given year was 11.9 percent for magazines that did not carry cigarette advertisements, as compared with 8.3 percent for those that did publish such advertisements (adjusted odds ratio, 0.73; 95 percent confidence interval, 0.42 to 1.30). For women's magazines alone, the probabilities were 11.7 percent and 5.0 percent, respectively (adjusted odds ratio, 0.13; 95 percent confidence interval, 0.02 to 0.69). When the proportion of revenues derived from cigarette advertising was the independent variable, the probability of publishing an article on the risks of smoking in a given year was reduced by 38 percent (95 percent confidence interval, 18 percent to 55 percent) for magazines with the average proportion of total advertising revenues derived from cigarette advertising for the entire sample of magazines (6 percent) as compared with magazines with no cigarette advertising. This relation was particularly strong in the case of women's magazines. An increase of 1 percent in the share of advertising revenue derived from cigarette advertisements decreased the probability of covering the risks of smoking by three times as much as in other magazines. Conclusions. This study provides strong statistical evidence that cigarette advertising in magazines is associated with diminished coverage of the hazards of smoking. This is particularly true for magazines directed to women.			WARNER, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT PUBL HLTH POLICY & ADM,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004091] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04091] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMOS A, 1991, LANCET, V337, P93, DOI 10.1016/0140-6736(91)90747-D; Bagdikian B., 1983, MEDIA MONOPOLY; BLUM A, 1986, WASHINGTON POST 0518, pF1; DALE KC, 1982, ACHS NEWS VIEWS, V3, P8; DOUGHERTY PH, 1988, NY TIMES        0406, P1; EMERY CE, 1986, PROVIDENCE J B  0423, pA1; ENGLANDER TJ, 1986, US TOBACCO CAND 0402, P46; GREENE W, 1990, ECONOMETRIC ANAL, P482; JACOBSON B, 1985, SMAOKE GETS YOUR EYE; KESSLER L, 1989, JOURNALISM QUART, V66, P316, DOI 10.1177/107769908906600207; MYERS ML, 1981, STAFF REPORT CIGARET; Seldes George, 1938, LORDS PRESS; SMITH RC, 1978, COLUMBIA JOURNAL REV, V16, P29; WARNER K E, 1989, Journal of Public Health Policy, V10, P32, DOI 10.2307/3342942; WARNER KE, 1979, POLICY ANAL, V5, P435; WARNER KE, 1985, NEW ENGL J MED, V312, P384, DOI 10.1056/NEJM198502073120627; WARNER KE, 1959, IN PRESS TOB CONTROL; Whelan E M, 1981, J Public Health Policy, V2, P28, DOI 10.2307/3342095; 1989, DHHS CDC898411 DEP H; 1964, DHEW PHS1103 PUBL, V1103; 1990, MMWR, V39, P261	21	59	60	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					305	309		10.1056/NEJM199201303260505	http://dx.doi.org/10.1056/NEJM199201303260505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA991	1728734				2022-12-28	WOS:A1992HA99100005
J	DIAZ, PT; CLANTON, TL; PACHT, ER				DIAZ, PT; CLANTON, TL; PACHT, ER			EMPHYSEMA-LIKE PULMONARY-DISEASE ASSOCIATED WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						PULMONARY EMPHYSEMA; HIV INFECTIONS; HIV SEROPOSITIVITY; DYSPNEA; RESPIRATORY FUNCTION TESTS	PNEUMOCYSTIS-CARINII; COMPUTED-TOMOGRAPHY; AIDS; PNEUMONITIS; DIAGNOSIS; DAMAGE	Objective: To describe a possible association between prolonged infection with human immunodeficiency virus (HIV) and a pathophysiologic process suggestive of pulmonary emphysema. Design: Case series. Setting: The Ohio State University Hospital, Columbus, Ohio. Measurements and Main Results: We describe four HIV-seropositive individuals ranging in age from 32 to 55 years who presented with dyspnea. Radiographic examination of the chest showed no infiltrates. All patients were presumed to have had prolonged HIV infection (mean CD4 count, 99.8 +/- 43 cells/mm3), but none had a previous history of pneumonia or opportunistic infections. Comprehensive examination of bronchoalveolar lavage fluid showed no pathogens or other complications of HIV infection. All patients had markedly abnormal pulmonary function tests that were suggestive of emphysema with air-trapping, hyperinflation, and a markedly decreased diffusing capacity. However, only minimal evidence of airflow obstruction was noted. Three patients subsequently had high-resolution computed tomographic scans of the chest that revealed emphysema-like bullous changes. Known causes of emphysema were not present in these patients. Conclusions: Our findings support an association between prolonged HIV infection and an emphysema-like process. This syndrome may occur in the absence of previous pulmonary infections or apparent pulmonary complications and is characterized by unusual pulmonary function test abnormalities.			DIAZ, PT (corresponding author), OHIO STATE UNIV, DEPT INTERNAL MED, DIV PULM & CRIT CARE, 1654 UPHAM DR, COLUMBUS, OH 43210 USA.		Clanton, Thomas/AAS-9422-2020	Clanton, Thomas/0000-0003-0600-7150				AGOSTINI C, 1991, AM REV RESPIR DIS, V144, P195, DOI 10.1164/ajrccm/144.1.195; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1299; Bates DV, 1989, RESPIRATORY FUNCTION, P172; BUHL R, 1990, American Review of Respiratory Disease, V141, pA618; COLP C, 1970, AM REV RESPIR DIS, V101, P615; COTES JE, 1979, LUNG FUNCTION, P225; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P185; FISHER BK, 1987, INT J DERMATOL, V26, P615, DOI 10.1111/j.1365-4362.1987.tb02267.x; GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; GOLDSTEIN DS, 1986, CHEST, V89, P266, DOI 10.1378/chest.89.2.266; GUILLON JM, 1988, CHEST, V94, P1264, DOI 10.1378/chest.94.6.1264; GURNEY JW, 1989, RADIOLOGY, V173, P27, DOI 10.1148/radiology.173.1.2789412; HRUBAN RH, 1987, AM REV RESPIR DIS, V136, P935, DOI 10.1164/ajrccm/136.4.935; Jenkins D E, 1965, Trans Assoc Am Physicians, V78, P218; JOHNSON J, 1991, AM REV RESPIR DIS, V144, P179, DOI 10.1164/ajrccm/144.1.179; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KUHLMAN JE, 1989, RADIOLOGY, V173, P23, DOI 10.1148/radiology.173.1.2781013; KUWANO K, 1990, AM REV RESPIR DIS, V141, P169, DOI 10.1164/ajrccm/141.1.169; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; ODONNELL CR, 1988, CHEST, V94, P945, DOI 10.1378/chest.94.5.945; OGNIBENE FP, 1988, ANN INTERN MED, V109, P874, DOI 10.7326/0003-4819-109-11-874; PETTY TL, 1965, AM REV RESPIR DIS, V92, P450; ROSEN M, 1990, American Review of Respiratory Disease, V141, pA618; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SHAW RJ, 1988, THORAX, V43, P436, DOI 10.1136/thx.43.6.436; STOVER DE, 1988, CLIN CHEST MED, V9, P473	28	92	93	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					124	128		10.7326/0003-4819-116-2-124	http://dx.doi.org/10.7326/0003-4819-116-2-124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727615				2022-12-28	WOS:A1992GZ35600004
J	DICKERSIN, K; MIN, YI; MEINERT, CL				DICKERSIN, K; MIN, YI; MEINERT, CL			FACTORS INFLUENCING PUBLICATION OF RESEARCH RESULTS - FOLLOW-UP OF APPLICATIONS SUBMITTED TO 2 INSTITUTIONAL REVIEW BOARDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; BIAS; SCIENCE; SOCIETY	Objective. - To investigate factors associated with the publication of research findings, in particular, the association between "significant" results and publication. Design. - Follow-up study. Setting. - Studies approved in 1980 or prior to 1980 by the two institutional review boards that serve The Johns Hopkins Health Institutions-one that serves the School of Medicine and Hospital and the other that serves the School of Hygiene and Public Health. Population. - A total of 737 studies were followed up. Results. - Of the studies for which analyses had been reported as having been performed at the time of interview, 81 % f rom the School of Medicine and Hospital and 66% from the School of Hygiene and Public Health had been published. Publication was not associated with sample size, presence of a comparison group, or type of study (eg, observational study vs clinical trial). External funding and multiple data collection sites were positively associated with publication. There was evidence of publication bias in that for both institutional review boards there was an association between results reported to be significant and publication (adjusted odds ratio, 2.54; 95% confidence interval, 1.63 to 3.94). Contrary to popular opinion, publication bias originates primarily with investigators, not journal editors: only six of the 124 studies not published were reported to have been rejected for publication. Conclusion. - There is a statistically significant association between significant results and publication.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University	DICKERSIN, K (corresponding author), UNIV MARYLAND, SCH MED, DEPT OPHTHALMOL, 419 W REDWOOD ST, SUITE 460, BALTIMORE, MD 21201 USA.		Dickersin, Kay/A-4576-2008	Min, Yuan-I/0000-0003-2470-0004	AHRQ HHS [R01 HS5523] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005523] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANGELL M, 1989, NEW ENGL J MED, V321, P464, DOI 10.1056/NEJM198908173210708; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; Breslow N.E., 1980, STAT METHODS CANC RE, P192; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS I, 1986, CONTROL CLIN TRIALS, V7, P306, DOI 10.1016/0197-2456(86)90038-3; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; COLE JR, 1987, SCI AM, V256, P119, DOI 10.1038/scientificamerican0287-119; DAVIDSON RA, 1975, J GEN INTERN MED, V13, P82; DICKERSIN K, 1988, CONTROL CLIN TRIALS, V9, P76; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; EASTERBROOK P, 1987, BRIT MED J, V295, P1347, DOI 10.1136/bmj.295.6609.1347-a; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; I Chalmers, 1988, OXFORD DATABASE PERI; MEINERT CL, 1988, CONTROL CLIN TRIALS, V9, P1, DOI 10.1016/0197-2456(88)90002-5; RELMAN AS, 1981, COPING BIOMEDICAL LI, P67; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; WILSON JD, 1978, J CLIN INVEST, V61, P1697, DOI 10.1172/JCI109091; ZUCKERMAN H, 1975, MINERVA, V13, P82, DOI 10.1007/BF01096243; ZUCKERMAN H, 1971, MINERVA, V9, P66, DOI 10.1007/BF01553188; 1990, SERIE MONOGRAFIAS TE, V17; 1982, CASE CONTROL STUDIES, P33; 1988, US DHEW88267 PUBL; 1985, DIFFICULT BALANCE ED, P56; 1986, SAS RELEASE 5 18	29	656	665	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					374	378		10.1001/jama.267.3.374	http://dx.doi.org/10.1001/jama.267.3.374			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727960				2022-12-28	WOS:A1992GY43700034
J	GORDEUK, V; MUKIIBI, J; HASSTEDT, SJ; SAMOWITZ, W; EDWARDS, CQ; WEST, G; NDAMBIRE, S; EMMANUAL, J; NKANZA, N; CHAPANDUKA, Z; RANDALL, M; BOONE, P; ROMANO, P; MARTELL, RW; YAMASHITA, T; EFFLER, P; BRITTENHAM, G				GORDEUK, V; MUKIIBI, J; HASSTEDT, SJ; SAMOWITZ, W; EDWARDS, CQ; WEST, G; NDAMBIRE, S; EMMANUAL, J; NKANZA, N; CHAPANDUKA, Z; RANDALL, M; BOONE, P; ROMANO, P; MARTELL, RW; YAMASHITA, T; EFFLER, P; BRITTENHAM, G			IRON OVERLOAD IN AFRICA - INTERACTION BETWEEN A GENE AND DIETARY IRON CONTENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; COMPLEX SEGREGATION; QUANTITATIVE TRAITS; PEDIGREES; MODEL; PREVALENCE; EXPRESSION; PATTERNS; DISEASE	Background and Methods. In contrast to hemochromatosis, which in white populations is inherited through a gene linked to the HLA locus, iron overload in sub-Saharan Africa is believed to result solely from increased dietary iron derived from traditional home-brewed beer. To examine the hypothesis that African iron overload also involves a genetic factor, we used likelihood analysis to test for an interaction between a gene (the hypothesized iron-loading locus) and an environmental factor (increased dietary iron) that determines transferrin saturation and unsaturated iron-binding capacity. We studied 236 members of 36 African families chosen because they contained index subjects with iron overload. Linkage to the HLA region was tested with use of lod scores. Results. In the index subjects, increased iron was present in both hepatocytes and cells of the mononuclear-phagocyte system. Among family members with increased dietary iron due to the consumption of traditional beer, transferrin saturation in serum was distributed bimodally, with 56 normal values (< 60 percent saturation) and 44 elevated values; the mean serum ferritin concentration was five times higher in the subjects with elevated transferrin saturation (P < 0.005). The pedigree analysis provided evidence of both a genetic effect (P < 0.005) and an effect of increased dietary iron (P < 0.005) on transferrin saturation and unsaturated iron-binding capacity. In the most likely model, increased dietary iron raised the mean transferrin saturation from 30 to 81 percent and lowered the mean unsaturated iron-binding capacity from 38 to 13-mu-mol per liter in subjects heterozygous for the iron-loading locus. The hypothesis of tight linkage to HLA was rejected. Conclusions. Iron overload in Africa may be caused by an interaction between the amount of dietary iron and a gene distinct from any HLA-linked gene.	BLOOD TRANSFUS SERV,HARARE,ZIMBABWE; SANYATI BAPTIST HOSP,SANYATI,ZIMBABWE; PROV LAB TISSUE IMMUNOL,CAPE TOWN,SOUTH AFRICA; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV ZIMBABWE,SCH MED,HARARE,ZIMBABWE; UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84112; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	Case Western Reserve University; University of Zimbabwe; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Gordeuk, Victor/AAG-6577-2019; Chapanduka, zivanai/AAE-5631-2022	Chapanduka, zivanai/0000-0002-5489-8392	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD017463, R01HD017463] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 17463] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1978, Br J Haematol, V38, P281, DOI 10.1111/j.1365-2141.1978.tb01044.x; BLOCK M, 1958, IRON CLINICAL MEDICI, P115; BORECKI IB, 1989, AM J MED GENET, V134, P435; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTHWELL TH, 1964, AM J CLIN NUTR, V14, P47, DOI 10.1093/ajcn/14.1.47; BOTHWELL TH, 1984, S AFR MED J, V65, P601; BOTHWELL TH, 1989, METABOLIC BASIS INHE, V1, P1433; BOYLE CR, 1979, BIOMETRICS, V35, P55, DOI 10.2307/2529936; BRINK B, 1976, J LAB CLIN MED, V88, P725; BUCHANAN W M, 1970, South African Medical Journal, V44, P43; BUCHANAN WM, 1967, U COLLEGE RHODESIA F, V1, P5; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; GILL P, 1986, SOL862 STANF U TECH; GORDEUK VR, 1986, LANCET, V1, P1310; HASSTEDT SJ, 1982, COMPUT BIOMED RES, V15, P295, DOI 10.1016/0010-4809(82)90064-7; HENRY RJ, 1960, AM J CLIN PATHOL, V34, P381; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; ISAACSON C, 1961, J LAB CLIN MED, V58, P845; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LOWE R F, 1981, Central African Journal of Medicine, V27, P1; MACPHAIL AP, 1979, AM J CLIN NUTR, V32, P1272, DOI 10.1093/ajcn/32.6.1272; MORTON NE, 1974, AM J HUM GENET, V26, P489; OTT J, 1978, ANN HUM GENET, V42, P255, DOI 10.1111/j.1469-1809.1978.tb00657.x; Robins-Browne R M, 1979, Contrib Microbiol Immunol, V5, P277; ROSIN IV, 1982, TERAPEVT ARKH, V54, P80; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SEFTEL HC, 1961, J LAB CLIN MED, V58, P837; SEFTEL HC, 1966, BRIT MED J, V1, P642, DOI 10.1136/bmj.1.5488.642; SIMON M, 1987, AM J HUM GENET, V41, P89; SIMON M, 1977, CLIN GENET, V11, P327; SZASZ G, 1969, CLIN CHEM, V15, P124; YOUNG MR, 1988, AM J HUM GENET, V43, P705; 1978, BRIT J HAEMATOL, V38, P291; [No title captured]	38	241	240	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					95	100		10.1056/NEJM199201093260204	http://dx.doi.org/10.1056/NEJM199201093260204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727237				2022-12-28	WOS:A1992GY04500004
J	PAULSHOCK, BZ				PAULSHOCK, BZ			A DOCTOR IN HER HOUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					297	297						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727531				2022-12-28	WOS:A1992GY04600038
J	MASON, JO				MASON, JO			THE WORLD-HEALTH-ORGANIZATION CRITICAL ROLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US DEPT HHS,WASHINGTON,DC 20201, USA.								0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					24	24						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727184				2022-12-28	WOS:A1992GW84800002
J	HIPSKIND, RA; RAO, VN; MUELLER, CGF; REDDY, ESP; NORDHEIM, A				HIPSKIND, RA; RAO, VN; MUELLER, CGF; REDDY, ESP; NORDHEIM, A			ETS-RELATED PROTEIN ELK-1 IS HOMOLOGOUS TO THE C-FOS REGULATORY FACTOR P62TCF	NATURE			English	Article							SERUM RESPONSE ELEMENT; LONG TERMINAL REPEAT; TERNARY COMPLEX; CHROMOSOME-X; DNA-BINDING; TRANSCRIPTION; TRANSLOCATION; STIMULATION; SEQUENCE; SARCOMA	A KEY event in the response of cells to proliferative signals is the rapid, transient induction of the c-fos proto-oncogene, which is mediated through the serum response element (SRE) in the fos promoter 1-4. Genomic footprinting 5,6 and transfection experiments 7-9 suggest that this activation occurs through a ternary complex that includes the serum response factor (SRF) 10 and the ternary complex factor p62 (ref. 7). Interaction of p62TCF with the SRF-SRE binary complex requires a CAGGA tract immediately upstream of the SRE (ref. 7). Proteins of the ets proto-oncogene family bind to similar sequences 11-13 and we have found that a member of this family, Elk-1 (ref. 14), forms SRF-dependent ternary complexes with the SRE. Elk-1 and p62TCF have the same DNA sequence requirements and antibodies against Elk-1 block the binding of both proteins. Furthermore, we show that like P62TCF, Elk-1 forms complexes with the yeast SRF-homologue MCM1 but not with yeast ARG80 (ref. 15). But ARG80 mutants that convey interaction with p62TCF can also form complexes with Elk-1. The similarity, or even identity, between Elk-1 and p62TCF suggests a novel regulatory role for Ets proteins that is effected through interaction with other proteins, such as SRF. Furthermore, the possible involvement of an Ets protein in the control of c-fos has interesting implications for proto-oncogene cooperation in cellular growth control 16.	HANOVER MED SCH,INST MOLEC BIOL,POB 610180,W-3000 HANNOVER 61,GERMANY; JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Hannover Medical School; Jefferson University				Mueller, Christopher/0000-0002-4119-2729				BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; MUELLER CGF, IN PRESS EMBO J; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, IN PRESS ONCOGENE; REDDY ESP, 1990, CANCER RES, V50, P5013; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1990, CANCER BIOL, V1, P47; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	25	413	417	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					531	534		10.1038/354531a0	http://dx.doi.org/10.1038/354531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1722028	Bronze			2022-12-28	WOS:A1991GW75100017
J	GODDARD, AD; BORROW, J; FREEMONT, PS; SOLOMON, E				GODDARD, AD; BORROW, J; FREEMONT, PS; SOLOMON, E			CHARACTERIZATION OF A ZINC FINGER GENE DISRUPTED BY THE T(15,17) IN ACUTE PROMYELOCYTIC LEUKEMIA	SCIENCE			English	Article							TRANS RETINOIC ACID; ACUTE LYMPHOCYTIC-LEUKEMIA; RET TRANSFORMING GENE; BINDING DOMAIN; VIRUS TYPE-1; PROTEIN; EXPRESSION; SEQUENCE; ENCODES; DIFFERENTIATION	The translocation t(15;17) associated with acute promyelocytic leukemia results in the fusion of the retinoic acid receptor alpha (RARA) gene to the PML gene. Characterization of PML revealed that it is a putative zinc finger protein and potential transcription factor that is commonly expressed, with at least three major transcription products. PML breakpoints cluster in two regions on either side of an alternatively spliced exon. Although leukemic cells with translocations characteristically express only one fusion product, both PML/RARA (on the 15q+ derivative chromosome) and RARA/PML (on the 17q- derivative) are transcribed.	IMPERIAL CANC RES FUND,SOMAT CELL GENET LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT STRUCT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK				Freemont, Paul/0000-0002-5658-8486				BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BORROW J, UNPUB; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS JF, 1988, COMPUT APPL BIOSCI, V4, P67; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELIOPOULOS E, 1982, INT J BIOL MACROMOL, V4, P263, DOI 10.1016/0141-8130(82)90053-8; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FREEMONT PS, UNPUB; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODARD AD, UNPUB; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAPPA R, 1990, J VIROL, V65, P805; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SEED B, 1987, NATURE, V329, P860; SELLERI L, 1990, BLOOD, V75, P1146; SHEER D, 1985, BRIT J CANCER, V52, P55, DOI 10.1038/bjc.1985.148; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; SQUIRE J, 1986, P NATL ACAD SCI USA, V83, P6573, DOI 10.1073/pnas.83.17.6573; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002	49	450	456	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1371	1374		10.1126/science.1720570	http://dx.doi.org/10.1126/science.1720570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720570				2022-12-28	WOS:A1991GR77700054
J	ANDERSON, MP; BERGER, HA; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ				ANDERSON, MP; BERGER, HA; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ			NUCLEOSIDE TRIPHOSPHATES ARE REQUIRED TO OPEN THE CFTR CHLORIDE CHANNEL	CELL			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; NUCLEOTIDE-BINDING FOLD; ADENYLATE KINASE; ATP-BINDING; MULTIDRUG RESISTANCE; ESCHERICHIA-COLI; TYROSINE KINASE; BETA-SUBUNIT	The CFTR Cl- channel contains two predicted nucleotide-binding domains (NBD1 and NBD2); therefore, we examined the effect of ATP on channel activity. Once phosphorylated by cAMP-dependent protein kinase (PKA), channels required cytosolic ATP to open. Activation occurred by a PKA-independent mechanism. ATP-gamma-S substituted for ATP in PKA phosphorylation, but it did not open the channel. Several hydrolyzable nucleotides (ATP > GTP > ITP almost-equal-to UTP > CTP) reversibly activated phosphorylated channels, but nonhydrolyzable analogs and Mg2+-free ATP did not. Studies of CFTR mutants indicated that ATP controls channel activity independent of the R domain and suggested that hydrolysis of ATP by NBD1 may be sufficient for channel opening. The finding that nucleoside triphosphates regulate CFTR begins to explain why CF-associated mutations in the NBDs block Cl- channel function.	GENZYME CORP,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.			Anderson, Matthew/0000-0003-4602-1811; Berger, Herbert/0000-0003-4383-2643; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, IN PRESS CELL; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GLYNN IM, 1971, PHYSIOLOGY, V218, P239; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KRUG F, 1973, J BIOL CHEM S, V24, P1203; LEMAIRE S, 1974, CAN J BIOCHEM CELL B, V52, P137, DOI 10.1139/o74-021; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; MOOS C, 1960, ARCH BIOCHEM BIOPHYS, V88, P183, DOI 10.1016/0003-9861(60)90220-4; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SCHULTZ SG, 1981, AM J PHYSIOL, V241, pF579, DOI 10.1152/ajprenal.1981.241.6.F579; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	64	484	493	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					775	784		10.1016/0092-8674(91)90072-7	http://dx.doi.org/10.1016/0092-8674(91)90072-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1718606				2022-12-28	WOS:A1991GQ40700014
J	ARUFFO, A; KOLANUS, W; WALZ, G; FREDMAN, P; SEED, B				ARUFFO, A; KOLANUS, W; WALZ, G; FREDMAN, P; SEED, B			CD62/P-SELECTIN RECOGNITION OF MYELOID AND TUMOR-CELL SULFATIDES	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; ENDOTHELIAL VONWILLEBRAND-FACTOR; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; ADHESIVE INTERACTION; MONOCLONAL-ANTIBODY; NEUTROPHIL ADHESION; SEQUENCE HOMOLOGY; HOMING RECEPTOR; SIALYL-LEX	CD62, also called PADGEM protein, GMP-140, or P-selectin, is a granule membrane protein of endothelial cells and platelets that is mobilized to the plasma membrane following exposure to mediators such as thrombin, histamine, complement components, or peroxides. Data presented to date suggest that one ligand of CD62 includes CD15 (Lewis x determinant) and sialic acid. We show here that sulfatides, heterogeneous 3-sulfated galactosyl ceramides, are an apparently unrelated ligand of CD62. Sulfatides are expressed on the plasma membrane of, and are excreted by, granulocytes, and constitute the principal ligand for CD62 on the plasma membrane of some tumor cells. CD62 binds to sulfatides adsorbed to plastic as avidly as it binds to myeloid or tumor cells. We find that granulocytes excrete sulfatides at a rate predicted to allow them to be rapidly released from CD62 once they have exited the bloodstream.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-40033 GOTHENBURG,SWEDEN; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Harvard University; Massachusetts General Hospital; University of Gothenburg; Bristol-Myers Squibb	ARUFFO, A (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DIETRICH CP, 1988, FASEB J, V2, P56, DOI 10.1096/fasebj.2.1.2961646; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GAMBLE JR, 1990, SCIENCE, V249, P414; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hakomori S I, 1974, Methods Enzymol, V32, P345; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HIRAIWA N, 1990, CANCER RES, V50, P2917; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; ISHIZUKA I, 1978, J BIOL CHEM, V253, P898; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PRENCE EM, 1986, BIOCHEM J, V237, P655, DOI 10.1042/bj2370655; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; SARLIEVE LL, 1984, BIOCHIM BIOPHYS ACTA, V795, P166, DOI 10.1016/0005-2760(84)90118-8; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	44	295	320	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					35	44		10.1016/0092-8674(91)90570-O	http://dx.doi.org/10.1016/0092-8674(91)90570-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717159				2022-12-28	WOS:A1991GJ32000005
J	NEWBURGER, JW; TAKAHASHI, M; BEISER, AS; BURNS, JC; BASTIAN, J; CHUNG, KJ; COLAN, SD; DUFFY, CE; FULTON, DR; GLODE, MP; MASON, WH; MEISSNER, HC; ROWLEY, AH; SHULMAN, ST; REDDY, V; SUNDEL, RP; WIGGINS, JW; COLTON, T; MELISH, ME; ROSEN, FS				NEWBURGER, JW; TAKAHASHI, M; BEISER, AS; BURNS, JC; BASTIAN, J; CHUNG, KJ; COLAN, SD; DUFFY, CE; FULTON, DR; GLODE, MP; MASON, WH; MEISSNER, HC; ROWLEY, AH; SHULMAN, ST; REDDY, V; SUNDEL, RP; WIGGINS, JW; COLTON, T; MELISH, ME; ROSEN, FS			A SINGLE INTRAVENOUS-INFUSION OF GAMMA-GLOBULIN AS COMPARED WITH 4 INFUSIONS IN THE TREATMENT OF ACUTE KAWASAKI SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY ARTERIAL ANEURYSM; DISEASE; ANGIOGRAPHY; REGRESSION; LESIONS; HEART	Background. Treatment of acute Kawasaki syndrome with a four-day course of intravenous gamma globulin, together with aspirin, has been demonstrated to be safe and effective in preventing coronary-artery lesions and reducing systemic inflammation. We hypothesized that therapy with a single, very high dose of gamma globulin would be at least as effective as the standard regimen. Methods. We conducted a multicenter, randomized, controlled trial involving 549 children with acute Kawasaki syndrome. The children were assigned to receive gamma globulin either as a single infusion of 2 g per kilogram of body weight over 10 hours or as daily infusions of 400 mg per kilogram for four consecutive days. Both treatment groups received aspirin (100 mg per kilogram per day through the 14th day of illness, then 3 to 5 mg per kilogram per day). Results. The relative prevalence of coronary abnormalities, adjusted for age and sex, among patients treated with the four-day regimen, as compared with those treated with the single-infusion regimen, was 1.94 (95 percent confidence limits, 1.01 and 3.71) two weeks after enrollment and 1.84 (95 percent confidence limits, 0.89 and 3.82) seven weeks after enrollment. Children treated with the single-infusion regimen had lower mean temperatures while hospitalized (day 2, P < 0.001; day 3, P = 0.004), as well as a shorter mean duration of fever (P = 0.028). Furthermore, in the single-infusion group the laboratory indexes of acute inflammation moved more rapidly toward normal, including the adjusted serum albumin level (P = 0.004), alpha-1-antitrypsin level (P = 0.007), and C-reactive protein level (P = 0.017). Lower IgG levels on day 4 were associated with a higher prevalence of coronary lesions (P = 0.005) and with a greater degree of systemic inflammation. The two groups had a similar incidence of adverse effects (including new or worsening congestive heart failure in nine children), which occurred in 2.7 percent of the children overall. All the adverse effects were transient. Conclusions. In children with acute Kawasaki disease, a single large dose of intravenous gamma globulin is more effective than the conventional regimen of four smaller daily doses and is equally safe.	CHILDRENS HOSP MED CTR,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS MEM HOSP,DEPT PEDIAT,CHICAGO,IL 60614; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; CHILDRENS HOSP,DENVER,CO 80218; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262; UNIV COLORADO,SCH MED,DENVER,CO 80202; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; UNIV CALIF SAN DIEGO,CHILDRENS HOSP,MED CTR,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,SCH MED,SAN DIEGO,CA 92103; TUCSON MED CTR,TUCSON,AZ 85733; TUFTS UNIV,SCH MED,BOSTON,MA 02111; KAPIOLANI CHILDRENS MED CTR,HONOLULU,HI; JOHN A BURNS SCH MED,HONOLULU,HI; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of California System; University of California San Diego; University of California System; University of California San Diego; Tufts University; Boston University	NEWBURGER, JW (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Burns, Jane C/J-6167-2015; Colan, Steven/ABB-4580-2020	Sundel, Robert/0000-0002-0083-5695; Rowley, Anne/0000-0003-4695-6676; Beiser, Alexa/0000-0001-8551-7778	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034545] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 02172, RR 69] Funding Source: Medline; NHLBI NIH HHS [HL 34545] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRON KS, 1990, J PEDIATR-US, V117, P638, DOI 10.1016/S0022-3476(05)80707-3; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BRESLOW NE, 1980, IARC32 INT AG RES CA, V1; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; ENGLE MA, 1989, AM J DIS CHILD, V143, P1300, DOI 10.1001/archpedi.1989.02150230058023; FUJIWARA H, 1978, PEDIATRICS, V61, P100; FUJIWARA T, 1988, CIRCULATION, V78, P345, DOI 10.1161/01.CIR.78.2.345; FUJIWARA T, 1987, KAWASAKI DIS PROGR C, V250, P519; FURUSHO K, 1984, LANCET, V2, P1055; FURUSHO K, 1987, KAWASAKI DISEASE, V250, P425; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KATO H, 1986, J PEDIATR-US, V108, P923, DOI 10.1016/S0022-3476(86)80928-3; KATOH T, 1988, 3RD INT KAW DIS S TO; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KURISU Y, 1987, AM HEART J, V114, P532, DOI 10.1016/0002-8703(87)90749-6; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATSUMURA K, 1988, ANGIOLOGY, V39, P141, DOI 10.1177/000331978803900203; MORENS DM, 1980, PEDIATRICS, V65, P21; NAKANO H, 1985, AM J CARDIOL, V56, P846, DOI 10.1016/0002-9149(85)90767-2; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; OGAWA M, 1988, 3RD INT KAW DIS S TO; SASAGURI Y, 1982, J PEDIATR-US, V100, P225, DOI 10.1016/S0022-3476(82)80639-2; SPEVAK PJ, 1987, AM J CARDIOL, V60, P640; SUZUKI A, 1986, PEDIATR CARDIOL, V7, P3, DOI 10.1007/BF02315475; TAKAHASHI M, 1987, CIRCULATION, V75, P387, DOI 10.1161/01.CIR.75.2.387; TANAKA N, 1986, ACTA PATHOL JAPON, V36, P1513; TATARA K, 1987, J PEDIATR-US, V111, P705, DOI 10.1016/S0022-3476(87)80246-9; TATARA K, 1987, KAWASAKI DISEASE, V250, P579; [No title captured]	32	860	895	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1633	1639		10.1056/NEJM199106063242305	http://dx.doi.org/10.1056/NEJM199106063242305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	1709446	Bronze			2022-12-28	WOS:A1991FP30700005
J	LAWRENCE, MB; SPRINGER, TA				LAWRENCE, MB; SPRINGER, TA			LEUKOCYTES ROLL ON A SELECTIN AT PHYSIOLOGICAL FLOW-RATES - DISTINCTION FROM AND PREREQUISITE FOR ADHESION THROUGH INTEGRINS	CELL			English	Article							INCREASED SURFACE EXPRESSION; GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; NEUTROPHIL ADHERENCE; INTERCELLULAR-ADHESION; ENDOTHELIAL-CELLS; BLOOD-FLOW; TRANSENDOTHELIAL MIGRATION; VASCULAR ENDOTHELIUM; CULTURED ENDOTHELIUM	Rolling of leukocytes on vascular endothelial cells, an early event in inflammation, can be reproduced in vitro on artificial lipid bilayers containing purified CD62, a selectin also named PADGEM and GMP-140 that is inducible on endothelial cells. Neutrophils roll onthis selectin under flow conditions similar to those found in postcapillary venules. Adhesion of resting or activated neutrophils through the integrins LFA-1 and Mac-1 to ICAM-1 in a lipid bilayer does not occur at physiologic shear stresses; however, static incubation of activated neutrophils allows development of adhesion that is greater than 100-fold more shear resistant than found on CD62. Addition of a chemoattractant to activate LFA-1 and Mac-1 results in the arrest of neutrophils rolling on bilayers containing both CD62 and ICAM-1. Thus, at physiologic shear stress, rolling on a selectin is a prerequisite for activation-induced adhesion strengthening through integrins.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	LAWRENCE, MB (corresponding author), HARVARD UNIV,CTR BLOOD RES,800 HUNTINGTON AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 31799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031799, R01CA031799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARFORS KE, 1987, BLOOD, V69, P338; ATHERTON A, 1973, J PHYSIOL-LONDON, V233, P157, DOI 10.1113/jphysiol.1973.sp010303; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BUCHANAN MR, 1982, BLOOD, V60, P160; BUYON JP, 1988, J IMMUNOL, V140, P3156; Chien S, 1982, Adv Shock Res, V8, P71; COHNHEIM J, 1989, LECTURES GENERAL PAT; DEFOUGEROLLES AR, 1991, IN PRESS J EXP MED; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FIEBIG E, 1991, INT J MICROCIRC, V10, P127; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GOLDSMITH HL, 1984, MICROVASC RES, V27, P204, DOI 10.1016/0026-2862(84)90054-2; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; HARLAN JM, 1985, BLOOD, V66, P167; HATTORI R, 1989, J BIOL CHEM, V264, P7768; Heisig N., 1968, ADV MICROCIRCULAT, V1, P89; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JUTILA MA, 1989, J IMMUNOL, V143, P3318; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1987, BLOOD, V70, P1284; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MARCHESI VT, 1961, Q J EXP PHYSIOL CMS, V46, P115, DOI 10.1113/expphysiol.1961.sp001522; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NOBIS U, 1985, MICROVASC RES, V29, P295, DOI 10.1016/0026-2862(85)90020-2; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; PRICE TH, 1987, J IMMUNOL, V139, P4174; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEGRE G, 1962, J FLUID MECH, V14, P136, DOI 10.1017/S0022112062001111; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; Tanford C., 1961, PHYS CHEM MACROMOLEC; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351	68	1984	2046	3	79	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					859	873		10.1016/0092-8674(91)90393-D	http://dx.doi.org/10.1016/0092-8674(91)90393-D			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710173				2022-12-28	WOS:A1991FP51600016
J	BLUM, B; STURM, NR; SIMPSON, AM; SIMPSON, L				BLUM, B; STURM, NR; SIMPSON, AM; SIMPSON, L			CHIMERIC GRNA MESSENGER-RNA MOLECULES WITH OLIGO(U) TAILS COVALENTLY LINKED AT SITES OF RNA EDITING SUGGEST THAT U-ADDITION OCCURS BY TRANSESTERIFICATION	CELL			English	Article							LEISHMANIA-TARENTOLAE; CYTOCHROME-OXIDASE; KINETOPLASTID MITOCHONDRIA; TRYPANOSOME MITOCHONDRIA; SUBUNIT-III; GUIDE RNAS; MODEL; SEQUENCES; ENZYME; INTRON	Chimeric RNA molecules were detected by polymerase chain reaction amplification of kinetoplast RNA using a 3' primer specific to mRNA and a 5' primer specific to guide RNA (gRNA), and directly by Northern analysis. Covalent linkage of the 3' oligo(U) tail of the gRNA to the mRNA occurs at editing sites. Chimeric molecules were isolated for NADH dehydrogenase subunit 7 and cytochrome oxidase subunits II and III. We propose that these molecules are intermediates in the editing process and that successive transesterifications result in the transfer of uridine residues from the gRNA 3' oligo(U) tail to an editing site, with the number of uridine residues determined by base pairing with adenine and guanine "guide" nucleotides in the gRNA.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	BLUM, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI 09102] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MOUNT SM, 1983, CELL, V33, P209; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8	29	132	132	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					543	550		10.1016/0092-8674(91)90087-F	http://dx.doi.org/10.1016/0092-8674(91)90087-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709591				2022-12-28	WOS:A1991FM03700005
J	KAECH, S; COVIC, L; WYSS, A; BALLMERHOFER, K				KAECH, S; COVIC, L; WYSS, A; BALLMERHOFER, K			ASSOCIATION OF P60C-SRC WITH POLYOMA-VIRUS MIDDLE-T-ANTIGEN ABROGATING MITOSIS-SPECIFIC ACTIVATION	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSFORMING PROTEIN; REGULATORY DOMAIN; PP60C-SRC; SITES; KINASE; GENE; PRODUCT; INVIVO	POLYOMA middle-T antigen is required for tumorigenesis in animals and for viral transformation of a variety of cells in culture (reviewed in ref. 1). Middle-T associates with and thereby activates p60c-src, a cellular tyrosine kinase homologous to the oncogene product of Rous sarcoma virus 2,3. Activation of p60c-src by middle-T is accompanied both by dephosphorylation of tyrosine 527, a site which negatively regulates src kinase activity (reviewed in refs 4-6) and by autophosphorylation on tyrosine 416 (refs 7-10). Phosphoprotein p60c-src is subject to cell cycle-specific regulation. It is most active during mitosis and repressed in interphase 11. Here we report that mitotic p60c-src is dephosphorylated at tyrosine 527. We also show that in cells expressing middle-T, src kinase activity is high both in mitosis and during interphase. An oncogenic mutant src protein, p60c-src(527F), where tyrosine 527 is substituted by phenylalanine, is also highly active in all phases of the cell cycle.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Kaech Petrie, Stefanie/0000-0002-6246-6434; Ballmer-Hofer, Kurt/0000-0002-3800-9129				BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DONOGHUE DJ, 1984, NATURE, V308, P748, DOI 10.1038/308748a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990	27	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1991	350	6317					431	433		10.1038/350431a0	http://dx.doi.org/10.1038/350431a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1707141				2022-12-28	WOS:A1991FF04200053
J	KAPLAN, DR; MARTINZANCA, D; PARADA, LF				KAPLAN, DR; MARTINZANCA, D; PARADA, LF			TYROSINE PHOSPHORYLATION AND TYROSINE KINASE-ACTIVITY OF THE TRK PROTOONCOGENE PRODUCT INDUCED BY NGF	NATURE			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELL LINE; ACETYLCHOLINE; ACTIVATION; INCREASE; RECEPTOR	NERVE growth factor (NGF) is a neurotrophic factor responsible for the differentiation and survival of sympathetic and sensory neurons as well as selective populations of cholinergic neurons 1,2. NGF binds to specific cell-surface receptors but the mechanism for transduction of the neurotrophic signal is unknown. Several experiments using the NGF-responsive pheochromocytoma cell line, PC12, have implicated tyrosine phosphorylation in NGF-mediated responses, although no NGF-specific tyrosine kinases have been identified 3. Here we show that NGF induces tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product, a tyrosine kinase receptor whose expression is restricted in vivo to neurons of the sensory spinal and cranial ganglia of neural crest origin 4. Tyrosine phosphorylation of trk by NGF is rapid, specific and occurs with picomolar quantities of factor, indicating that the response is mediated by physiological amounts of NGF. Activation of the trk tyrosine kinase receptor provides a possible mechanism for signal transduction by NGF.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KAPLAN, DR (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,EUKARYOT SIGNAL TRANSDUCT GRP,POB B,BETHESDA,MD 20892, USA.		Parada, luis F/B-9400-2014					ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; CHAO MV, 1990, HDB EXPT PHARM, V95, P135; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIM UH, IN PRESS J BIOL CHEM; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAHER PA, 1989, J NEUROSCI RES, V24, P29, DOI 10.1002/jnr.490240106; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284	21	963	994	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					158	160		10.1038/350158a0	http://dx.doi.org/10.1038/350158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1706478				2022-12-28	WOS:A1991FB64500060
J	BASSET, P; BELLOCQ, JP; WOLF, C; STOLL, I; HUTIN, P; LIMACHER, JM; PODHAJCER, OL; CHENARD, MP; RIO, MC; CHAMBON, P				BASSET, P; BELLOCQ, JP; WOLF, C; STOLL, I; HUTIN, P; LIMACHER, JM; PODHAJCER, OL; CHENARD, MP; RIO, MC; CHAMBON, P			A NOVEL METALLOPROTEINASE GENE SPECIFICALLY EXPRESSED IN STROMAL CELLS OF BREAST CARCINOMAS	NATURE			English	Article									FAC MED STRASBOURG, INST CHIM BIOL,INSERM, UNITE BIOL MOLEC & GEN GENET 184,CNRS, F-67085 STRASBOURG, FRANCE; CHU STRASBOURG, SERV ANAT PATHOL GEN, F-67098 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Chenard, Marie-Pierre/O-2373-2016	podhajcer, osvaldo/0000-0002-6512-8553				Ahmed A, 1990, PATHOL ANNU 2, V25, P237; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIS MM, 1984, P NATL ACAD SCI-BIOL, V81, P2194, DOI 10.1073/pnas.81.7.2194; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DEOME KB, 1978, CANCER RES, V38, P2103; ERICKSON HP, 1989, REV CELL BIOL, V5, P71; FERGUSON JE, 1990, J DIFFERENTIATION, V42, P199; FIDLER IJ, 1989, CYTOMETRY, V10, P673, DOI 10.1002/cyto.990100602; GARCIA M, 1987, J STEROID BIOCHEM, V27, P439, DOI 10.1016/0022-4731(87)90338-4; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; NOWELL PC, 1986, CANCER RES, V46, P2203; PETTMANN B, 1985, FEBS LETT, V189, P102, DOI 10.1016/0014-5793(85)80851-6; PRESCOTT J, 1989, BIOCHEM INT, V19, P257; RHYNER TA, 1986, J NEUROSCI RES, V16, P167, DOI 10.1002/jnr.490160116; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; RUBIN H, 1985, CANCER RES, V45, P2935; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAKAKURA T, 1979, DEV BIOL, V72, P201, DOI 10.1016/0012-1606(79)90111-8; SAKAKURA T, 1981, J NATL CANCER I, V66, P953; SALOMON DS, 1988, BREAST CANCER CELLUL, P363; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TREMBLAY G, 1979, EXP MOL PATHOL, V31, P248, DOI 10.1016/0014-4800(79)90026-1; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; ZIPORI D, 1990, CANCER J, V3, P164	50	1094	1134	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 20	1990	348	6303					699	704		10.1038/348699a0	http://dx.doi.org/10.1038/348699a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP049	1701851				2022-12-28	WOS:A1990EP04900047
J	JAVAHERIAN, K; LANGLOIS, AJ; LAROSA, GJ; PROFY, AT; BOLOGNESI, DP; HERLIHY, WC; PUTNEY, SD; MATTHEWS, TJ				JAVAHERIAN, K; LANGLOIS, AJ; LAROSA, GJ; PROFY, AT; BOLOGNESI, DP; HERLIHY, WC; PUTNEY, SD; MATTHEWS, TJ			BROADLY NEUTRALIZING ANTIBODIES ELICITED BY THE HYPERVARIABLE NEUTRALIZING DETERMINANT OF HIV-1	SCIENCE			English	Article									DUKE UNIV,SCH MED,DEPT SURG,DURHAM,NC 27710	Duke University	JAVAHERIAN, K (corresponding author), REPLIGEN CORP,CAMBRIDGE,MA 02139, USA.							EMINI E, UNPUB; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, UNPUB; KENEALY WR, 1989, AIDS RES HUM RETROV, V5, P173, DOI 10.1089/aid.1989.5.173; KINNEYTHOMAS E, 1988, AIDS, V2, P25; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MATTHEWS TJ, UNPUB; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; NARA PL, 1990, J VIROL, V64, P3770; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989	20	376	396	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 14	1990	250	4987					1590	1593		10.1126/science.1703322	http://dx.doi.org/10.1126/science.1703322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM931	1703322				2022-12-28	WOS:A1990EM93100046
J	ROTZSCHKE, O; FALK, K; DERES, K; SCHILD, H; NORDA, M; METZGER, J; JUNG, G; RAMMENSEE, HG				ROTZSCHKE, O; FALK, K; DERES, K; SCHILD, H; NORDA, M; METZGER, J; JUNG, G; RAMMENSEE, HG			ISOLATION AND ANALYSIS OF NATURALLY PROCESSED VIRAL PEPTIDES AS RECOGNIZED BY CYTOTOXIC T-CELLS	NATURE			English	Article									MAX PLANCK INST BIOL,IMMUNOGENET ABT,CORRENSSTR 42,W-7400 TUBINGEN,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY	Max Planck Society; Eberhard Karls University of Tubingen			Roetzschke, Olaf/GXH-0012-2022					AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; DERES K, 1989, NATURE, V342, P516; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; ROTZSCHKE O, 1990, NATURE, V249, P283; SCHNORRENBERG G, 1989, TETRAHEDRON, V45, P7759, DOI 10.1016/S0040-4020(01)85791-4; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANPEL A, 1985, SOMAT CELL MOLEC GEN, V11, P467; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0	12	732	782	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 15	1990	348	6298					252	254		10.1038/348252a0	http://dx.doi.org/10.1038/348252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700304				2022-12-28	WOS:A1990EH79600063
J	COOPER, ES; SPENCER, J; WHYTEALLENG, CAM; CROMWELL, O; WHITNEY, P; VENUGOPAL, S; BUNDY, DAP; HAYNES, B; MACDONALD, TT				COOPER, ES; SPENCER, J; WHYTEALLENG, CAM; CROMWELL, O; WHITNEY, P; VENUGOPAL, S; BUNDY, DAP; HAYNES, B; MACDONALD, TT			IMMEDIATE HYPERSENSITIVITY IN COLON OF CHILDREN WITH CHRONIC TRICHURIS-TRICHIURA DYSENTERY	LANCET			English	Article							MUCOSAL MAST-CELLS; DISEASE; ALLERGY; RATS; IGE	There are few data on mucosal immune responses to intestinal helminths in human beings, especially those involving the IgE system, which is thought to be important in parasite expulsion. We sought evidence of an immediate hypersensitivity reaction in the colon of children with chronic dysentery due to Trichuris trichiura. 28 children with Trichuris dysentery syndrome (TDS) were compared with 16 control children (with no TDS or worms visible on colonoscopy). All children were aged 1-11 years. Rectal biopsy samples were taken before and after expulsion of the worms by means of mebendazole treatment. Children with TDS had significantly greater numbers than controls of mast cells (mean [SD] 10.9 [1.3] vs 3.9 [0.6]% of all cells; p < 0.0003) and of cells with surface IgE (median [range] 11.1 [7.5-11.6] vs 1.0 [0-1.5]%; p < 0.001) in the subepithelial region of the mucosa. On electronmicroscopy, degranulating mast cells were prominent in parasitised children. In culture, rectal biopsy samples from parasitised children showed high rates of spontaneous histamine release, but only low rates of antigen-specific release. After treatment, spontaneous histamine release was significantly reduced and antigen-specific histamine release could be provoked. Thus, an IgE-mediated immune mucosal response to a helminth infection does occur in human beings but is not sufficient to cause appreciable parasite expulsion.	ST BARTHOLOMEWS HOSP, DEPT PAEDIAT GASTROENTEROL, LONDON EC1A 7BE, ENGLAND; ST BARTHOLOMEWS HOSP, DEPT HISTOPATHOL, LONDON EC1A 7BE, ENGLAND; IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON, ENGLAND; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; UNIV W INDIES, DEPT ZOOL, KINGSTON 7, JAMAICA; UNIV W INDIES, DEPT SURG, KINGSTON 7, JAMAICA; UNIV COLL & MIDDLESEX SCH MED, DEPT HISTOPATHOL, LONDON, ENGLAND; NATL HEART & LUNG INST, DEPT ALLERGY & CLIN IMMUNOL, LONDON, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; Imperial College London; University West Indies Mona Jamaica; University West Indies Mona Jamaica; University West Indies Mona Jamaica; University of London; University College London; Imperial College London				Spencer, Jo/0000-0002-7202-2431	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTH EEE, 1966, IMMUNOLOGY, V10, P459; BUNDY DAP, 1989, ADV PARASIT, V28, P107; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; CROMWELL O, 1986, HDB EXPT IMMUNOLOGY, V127, P1; CROW J, 1988, J PATHOL, V154, P347, DOI 10.1002/path.1711540411; FORBES D, 1988, AM J PHYSIOL, V255, pG201, DOI 10.1152/ajpgi.1988.255.2.G201; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; Gray I, 1940, ANN INTERN MED, V13, P2050, DOI 10.7326/0003-4819-13-11-2050; GUSTOWSKA L, 1983, INT ARCH ALLER A IMM, V71, P304, DOI 10.1159/000233412; ISAACSON PG, 1983, IMMUNOCYTOCHEMISTRY, P249; JENKINS HR, 1984, ARCH DIS CHILD, V59, P326, DOI 10.1136/adc.59.4.326; JENKINS SN, 1977, PARASITOLOGY, V74, P153, DOI 10.1017/S0031182000047648; KAY AB, 1985, INT ARCH ALLER A IMM, V77, P69, DOI 10.1159/000233755; LAKE AM, 1980, IMMUNOLOGY, V39, P173; LILLYWHITE JE, 1991, PARASITE IMMUNOL, V13, P491, DOI 10.1111/j.1365-3024.1991.tb00546.x; MACDONALD TT, 1991, J CLIN PATHOL, V44, P194, DOI 10.1136/jcp.44.3.194; MAYRHOFER G, 1976, EUR J IMMUNOL, V6, P537, DOI 10.1002/eji.1830060803; MONERETVAUTRIN DA, 1984, CLIN ALLERGY, V14, P471, DOI 10.1111/j.1365-2222.1984.tb02231.x; MOQBEL R, 1990, CLIN EXP ALLERGY, V20, P611, DOI 10.1111/j.1365-2222.1990.tb02699.x; OGILVIE BM, 1967, IMMUNOLOGY, V12, P113; OGILVIE BM, 1974, TRANSPLANT REV, V19, P147; PERDUE MH, 1984, AM J PHYSIOL, V247, pG632, DOI 10.1152/ajpgi.1984.247.6.G632; RAMSEY FRANK C., 1962, WEST INDIAN MED JOUR, V11, P235; REIMANN HJ, 1982, AGENTS ACTIONS, V12, P111, DOI 10.1007/BF01965119; SANDERSON IR, 1986, J CLIN PATHOL, V39, P279, DOI 10.1136/jcp.39.3.279; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0	26	41	42	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	1991	338	8775					1104	1107		10.1016/0140-6736(91)91964-V	http://dx.doi.org/10.1016/0140-6736(91)91964-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM784	1719315				2022-12-28	WOS:A1991GM78400004
J	LAYBOURN, PJ; KADONAGA, JT				LAYBOURN, PJ; KADONAGA, JT			ROLE OF NUCLEOSOMAL CORES AND HISTONE-H1 IN REGULATION OF TRANSCRIPTION BY RNA POLYMERASE-II	SCIENCE			English	Article							MINICHROMOSOMES ASSEMBLED INVITRO; INDUCIBLE MMTV PROMOTER; XENOPUS-LAEVIS OOCYTES; HIGH-SPEED SUPERNATANT; DNA-BINDING PROTEINS; CHROMATIN STRUCTURE; PREINITIATION COMPLEXES; IONIC-STRENGTH; MAJOR LATE; GENES	The relation between chromatin structure and transcriptional activity was examined by in vitro transcription analysis of chromatin reconstituted in the absence or presence of histone H1. To maintain well-defined template DNA, purified components were used in the reconstitution of chromatin. Reconstitution of nucleosomal cores to an average density of 1 nucleosome per 200 base pairs of DNA resulted in a mild reduction of basal RNA polymerase II transcription to 25 to 50 percent of that obtained with naked DNA templates. This nucleosome-mediated repression was due to nucleosomal cores located at the RNA start site and could not be counteracted by the sequence-specific transcription activators Sp1 and GAL4-VP16. When H1 was incorporated into the chromatin at 0.5 to 1.0 molecule per nucleosome (200 base pairs of DNA), RNA synthesis was reduced to 1 to 4 percent of that observed with chromatin containing only nucleosomal cores, and this H1-mediated repression could be counteracted by the addition of Sp1 or GAL4-VP16 (antirepression). With naked DNA templates, transcription was increased by a factor of 3 and 8 by Sp1 and GAL4-VP-16, respectively (true activation). With H1-repressed chromatin templates, however, the magnitude of transcriptional activation mediated by Sp1 and GAL4-VP16 was 90 and more than 200 times higher, respectively, because of the combined effects of true activation and antirepression. The data provide direct biochemical evidence that support and clarify previously proposed models in which there is depletion or reconfiguration of nucleosomal cores and histone H1 at the promoter regions of active genes.	UNIV CALIF SAN DIEGO, DEPT BIOL, 0322, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CAMERINIOTERO RD, 1977, NUCLEIC ACIDS RES, V4, P1159, DOI 10.1093/nar/4.5.1159-a; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CARTWRIGHT IL, 1987, EMBO J, V6, P3097, DOI 10.1002/j.1460-2075.1987.tb02618.x; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; CROSTON GE, IN PRESS PROTIEN EXP, V2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; JAVAHERIAN K, 1982, NUCLEIC ACIDS RES, V10, P6945, DOI 10.1093/nar/10.21.6945; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NELSON PP, 1979, J BIOL CHEM, V254, P1751; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALZMAN AG, 1989, FASEB J, V3, P1723; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1984, J MOL BIOL, V178, P341, DOI 10.1016/0022-2836(84)90148-7; STEIN A, 1983, NATURE, V302, P548, DOI 10.1038/302548a0; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; van Holde K.E., 1988, CHROMATIN; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	73	349	358	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1991	254	5029					238	245		10.1126/science.1718039	http://dx.doi.org/10.1126/science.1718039			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1718039				2022-12-28	WOS:A1991GJ64200031
J	LINGAPPA, VR				LINGAPPA, VR			MORE THAN JUST A CHANNEL - PROVOCATIVE NEW FEATURES OF PROTEIN TRAFFIC ACROSS THE ER MEMBRANE	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; STOP TRANSFER; SECRETORY PROTEINS; PRION PROTEIN; TRANSLOCATION; BIOGENESIS; PEPTIDE; EXPORT; DOMAIN		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LINGAPPA, VR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1990, CELL, V62, P1031; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MIZE NK, 1986, CELL, V47, P711, DOI 10.1016/0092-8674(86)90514-3; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SELKOE DJ, 1990, SCIENCE, V248, P1058, DOI 10.1126/science.2111582; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7292; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	25	38	38	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					527	530		10.1016/0092-8674(91)90081-9	http://dx.doi.org/10.1016/0092-8674(91)90081-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709589				2022-12-28	WOS:A1991FM03700001
J	LUNDGREN, K; WALWORTH, N; BOOHER, R; DEMBSKI, M; KIRSCHNER, M; BEACH, D				LUNDGREN, K; WALWORTH, N; BOOHER, R; DEMBSKI, M; KIRSCHNER, M; BEACH, D			MIK1 AND WEE1 COOPERATE IN THE INHIBITORY TYROSINE PHOSPHORYLATION OF CDC2	CELL			English	Article							CYCLE CONTROL GENE; YEAST SCHIZOSACCHAROMYCES-POMBE; P34CDC2 PROTEIN-KINASE; CELL-DIVISION CYCLE; FISSION YEAST; MITOTIC CONTROL; M-PHASE; SACCHAROMYCES-CEREVISIAE; MITOSIS; DNA	wee1 acts antagonistically to cdc25 in the tyrosine dephosphorylation and activation of cdc2, yet biochemical evidence suggests that wee1 is not required for tyrosine phosphorylation and its role is obscure. We show here that a related 66 kd kinase, called mik1, acts redundantly with wee1 in the negative regulation of cdc2 in S. pombe. A null allele of mik1 has no discernible phenotype, but a mik1 wee1 double mutant is hypermitotically lethal: all normal M phase checkpoints are bypassed, including the requirement for initiation of cell cycle "start," completion of S phase, and function of the cdc25+ mitotic activator. In the absence of mik1 and wee1 activity, cdc2 rapidly loses phosphate on tyrosine, both in strains undergoing mitotic lethality and in those that are viable owing to a compensating mutation within cdc2. The data suggest that mik1 and wee1 act cooperatively on cdc2, either directly as the inhibitory tyrosine kinase or as essential activators of that kinase.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LUNDGREN, K (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.			Walworth, Nancy/0000-0001-5940-8236	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034607] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34607] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; CREANOR J, 1979, J GEN MICROBIOL, V112, P385, DOI 10.1099/00221287-112-2-385; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FANTES PA, 1981, J BACTERIOL, V146, P746, DOI 10.1128/JB.146.2.746-754.1981; FEATHERSTONE C, 1991, IN PRESS NATURE; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KOHLI J, 1977, GENETICS, V87, P471; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1765, DOI 10.1093/nar/14.4.1765; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MITCHISON JMM, 1974, CELL CYCLE CONTROLS; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1980, GENETICS, V96, P101; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	67	586	596	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1111	1122		10.1016/0092-8674(91)90266-2	http://dx.doi.org/10.1016/0092-8674(91)90266-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1706223				2022-12-28	WOS:A1991FD55800009
J	WILDE, J; YOLKEN, R; WILLOUGHBY, R; EIDEN, J				WILDE, J; YOLKEN, R; WILLOUGHBY, R; EIDEN, J			IMPROVED DETECTION OF ROTAVIRUS SHEDDING BY POLYMERASE CHAIN-REACTION	LANCET			English	Article							COMMERCIAL IMMUNOASSAYS; COMPARATIVE EFFICIENCY; INFECTION; GASTROENTERITIS; DIAGNOSIS	To improve identification of children excreting rotavirus a method for the amplification of rotavirus RNA by the polymerase chain reaction (PCR) was developed. The assay was compared with a solid-phase enzyme immunoassay int he detection of rotavirus shedding by infants in hospital during the winter peak of rotavirus infections. Forty children were studied in an intermediate care unit after transfer from intensive care units. ONly two were admitted primarily because of diarrhoea; the other thirty-eight were admitted for management of various other disorders. Rotavirus shedding was detected by enzyme immunoassay in twenty of the infants, and nine of these (aged 1 week to 8 months) remained in hospital for more than 5 days after the initial detection of rotavirus and could be studied long term. Of 103 faecal samples from the nine infants, 60 (58%) contained rotavirus RNA detected by reverse-transcriptase (RT)/PCR, whereas only 37 (36%) were positive for rotavirus antigen by the immunoassay (chi-2 = 10.3, p < 0.002). The geometric mean time of rotavirus shedding was 9.5 (range 1-19) days as detected by RT/PCR and 5.7 (range 1-17) days by the immunoassay (p < 0.018). In five of the nine children, RT/PCR detected rotavirus shedding for 2-7 days longer than the immunoassay and in four children RT/PCR was positive 1 or more days before rotavirus antigen was detected. Further studies should attempt to find out whether infected infants are capable of spreading wild-type virus during periods when they are not shedding antigen as detectable by enzyme immunoassay.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University			yolken, robert/AAW-2556-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030420, R29AI024922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033089] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI 24922, U01 AI 30420] Funding Source: Medline; NIDDK NIH HHS [R01 DK 33089] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DENNEHY PH, 1989, PEDIATR INFECT DIS J, V8, P290; DENNEHY PH, 1985, AM J DIS CHILD, V139, P935, DOI 10.1001/archpedi.1985.02140110089037; DOLAN KT, 1985, J CLIN MICROBIOL, V21, P753, DOI 10.1128/JCM.21.5.753-758.1985; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; ESTES MK, 1984, NUCLEIC ACIDS RES, V12, P1875, DOI 10.1093/nar/12.4.1875; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; HANVANICH M, 1985, J CLIN MICROBIOL, V21, P184, DOI 10.1128/JCM.21.2.184-188.1985; HERRING AJ, 1982, J CLIN MICROBIOL, V16, P473, DOI 10.1128/JCM.16.3.473-477.1982; HJELT K, 1985, ACTA PAEDIATR SCAND, V74, P89, DOI 10.1111/j.1651-2227.1985.tb10926.x; KAPIKIAN AZ, 1985, VIROLOGY, P863; KITCHIN PA, 1990, NATURE, V344, P201, DOI 10.1038/344201a0; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MIOTTI PG, 1985, J CLIN MICROBIOL, V22, P693, DOI 10.1128/JCM.22.5.693-698.1985; RAAD II, 1990, AM J INFECT CONTROL, V18, P24, DOI 10.1016/0196-6553(90)90207-9; RINGENBERGS ML, 1989, AUST PAEDIATR J, V25, P156; RYDER RW, 1977, J PEDIATR-US, V90, P698, DOI 10.1016/S0022-3476(77)81230-4; WARD RL, 1986, J INFECT DIS, V154, P871, DOI 10.1093/infdis/154.5.871; WILDE J, 1990, J CLIN MICROBIOL, V28, P1300, DOI 10.1128/JCM.28.6.1300-1307.1990; WYATT RG, 1980, SCIENCE, V207, P189, DOI 10.1126/science.6243190; XU L, 1990, J VIROL METHODS, V27, P29, DOI 10.1016/0166-0934(90)90143-4; YOLKEN RH, 1978, J CLIN MICROBIOL, V8, P283; YOLKEN RH, 1986, MANUAL CLIN LABORATO, P573; 1985, PROSPECTS IMMUNIZING	23	74	76	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					323	326		10.1016/0140-6736(91)90945-L	http://dx.doi.org/10.1016/0140-6736(91)90945-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1703618	hybrid			2022-12-28	WOS:A1991EX36200004
J	BRANDLEY, BK; SWIEDLER, SJ; ROBBINS, PW				BRANDLEY, BK; SWIEDLER, SJ; ROBBINS, PW			CARBOHYDRATE LIGANDS OF THE LEC CELL-ADHESION MOLECULES	CELL			English	Review									MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	BRANDLEY, BK (corresponding author), GLYCOMED INC, 860 ATLANTIC AVE, ALAMEDA, CA 94501 USA.							BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRANDLEY BK, 1986, J LEUKOCYTE BIOL, V40, P97, DOI 10.1002/jlb.40.1.97; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GOELZ SE, 1990, IN PRESS CELL, V63; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LEE YC, 1989, CIBA F S, V145, P80; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1990, LEUKEMIA RES, V14, P119, DOI 10.1016/0145-2126(90)90040-G; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, IN PRESS SCIENCE; SCHNAAR RL, 1989, METHOD ENZYMOL, V179, P542; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TIEMEYER M, 1990, IN PRESS P NATL ACAD; TRUE DD, 1990, IN PRESS J CELL BIOL, V111; WALZ G, 1990, IN PRESS SCIENCE	20	348	390	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	1990	63	5					861	863		10.1016/0092-8674(90)90487-Y	http://dx.doi.org/10.1016/0092-8674(90)90487-Y			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EL759	1701693				2022-12-28	WOS:A1990EL75900001
J	VANBLEEK, GM; NATHENSON, SG				VANBLEEK, GM; NATHENSON, SG			ISOLATION OF AN ENDOGENOUSLY PROCESSED IMMUNODOMINANT VIRAL PEPTIDE FROM THE CLASS-I H-2KB MOLECULE	NATURE			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	VANBLEEK, GM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461, USA.							BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BHAYANI H, 1989, J EXP MED, V170, P1609, DOI 10.1084/jem.170.5.1609; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CERUNDOLO V, 1990, NATURE, V345, P499; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEWAAL LP, 1983, J IMMUNOL, V130, P1090; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GALLIONE CJ, 1981, J VIROL, V39, P529, DOI 10.1128/JVI.39.2.529-535.1981; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SCHILD H, 1990, SCIENCE, V247, P1587, DOI 10.1126/science.2321019; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHEIL JM, 1987, J IMMUNOL, V138, P3654; SHIMOJO N, 1989, J IMMUNOL, V143, P2939; TAKAHASHI H, 1989, J EXP MED, V170, P2023, DOI 10.1084/jem.170.6.2023; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANDERZEE R, 1989, EUR J IMMUNOL, V19, P43; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	46	733	759	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 15	1990	348	6298					213	216						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH796	1700303				2022-12-28	WOS:A1990EH79600049
J	IMAMURA, T; ENGLEKA, K; ZHAN, X; TOKITA, Y; FOROUGH, R; ROEDER, D; JACKSON, A; MAIER, JAM; HLA, T; MACIAG, T				IMAMURA, T; ENGLEKA, K; ZHAN, X; TOKITA, Y; FOROUGH, R; ROEDER, D; JACKSON, A; MAIER, JAM; HLA, T; MACIAG, T			RECOVERY OF MITOGENIC ACTIVITY OF A GROWTH-FACTOR MUTANT WITH A NUCLEAR TRANSLOCATION SEQUENCE	SCIENCE			English	Article									AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,MOLEC BIOL LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross			Hla, Timothy/G-5873-2012; Maier, Jeanette AM/H-4820-2012	Hla, Timothy/0000-0001-8355-4065; Maier, Jeanette AM/0000-0002-6326-9221	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32348, HL 35627] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURGESS WH, IN PRESS J CELL BIOL; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ENGLEKA K, UNPUB; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOROUGH R, UNPUB; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GAY CG, 1990, J BIOL CHEM, V265, P3284; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; GRUNZ H, 1988, CELL DIFFER DEV, V22, P183, DOI 10.1016/0045-6039(88)90010-3; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; LEE BA, 1987, MOL CELL BIOL, V7, P3527, DOI 10.1128/MCB.7.10.3527; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARCH CJ, 1985, NATURE, V315, P640; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RISAU W, 1988, EMBO J, V7, P959, DOI 10.1002/j.1460-2075.1988.tb02901.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENGART TK, 1988, J VASC SURG, V7, P311, DOI 10.1067/mva.1988.avs0070311; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SCHREIBER AB, 1985, J CELL BIOL, V101, P1623, DOI 10.1083/jcb.101.4.1623; SILVER P, 1989, CRIT REV BIOCHEM MOL, V24, P419, DOI 10.3109/10409238909082557; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, IN PRESS METHODS ENZ; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; YEH HJ, 1987, P NATL ACAD SCI USA, V84, P2317, DOI 10.1073/pnas.84.8.2317; Zhan X., UNPUB; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	55	365	398	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 28	1990	249	4976					1567	1570		10.1126/science.1699274	http://dx.doi.org/10.1126/science.1699274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA463	1699274				2022-12-28	WOS:A1990EA46300038
J	MAYES, LC; GRANGER, RH; BORNSTEIN, MH; ZUCKERMAN, B				MAYES, LC; GRANGER, RH; BORNSTEIN, MH; ZUCKERMAN, B			THE PROBLEM OF PRENATAL COCAINE EXPOSURE - A RUSH TO JUDGMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INFANT-DEATH-SYNDROME; MATERNAL COCAINE; PREGNANCY; DRUG; PREVALENCE; GROWTH; ABUSE; MARIJUANA; PATTERNS; INUTERO		NICHHD,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,BOSTON,MA 02118; BOSTON CITY HOSP,BOSTON,MA 02118	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Boston University; Boston Medical Center	MAYES, LC (corresponding author), YALE CHILD STUDY CTR,230 S FRONTAGE RD,NEW HAVEN,CT 06510, USA.			Zuckerman, Barry/0000-0002-0044-2592				BAUCHNER H, 1988, J PEDIATR-US, V113, P831, DOI 10.1016/S0022-3476(88)80009-X; BAUCHNER H, 1990, J PEDIATR-US, V117, P904, DOI 10.1016/S0022-3476(05)80131-3; BECKWITH L, 1986, CHILD DEV, V57, P777; Beckwith L., 1990, HDB EARLY CHILDHOOD, P53; BORNSTEIN M, 1989, INTERACTION HUMAN DE, P237; BORNSTEIN MH, 1989, PSYCHOL BULL, V105, P179, DOI 10.1037/0033-2909.105.2.179; CHASNOFF IJ, 1988, PEDIATR CLIN N AM, V35, P1403; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CHASNOFF IJ, 1989, AM J DIS CHILD, V143, P583, DOI 10.1001/archpedi.1989.02150170085028; CHASNOFF IJ, 1986, NEUROBEH TOXICOL TER, V8, P357; CHASNOFF IJ, 1989, JAMA-J AM MED ASSOC, V261, P1741, DOI 10.1001/jama.261.12.1741; CHASNOFF IJ, 1987, NEUROTOXICOL TERATOL, V9, P291, DOI 10.1016/0892-0362(87)90017-1; DAVIDSON SL, 1990, J PEDIATR, V117, P876; DIXON SD, 1989, J PEDIATR-US, V115, P770, DOI 10.1016/S0022-3476(89)80661-4; DOBERCZAK TM, 1988, J PEDIATR-US, V113, P354, DOI 10.1016/S0022-3476(88)80283-X; FRANK DA, 1988, PEDIATRICS, V82, P888; HADEED AJ, 1989, PEDIATRICS, V84, P205; ISENBERG SJ, 1987, AM J OPHTHALMOL, V103, P211, DOI 10.1016/S0002-9394(14)74229-1; Jacobs B.L., 1985, SLEEP NEUROTRANSMITT, P1; Jacobson, 1968, PYGMALION CLASSROOM; KANDALL SR, 1991, NEUROTOXICOL TERATOL, V13, P235, DOI 10.1016/0892-0362(91)90016-P; KOREN G, 1989, LANCET, V2, P1440; LESTER BM, 1991, CHILD DEV, V62, P694, DOI 10.2307/1131171; LIFSCHITZ MH, 1985, PEDIATRICS, V75, P269; LITTLE BB, 1989, OBSTET GYNECOL, V73, P157; NEERHOF MG, 1989, AM J OBSTET GYNECOL, V161, P633, DOI 10.1016/0002-9378(89)90368-2; OSTERLOH JD, 1989, AM J DIS CHILD, V143, P791, DOI 10.1001/archpedi.1989.02150190041017; Regan D O, 1984, NIDA Res Monogr, V49, P332; SALAMY A, 1990, J PEDIATR-US, V117, P627, DOI 10.1016/S0022-3476(05)80703-6; Sameroff AJ, 1983, HDB CHILD PSYCHOL FO, P237; SHIH L, 1988, INT J PEDIATR OTORHI, V15, P245, DOI 10.1016/0165-5876(88)90079-1; TESKE MP, 1987, AM J OPHTHALMOL, V103, P719, DOI 10.1016/S0002-9394(14)74343-0; WERNER EE, 1989, SCI AM           APR, P106; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; ZUCKERMAN B, 1989, J PEDIATR-US, V115, P812, DOI 10.1016/S0022-3476(89)80668-7; ZUCKERMAN B, IN PRESS MATERNAL SU; ZUCKERMAN B, 1991, PEDIATR CLIN N AM, V38, P1; ZUCKERMAN B, IN PRESS NIDA RES MO; 1991, NATIONAL HOUSEHOLD S; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1990, DRUG USE FORECASTING	41	156	156	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					406	408		10.1001/jama.267.3.406	http://dx.doi.org/10.1001/jama.267.3.406			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY437	1727966				2022-12-28	WOS:A1992GY43700041
J	BECKER, S; HINTON, GE				BECKER, S; HINTON, GE			SELF-ORGANIZING NEURAL NETWORK THAT DISCOVERS SURFACES IN RANDOM-DOT STEREOGRAMS	NATURE			English	Article								THE standard form of back-propagation learning 1 is implausible as a model of perceptual learning because it requires an external teacher to specify the desired output of the network. We show how the external teacher can be replaced by internally derived teaching signals. These signals are generated by using the assumption that different parts of the perceptual input have common causes in the external world. Small modules that look at separate but related parts of the perceptual input discover these common causes by striving to produce outputs that agree with each other (Fig. 1a). The modules may look at different modalities (such as vision and touch), or the same modality at different times (for example, the consecutive two-dimensional views of a rotating three-dimensional object), or even spatially adjacent parts of the same image. Our simulations show that when our learning procedure is applied to adjacent patches of two-dimensional images, it allows a neural network that has no prior knowledge of the third dimension to discover depth in random dot stereograms of curved surfaces.			BECKER, S (corresponding author), UNIV TORONTO,DEPT COMP SCI,10 KINGS COLL RD,TORONTO M5S 1A4,ONTARIO,CANADA.		Becker, Suzanna/H-8197-2013	Becker, Suzanna/0000-0002-2645-070X				Hastie T.J., 1990, GEN ADDITIVE MODELS; LEHKY SR, 1990, J NEUROSCI, V10, P2281; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Zemel R.S., 1991, DISCOVERING VIEWPOIN	4	198	199	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					161	163		10.1038/355161a0	http://dx.doi.org/10.1038/355161a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729650				2022-12-28	WOS:A1992GY62900058
J	DIPADOVA, C; ROINE, R; FREZZA, M; GENTRY, T; BARAONA, E; LIEBER, CS				DIPADOVA, C; ROINE, R; FREZZA, M; GENTRY, T; BARAONA, E; LIEBER, CS			EFFECTS OF RANITIDINE ON BLOOD-ALCOHOL LEVELS AFTER ETHANOL INGESTION - COMPARISON WITH OTHER H2-RECEPTOR ANTAGONISTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIMETIDINE; METABOLISM; DEHYDROGENASE; ELIMINATION	Objective. - To determine whether the H-2-receptor antagonist, ranitidine, which is a potent inhibitor of gastric alcohol dehydrogenase activity in vitro, increases the bioavailability of orally administered ethanol (0.3 g/kg of body weight) and to compare the resulting blood alcohol concentrations with those of two other H-2-antagonists, cimetidine and famotidine, the latter of which does not inhibit gastric alcohol dehydrogenase. Design. - For each of the H-2-receptor antagonists, a different group of subjects was used. In each group, a paired design was adopted with each subject serving as his own control. Setting. - Hospital laboratory. Subjects. - Normal, healthy men aged 24 to 46 years. Intervention. - Eight men were treated for 1 week with ranitidine (300 mg/d), six with cimetidine (1000 mg/d), and six with famotidine (40 mg/d). Measures. - Peak blood alcohol concentrations, areas under the blood alcohol curve, first-pass metabolism, and bioavailability of orally consumed ethanol. Results. - Relative to baseline, ranitidine increased the mean peak concentration and the area under the curve of blood alcohol concentrations by 34% (P < .05) and 41% (P < .01), respectively. First-pass metabolism of ethanol was decreased from 70 +/- 10 to 31 +/- 9 mg/kg of body weight, with a corresponding increase in ethanol bioavailability of 79.6% to 92.6%. By comparison, cimetidine had even a greater effect on blood alcohol levels, while famotidine had no significant effects. Conclusion. - Patients treated with ranitidine or cimetidine should be warned of possible functional impairments after consumption of amounts of ethanol considered safe in the absence of such therapy.	VET AFFAIRS MED CTR,CTR ALCOHOL RES & TREATMENT,130 W KINGSBRIDGE RD,BRONX,NY 10468; VET AFFAIRS MED CTR,LIVER DIS & NUTR SECT,BRONX,NY; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; HOSP CATTINARA,GASTROENTEROL & DIGEST ENDOSCOPY UNIT,TRIESTE,ITALY	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003508] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03508] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		CABALLERIA J, 1989, GASTROENTEROLOGY, V96, P388, DOI 10.1016/0016-5085(89)91562-X; CABALLERIA J, 1991, DIG DIS SCI      DEC; DIPADOVA C, 1987, GASTROENTEROLOGY, V92, P1169, DOI 10.1016/S0016-5085(87)91073-0; FALKENSSON M, 1989, CLIN CHEM, V35, P918; FEELY J, 1982, JAMA-J AM MED ASSOC, V247, P2819, DOI 10.1001/jama.247.20.2819; FRASER AG, 1991, ALIMENT PHARM THERAP, V5, P263; GURAM M, 1991, Gastroenterology, V100, pA749; HERNANDEZMUNOZ R, 1990, ALCOHOL CLIN EXP RES, V14, P946, DOI 10.1111/j.1530-0277.1990.tb01843.x; KLEIN K E, 1967, Internationale Zeitschrift fuer Angewandte Physiologie Einschliesslich Arbeitsphysiologie, V24, P254; KORSTEN MA, 1975, NEW ENGL J MED, V292, P386, DOI 10.1056/NEJM197502202920802; LIEBER CS, 1972, J PHARMACOL-PARIS, V181, P279; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; PALMER RH, 1989, GASTROENTEROLOGY, V97, P1066, DOI 10.1016/0016-5085(89)91540-0; RANGNO RE, 1981, BRIT J CLIN PHARMACO, V12, P667, DOI 10.1111/j.1365-2125.1981.tb01287.x; RENDIC S, 1979, XENOBIOTICA, V9, P555, DOI 10.3109/00498257909042321; ROINE R, 1990, GASTROENTEROLOGY, V98, P114; ROINE RP, 1991, ALCOHOL CLIN EXP RES, V15, P734, DOI 10.1111/j.1530-0277.1991.tb00589.x; SEITZ HK, 1984, HEPATOLOGY, V4, P1231, DOI 10.1002/hep.1840040623; SONNE J, 1988, UGESKRIFT LAEGER, V10, P625; WAGNER JG, 1973, J PHARMACOKINET BIOP, V1, P103, DOI 10.1007/BF01059625; Zar JH., 1999, BIOSTAT ANAL; 1990, NUTRITION YOUR HLTH, P25	22	100	103	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					83	86		10.1001/jama.267.1.83	http://dx.doi.org/10.1001/jama.267.1.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727201				2022-12-28	WOS:A1992GW84800028
J	WALLACE, MR; ANDERSEN, LB; SAULINO, AM; GREGORY, PE; GLOVER, TW; COLLINS, FS				WALLACE, MR; ANDERSEN, LB; SAULINO, AM; GREGORY, PE; GLOVER, TW; COLLINS, FS			A DENOVO ALU INSERTION RESULTS IN NEUROFIBROMATOSIS TYPE-1	NATURE			English	Article							GENE; RECOMBINATION; MUTATIONS; SEQUENCE; DELETION; REPEATS	NEUROFIBROMATOSIS type 1 (NF1) is a common autosomal dominant disorder with a high mutation rate and variable expression, characterized by neurofibromas, cafe-au-lait spots, Lisch nodules of the iris, and less frequent features including bone deformities and learning disabilities 1. The recently cloned NF1 gene encodes a transcript of 13 kilobases from a ubiquitously expressed locus on chromosome 17 (refs. 2-4). Most NF1 patients are expected to have unique mutations, but only a few have so far been characterized, restricting genetic and functional information and the design of DNA diagnostics. We report an unusual NF1 mutation, that of a de novo Alu repetitive element insertion into an intron, which results in deletion of the downstream exon during splicing and consequently shifts the reading frame. This previously undescribed mechanism of mutation indicates that Alu retrotransposition is an ongoing process in the human germ line.	UNIV MICHIGAN,HOWARD HUGHES MED INST,4570 MSRB 11,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED & HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT & COMMUNICABLE DIS,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BATZER MA, 1991, NUCLEIC ACIDS RES, V19, P3619, DOI 10.1093/nar/19.13.3619; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; BERKVENS TM, 1990, GENOMICS, V7, P486, DOI 10.1016/0888-7543(90)90190-6; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DANIELS GR, 1985, NUCLEIC ACIDS RES, V13, P8939, DOI 10.1093/nar/13.24.8939; GINSBURG D, 1989, P NATL ACAD SCI USA, V86, P3723, DOI 10.1073/pnas.86.10.3723; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; LABUDA D, 1989, NUCLEIC ACIDS RES, V17, P2477, DOI 10.1093/nar/17.7.2477; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; MARCHUK DA, IN PRESS GENOMICS; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; Sambrook J, 1989, MOL CLONING LABORATO; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734	19	396	402	2	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					864	866		10.1038/353864a0	http://dx.doi.org/10.1038/353864a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719426	Green Published			2022-12-28	WOS:A1991GM73200066
J	GODIN, I; DEED, R; COOKE, J; ZSEBO, K; DEXTER, M; WYLIE, CC				GODIN, I; DEED, R; COOKE, J; ZSEBO, K; DEXTER, M; WYLIE, CC			EFFECTS OF THE STEEL GENE-PRODUCT ON MOUSE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT; GROWTH-FACTOR; W-LOCUS; PROTO-ONCOGENE; SI-LOCUS; EXPRESSION; LIGAND; RAT	MUTATIONS at the steel (sl) and dominant white spotting (W) loci in the mouse affect primordial germ cells (PGC), melanoblasts and haemopoietic stem cells 1. The W gene encodes a cell-surface receptor of the tyrosine kinase family 2,3, the proto-oncogene c-kit. In situ analysis has shown c-kit messenger RNA expression in PGC in the early genital ridges 4. The Sl gene encodes the ligand for this receptor, a peptide growth factor, called here stem cell factor (SCF) 5-7. SCF mRNA is expressed in many regions of the early mouse embryo, including the areas of migration of these cell types 8. It is important now to identify the role of the Sl-W interaction in the development of these migratory embryonic stem cell populations. Using an in vitro assay system 9, we show that SCF increases both the overall numbers and colony sizes of migratory PGC isolated from wild-type mouse embryos, and cultured on irradiated feeder layers of STO cells (a mouse embryonic fibroblast line). In the absence of feeder cells, SCF causes a large increase in the initial survival and apparent motility of PGC in culture. But labelling with bromodeoxyuridine shows that SCF is not, by itself, a mitogen for PGC. SCF does not exert a chemotropic effect on PGC in in vitro assays. These results suggest that SCF in vivo is an essential requirement for PGC survival. This demonstrates the control of the early germ-line population by a specific trophic factor.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	University of Cambridge; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Amgen	GODIN, I (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1990, DEVELOPMENT, V108, P357; MANIATIS T, 1987, MOL CLONING; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Silver W. K., 1979, COAT COLORS MICE MOD, P243; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	15	372	382	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					807	809		10.1038/352807a0	http://dx.doi.org/10.1038/352807a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1715517				2022-12-28	WOS:A1991GC96400061
J	CRAWFORD, J; OZER, H; STOLLER, R; JOHNSON, D; LYMAN, G; TABBARA, I; KRIS, M; GROUS, J; PICOZZI, V; RAUSCH, G; SMITH, R; GRADISHAR, W; YAHANDA, A; VINCENT, M; STEWART, M; GLASPY, J				CRAWFORD, J; OZER, H; STOLLER, R; JOHNSON, D; LYMAN, G; TABBARA, I; KRIS, M; GROUS, J; PICOZZI, V; RAUSCH, G; SMITH, R; GRADISHAR, W; YAHANDA, A; VINCENT, M; STEWART, M; GLASPY, J			REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DOSE CHEMOTHERAPY; CLINICAL-APPLICATIONS; CARCINOMA; PROPHYLAXIS; UROTHELIUM; THERAPY	Background. Neutropenia and infection are major dose-limiting side effects of chemotherapy. Previous studies have suggested that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer. We conducted a randomized clinical trial to test this hypothesis and the clinical implications. Methods. Patients with small-cell lung cancer were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of recombinant methionyl G-CSF to study the incidence of infection as manifested by fever with neutropenia (absolute neutrophil count, < 1.0 x 10(9) per liter, with a temperature greater-than-or-equal-to 38.2-degrees-C) resulting from up to six cycles of chemotherapy with cyclophosphamide, doxorubicin, and etoposide. The patients were randomly assigned to receive either placebo or G-CSF, with treatment beginning on day 4 and continuing through day 17 of a 21-day cycle. Results. The safety of the study treatment could be evaluated in 207 of the 211 patients assigned to either drug, and its efficacy in 199. At least one episode of fever with neutropenia occurred in 77 percent of the placebo group, as compared with 40 percent of the G-CSF group (P < 0.001). Over all cycles of chemotherapy, the median duration of grade IV neutropenia (absolute neutrophil count, < 0.5 x 10(9) per liter) was six days with placebo as compared with one day with G-CSF. During cycles of blinded treatment, the number of days of treatment with intravenous antibiotics, the number of days of hospitalization, and the incidence of confirmed infections were reduced by approximately 50 percent when G-CSF was given, as compared with placebo. Mild-to-moderate medullary bone pain occurred in 20 percent of the patients receiving G-CSF. Conclusions. The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections; in the incidence, duration, and severity of grade IV neutropenia; and in the total number of days of treatment with intravenous antibiotics and days of hospitalization.	UNIV VIRGINIA, CHARLOTTESVILLE, VA 22903 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; H LEE MOFFITT CANC CTR, TAMPA, FL USA; ST ELIZABETH HOSP, BRIGHTON, MA 02135 USA; DURHAM VET AFFAIRS MED CTR, DURHAM, NC USA; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; VANDERBILT UNIV, NASHVILLE, TN 37240 USA; VIRGINIA MASON CLIN, SEATTLE, WA USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; STANFORD UNIV, STANFORD, CA 94305 USA; AMGEN INC, THOUSAND OAKS, CA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of Virginia; Memorial Sloan Kettering Cancer Center; H Lee Moffitt Cancer Center & Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University; Virginia Mason Medical Center; Johns Hopkins University; Medical College of Wisconsin; University of Chicago; Stanford University; Amgen; University of California System; University of California Los Angeles	CRAWFORD, J (corresponding author), DUKE UNIV, MED CTR, POB 3198, DURHAM, NC 27710 USA.		Lyman, Gary H/K-5227-2019	Lyman, Gary H/0000-0002-0823-8086				ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; BRYANT RE, 1971, ARCH INTERN MED, V127, P120, DOI 10.1001/archinte.127.1.120; COHEN AM, 1987, P NATL ACAD SCI USA, V84, P2484, DOI 10.1073/pnas.84.8.2484; DEJONGH CA, 1983, J CLIN ONCOL, V1, P302, DOI 10.1200/JCO.1983.1.5.302; DIXON WJ, 1988, BMDP STATISTICAL SOF; FIGUEREDO AT, 1985, J CLIN ONCOL, V3, P54, DOI 10.1200/JCO.1985.3.1.54; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GABRILOVE JL, 1988, J CLIN INVEST, V82, P1454, DOI 10.1172/JCI113751; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; Klastersky J, 1988, Recent Results Cancer Res, V108, P53; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; METCALF D, 1990, CANCER-AM CANCER SOC, V65, P2185, DOI 10.1002/1097-0142(19900515)65:10<2185::AID-CNCR2820651005>3.0.CO;2-4; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; OHNO R, 1990, NEW ENGL J MED, V323, P871, DOI 10.1056/NEJM199009273231304; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; PIZZO PA, 1982, MEDICINE, V61, P153, DOI 10.1097/00005792-198205000-00003; PLATZER E, 1985, J EXP MED, V162, P1788, DOI 10.1084/jem.162.6.1788; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; TALCOTT JA, 1988, ARCH INTERN MED, V148, P2561, DOI 10.1001/archinte.148.12.2561; 1988, SAS PROCEDURES GUIDE	23	1203	1227	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					164	170		10.1056/NEJM199107183250305	http://dx.doi.org/10.1056/NEJM199107183250305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	1711156	Bronze			2022-12-28	WOS:A1991FW75200005
J	VANDUYNE, GD; STANDAERT, RF; KARPLUS, PA; SCHREIBER, SL; CLARDY, J				VANDUYNE, GD; STANDAERT, RF; KARPLUS, PA; SCHREIBER, SL; CLARDY, J			ATOMIC-STRUCTURE OF FKBP-FK506, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; PROTEIN; FK506	The structure of the human FK506 binding protein (FKBP), complexed with the immunosuppressant FK506, has been determined to 1.7 angstroms resolution by x-ray crystallography. The conformation of the protein changes little upon complexation, but the conformation of FK506 is markedly different in the bound and unbound forms. The drug's association with the protein involves five hydrogen bonds, a hydrophobic binding pocket lined with conserved aromatic residues, and an unusual carbonyl binding pocket. The nature of this complex has implications for the mechanism of rotamase catalysis and for the biological actions of FK506 and rapamycin.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT CHEM,BAKER LAB,ITHACA,NY 14853	Harvard University; Cornell University; Cornell University			Standaert, Robert F/D-9467-2013; Standaert, Robert F./AAI-1532-2021	Standaert, Robert F/0000-0002-5684-1322; Karplus, Paul/0000-0001-8725-6292	NATIONAL CANCER INSTITUTE [R01CA024487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24487] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; FINDLAY JA, 1980, CAN J CHEM, V58, P579, DOI 10.1139/v80-090; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARUSO P, 1990, J AM CHEM SOC, V112, P9434, DOI 10.1021/ja00181a078; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083	23	615	636	6	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					839	842		10.1126/science.1709302	http://dx.doi.org/10.1126/science.1709302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709302				2022-12-28	WOS:A1991FL12300045
J	RODGERS, GP				RODGERS, GP			RECENT APPROACHES TO THE TREATMENT OF SICKLE-CELL-ANEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							FETAL-HEMOGLOBIN PRODUCTION; CLINICAL SEVERITY; HYDROXYUREA; DISEASE; 5-AZACYTIDINE; STIMULATION; AUGMENTATION; DETERMINANT; BABOONS				RODGERS, GP (corresponding author), NIDDKD,CHEM BIOL LAB,BLDG 10,ROOM 9N-318,BETHESDA,MD 20892, USA.							ALKHATTI A, 1987, NEW ENGL J MED, V317, P415, DOI 10.1056/NEJM198708133170704; ALTER BP, 1985, BLOOD, V66, P373; BRITTENHAM GM, 1985, BLOOD, V65, P183; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHARACHE S, 1987, BLOOD, V69, P109; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; Conley CL, 1980, BLOOD PURE ELOQUENT, P319; DOVER GJ, 1986, BLOOD, V67, P735; EATON WA, 1976, BLOOD, V47, P621; EMBURY SH, 1986, ANNU REV MED, V37, P361; GALANELLO R, 1988, J CLIN INVEST, V81, P1209, DOI 10.1172/JCI113437; GOLDBERG MA, 1990, NEW ENGL J MED, V323, P366, DOI 10.1056/NEJM199008093230602; HAM THOMAS H., 1940, TRANS ASSOC AMER PHYSICIANS, V55, P127; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1983, BLOOD, V62, P370; LUBIN B, 1990, HEMATOLOGY BASIC PRI, P450; MCDONAGH KT, 1989, HEMOGLOBIN SWITCHI B, P295; NIENHUIS AW, 1987, HEMATOLOGY INFANCY C, P699; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PAPAYANNOPOULOU T, 1984, SCIENCE, V224, P617, DOI 10.1126/science.6200940; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; RODGERS GP, 1988, BLOOD, V71, P597; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; Schechter A. N., 1987, MOL BASIS BLOOD DIS, P179; TORREALBADERON AT, 1984, BLOOD, V63, P201; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503	26	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2097	2101		10.1001/jama.265.16.2097	http://dx.doi.org/10.1001/jama.265.16.2097			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	1707463				2022-12-28	WOS:A1991FG90700028
J	MCGUINNESS, BT; CLARKE, IN; LAMBDEN, PR; BARLOW, AK; POOLMAN, JT; JONES, DM; HECKELS, JE				MCGUINNESS, BT; CLARKE, IN; LAMBDEN, PR; BARLOW, AK; POOLMAN, JT; JONES, DM; HECKELS, JE			POINT MUTATION IN MENINGOCOCCAL POR-A GENE ASSOCIATED WITH INCREASED ENDEMIC DISEASE	LANCET			English	Article							OUTER-MEMBRANE PROTEIN; NEISSERIA-MENINGITIDIS; ANTIBODIES; SEROTYPES; EPITOPES; VACCINE	The por A gene, which encodes expression of meningococcal class 1 outer membrane protein, responsible for antigenic subtype specificity, has been cloned and sequenced in an isolate of Neisseria meningitidis (B:15:P1.7,16) from a patient in the Gloucester area with meningococcal meningitis. Comparison of the sequence with that of the equivalent gene from the P1.7,16 reference strain reveals a point mutation which generates a single amino acid change in the epitope responsible for P1.16 specificity. Monoclonal antibodies with P1.16 specificity do not react with synthetic peptides that correspond to the altered epitope, and do not promote complement-mediated bactericidal killing of the isolate. Analysis of other strains shows widespread distribution of infections due to B:15:P1.7,16 meningococci with the altered epitope (P1.16b) in England and Wales.	UNIV SOUTHAMPTON,SCH MED,DEPT MICROBIOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; RIJKSINST VOLKSGEZONDHEID MILIEUHYG,3720 BA BILTHOVEN,NETHERLANDS; WITHINGTON HOSP,PUBL HLTH LAB SERV,MENINGOCOCCAL REFERENCE LAB,MANCHESTER M20 8LR,LANCS,ENGLAND	University of Southampton				Clarke, Ian/0000-0002-4938-1620				ABDILLAHI H, 1988, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P139, DOI 10.1016/0378-1097(88)90023-7; ABDILLAHI H, 1988, MICROB PATHOGENESIS, V4, P27, DOI 10.1016/0882-4010(88)90045-9; BARLOW AK, 1989, MOL MICROBIOL, V3, P131, DOI 10.1111/j.1365-2958.1989.tb01802.x; BARLOW AK, 1987, INFECT IMMUN, V55, P2734, DOI 10.1128/IAI.55.11.2734-2740.1987; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; FRASCH CE, 1985, REV INFECT DIS, V7, P504; FRASCH CE, 1986, CLIN INVEST MED, V9, P101; JONES DM, 1990, LANCET, V336, P53, DOI 10.1016/0140-6736(90)91566-S; KNIGHT, 1990, LANCET, V335, P1182; MANDRELL RE, 1989, INFECT IMMUN, V57, P1590, DOI 10.1128/IAI.57.5.1590-1598.1989; MCGUINNESS B, 1990, J EXP MED, V171, P1871, DOI 10.1084/jem.171.6.1871; POOLMAN JT, 1986, LANCET, V2, P555; POOLMAN JT, 1987, A VAN LEEUW J MICROB, V53, P261; SAUKKONEN K, 1989, VACCINE, V7, P325, DOI 10.1016/0264-410X(89)90194-1; VIRJI M, 1987, J GEN MICROBIOL, V133, P3393; WEDEGE E, 1986, INFECT IMMUN, V51, P571, DOI 10.1128/IAI.51.2.571-578.1986	16	168	183	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					514	517		10.1016/0140-6736(91)91297-8	http://dx.doi.org/10.1016/0140-6736(91)91297-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1705642				2022-12-28	WOS:A1991EZ87400004
J	GOELZ, SE; HESSION, C; GOFF, D; GRIFFITHS, B; TIZARD, R; NEWMAN, B; CHIROSSO, G; LOBB, R				GOELZ, SE; HESSION, C; GOFF, D; GRIFFITHS, B; TIZARD, R; NEWMAN, B; CHIROSSO, G; LOBB, R			ELFT - A GENE THAT DIRECTS THE EXPRESSION OF AN ELAM-1 LIGAND	CELL			English	Article							LEUKOCYTE-ENDOTHELIAL INTERACTIONS; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; MEMBRANE-PROTEIN; ANIMAL-CELLS; ADHESION; RECEPTOR; CDNA; NEUTROPHILS	The LECCAMs are a family of cell adhesion molecules implicated in certain inflammatory processes. ELAM-1, a LECCAM found on the surface of activated endothelial cells, can mediate adhesion of neutrophils, monocytes, and certain cell lines to endothelial cells in vitro. No ligand for any LECCAM has yet been fully characterized. Here we report the cloning of a cDNA, ELFT (ELAM-1 ligand fucosyltransferase), that can confer ELAM-1 binding activity when transfected into nonbinding cells lines. ELFT encodes a 46 kd protein that has alpha-(1,3)fucosyltransferase activity, suggesting that a fucosylated carbohydrate structure is an essential component of the ELAM-1 ligand. Furthermore, ELFT is expressed specifically in cell types that bind to ELAM-1, suggesting that this enzyme is an important regulator of inflammatory events in vivo.			GOELZ, SE (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARLOS T, 1990, IN PRESS BLOOD; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DAVIS MM, 1986, HDB EXPT IMMUNOLOGY, V2, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HARLAN JM, 1985, BLOOD, V65, P513; HARLOW E, 1988, ANTIBODIES LABORATOR; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAXAM A, 1980, METHOD ENZYMOL, V68, P499; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OHMORI K, 1989, BLOOD, V74, P255; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, IN PRESS SCIENCE; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	44	305	324	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1349	1356		10.1016/0092-8674(90)90430-M	http://dx.doi.org/10.1016/0092-8674(90)90430-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	1702034				2022-12-28	WOS:A1990EN92300025
J	BULLOCK, KD; REED, RJ; GRANT, I				BULLOCK, KD; REED, RJ; GRANT, I			REDUCED MORTALITY RISK IN ALCOHOLICS WHO ACHIEVE LONG-TERM ABSTINENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; FOLLOW-UP; 1ST ADMISSION; LATE 30S; MEN; SUICIDE	Objectives. - To determine if alcoholic men who achieved stable abstinence experienced fewer deaths than those who relapsed and to develop a model predictive of premature mortality. Design. - A cohort of alcoholic men recruited into a prospective study of neurocognitive effects of alcoholism was followed up from 1 through 11 years. A demographically equated group of nonalcoholic men was also followed up, Alcoholics were classified as stable abstainers or relapsers. Setting. - Alcoholics were patients or ex-patients from a Department of Veterans Affairs Alcoholism Treatment Program and/or members of local chapters of Alcoholics Anonymous. Participants. - There were 234 alcoholic men who met the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, criteria for alcohol dependence. Follow-up status regarding relapse and mortality was obtained for 199 alcoholic subjects (85%). Of these, 1 01 had relapsed and 98 had abstained. Ninety-eight nonalcoholic controls equated for age, education, and sex also participated. Mortality status was obtained for 92 subjects in this group (94%). Exclusions. - Major medical and psychiatric illness and history of nonalcoholic drug abuse. Main Outcome Measure. - Death during a follow-up period of 1 through 11 years. Death was ascertained through the National Death index, the California State Department of Health and Vital Statistics, the State Department of Motor Vehicles, and through personal contact with informants. relatives, and significant others of the subjects. Results. - There were 19 deaths among relapsed alcoholics compared with the expected number of 3.83 (99% confidence interval (CI), 9.64 to 33.38). Among abstinent alcoholics there were four deaths (expected = 3.21; 99% CI, 0.67 to 12.59). The standardized mortality ratio for relapsed alcoholics was 4.96, which significantly exceeded the expected ratio (P < .001), whereas the standardized mortality ratio for abstinent alcoholics (1.25) was indistinguishable from the expected. Cox proportional hazards analysis was used to determine if any of several demographic, medical, cognitive, or drinking history variables (in addition to relapse) helped predict mortality among alcoholics. Only relapse was significantly related to increased mortality (chi-2 = 9. 15, P = .003). Conclusions. - Alcoholic men who achieve stable abstinence do not differ from nonalcoholic men in mortality experience; however, alcoholics who relapse die at a rate 4.96 times that of an age-, sex-, and race-matched representative sample from the US Bureau of the Census.	DEPT VET AFFAIRS MED CTR,PSYCHIAT SERV 116,3350 LA JOLLA VILLAGE DR,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,RES SERV,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,SCH MED,DEPT PSYCHIAT,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego								ADAMS KM, 1980, AM J PSYCHIAT, V137, P928; ADAMS KM, 1981, AM J PSYCHIAT, V138, P445; BERGLUND M, 1985, ALCOHOL CLIN EXP RES, V9, P153, DOI 10.1111/j.1530-0277.1985.tb05541.x; BERGLUND M, 1984, ARCH GEN PSYCHIAT, V41, P888; BERGLUND M, 1984, ACTA PSYCHIAT SCAND, V70, P407, DOI 10.1111/j.1600-0447.1984.tb01228.x; BERGLUND M, 1985, ACTA PSYCHIAT SCAND, V71, P141, DOI 10.1111/j.1600-0447.1985.tb01264.x; COMBSORME T, 1985, J STUD ALCOHOL, V46, P443, DOI 10.15288/jsa.1985.46.443; COX DR, 1972, J R STAT SOC B, V34, P187; de Lint J, 1975, Can Med Assoc J, V113, P385; DIXON WJ, 1988, BMDP STATISTICAL SOF; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; EDWARDS G, 1978, J STUD ALCOHOL, V39, P1607, DOI 10.15288/jsa.1978.39.1607; GORWITZ R, 1966, PUBLIC HLTH REP, V81, P1095; GRANT I, 1984, ARCH GEN PSYCHIAT, V41, P710; GRANT I, 1978, ARCH GEN PSYCHIAT, V35, P1063; GRANT I, 1979, AM J PSYCHIAT, V136, P1263; IMAIZUMI Y, 1986, ALCOHOL ALCOHOLISM, V21, P159; KINNEY EL, 1989, ANGIOLOGY, V40, P270, DOI 10.1177/000331978904000405; Lachar D., 1974, MMPI CLIN ASSESSMENT; LEE ET, 1980, STATISTICAL METHODS; LINDBERG S, 1988, BRIT J ADDICT, V83, P1193; MACKENZIE A, 1986, INT J ADDICT, V21, P865, DOI 10.3109/10826088609027400; MACMAHON B, 1983, AM J PUBLIC HEALTH, V78, P1247; MURPHY GE, 1979, ARCH GEN PSYCHIAT, V36, P65; NICHOLLS P, 1974, Q J STUD ALCOHOL, V35, P841; Pell S, 1973, J Occup Med, V15, P120; Reitan RM, 1974, CLIN NEUROPSYCHOLOGY; ROGOT E, 1983, AM J PUBLIC HEALTH, V73, P1265, DOI 10.2105/AJPH.73.11.1265; SCHMIDT E, 1970, BR J ADDICT, V64, P327; SCHMIDT W, 1972, Q J STUD ALCOHOL, V33, P171; SCHUCKIT MA, 1974, Q J STUD ALCOHOL, V35, P856; SMITH EM, 1983, ALCOHOL CLIN EXP RES, V7, P237, DOI 10.1111/j.1530-0277.1983.tb05449.x; TAYLOR JR, 1983, J STUD ALCOHOL, V44, P17, DOI 10.15288/jsa.1983.44.17; TAYLOR JR, 1983, BIOL ALCOHOL, V6, P17; THORARINSSON AA, 1979, J STUD ALCOHOL, V40, P704, DOI 10.15288/jsa.1979.40.704; VAILLANT GE, 1983, NATURAL HIST ALCOHOL, P161; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; 1987, DIAGNOSTIC STATISTIC; 1987, CURRENT POPULATION P, V25; 1980, MORTALITY, V2, P7; 1984, TECHNICAL APPENDIX A, V2	41	39	39	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					668	672		10.1001/jama.267.5.668	http://dx.doi.org/10.1001/jama.267.5.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731133				2022-12-28	WOS:A1992HB35400023
J	RICHMAN, JA; FLAHERTY, JA; ROSPENDA, KM; CHRISTENSEN, ML				RICHMAN, JA; FLAHERTY, JA; ROSPENDA, KM; CHRISTENSEN, ML			MENTAL-HEALTH CONSEQUENCES AND CORRELATES OF REPORTED MEDICAL-STUDENT ABUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SCHOOL; FUTURE	Objective. - To assess the prevalence, correlates, and mental health consequences of reported medical training-related abuses. Design. - A longitudinal cohort study of 137 students surveyed from medical school entrance (time 1) through the winter of the fourth training year (time 4). Setting. - A state college of medicine. Outcome Measures. - Reported training-related abuses (measured at time 4) and mental health status measured at times 1 and 4 (depressive and anxiety symptoms, hostility, problem drinking, escapist drinking. alcohol consumption levels, and gender role orientations). Results. - Seventy-two percent of students reported at least one abusive experience during medical training. Females were significantly more likely than males to report gender discrimination, exclusion from informal settings, discomfort from sexual humor, and unwanted sexual advances. Abuse was significantly related to most psychopathological outcomes, controlling for pre-existing psychopathology. Males low in masculinity and females low in femininity were most likely to report abuse. Conclusions. - The data provide further support for the assumption that a high proportion of medical students not only experience the training process as abusive in nature but also suffer measurable psychopathological consequences. Efforts should be made to reform medical education, with a prominent focus on gender role-related issues.			RICHMAN, JA (corresponding author), UNIV ILLINOIS,DEPT PSYCHIAT,M-C 913,912 S WOOD ST,CHICAGO,IL 60612, USA.		Rospenda, Kathy/ABF-1383-2020	Rospenda, Kathy/0000-0002-6753-9874	NIAAA NIH HHS [R29AA07311] Funding Source: Medline; PHS HHS [R0107311] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA007311] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BALDWIN DWC, 1991, WESTERN J MED, V155, P140; DEROGATIS LR, 1975, SCL90R CLIN PSYCH RE; HEREK GM, 1989, AM PSYCHOL, V44, P948, DOI 10.1037/0003-066X.44.6.948; KAY J, 1990, JAMA-J AM MED ASSOC, V263, P572, DOI 10.1001/jama.263.4.572; LORBER J, 1984, WOMEN PHYSICIANS CAR; McNair DM, 1981, PROFILE MOOD STATES; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RICHMAN JA, 1990, J STUD ALCOHOL, V51, P296, DOI 10.15288/jsa.1990.51.296; RICHMAN JA, 1991, BRIT J ADDICT, V86, P1133; RICHMAN JA, 1988, SOC FORCES, V67, P208, DOI 10.2307/2579107; RICHMAN JA, IN PRESS J STUD ALCO; ROSENBERG DA, 1984, JAMA-J AM MED ASSOC, V251, P739, DOI 10.1001/jama.251.6.739; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SHEEHAN KH, 1990, JAMA-J AM MED ASSOC, V263, P533, DOI 10.1001/jama.263.4.533; SILVER HK, 1990, JAMA-J AM MED ASSOC, V263, P527, DOI 10.1001/jama.263.4.527; SILVER HK, 1982, JAMA-J AM MED ASSOC, V247, P309, DOI 10.1001/jama.247.3.309; Spence J.T., 1978, MASCULINITY FEMININI; SYMONDS A, 1983, AM J PSYCHOANAL, V43, P21, DOI 10.1007/BF01253496; TEMPLE M, 1986, J STUD ALCOHOL, V47, P274, DOI 10.15288/jsa.1986.47.274	19	174	185	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					692	694		10.1001/jama.267.5.692	http://dx.doi.org/10.1001/jama.267.5.692			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB354	1731137				2022-12-28	WOS:A1992HB35400028
J	WEGNER, DL; WITTE, DL; SCHRANTZ, RD				WEGNER, DL; WITTE, DL; SCHRANTZ, RD			INSENSITIVITY OF RAPID ANTIGEN-DETECTION METHODS AND SINGLE BLOOD AGAR PLATE CULTURE FOR DIAGNOSING STREPTOCOCCAL PHARYNGITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GROUP-A STREPTOCOCCI; STREP	Objective. - To compare the sensitivity of five group A streptococcal antigen detection systems and single blood agar plate culture with a two-plate culture method for diagnosis of streptococcal pharyngitis. Design. - Two simultaneous throat swabs were obtained from consecutive patients with suspected streptococcal pharyngitis. One swab was tested for streptococcal antigen by physicians' office nurses and the other was cultured on both aerobic blood agar and anaerobic trimethoprim-sulfamethoxazole blood agar plates. Setting. - Community office practice and community hospital laboratory. Participants. - Consecutive outpatients seen by one of four pediatricians or a family practice physician. Main Outcome Measures. - Results of rapid streptococcal antigen tests were compared with culture results either on a single aerobic blood agar plate or on the two-plate culture method. Results. - On throat swabs from 755 consecutive outpatients, the two-plate culture method detected 261 cases (defined as 100%) of group A streptococcal pharyngitis. The anaerobic trimethoprim-sulfamethoxazole plate alone, read at 1 and 2 days, detected 245 cases (94%). The blood agar plate used alone detected 189 cases (72%) at 2 days and 151 cases (58%) at 1 day. Antigen detection test results were positive for 106 throat specimens (41%), with individual kit sensitivity ranging from 31% to 50% compared with the two-plate culture method. Antigen detection test sensitivity decreased with decreasing colony counts. Antigen kit false-positivity rates varied from 0 to 28%. Conclusions. - We conclude that the single blood agar plate culture and the antigen detection tests are insensitive, possibly leading the physician toward undertreatment and risking immunologic, local, or distant sequelae. The two-plate culture method should be the standard of practice to rule out streptococcal pharyngitis.			WEGNER, DL (corresponding author), OTTUMWA REG HLTH FDN,1001 E PENN AVE,OTTUMWA,IA 52501, USA.							CAMPOS JM, 1985, J CLIN MICROBIOL, V22, P145, DOI 10.1128/JCM.22.2.145-148.1985; GERBER MA, 1986, J PEDIATR-US, V108, P654, DOI 10.1016/S0022-3476(86)81036-8; HUCK W, 1989, J CLIN MICROBIOL, V27, P1715, DOI 10.1128/JCM.27.8.1715-1718.1989; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KURZYNSKI TA, 1981, J CLIN MICROBIOL, V13, P891, DOI 10.1128/JCM.13.5.891-894.1981; MANASSE RJ, 1989, J CLIN MICROBIOL, V27, P1657, DOI 10.1128/JCM.27.7.1657-1658.1989; MIRRETT S, 1987, DIAGN MICR INFEC DIS, V6, P217, DOI 10.1016/0732-8893(87)90015-0; SLIFKIN M, 1984, J CLIN MICROBIOL, V20, P12, DOI 10.1128/JCM.20.1.12-14.1984; TOLLIVER PR, 1987, PEDIATR INFECT DIS J, V6, P515, DOI 10.1097/00006454-198706000-00005	9	54	54	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					695	697		10.1001/jama.267.5.695	http://dx.doi.org/10.1001/jama.267.5.695			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1731138				2022-12-28	WOS:A1992HB35400029
J	BUTTERWORTH, CE; HATCH, KD; MACALUSO, M; COLE, P; SAUBERLICH, HE; SOONG, SJ; BORST, M; BAKER, VV				BUTTERWORTH, CE; HATCH, KD; MACALUSO, M; COLE, P; SAUBERLICH, HE; SOONG, SJ; BORST, M; BAKER, VV			FOLATE-DEFICIENCY AND CERVICAL DYSPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; ORAL-CONTRACEPTIVES; LYMPHOCYTE CULTURE; ASCORBIC-ACID; FRAGILE SITES; FOLIC-ACID; CANCER; RISK; NEOPLASIA; PLASMA	Objective. - To test the hypothesis that nutritional deficiency affects the incidence of cervical dysplasia in young women. Design and Setting. - Case-control study. Participants were derived from community family-planning clinics and referrals to a colposcopy center. Participants. - A total of 726 subjects were screened, yielding 294 cases of dysplasia and 170 controls defined by coexistent cytologic and colposcopic evidence. Main Outcome Measures. - Planned prior to data collection. Odds ratios were computed using logistic regression models to evaluate association between cervical dysplasia and sociodemographic, sexual, and reproductive factors; smoking; oral contraceptive use; human papillomavirus (HPV) infection; and 12 nutritional indices determined by blind analysis of nonfasting blood specimens. Results. - The number of sexual partners, parity, oral contraceptive use, and HPV-16 infection were significantly associated with cervical dysplasia. Plasma nutrient levels were generally not associated with risk. However, red blood cell folate levels at or below 660 nmol/L interacted with HPV-16 infection. The adjusted odds ratio for HPV-16 was 1.1 among women with folate levels above 660 nmol/L but 5.1 (95% confidence interval, 2.3 to 11) among women with lower levels. Interactions of red blood cell folate levels with cigarette smoking and parity were also present but were not statistically significant. Conclusion. - Low red blood cell folate levels enhance the effect of other risk factors for cervical dysplasia and, in particular, that of HPV-16 infection.	UNIV ALABAMA, SCH MED, DEPT OBSTET & GYNECOL, BIRMINGHAM, AL 35233 USA; UNIV ALABAMA, SCH HLTH RELATED PROFESS, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR COMPREHENS CANC, DEPT BIOSTAT & BIOMATH, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH PUBL HLTH, DEPT EPIDEMIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	BUTTERWORTH, CE (corresponding author), UNIV ALABAMA, SCH MED, DEPT NUTR SCI, UAB STN, BIRMINGHAM, AL 35294 USA.		Macaluso, Maurizio/J-2076-2015	Macaluso, Maurizio/0000-0002-2977-9690	NCI NIH HHS [5 P01-CA 28103] Funding Source: Medline; NICHD NIH HHS [N01-HD-5-2927] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052927] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA028103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYOUMI RA, 1976, CLIN CHEM, V22, P327; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BORST M, 1991, J REPROD MED, V36, P95; BRESLOW NE, 1985, AM J EPIDEMIOL, V122, P149, DOI 10.1093/oxfordjournals.aje.a114074; Breslow NE, 1980, IARC SCI PUBL, V1, P1; BRINTON LA, 1986, JAMA-J AM MED ASSOC, V255, P3265, DOI 10.1001/jama.255.23.3265; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; BROCK KE, 1988, J NATL CANCER I, V80, P580, DOI 10.1093/jnci/80.8.580; BUTTERWORTH CE, 1982, AM J CLIN NUTR, V35, P73, DOI 10.1093/ajcn/35.1.73; BUTTERWORTH CE, IN PRESS AM J OBSTET; BUTTERWORTH CE, 1991, MICRONUTRIENTS HLTH, P165; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DAS KC, 1980, CLIN CHEM, V26, P72; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; Eto I, 1986, Adv Exp Med Biol, V206, P313; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P177; GARRY PJ, 1970, CLIN CHEM, V16, P766; HEATH CW, 1966, BLOOD-J HEMATOL, V27, P800, DOI 10.1182/blood.V27.6.800.800; HEIMBURGER DC, 1988, JAMA-J AM MED ASSOC, V259, P1525; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; JASKIEWICZ K, 1988, ANTICANCER RES, V8, P711; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P11; JONES CJ, 1990, CANCER RES, V50, P3657; KUTNINK MA, 1985, J LIQ CHROMATOGR, V8, P31, DOI 10.1080/01483918508067061; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MEANWELL CA, 1987, LANCET, V1, P703; MELCHERS WJG, 1989, J CLIN MICROBIOL, V27, P106, DOI 10.1128/JCM.27.1.106-110.1989; MUIR CS, 1990, CANCER RES, V50, P6441; OLSON AD, 1969, CLIN CHEM, V15, P438; ORR JW, 1985, AM J OBSTET GYNECOL, V151, P632, DOI 10.1016/0002-9378(85)90153-X; PALAN PR, 1991, NUTR CANCER, V15, P13, DOI 10.1080/01635589109514106; PALAN PR, 1988, J NATL CANCER I, V80, P454, DOI 10.1093/jnci/80.6.454; POPESCU NC, 1987, J VIROL, V61, P1682, DOI 10.1128/JVI.61.5.1682-1685.1987; POTISCHMAN N, 1991, CANCER RES, V51, P4785; RAN JY, 1990, BLOOD S, V76, pA114; REEVES WC, 1989, NEW ENGL J MED, V320, P1437, DOI 10.1056/NEJM198906013202201; ROMNEY SL, 1987, ANN NY ACAD SCI, V498, P132, DOI 10.1111/j.1749-6632.1987.tb23757.x; SCHNEIDER A, 1989, ARCH GYNECOL OBSTET, V246, P1, DOI 10.1007/BF00933072; SCOTT JM, 1974, AM J MED TECHNOL, V40, P125; SHOJANIA AM, 1968, LANCET, V1, P1376; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27; STREIFF RR, 1970, J AMER MED ASSOC, V214, P105, DOI 10.1001/jama.214.1.105; SUNDERMAN FW, 1973, HUM PATHOL, V4, P549, DOI 10.1016/S0046-8177(73)80066-8; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; VESSEY MP, 1983, LANCET, V2, P930; WASSERTHEILSMOL.S, 1983, NUTRITIONAL FACTORS, P289; WHITEHEAD N, 1973, JAMA-J AM MED ASSOC, V226, P1421, DOI 10.1001/jama.226.12.1421; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZIEGLER RG, 1990, AM J EPIDEMIOL, V132, P432, DOI 10.1093/oxfordjournals.aje.a115678	54	179	184	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					528	533		10.1001/jama.267.4.528	http://dx.doi.org/10.1001/jama.267.4.528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1729576				2022-12-28	WOS:A1992GZ43900029
J	ADOLPH, EA; LACY, WO; HERMONI, YI; WEXLER, LF; JAVAHERI, S				ADOLPH, EA; LACY, WO; HERMONI, YI; WEXLER, LF; JAVAHERI, S			REVERSIBLE ORTHODEOXIA AND PLATYPNEA DUE TO RIGHT-TO-LEFT INTRACARDIAC SHUNTING RELATED TO PERICARDIAL-EFFUSION	ANNALS OF INTERNAL MEDICINE			English	Note						ANOXEMIA; DYSPNEA; PERICARDIAL EFFUSION; ATRIAL FUNCTION, RIGHT; CORONARY ARTERY BYPASS	PNEUMONECTOMY; HYPOXEMIA	A patient developed platypnea and orthodeoxia 2 weeks after coronary artery bypass graft surgery. On room air, arterial PaO2 was 45 mm Hg with the patient seated and 54 mm Hg with the patient supine. When the patient breathed pure oxygen, the PaO2- values were 79 mm Hg (seated) and 170 mm Hg (supine). Echocardiographic and computed tomographic studies showed a loculated pericardial effusion that compressed the right heart chambers. A right-to-left shunt was confirmed by doppler and contrast echocardiography. Cardiac catheterization showed near-normal cardiac and pulmonary vascular pressures. The effusion and the shunt resolved in response to corticosteroid therapy. We believe that the right-to-left shunt, which worsened with the patient in the upright posture, was caused by directed flow from the inferior vena cava toward to the left atrium through a patient foramen ovale, as the result of a pericardial effusion.	DEPT VET AFFAIRS MED CTR, PULM SECT 111F, 3200 VINE ST, CINCINNATI, OH 45220 USA; UNIV CINCINNATI, COLL MED, CINCINNATI, OH 45221 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University of Cincinnati								ALTMAN M, 1969, NEW ENGL J MED, V281, P1347, DOI 10.1056/NEJM196912112812408; BEGIN R, 1975, NEW ENGL J MED, V293, P342, DOI 10.1056/NEJM197508142930707; FRANCO DP, 1984, AM REV RESPIR DIS, V129, P1021; KLEPPER JI, 1988, AM HEART J, V116, P189, DOI 10.1016/0002-8703(88)90268-2; LABRESH KA, 1981, CHEST, V79, P605, DOI 10.1378/chest.79.5.605; ROBIN ED, 1976, NEW ENGL J MED, V294, P941, DOI 10.1056/NEJM197604222941711; SEWARD JB, 1984, MAYO CLIN PROC, V59, P221, DOI 10.1016/S0025-6196(12)61253-1; SHAPIRO BA, 1973, CLIN APPLICATION BLO, P41; STREITZ JM, 1988, ANN THORAC SURG, V46, P104, DOI 10.1016/S0003-4975(10)65866-3; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; WINTERS WL, 1967, AM J CARDIOL, V19, P293, DOI 10.1016/0002-9149(67)90550-4	11	51	51	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					138	139		10.7326/0003-4819-116-2-138	http://dx.doi.org/10.7326/0003-4819-116-2-138			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727617				2022-12-28	WOS:A1992GZ35600006
J	CASALINO, LP				CASALINO, LP			BALANCING INCENTIVES - HOW SHOULD PHYSICIANS BE REIMBURSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATIONS; FINANCIAL INCENTIVES; COST CONTROL; EXPENDITURES	The May 15, 1991, JAMA theme issue presented 14 different proposals for reforming the US medical care system. Though these proposals varied widely, they encompassed only three proposed methods for paying physicians: fee-for-service, salary, and capitation. When examined from a perspective that considers the incentives affecting practicing physicians, each of these methods has serious flaws. I outline these flaws and suggest an alternative method for reimbursing primary care physicians: that of combining capitation and fee-for-service. Specialists would be paid fee-for-service, but the cost of specialty care would be limited by giving each primary care physician a budget for such care. Consistent failure by a physician to stay within the budget would result in ongoing review, but not in direct financial sanctions. This system of reimbursing physicians is intended to balance incentives so that physicians can concentrate on making medical decisions with a minimum of distraction by third parties and by personal financial considerations.			CASALINO, LP (corresponding author), COASTSIDE MED CLIN,225 S CABRILLO HWY,HALF MOON BAY,CA 94019, USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				BARER ML, 1988, MILBANK Q, V66, P1, DOI 10.2307/3349985; EVANS RG, 1990, J HEALTH POLIT POLIC, V15, P101, DOI 10.1215/03616878-15-1-101; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; EVANS RG, 1988, HLTH POLICY RES UNIT, V88, P8; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; HOLAHAN J, 1990, JAMA-J AM MED ASSOC, V263, P1658, DOI 10.1001/jama.263.12.1658; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; LEE PR, 1990, ANNU REV PUBL HEALTH, V11, P297; LOMAS J, 1989, HEALTH AFFAIR, V8, P80, DOI 10.1377/hlthaff.8.1.80; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; MURRAY JP, 1988, J FAM PRACTICE, V26, P576; PFAFF M, 1990, J HEALTH POLIT POLIC, V15, P1, DOI 10.1215/03616878-15-1-1; RODWIN VG, 1989, SUCCESS CRISIS NATIO, P265; WEDIG G, 1989, J HEALTH POLIT POLIC, V14, P601, DOI 10.1215/03616878-14-3-601; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; [No title captured]	20	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					403	405						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY437	1727965				2022-12-28	WOS:A1992GY43700040
J	SCHWOB, E; MARTIN, RP				SCHWOB, E; MARTIN, RP			NEW YEAST ACTIN-LIKE GENE REQUIRED LATE IN THE CELL-CYCLE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SEQUENCE; DISRUPTION; TUBULIN; PROTEIN	ACTIN, a major cytoskeletal component of all eukaryotic cells, is one of the most highly conserved proteins. It is involved in various cellular processes such as motility, cytoplasmic streaming, chromosome segregation and cytokinesis 1,2. The actin from the yeast Saccharomyces cerevisiae, encoded by the essential ACT1 gene 3-5, is 89% identical to mouse cytoplasmic actin and is involved in the organization and polarized growth of the cell surface 6-8. We report here the characterization of ACT2, a previously undescribed yeast split gene encoding a putative protein (391 amino acids, relative molecular mass (M(r)) 44,073) that is 47% identical to yeast actin. The requirement of the ACT2 gene for vegetative growth of yeast cells and the existence of related genes in other eukaryotes indicate an important and conserved role for these actin-like proteins. Superimposition of the Act2 polypeptide onto the three-dimensional structure 9,10 of known actins reveals that most of the divergence occurred in loops involved in actin polymerization, DNase I and myosin binding, leaving the core domain mainly unaffected. To our knowledge, the Act2 protein from S. cerevisiae is the first highly divergent actin molecule described. Structural and physiological data suggest that the Act2 protein might have an important role in cytoskeletal reorganization during the cell cycle.	CNRS,INST BIOL MOLEC & CELLULAIRE,BIOCHIM LAB,15 RUE RENE DESCARTES,F-67084 STRASBOURG,FRANCE; UNIV STRASBOURG 1,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Schwob, Etienne/AAC-3050-2020; Schwob, Etienne/H-4678-2015	Schwob, Etienne/0000-0002-9369-6419				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEGRAIN P, 1991, MOL GEN GENET, V225, P199, DOI 10.1007/BF00269848; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; SOLOMON LR, 1987, J BIOL CHEM, V262, P11382; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; VANDEKERCKHOVE J, 1985, EMBO J, V4, P2815, DOI 10.1002/j.1460-2075.1985.tb04008.x	31	115	116	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					179	182		10.1038/355179a0	http://dx.doi.org/10.1038/355179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729653				2022-12-28	WOS:A1992GY62900064
J	SANFILIPPO, FP; VAUGHN, WK; PETERS, TG; SHIELD, CF; ADAMS, PL; LORBER, MI; WILLIAMS, GM				SANFILIPPO, FP; VAUGHN, WK; PETERS, TG; SHIELD, CF; ADAMS, PL; LORBER, MI; WILLIAMS, GM			FACTORS AFFECTING THE WAITING TIME OF CADAVERIC KIDNEY-TRANSPLANT CANDIDATES IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENEFIT	Objective. - To evaluate the relative impact of various factors that could account for differences in waiting time of cadaveric kidney transplant candidates (eg, black and sensitized patients). Design. - A cohort study using multivariate analyses to identify associations between 36 patient, donor, and center factors with waiting time for all US cadaveric kidney transplant candidates listed between October 1, 1987, and June 30, 1990. Setting. - All US kidney transplant centers. Patients. - The study included 23 468 cadaveric renal transplant candidates on active waiting status. Results. - The patient characteristics most significantly associated with increased waiting time (adjusted for all other variables) were immunologic and included presensitization to HLA antigens, O or B blood type, candidacy for a repeat transplantation, and expression of rare HLA-A or HLA-B antigen phenotypes. Nonimmunologic factors also affected waiting times, which were significantly shorter for patients younger than 15 years vs those aged 15 through 44 years (8.4 vs 12.9 months, respectively; P < .0001), for those listed at multiple centers vs one center (7.0 vs 13.3 months, respectively; P < .0001), or for white vs black patients (11.9 vs 15.4 months, respectively; P < .0001). Local transplant center characteristics associated with a significantly shorter waiting time included a small number of transplantation candidates, a high (> 35 per million population) local kidney organ recovery rate, and an approved variance from the Organ Procurement and Transplantation Network allocation algorithm. Conclusions. - The time renal transplant candidates must wait for kidney transplantation is influenced by several factors in addition to those expected due to immunologic reasons of donor incompatibility, the algorithms used for organ distribution, or the effectiveness of local kidney recovery. The impact of these factors should be considered as the current US system for allocating scarce donor organs for kidney transplantation is modified.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705; METHODIST MED CTR,DEPT SURG,JACKSONVILLE,FL; ST FRANCIS REG MED CTR,DEPT SURG,WICHITA,KS 67214; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103; YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Wake Forest University; Wake Forest Baptist Medical Center; Yale University; Johns Hopkins University	SANFILIPPO, FP (corresponding author), UNITED NETWORK ORGAN SHARING,DEPT RES,POB 13770,RICHMOND,VA 23225, USA.		Sanfilippo, Fred/AAY-6503-2020					[Anonymous], 1986, ORGAN TRANSPLANTATIO; BALDWIN WM, 1991, TRANSPLANT REV, V5, P100; BOLLINGER RR, 1982, TRANSPL P, V14, P46; COX DR, 1972, J R STAT SOC B, V34, P187; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KERMAN RH, IN PRESS TRANSPLANTA; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; PARK MS, 1979, TRANSPLANT P, V11, P1947; PATEL R, 1969, NEW ENGL J MED, V280, P735, DOI 10.1056/NEJM196904032801401; SANFILIPPO F, 1991, CLIN LAB MED, V11, P537, DOI 10.1016/S0272-2712(18)30540-7; Sanfilippo F, 1988, Clin Transpl, P211; SANFILIPPO F, 1987, TRANSPLANTATION, V43, P240, DOI 10.1097/00007890-198702000-00015; Sanfilippo F, 1991, N C Med J, V52, P367; SHIBATA A, 1989, JPN J CLIN ONCOL, V19, P195; SUTHERLAND DER, 1989, CLIN TRANSPLANT, V3, P129; TAKIFF H, 1989, TRANSPLANTATION, V47, P102, DOI 10.1097/00007890-198901000-00023; 1991, OE1018900550 US DEP	17	125	125	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					247	252		10.1001/jama.267.2.247	http://dx.doi.org/10.1001/jama.267.2.247			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727521				2022-12-28	WOS:A1992GY04600028
J	CHOWDHURY, JR; GROSSMAN, M; GUPTA, S; CHOWDHURY, NR; BAKER, JR; WILSON, JM				CHOWDHURY, JR; GROSSMAN, M; GUPTA, S; CHOWDHURY, NR; BAKER, JR; WILSON, JM			LONG-TERM IMPROVEMENT OF HYPERCHOLESTEROLEMIA AFTER EXVIVO GENE-THERAPY IN LDLR-DEFICIENT RABBITS	SCIENCE			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN RECEPTORS; LIVER-TRANSPLANTATION; ALBUMIN	Familial hypercholesterolemia (FH) is an inherited disorder in humans that is caused by a deficiency of low density lipoprotein receptors (LDLRs). An animal model for FH, the Watanabe Heritable Hyperlipidemic rabbit, was used to develop an approach for liver-directed gene therapy based on transplantation of autologous hepatocytes that were genetically corrected ex vivo with recombinant retroviruses. Animals transplanted with LDLR-transduced autologous hepatocytes demonstrated a 30 to 50 percent decrease in total serum cholesterol that persisted for the duration of the experiment (122 days). Recombinant-derived LDLR RNA was harvested from tissues with no diminution for up to 6.5 months after transplantation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	WILSON, JM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042193, R01DK034357, P01DK042718] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK-42718, R01-DK-34357, R01-DK42193-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; Cochran WG, 1957, EXPT DESIGNS, P127; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; GROSSMAN MI, UNPUB; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PINTAR JE, 1987, IN SITU HYBRIDIZATIO, P179; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; STARZL TE, 1984, LANCET, V1, P1382; TRINDER P, 1974, ANN CLIN BIOCHEM, V12, P226; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WIEDERKEHR JC, 1990, TRANSPLANTATION, V50, P466, DOI 10.1097/00007890-199009000-00021; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P843; WILSON JM, 1991, CLIN BIOTECHNOL, V3, P21	18	323	423	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1802	1805						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722351				2022-12-28	WOS:A1991GW31600047
J	HAAS, ES; MORSE, DP; BROWN, JW; SCHMIDT, FJ; PACE, NR				HAAS, ES; MORSE, DP; BROWN, JW; SCHMIDT, FJ; PACE, NR			LONG-RANGE STRUCTURE IN RIBONUCLEASE-P RNA	SCIENCE			English	Article							ESCHERICHIA-COLI; RIBOSOMAL-RNA; DNA; CLONING; MUTANTS	Phylogenetic-comparative and mutational analyses were used to elucidate the structure of the catalytically active RNA component of eubacterial ribonuclease P (RNase P). In addition to the refinement and extension of known structural elements, the analyses revealed a long-range interaction that results in a second pseudoknot in the RNA. This feature strongly constrains the three-dimensional structure of RNase P RNA near the active site. Some RNase P RNAS lack this structure but contain a unique, possibly compensating, structural domain. This suggests that different RNA structures located at different positions in the sequence may have equivalent architectural functions in RNase P RNA.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	Indiana University System; Indiana University Bloomington; University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034527, R01GM034527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BROWN JW, 1991, J BACTERIOL, V173, P3855, DOI 10.1128/JB.173.12.3855-3863.1991; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; COATS JH, 1971, J BACTERIOL, V105, P880, DOI 10.1128/JB.105.3.880-885.1971; DARR SC, UNPUB; EICHENLAUB R, 1979, J BACTERIOL, V138, P559, DOI 10.1128/JB.138.2.559-566.1979; FISHBEIN L, 1970, CHEM MUTAGENS ENV EF, P27; GUERRIERTAKADA C, 1986, CELL, V45, P177, DOI 10.1016/0092-8674(86)90381-8; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MOTAMEDI H, 1982, J MOL BIOL, V162, P535, DOI 10.1016/0022-2836(82)90387-4; PACE NR, 1990, J BIOL CHEM, V265, P3587; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WAUGH DS, 1990, J BACTERIOL, V172, P6316, DOI 10.1128/jb.172.11.6316-6322.1990; WAUGH DS, 1989, THESIS INDIANA U; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	25	98	99	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					853	856		10.1126/science.1719634	http://dx.doi.org/10.1126/science.1719634			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1719634				2022-12-28	WOS:A1991GN83300044
J	FERNANDEZDELCASTILLO, C; HARRINGER, W; WARSHAW, AL; VLAHAKES, GJ; KOSKI, G; ZASLAVSKY, AM; RATTNER, DW				FERNANDEZDELCASTILLO, C; HARRINGER, W; WARSHAW, AL; VLAHAKES, GJ; KOSKI, G; ZASLAVSKY, AM; RATTNER, DW			RISK-FACTORS FOR PANCREATIC CELLULAR INJURY AFTER CARDIOPULMONARY BYPASS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL REVASCULARIZATION; DISCRIMINANT-ANALYSIS; LABORATORY TESTS; CARDIAC-SURGERY; BLOOD-FLOW; HYPERAMYLASEMIA; HYPERCALCEMIA; AMYLASE; SERUM; MORTALITY	Background. Pancreatitis is a known complication of cardiac surgery with cardiopulmonary bypass. Although ischemia is believed to be a factor, the cause of pancreatitis after cardiopulmonary bypass remains unknown. Methods. We prospectively studied 300 consecutive patients undergoing cardiac surgery with cardiopulmonary bypass. Serum amylase, pancreatic isoamylase, and serum lipase were measured on postoperative days 1, 2, 3, 7, and 10. Pancreatic cellular injury was defined as the presence of hyperamylasemia (> 123 U per liter) with an increase in either the serum level of lipase (> 24 U per liter) or the peak level of pancreatic isoamylase. Trypsinogen-activation peptides, which indicate intrapancreatic enzyme activation, were measured in the urine of the last 101 patients studied. Results. Evidence of pancreatic cellular injury was detected in 80 patients (27 percent), of whom 23 had associated abdominal signs or symptoms and 3 had severe pancreatitis (2 with pancreatic abscess and 1 with necrotizing hemorrhagic pancreatitis). Two of 19 postoperative deaths were secondary to pancreatitis. In multivariate analyses, the development of pancreatic cellular injury was significantly associated with preoperative renal insufficiency, valve surgery, postoperative hypotension, and perioperative administration of calcium chloride. The administration of more than 800 mg of calcium chloride per square meter of body-surface area was an independent predictor of pancreatic cellular injury, and the increase in risk was dose-related. No differences were found in the level of trypsinogen-activation peptides between patients who had pancreatic cellular injury and those who did not. Conclusions. Pancreatic cellular injury, as indicated by hyperamylasemia of pancreatic origin, is common after cardiac surgery. The administration of large doses of calcium chloride is an independent predictor of pancreatic cellular injury and may be a cause of it.	MASSACHUSETTS GEN HOSP, DEPT SURG, ACC337, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT STAT, CAMBRIDGE, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University			Castillo, Carlos Fenandez-del/AAO-2602-2020					AVRAM RM, 1982, NEPHRON, V32, P60, DOI 10.1159/000182804; AZIZ S, 1985, SURGERY, V97, P653; CATES MC, 1988, SURGERY, V104, P137; CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; DEWAELE B, 1989, PANCREAS, V4, P378, DOI 10.1097/00006676-198906000-00017; DROP LJ, 1985, ANESTH ANALG, V64, P432; ECKFELDT JH, 1989, CLIN LAB MED, V9, P731, DOI 10.1016/S0272-2712(18)30601-2; FRICK TW, 1987, AM J SURG, V154, P487, DOI 10.1016/0002-9610(87)90260-1; FRICK TW, 1990, GASTROENTEROLOGY, V98, P1675, DOI 10.1016/0016-5085(90)91106-G; GAFTER U, 1976, JAMA-J AM MED ASSOC, V235, P2004, DOI 10.1001/jama.235.18.2004; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; HAAS GS, 1985, AM J SURG, V149, P508, DOI 10.1016/S0002-9610(85)80048-9; HURLEY PR, 1988, J IMMUNOL METHODS, V111, P195, DOI 10.1016/0022-1759(88)90127-5; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; KAZMIERCZAK SC, 1988, CLIN CHEM, V34, P916; KOLARS JC, 1984, DIGEST DIS SCI, V29, P289, DOI 10.1007/BF01318510; Koski G, 1988, J Cardiothorac Anesth, V2, P570, DOI 10.1016/0888-6296(88)90239-6; LEFER AM, 1974, ANN SURG, V179, P868, DOI 10.1097/00000658-197406000-00009; Leijala M, 1988, Eur J Cardiothorac Surg, V2, P324; MCCORMICK PA, 1985, BRIT MED J, V290, P1472, DOI 10.1136/bmj.290.6480.1472-a; MCGRATH LB, 1990, ANN THORAC SURG, V49, P410, DOI 10.1016/0003-4975(90)90245-2; MELTZER LE, 1962, ANN INTERN MED, V57, P1008, DOI 10.7326/0003-4819-57-6-1008; MILLER DC, 1983, J THORAC CARDIOV SUR, V85, P197; MISSAVAGE AE, 1984, AM SURGEON, V50, P297; MIXTER CG, 1962, NEW ENGL J MED, V266, P265, DOI 10.1056/NEJM196202082660601; MORI A, 1988, JPN CIRC J, V52, P219, DOI 10.1253/jcj.52.219; NAUNHEIM KS, 1988, ANN THORAC SURG, V46, P666, DOI 10.1016/S0003-4975(10)64731-5; Panebianco A C, 1970, Ann Thorac Surg, V9, P562; PANTEGHINI M, 1989, CLIN CHEM, V35, P417; RATTNER DW, 1989, ANN SURG, V209, P279, DOI 10.1097/00000658-198903000-00005; ROBERT JH, 1988, INT J PANCREATOL, V3, P283; ROSE DM, 1984, ANN SURG, V199, P168, DOI 10.1097/00000658-198402000-00006; SANFEY H, 1985, AM J SURG, V150, P297, DOI 10.1016/0002-9610(85)90064-9; SCOTT WC, 1985, J THORAC CARDIOV SUR, V89, P400; SVENSSON LG, 1985, ANN THORAC SURG, V39, P409, DOI 10.1016/S0003-4975(10)61945-5; TIETZ NW, 1986, CLIN CHEM, V32, P301; TRAVERSO LW, 1977, AM J SURG, V133, P298, DOI 10.1016/0002-9610(77)90532-3; WALLWORK J, 1980, BRIT J SURG, V67, P410, DOI 10.1002/bjs.1800670609; WARSHAW AL, 1978, ANN SURG, V188, P197, DOI 10.1097/00000658-197808000-00012; WARSHAW AL, 1977, J SURG RES, V22, P362, DOI 10.1016/0022-4804(77)90158-5; 1990, 1990 HEART STROKE FA	42	148	150	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1991	325	6					382	387						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ804	1712076				2022-12-28	WOS:A1991FZ80400002
J	PLATT, OS; THORINGTON, BD; BRAMBILLA, DJ; MILNER, PF; ROSSE, WF; VICHINSKY, E; KINNEY, TR				PLATT, OS; THORINGTON, BD; BRAMBILLA, DJ; MILNER, PF; ROSSE, WF; VICHINSKY, E; KINNEY, TR			PAIN IN SICKLE-CELL DISEASE - RATES AND RISK-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GLOBIN GENE; FETAL HEMOGLOBIN; CRISIS; ANEMIA; THALASSEMIA; SEVERITY; GELATION; MODELS	Background and Methods. Acute episodes of pain are the principal symptom of sickle cell disease, but little is known about the epidemiologic features of these episodes or risk factors for them, nor is it known whether patients with high rates of such episodes die prematurely. We prospectively studied the natural history of sickle cell disease in 3578 patients ranging from newborns to persons up to 66 years old who were followed at clinical centers across the United States. Results. There were 12,290 episodes of pain in 18,356 patient-years. The average rate was 0.8 episode per patient-year in sickle cell anemia, 1.0 episode per patient-year in sickle beta-0-thalassemia, and 0.4 episode per patient-year in hemoglobin SC disease and sickle beta+-thalassemia. The rate varied widely within each of thesefour groups - e.g., 39 percent of patients with sickle cell anemia had no episodes of pain, and 1 percent had more than six episodes per year. The 5.2 percent of patients with 3 to 10 episodes per year had 32.9 percent of all episodes. Among patients with sickle cell anemia who were more than 20 years old, those with high rates of pain episodes tended to die earlier than those with low rates. High rates were associated with a high hematocrit and low fetal hemoglobin levels. Alpha-Thalassemia had no effect on pain apart from its association with an increased hematocrit. Conclusions. The "pain rate" (episodes per year) is a measure of clinical severity and correlates with early death in patients with sickle cell anemia over the age of 20. Even when the fetal hemoglobin level is low, one can predict that small increments in the level may have an ameliorating effect on the pain rate and may ultimately improve survival. This outcome is particularly encouraging to investigators studying hydroxyurea and other treatments designed to increase the fetal hemoglobin level.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; NEW ENGLAND RES INST, WATERTOWN, MA USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA; OAKLAND CHILDRENS MED CTR, OAKLAND, CA USA	Harvard University; Harvard Medical School; HealthCore, Inc; University System of Georgia; Augusta University; Duke University	PLATT, OS (corresponding author), CHILDRENS HOSP MED CTR, DANA FARBER CANC INST, DIV HEMATOL ONCOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				AITKIN M, 1989, STATISTICAL MODELLIN; BAKER RJ, 1978, GLIM SYSTEM; BALLAS SK, 1988, BLOOD, V72, P1216; BAUM KF, 1987, ARCH INTERN MED, V147, P1231, DOI 10.1001/archinte.147.7.1231; BILLETT HH, 1986, BLOOD, V68, P301; BRESLOW N, 1990, J AM STAT ASSOC, V85, P565, DOI 10.2307/2289799; BRESLOW NE, 1984, J R STAT SOC C-APPL, V33, P38; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1987, BLOOD, V69, P109; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; FARBER MD, 1985, J CHRON DIS, V38, P495, DOI 10.1016/0021-9681(85)90033-5; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; KONOTEYA.FI, 1974, ARCH INTERN MED, V133, P611, DOI 10.1001/archinte.133.4.611; LANDE WM, 1988, BLOOD, V72, P2056; LEIKIN SL, 1989, PEDIATRICS, V84, P500; MANKAD VN, 1990, BLOOD, V75, P274; Powars D R, 1987, Prog Clin Biol Res, V240, P393; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; Seber G.A., 1977, LINEAR REGRESSION AN; STEINBERG MH, 1984, BLOOD, V63, P1353; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; VICHINSKY EP, 1982, AM J PEDIAT HEMATOL, V4, P328	26	1145	1161	1	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					11	16		10.1056/NEJM199107043250103	http://dx.doi.org/10.1056/NEJM199107043250103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1710777				2022-12-28	WOS:A1991FU34200003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SCIENTIFIC-DATA SOUGHT ON HEALTH CLAIMS ON FOODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-28	WOS:A1991FJ95500008
J	PONNIGHAUS, JM; FINE, PEM; MORENO, C				PONNIGHAUS, JM; FINE, PEM; MORENO, C			HYPERSENSITIVITY TO DEXTRAN IN BCG VACCINE	LANCET			English	Letter									HAMMERSMITH HOSP,MRC,TB & RELATED INFECT UNIT,LONDON W12 0HS,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Imperial College London; University of London; London School of Hygiene & Tropical Medicine	PONNIGHAUS, JM (corresponding author), LEPRA,POB 46,CHILUMBA,MALAWI.							FINE PEM, 1988, T ROY SOC TROP MED H, V82, P810, DOI 10.1016/0035-9203(88)90003-X; GOODMAN JW, 1960, J IMMUNOL, V84, P333; KABAT EA, 1958, ARCH BIOCHEM BIOPHYS, V78, P306, DOI 10.1016/0003-9861(58)90354-0; RUDIN, 1991, LANCET, V337, P377	4	18	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1039	1039		10.1016/0140-6736(91)92697-Z	http://dx.doi.org/10.1016/0140-6736(91)92697-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1708069				2022-12-28	WOS:A1991FJ13500037
J	MACKINNON, R				MACKINNON, R			DETERMINATION OF THE SUBUNIT STOICHIOMETRY OF A VOLTAGE-ACTIVATED POTASSIUM CHANNEL	NATURE			English	Article							CHARYBDOTOXIN BLOCK; K+ CHANNELS; DROSOPHILA; INHIBITOR; JUNCTION	The voltage-activated K+, Na+ and Ca2+ channels are responsible for the generation and propagation of electrical signals in cell membranes. The K+ channels are multimeric membrane proteins formed by the aggregation of an unknown number of independent subunits 1-3. By studying the interaction of a scorpion toxin with coexpressed wild-type and toxin-insensitive mutant Shaker K+ channels, the subunit stoichiometry can be determined. The Shaker K+ channel is found to have a tetrameric structure. This is consistent with the sequence relationship between a K+ channel and each of the four internally homologous repeats of Na+ and Ca2+ channels 4-6.			MACKINNON, R (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115, USA.							AGNEW WS, 1988, NATURE, V331, P114, DOI 10.1038/331114a0; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1990, NEURON, V2, P405; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Hille B, 1984, IONIC CHANNELS EXCIT, P426; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MASSEFSKI W, 1990, SCIENCE, V249, P449; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; OLIVA C, 1991, Biophysical Journal, V59, p450A; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3	23	808	825	0	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					232	235		10.1038/350232a0	http://dx.doi.org/10.1038/350232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706481				2022-12-28	WOS:A1991FC77900058
J	SPERTINI, O; KANSAS, GS; MUNRO, JM; GRIFFIN, JD; TEDDER, TF				SPERTINI, O; KANSAS, GS; MUNRO, JM; GRIFFIN, JD; TEDDER, TF			REGULATION OF LEUKOCYTE MIGRATION BY ACTIVATION OF THE LEUKOCYTE ADHESION MOLECULE-1 (LAM-1) SELECTIN	NATURE			English	Article							NODE HOMING RECEPTOR; HIGH ENDOTHELIAL VENULES; PROTEIN KINASE-C; INTERACTION DOMAINS; HUMAN HOMOLOG; LYMPHOCYTES; LFA-1; PHOSPHORYLATION; MECHANISM; MAC-1	A CENTRAL feature of host defence is the ability of leukocytes to enter tissues in response to immune or inflammatory stimuli. The leukocyte adhesion molecule-1 (LAM-1) regulates the migration of human leukocytes by mediating the binding both of lymphocytes to high endothelial venules of peripheral lymph nodes and of neutrophils to endothelium at inflammatory sites 1-10. As lymphocytes and neutrophils express the same LAM-1 protein 11,12, it is not clear how lineage-specific differences in leukocyte migration are controlled. We now report that the affinity of LAM-1 for a carbohydrate-based ligand, PPME 13-16, is dramatically increased following lymphocyte and neutrophil activation by lineage-specific stimuli. In addition, activation of lymphocytes by physiological stimuli enhanced LAM-1-dependent binding to high endothelial venules. Thus, transient changes in LAM-1 affinity after leukocyte stimulation probably directly influence leukocyte migration.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	SPERTINI, O (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115, USA.							BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GLABE CG, 1983, J CELL SCI, V61, P475; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; HAMANN A, 1988, J IMMUNOL, V140, P693; HUCKLE WR, 1988, J BIOL CHEM, V263, P3296; JALKANEN ST, 1985, BLOOD, V66, P577; JUTILA MA, 1990, BLOOD, V76, P178; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; ORD DC, 1990, J BIOL CHEM, V265, P7760; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1989, J IMMUNOL, V142, P1895; ROUIS M, 1986, EXP CELL RES, V164, P556, DOI 10.1016/0014-4827(86)90054-6; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPERTINI O, IN PRESS LEUKEMIA; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1987, BLOOD, V70, P1842; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TEDER TF, 1990, J IMMUNOL, V144, P532; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2291; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713	30	284	306	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					691	694		10.1038/349691a0	http://dx.doi.org/10.1038/349691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1705015				2022-12-28	WOS:A1991EY62700046
J	AHRINGER, J; KIMBLE, J				AHRINGER, J; KIMBLE, J			CONTROL OF THE SPERM-OOCYTE SWITCH IN CAENORHABDITIS-ELEGANS HERMAPHRODITES BY THE FEM-3 3' UNTRANSLATED REGION	NATURE			English	Article							SEX-DETERMINATION GENE; C-ELEGANS; SPERMATOGENESIS; SEQUENCES	IN the Caenorhabditis elegans hermaphrodite germ line, sperm and then oocytes are made from a common pool of germ-cell precursors. The decision to differentiate as a sperm or an oocyte is regulated by the sex-determining gene, fem-3. Expression of fem-3 in the hermaphrodite germ line directs spermatogenesis and must be negatively regulated to allow the switch to oogenesis1,2. In adult hermaphrodites (which are producing oocytes), most fem-3 RNA is found in the germ line3, consistent with both the requirement for fem-3 in hermaphrodite spermatogenesis and the maternal effects of fem-3 on embryonic sex determination1,2. Whereas loss-of-function mutants in fem-3 produce only oocytes, hermaphrodites carrying any of nine fem-3 gain-of-function (gf) mutations make none; instead sperm are produced continuously and in vast excess over wild-type amounts1. Genetic analyses suggest that fem-3(gf) mutations have escaped a negative control required for the switch to oogenesis1. Here we report that all nine fem-3(gf) mutants carry sequence alterations in the fem-3 3' untranslated region (3' UTR). There is no increase in the steady-state level of fem-3(gf) RNA over wild-type, but there is an increase in the polyadenylation of fem-3(gf) RNA that is coincident with the unregulated fem-3 activity. Results of a titration experiment support the hypothesis that a regulatory factory may bind the fem-3 3' UTR. We speculate that fem-3 RNA is regulated through its 3' UTR by binding a factor that inhibits translation, and discuss the idea that this control may be part of a more general regulation of maternal RNAs.	UNIV WISCONSIN, GRAD SCH, MOLEC BIOL LAB, 1525 LINDEN DR, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Ahringer, Julie/0000-0002-7074-4051				BARTON MK, 1987, GENETICS, V115, P107; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DONIACH T, 1986, GENETICS, V114, P53; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HODGKIN J, 1986, GENETICS, V114, P15; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; SCHEDL T, 1988, GENETICS, V119, P43; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VOURNAKIS JN, 1975, P NATL ACAD SCI USA, V72, P2959, DOI 10.1073/pnas.72.8.2959; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4	16	193	198	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 24	1991	349	6307					346	348		10.1038/349346a0	http://dx.doi.org/10.1038/349346a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702880				2022-12-28	WOS:A1991EU50100058
J	SHIBUKI, K; OKADA, D				SHIBUKI, K; OKADA, D			ENDOGENOUS NITRIC-OXIDE RELEASE REQUIRED FOR LONG-TERM SYNAPTIC DEPRESSION IN THE CEREBELLUM	NATURE			English	Article							PURKINJE-CELLS; ACTIVATION; RAT	CONJUNCTIVE stimulation of climbing and parallel fibres in the cerebellum evokes a long-term depression of parallel-fibre Purkinje-cell transmission 1,2, a phenomenon implicated as the cellular mechanism for cerebellar motor learning 3. It is suspected that the increase in cyclic GMP concentration that occurs after activation of climbing fibres 4 is required to evoke long-term depression 3. Excitatory amino acids are known to cause the release of nitric oxide (NO), resulting in elevation of the cGMP level in the cerebellum 5. Here we report that endogenous NO is released after stimulation of climbing fibres, that long-term depression evoked by conjunctive stimulation of parallel and climbing fibres is blocked by haemoglobin (which strongly binds NO) or L-N(G)-monomethyl-arginine (an inhibitor of NO synthase), and that exogenous NO or cGMP can substitute for the stimulation of climbing fibres to cause long-term depression in rat cerebellar slices. These results demonstrate that the release of endogenous NO is essential for the induction of synaptic plasticity in the cerebellum.			SHIBUKI, K (corresponding author), INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL NETWORKS LAB,WAKO,SAITAMA 35101,JAPAN.							BIGGIO G, 1976, BRAIN RES, V107, P365, DOI 10.1016/0006-8993(76)90233-X; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; DECAMILLI P, 1984, NEUROSCIENCE, V11, P761, DOI 10.1016/0306-4522(84)90193-3; DEVENTE J, 1989, BRAIN RES, V504, P332, DOI 10.1016/0006-8993(89)91380-2; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1990, Neuroreport, V1, P129; KARACHOT L, 1987, EXP BRAIN RES, V66, P229; KNOPFEL T, 1990, EUR J NEUROSCI, V2, P726, DOI 10.1111/j.1460-9568.1990.tb00463.x; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; SHIBUKI K, 1990, NEUROSCI LETT, V113, P34, DOI 10.1016/0304-3940(90)90490-Z	18	837	849	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					326	328		10.1038/349326a0	http://dx.doi.org/10.1038/349326a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702879				2022-12-28	WOS:A1991EU50100051
J	CRIQUI, MH; LANGER, RD; FRONEK, A; FEIGELSON, HS; KLAUBER, MR; MCCANN, TJ; BROWNER, D				CRIQUI, MH; LANGER, RD; FRONEK, A; FEIGELSON, HS; KLAUBER, MR; MCCANN, TJ; BROWNER, D			MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT CLAUDICATION; RISK-FACTORS; DEFINED POPULATION; PREVALENCE; REGRESSION; CESSATION; SMOKING; FATE; MEN	Background. Previous investigators have observed a doubling of the mortality rate among patients with intermittent claudication, and we have reported a fourfold increase in the overall mortality rate among subjects with large-vessel peripheral arterial disease, as diagnosed by noninvasive testing. In this study, we investigated the association of large-vessel peripheral arterial disease with rates of mortality from all cardiovascular diseases and from coronary heart disease. Methods. We examined 565 men and women (average age, 66 years) for the presence of large-vessel peripheral arterial disease by means of two noninvasive techniques measurement of segmental blood pressure and determination of flow velocity by Doppler ultrasound. We identified 67 subjects with the disease (11.9 percent), whom we followed prospectively for 10 years. Results. Twenty-one of the 34 men (61.8 percent) and 11 of the 33 women (33.3 percent) with large-vessel peripheral arterial disease died during follow-up, as compared with 31 of the 183 men (16.9 percent) and 26 of the 225 women (11.6 percent) without evidence of peripheral arterial disease. After multivariate adjustment for age, sex, and other risk factors for cardiovascular disease, the relative risk of dying among subjects with large-vessel peripheral arterial disease as compared with those with no evidence of such disease was 3.1 (95 percent confidence interval, 1.9 to 4.9) for deaths from all causes, 5.9 (95 percent confidence interval, 3.0 to 11.4) for all deaths from cardiovascular disease, and 6.6 (95 percent confidence interval, 2.9 to 14.9) for deaths from coronary heart disease. The relative risk of death from causes other than cardiovascular disease was not significantly increased among the subjects with large-vessel peripheral arterial disease. After the exclusion of subjects who had a history of cardiovascular disease at base line, the relative risks among those with large-vessel peripheral arterial disease remained significantly elevated. Additional analyses revealed a 15-fold increase in rates of mortality due to cardiovascular disease and coronary heart disease among subjects with large-vessel peripheral arterial disease that was both severe and symptomatic. Conclusions. Patients with large-vessel peripheral arterial disease have a high risk of death from cardiovascular causes.	UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV HLTH CARE SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV CARDIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT SURG,DIV GEN SURG,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	CRIQUI, MH (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV EPIDEMIOL 0607,LA JOLLA,CA 92093, USA.				NHLBI NIH HHS [HL 22255, HL 42973] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022255, R01HL042973] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1985, CIRCULATION, V72, P768, DOI 10.1161/01.CIR.72.4.768; CRIQUI MH, 1990, CIRCULATION, V82, P2246, DOI 10.1161/01.CIR.82.6.2246; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; FRONEK A, 1973, AM J SURG, V126, P205, DOI 10.1016/S0002-9610(73)80154-0; FRONEK A, 1976, CIRCULATION, V53, P957, DOI 10.1161/01.CIR.53.6.957; FRONEK A, 1989, NONINVASIVE DIAGNOST, P88; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; HUGHSON WG, 1978, BRIT MED J, V1, P1377, DOI 10.1136/bmj.1.6124.1377; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; JONASON T, 1987, ACTA MED SCAND, V221, P253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PEABODY CN, 1974, ARCH SURG-CHICAGO, V109, P693; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STRANDNESS DE, 1969, PERIPHERAL ARTERIAL; WINSOR T, 1950, AM J MED SCI, V220, P117, DOI 10.1097/00000441-195008000-00001; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1975, DHEW NIH75628 PUBL, V1; 1989, DHHS PHS891260 DEP H; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1967, JAMA-J AM MED ASSOC, V202, P1028; 1984, JAMA-J AM MED ASSOC, V251, P351; 1979, CIRCULATION, V60, P427	30	1932	2013	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					381	386		10.1056/NEJM199202063260605	http://dx.doi.org/10.1056/NEJM199202063260605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729621				2022-12-28	WOS:A1992HC38600005
J	BERENSON, R; HOLAHAN, J				BERENSON, R; HOLAHAN, J			SOURCES OF THE GROWTH IN MEDICARE PHYSICIAN EXPENDITURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									URBAN INST,CTR POLICY,2100 M ST NW,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,SCH MED,WASHINGTON,DC 20052	Urban Institute; George Washington University								BERENSON R, 1990, 398301 URB I WORK PA; CAHILL KR, 1989, OCT C RES SERV REP C; KAY T, 1990, HLTH CARE FINANCING, V2, P133; MCMENAMIN P, 1988, CHANGES MEDICARE B; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; 1988, ANN REPORT C; 1990, ANN REPORT C	7	47	47	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					687	691		10.1001/jama.267.5.687	http://dx.doi.org/10.1001/jama.267.5.687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1731136				2022-12-28	WOS:A1992HB35400027
J	AACH, RD; GIRARD, DE; HUMPHREY, H; MCCUE, JD; REUBEN, DB; SMITH, JW; WALLENSTEIN, L; GINSBURG, J; DALEY, D				AACH, RD; GIRARD, DE; HUMPHREY, H; MCCUE, JD; REUBEN, DB; SMITH, JW; WALLENSTEIN, L; GINSBURG, J; DALEY, D			ALCOHOL AND OTHER SUBSTANCE-ABUSE AND IMPAIRMENT AMONG PHYSICIANS IN RESIDENCY TRAINING	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL-STUDENTS	Substance abuse and impairment are serious societal problems. Physicians have historically had high rates of substance abuse, which has been viewed as an occupational hazard. Most authorities agree that the rate of alcoholism among practicing physicians is similar to that among control populations and that the rates of other substance abuse are greater, although some studies have shown no difference. Data about substance abuse among residents in training are limited but suggest that the use of benzodiazepines is greater than that among aged-matched peers, whereas the use of alcohol is similar between the two groups. Medical institutions, including those with teaching programs, have legal and ethical responsibilities concerning substance abuse among current and future physicians. Many training programs, however, do not provide educational programs on this subject, do not have faculty trained in substance abuse medicine, and do not have a formal system to address the problem of residents who are suspected or known to be substance abusers. This position paper examines the extent of substance abuse, including alcohol abuse, among physicians in residency training. It outlines approaches to the problem and delineates responsibilities of institutions and residency program directors. Recommendations are made to establish an informational program and a clearly defined, organized process to address the problems of substance abuse among residents. Careful and humane approaches can be used to identify and treat residents with substance abuse problems and thus allowing them to complete their training as competent and drug-free professionals.	ASSOC PROGRAM DIRECTORS INTERNAL MED, 700 13TH ST NW, SUITE 250, WASHINGTON, DC 20005 USA									ANGRES DH, 1989, NEW DIR MENT HLTH SE, V41, P21; [Anonymous], 1973, JAMA, V223, P684; BALDWIN DC, 1991, JAMA-J AM MED ASSOC, V265, P2074, DOI 10.1001/jama.265.16.2074; BIGBY JA, 1989, J GEN INTERN MED, V4, P74, DOI 10.1007/BF02596497; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; Canavan D I, 1983, J Med Soc N J, V80, P369; CLARK DC, 1987, JAMA-J AM MED ASSOC, V257, P2921, DOI 10.1001/jama.257.21.2921; COHEN T, 1986, WASHINGTON POST 0825, V3, P29; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; JOHNSTON LD, 1989, DHHS ADM891638 PUBL; KEEVE JP, 1984, J OCCUP ENVIRON MED, V26, P503; KRIZEK CR, 1989, NEW DIR MENT HLTH SE, V41, P11; LEWY R, 1988, NEW YORK STATE J MED, V88, P553; MADDUX JF, 1986, AM J PSYCHIAT, V143, P187; McAuliffe W E, 1984, Adv Alcohol Subst Abuse, V4, P67; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MORSE RM, 1984, JAMA-J AM MED ASSOC, V251, P743, DOI 10.1001/jama.251.6.743; NESBITT D, 1988, ANN INTERN MED, V109, P154, DOI 10.7326/0003-4819-109-2-154; ROWLEY BD, 1988, J MED EDUC, V63, P759; SHORE JH, 1987, JAMA-J AM MED ASSOC, V257, P2931; SIEGEL BJ, 1988, WESTERN J MED, V148, P593; Talbott G D, 1981, J Med Assoc Ga, V70, P545; TOKARZ JP, 1979, SURVIVAL; VAILLANT GE, 1970, NEW ENGL J MED, V282, P365, DOI 10.1056/NEJM197002122820705; WEBSTER TG, 1983, IMPAIRED PHYSICIAN; WILLIAMS GD, 1987, EPIDEMIOLOGIC B IAAA, V15; 1989, DHHS ADM891636 US DE	29	47	48	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					245	254		10.7326/0003-4819-116-3-245	http://dx.doi.org/10.7326/0003-4819-116-3-245			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728207				2022-12-28	WOS:A1992HB35600011
J	GOLDEN, RL				GOLDEN, RL			OSLER LEGACY - THE CENTENNIAL OF THE PRINCIPLES AND PRACTICE OF MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Article						HISTORY OF MEDICINE; TEXTBOOKS; OSLER, WILLIAM; EDUCATION, MEDICAL		William Osler (1849 to 1919) is the most revered physician of our time. He held successive professorships at McGill University, the University of Pennsylvania, The Johns Hopkins University, and Oxford University. A superb clinician, teacher, researcher, and writer, he combined these talents with a quintessential humanism. Among the most important of Osler's legacies is his textbook, The Principles and Practice of Medicine, now in its centennial year. The book, written in a remarkable literary style, was acclaimed as a masterpiece of precision clarity, and medical information. It went through 16 editions from 1892 to 1947 and quickly became the standard textbook of medicine. Osler's magnum opus profoundly influenced medical philanthropy, including the establishment of the Rockefeller Institute of Medical Research. Its major effect was on the education and practice of generations of physicians in the English-speaking world and beyond. The many translations of The Principles and Practice gave Osler's work a truly global influence.										ABBOTT ME, 1937, B I HIST MED, V5, P765; ABBOTT ME, 1939, CLASSIFIED ANNOTATED; BEAN RB, 1961, W OSLER APHORISMS HI, P210; BLOGG MW, 1921, BIBLIO WRITINGS W OS; BROOKHOUSE HO, 1909, GUYS HOSP GAZ, V23, P420; BURWELL CS, 1959, AM J MED, V21, P811; CUSHING H, 1915, LIFE W OSLER, V1, P351; CUSHING H, 1925, LIFE W OSLER, V1, P349; CUSHING H, 1925, LIFE W OSLER, V1, P339; CUSHING H, 1920, ANN MED HIST, V2, P157; CUSHING H, 1925, LIFE W OSLER, V1, P422; DUGDEON LS, 1902, ST THOMAS HOSP GAZ, V12, P59; Francis W W, 1937, Bull Med Libr Assoc, V26, P1; Garrison Fielding H, 1919, Ann Med Hist, V2, P184; GILCREEST EL, 1926, INT ASS MED MUS B, V9, P409; GOLDEN RL, 1984, HONG KONG LIBRARY AS, V8, P27; GOLDEN RL, 1988, W OSLER ANNOTATED BI, P152; GOLDEN RL, 1982, OSLER ORIENTAL MED, P5; GOLDEN RL, 1990, J HIST MED ALL SCI, V45, P490; GOLDEN RL, 1988, W OSLER ANNOTATED BI, P1394; GOLDEN RL, 1988, W OSLER ANNOTATED BI, P1399; GOLDEN RL, 1988, W OSLER ANNOTATED BI, P1375; Harrell G T, 1973, Bull Hist Med, V47, P545; HARVEY AM, 1967, OSLERS TXB REVISITED, P1; HARVEY AM, 1968, PRINCIPLES PRACTICE; KEATING JM, 1889, CYCLOPAEDIA DISEASES; LAMBERT RH, 1983, T STUD COLL PHYS SUR, V5, P177; LeRoy E C, 1989, Can Bull Med Hist, V6, P57; MacDermot H E, 1934, Ann Med Hist, V6, P224; MACDERMOT HE, 1949, CAN MED ASSOC J, V61, P628; Osler W, 1903, LANCET, V1, P1058; OSLER W, 1969, BIBLIOTHECA OSLERIAN, P3544; OSLER W, 1895, PRINCIPLES PRACTICE, P1077; OSLER W, 1969, BIBLIOTHECA OSLERIAN, pR23; Osler W, 1901, PRINCIPLES PRACTICE, V108; Osler W, 1885, AM J MED SCI, V89, P175; OSLER W, 1892, PRINCIPLES PRACTICE, P529; OSLER W, 1969, BIBLIOTHECA OSLERIAN, P3586; OSLER W, 1969, BIBLIOTHECA OSLERIAN, P3543; OSLER W, 1905, PRINCIPLES PRACTICE, P431; PEPPER W, 1985, SYSTEM PRACTICAL MED; ROBBSMITH AH, 1989, OX MED SCH GAZ, V29, P18; ROBBSMITH AH, 1989, OX MED SCH GAZ, V29, P17; ROBBSMITH AH, 1988, OX MED SCH GAZ, V28, P18; RODIN AE, 1981, OSLERIAN PATHOLOGY A, P5; STERNE L, 1935, TRISTRAM SHANDY, pCH12; TIGERTT WD, 1973, ANN INTERN MED, V79, P460, DOI 10.7326/0003-4819-79-3-460; TOULMIN H, 1926, INT ASS MED MUS B, V9, P229	48	16	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					255	260		10.7326/0003-4819-116-3-255	http://dx.doi.org/10.7326/0003-4819-116-3-255			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728208				2022-12-28	WOS:A1992HB35600012
J	RYAN, ET; PAK, PH; DESANCTIS, RW				RYAN, ET; PAK, PH; DESANCTIS, RW			MYOCARDIAL-INFARCTION MIMICKED BY ACUTE CHOLECYSTITIS	ANNALS OF INTERNAL MEDICINE			English	Note						MYOCARDIAL INFARCTION; CHOLECYSTITIS; ELECTROCARDIOGRAPHY; CHOLECYSTECTOMY; DIAGNOSIS, DIFFERENTIAL	ELECTROCARDIOGRAPHIC CHANGES; DISEASE	We describe a patient with acute cholecystitis whose presenting symptoms and electrocardiographic results mimicked anterior myocardial infarction. Electrocardiographic ST-segment elevations persisted despite angiographically normal coronary arteries and normal cardiac enzyme values. Removal of an acutely inflamed gallbladder resulted in resolution of electrocardiographic abnormalities.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	RYAN, ET (corresponding author), MASSACHUSETTS GEN HOSP, DIV INFECT DIS, FRUIT ST, BOSTON, MA 02114 USA.							DICKERMAN JL, 1989, J AM OSTEOPATH ASSOC, V89, P630; FERGUSON DW, 1988, WESTERN J MED, V148, P664; FULTON MC, 1963, ANN INTERN MED, V59, P730, DOI 10.7326/0003-4819-59-5-730; HAMPTON AG, 1959, ANN INTERN MED, V50, P1135, DOI 10.7326/0003-4819-50-5-1135; HODGE GB, 1947, ARCH SURG-CHICAGO, V55, P710, DOI 10.1001/archsurg.1947.01230080721007; HODGE GB, 1948, SURG GYNECOL OBSTET, V86, P617; KRASNA MJ, 1986, AM SURGEON, V52, P541; TERRADELLAS JB, 1982, CHEST, V81, P444, DOI 10.1378/chest.81.4.444; WALDMAN HM, 1988, CIRCULATION S2, V78, P457; WEIL MH, 1964, ANN INTERN MED, V60, P384, DOI 10.7326/0003-4819-60-3-384	10	25	26	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					218	220		10.7326/0003-4819-116-3-218	http://dx.doi.org/10.7326/0003-4819-116-3-218			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728205				2022-12-28	WOS:A1992HB35600007
J	MASON, JO				MASON, JO			A NATIONAL AGENDA FOR WOMENS HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,WASHINGTON,DC 20201, USA.							[Anonymous], 1988, NEW ENGL J MED; COTTON P, 1992, JAMA-J AM MED ASSOC, V267, P469	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					482	482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ439	1729563				2022-12-28	WOS:A1992GZ43900007
J	BENRUBI, GI				BENRUBI, GI			EUTHANASIA - THE NEED FOR PROCEDURAL SAFEGUARDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							KILL				BENRUBI, GI (corresponding author), UNIV FLORIDA,HLTH SCI CTR,JACKSONVILLE,FL 32209, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COLE JJ, 1989, DEATH STUD, V13, P393, DOI 10.1080/07481188908252317; Hunter S F, 1989, JAMA, V262, P3074, DOI 10.1001/jama.262.21.3074; JONSEN AR, 1988, WESTERN J MED, V149, P195; PARKER M, 1990, J MED ETHICS, V16, P28, DOI 10.1136/jme.16.1.28; REICHEL W, 1989, LANCET, V2, P1321; Schoonheim P L, 1989, J Cancer Educ, V4, P109; SINGER PA, 1988, CAN MED ASSOC J, V138, P1000; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610	10	54	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					197	199		10.1056/NEJM199201163260311	http://dx.doi.org/10.1056/NEJM199201163260311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727551				2022-12-28	WOS:A1992GZ21300011
J	ANDERSON, DC; ASINGER, RW; NEWBURG, SM; FARMER, CC; WANG, K; BUNDLIE, SR; KOLLER, RL; JAGIELLA, WM; KREHER, S; JORGENSEN, CR; SHARKEY, SW; FLAKER, GC; WEBEL, R; NOLTE, B; STEVENSON, P; BYER, J; WRIGHT, W; CHESEBRO, JH; WIEBERS, DO; HOLLAND, AE; MILLER, DM; BARDSLEY, WT; LITIN, SC; MEISSNER, I; ZERBE, DM; MCANULTY, JH; MARCHANT, C; COULL, BM; FELDMAN, G; HAYWARD, A; GANDARA, E; MACMILLAN, K; BLANK, N; LEONARD, AD; KANTER, MC; ISENSEE, LM; QUIROGA, ES; PRESTI, CH; TEGELER, CH; LOGAN, WR; HAMILTON, WP; GREEN, BJ; BACON, RS; REDD, RM; CADELL, DJ; GOMEZ, CR; JANOSIK, DL; LABOVITZ, AJ; KELLEY, RE; CHAHINE, R; CRISTO, L; PALERMO, M; PEREZ, O; FEINBERG, WM; VOLD, BK; KERN, KB; APPLETON, C; MILLER, VT; HOCKERSMITH, CJ; COHEN, BA; MARTIN, GJ; PAWLOW, AJ; HALPERIN, JL; ROTHLAUF, EB; WEINBERGER, JM; GOLDMAN, ME; FUSTER, V; DITTRICH, HC; ROTHROCK, JF; HAGENHOFF, C; HELGASON, CM; KONDOS, GT; HOFF, J; KAUFMANN, L; RABJOHNS, RR; MCRAE, RP; GHALI, J; ADAMS, HP; THEILEN, EO; BILLER, J; BROWN, DD; MARSH, EE; SIRNA, SJ; MITCHELL, VL; ROTHBART, RM; BAILEY, GH; BURKHARDT, C; BLACKSHEAR, JL; WEAVER, L; LEE, G; LANE, G; RUBINO, F; SAFFORD, R; KRONMAL, RA; MCBRIDE, R; ATHEARN, MW; PEARCE, LA; NASCO, E; HART, RG; SHERMAN, CP; SHERMAN, DG; TALBERT, RL; DACY, TL; HEBERLING, PA				ANDERSON, DC; ASINGER, RW; NEWBURG, SM; FARMER, CC; WANG, K; BUNDLIE, SR; KOLLER, RL; JAGIELLA, WM; KREHER, S; JORGENSEN, CR; SHARKEY, SW; FLAKER, GC; WEBEL, R; NOLTE, B; STEVENSON, P; BYER, J; WRIGHT, W; CHESEBRO, JH; WIEBERS, DO; HOLLAND, AE; MILLER, DM; BARDSLEY, WT; LITIN, SC; MEISSNER, I; ZERBE, DM; MCANULTY, JH; MARCHANT, C; COULL, BM; FELDMAN, G; HAYWARD, A; GANDARA, E; MACMILLAN, K; BLANK, N; LEONARD, AD; KANTER, MC; ISENSEE, LM; QUIROGA, ES; PRESTI, CH; TEGELER, CH; LOGAN, WR; HAMILTON, WP; GREEN, BJ; BACON, RS; REDD, RM; CADELL, DJ; GOMEZ, CR; JANOSIK, DL; LABOVITZ, AJ; KELLEY, RE; CHAHINE, R; CRISTO, L; PALERMO, M; PEREZ, O; FEINBERG, WM; VOLD, BK; KERN, KB; APPLETON, C; MILLER, VT; HOCKERSMITH, CJ; COHEN, BA; MARTIN, GJ; PAWLOW, AJ; HALPERIN, JL; ROTHLAUF, EB; WEINBERGER, JM; GOLDMAN, ME; FUSTER, V; DITTRICH, HC; ROTHROCK, JF; HAGENHOFF, C; HELGASON, CM; KONDOS, GT; HOFF, J; KAUFMANN, L; RABJOHNS, RR; MCRAE, RP; GHALI, J; ADAMS, HP; THEILEN, EO; BILLER, J; BROWN, DD; MARSH, EE; SIRNA, SJ; MITCHELL, VL; ROTHBART, RM; BAILEY, GH; BURKHARDT, C; BLACKSHEAR, JL; WEAVER, L; LEE, G; LANE, G; RUBINO, F; SAFFORD, R; KRONMAL, RA; MCBRIDE, R; ATHEARN, MW; PEARCE, LA; NASCO, E; HART, RG; SHERMAN, CP; SHERMAN, DG; TALBERT, RL; DACY, TL; HEBERLING, PA			PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK	ANNALS OF INTERNAL MEDICINE			English	Article						ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; HEART FAILURE, CONGESTIVE; HYPERTENSION; THROMBOEMBOLISM	SYSTEMIC EMBOLIZATION; STROKE; FRAMINGHAM; COMPLICATIONS; TRIAL	Objective: To identify those patients with nonrheumatic atrial fibrillation who are at high risk and those at low risk for arterial thromboembolism. Design: Cohort study of patients assigned to placebo in a randomized clinical trial. Setting: Five hundred sixty-eight inpatients and outpatients with nonrheumatic atrial fibrillation assigned to placebo therapy at 15 U.S. medical centers from 1987 to 1989 in the Stroke Prevention in Atrial Fibrillation study. Patients were followed for a mean of 1.3 years. Measurements: Clinical variables were assessed at study entry and correlated with subsequent ischemic stroke and systemic embolism by multivariate analysis. Main Results: Recent (within 3 months) congestive heart failure, a history of hypertension, and previous arterial thromboembolism were each significantly and independently associated with a substantial risk for thromboembolism (> 7% per year; P less-than-or-equal-to 0.05). The presence of these three independent clinical predictors (recent congestive heart failure, history of hypertension, previous thromboembolism) defined patients with rates of thromboembolism of 2.5% per year (no risk factors), 7.2% per year (one risk factor), and 17.6% per year (two or three risk factors). Nondiabetic patients without these risk factors, comprising 38% of the cohort, had a low risk for thromboembolism (1.4% per year; 95% Cl, 0.05% to 3.7%). Patients without clinical risk factors who were under 60 years of age had no thromboembolic events. Conclusion: Patients with atrial fibrillation at high risk (> 7% per year) and low risk (< 3% per year) for thromboembolism can be identified by readily available clinical variables.	STAT & EPIDEMIOL RES CORP, SPAF STAT COORDINAT CTR, 1107 NE 45TH ST, SUITE 520, SEATTLE, WA 98105 USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN 55415 USA; ABBOTT NW HOSP, MINNEAPOLIS, MN USA; UNIV MISSOURI, COLUMBIA, MO 65201 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; KAISER PERMANENTE, PORTLAND, OR USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; ST JOHNS MERCY MED CTR, ST LOUIS, MO 63141 USA; ST LOUIS UNIV, MED CTR, ST LOUIS, MO 63103 USA; UNIV MIAMI, SCH MED, MIAMI, FL 33152 USA; UNIV ARIZONA, COLL MED, TUCSON, AZ 85721 USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; UNIV CALIF SAN DIEGO, MED CTR, LA JOLLA, CA 92093 USA; UNIV ILLINOIS, COLL MED, CHICAGO, IL 60680 USA; UNIV ILLINOIS, COLL MED, PEORIA, IL 61656 USA; UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA; UNIV COLORADO, COLL MED, BOULDER, CO 80309 USA; MAYO CLIN, JACKSONVILLE, FL USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV TEXAS, HLTH SCI CTR, CTR CLIN COORDINAT, SAN ANTONIO, TX 78284 USA	Hennepin County Medical Center; University of Missouri System; University of Missouri Columbia; Mayo Clinic; Oregon Health & Science University; Kaiser Permanente; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Saint Johns Mercy Medical Center; Saint Louis University; University of Miami; University of Arizona; Northwestern University; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Peoria; University of Iowa; University of Colorado System; University of Colorado Boulder; Mayo Clinic; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio			Fuster, Valentin/H-4319-2015; Halperin, Jonathan/AAJ-4721-2020; Tegeler, Charles/R-3623-2019	Fuster, Valentin/0000-0002-9043-9986; Halperin, Jonathan/0000-0002-8318-5471; 	NINDS NIH HHS [R01-NS-24224] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024224] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1988, LANCET, V2, P349; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; FLEGEL KM, 1987, LANCET, V1, P526; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; HALPERIN JL, 1988, STROKE, V19, P937, DOI 10.1161/01.STR.19.8.937; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCBRIDE R, 1990, STROKE, V21, P538; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; RODSTEIN M, 1989, J INSURANCE MED, V21, P192; WIENER I, 1987, AM J CARDIOL, V59, P177, DOI 10.1016/S0002-9149(87)80102-9; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; YUSUF S, 1990, AM J CARDIOL, V66, P220, DOI 10.1016/0002-9149(90)90592-O	24	442	446	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					1	5		10.7326/0003-4819-116-1-1	http://dx.doi.org/10.7326/0003-4819-116-1-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727091				2022-12-28	WOS:A1992GX15700001
J	BADING, H; GREENBERG, ME				BADING, H; GREENBERG, ME			STIMULATION OF PROTEIN TYROSINE PHOSPHORYLATION BY NMDA RECEPTOR ACTIVATION	SCIENCE			English	Article							LONG-TERM POTENTIATION; SERINE-THREONINE KINASE; NERVOUS-SYSTEM; GENE-PRODUCT; MAP KINASE; INSULIN; ANTAGONIST; EXPRESSION; BLOCKADE; CORTEX	The N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays a key role in synaptic plasticity in the nervous system. After NMDA receptor activation, calcium entry into the postsynaptic neuron is a critical initial event. However, the subsequent mechanisms by which the NMDA receptor signal is processed are incompletely understood. Stimulation of cultured rat hippocampal cells with glutamate resulted in the rapid and transient tyrosine phosphorylation of a 39-kilodalton protein (p39). Tyrosine phosphorylation of p39 was triggered by the NMDA receptor and required an influx of Ca2+ from the extracellular medium. Because p39 was found to be highly related or identical to the microtubule-associated protein 2 kinase, the NMDA receptor signal may be processed by a sequential activation of protein kinases.			BADING, H (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 43855] Funding Source: Medline; NINDS NIH HHS [NS 28829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; BADING H, UNPUB; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Chung J.-H., UNPUB; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GREENGARD P, 1989, NATURE, V340, P554; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSAMONDO AJ, IN PRESS J BIOL CHEM; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Weber M., UNPUB	36	448	455	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					912	914		10.1126/science.1715095	http://dx.doi.org/10.1126/science.1715095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1715095				2022-12-28	WOS:A1991GC15200048
J	PANINABORDIGNON, P; CORRADIN, G; ROOSNEK, E; SETTE, A; LANZAVECCHIA, A				PANINABORDIGNON, P; CORRADIN, G; ROOSNEK, E; SETTE, A; LANZAVECCHIA, A			RECOGNITION BY CLASS-II ALLOREACTIVE T-CELLS OF PROCESSED DETERMINANTS FROM HUMAN SERUM-PROTEINS	SCIENCE			English	Article							MHC CLASS-II; HLA PEPTIDE; ANTIGENS; BINDING; COMPLEXES; MOLECULE; EPITOPES	Alloreactive T cells recognize a complex composed of an allogeneic major histocompatibility complex (MHC) molecule and a peptide derived from the processing of nonpolymorphic proteins. A sizable fraction of MHC class II alloreactive T cells is shown to recognize peptides derived from constitutive processing of human serum proteins. One such epitope is a fragment of human serum albumin. This epitope bound selectively to the human class II molecule DRw11 and was constitutively present on antigen-presenting cells in vivo. These data indicate that, in the case of MHC class II, peptides involved in allorecognition may originate from exogenous proteins.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; CYTEL,LA JOLLA,CA 92037; UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne			Panina, Paola/AAO-4563-2020; Panina, Paola/AAC-2424-2021; Sette, Alessandro/AFO-8916-2022	Panina, Paola/0000-0001-9913-8568; 				BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; DEKOSTER HS, 1989, J EXP MED, V169, P1191, DOI 10.1084/jem.169.3.1191; DEMOTZ S, 1989, J IMMUNOL METHODS, V122, P67, DOI 10.1016/0022-1759(89)90335-9; ECKELS DD, 1988, P NATL ACAD SCI USA, V85, P8191, DOI 10.1073/pnas.85.21.8191; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LIN RH, 1989, EUR J IMMUNOL, V19, P105, DOI 10.1002/eji.1830190117; LOMBARDI G, 1989, J IMMUNOL, V142, P753; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1990, J IMMUNOL, V145, P1850; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PANINABORDIGNON P, UNPUB; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	20	73	73	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1548	1550		10.1126/science.1710827	http://dx.doi.org/10.1126/science.1710827			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1710827				2022-12-28	WOS:A1991FR04000047
J	MICHNICK, SW; ROSEN, MK; WANDLESS, TJ; KARPLUS, M; SCHREIBER, SL				MICHNICK, SW; ROSEN, MK; WANDLESS, TJ; KARPLUS, M; SCHREIBER, SL			SOLUTION STRUCTURE OF FKBP, A ROTAMASE ENZYME AND RECEPTOR FOR FK506 AND RAPAMYCIN	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; PEPTIDYL-PROLYL ISOMERASE; CYTOSOLIC BINDING-PROTEIN; LAC REPRESSOR HEADPIECE; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; IMMUNOSUPPRESSANT FK506; CYCLOSPORIN-A; CONFORMATION; CYCLOPHILIN	Immunophilins, when complexed to immunosuppressive ligands, appear to inhibit signal transduction pathways that result in exocytosis and transcription. The solution structure of one of these, the human FK506 and rapamycin binding protein (FKBP), has been determined by nuclear magnetic resonance (NMR). FKBP has a previously unobserved antiparallel beta-sheet folding topology that results in a novel loop crossing and produces a large cavity lined by a conserved array of aromatic residues; this cavity serves as the rotamase active site and drug-binding pocket. There are other significant structural features (such as a protruding positively charged loop and an apparently flexible loop) that may be involved in the biological activity of FKBP.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030804, R37GM038627, R01GM038627, R01GM030804] Funding Source: NIH RePORTER; NCRR NIH HHS [I-S10-RR04870] Funding Source: Medline; NIGMS NIH HHS [GM-38627, GM-30804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALBERS MW, IN PRESS BIOMED CHEM; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CHIRGADZE YN, 1987, ACTA CRYSTALLOGR A, V43, P405, DOI 10.1107/S0108767387099239; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; FISHER G, 1989, NATURE, V337, P476; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GOEBL MG, 1991, CELL, V64, P1051, DOI 10.1016/0092-8674(91)90258-Z; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; HULTSCH T, IN PRESS P NATL ACAD; JIN Y, UNPUB; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MORAS D, 1975, J BIOL CHEM, V250, P9137; NEUHAUS D, 1985, EUR J BIOCHEM, V151, P257, DOI 10.1111/j.1432-1033.1985.tb09096.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, IN PRESS COMPUTATION; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; ROSEN MK, IN PRESS BIOCHEMISTR; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P601, DOI 10.1002/bip.360240402	42	291	303	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					836	839		10.1126/science.1709301	http://dx.doi.org/10.1126/science.1709301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709301				2022-12-28	WOS:A1991FL12300044
J	BLACKBURN, EH				BLACKBURN, EH			STRUCTURE AND FUNCTION OF TELOMERES	NATURE			English	Review							TERMINAL TRANSFERASE-ACTIVITY; OXYTRICHA MACRONUCLEAR DNA; SACCHAROMYCES-CEREVISIAE; YEAST TELOMERES; 3' TERMINUS; SEQUENCES; IDENTIFICATION; CHROMOSOMES; ENDS; TETRAHYMENA	The DNA of telomeres - the terminal DNA-protein complexes of chromosomes - differs notably from other DNA sequences in both structure and function. Recent work has highlighted its remarkable mode of synthesis by the ribonucleoprotein reverse transcriptase, telomerase 1-4, as well as its ability to form unusual structures in vitro. Moreover, telomere synthesis by telomerase has been shown to be essential for telomere maintenance and long-term viability.	DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143		BLACKBURN, EH (corresponding author), DEPT MICROBIOL & IMMUNOL,BOX 0414,SAN FRANCISCO,CA 94143, USA.		Vidaud, Michel/O-7346-2017; Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; BLACKBURN EH, 1990, SCIENCE, V249, P489, DOI 10.1126/science.2200120; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUDARF M, 1987, NUCLEIC ACIDS RES, V15, P6273, DOI 10.1093/nar/15.15.6273; BUDARF M, 1986, J BIOL CHEM, V261; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; FRANKKAMENETSKII M, 1989, NATURE, V342, P737, DOI 10.1038/342737a0; GILLEY D, 1988, MOL CELL BIOL, V8, P4765, DOI 10.1128/MCB.8.11.4765; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GOTTSCHLING DE, 1990, CELL, V63; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HARDIN CC, IN PRESS BIOCHEMISTR; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON E, 1988, EUKARYOTIC DNA REPLI, V6, P453; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; JGER D, 1989, EMBO J, V8, P247; KAMPER J, 1989, MOL CELL BIOL, V9, P3931; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; LUSTIG AJ, 1990, MOLEC CELL BIOL, V250, P549; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUNDQUIST WI, IN PRESS NUCLEIC ACI, V5; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; USDIN K, 1988, P NATL ACAD SCI USA, V85, P4416, DOI 10.1073/pnas.85.12.4416; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1989, NUCLEIC ACIDS RES, V17, P6299, DOI 10.1093/nar/17.15.6299; ZAHLER AM, IN PRESS NATURE; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	72	3016	3150	13	572	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					569	573		10.1038/350569a0	http://dx.doi.org/10.1038/350569a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1708110				2022-12-28	WOS:A1991FH11200047
J	PICKER, LJ; KISHIMOTO, TK; SMITH, CW; WARNOCK, RA; BUTCHER, EC				PICKER, LJ; KISHIMOTO, TK; SMITH, CW; WARNOCK, RA; BUTCHER, EC			ELAM-1 IS AN ADHESION MOLECULE FOR SKIN-HOMING T-CELLS	NATURE			English	Article							LEUKOCYTE ADHESION; ENDOTHELIAL ACTIVATION; LYMPH-NODES; LYMPHOCYTES; RECEPTOR; PROTEINS; ANTIGEN; CD2	ENDOTHELIAL cell leukocyte adhesion molecule-1 (ELAM-1) has been described as an inducible endothelial cell-adhesion molecule for neutrophils, and is believed to have a key role in the extravasation of these cells at sites of acute inflammation 1-3. Here we report that ELAM-1-transfected COS cells also bind a unique skin-associated subset of circulating memory T cells defined by the expression of the cutaneous lymphocyte-associated antigen 4,5. T cells expressing this antigen bind at least as well as neutrophils to expressed ELAM-1, whereas other lymphocytes in the peripheral blood bind poorly, or not at all. Immunohistological survey of chronically inflamed tissue specimens revealed that vascular expression of ELAM-1 occurs at cutaneous sites in preference to noncutaneous sites. We conclude that at sites of chronic inflammation, ELAM-1 may function as a skin vascular addressin, a tissue-selective endothelial cell-adhesion molecule for skin-homing memory T lymphocytes.	VET ADM MED CTR,CTR MOLEC MED,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,CTR DIGEST DIS,STANFORD,CA 94305; BAYLOR UNIV,DEPT PEDIAT,LEUKOCYTE BIOL SECT,HOUSTON,TX 77030	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Baylor University	PICKER, LJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.							BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHIN W, 1980, GASTROENTEROLOGY, V79, P1231; CHIN YH, 1990, J INVEST DERMATOL, V94, P413, DOI 10.1111/1523-1747.ep12874486; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; ISSEKUTZ TB, 1980, CELL IMMUNOL, V54, P79, DOI 10.1016/0008-8749(80)90191-4; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MUNRO JM, 1989, AM J PATHOL, V135, P121; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; SAKSTEIN R, 1988, J INVEST DERMATOL, V91, P423; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TERSTAPPEN WMM, 1990, J LEUKOCYTE BIOL, V48, P138; WELLICOME SM, 1990, J IMMUNOL, V144, P2558	23	812	840	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					796	799		10.1038/349796a0	http://dx.doi.org/10.1038/349796a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705666				2022-12-28	WOS:A1991EZ66600058
J	SCHREIBER, SL				SCHREIBER, SL			CHEMISTRY AND BIOLOGY OF THE IMMUNOPHILINS AND THEIR IMMUNOSUPPRESSIVE LIGANDS	SCIENCE			English	Article							A-BINDING-PROTEIN; CIS-TRANS-ISOMERASE; T-CELL ACTIVATION; PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORINE-A; CYCLOPHILIN BINDING; TRANSPLANTATION; FK-506; FK506; GENE	Cyclosporin A, FK506, and rapamycin are inhibitors of specific signal transduction pathways that lead to T lymphocyte activation. These immunosuppressive agents bind with high affinity to cytoplasmic receptors termed immunophilins (immunosuppressant binding proteins). Studies in this area have focused on the structural basis for the molecular recognition of immunosuppressants by immunophilins and the biological consequences of their interactions. Defining the biological roles of this emerging family of receptors and their ligands may illuminate the process of protein trafficking in cells and the mechanisms of signal transmission through the cytoplasm.			SCHREIBER, SL (corresponding author), HARVARD UNIV,CHEM,CAMBRIDGE,MA 02138, USA.		Agena, Fabiana A/C-5819-2015	Agena, Fabiana A/0000-0002-4526-4857	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, IN PRESS P NATL ACAD; BIERER BE, UNPUB; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEVLIN JP, 1989, TETRAHEDRON, V45, P4327, DOI 10.1016/S0040-4020(01)89072-4; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; DURETTE PL, 1988, TRANSPLANT P, V20, P51; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISCHER G, 1989, FEBS LETT, V250, P267, DOI 10.1016/0014-5793(89)80735-5; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, P35; FRETZ H, 1990, J AM CHEM SOC, V87, P9231; GALARDY RE, 1982, INT J PEPT PROT RES, V19, P123; GALAT A, UNPUB; GUNASEKERA SP, 1990, J ORG CHEM, V55, P4912, DOI 10.1021/jo00303a029; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HANDSCHUMACHER RE, 1988, TRANSPLANTATION, V46, pS29; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3831; HULTSCH T, 1990, J IMMUNOL, V144, P2659; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; KNAPP W, 1989, IMMUNOL TODAY, V10, P253, DOI 10.1016/0167-5699(89)90135-7; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MATILA PS, IN PRESS EMBO J; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; NAKATSUKA M, 1990, J AM CHEM SOC, V112, P5583, DOI 10.1021/ja00170a024; NEMOTO K, 1987, TRANSPLANT P, V19, P3520; OATES JA, 1989, NEW ENGL J MED, V321, P1725; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1988, TETRAHEDRON LETT, V29, P6577, DOI 10.1016/S0040-4039(00)82401-6; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SHOWSTACK J, 1989, NEW ENGL J MED, V321, P1086, DOI 10.1056/NEJM198910193211605; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; STARZL TE, 1990, JAMA-J AM MED ASSOC, V264, P63, DOI 10.1001/jama.264.1.63; STARZL TE, IN PRESS TRANSPLANTA; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0	57	1436	1508	5	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 18	1991	251	4991					283	287		10.1126/science.1702904	http://dx.doi.org/10.1126/science.1702904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1702904				2022-12-28	WOS:A1991ET67800024
J	INGBER, D; FUJITA, T; KISHIMOTO, S; SUDO, K; KANAMARU, T; BREM, H; FOLKMAN, J				INGBER, D; FUJITA, T; KISHIMOTO, S; SUDO, K; KANAMARU, T; BREM, H; FOLKMAN, J			SYNTHETIC ANALOGS OF FUMAGILLIN THAT INHIBIT ANGIOGENESIS AND SUPPRESS TUMOR-GROWTH	NATURE			English	Article									BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; TAKEDA CHEM IND LTD,DIV RES & DEV,OSAKA 532,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Takeda Chemical Industries	INGBER, D (corresponding author), CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115, USA.		Ingber, Donald E/AAC-5894-2019					CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; DIPAOLO JA, 1958, ANTIBIOT ANNU, P541; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; INGBER D, 1988, LAB INVEST, V59, P44; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; KILLOUGH JH, 1952, SCIENCE, V115, P71, DOI 10.1126/science.115.2977.71; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCCOWEN MC, 1951, SCIENCE, V113, P202, DOI 10.1126/science.113.2930.202; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; OIKAWA T, 1989, J ANTIBIOT, V42, P1202, DOI 10.7164/antibiotics.42.1202; TANAKA NG, 1989, CANCER RES, V49, P6727; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807	20	1221	1353	1	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 6	1990	348	6301					555	557		10.1038/348555a0	http://dx.doi.org/10.1038/348555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL760	1701033				2022-12-28	WOS:A1990EL76000069
J	WALZ, G; ARUFFO, A; KOLANUS, W; BEVILACQUA, M; SEED, B				WALZ, G; ARUFFO, A; KOLANUS, W; BEVILACQUA, M; SEED, B			RECOGNITION BY ELAM-1 OF THE SIALYL-LEX DETERMINANT ON MYELOID AND TUMOR-CELLS	SCIENCE			English	Article									MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	WALZ, G (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36028] Funding Source: Medline; NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRECHTSEN M, 1989, BRIT J HAEMATOL, V72, P312, DOI 10.1111/j.1365-2141.1989.tb07710.x; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BALL ED, 1983, J IMMUNOL, V130, P2937; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIOU D, 1987, BIOCHIM BIOPHYS ACTA, V913, P308, DOI 10.1016/0167-4838(87)90140-3; BOLSCHER JGM, 1989, CLIN EXP METASTAS, V7, P557, DOI 10.1007/BF01753815; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; FORSYTH KD, 1989, EUR J IMMUNOL, V19, P1331, DOI 10.1002/eji.1830190727; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GOOI HC, 1983, EUR J IMMUNOL, V13, P306, DOI 10.1002/eji.1830130407; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HANISCH FG, 1988, CARBOHYD RES, V178, P29, DOI 10.1016/0008-6215(88)80100-9; HUANG LC, 1983, BLOOD, V61, P1020; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAGNANI JL, 1984, ARCH BIOCHEM BIOPHYS, V233, P501, DOI 10.1016/0003-9861(84)90473-9; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; MITSAKOS A, 1988, BIOL CHEM H-S, V369, P661, DOI 10.1515/bchm3.1988.369.2.661; MITSAKOS A, 1989, BIOL CHEM H-S, V370, P239, DOI 10.1515/bchm3.1989.370.1.239; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SYMINGTON FW, 1984, J BIOL CHEM, V259, P6008; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TETTEROO PAT, 1984, EUR J IMMUNOL, V14, P1089, DOI 10.1002/eji.1830141205; WALZ G, UNPUB; WIERUSZESKI JM, 1988, FEBS LETT, V238, P390, DOI 10.1016/0014-5793(88)80518-0	43	887	972	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 23	1990	250	4984					1132	1135		10.1126/science.1701275	http://dx.doi.org/10.1126/science.1701275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ581	1701275				2022-12-28	WOS:A1990EJ58100035
J	STEVENSON, H; GAZDAR, AF; PHELPS, R; LINNOILA, RI; IHDE, DC; GHOSH, B; WALSH, T; WOODS, EL; OIE, H; OCONNOR, T; MAKUCH, R; KRAMER, BS; MULSHINE, JL				STEVENSON, H; GAZDAR, AF; PHELPS, R; LINNOILA, RI; IHDE, DC; GHOSH, B; WALSH, T; WOODS, EL; OIE, H; OCONNOR, T; MAKUCH, R; KRAMER, BS; MULSHINE, JL			TUMOR-CELL LINES ESTABLISHED INVITRO - AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NON-SMALL-CELL LUNG-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article									NATL NAVAL MED CTR, NCI,MED ONCOL BRANCH,BIOTHERAPY SECT,BLDG 8, ROOM 5101, BETHESDA, MD 20814 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA; YALE UNIV, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA; Yale University								AAPRO MS, 1987, J CLIN ONCOL, V5, P890, DOI 10.1200/JCO.1987.5.6.890; BERTONCELLO I, 1982, BRIT J CANCER, V45, P803, DOI 10.1038/bjc.1982.131; BROWER M, 1986, CANCER RES, V46, P798; CARNEY DN, 1985, CANCER RES, V45, P2913; COX DR, 1972, J R STAT SOC B, V34, P187; DITTRICH C, 1985, BRIT J CANCER, V52, P197, DOI 10.1038/bjc.1985.178; EAGAN RT, 1979, CANCER, V44, P1125, DOI 10.1002/1097-0142(197909)44:3<1125::AID-CNCR2820440348>3.0.CO;2-4; ERWIN TJ, 1982, P AN M AM SOC CLIN, V1, P195; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1986, CANCER RES, V46, P6011; GAZDAR AF, 1988, BIOL LUNG CANCER DIA, P1; HUG V, 1984, CONTROVERSIES BREAST, P553; IHDE DC, 1987, P AN M AM SOC CLIN, V6, P181; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAD T, 1988, J CLIN ONCOL, V6, P9; LEHMAN EL, 1975, STATISTICAL METHODS, P55; LONGEVAL E, 1982, CANCER, V50, P2751, DOI 10.1002/1097-0142(19821215)50:12<2751::AID-CNCR2820501210>3.0.CO;2-3; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARTINI N, 1977, J THORAC CARDIOV SUR, V74, P499; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MILLER OL, 1984, SURG ONCOL, V30, P435; MINNA J, 1988, ACCOMPLISHMENTS CANC, P155; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; MULSHINE J, 1987, P AN M AM SOC CLIN, V6, P713; MULSHINE JL, 1986, J CLIN ONCOL, V4, P1704, DOI 10.1200/JCO.1986.4.11.1704; MULSHINE JL, 1988, THORACIC ONCOLOGY, P220; NAKANISHI Y, 1988, BIOL LUNG CANCER DIA, P59; NOMURA Y, 1989, CANCER RES, V49, P5288; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Reynolds C P, 1980, Trans Assoc Am Physicians, V93, P203; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; STEVENSON HC, 1989, J CLIN ONCOL, V7, P923, DOI 10.1200/JCO.1989.7.7.923; SUTHERLAND CM, 1983, SURGERY, V94, P370; TWEEDDALE ME, 1987, BLOOD, V69, P1307; 1978, STAGING LUNG CANCER; 1989, CANCER FACTS FIGURES, P9	38	48	48	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1990	113	10					764	770		10.7326/0003-4819-113-10-764	http://dx.doi.org/10.7326/0003-4819-113-10-764			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH363	1700655				2022-12-28	WOS:A1990EH36300008
J	BLEICHER, PA; BALK, SP; HAGEN, SJ; BLUMBERG, RS; FLOTTE, TJ; TERHORST, C				BLEICHER, PA; BALK, SP; HAGEN, SJ; BLUMBERG, RS; FLOTTE, TJ; TERHORST, C			EXPRESSION OF MURINE CD1 ON GASTROINTESTINAL EPITHELIUM	SCIENCE			English	Article									MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,MOLEC IMMUNOL LAB,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT HEMATOL & ONCOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT GASTROENTEROL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	BLEICHER, PA (corresponding author), MASSACHUSETTS GEN HOSP,DEPT DERMATOL,WELLMAN LABS,BOSTON,MA 02114, USA.				NCI NIH HHS [CA 01310] Funding Source: Medline; NIAMS NIH HHS [AR 01805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; AMIOT M, 1987, BLOOD, V70, P676; ARUFFO A, 1989, J IMMUNOL, V143, P1723; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BLEICHER PA, UNPUB; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; HAGEN SJ, 1988, J HISTOCHEM CYTOCHEM, V36, P717, DOI 10.1177/36.7.3290330; HAGEN SJ, 1987, CELL TISSUE RES, V248, P709, DOI 10.1007/BF00216503; HARLOW E, 1988, ANTIBODIES LAB MANUA, P367; HAVRAN WL, 1989, P NATL ACAD SCI USA, V86, P4185, DOI 10.1073/pnas.86.11.4185; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; KONING F, 1988, J IMMUNOL, V141, P2057; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LERCH PG, 1986, MOL IMMUNOL, V23, P131, DOI 10.1016/0161-5890(86)90034-9; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MCCONNELL TJ, 1989, J IMMUNOL, V142, P2924; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; Sambrook J, 1989, MOL CLONING LABORATO; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SMALL TN, 1987, J IMMUNOL, V138, P2864; STALLCUP KC, 1981, J IMMUNOL, V127, P923; STEINER G, 1988, EUR J IMMUNOL, V18, P1323, DOI 10.1002/eji.1830180904; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERHORST C, 1983, J IMMUNOL, V131, P851; VANDERIJN M, 1983, J IMMUNOL, V131, P851; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VINEY JL, 1989, IMMUNOLOGY, V66, P583; YU CY, 1989, EMBO J, V8, P3727, DOI 10.1002/j.1460-2075.1989.tb08548.x	42	220	229	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 2	1990	250	4981					679	682		10.1126/science.1700477	http://dx.doi.org/10.1126/science.1700477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EF904	1700477				2022-12-28	WOS:A1990EF90400037
J	BREDT, DS; HWANG, PM; SNYDER, SH				BREDT, DS; HWANG, PM; SNYDER, SH			LOCALIZATION OF NITRIC-OXIDE SYNTHASE INDICATING A NEURAL ROLE FOR NITRIC-OXIDE	NATURE			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								BRECT DS, 1989, P NATL ACAD SCI USA, V86, P9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; DOHI T, 1983, EUR J PHARMACOL, V94, P331, DOI 10.1016/0014-2999(83)90423-5; Ferrendelli J A, 1978, Adv Cyclic Nucleotide Res, V9, P453; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HIBBS JB, 1987, J IMMUNOL, V138, P550; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KWON NS, 1989, J BIOL CHEM, V264, P20496; MARJORIE AA, 1982, P NATL ACAD SCI USA, V79, P1316; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; NOVELLI A, 1987, J NEUROSCI, V7, P40; OSULLIVAN AJ, 1990, J NEUROCHEM, V54, P1805, DOI 10.1111/j.1471-4159.1990.tb01238.x; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; RAMAGOPAL MW, 1989, BRIT J PHARMACOL, V174, P297; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SCHMIDT HHHW, 1989, BIOCHEM BIOPH RES CO, V165, P284, DOI 10.1016/0006-291X(89)91067-X; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TODA N, 1990, JPN J PHARMACOL, V52, P170, DOI 10.1254/jjp.52.170; ZWILLER J, 1981, NEUROSCI LETT, V23, P31	28	2870	2925	0	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 25	1990	347	6295					768	770		10.1038/347768a0	http://dx.doi.org/10.1038/347768a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE659	1700301	Bronze			2022-12-28	WOS:A1990EE65900064
J	HOWSON, CP; FINEBERG, HV				HOWSON, CP; FINEBERG, HV			ADVERSE EVENTS FOLLOWING PERTUSSIS AND RUBELLA VACCINES - SUMMARY OF A REPORT OF THE INSTITUTE-OF-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In August 1991, the Institute of Medicine released a report entitled Adverse Effects of Pertussis and Rubella Vaccines, which examined 18 adverse events in relation to diphtheria-tetanus-pertussis (DTP) vaccine and four adverse events in relation to the currently used rubella vaccine strain, RA 27/3. The committee spent 20 months reviewing a wide range of information sources, including case series and individual case reports, both published and unpublished, epidemiologic studies, studies in animals, and other laboratory studies. The committee found that the evidence indicates a causal relation between DTP vaccine and anaphylaxis and between the pertussis component of DTP vaccine and extended periods of inconsolable crying or screaming. The committee also reported that the evidence indicates a causal relation between the rubella vaccine and acute arthritis in adult women. The committee found the available evidence weaker but still consistent with a causal relation between DTP vaccine and two conditions-acute encephalopathy and hypotonic, hyporesponsive episodes-and between rubella vaccine and chronic arthritis in adult women. Estimated incidence rates of these adverse events following vaccination are provided, where possible. The committee found that the evidence does not indicate a causal relation between the DTP vaccine and infantile spasms, hypsarrhythmia, Reye's syndrome, and sudden infant death syndrome. The committee found insufficient evidence to indicate either the presence or absence of a causal relation between DTP vaccine and chronic neurologic damage, aseptic meningitis, erythema multiforme or other rash, Guillain-Barre syndrome, hemolytic anemia, juvenile diabetes, learning disabilities and attention-deficit disorder, peripheral mononeuropathy, or thrombocytopenia, and between rubella vaccine and radiculoneuritis and other neuropathies or thrombocytopenic purpura. The committee's evaluative methods are briefly described and a summary of research needs is provided.	NATL ACAD SCI,INST MED,DIV HLTH PROMOT & DIS PREVENT,WASHINGTON,DC 20418; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	National Academies of Sciences, Engineering & Medicine; Harvard University; Harvard T.H. Chan School of Public Health								ALDERSLADE R, 1981, WHOOPING COUGH, P79; Howson CP, 1991, ADVERSE EFFECTS PERT	2	84	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					392	396		10.1001/jama.267.3.392	http://dx.doi.org/10.1001/jama.267.3.392			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727962				2022-12-28	WOS:A1992GY43700037
J	ALDHOUS, P				ALDHOUS, P			AIDS TREATMENT - CONFUSION OVER THERAPY	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					102	102						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729639				2022-12-28	WOS:A1992GY62900011
J	SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML; KINNE, DW				SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML; KINNE, DW			OBESITY AT DIAGNOSIS OF BREAST-CARCINOMA INFLUENCES DURATION OF DISEASE-FREE SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Article						OBESITY; BREAST NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; BODY MASS INDEX; WOMENS HEALTH	POST-MENOPAUSAL WOMEN; BODY-WEIGHT; ESTROGEN-RECEPTORS; CANCER SURVIVAL; MENSTRUAL STATUS; BOUND ESTRADIOL; RISK-FACTORS; DIETARY-FAT; EPIDEMIOLOGY; ASSOCIATION	Objective: To study disease-free survival at 10 years in relation to obesity at the time of diagnosis. Design: A prospective study of consecutively treated patients with primary breast cancer. Setting: Memorial Sloan-Kettering Cancer Center, New York. Patients: Nine hundred twenty-three women treated by mastectomy and axillary dissection. Main Results: Women who were obese (25% or more over optimal weight for height) at the time of primary breast cancer treatment were at significantly greater risk for recurrence (42%) compared with nonobese patients (32%) 10 years after diagnosis (P < 0.01). In multivariate analyses, obesiTy remained a statistically significant prognostic factor after controLling for measured tumor size, number of positive axillary lymph nodes, age at diagnosis, and adjuvant chemotherapy with a hazard ratio of 1.29 (95% Cl, 1.0 to 1.67). When analyses were restricted to the 557 patients free of lymph node metastases, the hazard ratio of recurrence associated with obesity was 1.59 (CL, 1.06 to 2.39); 32% of obese patients developed recurrent disease compared with 19% of nonobese women. Conclusions: Obesity at the time of diagnosis is a significant prognostic factor that may Limit the reduction in breast cancer mortality attainable through detection at an early stage of disease. Because obesity and the risk for breast cancer increase with age, interventions that encourage weight controL may influence breast cancer survival rates.	MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, MANHASSET, NY 11030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital	SENIE, RT (corresponding author), CTR DIS CONTROL, DIV REPROD HLTH, WOMENS HLTH & FERTIL BRANCH, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							ABE R, 1976, TOHOKU J EXP MED, V120, P351, DOI 10.1620/tjem.120.351; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; CHANDRA RK, 1981, CANCER RES, V41, P3795; COX DR, 1972, J R STAT SOC B, V34, P187; de Waard F, 1981, Nutr Cancer, V2, P237; DONEGAN WL, 1978, CANCER, V41, P1590, DOI 10.1002/1097-0142(197804)41:4<1590::AID-CNCR2820410449>3.0.CO;2-N; EBERLEIN T, 1985, BREAST CANCER RES TR, V5, P81, DOI 10.1007/BF01807654; GOODWIN PJ, 1988, BREAST CANCER RES TR, V11, P59, DOI 10.1007/BF01807559; GRAY DS, 1991, J CLIN EPIDEMIOL, V44, P545, DOI 10.1016/0895-4356(91)90218-X; GREENBERG ER, 1985, BRIT J CANCER, V51, P691, DOI 10.1038/bjc.1985.104; GREGORIO DI, 1985, JNCI-J NATL CANCER I, V75, P37; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIRSCHNER MA, 1982, CANCER RES, V42, P3281; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; LESSER ML, 1982, SURGERY, V91, P234; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASON B, 1982, J SURG ONCOL, V19, P62, DOI 10.1002/jso.2930190116; MCNEE RK, 1987, BREAST CANCER RES TR, V9, P145, DOI 10.1007/BF01807367; MOHLEBOETANI JC, 1988, PREV MED, V17, P634, DOI 10.1016/0091-7435(88)90056-4; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; NEWBERNE PM, 1983, CANCER RES, V43, P2426; NEWMAN SC, 1986, AM J EPIDEMIOL, V123, P767, DOI 10.1093/oxfordjournals.aje.a114305; NOMURA Y, 1981, GANN, V72, P468; OTA DM, 1986, CANCER, V57, P558, DOI 10.1002/1097-0142(19860201)57:3<558::AID-CNCR2820570326>3.0.CO;2-1; REED MJ, 1983, CANCER RES, V43, P3940; ROSE DP, 1986, DIET NUTRITION CANCE, P151; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; ROSEN PP, 1979, SURGERY, V85, P219; Rowland M L, 1989, Stat Bull Metrop Insur Co, V70, P2; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SENIE RT, 1980, CANCER, V46, P1705, DOI 10.1002/1097-0142(19801001)46:7<1705::AID-CNCR2820460734>3.0.CO;2-Q; SENIE RT, 1985, BREAST CANCER RES TR, V5, P301, DOI 10.1007/BF01806025; SHERMAN BM, 1974, CANCER, V33, P1306, DOI 10.1002/1097-0142(197405)33:5<1306::AID-CNCR2820330515>3.0.CO;2-#; SOHRABI A, 1980, JAMA-J AM MED ASSOC, V244, P264, DOI 10.1001/jama.244.3.264; TARTTER PI, 1981, CANCER, V47, P2222, DOI 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; TRICHOPOULOS D, 1987, INT J CANCER, V40, P721, DOI 10.1002/ijc.2910400602; VERREAULT R, 1989, AM J EPIDEMIOL, V129, P260, DOI 10.1093/oxfordjournals.aje.a115131; WAARD FD, 1975, CANCER RES, V35, P3351; ZUMOFF B, 1983, J SURG ONCOL, V22, P217, DOI 10.1002/jso.2930220402; Zumoff B, 1988, Acta Med Scand Suppl, V723, P153; 1959, STAT B METROP INSUR, V40, P1	51	143	143	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					26	32		10.7326/0003-4819-116-1-26	http://dx.doi.org/10.7326/0003-4819-116-1-26			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727092				2022-12-28	WOS:A1992GX15700005
J	STEWART, WF; LIPTON, RB; CELENTANO, DD; REED, ML				STEWART, WF; LIPTON, RB; CELENTANO, DD; REED, ML			PREVALENCE OF MIGRAINE HEADACHE IN THE UNITED-STATES - RELATION TO AGE, INCOME, RACE, AND OTHER SOCIODEMOGRAPHIC FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY; SYMPTOMS; WOMEN	Objective. - To describe the magnitude and distribution of the public health problem posed by migraine in the United States by examining migraine prevalence, attack frequency, and attack-related disability by gender, age, race, household income, geographic region, and urban vs rural residence. Design. - In 1989, a self-administered questionnaire was sent to a sample of 15000 households. A designated member of each household initially responded to the questionnaire. Each household member with severe headache was asked to respond to detailed questions about symptoms, frequency, and severity of headaches. Setting. - A sample of households selected from a panel to be representative of the US population in terms of age, gender, household size, and geographic area. Participants. - After a single mailing, 20468 subjects (63.4% response rate) between 12 and 80 years of age responded to the survey. Respondents and nonrespondents did not differ by gender, household income, region of the country, urban vs rural status. Whites and the elderly were more likely to respond. Migraine headache cases were identified on the basis of reported symptoms using established diagnostic criteria. Results. - 17.6% of females and 5.7% of males were found to have one or more migraine headaches per year. The prevalence of migraine varied considerably by age and was highest in both men and women between the ages of 35 to 45 years. Migraine prevalence was strongly associated with household income; prevalence in the lowest income group (< $10 000) was more than 60% higher than in the two highest income groups (greater-than-or-equal-to $30 000). The proportion of migraine sufferers who experienced moderate to severe disability was not related to gender, age, income, urban vs rural residence, or region of the country. In contrast, the frequency of headaches was lower in higher-income groups. Attack frequency was inversely related to disability. Conclusions. - A projection to the US population suggests that 8.7 million females and 2.6 million males suffer from migraine headache with moderate to severe disability. Of these, 3.4 million females and 1.1 million males experience one or more attacks per month. Females between ages 30 to 49 years from lower-income households are at especially high risk of having migraines and are more likely than other groups to use emergency care services for their acute condition.	JOHNS HOPKINS UNIV,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461; GLAXO INC,RES TRIANGLE PK,NC	Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; GlaxoSmithKline	STEWART, WF (corresponding author), JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Lipton, Richard B/B-5060-2011; Lipton, Richard Bruce/AAY-2818-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019381, T32NS007153] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19381, 5-T32 NSO-7153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen R, 1979, TOTAL SURVEY ERROR; ANDERSON RJ, 1984, CLIN CHIM ACTA, V138, P185, DOI 10.1016/0009-8981(84)90233-X; BRESLOW NE, 1987, DESIGN ANAL COHORT S, V2, P152; BRUYN GW, 1983, HEADACHE, V23, P127; CELENTANO DD, 1990, SOC SCI MED, V30, P1289, DOI 10.1016/0277-9536(90)90309-G; CELENTANO DD, 1990, J CLIN EPIDEMIOL, V43, P983, DOI 10.1016/0895-4356(90)90082-Z; CHEN TC, 1987, ARCH NEUROL-CHICAGO, V44, P1024, DOI 10.1001/archneur.1987.00520220030011; CLARKE GJR, 1974, EPIDEMIOLOGY MIGRAIN, P14; DALLESANDRO R, 1988, J NEUROL NEUROSUR PS, V51, P21; DEUBNER DC, 1977, HEADACHE, V17, P173, DOI 10.1111/j.1526-4610.1977.hed1704173.x; EATON WW, 1988, HDB SCHIZOPHRENIA, V3, P169; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; JOHANNES CB, 1989, THESIS J HOPKINS U A; KAPPIUS REK, 1987, HEADACHE, V27, P491, DOI 10.1111/j.1526-4610.1987.hed2709491.x; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LINET MS, 1989, JAMA-J AM MED ASSOC, V261, P2211, DOI 10.1001/jama.261.15.2211; LIPTON RB, 1991, CEPHALALGIA, V11, P89, DOI 10.1177/0333102491011S1148; MARKUSH RE, 1975, NEUROLOGY, V25, P430, DOI 10.1212/WNL.25.5.430; MCCULLUGH P, 1983, GENERALIZED LINEAR M, P142; MOSS G, 1974, EPIDEMIOLOGY MIGRAIN, P49; SCHNARCH DM, 1980, PSYCHOSOMATICS, V21, P314; SILBERSTEIN SD, 1991, NEUROLOGY, V41, P786, DOI 10.1212/WNL.41.6.786; WATERS W E, 1970, Headache, V9, P178, DOI 10.1111/j.1526-4610.1970.hed0904178.x; ZIEGLER DK, 1990, NEUROL CLIN, V8, P781, DOI 10.1016/S0733-8619(18)30316-5; 1988, NATIONAL DATA BOOK G	25	1264	1299	3	57	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					64	69		10.1001/jama.267.1.64	http://dx.doi.org/10.1001/jama.267.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727198				2022-12-28	WOS:A1992GW84800025
J	MORLEY, D; NICKSON, P; BROWN, R				MORLEY, D; NICKSON, P; BROWN, R			TALC DIRECT RECORDING SCALES	LANCET			English	Letter											MORLEY, D (corresponding author), INST CHILD HLTH,DEPT GROWTH & DEV,INT CTR GROWTH PROMOT,LONDON WC1N 1EH,ENGLAND.								0	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1991	338	8782-3					1600	1600		10.1016/0140-6736(91)92432-2	http://dx.doi.org/10.1016/0140-6736(91)92432-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW036	1720857				2022-12-28	WOS:A1991GW03600055
J	WEISS, MS; ABELE, U; WECKESSER, J; WELTE, W; SCHILTZ, E; SCHULZ, GE				WEISS, MS; ABELE, U; WECKESSER, J; WELTE, W; SCHILTZ, E; SCHULZ, GE			MOLECULAR ARCHITECTURE AND ELECTROSTATIC PROPERTIES OF A BACTERIAL PORIN	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; COLI OUTER MEMBRANES; X-RAY-ANALYSIS; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; ALPHA-HELIX; RESOLUTION; CRYSTALLIZATION; DIPOLES; PROGRAM	The integral membrane protein porin from Rhodobacter capsulatus consists of three tightly associated 16-stranded beta-barrels that give rise to three distinct diffusion channels for small solutes through the outer membrane. The x-ray structure of this porin has revealed details of its shape, the residue distributions within the pore and at the membrane-facing surface, and the location of calcium sites. The electrostatic potential has been calculated and related to function. Moreover, potential calculations were found to predict the Ca2+ sites.	INST ORGAN CHEM & BIOCHEM,ALBERTSTR 21,W-7800 FREIBURG,GERMANY; INST BIOL 2,W-7800 FREIBURG,GERMANY; INST BIOPHYS & STRAHLENBIOL,W-7800 FREIBURG,GERMANY		SCHULZ, GE (corresponding author), INST ORGAN CHEM & BIOCHEM,ALBERTSTR 21,W-7800 FREIBURG,GERMANY.		Weiss, Manfred S/B-6857-2013	Weiss, Manfred S/0000-0002-2362-7047				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; KARSHIKOV A, 1989, PROTEINS, V5, P248, DOI 10.1002/prot.340050308; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KREUSCH A, 1991, J MOL BIOL, V217, P9, DOI 10.1016/0022-2836(91)90604-5; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; NESTEL U, 1989, FEBS LETT, V242, P405, DOI 10.1016/0014-5793(89)80511-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; STAUFFER KA, 1990, J MOL BIOL, V211, P297, DOI 10.1016/0022-2836(90)90351-L; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WELTE W, IN PRESS BIOCH BIOPH; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	29	579	595	3	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1627	1630		10.1126/science.1721242	http://dx.doi.org/10.1126/science.1721242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721242				2022-12-28	WOS:A1991GV07300040
J	LISTERUD, M; BRUSSAARD, AB; DEVAY, P; COLMAN, DR; ROLE, LW				LISTERUD, M; BRUSSAARD, AB; DEVAY, P; COLMAN, DR; ROLE, LW			FUNCTIONAL CONTRIBUTION OF NEURONAL ACHR SUBUNITS REVEALED BY ANTISENSE OLIGONUCLEOTIDES	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS	Although multiple related genes encoding nicotinic acetylcholine receptor (AChR) subunits have been identified, how each of these subunits contributes to AChRs in neurons is not known. Sympathetic neurons express four classes of AChR channels and six AChR subunit genes (alpha-3, alpha-4, alpha-5, alpha-7, beta-2, and beta-4). The contribution of individual subunits to AChR channel subtypes in these neurons was examined by selective deletion with antisense oligonucleotides. An alpha-3 antisense oligonucleotide decreased the number and altered the properties of the normally expressed ACh-activated channels. The remaining AChR channels have distinct biophysical and pharmacological properties that indicate an important functional contribution of the alpha-7 subunit.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027680, P50NS027680, R01NS029071] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS029071-14, NS27680, R01 NS029071-15, NS 29071, R01 NS029071-10, R01 NS029071-13S1, R01 NS029071, R01 NS029071-12, R01 NS029071-13, R01 NS029071-09, R01 NS029071-17, R01 NS029071-16, R01 NS029071-11] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD RT, 1988, NEURON, V1, P495; BRUSSAARD A, UNPUB; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; GARDETTE R, 1991, DEV BIOL, V147, P83, DOI 10.1016/S0012-1606(05)80009-0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; LEPRINCE P, 1983, BIOCHEMISTRY-US, V22, P5551, DOI 10.1021/bi00293a015; LUETJE CW, 1991, J NEUROSCI, V11, P837; MOSS BL, 1989, NEURON, V3, P597, DOI 10.1016/0896-6273(89)90270-5; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHOEPFER R, 1989, FEBS LETT, V257, P393, DOI 10.1016/0014-5793(89)81580-7; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; SNEDECOR GW, 1967, STATISTICAL METHODS, P329; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001	17	164	165	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1518	1521		10.1126/science.1720573	http://dx.doi.org/10.1126/science.1720573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1720573	Green Accepted			2022-12-28	WOS:A1991GT90300044
J	JORGENSEN, WL				JORGENSEN, WL			RUSTING OF THE LOCK AND KEY MODEL FOR PROTEIN-LIGAND BINDING	SCIENCE			English	Editorial Material							3-DIMENSIONAL STRUCTURE; COMPLEX; ANTIBODY; RESOLUTION; ANTIGEN; PEPTIDE				JORGENSEN, WL (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.		/AAW-1187-2021					AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CRUMPTON MJ, 1966, BIOCHEM J, V100, P223, DOI 10.1042/bj1000223; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; KIM PS, 1982, J MOL BIOL, V162, P187, DOI 10.1016/0022-2836(82)90168-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, SCIENCE, V252, P6574; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722	16	178	186	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					954	955		10.1126/science.1719636	http://dx.doi.org/10.1126/science.1719636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1719636				2022-12-28	WOS:A1991GP88300031
J	VU, TKH; WHEATON, VI; HUNG, DT; CHARO, I; COUGHLIN, SR				VU, TKH; WHEATON, VI; HUNG, DT; CHARO, I; COUGHLIN, SR			DOMAINS SPECIFYING THROMBIN-RECEPTOR INTERACTION	NATURE			English	Article							HUMAN ALPHA-THROMBIN; RECOMBINANT HIRUDIN; SITE	PLATELET activation by the coagulation protease thrombin is central to arterial thrombosis, a major cause of morbidity and mortality. We recently isolated a complementary DNA encoding the platelet thrombin receptor. The extracellular amino-terminal extension of this seven transmembrane domain receptor contains the putative thrombin cleavage site LDPR/S which is critical for receptor activation. By replacing this cleavage site with the cleavage site for enterokinase, we have created a functional enterokinase receptor. This result demonstrates that all information necessary for receptor activation is provided by receptor proteolysis. Nanomolar enterokinase concentrations are required to activate this new receptor, in contrast to the picomolar thrombin concentrations that activate wild-type thrombin receptor. We identified a receptor domain critical for thrombin's remarkable potency at its receptor. This domain resembles the carboxyl tail of the leech anticoagulant hirudin and functions by binding to thrombin's anion-binding exosite. Our studies thus define a model for thrombin-receptor interaction. The utility of this model was demonstrated by the design of novel thrombin inhibitors based on receptor peptides.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; COR THERAPEUT INC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BIGGS R, 1976, HUMAN BLOOD COAGULAT, P722; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; KRSTENANSKY JL, 1987, J MED CHEM, V30, P1688, DOI 10.1021/jm00392a030; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LIU LW, IN PRESS J BIOL CHEM; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	12	531	563	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					674	677		10.1038/353674a0	http://dx.doi.org/10.1038/353674a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1717851				2022-12-28	WOS:A1991GK67200076
J	SMITH, JC; PRICE, BMJ; GREEN, JBA; WEIGEL, D; HERRMANN, BG				SMITH, JC; PRICE, BMJ; GREEN, JBA; WEIGEL, D; HERRMANN, BG			EXPRESSION OF A XENOPUS HOMOLOG OF BRACHYURY (T) IS AN IMMEDIATE-EARLY RESPONSE TO MESODERM INDUCTION	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; ACTIVIN-A; AMPHIBIAN DEVELOPMENT; PROSPECTIVE AREAS; NEURAL INDUCTION; MOUSE EMBRYO; LAEVIS; GENE; CELLS; RNA	The Brachyury (T) gene is required for mesoderm formation in the mouse. In this paper we describe the cloning and expression of a Xenopus homolog of Brachyury, Xbra. As with Brachyury in the mouse, Xbra is expressed in presumptive mesodermal cells around the blastopore, and then in the notochord. We show that expression of Xbra occurs as a result of mesoderm induction in Xenopus, both in response to the natural signal and in response to the mesoderm-inducing factors activin A and basic FGF. Expression of Xbra in response to these factors is rapid, and will occur in dispersed cells and in the presence of a protein synthesis inhibitor, indicating that this is an "immediate-early" response to mesoderm induction.	MAX PLANCK INST ENTWICKLUNGSBIOL,BIOCHEM ABT,W-7400 TUBINGEN,GERMANY	Max Planck Society	SMITH, JC (corresponding author), NATL INST MED RES,DEV BIOL LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Green, Jeremy/F-3630-2010; Pillay, Nischalan/F-9536-2012	Green, Jeremy/0000-0002-6102-2620; 				ALBANO RM, 1990, DEVELOPMENT, V110, P435; ALTABA AR, 1989, NATURE, V341, P33; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CASCIO S, 1987, DEVELOPMENT, V100, P297; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; JONES EA, 1987, DEVELOPMENT, V101, P557; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; New HV, 1990, CURR OPIN CELL BIOL, V2, P969, DOI 10.1016/0955-0674(90)90143-3; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; RASHBASS P, 1991, IN PRESS NATURE; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLAGER HG, 1991, DEV BIOL, V145, P205, DOI 10.1016/0012-1606(91)90120-R; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1983, DEV BIOL, V98, P250, DOI 10.1016/0012-1606(83)90354-8; SMITH JC, 1989, DEVELOPMENT, V105, P665; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLISON K, 1990, TRENDS GENET, V6, P104, DOI 10.1016/0168-9525(90)90106-G; YANAGISAWA KO, 1990, JPN J GENET, V65, P287, DOI 10.1266/jjg.65.287; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0	51	911	920	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					79	87		10.1016/0092-8674(91)90573-H	http://dx.doi.org/10.1016/0092-8674(91)90573-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717160				2022-12-28	WOS:A1991GJ32000008
J	RICH, DP; GREGORY, RJ; ANDERSON, MP; MANAVALAN, P; SMITH, AE; WELSH, MJ				RICH, DP; GREGORY, RJ; ANDERSON, MP; MANAVALAN, P; SMITH, AE; WELSH, MJ			EFFECT OF DELETING THE R-DOMAIN ON CFTR-GENERATED CHLORIDE CHANNELS	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; PATCH-CLAMP; CELLS; IDENTIFICATION; EXPRESSION; MUTATIONS; INACTIVATION	The cystic fibrosis transmembrane conductance regulator (CFTR), which forms adenosine 3',5'-monophosphate (cAMP)-regulated chloride channels, is defective in patients with cystic fibrosis. This protein contains two putative nucleotide binding domains (NBD1 and NBD2) and an R domain. CFTR in which the R domain was deleted (CFTR-DELTA-R) conducted chloride independently of the presence of cAMP. However, sites within CFTR other than those deleted also respond to cAMP, because the chloride current of CFTR-DELTA-R increased further in response to cAMP stimulation. In addition, deletion of the R domain suppressed the inactivating effect of a mutation in NBD2 (but not NBD1), a result which suggests that NBD2 interacts with the channel through the R domain.	GENZYME CORP, FRAMINGHAM, MA 01701 USA; MIT, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, CAMBRIDGE, MA 02142 USA	Sanofi-Aventis; Genzyme Corporation; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	RICH, DP (corresponding author), MIT, HOWARD HUGHES MED INST, DEPT INTERNAL MED, CAMBRIDGE, MA 02142 USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BOAT TF, 1989, METABOLIC BASIS INHE; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING G, 1991, FASEB J, V5, pA1760; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, IN PRESS MOL CELL BI; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OSTEDGAARD LS, UNPUB; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	31	250	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					205	207		10.1126/science.1712985	http://dx.doi.org/10.1126/science.1712985			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712985				2022-12-28	WOS:A1991FW16000040
J	HOHLFELD, R; ENGEL, AG; II, K; HARPER, MC				HOHLFELD, R; ENGEL, AG; II, K; HARPER, MC			POLYMYOSITIS MEDIATED BY LYMPHOCYTES-T THAT EXPRESS THE GAMMA-DELTA RECEPTOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL RECEPTOR; IMMUNE-SYSTEM; COMPLEX; RECOGNITION; DEFINITION; MYOPATHIES; MOLECULES; ANTIGENS; DISEASE; SUBSET	Background. The invasion and destruction of nonnecrotic muscle fibers by CD8+ cytotoxic T cells is considered a hallmark of polymyositis. In the cases of polymyositis reported so far, the autoinvasive CD8+ T cells expressed the common form of T-cell receptor for the recognition of antigen, the so-called alpha/beta-T-cell receptor. We describe a 69-year-old man with polymyositis mediated by CD4-, CD8- T cells expressing the recently discovered, uncommon gamma/delta-T-cell receptor. Methods. We used immunofluorescence or immunoperoxidase techniques to study frozen sections of muscle from our patient, who had mild weakness of cervical and proximal limb muscles, and from control patients with polymyositis, inclusion-body myositis, dermatomyositis, or granulomatous myopathy with monoclonal antibodies against T-cell-related antigens (CD2, CD3, CD4, CD8, and gamma/delta-T-cell receptor), B cells (CD22), major histocompatibility complex (MHC) and MHC-related antigens (MHC Class I, CD1a, CD1b, and CD1c), and the 65-kd heat-shock protein. The membrane contacts between the autoinvasive cells and the sarcolemma were investigated by electron microscopy. Results. In the patient described here, but not in 28 others with inflammatory myopathies, myriad gamma/delta-T cells surrounded and invaded nonnecrotic muscle fibers. All muscle fibers were highly reactive for MHC Class I antigen and the 65-kd heat-shock protein. Treatment with prednisone improved the clinical and histologic findings. Conclusions. Polymyositis can be mediated by gamma/delta-T cells. This new form of polymyositis appears to be highly responsive to steroids.	MAYO CLIN & MAYO FDN, NEUROMUSCULAR RES LAB, GUGGENHEIM BLDG 801, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT NEUROL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS006277, R01NS006277] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-6277] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAHATA K, 1986, ANN NEUROL, V19, P112, DOI 10.1002/ana.410190203; BANKER BQ, 1986, MYOLOGY, P1385; BLUESTONE JA, 1989, J IMMUNOL, V142, P1785; BORN W, 1990, IMMUNOL TODAY, V11, P40; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BRENNER MB, 1988, ADV IMMUNOL, V43, P133; CICCONE E, 1988, J EXP MED, V168, P1, DOI 10.1084/jem.168.1.1; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; ENGEL AG, 1986, MYOLOGY, P833; FERRINI S, 1989, EUR J IMMUNOL, V19, P1183, DOI 10.1002/eji.1830190705; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HOHLFELD R, 1989, ANN NEUROL, V25, P531, DOI 10.1002/ana.410250602; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; IVANYI J, 1983, CLIN EXP IMMUNOL, V52, P528; JANEWAY CA, 1988, NATURE, V333, P804, DOI 10.1038/333804a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JITSUKAWA S, 1987, J EXP MED, V166, P1192, DOI 10.1084/jem.166.4.1192; KNAPP W, 1989, IMMUNOL TODAY, V10, P253, DOI 10.1016/0167-5699(89)90135-7; LANIER LL, 1986, NATURE, V324, P268, DOI 10.1038/324268a0; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; RAULET DH, 1989, NATURE, V339, P342, DOI 10.1038/339342a0; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; ROYER HD, 1987, NEW ENGL J MED, V317, P1136, DOI 10.1056/NEJM198710293171807; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; TRIEBEL F, 1989, IMMUNOL TODAY, V10, P186, DOI 10.1016/0167-5699(89)90321-6; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401	29	137	137	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					877	881		10.1056/NEJM199103283241303	http://dx.doi.org/10.1056/NEJM199103283241303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD111	1705662				2022-12-28	WOS:A1991FD11100003
J	COMPTON, J				COMPTON, J			NUCLEIC-ACID SEQUENCE-BASED AMPLIFICATION	NATURE			English	Article								Nucleic acid sequence-based amplification (NASBA) is a primer-dependent technology that can be used for the continuous amplification of nucleic acids in a single mixture at one temperature.			COMPTON, J (corresponding author), CANGENE CORP,3403 AMER DR,MISSISSAUGA L4V 1T4,ONTARIO,CANADA.							SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875	1	919	1237	19	258	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					91	92		10.1038/350091a0	http://dx.doi.org/10.1038/350091a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706072				2022-12-28	WOS:A1991FA69300075
J	PHILLIPS, WD; KOPTA, C; BLOUNT, P; GARDNER, PD; STEINBACH, JH; MERLIE, JP				PHILLIPS, WD; KOPTA, C; BLOUNT, P; GARDNER, PD; STEINBACH, JH; MERLIE, JP			ACH RECEPTOR RICH MEMBRANE DOMAINS ORGANIZED IN FIBROBLASTS BY RECOMBINANT 43-KILDALTON PROTEIN	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; MOUSE NEUROMUSCULAR-JUNCTIONS; TORPEDO-MARMORATA; ALKALINE TREATMENT; ELECTRIC ORGAN; MUSCLE FIBERS; BETA-SUBUNIT; BINDING; CELLS; CHANNELS	Neurotransmitter receptors are generally clustered in the postsynaptic membrane. The mechanism of clustering was analyzed with fibroblast cell lines that were stably transfected with the four subunits for fetal (alpha, beta, gamma, delta) or adult (alpha, beta, epsilon, delta) type mouse muscle nicotinic acetylcholine receptors (AChRs). Immunofluorescent staining indicated that AChRs were dispersed on the surface of these cells. When transiently transfected with an expression construct encoding a 43-kilodalton protein that is normally concentrated under the postsynaptic membrane, AChRs expressed in these cells became aggregated in large cell-surface clusters, colocalized with the 43-kilodalton protein. This suggests that 43-kilodalton protein can induce AChR clustering and that cluster induction involves direct contact between AChR and 43-kilodalton protein.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Washington University (WUSTL); Dartmouth College	PHILLIPS, WD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Phillips, William/0000-0002-5405-8422	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022356] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS022356] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BARRANTES FJ, 1980, FEBS LETT, V112, P73, DOI 10.1016/0014-5793(80)80131-1; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BREHM P, 1987, P NATL ACAD SCI USA, V84, P2550, DOI 10.1073/pnas.84.8.2550; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARTAUD J, 1981, J CELL BIOL, V90, P418, DOI 10.1083/jcb.90.2.418; COVARRUBIAS M, 1990, PFLUG ARCH EUR J PHY, V416, P385, DOI 10.1007/BF00370744; COVARRUBIAS M, 1989, J GEN PHYSIOL, V93, P765, DOI 10.1085/jgp.93.5.765; ELLIOTT J, 1980, BIOCHEM J, V185, P667, DOI 10.1042/bj1850667; FAMBROUGH DM, 1972, SCIENCE, V176, P189, DOI 10.1126/science.176.4031.189; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FISCHBACH GD, 1973, DEV BIOL, V31, P147, DOI 10.1016/0012-1606(73)90326-6; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; FROEHNER SC, 1986, TRENDS NEUROSCI, V9, P37, DOI 10.1016/0166-2236(86)90013-5; GARDNER PJ, UNPUB; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; KULLBERG R, 1990, P NATL ACAD SCI USA, V87, P2067, DOI 10.1073/pnas.87.6.2067; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LO MMS, 1980, FEBS LETT, V111, P407, DOI 10.1016/0014-5793(80)80838-6; MATTHEWSBELLINGER JA, 1983, J NEUROSCI, V3, P644; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; ROUSSELET A, 1982, EMBO J, V1, P439, DOI 10.1002/j.1460-2075.1982.tb01188.x; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; SCHUETZE SM, 1978, P NATL ACAD SCI USA, V75, P520, DOI 10.1073/pnas.75.1.520; SLATER CR, 1982, DEV BIOL, V94, P11, DOI 10.1016/0012-1606(82)90063-X; SOBEL A, 1978, P NATL ACAD SCI USA, V75, P510, DOI 10.1073/pnas.75.1.510; STEINBACH JH, 1981, DEV BIOL, V84, P367; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180	36	203	205	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					568	570		10.1126/science.1703661	http://dx.doi.org/10.1126/science.1703661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1703661				2022-12-28	WOS:A1991EV45900054
J	MITSUYA, H; YARCHOAN, R; BRODER, S				MITSUYA, H; YARCHOAN, R; BRODER, S			MOLECULAR TARGETS FOR AIDS THERAPY	SCIENCE			English	Review											MITSUYA, H (corresponding author), NCI, BETHESDA, MD 20892 USA.							ABRAMS DI, 1989, ANN INTERN MED, V110, P183, DOI 10.7326/0003-4819-110-3-183; AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; AHLUWALIA G, 1988, J BIOL CHEM, V29, P349; AHLUWALIA GS, UNPUB; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BABA M, 1987, ANTIMICROB AGENTS CH, V31, P1613, DOI 10.1128/AAC.31.10.1613; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BABA M, 1987, BIOCHEM BIOPH RES CO, V145, P1080, DOI 10.1016/0006-291X(87)91547-6; BALZARINI J, 1986, BIOCHEM BIOPH RES CO, V140, P735, DOI 10.1016/0006-291X(86)90793-X; BALZARINI J, 1989, BIOCHEM PHARMACOL, V38, P869, DOI 10.1016/0006-2952(89)90273-6; BALZARINI J, 1987, MOL PHARMACOL, V32, P162; BERGER EA, 1989, P NATL ACAD SCI USA, V86, P9539, DOI 10.1073/pnas.86.23.9539; BIESERT L, 1988, AIDS, V2, P449, DOI 10.1097/00002030-198812000-00007; BLUNDELL T, 1989, NATURE, V337, P596, DOI 10.1038/337596a0; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWNE M, UNPUB; BUCK HM, 1990, SCIENCE, V248, P208, DOI 10.1126/science.2326635; BUTLER K, UNPUB; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHANG PS, 1990, CLIN BIOTECHNOL, V2, P23; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P2065, DOI 10.1016/0006-2952(86)90571-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAAR ES, IN PRESS P NATL ACAD; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DOERING AM, 1966, J BACTERIOL, V92, P565, DOI 10.1128/JB.92.3.565-574.1966; DOLL DC, 1982, LANCET, V1, P1026; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P1729, DOI 10.1128/AAC.33.10.1729; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FINE RL, 1990, 1990 P AM ASS CANC R, V31, P431; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; FURMANSKI P, 1980, CANCER LETT, V8, P307, DOI 10.1016/0304-3835(80)90146-9; GAO W, 1989, J BIOL CHEM, V264, P11521; GAO WY, 1990, ANTIMICROB AGENTS CH, V34, P808, DOI 10.1128/AAC.34.5.808; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GATTI RA, 1971, CANCER-AM CANCER SOC, V28, P89, DOI 10.1002/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; GROOPMAN JE, 1984, ANN INTERN MED, V100, P671, DOI 10.7326/0003-4819-100-5-671; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; HAMAMOTO Y, 1987, ANTIMICROB AGENTS CH, V31, P907, DOI 10.1128/AAC.31.6.907; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HARTMAN NR, 1990, AIDS RES HUM RETROV, V6, P805, DOI 10.1089/aid.1990.6.805; HARTMANN H, 1987, LANCET, V1, P40; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HAYASHI S, 1988, P NATL ACAD SCI USA, V85, P6127, DOI 10.1073/pnas.85.16.6127; HAYASHI S, 1990, ANTIMICROB AGENTS CH, V34, P82, DOI 10.1128/AAC.34.1.82; HAYASHI S, 1990, ANTIMICROB AGENTS CH, V34, P287, DOI 10.1128/AAC.34.2.287; Henderson L.E., 1988, UCLA S MOL CELL BIOL, V71, P135; HO DD, 1985, LANCET, V1, P602; HORWITZ JP, 1966, J ORG CHEM, V31, P205, DOI 10.1021/jo01339a045; HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546; HORWITZ JP, 1967, J ORG CHEM, V32, P817, DOI 10.1021/jo01278a070; HOSHINO H, 1987, J ANTIBIOT, V40, P1077, DOI 10.7164/antibiotics.40.1077; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; ITO M, 1987, ANTIVIR RES, V7, P361, DOI 10.1016/0166-3542(87)90018-0; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; JOHNSON MA, 1988, J BIOL CHEM, V263, P15354; JOHNSON VA, 1989, J INFECT DIS, V159, P837, DOI 10.1093/infdis/159.5.837; JOHNSON VA, 1990, J INFECT DIS, V161, P1059, DOI 10.1093/infdis/161.6.1059; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229; KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIM CH, 1987, J MED CHEM, V30, P862, DOI 10.1021/jm00388a020; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LAVIE G, 1989, P NATL ACAD SCI USA, V86, P5963, DOI 10.1073/pnas.86.15.5963; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LIN TS, 1978, J MED CHEM, V21, P109, DOI 10.1021/jm00199a020; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LOONEY DJ, 1990, J ACQ IMMUN DEF SYND, V3, P649; LORENTSEN KJ, 1989, ANN INTERN MED, V111, P561, DOI 10.7326/0003-4819-111-7-561; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MARQUEZ VE, 1987, BIOCHEM PHARMACOL, V36, P2719, DOI 10.1016/0006-2952(87)90254-1; MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015; MARTI G, UNPUB; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MATSUSHITA S, 1990, AIDS RES HUM RETROV, V6, P193, DOI 10.1089/aid.1990.6.193; MATSUYAMA T, 1989, AIDS RES HUM RETROV, V5, P139, DOI 10.1089/aid.1989.5.139; MATTHEWS TJ, 1988, SCI AM, V259, P120, DOI 10.1038/scientificamerican1088-120; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCGOWAN JJ, 1990, REV INFECT DIS, V12, pS513; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; MCKEATING JA, 1990, NATURE, V343, P659, DOI 10.1038/343659a0; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MERUELO D, UNPUB; MILLER FA, 1968, ANTIMICROB AGENTS CH, P136; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MITSUYA H, 1988, 4 P INT C AIDS STOCK, P226; MITSUYA H, 1989, MECHANISMS ACTION TH, P331; MITSUYA H, UNPUB; MITSUYA H, 1990, HUMAN RETROVIRUSES; MOLINA JM, 1989, NEW ENGL J MED, V321, P1478; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; NAKASHIMA H, 1987, ANTIMICROB AGENTS CH, V31, P1524, DOI 10.1128/AAC.31.10.1524; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; NORBECK DW, 1990, J MED CHEM, V33, P1281, DOI 10.1021/jm00167a002; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; ONO K, 1979, BIOCHEM BIOPH RES CO, V88, P1255, DOI 10.1016/0006-291X(79)91115-X; OSTERTAG W, 1974, P NATL ACAD SCI USA, V71, P4980, DOI 10.1073/pnas.71.12.4980; PAL R, 1988, P NATL ACAD SCI USA, V85, P9283, DOI 10.1073/pnas.85.23.9283; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PAVLAKIS G N, 1990, New Biologist, V2, P20; Penn I, 1978, Adv Cancer Res, V28, P31, DOI 10.1016/S0065-230X(08)60645-4; PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933; PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111; PHADTARE S, 1989, J AM CHEM SOC, V111, P5925, DOI 10.1021/ja00197a063; PITHA PM, 1979, J GEN VIROL, V42, P467, DOI 10.1099/0022-1317-42-3-467; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1990, REV INFECT DIS, V12, pS507; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROBERTS NA, 1990, NATURE, V248, P358; ROBINS MJ, 1964, J AM CHEM SOC, V86, P3585, DOI 10.1021/ja01071a055; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHINAZI RF, 1987, J CELL BIOCHEM, P74; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SCZAKIEL G, 1990, 6 P INT C AIDS SAN F, V1, P181; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHIRASAKA T, IN PRESS P NATL ACAD; SHIRASAKA T, 1990, 6 P INT C AIDS SAN F, P185; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SOMMADOSSI JP, 1988, ANTIMICROB AGENTS CH, V32, P997, DOI 10.1128/AAC.32.7.997; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STARNES MC, 1987, J BIOL CHEM, V262, P988; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; UENO R, 1987, LANCET, V1, P1379; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; VOGT MW, 1987, SCIENCE, V235, P1376, DOI 10.1126/science.2435003; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120; WAQAR MA, 1984, J CELL PHYSIOL, V121, P402, DOI 10.1002/jcp.1041210218; WEBB TR, 1988, J MED CHEM, V31, P1475, DOI 10.1021/jm00402a038; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; WILLARDGALLO K, 1990, 6 P INT C AIDS SAN F, V2, P171; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; WONGSTAAL F, UNPUB; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; YARCHOAN R, 1990, REV INFECT DIS, V12, pS522; YARCHOAN R, 1989, 5TH INT C AIDS MONTR, P564; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748; 1990, HIV AIDS SURVEILLANC, P1; [No title captured]	244	784	861	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	1990	249	4976					1533	1544		10.1126/science.1699273	http://dx.doi.org/10.1126/science.1699273			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA463	1699273	Green Submitted			2022-12-28	WOS:A1990EA46300030
J	MICHELS, VV; MOLL, PP; MILLER, FA; TAJIK, AJ; CHU, JS; DRISCOLL, DJ; BURNETT, JC; RODEHEFFER, RJ; CHESEBRO, JH; TAZELAAR, HD				MICHELS, VV; MOLL, PP; MILLER, FA; TAJIK, AJ; CHU, JS; DRISCOLL, DJ; BURNETT, JC; RODEHEFFER, RJ; CHESEBRO, JH; TAZELAAR, HD			THE FREQUENCY OF FAMILIAL DILATED CARDIOMYOPATHY IN A SERIES OF PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; POPULATION; HEART; EPIDEMIOLOGY; FEATURES; HISTORY; ADULT	Background. Dilated cardiomyopathy is characterized by an increase in ventricular size and impairment of ventricular function. Most cases are believed to be sporadic, and familial dilated cardiomyopathy is usually considered to be a rare and distinct disorder. We studied the proportion of cases of idiopathic dilated cardiomyopathy that were familial in a large sequential series of patients whose first-degree relatives were investigated regardless of whether these relatives had cardiac symptoms. Methods. We studied the relatives of 59 index patients with idiopathic dilated cardiomyopathy by obtaining a family history and performing a physical examination, electrocardiography, and two-dimensional, M-mode, and Doppler echocardiography. A total of 315 relatives were examined. Results. Eighteen relatives from 12 families were shown to have dilated cardiomyopathy. Thus, 12 of the 59 index patients (20.3 percent) had familial disease. There was no difference in age, sex, severity of disease, exposure to selected environmental factors, or electrocardiographic or echocardiographic features between the index patients with familial disease and those with nonfamilial disease. A noteworthy finding was that 22 of 240 healthy relatives (9.2 percent) with normal ejection fractions had increased left ventricular diameters during systole or diastole (or both), as compared with 2 of 112 healthy control subjects (1.8 percent) who were studied separately. Conclusions. Dilated cardiomyopathy was found to be familial in at least one in five of the patients in this study, a considerably higher percentage than in previous reports. This finding has important implications for family screening and provides direction for further investigation into the causes and natural history of dilated cardiomyopathy.	MAYO CLIN & MAYO FDN, DEPT PEDIAT, CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL, CARDIOL SECT, ROCHESTER, MN 55905 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MICHELS, VV (corresponding author), MAYO CLIN & MAYO FDN, DEPT MED GENET, ROCHESTER, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036879] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL36879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELMANN WH, 1989, J AM COLL CARDIOL, V13, P1219, DOI 10.1016/0735-1097(89)90293-3; ARETZ HT, 1986, MED CLIN N AM, V70, P1215; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COUGHLIN SS, 1990, AM J EPIDEMIOL, V131, P48, DOI 10.1093/oxfordjournals.aje.a115484; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; FRAGOLA PV, 1988, AM HEART J, V115, P912, DOI 10.1016/0002-8703(88)90900-3; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GARDIN JM, 1979, J CLIN ULTRASOUND, V7, P439, DOI 10.1002/jcu.1870070606; HENRY WL, 1978, CIRCULATION, V57, P278, DOI 10.1161/01.CIR.57.2.278; HONEY M, 1986, BRIT HEART J, V55, P114; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; KEREN A, 1985, CIRCULATION, V72, P302, DOI 10.1161/01.CIR.72.2.302; KHANDHERIA BK, 1986, MAYO CLIN PROC, V61, P623, DOI 10.1016/S0025-6196(12)62026-6; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P165; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1985, AM J CARDIOL, V55, P1232, DOI 10.1016/0002-9149(85)90675-7; NISHIMURA RA, 1985, MAYO CLIN PROC, V60, P321, DOI 10.1016/S0025-6196(12)60540-0; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PERRAULT H, 1982, INT J SPORTS MED, V3, P141, DOI 10.1055/s-2008-1026077; QUINONES MA, 1981, CIRCULATION, V64, P744, DOI 10.1161/01.CIR.64.4.744; SCHMITZ A, 1983, CAN J AGR ECON, V31, P135, DOI 10.1111/j.1744-7976.1983.tb01193.x; SUGRUE DD, 1989, BRIT HEART J, V61, P88; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; URIE PM, 1988, AM J CARDIOL, V62, P325, DOI 10.1016/0002-9149(88)90238-X; VALANTINE HA, 1989, AM J CARDIOL, V63, P959, DOI 10.1016/0002-9149(89)90148-3	27	509	522	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					77	82		10.1056/NEJM199201093260201	http://dx.doi.org/10.1056/NEJM199201093260201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727235				2022-12-28	WOS:A1992GY04500001
J	SHERMAN, W; GORLIN, R				SHERMAN, W; GORLIN, R			BALLOON AORTIC VALVULOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							STENOSIS		CUNY MT SINAI SCH MED,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	SHERMAN, W (corresponding author), BETH ISRAEL MED CTR,NEW YORK,NY 10003, USA.							DAVIDSON CJ, 1991, AM J CARDIOL, V68, P75, DOI 10.1016/0002-9149(91)90714-V; KUNTZ RE, 1991, NEW ENGL J MED, V325, P17, DOI 10.1056/NEJM199107043250104; PELLIKKA PA, 1990, J AM COLL CARDIOL, V15, P1012, DOI 10.1016/0735-1097(90)90234-G; SHERMAN W, 1989, ANN INTERN MED, V110, P421, DOI 10.7326/0003-4819-110-6-421	4	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					138	138						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727231				2022-12-28	WOS:A1992GY04500024
J	HEBELL, T; AHEARN, JM; FEARON, DT				HEBELL, T; AHEARN, JM; FEARON, DT			SUPPRESSION OF THE IMMUNE-RESPONSE BY A SOLUBLE COMPLEMENT RECEPTOR OF LYMPHOCYTES-B	SCIENCE			English	Article							EPSTEIN-BARR-VIRUS; MONOCLONAL-ANTIBODY; CR-2 CD21; PROLIFERATION; BINDING; C3D; DEFICIENCIES; ACTIVATION; INVIVO; CELLS	The CD19-CR2 complex of B lymphocytes contains proteins that participate in two host-defense systems, the immune and complement systems. The ligand for the subunit of the immune system, CD19, is not known, but the complement receptor subunit, CR2 (CD21), binds activation fragments of the C3 component of the complement system and may mediate immunopotentiating effects of complement. A recombinant, soluble CR2 was prepared by fusing the C3-binding region of the receptor to immunoglobulin G1 (IgG1). The (CR2)2-IgG1 chimera competed with cellular CR2 for C3 binding and suppressed the antibody response to a T cell-dependent antigen when administered to mice at the time of immunization. This inhibitory effect of (CR2)2-IgG1 demonstrates the B cell-activating function of the CD19-CR2 complex and suggests a new method for humoral immunosuppression.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI-22833, AI-28191] Funding Source: Medline; NIGMS NIH HHS [GM-43803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028191, R01AI022833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BIRD P, 1988, EUR J IMMUNOL, V18, P1217, DOI 10.1002/eji.1830180811; BOTTGER EC, 1985, J IMMUNOL, V135, P4100; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CAREL JC, 1990, J BIOL CHEM, V265, P12293; CARTER R, UNPUB; CARTER RH, 1989, J IMMUNOL, V143, P1755; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; COULIE PG, 1985, EUR J IMMUNOL, V15, P793, DOI 10.1002/eji.1830150810; FINGEROTH JD, 1989, IMMUNOL LETT, V21, P291, DOI 10.1016/0165-2478(89)90022-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HEYMAN B, 1984, J IMMUNOL METHODS, V68, P193, DOI 10.1016/0022-1759(84)90150-9; JACKSON CG, 1979, NEW ENGL J MED, V300, P1124, DOI 10.1056/NEJM197905173002002; KALLI KR, 1991, J IMMUNOL, V147, P590; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; MARTINELLI GP, 1978, J IMMUNOL, V121, P2043; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MOORE MD, 1989, J BIOL CHEM, V264, P20576; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047	30	232	248	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1991	254	5028					102	105		10.1126/science.1718035	http://dx.doi.org/10.1126/science.1718035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718035				2022-12-28	WOS:A1991GH60500038
J	CARLSON, CA				CARLSON, CA			INTERNATIONAL MEDICAL-EDUCATION - COMMON ELEMENTS IN DIVERGENT SYSTEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											CARLSON, CA (corresponding author), AMER MED ASSOC,MED EDUC GRP,CHICAGO,IL 60610, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					921	923		10.1001/jama.266.7.921	http://dx.doi.org/10.1001/jama.266.7.921			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1714526				2022-12-28	WOS:A1991GB20500003
J	HALL, DH; HEDGECOCK, EM				HALL, DH; HEDGECOCK, EM			KINESIN-RELATED GENE UNC-104 IS REQUIRED FOR AXONAL-TRANSPORT OF SYNAPTIC VESICLES IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTION; CELL; MIGRATIONS; EXPRESSION; SYNAPSIN; NEURONS; MUTANTS; GROWTH	unc-104 encodes a novel kinesin paralog that may act as a microtubule-based motor in the nervous system. Neuronal cell lineages and axonogenesis are normal in unc-104 null mutants, but axons have few synaptic vesicles and make only a few small synapses. By contrast, neuron cell bodies have surfeits of similar vesicles tethered together within the cytoplasm. Based on behavioral and cellular phenotypes, we suggest that UNC-104 is a neuron-specific motor used for anterograde translocation of synaptic vesicles along axonal microtubules. Other membrane-bounded organelles are transported normally.	ROCHE INST MOLEC BIOL,DEPT CELL & DEV BIOL,NUTLEY,NJ 07110; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	HALL, DH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461, USA.				NINDS NIH HHS [NS26295, NS07512] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHENG TPO, 1988, J NEUROSCI, V8, P3190; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; HALL DH, 1991, J NEUROSCI, V11, P1; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MORI I, 1988, GENETICS, V120, P397; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; ROGALSKI TM, 1988, GENETICS, V118, P61; ROSE M, 1991, GUIDE CYTOSKELETAL S; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHUBERT D, 1991, TRENDS NEUROSCI, V14, P127, DOI 10.1016/0166-2236(91)90078-9; SIGURDSON DC, 1984, GENETICS, V108, P331; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS JH, 1990, GENETICS, V124, P855; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VENOLIA L, 1990, GENETICS, V126, P345; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; [No title captured]	43	441	449	2	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					837	847		10.1016/0092-8674(91)90391-B	http://dx.doi.org/10.1016/0092-8674(91)90391-B			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710172				2022-12-28	WOS:A1991FP51600014
J	SPRINGALL, DR; HOWARTH, PH; COUNIHAN, H; DJUKANOVIC, R; HOLGATE, ST; POLAK, JM				SPRINGALL, DR; HOWARTH, PH; COUNIHAN, H; DJUKANOVIC, R; HOLGATE, ST; POLAK, JM			ENDOTHELIN IMMUNOREACTIVITY OF AIRWAY EPITHELIUM IN ASTHMATIC-PATIENTS	LANCET			English	Article							SMOOTH-MUSCLE CELLS; VASOCONSTRICTOR PEPTIDE; VASOACTIVE PEPTIDE; GUINEA-PIG	There is extensive pharmacological and physiological evidence that endothelin-1 influences airway calibre. In mammals, endothelin receptors occur on airway smooth muscle, local storage and release of the peptide have been demonstrated, and inhalation of endothelin-1 induces bronchoconstriction. To investigate the relation between endothelins and asthma the expression of this peptide in endobronchial biopsy specimens was examined immunohistochemically with an antiserum against endothelin-1. Biopsy specimens from 17 asthmatic patients and 11 atopic and non-atopic healthy controls revealed striking differences, with endothelin expression being evident in airways epithelium and vascular endothelium in 11 of the 17 asthmatic patients but in only 1 of 11 controls. These results suggest that endothelins may play a part in the exaggerated bronchomotor tone of asthma.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	SPRINGALL, DR (corresponding author), ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0NN,ENGLAND.			Howarth, Peter/0000-0003-0619-7927; Djukanovic, Ratko/0000-0001-6039-5612				BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; CARDELL LO, 1990, ACTA PHYSIOL SCAND, V139, P103, DOI 10.1111/j.1748-1716.1990.tb08902.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; FRANCOCERECEDA A, 1990, ACTA PHYSIOL SCAND, V138, P539, DOI 10.1111/j.1748-1716.1990.tb08882.x; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOSKA T, 1989, FEBS LETT, V249, P42; LAGENTE V, 1989, BIOCHEM BIOPH RES CO, V158, P625, DOI 10.1016/0006-291X(89)92767-8; MAGGI CA, 1989, EUR J PHARMACOL, V160, P179; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; NAGASE T, 1990, BIOCHEM BIOPH RES CO, V168, P485, DOI 10.1016/0006-291X(90)92347-3; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NOMURA A, 1989, LANCET, V2, P747; Pepys J., 1975, BRIT J HOSP MED, V14, P412; POEER RF, 1989, J CARDIOVASC PHARM, V13, pS50; ROCHE WR, 1989, LANCET, V1, P520; ROZENGURT N, 1990, J PATHOL, V160, P5, DOI 10.1002/path.1711600104; SAKATA K, 1989, BRIT J PHARMACOL, V98, P483, DOI 10.1111/j.1476-5381.1989.tb12621.x; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SPRINGALL DR, 1990, AM REV RESPIR DIS, V141, P1538, DOI 10.1164/ajrccm/141.6.1538; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; SUNNERGREN KP, 1990, MOL CELL ENDOCRINOL, V68, P7; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TURNER NC, 1989, BRIT J PHARMACOL, V98, P361, DOI 10.1111/j.1476-5381.1989.tb12605.x; WATANABE A, 1990, 13TH WORLD C ASTHM G, P4; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	30	280	282	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					697	701		10.1016/0140-6736(91)90279-X	http://dx.doi.org/10.1016/0140-6736(91)90279-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1706044				2022-12-28	WOS:A1991FD36700009
J	ABRAHAM, N; MICELI, MC; PARNES, JR; VEILLETTE, A				ABRAHAM, N; MICELI, MC; PARNES, JR; VEILLETTE, A			ENHANCEMENT OF T-CELL RESPONSIVENESS BY THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK	NATURE			English	Article							MONOCLONAL-ANTIBODY; CD4 RECEPTOR; SURFACE-ANTIGENS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION; EXPRESSION; DOMAIN; LINES	LYMPHOCYTE-specific tyrosine protein kinase p56lck is physically associated with CD4 and CD8 T-cell surface molecules, suggesting that it may transduce CD4/CD8-triggered tyrosine phosphorylation signals during antigen stimulation 1,2. Indeed, antibody-mediated aggregation of CD4 (to mimic interaction with its ligand, major histocompatibility complex (MHC) class II molecules), rapidly elevates the kinase activity of p56lck (refs 3, 4) and is associated with marked changes in tyrosine protein phosphorylation 4-6. Genetic analyses suggest that the interaction of CD4/CD8 with p56lck results in a positive signal during antigen-induced T-cell activation 7-10. To evaluate directly the role of p56lck in T-cell activation, we introduced a constitutively activated form of Lck protein (tyrosine 505 to phenylalanine 505 mutant; refs 11-13) in a CD4-negative, MHC-class II restricted mouse T-cell hybridoma 14. We report here that, as for transfection of CD4 10,15,16, expression of the Lck mutant enhanced T-lymphocyte responsiveness. The finding provides direct evidence that p56lck can positively regulate T-cell functions and that it mediates at least some of the effects of CD4 and CD8 on T-cell activation.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA; STANFORD UNIV,MED CTR,DEPT MED,DIV IMMUNOL & RHEUMATOL,STANFORD,CA 94305	McGill University; McGill University; Stanford University			Abraham, Ninan/K-5572-2012	Abraham, Ninan/0000-0002-2747-1246				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARNES JR, 1989, COLD SPRING HARB SYM, V54, P649; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WILDE DB, 1983, J IMMUNOL, V131, P2178; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	37	315	321	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					62	66		10.1038/350062a0	http://dx.doi.org/10.1038/350062a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706070				2022-12-28	WOS:A1991FA69300065
J	STANWORTH, DR; JONES, VM; LEWIN, IV; NAYYAR, S				STANWORTH, DR; JONES, VM; LEWIN, IV; NAYYAR, S			ALLERGY TREATMENT WITH A PEPTIDE VACCINE	LANCET			English	Article											STANWORTH, DR (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,RHEUMATOL & ALLERGY RES UNIT,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BURT DS, 1986, MOL IMMUNOL, V23, P181, DOI 10.1016/0161-5890(86)90041-6; COOPER PH, 1976, METHOD CELL BIOL, P365; JASANI B, 1979, J IMMUNOL METHODS, V30, P55, DOI 10.1016/0022-1759(79)90273-4; Noon L, 1911, LANCET, V1, P1572; SHEPPARD RC, 1986, SCI TOOLS, V33, P9; STANWORTH DR, 1984, MOL IMMUNOL, V21, P1183, DOI 10.1016/0161-5890(84)90008-7; STANWORTH DR, IN PRESS MOL IMMUNOL; 1989, LANCET, V1, P259	9	48	59	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 24	1990	336	8726					1279	1281		10.1016/0140-6736(90)92963-I	http://dx.doi.org/10.1016/0140-6736(90)92963-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ943	1700248				2022-12-28	WOS:A1990EJ94300004
J	KONARSKA, MM; SHARP, PA				KONARSKA, MM; SHARP, PA			STRUCTURE OF RNAS REPLICATED BY THE DNA-DEPENDENT T7 RNA-POLYMERASE	CELL			English	Article									MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Massachusetts Institute of Technology (MIT); Rockefeller University	KONARSKA, MM (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.		Konarska, Maria M./AAT-2572-2021	Konarska, Maria M./0000-0001-9235-1702	NCI NIH HHS [CA14051] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, R01GM034277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARON MH, 1982, J BIOL CHEM, V257, P2351; BAUSCH JN, 1983, J BIOL CHEM, V258, P1978; BIEBRICH.CK, 1973, P NATL ACAD SCI USA, V70, P934, DOI 10.1073/pnas.70.3.934; CAVALIERSMITH T, 1987, COLD SPRING HARB SYM, V52, P805, DOI 10.1101/SQB.1987.052.01.089; CECH TR, 1988, HARVEY LECT, V82, P123; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GUERRIERTAKADA C, 1988, CELL, V53, P267, DOI 10.1016/0092-8674(88)90388-1; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HAENNI AL, 1982, PROG NUCLEIC ACID RE, V27, P85, DOI 10.1016/S0079-6603(08)60598-X; HAENNI AL, 1973, NATURE-NEW BIOL, V241, P166, DOI 10.1038/newbio241166a0; Hall T C, 1979, Int Rev Cytol, V60, P1, DOI 10.1016/S0074-7696(08)61257-7; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANE CM, 1985, BIOCHEMISTRY-US, V24, P2254, DOI 10.1021/bi00330a020; KOHL RJ, 1974, J GEN VIROL, V25, P257, DOI 10.1099/0022-1317-25-2-257; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; Maniatis T., 1982, MOL CLONING; MARSH LE, 1987, COLD SPRING HARB SYM, V52, P331, DOI 10.1101/SQB.1987.052.01.038; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MINKLEY EG, 1973, J MOL BIOL, V77, P255, DOI 10.1016/0022-2836(73)90335-5; PINCK M, 1978, VIROLOGY, V88, P281, DOI 10.1016/0042-6822(78)90285-4; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; PROCHIANTZ A, 1973, NATURE-NEW BIOL, V241, P168, DOI 10.1038/newbio241168a0; RACKWITZ HR, 1981, NATURE, V291, P297, DOI 10.1038/291297a0; Randerath K, 1980, Methods Enzymol, V65, P638; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; ROBERTSON HD, 1987, VIROIDS VIROID LIKE, P49; SEMANCIK JS, 1984, P NATL ACAD SCI-BIOL, V81, P4429, DOI 10.1073/pnas.81.14.4429; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR JM, 1990, CELL, V61, P371, DOI 10.1016/0092-8674(90)90516-H; VANBELKUM A, 1987, BIOCHEMISTRY-US, V26, P1144, DOI 10.1021/bi00378a024; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383	43	51	80	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	1990	63	3					609	618		10.1016/0092-8674(90)90456-O	http://dx.doi.org/10.1016/0092-8674(90)90456-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EG687	1699668				2022-12-28	WOS:A1990EG68700018
J	GRANT, ER; COOKS, RG				GRANT, ER; COOKS, RG			MASS-SPECTROMETRY AND ITS USE IN TANDEM WITH LASER SPECTROSCOPY	SCIENCE			English	Review											GRANT, ER (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.		Grant, Edward/Q-7284-2019; Cooks, R Graham/G-1051-2015	Grant, Edward/0000-0001-5264-2644; Cooks, R Graham/0000-0002-9581-9603				ALEXANDER ML, 1988, J CHEM PHYS, V88, P6200, DOI 10.1063/1.454458; ALLEN JM, 1988, CHEM PHYS LETT, V149, P1, DOI 10.1016/0009-2614(88)80337-3; Ashfold M. N. R., 1987, Comments on Atomic and Molecular Physics, V19, P181; ASHFOLD MNR, 1989, MOL PHYS, V66, P981, DOI 10.1080/00268978900100671; ASHFOLD MNR, 1986, FARADAY DISCUSS, V82, P163, DOI 10.1039/dc9868200163; ASHFOLD MNR, 1988, CONTEMP PHYS, V29, P125, DOI 10.1080/00107518808213758; BAER T, 1989, ANNU REV PHYS CHEM, V40, P637; BEAVIS R, 1988, J AM CHEM SOC, V110, P7534, DOI 10.1021/ja00230a042; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P436, DOI 10.1002/rcm.1290031208; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BERGMANN T, 1989, REV SCI INSTRUM, V60, P792, DOI 10.1063/1.1141022; BERNARD DM, 1990, INT J MASS SPECTROM, V95, P327, DOI 10.1016/0168-1176(90)80031-W; BERNSTEIN RB, 1982, J PHYS CHEM-US, V86, P1178, DOI 10.1021/j100396a025; BERRY RS, 1970, PHYS REV A-GEN PHYS, V1, P383, DOI 10.1103/PhysRevA.1.383; BIESKE EJ, 1990, J PHYS CHEM-US, V94, P3962, DOI 10.1021/j100373a018; BIESKE EJ, 1989, J CHEM PHYS, V90, P2068, DOI 10.1063/1.455998; BIESNER J, 1988, J CHEM PHYS, V88, P3607, DOI 10.1063/1.453910; BIESNER J, 1989, J CHEM PHYS, V91, P2901, DOI 10.1063/1.457644; BIGGERSTAFF J, 1988, CHEM PHYS LETT, V151, P507, DOI 10.1016/S0009-2614(88)85027-9; BIGIO L, 1985, J CHEM PHYS, V83, P5369, DOI 10.1063/1.449706; BIGIO L, 1985, J CHEM PHYS, V83, P5361, DOI 10.1063/1.449705; BIGIO L, 1985, J PHYS CHEM-US, V89, P5855, DOI 10.1021/j100272a056; BIGIO L, 1987, J CHEM PHYS, V87, P360, DOI 10.1063/1.453581; BLACK JF, 1988, CHEM PHYS, V125, P375, DOI 10.1016/0301-0104(88)87090-3; BLACK JF, 1988, J CHEM PHYS, V89, P3986, DOI 10.1063/1.454832; BLACK JF, 1988, CHEM PHYS LETT, V148, P479, DOI 10.1016/0009-2614(88)80317-8; BLACK JF, 1988, LASER CHEM, V9, P339, DOI 10.1155/LC.9.339; BOESIGER J, 1989, PHYS REV LETT, V62, P3058; BORDAS C, 1989, CHEM PHYS, V129, P21, DOI 10.1016/0301-0104(89)80016-3; BORDAS C, 1988, PHYS REV LETT, V60, P917, DOI 10.1103/PhysRevLett.60.917; BORDAS C, 1987, J PHYS PARIS; BOWERS WD, 1986, ANAL CHEM, V58, P972; BREEN JJ, 1989, J CHEM PHYS, V90, P11, DOI 10.1063/1.456517; BRINEGAR AC, 1988, P NATL ACAD SCI USA, V85, P5927, DOI 10.1073/pnas.85.16.5927; BRODBELT JS, 1987, ANAL CHEM, V59, P1278, DOI 10.1021/ac00136a007; BROYER M, 1989, J CHEM PHYS, V90, P4620, DOI 10.1063/1.456599; BRUMER P, 1989, ACCOUNTS CHEM RES, V22, P407, DOI 10.1021/ar00168a001; BRUNNEE C, IN PRESS RAPID COMMU; BUCHANAN MV, 1987, ACS S SERIES, V359; BURGERS PC, 1989, INT J MASS SPECTROM, V95, P157, DOI 10.1016/0168-1176(89)83038-1; BUSCH GE, 1972, J CHEM PHYS, V56, P3626, DOI 10.1063/1.1677740; Busch K.L., 1988, MASS SPECTROMETRY MA; CAMPOS FX, 1990, J CHEM PHYS, V92, P2308; CASTLEMAN AW, 1988, SCIENCE, V241, P36, DOI 10.1126/science.241.4861.36; CASTLEMAN AW, 1986, ANNU REV PHYS CHEM, V37, P525, DOI 10.1146/annurev.pc.37.100186.002521; CHANDLER DW, 1989, CHEM PHYS LETT, V156, P151, DOI 10.1016/S0009-2614(89)87111-8; CHANDLER DW, 1987, J CHEM PHYS, V87, P1445, DOI 10.1063/1.453276; CHEN C, 1990, PHYS REV LETT, V64, P507, DOI 10.1103/PhysRevLett.64.507; CHEN P, 1987, J CHEM PHYS, V86, P516, DOI 10.1063/1.452303; CHEN P, 1988, CHEM PHYS LETT, V147, P466, DOI 10.1016/0009-2614(88)85009-7; CHESHNOVSKY O, 1988, J CHEM PHYS, V88, P4127, DOI 10.1063/1.453820; CHOWDHURY SK, 1990, RAPID COMMUN MASS SP, V4, P81, DOI 10.1002/rcm.1290040305; COFFMAN JD, 1989, Z PHYS D ATOM MOL CL, V12, P297, DOI 10.1007/BF01426961; COOKS RG, 1990, ACCOUNTS CHEM RES, V23, P213, DOI 10.1021/ar00175a002; COOKS RG, 1977, COLLISION SPECTROSCO; COOPER DE, 1981, PHYS REV LETT, V46, P324, DOI 10.1103/PhysRevLett.46.324; CORNISH TJ, 1988, J AM CHEM SOC, V110, P3099, DOI 10.1021/ja00218a018; CORNISH TJ, 1990, J PHYS CHEM-US, V94, P2852, DOI 10.1021/j100370a024; CORNISH TJ, 1989, J PHYS CHEM-US, V93, P6060; COTTRELL JS, 1987, ANAL CHEM, V59, P1990, DOI 10.1021/ac00142a021; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CURL RF, 1988, SCIENCE, V242, P1017, DOI 10.1126/science.242.4881.1017; DANIS PO, 1988, J CHEM PHYS, V88, P3451, DOI 10.1063/1.453893; Dawson P. H, 1995, QUADRUPOLE MASS SPEC; DERRICK PJ, 1987, INT J MASS SPECTROM, V78; ELAND JHD, 1983, PHOTOELECTRON SPECTR; ELSHALL MS, 1989, CHEM PHYS LETT, V163, P41, DOI 10.1016/0009-2614(89)80008-9; EVARD DD, 1989, J PHYS CHEM-US, V93, P3522, DOI 10.1021/j100346a032; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENSELAU C, 1987, CHEM REV, V87, P501, DOI 10.1021/cr00079a002; FREISER BS, 1985, TALANTA, V32, P697, DOI 10.1016/0039-9140(85)80173-9; FUJII A, 1989, J CHEM PHYS, V90, P6993, DOI 10.1063/1.456274; GADE G, 1988, PEPTIDES, V9, P681, DOI 10.1016/0196-9781(88)90107-6; Gaskell S.J., 1986, MASS SPECTROMETRY BI; GEORGIADIS R, 1989, INT J MASS SPECTROM, V91, P123, DOI 10.1016/0168-1176(89)83003-4; GLISH GL, 1989, INT J MASS SPECTROM, V94, P15, DOI 10.1016/0168-1176(89)80057-6; GLISH GL, 1990, ANAL CHEM, V62, P1284; GOERKE R, 1989, GEN PHYS, V39, P5085; GREENE CH, 1985, ADV ATOM MOL PHYS, V21, P51, DOI 10.1016/S0065-2199(08)60141-4; GREER JC, 1989, CHEM PHYS, V133, P191, DOI 10.1016/0301-0104(89)80200-9; GROSS ML, 1984, SCIENCE, V226, P261, DOI 10.1126/science.6385250; GROTEMEYER J, 1988, BIOMED ENVIRON MASS, V16, P143, DOI 10.1002/bms.1200160125; GUEVREMONT R, 1988, RAPID COMMUN MASS SP, V2, P50; HABENICHT W, 1988, BER BUNSEN PHYS CHEM, V92, P414, DOI 10.1002/bbpc.198800085; HABER KS, 1989, CHEM PHYS, V129, P73, DOI 10.1016/0301-0104(89)80020-5; HABER KS, UNPUB; HAHN MY, 1987, J CHEM PHYS, V87, P6764, DOI 10.1063/1.453414; HAHN MY, 1988, J CHEM PHYS, V88, P4242, DOI 10.1063/1.453832; HAHN MY, 1988, PHYS REV LETT, V61, P1190, DOI 10.1103/PhysRevLett.61.1190; HAMMERUM S, 1988, MASS SPECTROM REV, V7, P123, DOI 10.1002/mas.1280070202; HELLER DN, 1989, ANAL CHEM, V61, P1083, DOI 10.1021/ac00185a008; HILL JA, 1989, INT J MASS SPECTROM, V92, P211, DOI 10.1016/0168-1176(89)83029-0; HONEA EC, 1989, PHYS REV LETT, V63, P394, DOI 10.1103/PhysRevLett.63.394; HUDGENS JW, 1987, J CHEM PHYS, V87, P4546, DOI 10.1063/1.452867; HUDGENS JW, 1988, ADV MULTIPHOTON PROC, V4, P171; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; HUNT DF, 1989, 37TH P ASMS C MASS S, P1125; ITO M, 1988, ANNU REV PHYS CHEM, V39, P123, DOI 10.1146/annurev.physchem.39.1.123; JARDINE I, UNPUB; JOHNSON MA, 1984, CHEM PHYS LETT, V112, P285, DOI 10.1016/0009-2614(84)85742-5; JOHNSON PM, 1981, ANNU REV PHYS CHEM, V32, P139, DOI 10.1146/annurev.pc.32.100181.001035; JOHNSON RD, 1988, J PHYS CHEM-US, V92, P3880, DOI 10.1021/j100324a040; JOHNSON RD, 1988, J CHEM PHYS, V89, P6064, DOI 10.1063/1.455421; JOHNSON RD, 1989, J CHEM PHYS, V91, P3340, DOI 10.1063/1.456909; JOHNSON RD, 1990, J CHEM PHYS, V93, P6268; JONSSON G, 1989, RAPID COMMUN MASS SP, V3, P190, DOI DOI 10.1002/RCM.1290030607); Kaiser Jr R.E., 1990, RAPID COMMUN MASS SP, V4, P30; Kaiser R. E., 1989, RAPID COMMUN MASS SP, V3, P225; KAMKE B, 1989, Z PHYS D ATOM MOL CL, V11, P153, DOI 10.1007/BF01444432; KAMKE W, 1987, NATO ASI SER B, V158, P675; KAPPES MM, 1988, CHEM PHYS LETT, V143, P251, DOI 10.1016/0009-2614(88)87376-7; KAPPES MM, 1988, CHEM REV, V88, P369, DOI 10.1021/cr00084a002; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KHUNDKAR LR, 1987, CHEM PHYS LETT, V142, P426, DOI 10.1016/0009-2614(87)85137-0; KIERMEIER A, 1988, J PHYS CHEM-US, V92, P3785, DOI 10.1021/j100324a020; KIERMEIER A, 1988, J CHEM PHYS, V88, P6182, DOI 10.1063/1.454457; KIM HS, 1986, J CHEM PHYS, V84, P4882, DOI 10.1063/1.449976; KNOCHENMUSS R, 1989, J CHEM PHYS, V91, P1268, DOI 10.1063/1.457202; KNOCHENMUSS R, 1988, CHEM PHYS LETT, V144, P317, DOI 10.1016/0009-2614(88)87121-5; KORNIG S, 1989, INT J MASS SPECTROM, V93, P49, DOI 10.1016/0168-1176(89)83074-5; LAMMERTSMA K, 1989, ANGEW CHEM INT EDIT, V28, P1321, DOI 10.1002/anie.198913211; LARAMEE JA, 1989, ANAL CHEM, V61, P2154, DOI 10.1021/ac00194a008; LEE AR, 1990, RAPID COMMUN MASS SP, V4, P242, DOI 10.1002/rcm.1290040704; LEE YT, 1986, ATOMIC MOL BEAM METH; LEVICK AP, 1989, J MOL SPECTROSC, V133, P227, DOI 10.1016/0022-2852(89)90257-9; LEVICK AP, 1989, PHYS REV LETT, V63, P2216, DOI 10.1103/PhysRevLett.63.2216; LEVINGER NE, UNPUB; Levy D.H., 1981, ADV CHEM PHYS, V47, P323; LI LP, 1987, J CHEM PHYS, V87, P6767, DOI 10.1063/1.453416; LIPERT RJ, 1990, J PHYS CHEM-US, V94, P2358, DOI 10.1021/j100369a031; LIPERT RJ, 1989, CHEM PHYS LETT, V161, P303, DOI 10.1016/0009-2614(89)85089-4; LIPERT RJ, 1989, J PHYS CHEM-US, V93, P3894, DOI 10.1021/j100347a008; LIPERT RJ, 1988, J CHEM PHYS, V89, P4579, DOI 10.1063/1.454798; LIPERT RJ, 1988, J PHYS CHEM-US, V92, P3801, DOI 10.1021/j100324a024; LIU WL, 1988, J CHEM PHYS, V89, P606; LOMBARDI M, 1988, J CHEM PHYS, V89, P3479, DOI 10.1063/1.454918; LOO JA, 1990, SCIENCE, V248, P201, DOI 10.1126/science.2326633; LOURIS JN, 1989, INT J MASS SPECTROM, V88, P97, DOI 10.1016/0168-1176(89)85010-4; LOURIS JN, 1987, INT J MASS SPECTROM, V75, P345, DOI 10.1016/0168-1176(87)83045-8; LOURIS JN, 1985, ANAL CHEM, V57, P2918, DOI 10.1021/ac00291a039; LOURIS JN, 1990, INT J MASS SPECTROM, V96, P117, DOI 10.1016/0168-1176(90)87025-C; LOURIS JN, 1987, ANAL CHEM, V59, P1677, DOI 10.1021/ac00140a021; LUBMAN DM, 1990, LASERS MASS SPECTROM, P353; MAAS WPM, 1989, INT J MASS SPECTROM, V88, P257, DOI 10.1016/0168-1176(89)85020-7; MAIER JP, 1989, ION CLUSTER ION SPEC; MAJUMDAR T, UNPUB; MARCH RE, 1989, QUADRUPOLE STORAGE M; MARSHALL AG, 1985, ACCOUNTS CHEM RES, V18, P316, DOI 10.1021/ar00118a006; MARTIN SA, 1987, INT J MASS SPECTROM, V78, P213, DOI 10.1016/0168-1176(87)87050-7; Martin T., UNPUB; MCLAFFERTY FW, 1990, SCIENCE, V247, P925, DOI 10.1126/science.2305261; MCLUCKEY SA, 1989, INT J MASS SPECTROM, V94, P115; MCNEAL CJ, 1988, 4TH P TEX S MASS SPE, P55; MCNEAL CJ, 1988, ANAL PEPTIDES PROTEI; MILLER RJ, 1989, J CHEM PHYS, V90, P754, DOI 10.1063/1.456099; Morris HR, 1989, RAPID COMMUN MASS SP, V3, P110, DOI 10.1002/rcm.1290030406; MORRISON RJS, 1981, J CHEM PHYS, V75, P2643, DOI 10.1063/1.442419; MORSE MD, 1986, CHEM REV, V86, P1049, DOI 10.1021/cr00076a005; NEWMAN AR, 1990, ANAL CHEM, V62, pA671; NG CY, 1988, TECHNIQUES CHEM, V20, P417; NIEDNER G, 1987, J CHEM PHYS, V87, P2067, DOI 10.1063/1.453182; NOURSE BD, 1990, ANAL CHIM ACTA, V228, P1, DOI 10.1016/S0003-2670(00)80473-0; OBRIEN SC, 1988, J CHEM PHYS, V88, P220, DOI 10.1063/1.454640; OHALLORAN MA, 1989, J CHEM PHYS, V90, P930, DOI 10.1063/1.456119; OKA T, 1988, PHILOS T R SOC A, V324, P81, DOI 10.1098/rsta.1988.0002; OKUMURA M, 1988, J CHEM PHYS, V88, P79, DOI 10.1063/1.454488; OLEAR JR, 1987, ORG MASS SPECTROM, V22, P348, DOI 10.1002/oms.1210220608; ORLANDO R, 1990, ANAL CHEM, V62, P125, DOI 10.1021/ac00201a008; OTIS CE, 1983, J PHYS CHEM-US, V87, P2232, DOI 10.1021/j100235a037; OVERBERG A, 1990, RAPID COMMUN MASS SP, V4, P293, DOI 10.1002/rcm.1290040808; PACHUTA SJ, 1987, CHEM REV, V87, P647, DOI 10.1021/cr00079a009; PATSILINAKOU E, 1989, J CHEM PHYS, V91, P3916, DOI 10.1063/1.456823; PAUL W, 1959, Z PHYS, V156, P1; PHILIPS LA, 1988, J CHEM PHYS, V89, P85, DOI 10.1063/1.455464; POWIS I, 1989, J PHYS CHEM-US, V93, P2461, DOI 10.1021/j100343a047; POWIS I, 1990, J CHEM PHYS, V92, P1643, DOI 10.1063/1.458098; PRATT ST, 1989, J CHEM PHYS, V90, P2201, DOI 10.1063/1.456015; PRATT ST, 1989, J CHEM PHYS, V90, P5971, DOI 10.1063/1.456363; PRICE JM, 1989, J CHEM PHYS, V91, P2749, DOI 10.1063/1.456986; RAY D, 1989, J CHEM PHYS, V91, P6533, DOI 10.1063/1.457370; REINHOLD VN, 1987, CARBOHYD RES, V161, P305, DOI 10.1016/S0008-6215(00)90088-0; RINEHART KL, 1988, J AM CHEM SOC, V110, P8557, DOI 10.1021/ja00233a049; ROCKNEY BH, 1981, CHEM PHYS LETT, V79, P15, DOI 10.1016/0009-2614(81)85278-5; RUSCIC B, 1989, J CHEM PHYS, V91, P6780, DOI 10.1063/1.457347; RUSCIC B, 1989, J CHEM PHYS, V91, P4183, DOI 10.1063/1.456795; Salehpour M, 1989, Rapid Commun Mass Spectrom, V3, P259, DOI 10.1002/rcm.1290030804; SAPPEY AD, 1989, J CHEM PHYS, V91, P3731; SARRE PJ, 1988, CHEM PHYS, V124, P439, DOI 10.1016/0301-0104(88)87067-8; SARRE PJ, 1988, PHILOS T R SOC A, V324, P233, DOI 10.1098/rsta.1988.0014; SAYKALLY RJ, 1988, SCIENCE, V239, P157, DOI 10.1126/science.239.4836.157; Schey K. L., 1989, RAPID COMMUN MASS SP, V3, P305, DOI DOI 10.1002/RCM.1290030910; SCHRIVER KE, 1987, PHYS REV LETT, V59, P1906, DOI 10.1103/PhysRevLett.59.1906; SCHRIVER KE, 1989, J PHYS CHEM-US, V93, P2869, DOI 10.1021/j100345a001; SCHUMACHER E, 1987, JERUSALEM S QUANTUM, V20, P289; SCHWARTZ JC, 1990, ANAL CHEM, V62, P1809, DOI 10.1021/ac00216a016; SCHWARZ M, 1988, J CHEM PHYS, V89, P5460, DOI 10.1063/1.455598; SEAVER M, 1982, AIP C P, V90, P45; SEKRETA E, 1988, CHEM PHYS LETT, V149, P42; SELGREN SF, 1988, ANAL INSTRUM, V27, P131; SMITH RD, 1990, J AM SOC MASS SPECTR, V1, P53, DOI 10.1016/1044-0305(90)80006-9; SMITH RD, 1990, RAPID COMMUN MASS SP, V4, P54, DOI 10.1002/rcm.1290040205; SMITH RD, 1988, ANAL CHEM, V60, P436, DOI 10.1021/ac00156a013; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; SMITH RD, 1990, 2ND INT S APPL MASS; SPENGLER B, 1990, ANAL CHEM, V62, P793, DOI 10.1021/ac00207a004; SPIGLANIN TA, 1987, CHEM PHYS LETT, V141, P428, DOI 10.1016/0009-2614(87)85054-6; STAFFORD GC, 1984, INT J MASS SPECTROM, V60, P85, DOI 10.1016/0168-1176(84)80077-4; STANLEY MS, 1988, JPC-J PLANAR CHROMAT, V1, P138; STANLEY RJ, 1990, J CHEM PHYS, V92, P5770, DOI 10.1063/1.458397; STEADMAN J, 1988, J CHEM PHYS, V89, P5507, DOI 10.1063/1.455603; STEADMAN J, 1989, J CHEM PHYS, V91, P6113, DOI 10.1063/1.457430; SULZLE D, 1989, CHEM BER-RECL, V122, P1803, DOI 10.1002/cber.19891220930; SULZLE D, 1990, J AM CHEM SOC, V112, P3750; SULZLE D, 1989, CHEM BER, V122, P2411, DOI 10.1002/cber.19891221233; SULZLE D, 1990, J AM CHEM SOC, V112, P628; SYAGE JA, 1989, J PHYS CHEM-US, V93, P170, DOI 10.1021/j100338a037; SYAGE JA, 1990, J CHEM PHYS, V92, P1804, DOI 10.1063/1.458062; TANNOR DJ, 1986, J CHEM PHYS, V85, P5805, DOI 10.1063/1.451542; TAPPER RS, 1984, J PHYS CHEM-US, V88, P1273, DOI 10.1021/j150651a003; TECKLENBURG RE, 1990, MASS SPECTROM REV, V9, P405, DOI 10.1002/mas.1280090403; TEE ED, 1988, ANAL CHEM, V60, P1990; TJOSSEM PJH, 1988, J CHEM PHYS, V88, P617, DOI 10.1063/1.454188; TOMER KB, 1988, ANAL CHEM, V60, P2232, DOI 10.1021/ac00171a014; TONKYN RG, 1989, CHEM PHYS LETT, V164, P137, DOI 10.1016/0009-2614(89)85005-5; TONKYN RG, UNPUB; TRICKL T, 1989, J CHEM PHYS, V91, P6006, DOI 10.1063/1.457417; TROXLER T, 1989, CHEM PHYS LETT, V159, P554, DOI 10.1016/0009-2614(89)87531-1; TSAI BP, 1989, J PHYS CHEM-US, V93, P5334, DOI 10.1021/j100351a004; TSUCHIYA Y, 1989, J CHEM PHYS, V90, P6965, DOI 10.1063/1.456272; VANBERKEL GJ, 1990, ANAL CHEM, V62, P1284, DOI 10.1021/ac00212a016; WANG CRC, 1990, CHEM PHYS LETT, V166, P26, DOI 10.1016/0009-2614(90)87044-R; WEISS FD, 1988, J AM CHEM SOC, V110, P4464, DOI 10.1021/ja00221a085; WHETTEN RL, 1984, J CHEM PHYS, V81, P691, DOI 10.1063/1.447751; WHETTEN RL, 1986, J CHEM PHYS, V84, P654, DOI 10.1063/1.450559; WHETTEN RL, 1984, J CHEM PHYS, V80, P1711, DOI 10.1063/1.446927; WHETTEN RL, 1984, J CHEM PHYS, V80, P5999, DOI 10.1063/1.446681; WHETTEN RL, 1983, J PHYS CHEM-US, V87, P1484, DOI 10.1021/j100232a006; WHETTEN RL, 1985, SURF SCI, V156, P8, DOI 10.1016/0039-6028(85)90554-0; WHETTEN RL, 1985, ANNU REV PHYS CHEM, V36, P277, DOI 10.1146/annurev.physchem.36.1.277; WHETTEN RL, 1984, J CHEM PHYS, V81, P1270; WODTKE AM, 1985, J PHYS CHEM-US, V89, P4744, DOI 10.1021/j100268a019; WORKMAN DB, 1988, INORG CHEM, V27, P1846, DOI 10.1021/ic00284a003; WU M, 1989, J CHEM PHYS, V91, P7399, DOI 10.1063/1.457264; WYTTENBACH T, 1989, J CHEM PHYS, V90, P4645, DOI 10.1063/1.456608; XIE XX, 1990, J CHEM PHYS, V92, P1608, DOI 10.1063/1.458093; YEH LI, 1989, J CHEM PHYS, V91, P7319, DOI 10.1063/1.457305; YOKOYAMA A, 1990, J CHEM PHYS, V92, P4222, DOI 10.1063/1.457780; Zewail A. H., 1978, ADV LASER CHEM; ZHANG MY, 1989, J AM CHEM SOC, V111, P8341, DOI 10.1021/ja00204a003; ZHAO X, 1989, J CHEM PHYS, V90, P5517; ZWANZIGER JW, 1988, J CHEM PHYS, V89, P4012, DOI 10.1063/1.454834	252	22	23	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 5	1990	250	4977					61	68		10.1126/science.1699276	http://dx.doi.org/10.1126/science.1699276			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB467	1699276				2022-12-28	WOS:A1990EB46700022
J	ANNAS, GJ				ANNAS, GJ			USING GENES TO DEFINE MOTHERHOOD - THE CALIFORNIA SOLUTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Annas, George/0000-0001-5836-7831				ANGELL M, 1990, NEW ENGL J MED, V323, P1200, DOI 10.1056/NEJM199010253231709; Annas G J, 1988, Law Med Health Care, V16, P27; BALKIN, 1990, CARDOZO L REV, V11, P1613; Balkin J. M., 1990, CARDOZO L REV, V11, P1618; ELIAS S, 1986, JAMA-J AM MED ASSOC, V255, P62, DOI 10.1001/jama.255.1.62; HARRISON M, 1990, WALL STREET J   1024, pA12; Kolata Gina, 1991, N Y Times Web, P30; LEVRAN D, 1990, NEW ENGL J MED, V323, P1153, DOI 10.1056/NEJM199010253231701; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; 1990, ETHICAL ISSUES SURRO	10	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					417	420		10.1056/NEJM199202063260618	http://dx.doi.org/10.1056/NEJM199202063260618			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729636	Green Published			2022-12-28	WOS:A1992HC38600033
J	GLOVER, ED				GLOVER, ED			TRANSDERMAL NICOTINE PATCH FOR SMOKING CESSATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											GLOVER, ED (corresponding author), W VIRGINIA UNIV,MED CTR,SCH MED,MORGANTOWN,WV 26506, USA.							TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503	1	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728741				2022-12-28	WOS:A1992HA99100012
J	MIZUNO, K; SATOMURA, K; MIYAMOTO, A; ARAKAWA, K; SHIBUYA, T; ARAI, T; KURITA, A; NAKAMURA, H; AMBROSE, JA				MIZUNO, K; SATOMURA, K; MIYAMOTO, A; ARAKAWA, K; SHIBUYA, T; ARAI, T; KURITA, A; NAKAMURA, H; AMBROSE, JA			ANGIOSCOPIC EVALUATION OF CORONARY-ARTERY THROMBI IN ACUTE CORONARY SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNSTABLE ANGINA-PECTORIS; PLACEBO-CONTROLLED TRIAL; TISSUE PLASMINOGEN-ACTIVATOR; ANGIOGRAPHIC MORPHOLOGY; INTRACORONARY THROMBUS; THROMBOLYTIC THERAPY; DOUBLE-BLIND; PATHOGENESIS; INFARCTION; DISEASE	Background. Disruption of an atherosclerotic plaque in a coronary artery followed by the formation of a thrombus is believed to be the cause of both unstable angina and acute myocardial infarction. Although thrombolytic therapy is efficacious in patients with acute myocardial infarction, for unknown reasons it is far less effective in patients with unstable angina. We postulated that there might be differences in the composition of the coronary-artery thrombi in unstable angina and acute myocardial infarction. Methods. To investigate the appearance of coronary-artery thrombi, we performed percutaneous transluminal coronary angioscopy in 15 patients with unstable angina and 16 with acute myocardial infarction. Angioscopy was performed within 48 hours after an episode of pain at rest in the patients with unstable angina and within 8 hours of onset in those with acute myocardial infarction. per Results. Angioscopy revealed coronary thrombi in all but two patients (one in each group). Of the 29 patients with thrombi, those with unstable angina were frequently observed to have grayish-white thrombi (10 of 14, 71 percent), but none were seen in the 15 patients with acute myocardial infarction (P < 0.01). By contrast, reddish thrombi were observed in all 15 patients with acute myocardial infarction who had thrombi, but in only 4 of the 14 patients with unstable angina and thrombi (P < 0.01). As assessed by coronary angiography, occlusive thrombi occurred frequently in patients with acute myocardial infarction (13 of 16 patients) but were not seen in any of the 15 patients with unstable angina (P < 0.01). Conclusions. Coronary-artery thrombi play an important part in the pathogenesis of unstable angina and acute myocardial infarction. However, the appearance of the thrombi is different in the two conditions, possibly reflecting differences in the composition or age of the thrombi or the presence or absence of blood flow in the artery. This difference may account for the contrasting results of thrombolytic therapy.	NATL DEF MED COLL,DEPT MED ENGN,TOKOROZAWA,SAITAMA 359,JAPAN; CUNY MT SINAI SCH MED,DEPT MED,DIV CARDIOL,NEW YORK,NY 10029	National Defense Medical College - Japan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MIZUNO, K (corresponding author), NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN.							AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; AMBROSE JA, 1987, J AM COLL CARDIOL, V9, P1156, DOI 10.1016/S0735-1097(87)80321-2; AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2; AMBROSE JA, 1989, J AM COLL CARDIOL, V13, P1661; ANDERSON JR, 1985, MUIRS TXB PATHOLOGY, P1012; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CAPONE G, 1985, AM J CARDIOL, V56, P403, DOI 10.1016/0002-9149(85)90875-6; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEZWAAN C, 1988, J AM COLL CARDIOL, V12, P301, DOI 10.1016/0735-1097(88)90398-1; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FORRESTER JS, 1987, CIRCULATION, V75, P505, DOI 10.1161/01.CIR.75.3.505; FREEMAN MR, 1989, CIRCULATION, V80, P17, DOI 10.1161/01.CIR.80.1.17; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GOLD HK, 1987, CIRCULATION, V75, P1192, DOI 10.1161/01.CIR.75.6.1192; GOTOH K, 1988, CIRCULATION, V77, P526, DOI 10.1161/01.CIR.77.3.526; HOLMES DR, 1981, BRIT HEART J, V45, P411; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; MIZUNO K, 1991, LANCET, V337, P809, DOI 10.1016/0140-6736(91)92514-3; Neri Serneri G G, 1990, Lancet, V335, P615, DOI 10.1016/0140-6736(90)90407-V; NERISERNERI GG, 1990, LANCET, V335, P868; NICKLAS JM, 1989, J AM COLL CARDIOL, V13, P434, DOI 10.1016/0735-1097(89)90524-X; PASTERNAK RC, 1988, HEART DISEASE TXB CA, V2, P1222; RAMEE SR, 1991, J AM COLL CARDIOL, V17, P100, DOI 10.1016/0735-1097(91)90710-Q; REHR R, 1989, J AM COLL CARDIOL, V14, P1429, DOI 10.1016/0735-1097(89)90376-8; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1987, CIRCULATION, V75, P156, DOI 10.1161/01.CIR.75.1.156; TOPOL EJ, 1988, AM J CARDIOL, V62, P368, DOI 10.1016/0002-9149(88)90960-5; UCHIDA Y, 1986, AM HEART J, V112, P691, DOI 10.1016/0002-8703(86)90462-X; VETROVEC GW, 1981, AM HEART J, V102, P1201; WILLIAMS DO, 1990, CIRCULATION, V82, P376, DOI 10.1161/01.CIR.82.2.376; YANAGIDA S, 1989, CIRCULATION S2, V80, P376	35	462	470	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					287	291		10.1056/NEJM199201303260502	http://dx.doi.org/10.1056/NEJM199201303260502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728732				2022-12-28	WOS:A1992HA99100002
J	WACHTEL, T; PIETTE, J; MOR, V; STEIN, M; FLEISHMAN, J; CARPENTER, C				WACHTEL, T; PIETTE, J; MOR, V; STEIN, M; FLEISHMAN, J; CARPENTER, C			QUALITY-OF-LIFE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - MEASUREMENT BY THE MEDICAL OUTCOMES STUDY INSTRUMENT	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF LIFE; HIV INFECTIONS; OUTCOME ASSESSMENT (HEALTHY CARE); ACQUIRED IMMUNODEFICIENCY SYNDROME; HEALTH STATUS	AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; CARE	Objective: To assess the reliability and validity of the Medical Outcomes Study (MOS) Short Form Health Survey as an indicator for quality of life in patients infected with the human immunodeficiency virus (HIV). Design: Patient interview survey. Setting: The AIDS Health Services Program in seven sites: Newark and Jersey City, New Jersey; Nassau County, New York; Atlanta, Georgia; Dallas, Texas; Fort Lauderdale and Miami, Florida; New Orleans, Louisiana; and Seattle, Washington. Patients: Patients (520) with HIV infection receiving health services at one of the above sites. Measurements: All components of the MOS Short Form Health Survey were included in the interview. Minor modifications were made to adapt the survey to the particular circumstances of the study. Measured sociodemographic characteristics included age, sex, race, intravenous drug use, and education. Symptoms were assessed by closed-ended questions concerning memory, seizure, weakness or numbness, fever, chills, diaphoreses, dyspnea, diarrhea, and weight loss. Information on the frequency of symptoms was also collected. History of Pneumocystis carinii pneumonia and Kaposi sarcoma was noted. Main Results: The sociodemographic characteristics resemble those of patients with the acquired immunodeficiency syndrome (AIDS) reported to the Centers for Disease Control (CDC): mean age, 36; men, 89%; nonwhite, 31%; intravenous drug use, 34%. Neurologic symptoms (memory trouble, seizures, weakness or numbness) occurred in 71% of patients; constitutional symptoms (fever, chills, night sweats, weight loss) in 69%; dyspnea in 50%; and diarrhea in 47%. Although older age, female sex, nonwhite race, and intravenous drug use were associated with lower MOS scores in several areas, the strongest single or adjusted indicator of lower MOS scores was the presence of symptoms. Finally, patients with HIV infection had significantly lower scores than did previously reported patients with other chronic medical conditions (P < 0.001). Conclusions: The MOS survey is a reliable measure of quality of life for patients with HIV infection. These patients tend to have low scores, suggesting validity of the survey. The MOS survey is extremely sensitive to the effect of symptoms, which suggests that it might be useful as a quality-of-life indicator for AIDS clinical drug trails.			WACHTEL, T (corresponding author), RHODE ISL HOSP, DIV GEN INTERNAL MED, 593 EDDY ST, PROVIDENCE, RI 02903 USA.							BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BARKER S, 1990, LANCET, V335, P1045, DOI 10.1016/0140-6736(90)91117-S; BINDMAN AB, 1990, MED CARE, V28, P1142, DOI 10.1097/00005650-199012000-00003; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISHMAN J, DHHS PHS893447 PUB; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; MOR V, 1989, HEALTH AFFAIR, V8, P139, DOI 10.1377/hlthaff.8.4.139; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; PIETTE J, 1991, HEALTH SERV RES, V26, P75; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; RAGSDALE D, 1990, NURS RES, V39, P355; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHROEDER SA, 1987, NEW ENGL J MED, V316, P160, DOI 10.1056/NEJM198701153160309; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; 1990, MMWR, V39, P81	26	283	286	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					129	137		10.7326/0003-4819-116-2-129	http://dx.doi.org/10.7326/0003-4819-116-2-129			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727616				2022-12-28	WOS:A1992GZ35600005
J	ALDHOUS, P				ALDHOUS, P			TECHNOLOGY - STAFF BUYOUT FOR BTG	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					102	102						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1729639				2022-12-28	WOS:A1992GY62900012
J	DWYER, JM				DWYER, JM			DRUG-THERAPY - MANIPULATING THE IMMUNE-SYSTEM WITH IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTRAVENOUS GAMMA-GLOBULIN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; AUTOIMMUNE HEMOLYTIC-ANEMIA; PLACEBO-CONTROLLED TRIAL; CHRONIC FATIGUE SYNDROME; ANTI-IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN-G IGG; RED-CELL APLASIA; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS				DWYER, JM (corresponding author), PRINCE WALES HOSP, DIV MED, HIGH ST, RANDWICK, NSW 2031, AUSTRALIA.							ABDOU NI, 1981, J CLIN INVEST, V67, P1297, DOI 10.1172/JCI110158; ANDERSON CL, 1989, CLIN IMMUNOL IMMUNOP, V53, pS63, DOI 10.1016/0090-1229(89)90071-8; ARSURA E, 1989, CLIN IMMUNOL IMMUNOP, V53, pS170, DOI 10.1016/0090-1229(89)90083-4; BALLOW M, 1990, J CLIN IMMUNOL, V10, pS3, DOI 10.1007/BF00918685; BARANDUN S, 1986, VOX SANG, V51, P157, DOI 10.1111/j.1423-0410.1986.tb00235.x; BARBUI T, 1984, BRIT J HAEMATOL, V58, P554, DOI 10.1111/j.1365-2141.1984.tb04004.x; BERCHTOLD P, 1991, P245; BERLIN G, 1985, LANCET, V1, P1153; BERNEY SI, 1985, BRIT J HAEMATOL, V61, P627, DOI 10.1111/j.1365-2141.1985.tb02876.x; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BREEDVELD FC, 1985, J RHEUMATOL, V12, P700; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; BUSSEL J, 1988, J PEDIATR-US, V112, P298, DOI 10.1016/S0022-3476(88)80074-X; BUSSEL J B, 1991, P253; BUSSEL JB, 1986, PROG HEMOST THROMB, V8, P103; BUSSEL JB, 1984, BRIT J HAEMATOL, V56, P1, DOI 10.1111/j.1365-2141.1984.tb01266.x; BUSSEL JB, 1989, CLIN IMMUNOL IMMUNOP, V53, pS147, DOI 10.1016/0090-1229(89)90080-9; CARRERAS LO, 1988, LANCET, V2, P393; CARROLL RR, 1984, AM J MED, V76, P181, DOI 10.1016/0002-9343(84)90339-5; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; COMBE B, 1985, AM J MED, V78, P920, DOI 10.1016/0002-9343(85)90213-X; COOK L, 1988, J CLIN IMMUNOL, V8, P23, DOI 10.1007/BF00915153; COTTIER H, 1986, VOX SANG, V51, P39, DOI 10.1111/j.1423-0410.1986.tb02006.x; COULAM C, 1991, P395; COUTINHO A, 1984, IMMUNOL REV, V79, P151, DOI 10.1111/j.1600-065X.1984.tb00492.x; DAFFOS F, 1988, LANCET, V2, P910; DELACAMARA C, 1988, NEW ENGL J MED, V318, P519; DIETRICH G, 1990, J CLIN INVEST, V85, P620, DOI 10.1172/JCI114483; DIETRICH G, 1989, PROGR IMMUNOLOGY, V7, P1221; DORF ME, 1989, PROGR IMMUNOLOGY, V7, P874; Dwyer J M, 1987, Adv Intern Med, V32, P111; DWYER J M, 1991, P427; DWYER J M, 1991, P387; DWYER JM, 1981, CLIN EXP IMMUNOL, V46, P237; Eibl M M, 1989, Immunodefic Rev, V1 Suppl, P1; EKERT H, 1985, LANCET, V2, P1310; ENGLE MA, 1989, AM J DIS CHILD, V143, P1300, DOI 10.1001/archpedi.1989.02150230058023; FASTH A, 1986, ARCH DIS CHILD, V61, P86, DOI 10.1136/adc.61.1.86; FATEHMOGHADAM A, 1984, LANCET, V1, P848; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FINN NG, 1987, ARCH INTERN MED, V147, P2165, DOI 10.1001/archinte.147.12.2165; FONG S, 1986, J IMMUNOL, V137, P122; FURUSHO K, 1984, LANCET, V2, P1055; GAEDICKE G, 1984, BLUT, V48, P387, DOI 10.1007/BF00319968; GAJDOS P, 1984, LANCET, V1, P406; GELFAND EW, 1989, J ALLERGY CLIN IMMUN, V84, P613, DOI 10.1016/0091-6749(89)90199-1; GELFAND EW, 1989, CLIN IMMUNOL IMMUNOP, V53, pS1, DOI 10.1016/0090-1229(89)90064-0; GIANELLABORRADORI A, 1984, BLUT, V48, P403, DOI 10.1007/BF00319972; GODARD W, 1985, ANN INTERN MED, V103, P965, DOI 10.7326/0003-4819-103-6-965_1; GOLDSTEIN R, 1986, ARTHRITIS RHEUM, V29, P426, DOI 10.1002/art.1780290319; GROOTHOFF JW, 1988, BRIT MED J, V296, P1362, DOI 10.1136/bmj.296.6633.1362; GUPTA A, 1986, AM J DIS CHILD, V140, P143, DOI 10.1001/archpedi.1986.02140160061033; HANADA T, 1987, EUR J HAEMATOL, V38, P400; HEINZE E, 1985, ACTA PAEDIATR SCAND, V74, P605, DOI 10.1111/j.1651-2227.1985.tb11039.x; HEYMAN MR, 1990, SOUTHERN MED J, V83, P1471, DOI 10.1097/00007611-199012000-00025; HIERNAUX J, 1981, J EXP MED, V153, P1004, DOI 10.1084/jem.153.4.1004; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; IMBACH P, 1981, LANCET, V1, P1228; IMBACH P, 1981, HELV PAEDIATR ACTA, V36, P81; IMBACH P, 1991, P239; Imbach P., 1991, IMMUNOTHERAPY INTRAV; JERNE NK, 1976, IMMUNE SYSTEM WEB V; JORDAN SC, 1989, CLIN IMMUNOL IMMUNOP, V53, pS164, DOI 10.1016/0090-1229(89)90082-2; KEARNEY JF, 1989, FUNDAMENTAL IMMUNOLO, P663; KICKLER T, 1990, BLOOD, V75, P313; KINCADE PW, 1989, FUNDAMENTAL IMMUNOLO, P41; KLEYWEG RP, 1988, NEUROLOGY, V38, P1639, DOI 10.1212/WNL.38.10.1639; KURTZBERG J, 1987, AM J MED, V83, P4, DOI 10.1016/0002-9343(87)90544-4; KURTZBERG J, 1987, AM J MED, V83, P30, DOI 10.1016/0002-9343(87)90548-1; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; LAKOS A, 1987, AM J DIS CHILD, V141, P12, DOI 10.1001/archpedi.1987.04460010012006; LANG B A, 1988, Arthritis and Rheumatism, V31, pS117; LARSEN G L, 1991, P319; LEKOVA ES, 1990, PEDIATR INFECT DIS J, V9, P620; LEONG G M, 1991, P269; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LIN CY, 1989, NEPHRON, V53, P303, DOI 10.1159/000185772; LINDER N, 1990, DEV PHARMACOL THERAP, V14, P205, DOI 10.1159/000480899; LLOYD A, 1990, AM J MED, V89, P561, DOI 10.1016/0002-9343(90)90173-B; LUM LG, 1980, NEW ENGL J MED, V302, P892, DOI 10.1056/NEJM198004173021604; LUSHER JM, 1987, AM J MED, V83, P10, DOI 10.1016/0002-9343(87)90545-6; MACINTYRE EA, 1985, BRIT J HAEMATOL, V60, P387, DOI 10.1111/j.1365-2141.1985.tb07430.x; MCDEVITT HO, 1989, PROGR IMMUNOLOGY, V7, P68; MCGUIRE WA, 1987, NEW ENGL J MED, V317, P1004, DOI 10.1056/NEJM198710153171606; MELLMAN I, 1988, J CELL SCI, P45; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; MORGENSTERN GR, 1983, BRIT MED J, V287, P584, DOI 10.1136/bmj.287.6392.584; MORI PG, 1983, ARCH DIS CHILD, V58, P851, DOI 10.1136/adc.58.11.851; MOSSMAN S, 1986, LANCET, V1, P116; MURAKAMI H, 1985, Keio Journal of Medicine, V34, P227; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; NILSSON IM, 1983, SCAND J HAEMATOL, V30, P458; NILSSON IM, 1988, NEW ENGL J MED, V318, P947, DOI 10.1056/NEJM198804143181503; OCHS H D, 1991, P359; ODA H, 1985, J PEDIATR-US, V107, P744, DOI 10.1016/S0022-3476(85)80405-4; OXELIUS VA, 1984, AM J MED, V76, P7, DOI 10.1016/0002-9343(84)90314-0; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; PHILLIPS RA, 1989, PROG IMMUNOL, V7, P305; POCECCO M, 1986, J PEDIATR-US, V109, P726, DOI 10.1016/S0022-3476(86)80252-9; POCECCO M, 1988, HELV PAEDIATR ACTA, V42, P289; POLLACK S, 1982, NEW ENGL J MED, V307, P253; RICEVUTI G, 1986, CLIN LAB HAEMATOL, V8, P325, DOI 10.1111/j.1365-2257.1986.tb00120.x; ROHR G, 1987, LANCET, V1, P170; ROSSI F, 1988, CLIN EXP IMMUNOL, V74, P311; ROSSI F, 1989, J IMMUNOL, V143, P4104; RUBINSTEIN A, 1984, Pediatric Research, V18, p264A, DOI 10.1203/00006450-198404001-01026; SALAMA A, 1983, LANCET, V2, P193; SALAMA A, 1984, BLUT, V48, P391, DOI 10.1007/BF00319969; SANY J, 1982, ARTHRITIS RHEUM, V25, P17, DOI 10.1002/art.1780250103; SCHAAD U B, 1991, P201; SCHMIDT RE, 1981, LANCET, V2, P475; SCHULLER E, 1983, EUR NEUROL, V22, P205, DOI 10.1159/000115560; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SEIFRIED E, 1984, BLUT, V48, P397, DOI 10.1007/BF00319971; SHETH KJ, 1990, AM J DIS CHILD, V144, P268, DOI 10.1001/archpedi.1990.02150270014009; SHULMAN ST, 1991, IMMUNOTHERAPY INTRAV, P261; SILVERMAN ED, 1990, ARTHRITIS RHEUM, V33, P1015, DOI 10.1002/art.1780330714; SOUKOP W, 1986, WIEN MED WOCHENSCHR, V136, P477; STASZEWSKI H, 1989, ACTA HAEMATOL-BASEL, V82, P201; Stokes J, 1944, J CLIN INVEST, V23, P531, DOI 10.1172/JCI101518; SULTAN Y, 1987, P NATL ACAD SCI USA, V84, P828, DOI 10.1073/pnas.84.3.828; SULTAN Y, 1984, LANCET, V2, P765; Sunakawa M, 1989, Metab Pediatr Syst Ophthalmol (1985), V12, P93; TANKERSLEY DL, 1988, MOL IMMUNOL, V25, P41, DOI 10.1016/0161-5890(88)90088-0; TUMIATI B, 1991, P458; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; VENTURA A, 1987, HELV PAEDIATR ACTA, V41, P495; VERMEULEN M, 1985, J NEUROL SCI, V70, P317, DOI 10.1016/0022-510X(85)90173-X; VERMEULEN M, 1991, P351; von Pirquet CE, 1911, ARCH INTERN MED, V7, P259; WENSKE C, 1983, BLUT, V46, P347, DOI 10.1007/BF00320695; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSTON DJ, 1985, IMMUN INFEKT, V13, P296; ZUBLER R, 1981, IMMUNOCHEMOTHERAPY G, P65; 1990, 1990 NIH CONS DEV C, V8; 1989, LANCET, V1, P137	137	613	629	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					107	116						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727218				2022-12-28	WOS:A1992GY04500006
J	PAN, T; GUTELL, RR; UHLENBECK, OC				PAN, T; GUTELL, RR; UHLENBECK, OC			FOLDING OF CIRCULARLY PERMUTED TRANSFER-RNAS	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; ESCHERICHIA-COLI; CLEAVAGES; SEQUENCE; ENZYME; INVIVO; ACID; GENE	All of the ribose-phosphate linkages in yeast tRNA(Phe) that could be cleaved without affecting the folding of the molecule have been determined in a single experiment. Circular permutation analysis subjects circular tRNA molecules to limited alkaline hydrolysis in order to generate one random break per molecule. Correctly folded tRNAs were identified by lead cleavage at neutral pH, a well-characterized reaction that requires proper folding of tRNA(Phe). Surprisingly, most of the circularly permuted tRNA molecules folded correctly. This result suggests that the tRNA folding motif could occur internally within other RNA sequences, and a computer search of Genbank entries has identified many examples of such motifs.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT MOLEC & CELLULAR DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM37552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BEHLEN LS, UNPUB; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; DREHER TW, 1989, J MOL BIOL, V206, P425, DOI 10.1016/0022-2836(89)90491-9; DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6; GAUTHERET D, 1990, COMPUT APPL BIOSCI, V6, P325; GRAY MW, 1990, RIBOSOME, P589; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; KIM SH, 1978, TRANSFER RNA, P248; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAN T, UNPUB; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P368, DOI DOI 10.1007/978-1-4612-5190-3_17; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WERNER C, 1976, BIOCHIM BIOPHYS ACTA, V432, P161, DOI 10.1016/0005-2787(76)90158-1; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	24	103	105	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1991	254	5036					1361	1364		10.1126/science.1720569	http://dx.doi.org/10.1126/science.1720569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1720569				2022-12-28	WOS:A1991GR77700051
J	GODLEE, F				GODLEE, F			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR A HEALTHY ENVIRONMENT	BRITISH MEDICAL JOURNAL			English	Article																		ALFRED EN, 1989, NEW ENGL J MED, V321, P1426; FERGUSSON M, 1989, ATMOSPHERIC EMISSION, V1; OSTRO BD, 1991, AM J PUBLIC HEALTH, V81, P694, DOI 10.2105/AJPH.81.6.694; READ C, 1990, AIR POLLUTION CHILD; READ RC, 1990, BRIT MED J, V300, P761, DOI 10.1136/bmj.300.6727.761; REID DD, 1964, P ROY SOC MED, V57, P965, DOI 10.1177/003591576405710P201; STEENLAND K, 1986, AM J IND MED, V10, P177; WHEELER D, 1990, ENG HLTH; 1990, AIR QUALITY BRIEFING; 1991, HLTH MOVE POLICY STA; 1987, AIR QUALITY GUIDELIN; 1989, IARC MONOGRAPHS EVAL, V46; 1991, CM1523	13	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					836	838		10.1136/bmj.303.6806.836	http://dx.doi.org/10.1136/bmj.303.6806.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH946	1718513	Green Published, Bronze			2022-12-28	WOS:A1991GH94600029
J	HUBER, AR; KUNKEL, SL; TODD, RF; WEISS, SJ				HUBER, AR; KUNKEL, SL; TODD, RF; WEISS, SJ			REGULATION OF TRANSENDOTHELIAL NEUTROPHIL MIGRATION BY ENDOGENOUS INTERLEUKIN-8	SCIENCE			English	Article							HUMAN-ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ACTIVATING PEPTIDE NAP/IL-8; MGSA-GRO PROTEIN; MONOCLONAL-ANTIBODIES; POLYMORPHONUCLEAR LEUKOCYTES; BIOCHEMICAL-CHARACTERIZATION; RECOMBINANT EXPRESSION; BIOLOGICAL-ACTIVITIES; GENE-EXPRESSION	Movement of neutrophils from the bloodstream to inflamed tissue depends on the activation of both the neutrophil and the endothelial cell. Endothelial cells lining the postcapillary venule respond to proinflammatory mediators by expressing adhesion molecules and synthesizing a variety of neutrophil-activating factors. Endothelial cell production of a 77-amino acid variant of interleukin-8 (IL-8) was found to be a requirement for the invasion of neutrophils through a vessel wall model. IL-8 secreted by cytokine- or lipopolysaccharide-stimulated endothelial cells induced the rapid shedding of neutrophil lectin adhesion molecule-1, the up-regulation of leukocyte beta-2 integrins, and the attachment and transmigration of the neutrophils. Thus, endogenous endothelial IL-8 regulates transvenular traffic during acute inflammatory responses.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Todd, Robert/GWM-4486-2022		NATIONAL CANCER INSTITUTE [R01CA039064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028024] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39064] Funding Source: Medline; NHLBI NIH HHS [HL 28024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREVIARIO F, 1988, J IMMUNOL, V141, P3391; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11586; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FURIE MB, 1989, J IMMUNOL, V143, P3309; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUBER AM, UNPUB; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MOVAT HZ, 1987, J LAB CLIN MED, V110, P668; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SICA A, 1990, J IMMUNOL, V144, P3034; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STICHERLING M, 1989, J IMMUNOL, V143, P1628; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; TEDDER TF, 1990, J IMMUNOL, V144, P532; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WANG JM, 1987, IMMUNOLOGY, V60, P439; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	40	742	770	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					99	102		10.1126/science.1718038	http://dx.doi.org/10.1126/science.1718038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718038				2022-12-28	WOS:A1991GH60500037
J	SCHENKMAN, S; JIANG, MS; HART, GW; NUSSENZWEIG, V				SCHENKMAN, S; JIANG, MS; HART, GW; NUSSENZWEIG, V			A NOVEL CELL-SURFACE TRANS-SIALIDASE OF TRYPANOSOMA-CRUZI GENERATES A STAGE-SPECIFIC EPITOPE REQUIRED FOR INVASION OF MAMMALIAN-CELLS	CELL			English	Article							ALTERNATIVE COMPLEMENT PATHWAY; MONOCLONAL-ANTIBODIES; SIALYL-LEX; ACID; ADHESION; TRYPOMASTIGOTES; NEURAMINIDASE; RECOGNITION; FORMS; GLYCOSYLTRANSFERASES	When trypomastigotes of T. cruzi emerge from cells of the mammalian host, they contain little or no sialic acids on their surfaces. However, rapidly upon entering the circulation, they express a unique cell surface trans-sialidase activity. This enzyme specifically transfers alpha(2-3)-linked sialic acid from extrinsic host-derived macromolecules to parasite surface molecules, leading to the assembly of Ssp-3, a trypomastigote-specific epitope. The T. cruzi trans-sialidase does not utilize cytidine 5' monophospho-N-acetylneuraminic acid as a donor substrate, but readily transfers sialic acid from exogenously supplied alpha(2-3)-sialyllactose. Monoclonal antibodies that recognize sialic acid residues of Ssp-3 inhibit attachment of trypomastigotes to host cells, suggesting that the unusual trans-sialidase provides Ssp-3 with structural features required for target cell recognition.	NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; JOHNS HOPKINS UNIV,DEPT BIOL CHEM,BALTIMORE,MD 21218	New York University; Johns Hopkins University	SCHENKMAN, S (corresponding author), NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016, USA.		Schenkman, Sergio/A-9227-2013	Schenkman, Sergio/0000-0001-9353-8480; Hart, Gerald/0000-0001-7812-4351	NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUIN G, 1989, MOL BIOCHEM PARASIT, V35, P229, DOI 10.1016/0166-6851(89)90209-0; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BOSCHETTI MA, 1987, MOL BIOCHEM PARASIT, V24, P175, DOI 10.1016/0166-6851(87)90104-6; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CROWELL RL, 1986, VIRAL ATTACHMENT ENT; DEARAUJOJORGE TC, 1989, MEM I OSWALDO CRUZ, V84, P441, DOI 10.1590/S0074-02761989000400001; DEARRUDA MV, 1989, EUR J BIOCHEM, V182, P413, DOI 10.1111/j.1432-1033.1989.tb14847.x; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DETITTO EH, 1987, ACTA TROP, V44, P273; EDWARDS MS, 1982, J IMMUNOL, V128, P1278; HADLEY LH, 1987, ANNU REV MICROBIOL, V40, P415; HARTH G, 1987, P NATL ACAD SCI USA, V84, P8320, DOI 10.1073/pnas.84.23.8320; JARVIS GA, 1987, INFECT IMMUN, V55, P174, DOI 10.1128/IAI.55.1.174-180.1987; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KIPNIS TL, 1981, P NATL ACAD SCI-BIOL, V78, P602, DOI 10.1073/pnas.78.1.602; Kirchhoff L. V., 1990, Principles and practice of infectious diseases., P2077; LEY V, 1988, J EXP MED, V168, P649, DOI 10.1084/jem.168.2.649; Marsden P. D., 1988, The biology of parasitism. A molecular and immunological approach., P77; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; PASSANITI A, 1988, J BIOL CHEM, V263, P7591; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; POWELL LD, 1986, ANAL BIOCHEM, V157, P179, DOI 10.1016/0003-2697(86)90211-3; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; RIMOLDI MT, 1989, J CLIN INVEST, V84, P1982, DOI 10.1172/JCI114388; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; RUNYAN RB, 1986, J CELL BIOL, V102, P432, DOI 10.1083/jcb.102.2.432; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X; VEH RW, 1981, J CHROMATOGR, V212, P313, DOI 10.1016/S0021-9673(01)84044-9; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	46	385	393	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1117	1125		10.1016/0092-8674(91)90008-M	http://dx.doi.org/10.1016/0092-8674(91)90008-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1712251				2022-12-28	WOS:A1991FU89900005
J	KIM, HK; KIM, JW; ZILBERSTEIN, A; MARGOLIS, B; KIM, JG; SCHLESSINGER, J; RHEE, SG				KIM, HK; KIM, JW; ZILBERSTEIN, A; MARGOLIS, B; KIM, JG; SCHLESSINGER, J; RHEE, SG			PDGF STIMULATION OF INOSITOL PHOSPHOLIPID HYDROLYSIS REQUIRES PLC-GAMMA-1 PHOSPHORYLATION ON TYROSINE RESIDUES 783 AND 1254	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; C-GAMMA; FACTOR RECEPTOR; KINASES INVIVO; BOVINE BRAIN; SUBSTRATE; CALCIUM; INVITRO	PDGF binding to its receptor promotes the association with and stimulates the phosphorylation of PLC-gamma-1 at tyrosine and serine residues. Also, PDGF induces an increase in the hydrolysis of inositol phospholipids by PLC. How PDGF activates PLC was investigated by substituting phenylalanine for tyrosine at PLC-gamma-1 phosphorylation sites 771, 783, and 1254 and expressing the mutant enzymes in NIH 3T3 cells. Phenylalanine substitution at Tyr-783 completely blocked the activation of PLC by PDGF, whereas mutation at Tyr-1254 inhibited and mutation at Tyr-771 enhanced the response. Like the wild type, PLC-gamma-1 substituted with phenylalanine at Tyr-783 became associated with the PDGF receptor and underwent phosphorylation at serine residues in response to PDGF. These results suggest that PLC-gamma-1 is the PLC isozyme that mediates PDGF-induced inositol phospholipid hydrolysis, that phosphorylation on Tyr-783 is essential for PLC-gamma-1 activation. These results provide direct evidence that growth factor receptors activate the function of intracellular protein by tyrosine phosphorylation.	NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892; RORER BIOTECHNOL INC,KING OF PRUSSIA,PA 19406; NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); New York University	KIM, HK (corresponding author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KIM JW, 1990, J BIOL CHEM, V265, P3940; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	33	530	539	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					435	441		10.1016/0092-8674(91)90461-7	http://dx.doi.org/10.1016/0092-8674(91)90461-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1708307				2022-12-28	WOS:A1991FK18200010
J	GOLDSCHMIDTCLERMONT, M; CHOQUET, Y; GIRARDBASCOU, J; MICHEL, F; SCHIRMERRAHIRE, M; ROCHAIX, JD				GOLDSCHMIDTCLERMONT, M; CHOQUET, Y; GIRARDBASCOU, J; MICHEL, F; SCHIRMERRAHIRE, M; ROCHAIX, JD			A SMALL CHLOROPLAST RNA MAY BE REQUIRED FOR TRANSSPLICING IN CHLAMYDOMONAS-REINHARDTII	CELL			English	Article							NUCLEAR; INTRONS; GENE; DNA; TRANSFORMATION; MUTATIONS; STABILITY	In C. reinhardtii, the mature psaA mRNA is assembled by a process involving trans-splicing of three separate transcripts encoded at three widely scattered loci of the chloroplast genome. At least one additional chloroplast locus (tscA) is required for trans-splicing of exons 1 and 2. We have mapped this gene by transformation of a deletion mutant with a particle gun. The 0.7 kb region of the chloroplast genome that is sufficient to rescue tscA function has been subjected to insertion mutagenesis, showing that it does not contain significant open reading frames. We suggest from these experiments that the products of the tscA gene may be a small chloroplast RNA that acts in trans in the first trans-splicing reaction of psaA. A model for the mode of action of this RNA is presented, in which the characteristic structure of group II introns is assembled from three separate transcripts.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND; INST BIOL PHYS CHIM,F-75005 PARIS,FRANCE; CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	GOLDSCHMIDTCLERMONT, M (corresponding author), UNIV GENEVA,DEPT PLANT BIOL,30 QUAI E ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.		Choquet, Yves/M-5533-2019; Choquet, Yves/ABE-3084-2020; Rochaix, Jean-David/ABC-5243-2020	Choquet, Yves/0000-0003-4760-3397; 				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLOWERS AD, 1989, PLANT CELL, V1, P123, DOI 10.1105/tpc.1.1.123; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRIN DL, 1988, J BIOL CHEM, V263, P14601; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P1025; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; OZEKI H, 1987, COLD SPRING HARB SYM, V52, P791, DOI 10.1101/SQB.1987.052.01.088; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; SAMBROOK KJ, 1989, MOL CLONING LABORATO; ZUMBRUNN G, 1989, TECHNIQUE, V1, P204	30	148	155	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					135	143		10.1016/0092-8674(91)90415-U	http://dx.doi.org/10.1016/0092-8674(91)90415-U			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707343				2022-12-28	WOS:A1991FF77300016
J	DILLON, N; GROSVELD, F				DILLON, N; GROSVELD, F			HUMAN GAMMA-GLOBIN GENES SILENCED INDEPENDENTLY OF OTHER GENES IN THE BETA-GLOBIN LOCUS	NATURE			English	Article							TRANSGENIC MICE; EXPRESSION	ERYTHROPOIESIS during human development is characterized by switches in expression of beta-like globin genes during the transition from the embryonic through fetal to adult stages. Activation and high-level expression of the genes is directed by the locus control region (LCR), located 5' to the epsilon-gene 1-3. The location of the LCR and its role in directing high-level expression of the globin genes has led to the suggestion that competition from the beta-gene for interaction with the LCR has a major role in silencing the fetal gamma-genes during adult life 4,5. We have now constructed lines of transgenic mice containing the human A-gamma-globin gene linked to the LCR. We observe high-level expression of the transgene in the embryonic stages but silencing of the gene in adult animals. We conclude that the gamma-gene is not deregulated by the presence of the LCR and that competition from the beta-gene is not required for silencing of the gamma-genes in adult life. The silencing is therefore likely to be mediated by stage-specific factors binding to sequences immediately flanking the genes.			DILLON, N (corresponding author), NATL INST MED RES,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.							ANAGNOU NP, 1990, CLIN RES, V38, pA301; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FEINGOLD EA, 1989, BLOOD, V74, P2178; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONCZ M, 1989, GLOBIN GENE EXPRESSI; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596	19	165	167	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					252	254		10.1038/350252a0	http://dx.doi.org/10.1038/350252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706482	Green Submitted			2022-12-28	WOS:A1991FC77900065
J	NUNN, P; KIBUGA, D; GATHUA, S; BRINDLE, R; IMALINGAT, A; WASUNNA, K; LUCAS, S; GILKS, C; OMWEGA, M; WERE, J; MCADAM, K				NUNN, P; KIBUGA, D; GATHUA, S; BRINDLE, R; IMALINGAT, A; WASUNNA, K; LUCAS, S; GILKS, C; OMWEGA, M; WERE, J; MCADAM, K			CUTANEOUS HYPERSENSITIVITY REACTIONS DUE TO THIACETAZONE IN HIV-1 SEROPOSITIVE PATIENTS TREATED FOR TUBERCULOSIS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ASSOCIATION; INFECTION; VIRUS	The effects of the human immunodeficiency virus (HIV) on tuberculosis management was investigated in 227 patients initially treated with a regimen containing streptomycin, isoniazid, and thiacetazone (STH). 93 of these 227 were HIV-seropositive. 60 patients, of whom 18 were HIV-seropositive, received a regimen consisting of streptomycin, isoniazid, rifampicin, and pyrazinamide (SHRZ) in the initial phase, and thiacetazone and isoniazid (TH) in the continuation phase. Cutaneous hypersensitivity reactions occurred in 22 of 111 (20%) HIV-seropositive patients, and in 2 of 176 (1%) HIV-seronegative patients (RR = 18, 95% CI 4.4-76, p < 10(-7). During the first 8 weeks of treatment 18 reactions occurred among the 93 HIV-seropositive patients on STH, whereas no reaction occurred in 17 HIV-seropositive patients during the initial phase of SHRZ/TH (p = 0.04). None of the 18 HIV-seropositive patients with cutaneous reactions who were subsequently challenged with isoniazid reacted, nor did any of the 10 tested with streptomycin, but 6 of the 7 challenged with thiacetazone reacted. 3 patients (all HIV-positive and with toxic epidermal necrolysis) died as a result of the cutaneous reaction. These results have major implications for tuberculosis control programmes in Africa.	KENYA GOVT MED RES CTR,NAIROBI,KENYA; UNIV COLL & MIDDLESEX HOSP MED SCH LONDON,LONDON,ENGLAND; NUFFIELD DEPT MED,OXFORD,ENGLAND; KENYATTA NATL HOSP,HOSP INFECT DIS,NAIROBI,KENYA; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LAB,OXFORD,ENGLAND	Kenya Medical Research Institute; University of London; University College London; University of Oxford; Kenyatta National Hospital; University of London; London School of Hygiene & Tropical Medicine			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN A, 1987, DIFFERENTIAL DIAGNOS, P28; BRICE SL, 1989, J INVEST DERMATOL, V93, P183, DOI 10.1111/1523-1747.ep12277397; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Chonde T M, 1989, Bull Int Union Tuberc Lung Dis, V64, P37; CITRON KM, 1983, OXFORD TXB MED, V1; FERGUSON G C, 1971, Tubercle, V52, P166, DOI 10.1016/0041-3879(71)90040-7; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HIRA SK, 1988, J AM ACAD DERMATOL, V19, P451, DOI 10.1016/S0190-9622(88)70197-8; Kadende P, 1988, Med Trop (Mars), V48, P19; KIBUGA D, 4TH INT C AIDS ASS C, P99; MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346, DOI 10.1001/jama.1986.03380030048011; Miller A B, 1966, Tubercle, V47, P33; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; SEN PK, 1974, INDIAN J MED RES, V62, P557; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; SUGARMAN J, 1990, 4TH INT C AIDS SAN F, V1, P249; WILLAME JC, 1988, ANN SOC BELG MED TR, V68, P165; 1973, TUBERCLE, V54, P169	19	176	177	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					627	630						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1705647				2022-12-28	WOS:A1991FB73000001
J	WAGNER, JA; COZENS, AL; SCHULMAN, H; GRUENERT, DC; STRYER, L; GARDNER, P				WAGNER, JA; COZENS, AL; SCHULMAN, H; GRUENERT, DC; STRYER, L; GARDNER, P			ACTIVATION OF CHLORIDE CHANNELS IN NORMAL AND CYSTIC-FIBROSIS AIRWAY EPITHELIAL-CELLS BY MULTIFUNCTIONAL CALCIUM CALMODULIN-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							PHOSPHORYLATION; IDENTIFICATION; CONDUCTANCE; GENE	CYSTIC fibrosis is associated with defective regulation of apical membrane chloride channels in airway epithelial cells. These channels in normal cells are activated by cyclic AMP-dependent protein kinase 1,2 and protein kinase C 3,4. In cystic fibrosis these kinases fail to activate otherwise normal Cl- channels 1-4. But Cl- flux in cystic fibrosis cells, as in normal cells, can be activated by raising intracellular Ca2+ (refs 5-10). We report here whole-cell patch clamp studies of normal and cystic fibrosis-derived airway epithelial cells showing that Cl- channel activation by Ca2+ is mediated by multifunctional Ca2+/calmodulin-dependent protein kinase. We find that intracellular application of activated kinase and ATP activates a Cl- current similar to that activated by a Ca2+ ionophore, that peptide inhibitors of either the kinase or calmodulin block Ca2+-dependent activation of Cl- channels, and that a peptide inhibitor of protein kinase C does not block Ca2+-dependent activation. Ca2+/calmodulin activation of Cl- channels presents a pathway with therapeutic potential for circumventing defective regulation of Cl- channels in cystic fibrosis.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,FALK CVRC,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University; University of California System; University of California San Francisco; Stanford University								CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COZENS AL, IN PRESS IDENTIFICAT; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GORMAN ALF, 1982, BIOPHYS J, V38, P319, DOI 10.1016/S0006-3495(82)84565-7; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRUENERT DC, 1988, PEDIATR PULMONOL S2, V17, P100; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	24	194	194	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					793	796		10.1038/349793a0	http://dx.doi.org/10.1038/349793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705665				2022-12-28	WOS:A1991EZ66600057
J	SNIDER, RM; CONSTANTINE, JW; LOWE, JA; LONGO, KP; LEBEL, WS; WOODY, HA; DROZDA, SE; DESAI, MC; VINICK, FJ; SPENCER, RW; HESS, HJ				SNIDER, RM; CONSTANTINE, JW; LOWE, JA; LONGO, KP; LEBEL, WS; WOODY, HA; DROZDA, SE; DESAI, MC; VINICK, FJ; SPENCER, RW; HESS, HJ			A POTENT NONPEPTIDE ANTAGONIST OF THE SUBSTANCE-P (NK1) RECEPTOR	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; SELECTIVE AGONISTS; TACHYKININS; ACTIVATION; SECRETION; NEURONS; BINDING; TISSUE	CP-96,345 [(2S, 3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]octan-3-amine] is a potent neopeptide antagonist of the substance P (NK1) receptor. CP-96,345 inhibited H-3-labeled substance P binding and was a classical competitive antagonist in the NK1 monoreceptor dog carotid artery preparation. CP-96,345 inhibited substance P-induced salivation in the rat, a classical in vivo bioassay, but did not inhibit NK2, NK3, or numerous other receptors; it is thus a selective NK1 antagonist. This compound may prove to be a powerful tool for investigation of the physiological properties of substance P and exploration of its role in diseases.			SNIDER, RM (corresponding author), PFIZER INC,CENT RES DIV,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340, USA.							ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CHANG MM, 1970, J BIOL CHEM, V245, P4784; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONSTANTINE JW, IN PRESS NAUNYNSCHMI; ENBERG G, 1981, NATURE, V293, P222; GIULIANI S, 1988, EUR J PHARMACOL, V150, P377, DOI 10.1016/0014-2999(88)90022-2; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; LEEMAN SE, 1967, ENDOCRINOLOGY, V81, P803, DOI 10.1210/endo-81-4-803; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MELCHIORRI P, 1977, NOBEL S, V37, P311; NICOLL RA, 1980, ANNU REV NEUROSCI, V3, P227, DOI 10.1146/annurev.ne.03.030180.001303; NILSSON G, 1974, MED BIOL, V52, P424; PAYAN DG, 1984, J CLIN INVEST, V74, P1532, DOI 10.1172/JCI111567; PERIANIN A, 1989, BIOCHEM BIOPH RES CO, V161, P520, DOI 10.1016/0006-291X(89)92630-2; PERNOW B, 1975, ACTA PHYSIOL SCAND, V93, P139, DOI 10.1111/j.1748-1716.1975.tb05800.x; PERNOW B, 1983, PHARMACOL REV, V35, P85; PERNOW B, 1953, Acta Physiol Scand Suppl, V29, P1; PERRONE MH, 1983, EUR J PHARMACOL, V95, P131, DOI 10.1016/0014-2999(83)90277-7; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SNIDER RS, UNPUB; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P392, DOI 10.1073/pnas.86.1.392; VOGLER K, 1963, ANN NY ACAD SCI, V104, P378, DOI 10.1111/j.1749-6632.1963.tb17682.x; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; WARAWA EJ, 1974, J MED CHEM, V17, P479; WOMACK MD, 1988, NATURE, V334, P351, DOI 10.1038/334351a0	29	925	947	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					435	437		10.1126/science.1703323	http://dx.doi.org/10.1126/science.1703323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1703323				2022-12-28	WOS:A1991EU50400043
J	VASSAR, R; COULOMBE, PA; DEGENSTEIN, L; ALBERS, K; FUCHS, E				VASSAR, R; COULOMBE, PA; DEGENSTEIN, L; ALBERS, K; FUCHS, E			MUTANT KERATIN EXPRESSION IN TRANSGENIC MICE CAUSES MARKED ABNORMALITIES RESEMBLING A HUMAN GENETIC SKIN-DISEASE	CELL			English	Article							EPIDERMOLYSIS BULLOSA SIMPLEX; INTERMEDIATE-SIZED FILAMENTS; CULTURED EPIDERMAL-CELLS; CYTOKERATIN EXPRESSION; DOWLING-MEARA; MOLECULAR MARKERS; NORMAL EPITHELIA; DIFFERENTIATION; COMPLEX; FAMILY	To explore the relationship between keratin gene mutations and genetic disease, we made transgenic mice expressing a mutant keratin in the basal layer of their stratified squamous epithelia. These mice exhibited abnormalities in epidermal architecture and often died prematurely. Blistering occurred easily, and basal cell cytolysis was evident at the light and electron microscopy levels. Keratin filament formation was markedly altered, with keratin aggregates in basal cells. In contrast, terminally differentiating cells made keratin filaments and formed a stratum corneum. Recovery of outer layer cells was attributed to down-regulation of mutant keratin expression and concomitant induction of differentiation-specific keratins as cells terminally differentiate, and the fact that these cells arose from basal cells developing at a time when keratin expression was relatively low. Collectively, the pathobiology and biochemistry of the transgenic mice and their cultured keratinocytes bore a resemblance to a group of genetic disorders known as epidermolysis bullosa simplex.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago	VASSAR, R (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA.		Fuchs, Elaine/G-1565-2016	Albers, Kathryn/0000-0003-4597-9323	NIAMS NIH HHS [AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBINDER LH, 1986, ARCH DERMATOL, V122, P190, DOI 10.1001/archderm.122.2.190; BURGE SM, 1989, J ROY SOC MED, V82, P673, DOI 10.1177/014107688908201113; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1990, IN PRESS J CELL BIOL; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; FINE JD, 1986, INT J DERMATOL, V25, P143, DOI 10.1111/j.1365-4362.1986.tb02206.x; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL, V1; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1978, CELL, V15, P887, DOI 10.1016/0092-8674(78)90273-8; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; JACKSON BW, 1981, DIFFERENTIATION, V20, P203, DOI 10.1111/j.1432-0436.1981.tb01177.x; KERO M, 1986, INT J DERMATOL, V25, P75, DOI 10.1111/j.1365-4362.1986.tb04542.x; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KOPAN R, 1989, GENE DEV, V3, P1, DOI 10.1101/gad.3.1.1; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; NAGLE RB, 1985, DIFFERENTIATION, V30, P130, DOI 10.1111/j.1432-0436.1985.tb00524.x; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PEARSON RW, 1961, J INVEST DERMATOL, V36, P213, DOI 10.1038/jid.1961.35; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; SANCHEZ G, 1983, J INVEST DERMATOL, V81, P576, DOI 10.1111/1523-1747.ep12523269; SAVOLAINEN ER, 1981, NEW ENGL J MED, V304, P197, DOI 10.1056/NEJM198101223040403; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; STROMER MH, 1988, CELL MOTIL CYTOSKEL, V11, P117, DOI 10.1002/cm.970110205; Sun TT, 1984, CANCER CELLS, V1, P169; TIDMAN MJ, 1988, ACTA DERM-VENEREOL, V68, P15; TYNER AL, 1986, J CELL BIOL, V103, P1945, DOI 10.1083/jcb.103.5.1945; VANMUIJEN GNP, 1986, EXP CELL RES, V162, P97, DOI 10.1016/0014-4827(86)90429-5; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VENETIANER A, 1983, NATURE, V305, P730, DOI 10.1038/305730a0; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5	54	368	370	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					365	380		10.1016/0092-8674(91)90645-F	http://dx.doi.org/10.1016/0092-8674(91)90645-F			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1703046				2022-12-28	WOS:A1991EV33600013
J	WU, L; SCOLLAY, R; EGERTON, M; PEARSE, M; SPANGRUDE, GJ; SHORTMAN, K				WU, L; SCOLLAY, R; EGERTON, M; PEARSE, M; SPANGRUDE, GJ; SHORTMAN, K			CD4 EXPRESSED ON EARLIEST T-LINEAGE PRECURSOR CELLS IN THE ADULT MURINE THYMUS	NATURE			English	Article							HOMING PROGENITOR CELLS; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; PGP-1 GLYCOPROTEIN; MOUSE THYMUS; STEM-CELLS; THYMOCYTES; SURFACE; ANTIGEN; SUBPOPULATIONS	A CONTINUOUS but low input of stem cells or 'prothymocytes' is necessary to maintain T-cell development in the adult thymus1, but the colonizing cell has not been characterized. Precursors of T cells have been found in the minor CD4-8- population2 of thymocytes, but even the earliest cells of this population already have partially rearranged T-cell antigen receptor (TCR) genes3. We now demonstrate that the thymus contains a minute population of lymphoid cells similar in some but not all respects to bone marrow-derived haemopoietic stem cells. This population has TCR genes in a germline state. It gives a slow but extensive reconstitution of both alpha-beta and gamma-delta-lineages on transfer into an irradiated thymus, with kinetics indicating that it includes the earliest intrathymic precursor cells so far isolated. Surprisingly, these cells express low surface levels of the mature T-cell marker CD4.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute				Shortman, Ken/0000-0002-9107-3007				CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; Coffman R L, 1982, Immunol Rev, V69, P5; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P3301, DOI 10.1073/pnas.86.9.3301; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; HOLMES KL, 1986, J IMMUNOL, V137, P679; HYMAN R, 1986, CELL IMMUNOL, V101, P320, DOI 10.1016/0008-8749(86)90145-0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LESLEY J, 1985, CELL IMMUNOL, V91, P397, DOI 10.1016/0008-8749(85)90237-0; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MIESCHER GC, 1989, IMMUNOL LETT, V23, P113, DOI 10.1016/0165-2478(89)90122-3; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PEARSE MJ, 1988, IMMUNOL LETT, V18, P219, DOI 10.1016/0165-2478(88)90022-3; QUIN S, 1987, EUR J IMMUNOL, V17, P1159; SCOLLAY R, 1986, IMMUNOL REV, V91, P129, DOI 10.1111/j.1600-065X.1986.tb01487.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; Shortman K, 1990, Semin Immunol, V2, P3; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, EXP HEMATOL, V18, P920; SPANGRUDE GJ, IN PRESS J IMMUN; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; WILSON A, 1988, J IMMUNOL, V140, P1461; YAGITA H, 1989, EUR J IMMUNOL, V19, P2211, DOI 10.1002/eji.1830191206; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	30	339	345	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					71	74		10.1038/349071a0	http://dx.doi.org/10.1038/349071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1702186				2022-12-28	WOS:A1991EQ60100054
J	SIMPSON, L				SIMPSON, L			RNA EDITING - A NOVEL GENETIC PHENOMENON	SCIENCE			English	Article									UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	SIMPSON, L (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.							ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; ALTMAN S, 1989, GENE, V82, P63, DOI 10.1016/0378-1119(89)90030-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHEN SH, 1990, J BIOL CHEM, V265, P6811; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; MAHENDRAN R, IN PRESS CELL; POLLARD VW, IN PRESS CELL; RIOU G, 1969, P NATL ACAD SCI USA, V62, P210, DOI 10.1073/pnas.62.1.210; SIMPSON A, UNPUB; SIMPSON L, 1971, J MOL BIOL, V56, P443, DOI 10.1016/0022-2836(71)90394-9; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; THOMAS SM, 1988, CELL, V54, P891, DOI 10.1016/S0092-8674(88)91285-8	26	77	77	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 26	1990	250	4980					512	513		10.1126/science.1700474	http://dx.doi.org/10.1126/science.1700474			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE660	1700474				2022-12-28	WOS:A1990EE66000026
J	PHILLIPS, TJ; DOVER, JS				PHILLIPS, TJ; DOVER, JS			MEDICAL PROGRESS - RECENT ADVANCES IN DERMATOLOGY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SWITCHED RUBY-LASER; PORT-WINE STAINS; HUMAN PAPILLOMAVIRUS INFECTION; RANDOMIZED CLINICAL-TRIAL; EPIDEMIC KAPOSIS-SARCOMA; SQUAMOUS-CELL CARCINOMA; TUNABLE DYE-LASER; GUINEA-PIG SKIN; MYCOSIS-FUNGOIDES		BOSTON UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02118; NEW ENGLAND DEACONESS HOSP,DIV DERMATOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115	Boston University; Harvard University; Harvard Medical School				Phillips, Tania/0000-0003-2744-4931				ACKERMAN AB, 1990, CUTANEOUS MELANOMA B, P127; ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ASHINOFF R, 1991, J AM ACAD DERMATOL, V24, P467, DOI 10.1016/0190-9622(91)70075-D; ASHINOFF R, 1991, ARCH DERMATOL, V127, P202, DOI 10.1001/archderm.127.2.202; BAADSGAARD O, 1990, J INVEST DERMATOL, V95, pS32, DOI 10.1111/1523-1747.ep12505715; BARI MM, 1989, J AM ACAD DERMATOL, V21, P1310, DOI 10.1016/S0190-9622(89)80316-0; BARR BBB, 1989, LANCET, V1, P124; Barton L L, 1988, Pediatr Dermatol, V5, P88, DOI 10.1111/j.1525-1470.1988.tb01144.x; Barton L L, 1987, Pediatr Dermatol, V4, P185, DOI 10.1111/j.1525-1470.1987.tb00776.x; BARTON LL, 1989, PEDIATR DERMATOL, V6, P134, DOI 10.1111/j.1525-1470.1989.tb01012.x; BENDER ME, 1986, ARCH DERMATOL, V122, P1121, DOI 10.1001/archderm.122.10.1121; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BERSHAD S, 1985, NEW ENGL J MED, V313, P981, DOI 10.1056/NEJM198510173131604; BEUTNER KR, 1989, LANCET, V1, P831, DOI 10.1016/S0140-6736(89)92282-4; BEUTNER KR, 1989, J AM ACAD DERMATOL, V20, P114, DOI 10.1016/S0190-9622(89)80004-0; Bjerke J R, 1989, Acta Derm Venereol Suppl (Stockh), V146, P206; BOYLE J, 1984, LANCET, V1, P702; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CAMP R, 1984, J INVEST DERMATOL, V82, P202, DOI 10.1111/1523-1747.ep12259945; CASSILETH BR, 1986, J AM ACAD DERMATOL, V14, P555, DOI 10.1016/S0190-9622(86)70068-6; CHACHOUA A, 1989, J CLIN ONCOL, V7, P774, DOI 10.1200/JCO.1989.7.6.774; CLAAS ECJ, 1989, AM J PATHOL, V135, P703; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLEMENTE C, 1991, HUM PATHOL, V22, P313, DOI 10.1016/0046-8177(91)90078-4; COBB MW, 1990, J AM ACAD DERMATOL, V22, P547, DOI 10.1016/0190-9622(90)70073-Q; COCKERELL CJ, 1987, LANCET, V2, P654; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DAGAN R, 1989, AM J DIS CHILD, V143, P916, DOI 10.1001/archpedi.1989.02150200068020; DEMIDOVICH CW, 1990, AM J DIS CHILD, V144, P1313, DOI 10.1001/archpedi.1990.02150360037015; DOVER JS, 1989, ARCH DERMATOL, V125, P43, DOI 10.1001/archderm.125.1.43; DOVER JS, 1987, JAMA-J AM MED ASSOC, V258, P2236, DOI 10.1001/jama.1987.03400160090018; DUVIC M, 1987, ARCH DERMATOL, V123, P1622, DOI 10.1001/archderm.123.12.1622; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; ELAKKAD S, 1986, ARCH DERMATOL, V122, P1396, DOI 10.1001/archderm.122.12.1396; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; ELLIS CN, 1987, J AM ACAD DERMATOL, V16, P267, DOI 10.1016/S0190-9622(87)70037-1; EPSTEIN JB, 1989, CANCER, V64, P2424, DOI 10.1002/1097-0142(19891215)64:12<2424::AID-CNCR2820641205>3.0.CO;2-X; ESTERLY NB, 1991, AM J DIS CHILD, V145, P125; FINNERTY EF, 1979, CUTIS, V23, P227; FISHER GJ, 1990, J INVEST DERMATOL, V95, pS15, DOI 10.1111/1523-1747.ep12505672; FRAUNFELDER FT, 1985, AM J OPHTHALMOL, V100, P534, DOI 10.1016/0002-9394(85)90676-2; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; FRIEDMANKIEN AE, 1986, J AM ACAD DERMATOL, V14, P1023, DOI 10.1016/S0190-9622(86)70127-8; FRIEDMANKIEN AE, 1990, J AM ACAD DERMATOL, V22, P1237, DOI 10.1016/0190-9622(90)70169-I; FRY L, 1988, BRIT J DERMATOL, V119, P445, DOI 10.1111/j.1365-2133.1988.tb03248.x; GARDEN JM, 1988, ARCH DERMATOL, V124, P889, DOI 10.1001/archderm.124.6.889; GILL PS, 1990, CANCER, V65, P1074, DOI 10.1002/1097-0142(19900301)65:5<1074::AID-CNCR2820650505>3.0.CO;2-1; GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V; GISSMANN L, 1986, CIBA F SYMP, V120, P190; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOLDFARB J, 1988, ANTIMICROB AGENTS CH, V32, P1780, DOI 10.1128/AAC.32.12.1780; GOTTLIEB AB, 1986, J EXP MED, V164, P1013, DOI 10.1084/jem.164.4.1013; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; GREGORY N, 1990, J AM ACAD DERMATOL, V22, P1061, DOI 10.1016/0190-9622(90)70153-9; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; GROOPMAN JE, 1989, ANN INTERN MED, V110, P335, DOI 10.7326/0003-4819-110-5-335; GUPTA AK, 1989, J AM ACAD DERMATOL, V21, P1245, DOI 10.1016/S0190-9622(89)70339-X; HEVIA O, 1991, J AM ACAD DERMATOL, V24, P231, DOI 10.1016/0190-9622(91)70033-X; HICKS CB, 1987, ANN INTERN MED, V107, P946, DOI 10.7326/0003-4819-107-6-946_4; HIRSCHMANN JV, 1988, ARCH DERMATOL, V124, P1691, DOI 10.1001/archderm.124.11.1691; HOBBY LW, 1986, LASER SURG MED, V6, P16, DOI 10.1002/lsm.1900060106; HOBBY LW, 1986, LASER SURG MED, V6, P46; HOLICK MF, 1989, ARCH DERMATOL, V125, P1692, DOI 10.1001/archderm.125.12.1692; HOPPENJANS WB, 1990, ARCH DERMATOL, V126, P1048, DOI 10.1001/archderm.126.8.1048; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; KAYE FJ, 1989, NEW ENGL J MED, V321, P1784, DOI 10.1056/NEJM198912283212603; KIRBY P, 1990, AM J MED, V88, P465, DOI 10.1016/0002-9343(90)90424-C; KOH HK, 1990, CANCER, V65, P375, DOI 10.1002/1097-0142(19900115)65:2<375::AID-CNCR2820650233>3.0.CO;2-Z; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; KRAGBALLE K, 1985, BRIT J DERMATOL, V112, P63; KRIGEL RL, 1990, SEMIN ONCOL, V17, P350; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; KUZEL TM, 1991, J CLIN ONCOL, V9, P1298, DOI 10.1200/JCO.1991.9.7.1298; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANE HC, 1990, ANN INTERN MED, V112, P388, DOI 10.7326/0003-4819-112-5-388_2; Levins PC, 1991, LASERS SURG MED S, V3, P63; LEW RA, 1983, J DERMATOL SURG ONC, V9, P981, DOI 10.1111/j.1524-4725.1983.tb01051.x; LEYDEN JJ, 1986, J AM ACAD DERMATOL, V15, P907, DOI 10.1016/S0190-9622(86)70250-8; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MARTE C, 1990, 6TH INT C AIDS SAN F, V2, P211; MORELLI JG, 1986, LASER SURG MED, V6, P94, DOI 10.1002/lsm.1900060119; MOY RL, 1989, JAMA-J AM MED ASSOC, V261, P2669, DOI 10.1001/jama.261.18.2669; MUHLEMANN MF, 1986, BRIT J DERMATOL, V115, P227, DOI 10.1111/j.1365-2133.1986.tb05722.x; MUI BSK, 1990, AM J MED, V89, P229, DOI 10.1016/0002-9343(90)90303-U; MULLIKEN JB, 1991, ARCH DERMATOL, V127, P243, DOI 10.1001/archderm.127.2.243; OBALEK S, 1990, J AM ACAD DERMATOL, V23, P205, DOI 10.1016/0190-9622(90)70200-2; ORIEL JD, 1988, BRIT MED J, V296, P1484, DOI 10.1136/bmj.296.6635.1484-a; PACE WE, 1965, CAN MED ASSOC J, V93, P252; PADEL AF, 1990, BRIT MED J, V300, P1491, DOI 10.1136/bmj.300.6738.1491; PECK GL, 1979, NEW ENGL J MED, V300, P329, DOI 10.1056/NEJM197902153000701; PITTSLEY RA, 1983, NEW ENGL J MED, V308, P1012, DOI 10.1056/NEJM198304283081707; POCHI PE, 1990, ANNU REV MED, V41, P187; POCHI PE, 1985, NEW ENGL J MED, V313, P1013, DOI 10.1056/NEJM198510173131608; POLLA LL, 1987, J INVEST DERMATOL, V89, P281, DOI 10.1111/1523-1747.ep12471397; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; REID WH, 1983, BRIT J PLAST SURG, V36, P455, DOI 10.1016/0007-1226(83)90128-5; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; REYES BA, 1990, J AM ACAD DERMATOL, V23, P1142, DOI 10.1016/0190-9622(90)70348-L; ROLFS RT, 1989, ARCH DERMATOL, V125, P107, DOI 10.1001/archderm.125.1.107; ROSENTHAL D, 1991, ARCH DERMATOL, V127, P206, DOI 10.1001/archderm.127.2.206; RUDIKOFF D, 1989, ARCH DERMATOL, V125, P706, DOI 10.1001/archderm.125.5.706b; RUDLINGER R, 1986, BRIT J DERMATOL, V115, P681, DOI 10.1111/j.1365-2133.1986.tb06649.x; RUTHERFORD GW, 1990, J ACQUIR IMMUNE D S1, V1, pS4; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; SAUDER DN, 1990, J INVEST DERMATOL, V95, pS27, DOI 10.1111/1523-1747.ep12505705; SAUSVILLE EA, 1988, ANN INTERN MED, V109, P372, DOI 10.7326/0003-4819-109-5-372; SCHULTEN EAJM, 1991, ORAL SURG ORAL MED O, V71, P32, DOI 10.1016/0030-4220(91)90516-F; SCOTTO J, 1983, NIH832433 DEP HLTH H; SILVER L, 1986, LASER SURG MED, V6, P24, DOI 10.1002/lsm.1900060108; SILVER L, 1986, LASER SURG MED, V6, P52; SIM FH, 1986, MAYO CLIN PROC, V61, P697, DOI 10.1016/S0025-6196(12)62768-2; SOBER AJ, 1979, JAMA-J AM MED ASSOC, V242, P2795, DOI 10.1001/jama.242.25.2795; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; STERN RS, 1986, ARCH DERMATOL, V122, P537, DOI 10.1001/archderm.122.5.537; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1989, ARCH DERMATOL, V125, P545; STERN RS, 1989, J INVEST DERMATOL, V92, P300; SULIS E, 1989, EUR J CANCER CLIN ON, V25, P759, DOI 10.1016/0277-5379(89)90217-4; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; TAYLOR CR, 1990, ARCH DERMATOL, V126, P893, DOI 10.1001/archderm.126.7.893; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804; WEINSTOCK MA, 1989, JAMA-J AM MED ASSOC, V262, P2138, DOI 10.1001/jama.262.15.2138; WEINSTOCK MA, 1991, NIH902789 DEP HLTH H, V127, P1194; WEISS LM, 1985, NEW ENGL J MED, V313, P539, DOI 10.1056/NEJM198508293130903; WEISS LM, 1989, J INVEST DERMATOL, V92, P601, DOI 10.1111/1523-1747.ep12712131; YOUNG RC, 1989, NEW ENGL J MED, V321, P1822, DOI 10.1056/NEJM198912283212608; 1989, MMWR, V38, P664; 1983, MMWR, V32, P306; 1989, ARCH DERMATOL, V125, P1485	136	21	27	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					167	178		10.1056/NEJM199201163260305	http://dx.doi.org/10.1056/NEJM199201163260305			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1728936				2022-12-28	WOS:A1992GZ21300005
J	EVANS, RW; ORIANS, CE; ASCHER, NL				EVANS, RW; ORIANS, CE; ASCHER, NL			THE POTENTIAL SUPPLY OF ORGAN DONORS - AN ASSESSMENT OF THE EFFICIENCY OF ORGAN PROCUREMENT EFFORTS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOLIC LIVER-DISEASE; HEART-TRANSPLANTATION; KIDNEY-TRANSPLANTATION; BRAIN-DEATH; CADAVERIC KIDNEYS; DONATION; ATTITUDES; SHORTAGE; RECIPIENTS; PROFESSIONALS	Objectives.-To estimate the potential supply of organ donors and to measure the efficiency of organ procurement efforts in the United States. Methods. - A geographic database has been developed consisting of multiple cause of death and sociodemographic data compiled by the National Center for Health Statistics. All deaths are evaluated as to their potential for organ donation. Two classes of potential donors are identified: class 1 estimates are restricted to causes of death involving significant head trauma only, and class 2 estimates include class 1 estimates as well as deaths in which brain death was less probable. Results. - Over 23000 people are currently awaiting a kidney, heart, liver, heart-lung, pancreas, or lung transplantation. Donor supply is inadequate, and the number of donors remained unchanged at approximately 4000 annually for 1986 through 1989, with a modest 9.1% increase in 1990. Between 6900 and 10700 potential donors are available annually (eg, 28.5 to 43.7 per million population). Depending on the class of donor considered, organ procurement efforts are between 37% and 59% efficient. Efficiency greatly varies by state and organ procurement organization. Conclusions. - Many more organ donors are available than are being accessed through existing organ procurement efforts. Realistically, it may be possible to increase by 80% the number of donors available in the United States (up to 7300 annually). It is conceivable, although unlikely, that the supply of donor organs could achieve a level to meet demand.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	EVANS, RW (corresponding author), BATTELLE SEATTLE RES CTR,4000 NE 41ST ST,SEATTLE,WA 98105, USA.							ANAISE D, 1990, TRANSPLANTATION, V49, P290, DOI 10.1097/00007890-199002000-00013; ANDERSEN KS, 1988, HEALTH AFFAIR, V7, P65, DOI 10.1377/hlthaff.7.5.65; [Anonymous], 1986, ORGAN TRANSPLANTATIO; ARMITAGE JM, 1990, J HEART TRANSPLANT, V9, P627; BAILY MA, 1988, ORGAN SUBSTITUTION T, P198; BART KJ, 1979, TRANSPLANT P, V11, P455; BART KJ, 1981, TRANSPLANTATION, V31, P379, DOI 10.1097/00007890-198105010-00015; BART KJ, 1981, TRANSPLANTATION, V31, P383, DOI 10.1097/00007890-198105010-00016; BOYD AS, 1990, NEW ENGL J MED, V323, P1492, DOI 10.1056/NEJM199011223232120; CALLENDER CO, 1987, TRANSPLANT P, V19, P36; CARTER JR, 1985, NEW ENGL J MED, V313, P1285, DOI 10.1056/NEJM198511143132009; DARBY JM, 1989, JAMA-J AM MED ASSOC, V261, P2222, DOI 10.1001/jama.261.15.2222; ELICK BA, 1990, TRANSPLANT P, V22, P343; Evans R W, 1987, Mich Hosp, V23, P13; Evans R W, 1990, Clin Transpl, P319; Evans R W, 1990, Clin Transpl, P329; Evans R W, 1986, Int J Technol Assess Health Care, V2, P425; EVANS RW, 1986, JAMA-J AM MED ASSOC, V255, P1892; EVANS RW, 1990, DIALYSIS TRANSPLANT, V19, P234; EVANS RW, 1990, TRANSPLANT P, V22, P975; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P1913, DOI 10.1001/jama.1990.03440140033014; EVANS RW, 1989, TRANSPLANT P, V21, P3419; EVANS RW, 1988, TRANSPLANT P, V20, P781; EVANS RW, 1986, SURG CLIN N AM, V66, P603; EVANS RW, 1987, CIRCULATION, V75, P63, DOI 10.1161/01.CIR.75.1.63; EVANS RW, 1984, J HEART TRANSPLANT, V4, P57; EVANS RW, 1991, NATIONAL COOPERATIVE; EVANS RW, 1990, DIALYSIS TRANSPLANT, V19, P240; EVANSRW, 1987, MED SOC CLIN DECISIO, P61; EVERS S, 1988, CAN MED ASSOC J, V138, P237; FAGLIA E, 1990, DIABETES, V39, P740, DOI 10.2337/diabetes.39.6.740; FEHRMAN I, 1989, TRANSPLANT P, V21, P2018; FOST N, 1988, HASTINGS CENT REP, V18, P5, DOI 10.2307/3562216; GABER AO, 1990, TRANSPLANT P, V22, P313; GREENBERG DS, 1991, LANCET, V337, P164, DOI 10.1016/0140-6736(91)90816-8; Gunby P, 1983, JAMA, V250, P455, DOI 10.1001/jama.250.4.455; HAGLE ME, 1989, TRANSPLANTATION, V48, P421, DOI 10.1097/00007890-198909000-00013; HARRISON MR, 1986, LANCET, V2, P1383; HOWARD RJ, 1990, CLIN TRANSPLANT, V4, P181; HULL AR, 1989, NEPHROL NEWS ISSUES, V3, P16; HULL AR, 1989, NEPHROL NEWS ISSUES, V3, P14; HULL AR, 1990, NEPHROL NEWS ISSUES, V4, P28; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KOLATA G, 1983, SCIENCE, V221, P32, DOI 10.1126/science.6857260; KOOP CE, 1983, PUBLIC HEALTH REP, V98, P566; KOOTSTRA G, 1986, TRANSPLANT P, V18, P1410; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; LADOWSKI JS, 1990, TRANSPLANTATION, V49, P303, DOI 10.1097/00007890-199002000-00015; LAND W, 1986, TRANSPLANT P, V18, P1; MANNINEN DL, 1985, JAMA-J AM MED ASSOC, V253, P3111, DOI 10.1001/jama.253.21.3111; MERRIKIN KJ, 1985, J HEALTH POLIT POLIC, V10, P7, DOI 10.1215/03616878-10-1-7; NATHAN HM, 1991, TRANSPLANTATION, V51, P142, DOI 10.1097/00007890-199101000-00022; NEUBERGER JM, 1989, BRIT MED J, V299, P693, DOI 10.1136/bmj.299.6701.693; NORTON DJ, 1990, TRANSPL P, V22, P308; OLIVARI MT, 1988, J HEART TRANSPLANT, V7, P258; PARISI N, 1986, HEALTH PSYCHOL, V5, P565, DOI 10.1037/0278-6133.5.6.565; PERREZ LM, 1988, TRANSPLANTATION, V46, P553; PLAWECKI AM, 1989, AM NEPHROL NURSES AS, V16, P321; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P176, DOI 10.1001/jama.1991.03460020020005; ROBERTS KY, 1988, J NATL MED ASSOC, V80, P1121; ROBERTS KY, 1988, J NATL MED ASSOC, V80, P1123; ROPER WL, 1987, FED REG         0731, V52, P28666; ROSENBERG HM, 1989, AM J PUBLIC HEALTH, V79, P563, DOI 10.2105/AJPH.79.5.563; SALAHUDEEN AK, 1990, LANCET, V336, P725, DOI 10.1016/0140-6736(90)92214-3; SALVATIERRA O, 1989, TRANSPLANT P, V21, P3916; SHORT P, 1989, PHS893443 US DEP HLT; SUTHERLAND DER, 1990, CLIN TRANSPLANT, V4, P242; TAYLOR C, 1989, TRANSPLANTATION, V48, P421; TAYLOR RMR, 1988, LANCET, V1, P985; TOLLE SW, 1987, ANN INTERN MED, V106, P740, DOI 10.7326/0003-4819-106-5-740; TOWNSEND ME, 1990, TRANSPLANT P, V22, P324; WALKER JA, 1990, CAN MED ASSOC J, V142, P1383; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; WILENSKY GR, 1991, FED REG         0621, V56, P28513; YOUNGNER SJ, 1990, DIALYSIS TRANSPLANT, V19, P12; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; YOUNGNER SJ, 1990, DIALYSIS TRANSPLANT, V19, P14; YOUNGNER SJ, 1990, DIALYSIS TRANSPLANT, V19, P17; 1990, UNITED NETWORK ORGAN; 1987, US PUBLICS ATTITUDES; 1981, JAMA-J AM MED ASSOC, V246, P2157; 1983, ATTITUDES OPINIONS A; 1990, ANN REPORT US SCI RE; 1986, PUBLIC USE DATA TAPE; 1979, MMWR, V28, P345; 1986, US PUBLICS ATTITUDES; 1985, ASSESSMENT POTENTIAL; 1990, POSITION RECOMMENDAT; 1985, US PUBLICS ATTITUDES; 1990, UNOS UPDATE, V6, P8; 1990, LANCET, V335, P1371; 1989, GAOHRD8961 US GEN AC; 1979, MMWR, V28, P337	93	251	259	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					239	246		10.1001/jama.267.2.239	http://dx.doi.org/10.1001/jama.267.2.239			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY046	1727520				2022-12-28	WOS:A1992GY04600027
J	ANSARI, AZ; CHAEL, ML; OHALLORAN, TV				ANSARI, AZ; CHAEL, ML; OHALLORAN, TV			ALLOSTERIC UNDERWINDING OF DNA IS A CRITICAL STEP IN POSITIVE CONTROL OF TRANSCRIPTION BY HG-MERR	NATURE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; UNWINDING ANGLE; MERCURIC ION; PROTEIN; PROMOTER; COMPLEX; SEQUENCE; BINDING; TN501	POSITIVE control of transcription often involves stimulatory protein-protein interactions between regulatory factors and RNA polymerase 1. Critical steps in the activation process itself are seldom ascribed to protein-DNA distortions. Activator-induced DNA bending is typically assigned a role in binding-site recognition 2, alterations in DNA loop structures 3 or optimal positioning of the activator for interaction with polymerase 4. Here we present a transcriptional activation mechanism that does not require a signal-induced DNA bend but rather a receptor-induced untwisting of duplex DNA. The allosterically modulated transcription factor MerR is a repressor and an Hg(II)-responsive activator of bacterial mercury-resistance genes 5-7. Escherichia coli RNA polymerase binds to the MerR-promoter complex but cannot proceed to a transcriptionally active open complex until Hg(II) binds to MerR (ref. 6). Chemical nuclease studies show that the activator form, but not the repressor, induces a unique alteration of the helical structure localized at the centre of the DNA-binding site 6. Data presented here indicate that this Hg-MerR-induced DNA distortion corresponds to a local underwinding of the spacer region of the promoter by about 33-degrees relative to the MerR-operator complex. The magnitude and the direction of the Hg-MerR-induced change in twist angle are consistent with a positive control mechanism involving reorientation of conserved, but suboptimally phased, promoter elements and are consistent with a role for torsional stress in formation of an open complex.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,2145 SHERIDAN RD,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University; Northwestern University			Ansari, Aseem/AAF-4945-2019; O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [R01 GM038784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BROWN NL, 1986, MOL GEN GENET, V202, P143, DOI 10.1007/BF00330531; BUCH H, 1987, RNA POLYM REGULATION, P115; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM R, 1982, COLD SPRING HARB SYM, V47, P451, DOI 10.1101/SQB.1983.047.01.053; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KOLB A, 1982, NUCLEIC ACIDS RES, V10, P473, DOI 10.1093/nar/10.2.473; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LUND P, 1989, NUCLEIC ACIDS RES, V17, P5517, DOI 10.1093/nar/17.14.5517; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	30	157	160	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					87	89		10.1038/355087a0	http://dx.doi.org/10.1038/355087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1731201				2022-12-28	WOS:A1992GY22800058
J	HENRY, K; RATHGABER, S; SULLIVAN, C; MCCABE, K				HENRY, K; RATHGABER, S; SULLIVAN, C; MCCABE, K			DIABETES-MELLITUS INDUCED BY MEGESTROL-ACETATE IN A PATIENT WITH AIDS AND CACHEXIA	ANNALS OF INTERNAL MEDICINE			English	Note						DIABETES-MELLITUS; MEGESTROL; CACHEXIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; INSULIN	VIRUS HIV INFECTION; BREAST-CANCER	Megestrol acetate is a synthetic progestin that is licensed in the United States for palliation of advanced metastatic endometrial or breast cancer. It is an appetite stimulant in patients with cancer and has been used in a small, open-label study to treat patients with the acquired immunodeficiency syndrome (AIDS) and cachexia. The drug has been considered to be relatively nontoxic. Hyperglycemia has been observed rarely. We report a case of diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. The diabetic state was characterized by relative insulin resistance, necessitating the institution of insulin therapy and the withdrawal of megestrol acetate for glucose control. Rechallenge with megestrol acetate after stabilization of the diabetic state resulted in recurrence.			HENRY, K (corresponding author), ST PAUL RAMSEY MED CTR, HIV AIDS PROGRAMS, SUITE 125, 640 JACKSON ST, ST PAUL, MN 55101 USA.							FOITL DR, 1989, CANCER, V63, P438, DOI 10.1002/1097-0142(19890201)63:3<438::AID-CNCR2820630307>3.0.CO;2-O; FURTH PA, 1989, ANN INTERN MED, V110, P667, DOI 10.7326/0003-4819-110-8-667; HELLERSTEIN MK, 1990, SEMIN ONCOL, V17, P17; MCEVOY GK, 1990, AM HOSPITAL FORMULAR, P526; NATHWANI D, 1990, ACTA DERM-VENEREOL, V70, P520; OTTEMAN LA, 1984, CANCER TREAT REP, V68, P1420; SCHACTER LP, 1990, SEMIN ONCOL, V17, P38; VONROENN JH, 1988, ANN INTERN MED, V109, P840, DOI 10.7326/0003-4819-109-10-840; VONROENN JH, 1990, SEMIN ONCOL, V17, P13; 1991, PHYSICIANS DESK REFE, P728	10	47	47	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					53	54		10.7326/0003-4819-116-1-53	http://dx.doi.org/10.7326/0003-4819-116-1-53			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1727096				2022-12-28	WOS:A1992GX15700009
J	MATHIAS, SL; SCOTT, AF; KAZAZIAN, HH; BOEKE, JD; GABRIEL, A				MATHIAS, SL; SCOTT, AF; KAZAZIAN, HH; BOEKE, JD; GABRIEL, A			REVERSE-TRANSCRIPTASE ENCODED BY A HUMAN TRANSPOSABLE ELEMENT	SCIENCE			English	Article							SITE-SPECIFIC MUTAGENESIS; VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; TY1 TRANSPOSITION; EUKARYOTIC GENOME; SPT3 GENE; RETROTRANSPOSONS; SEQUENCES; PROTEIN; DNA	L1 elements are highly repeated mammalian DNA sequences whose structure suggests dispersal by retrotransposition. A consensus L1 clement encodes a protein with sequence similarity to known reverse transcriptases. The second open reading frame from the human L1 element L1.2A was expressed as a fusion protein targeted to Tyl virus-like particles in Saccharomyces cerevisiae and shown to have reverse transcriptase activity. This activity was eliminated by a missense mutation in the highly conserved amino acid motif Y/F-X-D-D. Thus, L1 represents a potential source of the reverse transcriptase activity necessary for dispersion of the many classes of mammalian retroelements.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CTR MED GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	GABRIEL, A (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.			Boeke, Jef/0000-0001-5322-4946	NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028931] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline; NIAID NIH HHS [AI00803] Funding Source: Medline; NIGMS NIH HHS [GM28931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOEKE JD, 1986, MOL CELL BIOL, V6, P3575, DOI 10.1128/MCB.6.11.3575; BOEKE JD, 1989, MOBILE DNA, P335; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; GARFINKEL DJ, 1991, J VIROL, V65, P4573, DOI 10.1128/JVI.65.9.4573-4581.1991; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JACOBS E, 1988, GENE, V67, P259, DOI 10.1016/0378-1119(88)90402-7; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINSEY J, COMMUNICATION; KINSEY JA, 1990, GENETICS, V126, P317; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LAWRENCE W, 1978, METHODS YEAST GENETI; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, UNPUB; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; NATSOULIS G, 1989, GENETICS, V123, P269; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XU H, 1991, MOL CELL BIOL, V11, P2736, DOI 10.1128/MCB.11.5.2736; XU H, 1990, Proceedings of the National Academy of Sciences of the United States of America, V87, P8360, DOI 10.1073/pnas.87.21.8360; [No title captured]	41	587	597	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1808	1810		10.1126/science.1722352	http://dx.doi.org/10.1126/science.1722352			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1722352				2022-12-28	WOS:A1991GW31600049
J	WEIS, WI; KAHN, R; FOURME, R; DRICKAMER, K; HENDRICKSON, WA				WEIS, WI; KAHN, R; FOURME, R; DRICKAMER, K; HENDRICKSON, WA			STRUCTURE OF THE CALCIUM-DEPENDENT LECTIN DOMAIN FROM A RAT MANNOSE-BINDING PROTEIN DETERMINED BY MAD PHASING	SCIENCE			English	Article							MULTIWAVELENGTH ANOMALOUS DIFFRACTION; LIVER ASIALOGLYCOPROTEIN RECEPTOR; CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; AREA-DETECTOR DIFFRACTOMETER; PROTEOGLYCAN CORE PROTEIN; CARTILAGE PROTEOGLYCAN; SYNCHROTRON RADIATION; CONCANAVALIN-A; MACROMOLECULAR CRYSTALLOGRAPHY	Calcium-dependent (C-type) animal lectins participate in many cell surface recognition events mediated by protein-carbohydrate interactions. The C-type lectin family includes cell adhesion molecules, endocytic receptors, and extracellular matrix proteins. Mammalian mannose-binding proteins are C-type lectins that function in antibody-independent host defense against pathogens. The crystal structure of the carbohydrate-recognition domain of a rat mannose-binding protein, determined as the holmium-substituted complex by multiwavelength anomalous dispersion (MAD) phasing, reveals an unusual fold consisting of two distinct regions, one of which contains extensive nonregular secondary structure stabilized by two holmium ions. The structure explains the conservation of 32 residues in all C-type carbohydrate-recognition domains, suggesting that the fold seen here is common to these domains. The strong anomalous scattering observed at the Ho L(III) edge demonstrates that traditional heavy atom complexes will be generally amenable to the MAD phasing method.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; CNRS, UTILISAT RAYONNEMENT ELECTROMAGNET LAB, F-91405 ORSAY, FRANCE; UNIV PARIS 11, F-91405 ORSAY, FRANCE	Columbia University; Howard Hughes Medical Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	WEIS, WI (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM42628, GM34102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R37GM034102, R01GM042628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; BRUNGER AT, 1990, X PLOR MANUAL; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EZEKOWITZ R A B, 1991, Current Biology, V1, P60; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FANCHON E, 1990, ACTA CRYSTALLOGR A, V46, P809, DOI 10.1107/S0108767390005967; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAHN R, 1985, FEBS LETT, V179, P133, DOI 10.1016/0014-5793(85)80207-6; KAHN R, 1986, NUCL INSTRUM METH A, V246, P596, DOI 10.1016/0168-9002(86)90158-0; KRAULIS P, IN PRESS J APPL CRYS; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOEB JA, 1987, J BIOL CHEM, V262, P3022; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; QUESENBERRY MS, UNPUB; QUESENBERRY MS, IN PRESS GLYCOBIOLOG; REEKE GN, 1975, J BIOL CHEM, V250, P1525; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SANDY JD, 1990, J BIOL CHEM, V265, P21108; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1989, LANCET, V2, P1236; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; TEMPLETON LK, 1982, ACTA CRYSTALLOGR A, V38, P74, DOI 10.1107/S056773948200014X; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	57	508	530	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1608	1615		10.1126/science.1721241	http://dx.doi.org/10.1126/science.1721241			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1721241				2022-12-28	WOS:A1991GV07300035
J	THOMAS, JE; SORIANO, P; BRUGGE, JS				THOMAS, JE; SORIANO, P; BRUGGE, JS			PHOSPHORYLATION OF C-SRC ON TYROSINE-527 BY ANOTHER PROTEIN TYROSINE KINASE	SCIENCE			English	Article							MIDDLE TUMOR-ANTIGEN; ATP-BINDING SITE; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEIN; CARBOXY TERMINUS; PP60C-SRC; ACTIVATION; DEPHOSPHORYLATION; FIBROBLASTS; P60C-SRC	The protein tyrosine kinase activity of the cellular Src protein is negatively regulated by phosphorylation at tyrosine residue 527 (Tyr527). It has not been established whether this regulatory modification of Src is mediated by autophosphorylation or by another cellular protein kinase. The phosphorylation of a modified form of c-Src that lacks kinase activity was examined in mouse cells that do not express endogenous Src (because of the targeted disruption of both src alleles). Phosphorylation of the inactive form of Src on Tyr527 occurred to a similar extent in cells lacking endogenous Src as it did in cells expressing Src. Therefore, Tyr527 phosphorylation, and thus negative control of Src kinase activity, is mediated by another cellular protein tyrosine kinase.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA	Howard Hughes Medical Institute; University of Pennsylvania; Baylor College of Medicine; Howard Hughes Medical Institute			Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN J, COMMUNICATION; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, ONCOGENE RES, V1, P297; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOO D, 1988, CELL GROWTH DIVISION; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SCHMIDT J, UNPUB; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O	32	94	96	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1991	254	5031					568	571		10.1126/science.1719633	http://dx.doi.org/10.1126/science.1719633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1719633				2022-12-28	WOS:A1991GL79900048
J	DRYER, SE; HENDERSON, D				DRYER, SE; HENDERSON, D			A CYCLIC GMP-ACTIVATED CHANNEL IN DISSOCIATED CELLS OF THE CHICK PINEAL-GLAND	NATURE			English	Article							SINGLE ION CHANNELS; ROD INNER SEGMENTS; PHOTOENDOCRINE TRANSDUCTION; CONCENTRATION-DEPENDENCE; MELATONIN RHYTHM; LIGHT	PHOTOTRANSDUCTION in the vertebrate retina is dependent in part on a cyclic GMP-activated ionic channel in the plasma membrane of rods and cones 1,2. But other vertebrate cells are also photosensitive. Cells of the chick pineal gland have a photosensitive circadian rhythm in melatonin secretion that persists in dissociated cell culture 3,4. Exposure to light causes inhibition of melatonin secretion, and entrainment of the intrinsic circadian oscillator 5,6. Chick pinealocytes express several 'retinal' proteins, including arrestin 7, transducin 8 and a protein similar to the visual pigment rhodopsin 9. Pinealocytes of lower vertebrates display hyperpolarizing responses to brief pulses of light 10,11. Thus it is possible that some of the mechanisms of phototransduction are similar in retinal and pineal photoreceptors. We report here the first recordings of cyclic GMP-activated channels in an extraretinal photoreceptor. Application of GMP, but not cyclic AMP, to excised inside-out patches caused activation of a 15-25 pS cationic channel. These channels may be essential for phototransduction in the chick pineal gland.			DRYER, SE (corresponding author), FLORIDA STATE UNIV, DEPT BIOL SCI B157, PROGRAM PSYCHOBIOL & NEUROSCI, TALLAHASSEE, FL 32306 USA.							COLLIN JP, 1986, NEUROSCIENCE, V19, P657, DOI 10.1016/0306-4522(86)90288-5; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; HARRISON NL, 1989, J NEUROSCI, V9, P2462; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; KAUPP UB, 1988, COLD SPRING HARB SYM, V53, P407, DOI 10.1101/SQB.1988.053.01.048; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MENINI A, 1990, J PHYSIOL-LONDON, V424, P167, DOI 10.1113/jphysiol.1990.sp018061; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAMOTSU S, 1986, J COMP PHYSIOL A, V159, P1, DOI 10.1007/BF00612489; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; WAINWRIGHT SD, 1988, J NEUROCHEM, V413, P358; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X	19	97	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					756	758		10.1038/353756a0	http://dx.doi.org/10.1038/353756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1719422				2022-12-28	WOS:A1991GL69600069
J	MARICQ, AV; PETERSON, AS; BRAKE, AJ; MYERS, RM; JULIUS, D				MARICQ, AV; PETERSON, AS; BRAKE, AJ; MYERS, RM; JULIUS, D			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE 5HT3 RECEPTOR, A SEROTONIN-GATED ION CHANNEL	SCIENCE			English	Article							5-HT3 RECOGNITION SITES; NEURO-BLASTOMA CELLS; NICOTINIC ACETYLCHOLINE-RECEPTOR; CAPSAICIN-SENSITIVE FIBERS; NEUROBLASTOMA-GLIOMA CELLS; H-3 QUIPAZINE BINDING; RAT-BRAIN MEMBRANES; RADIOLIGAND BINDING; GLYCINE RECEPTOR; GABAA RECEPTOR	The neurotransmitter serotonin (5HT) activates a variety of second messenger signaling systems and through them indirectly regulates the function of ion channels. Serotonin also activates ion channels directly, suggesting that it may also mediate rapid, excitatory responses. A complementary DNA clone containing the coding sequence of one of these rapidly responding channels, a 5HT3 subtype of the serotonin receptor, has been isolated by screening a neuroblastoma expression library for functional expression of serotonin-gated currents in Xenopus oocytes. The predicted protein product has many of the features shared by other members of the ligand-gated ion channel family. The pharmacological and electrophysiological characteristics of the cloned receptor are largely consistent with the properties of native 5HT3 receptors. Messenger RNA encoding this receptor is found in the brain, spinal cord, and heart. This receptor defines a new class of excitatory ligand-gated channels.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM44298] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044298] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; BRANCHEK T, 1984, BRAIN RES, V324, P107, DOI 10.1016/0006-8993(84)90627-9; BUNCE K, 1991, TRENDS PHARMACOL SCI, V12, P46, DOI 10.1016/0165-6147(91)90493-C; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANGEUX JP, 1990, TRENDS PHARM SCI; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COSTALL B, 1988, REV NEUROSCI, V2, P41; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DANI JA, 1989, TRENDS NEUROSCI, V12, P125, DOI 10.1016/0166-2236(89)90049-0; DERKACH V, 1989, NATURE, V339, P706, DOI 10.1038/339706a0; FRAZER A, 1990, ANNU REV PHARMACOL, V30, P307; GADDUM JH, 1957, BRIT J PHARM CHEMOTH, V12, P323, DOI 10.1111/j.1476-5381.1957.tb00142.x; GORDON JC, 1989, J PHARMACOL EXP THER, V251, P962; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V330, P25, DOI 10.1038/330025b0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAMON M, 1989, EUR J PHARMACOL, V164, P315, DOI 10.1016/0014-2999(89)90472-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOYER D, 1987, EUR J PHARMACOL, V143, P291, DOI 10.1016/0014-2999(87)90547-4; HOYER D, 1988, MOL PHARMACOL, V33, P303; HOYER D, 1989, N-S ARCH PHARMACOL, V340, P396, DOI 10.1007/BF00167040; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KILPATRICK GJ, 1990, EUR J PHARMACOL, V182, P193, DOI 10.1016/0014-2999(90)90513-6; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT JJ, 1989, BRIT J PHARMACOL, V97, P27, DOI 10.1111/j.1476-5381.1989.tb11920.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MCKERNAN RM, 1990, J NEUROCHEM, V54, P924, DOI 10.1111/j.1471-4159.1990.tb02339.x; MCKERNAN RM, 1990, J BIOL CHEM, V265, P13572; MILBURN CM, 1989, J NEUROCHEM, V52, P1787, DOI 10.1111/j.1471-4159.1989.tb07258.x; MINNA JD, 1975, GENETICS, V79, P372; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NEIJT HC, 1988, NEUROPHARMACOLOGY, V27, P301, DOI 10.1016/0028-3908(88)90048-2; NEIJT HC, 1989, J PHYSIOL-LONDON, V411, P257, DOI 10.1113/jphysiol.1989.sp017572; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; NUMA S, 1989, HARVEY LECT, V83, P121; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PEROUTKA SJ, 1988, ANNU REV NEUROSCI, V11, P45, DOI 10.1146/annurev.ne.11.030188.000401; PETERS JA, 1988, EUR J PHARMACOL, V151, P491, DOI 10.1016/0014-2999(88)90550-X; RAPPORT MM, 1948, J BIOL CHEM, V176, P1243; RICHARDSON BP, 1986, TRENDS NEUROSCI, V9, P424, DOI 10.1016/0166-2236(86)90137-2; RICHARDSON BP, 1985, NATURE, V316, P126, DOI 10.1038/316126a0; Richardson BP, 1988, NEURONAL SEROTONIN, P465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHAO XM, 1991, J NEUROPHYSIOL, V65, P630, DOI 10.1152/jn.1991.65.3.630; TUTTON PJM, 1987, ANTICANCER RES, V7, P1; YAKEL JL, 1988, NEURON, V1, P615, DOI 10.1016/0896-6273(88)90111-0; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177	62	891	917	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1991	254	5030					432	437		10.1126/science.1718042	http://dx.doi.org/10.1126/science.1718042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1718042				2022-12-28	WOS:A1991GK72900050
J	NUGENT, JM; PALMER, JD				NUGENT, JM; PALMER, JD			RNA-MEDIATED TRANSFER OF THE GENE COXII FROM THE MITOCHONDRION TO THE NUCLEUS DURING FLOWERING PLANT EVOLUTION	CELL			English	Article							OXIDASE SUBUNIT-II; CHLOROPLAST DNA; STRUCTURAL ORGANIZATION; OENOTHERA MITOCHONDRIA; RIBOSOMAL-PROTEIN; COMPLETE SEQUENCE; MESSENGER-RNAS; NO INTRON; EXPRESSION; GENOME	The gene coxII, normally present in the mitochondrion, was functionally transferred to the nucleus during flowering plant evolution. coxII transfer is estimated to have occurred between 60 and 200 million years ago, whereas loss of coxII from the mitochondrion occurred much more recently, being restricted to a single genus of legumes. Most legumes have coxII in both the nucleus and the mitochondrion; however, no evidence is found for simultaneous coxII expression in both compartments. The nuclear coxII sequence more closely resembles edited mitochondrial coxII transcripts than the genes encoding these RNAs. Hence, gene transfer appears to have involved reverse transcription of an edited RNA intermediate. The nuclear gene contains an intron at the junction of the transit peptide sequence and the mature protein-coding sequence; exon shuffling may have played a role in assembling a functional coxII gene in the nucleus.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	NUGENT, JM (corresponding author), UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48104 USA.		Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDAUF SL, 1990, NATURE, V344, P262, DOI 10.1038/344262a0; BARTNIK E, 1986, NUCLEIC ACIDS RES, V14, P2407, DOI 10.1093/nar/14.5.2407; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BINDER S, 1990, CURR GENET, V17, P353, DOI 10.1007/BF00314884; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; CREPET WL, 1985, SCIENCE, V228, P1087, DOI 10.1126/science.228.4703.1087; Cronquist A., 1988, EVOLUTION CLASSIFICA; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DONOGHUE MJ, 1989, INT CONGR SER, V824, P181; Doyle JJ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; DROUIN G, 1987, NATURE, V328, P557, DOI 10.1038/328557a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FROMAN BE, 1989, MOL GEN GENET, V217, P126, DOI 10.1007/BF00330951; GANTT JS, IN PRESS EMBO J; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GRABAU EA, 1987, CURR GENET, V11, P287, DOI 10.1007/BF00355402; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUALBERTO JM, 1990, NUCLEIC ACIDS RES, V18, P3771, DOI 10.1093/nar/18.13.3771; Hamby R.K., 1988, PLANT MOL BIOL REP, V6, P175, DOI [DOI 10.1007/BF02669591, 10.1007/BF02669591]; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1983, EMBO J, V2, P2173, DOI 10.1002/j.1460-2075.1983.tb01719.x; HIESEL R, 1990, CURR GENET, V18, P371, DOI 10.1007/BF00318219; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; IZUCHI S, 1990, CURR GENET, V18, P239, DOI 10.1007/BF00318387; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KAO TH, 1984, NUCLEIC ACIDS RES, V12, P7305, DOI 10.1093/nar/12.19.7305; KIM YH, 1990, J BIOL CHEM, V265, P848; KOLODNER R, 1972, P NATL ACAD SCI USA, V69, P1830, DOI 10.1073/pnas.69.7.1830; Maniatis T., 1982, MOL CLONING; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MOON E, 1985, NUCLEIC ACIDS RES, V13, P3195, DOI 10.1093/nar/13.9.3195; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; NUGENT JM, 1988, CURR GENET, V14, P501, DOI 10.1007/BF00521276; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; Polhill R.M., 1981, ADV LEGUME SYSTEMATI, P191; PRUITT KD, 1989, CURR GENET, V16, P281, DOI 10.1007/BF00422115; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1990, MOL CELL BIOL, V10, P2428, DOI 10.1128/MCB.10.5.2428; SCHUSTER W, 1987, EMBO J, V6, P2857, DOI 10.1002/j.1460-2075.1987.tb02587.x; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; Stern D. B., 1988, METHODS PLANT MOL BI, P309; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TSUZUKI T, 1987, J MOL BIOL, V198, P21, DOI 10.1016/0022-2836(87)90454-2; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WAHLEITHNER JA, 1988, NUCLEIC ACIDS RES, V16, P6897, DOI 10.1093/nar/16.14.6897; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; WOLFE KH, 1989, J MOL EVOL, V29, P208, DOI 10.1007/BF02100204; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	66	284	291	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					473	481		10.1016/0092-8674(81)90011-8	http://dx.doi.org/10.1016/0092-8674(81)90011-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1714355	Green Published			2022-12-28	WOS:A1991GA94100009
J	HEUS, HA; PARDI, A				HEUS, HA; PARDI, A			STRUCTURAL FEATURES THAT GIVE RISE TO THE UNUSUAL STABILITY OF RNA HAIRPINS CONTAINING GNRA LOOPS	SCIENCE			English	Article							SECONDARY STRUCTURE; CONFORMATIONAL-ANALYSIS; RIBOSOMAL-RNA; SRP RNA; ACID; REGION; DNA	The most frequently occurring RNA hairpins in 16S and 23S ribosomal RNA contain a tetranucleotide loop that has a GNRA consensus sequence. The solution structures of the GCAA and GAAA hairpins have been determined by nuclear magnetic resonance spectroscopy. Both loops contain an unusual G-A base pair between the first and last residue in the loop, a hydrogen bond between a G base and a phosphate, extensive base stacking, and a hydrogen bond between a sugar 2'-end OH and a base. These interactions explain the high stability of these hairpins and the sequence requirements for the variant and invariant nucleotides in the GNRA tetranucleotide loop family.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder			Heus, Hans/F-9696-2015	Heus, Hans/0000-0001-7256-4241	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027026, R37AI030726, R01AI030726] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03283] Funding Source: Medline; NIAID NIH HHS [AI 27026, AI 30726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHIN MR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P110, DOI 10.1016/0167-4781(90)90150-Z; ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; ENDO Y, 1988, J BIOL CHEM, V263, P7917; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HANEY J, COMMUNICATION; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HEUS HA, UNPUB; JAQUIR A, 1987, CELL, V54, P17; LANKHORST PP, 1984, J BIOMOL STRUCT DYN, V1, P1387, DOI 10.1080/07391102.1984.10507527; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; LIAO X, 1989, P NATL ACAD SCI USA, V86, P4837; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0; van Knippenberg PH, 1986, STRUCTURE FUNCTION G, P412; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44	23	613	631	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					191	194		10.1126/science.1712983	http://dx.doi.org/10.1126/science.1712983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1712983				2022-12-28	WOS:A1991FW16000035
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW THERAPY FOR CHRONIC LYMPHOCYTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V263, P793	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					190	190						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1711593				2022-12-28	WOS:A1991FU89600004
J	CARREL, T; BAUER, E; LASKE, A; VONSEGESSER, L; TURINA, M				CARREL, T; BAUER, E; LASKE, A; VONSEGESSER, L; TURINA, M			LOW-DOSE APROTININ FOR REDUCTION OF BLOOD-LOSS AFTER CARDIOPULMONARY BYPASS	LANCET			English	Letter											CARREL, T (corresponding author), UNIV HOSP ZURICH,CARDIOVASC SURG CLIN,CH-8091 ZURICH,SWITZERLAND.		Carrel, Thierry/AAI-5910-2021					BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; ROYSTON D, 1986, ANAESTH INTENSIVE ME, V17, P20; VANOEVEREN W, 1990, J THORAC CARDIOV SUR, V99, P788	3	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					673	673		10.1016/0140-6736(91)92485-K	http://dx.doi.org/10.1016/0140-6736(91)92485-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1705649				2022-12-28	WOS:A1991FB73000030
J	LO, SC; TSAI, S; BENISH, JR; SHIH, JWK; WEAR, DJ; WONG, DM				LO, SC; TSAI, S; BENISH, JR; SHIH, JWK; WEAR, DJ; WONG, DM			ENHANCEMENT OF HIV-1 CYTOCIDAL EFFECTS IN CD4+ LYMPHOCYTES BY THE AIDS-ASSOCIATED MYCOPLASMA	SCIENCE			English	Article							INFECTIOUS AGENT VLIA; HTLV-III/LAV ENVELOPE; CELL-FUSION; VIRUS; IDENTIFICATION; INCOGNITUS; INDUCTION	Coinfection with Mycoplasma fermentans (incognitus strain) enhances the ability of human immunodeficiency virus type-1 (HIV-1) to induce cytopathic effects on human T lymphocytes in vitro. Syncytium formation of HIV-infected T cells was essentially eliminated in the presence of M. fermentans (incognitus strain), despite prominent cell death. However, replication and production of HIV-1 particles continued during the coinfection. Furthermore, the supernatant from cultures coinfected with HIV-1 and the mycoplasma contained a factor that inhibited the standard reverse transcriptase enzyme assay. The modification of the biological properties of HIV-1 by coinfection with mycoplasma may be involved in the pathogenesis of acquired immunodeficiency syndrome (AIDS).	BIOTECH RES LABS INC,ROCKVILLE,MD 20852; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	LO, SC (corresponding author), ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,AMER REGISTRY PATHOL,WASHINGTON,DC 20306, USA.							BALTIMORE D, 1971, P NATL ACAD SCI USA, V68, P1507, DOI 10.1073/pnas.68.7.1507; CHOWDHURY MIH, 1990, LANCET, V336, P247; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; LEMAITRE M, 1990, RES VIROLOGY, V141, P5, DOI 10.1016/0923-2516(90)90052-K; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LO SC, 1986, AM J TROP MED HYG, V35, P675, DOI 10.4269/ajtmh.1986.35.675; LO SC, 1989, AM J TROP MED HYG, V40, P399, DOI 10.4269/ajtmh.1989.40.399; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LO SC, 1989, AM J TROP MED HYG, V40, P213, DOI 10.4269/ajtmh.1989.40.213; LO SC, 1989, AM J TROP MED HYG, V41, P586, DOI 10.4269/ajtmh.1989.41.586; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO ST, UNPUB; MARCUS JI, 1990, J CELL PHYSL, V143, P416; SAILLARD C, 1990, RES VIROLOGY, V141, P385, DOI 10.1016/0923-2516(90)90010-G; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; VASNDEVACHARI MB, 1990, AIDS RES HUM RETROV, V6, P411; Wright K, 1990, Science, V248, P682, DOI 10.1126/science.2333519; 1989, 5 INT C AIDS MONTR	20	141	145	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1074	1076		10.1126/science.1705362	http://dx.doi.org/10.1126/science.1705362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1705362				2022-12-28	WOS:A1991EZ66500051
J	ALIFANO, P; RIVELLINI, F; LIMAURO, D; BRUNI, CB; CARLOMAGNO, MS				ALIFANO, P; RIVELLINI, F; LIMAURO, D; BRUNI, CB; CARLOMAGNO, MS			A CONSENSUS MOTIF COMMON TO ALL RHO-DEPENDENT PROKARYOTIC TRANSCRIPTION TERMINATORS	CELL			English	Article							ESCHERICHIA-COLI K-12; RIBOSOMAL-RNA TRANSCRIPTION; SALMONELLA-TYPHIMURIUM; HISTIDINE OPERON; BACTERIOPHAGE-LAMBDA; INTERCISTRONIC REGION; REGULATORY REGION; GENE-EXPRESSION; BINDING DOMAIN; SITES	We have characterized at the molecular level several polar mutations in four different cistrons of the his operon of S. typhimurium. An analysis of the his-specific transcripts produced in vivo in the mutant strains, together with in vitro transcription assays, led to the identification of several cryptic Rho-dependent transcription termination elements within the his operon that are activated by the uncoupling of transcription and translation. Common features of these elements were sought and found with a computer program. We have identified a consensus motif, consisting of a cytosine-rich and guanosine-poor region, that is located upstream of the heterogeneous 3' endpoints of the prematurely terminated in vivo transcripts and that is present in all the Rho-dependent transcription terminators described thus far.			ALIFANO, P (corresponding author), NAPLES UNIV,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY.							ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; AKSOY S, 1984, J BACTERIOL, V159, P260, DOI 10.1128/JB.159.1.260-264.1984; ALIFANO P, 1988, CELL, V55, P351, DOI 10.1016/0092-8674(88)90058-X; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRUNI CB, 1980, J BACTERIOL, V142, P32, DOI 10.1128/JB.142.1.32-42.1980; BURGIN AB, 1990, CELL, V60, P405, DOI 10.1016/0092-8674(90)90592-3; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CARLOMAGNO MS, 1985, J BACTERIOL, V163, P362, DOI 10.1128/JB.163.1.362-368.1985; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; CERUZZI MAF, 1985, J BIOL CHEM, V260, P9412; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CIAMPI MS, 1989, J BACTERIOL, V171, P4472, DOI 10.1128/JB.171.8.4472-4478.1989; CIAMPI MS, 1988, GENETICS, V218, P193; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; COURT D, 1980, J MOL BIOL, V138, P231, DOI 10.1016/0022-2836(80)90285-5; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; Favaloro J, 1980, Methods Enzymol, V65, P718; FINK GR, 1967, J MOL BIOL, V30, P97, DOI 10.1016/0022-2836(67)90246-X; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GARRICKS.L, 1970, GENETICS, V66, P231; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GOODMAN HM, 1980, METHOD ENZYMOL, V75, P63; GOTTESMAN M, 1982, CELL, V29, P727, DOI 10.1016/0092-8674(82)90434-2; GRISOLIA V, 1982, J BACTERIOL, V151, P692, DOI 10.1128/JB.151.2.692-700.1982; HARTMAN PE, 1971, ADV GENET, V16, P1, DOI 10.1016/S0065-2660(08)60352-1; HIGGINS CF, 1986, SOC GENERAL MICROBIO, V39, P179; HOLBEN WE, 1984, P NATL ACAD SCI-BIOL, V81, P6789, DOI 10.1073/pnas.81.21.6789; HOPPE I, 1979, GENETICS, V92, P17; HYMAN HC, 1986, J MOL BIOL, V189, P131, DOI 10.1016/0022-2836(86)90386-4; JOHNSTON HM, 1979, GENETICS, V92, P1; KASAI T, 1974, NATURE, V249, P523, DOI 10.1038/249523a0; KIESER T, 1988, GENE, V65, P83, DOI 10.1016/0378-1119(88)90419-2; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1966, J MOL BIOL, V21, P357, DOI 10.1016/0022-2836(66)90104-5; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NEWTON WA, 1965, J MOL BIOL, V14, P290, DOI 10.1016/S0022-2836(65)80250-9; RECHLER MM, 1972, J MOL BIOL, V69, P427, DOI 10.1016/0022-2836(72)90256-2; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENTHAL ER, 1987, J MOL BIOL, V194, P443, DOI 10.1016/0022-2836(87)90673-5; ROSSI J, 1981, CELL, V26, P305, DOI 10.1016/0092-8674(81)90199-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; STANSSENS P, 1986, CELL, V44, P711, DOI 10.1016/0092-8674(86)90837-8; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STITT BL, 1988, J BIOL CHEM, V263, P11130; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERDE P, 1981, NUCLEIC ACIDS RES, V9, P2075, DOI 10.1093/nar/9.9.2075; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; VOLL MJ, 1967, J MOL BIOL, V30, P109, DOI 10.1016/0022-2836(67)90247-1; WEK RC, 1987, J BIOL CHEM, V262, P15256; WHITFIELD HJ, 1966, J MOL BIOL, V21, P335, DOI 10.1016/0022-2836(66)90103-3; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YAGER TD, 1987, ESCHERICHIA COLI SAL, V1, P1241; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0	72	123	124	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					553	563						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1703923				2022-12-28	WOS:A1991EX36100011
J	GOTOH, Y; NISHIDA, E; MATSUDA, S; SHIINA, N; KOSAKO, H; SHIOKAWA, K; AKIYAMA, T; OHTA, K; SAKAI, H				GOTOH, Y; NISHIDA, E; MATSUDA, S; SHIINA, N; KOSAKO, H; SHIOKAWA, K; AKIYAMA, T; OHTA, K; SAKAI, H			INVITRO EFFECTS ON MICROTUBULE DYNAMICS OF PURIFIED XENOPUS M-PHASE-ACTIVATED MAP KINASE	NATURE			English	Article							SERINE-THREONINE KINASE; PROTEIN-KINASE; PHOSPHORYLATION; INSULIN; OOCYTES; EGGS; CENTROSOMES; MATURATION; TYROSINE; EXTRACTS	THE protein kinase MAP kinase, also called MAP2 kinase, is a serine/threonine kinase whose activation and phosphorylation are induced by a variety of mitogens 1-6, and which is thought to have a critical role in a network of protein kinases in mitogenic signal transduction 1-7. A burst in kinase activation 8,9 and protein phosphorylation 10 may also be important in triggering the dramatic reorganization of the cell during the transition from interphase to mitosis. The interphase-metaphase transition of microtubule arrays is under the control of p34cd2 kinase 11, a central control element in the G2-M transition of the cell cycle 12. Here we show that a Xenopus kinase, closely related to the mitogen-activated mammalian MAP kinase, is phosphorylated and activated during M phase of meiotic and mitotic cell cycles, and that the interphase-metaphase transition of microtubule arrays can be induced by the addition of purified Xenous M phase-activated MAP kinase or mammalian mitogen-activated MAP kinase to interphase extracts in vitro.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,INST ZOOL,TOKYO 113,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo; University of Tokyo; Osaka University				Shiina, Nobuyuki/0000-0002-1854-4239				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; STITH BJ, 1984, DEV BIOL, V102, P79, DOI 10.1016/0012-1606(84)90176-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0	26	424	430	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					251	254		10.1038/349251a0	http://dx.doi.org/10.1038/349251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1702878				2022-12-28	WOS:A1991ET51900060
J	OCONNELL, AM; KOEPPE, RE; ANDERSEN, OS				OCONNELL, AM; KOEPPE, RE; ANDERSEN, OS			KINETICS OF GRAMICIDIN CHANNEL FORMATION IN LIPID BILAYERS - TRANSMEMBRANE MONOMER ASSOCIATION	SCIENCE			English	Article									UNIV ARKANSAS,DEPT CHEM & BIOCHEM,FAYETTEVILLE,AR 72701	University of Arkansas System; University of Arkansas Fayetteville	OCONNELL, AM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10021, USA.			Koeppe, Roger/0000-0003-0676-6413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034968, R01GM021342] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34968, GM21342, R01 GM021342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMDUR I, 1965, CHEM KINETICS PRINCI, P16; ANDERSEN OS, 1990, BIOPHYS J, V57, pA100; ANDERSEN OS, 1982, J GEN PHYSIOL, V80, P403, DOI 10.1085/jgp.80.3.403; ARSENIEV AS, 1985, FEBS LETT, V186, P168, DOI 10.1016/0014-5793(85)80702-X; BANO MC, 1989, FEBS LETT, V250, P67, DOI 10.1016/0014-5793(89)80686-6; BUSTER DC, 1988, BIOPHYS J, V53, P145, DOI 10.1016/S0006-3495(88)83076-5; BYSTROV VF, 1988, TETRAHEDRON, V44, P925, DOI 10.1016/S0040-4020(01)86126-3; CIFU AS, 1989, BIOPHYS J, V55, pA503; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; DURKIN JT, 1987, BIOPHYS J, V51, pA451; DURKIN JT, 1990, J MOL BIOL, V211, P221, DOI 10.1016/0022-2836(90)90022-E; EASTON PL, 1989, THESIS U ARKANSAS FA; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HAWKES GE, 1987, EUR J BIOCHEM, V166, P437, DOI 10.1111/j.1432-1033.1987.tb13535.x; HLADKY SB, 1974, DRUGS TRANSPORT PROC, P193; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; KEMP G, 1976, ARCH BIOCHEM BIOPHYS, V176, P547, DOI 10.1016/0003-9861(76)90198-3; KILLIAN JA, 1988, BIOPHYS J, V53, P111, DOI 10.1016/S0006-3495(88)83072-8; KILLIAN JA, 1988, BIOCHEMISTRY-US, V27, P7295, DOI 10.1021/bi00419a018; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LINGAPPA VR, 1989, J CLIN INVEST, V83, P739, DOI 10.1172/JCI113952; LOGRASSO PV, 1988, BIOPHYS J, V54, P259, DOI 10.1016/S0006-3495(88)82955-2; MADDOCK AK, 1989, ICSU SHORT REP, V9, P24; MAZET JL, 1984, BIOPHYS J, V45, P263, DOI 10.1016/S0006-3495(84)84153-3; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; PULLMAN A, 1988, TRANSPORT MEMBRANES; ROUX B, 1990, THESIS HARVARD U CAM; RUSSELL EWB, 1986, BIOPHYS J, V49, P673, DOI 10.1016/S0006-3495(86)83694-3; SALEMME FR, 1988, SCIENCE, V241, P145, DOI 10.1126/science.2455343; SARGES R, 1965, J AM CHEM SOC, V87, P2011, DOI 10.1021/ja01087a027; SAWYER DB, 1990, BIOPHYS J, V57, P515, DOI 10.1016/S0006-3495(90)82567-4; SAWYER DB, 1989, BIOCHEMISTRY-US, V28, P6571, DOI 10.1021/bi00442a007; SYCHEV SV, 1980, BIOORG CHEM, V9, P121, DOI 10.1016/0045-2068(80)90035-8; URRY DW, 1975, ANN NY ACAD SCI, V264, P203, DOI 10.1111/j.1749-6632.1975.tb31484.x; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; VEATCH WR, 1974, BIOCHEMISTRY-US, V13, P5257, DOI 10.1021/bi00723a002; WALLACE BA, 1988, SCIENCE, V241, P181; WALLACE BA, 1987, ION TRANSPORT MEMBRA, P255	39	227	229	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 30	1990	250	4985					1256	1259		10.1126/science.1700867	http://dx.doi.org/10.1126/science.1700867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK723	1700867				2022-12-28	WOS:A1990EK72300037
J	LARSEN, E; PALABRICA, T; SAJER, S; GILBERT, GE; WAGNER, DD; FURIE, BC; FURIE, B				LARSEN, E; PALABRICA, T; SAJER, S; GILBERT, GE; WAGNER, DD; FURIE, BC; FURIE, B			PADGEM-DEPENDENT ADHESION OF PLATELETS TO MONOCYTES AND NEUTROPHILS IS MEDIATED BY A LINEAGE-SPECIFIC CARBOHYDRATE, LNF-III (CD15)	CELL			English	Article									TUFTS UNIV,SCH MED,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CARDIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Tufts University; Tufts Medical Center; Tufts University; Tufts University; Tufts University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007437, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443, HL07437, HL07574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTSEN M, 1989, BRIT J HAEMATOL, V72, P312, DOI 10.1111/j.1365-2141.1989.tb07710.x; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BRANDLEY BK, 1986, J LEUKOCYTE BIOL, V40, P97, DOI 10.1002/jlb.40.1.97; CALLOW AD, 1982, ARCH SURG-CHICAGO, V117, P1447; CARLSSON SR, 1986, J BIOL CHEM, V261, P1287; CHRISTIANSEN NP, 1988, BLOOD, V71, P1624; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; HALL PA, 1987, J CLIN PATHOL, V40, P1298, DOI 10.1136/jcp.40.11.1298; HAMBURGER SA, 1990, BLOOD, V75, P550; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; HUANG LC, 1983, BLOOD, V61, P1020; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUNGI TW, 1986, BLOOD, V67, P629; KOBATA A, 1969, J BIOL CHEM, V244, P5496; KOLBER MA, 1988, J IMMUNOL METHODS, V108, P255, DOI 10.1016/0022-1759(88)90427-9; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LINDENBERG S, 1988, J REPROD FERTIL, V83, P149; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; NAUSEEF WM, 1983, BLOOD, V62, P636; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; SANDERS DSA, 1988, J PATHOL, V154, P255, DOI 10.1002/path.1711540308; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SILVERSTEIN RL, 1987, J CLIN INVEST, V79, P867, DOI 10.1172/JCI112896; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V1648, P1373; SKUBITZ KM, 1988, J IMMUNOL, V141, P4318; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1987, BLOOD, V70, P1842; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TEDDER TF, 1989, J IMMUNOL, V143, P712; YANG HJ, 1971, J BIOL CHEM, V246, P1192	40	345	384	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 2	1990	63	3					467	474		10.1016/0092-8674(90)90443-I	http://dx.doi.org/10.1016/0092-8674(90)90443-I			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EG687	1699666				2022-12-28	WOS:A1990EG68700005
J	BIERER, BE; SOMERS, PK; WANDLESS, TJ; BURAKOFF, SJ; SCHREIBER, SL				BIERER, BE; SOMERS, PK; WANDLESS, TJ; BURAKOFF, SJ; SCHREIBER, SL			PROBING IMMUNOSUPPRESSANT ACTION WITH A NONNATURAL IMMUNOPHILIN LIGAND	SCIENCE			English	Article									HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; BRIGHAM & WOMENS HOSP,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Bierer, Barbara/0000-0001-6448-8170	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-39542] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BIERER BE, IN PRESS P NATL ACAD; BLANCHETTE MA, 1984, TETRAHEDRON LETT, V25, P2183, DOI 10.1016/S0040-4039(01)80205-7; BURKE SD, 1987, TETRAHEDRON LETT, V28, P3905, DOI 10.1016/S0040-4039(00)96416-5; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, pS35; GILLIS S, 1978, J IMMUNOL, V120, P2027; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HENTGES SG, 1980, J AM CHEM SOC, V102, P4263, DOI 10.1021/ja00532a050; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; NAKATA T, 1983, TETRAHEDRON LETT, V24, P2653, DOI 10.1016/S0040-4039(00)87969-1; NAKATSUKA M, 1990, J AM CHEM SOC, V112, P5583, DOI 10.1021/ja00170a024; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; WANDLESS TJ, UNPUB; WILLIAMS DR, 1988, J ORG CHEM, V53, P4643, DOI 10.1021/jo00254a060	24	340	359	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 26	1990	250	4980					556	559		10.1126/science.1700475	http://dx.doi.org/10.1126/science.1700475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE660	1700475				2022-12-28	WOS:A1990EE66000037
J	KHABBAZ, RF; ONORATO, IM; CANNON, RO; HARTLEY, TM; ROBERTS, B; HOSEIN, B; KAPLAN, JE				KHABBAZ, RF; ONORATO, IM; CANNON, RO; HARTLEY, TM; ROBERTS, B; HOSEIN, B; KAPLAN, JE			SEROPREVALENCE OF HTLV-I AND HTLV-II AMONG INTRAVENOUS-DRUG-USERS AND PERSONS IN CLINICS FOR SEXUALLY-TRANSMITTED DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS TYPE-I; UNITED-STATES; INFECTION; TRANSMISSION; ABUSERS; PREVALENCE; AIDS; MEN	Background. The human T-cell lymphotropic virus Type I (HTLV-I) is associated with adult T-cell leukemia and myelopathy, whereas HTLV-II infection has uncertain clinical consequences. We assessed the seroprevalence of these retroviruses among intravenous drug users and among patients seen at clinics for sexually transmitted diseases (STD clinics). Methods. We used serum samples that were collected in eight cities in 1988 and 1989 during surveys of human immunodeficiency virus infection among intravenous drug users entering treatment and persons seen in STD clinics. The serum samples were tested for antibodies to HTLV, and positive specimens were tested further by a synthetic peptide-based enzyme-linked immunosorbent assay to differentiate between HTLV-I and HTLV-II. Results. Among 3217 intravenous drug users in 29 drug-treatment centers, the median seroprevalence rates of HTLV varied widely according to city (range, 0.4 percent in Atlanta to 17.6 percent in Los Angeles). Seroprevalence increased sharply with age, to 32 percent in persons over 44 years of age. HTLV infection was more common among blacks (15.5 percent) and Hispanics (10.7 percent) than among whites (4.1 percent), and it was strongly associated with a history of heroin injection (P less-than-or-equal-to 0.001). Among 5264 patients in 24 STD clinics, the median rates of HTLV infection were much lower (range, 0.1 percent in Atlanta and Newark to 2.0 percent in Los Angeles). Again, this infection was more common among intravenous drug users (7.6 percent) than among non-drug users (0.7 percent). Eighty-four percent of the seropositive samples from drug-treatment centers and 69 percent of those from STD clinics were due to HTLV-II infection (P = 0.03). Conclusions. HTLV infection is common among intravenous drug users and is primarily caused by HTLV-II. Among patients seen at STD clinics, HTLV is strongly associated with intravenous drug use, but the retrovirus is also prevalent among non-drug users.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV STD HIV PREVENT,ATLANTA,GA 30333; UNITED BIOMED INC,LAKE SUCCESS,NY	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,RETROVIRUS DIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,MS-A32,ATLANTA,GA 30333, USA.							BIGGAR RJ, 1991, J INFECT DIS, V163, P57, DOI 10.1093/infdis/163.1.57; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; CANTOR KP, 1991, J ACQ IMMUN DEF SYND, V4, P460; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P646, DOI 10.1128/JCM.28.4.646-650.1990; HARTLEY TM, 1990, J CLIN MICROBIOL, V28, P1491; HASELTINE WA, 1985, CURR TOP MICROBIOL, V115, P177; HJELLE B, 1990, BLOOD, V76, P450; KHABBAZ RF, 1990, J INFECT DIS, V162, P241, DOI 10.1093/infdis/162.1.241; KHABBAZ RF, 1991, J INFECT DIS, V163, P252, DOI 10.1093/infdis/163.2.252; KHABBAZ RF, 1990, JAMA-J AM MED ASSOC, V263, P60, DOI 10.1001/jama.263.1.60; KWOK S, 1990, AIDS RES HUM RETROV, V6, P561, DOI 10.1089/aid.1990.6.561; LAIRMORE MD, 1989, BLOOD, V74, P2596; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE HH, 1991, LANCET, V337, P1435, DOI 10.1016/0140-6736(91)93126-T; MANNS A, 1988, NEW ENGL J MED, V319, P516, DOI 10.1056/NEJM198808253190811; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; NAKANO S, 1986, J INFECTION, V12, P205, DOI 10.1016/S0163-4453(86)94086-7; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; WEISS SH, 1987, 3RD P INT C AIDS WAS, P211; 1990, MMWR, V39, P921; 1990, NATIONAL HIV SEROPRE; 1988, MMWR, V37, P736; 1990, MMWR, V39, P915; 1988, MMWR, V37, P745; 1989, MMWR S7, V38, P1	30	167	167	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1992	326	6					375	380		10.1056/NEJM199202063260604	http://dx.doi.org/10.1056/NEJM199202063260604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC386	1729620	Bronze			2022-12-28	WOS:A1992HC38600004
J	CLASSEN, DC; EVANS, RS; PESTOTNIK, SL; HORN, SD; MENLOVE, RL; BURKE, JP				CLASSEN, DC; EVANS, RS; PESTOTNIK, SL; HORN, SD; MENLOVE, RL; BURKE, JP			THE TIMING OF PROPHYLACTIC ADMINISTRATION OF ANTIBIOTICS AND THE RISK OF SURGICAL-WOUND INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-MICROBIAL PROPHYLAXIS; ANTIMICROBIAL PROPHYLAXIS; SURGERY; PRINCIPLES	Background. Randomized, controlled trials have shown that prophylactic antibiotics are effective in preventing surgical-wound infections. However, it is uncertain how the timing of antibiotic administration affects the risk of surgical-wound infection in actual clinical practice. Methods. We prospectively monitored the timing of antibiotic prophylaxis and studied the occurrence of surgical-wound infections in 2847 patients undergoing elective clean or "clean-contaminated" surgical procedures at a large community hospital. The administration of antibiotics 2 to 24 hours before the surgical incision was defined as early; that during the 2 hours before the incision, as preoperative; that during the 3 hours after the incision, as peri-operative; and that more than 3 but less than 24 hours after the incision, as postoperative. Results. Of the 1708 patients who received the prophylactic antibiotics preoperatively, 10 (0.6 percent) subsequently had surgical-wound infections. Of the 282 patients who received the antibiotics perioperatively, 4 (1.4 percent) had such infections (P = 0.12; relative risk as compared with the preoperatively treated group, 2.4; 95 percent confidence interval, 0.9 to 7.9). Of 488 patients who received the antibiotics postoperatively, 16 (3.3 percent) had wound infections (P < 0.0001; relative risk, 5.8; 95 percent confidence interval, 2.6 to 12.3). Finally, of 369 patients who had antibiotics administered early, 14 (3.8 percent) had wound infections (P < 0.0001; relative risk, 6.7; 95 percent confidence interval, 2.9 to 14.7). Stepwise logistic-regression analysis confirmed that the administration of antibiotics in the preoperative period was associated with the lowest risk of surgical-wound infection. Conclusions. In surgical practice there is considerable variation in the timing of the prophylactic administration of antibiotics, and administration in the two hours before surgery reduces the risk of wound infection.	LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, 8TH AVE & C ST, SALT LAKE CITY, UT 84143 USA; UNIV UTAH, SCH MED, DIV INFECT DIS, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah								BERGQUIST EJ, 1987, MED CLIN N AM, V71, P357, DOI 10.1016/S0025-7125(16)30845-8; BERMAN GD, 1990, MAYO CLIN PROC, V65, P657, DOI 10.1016/S0025-6196(12)65128-3; BURDON DW, 1982, WORLD J SURG, V6, P262, DOI 10.1007/BF01653540; BURKE JF, 1961, SURGERY, V50, P161; CROSSLEY K, 1981, JAMA-J AM MED ASSOC, V245, P722, DOI 10.1001/jama.245.7.722; DONABEDIAN A, 1990, INFECT CONT HOSP EP, V11, P117; EHRENKRANZ NJ, 1981, AM J MED, V70, P909, DOI 10.1016/0002-9343(81)90554-4; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; FINLAND M, 1960, R I Med J, V43, P499; FINLAND M, 1960, R I MED J, V43, P513; GILEGEA MJ, 1987, INFECT CONT HOSP EP, V8, P277, DOI 10.1017/S0195941700066236; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; GUGLIELMO BJ, 1983, ARCH SURG-CHICAGO, V118, P943; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNT TK, 1981, AM J MED, V70, P712, DOI 10.1016/0002-9343(81)90602-1; KAISER AB, 1986, NEW ENGL J MED, V315, P1129; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; MOLESKI RJ, 1986, REV INFECT DIS, V8, P488; OLSON M, 1984, ANN SURG, V199, P253, DOI 10.1097/00000658-198403000-00001; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; POLK HC, 1969, SURGERY, V66, P97; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; RONALD AR, 1983, SURGERY, V93, P172; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SHAPIRO M, 1979, NEW ENGL J MED, V301, P351, DOI 10.1056/NEJM197908163010703; SHAPIRO M, 1980, J INFECT DIS, V141, P532, DOI 10.1093/infdis/141.4.532; SIMMONS RL, 1982, INFECT CONT HOSP EP, V3, P44, DOI 10.1017/S0195941700057118; STONE HH, 1984, J ANTIMICROB CHEMOTH, V14, P33, DOI 10.1093/jac/14.suppl_B.33; STONE HH, 1976, ANN SURG, V184, P443, DOI 10.1097/00000658-197610000-00007; 1980, AM J EPIDEMIOL, V111, P635; 1985, MED LETT DRUGS THER, V27, P105	32	1176	1220	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					281	286		10.1056/NEJM199201303260501	http://dx.doi.org/10.1056/NEJM199201303260501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728731				2022-12-28	WOS:A1992HA99100001
J	LUDLOW, CL; HALLETT, M; RHEW, K; COLE, R; SHIMIZU, T; SAKAGUCHI, G; BAGLEY, JA; SCHULZ, GM; YIN, SG; KODA, J				LUDLOW, CL; HALLETT, M; RHEW, K; COLE, R; SHIMIZU, T; SAKAGUCHI, G; BAGLEY, JA; SCHULZ, GM; YIN, SG; KODA, J			THERAPEUTIC USE OF TYPE-F BOTULINUM TOXIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							HEMIFACIAL SPASM; FOCAL DYSTONIAS; INJECTIONS		NINCDS,BETHESDA,MD 20892; CHIBA SERUM INST,CHIBA,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,SAKAI,OSAKA 591,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Osaka Metropolitan University	LUDLOW, CL (corresponding author), NIDOCD,BETHESDA,MD 20892, USA.			Schulz, Geralyn/0000-0003-3831-8105; Ludlow, Christy/0000-0002-2015-6171				BARKER AT, 1990, J PHYSIOL-LONDON, V423, pP66; BLITZER A, 1989, ANN OTO RHINOL LARYN, V98, P93, DOI 10.1177/000348948909800202; BRIN MF, 1987, MOVEMENT DISORD, V2, P237, DOI 10.1002/mds.870020402; COHEN LG, 1989, J NEUROL NEUROSUR PS, V52, P355, DOI 10.1136/jnnp.52.3.355; GREENE P, 1990, NEUROLOGY, V40, P1213, DOI 10.1212/WNL.40.8.1213; JANKOVIC J, 1990, J NEUROL NEUROSUR PS, V53, P633, DOI 10.1136/jnnp.53.8.633; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KAUFFMAN JA, 1985, TOXICOL APPL PHARM, V79, P211, DOI 10.1016/0041-008X(85)90342-4; LUDLOW CL, 1990, JAMA-J AM MED ASSOC, V264, P2671, DOI 10.1001/jama.264.20.2671; YANG KH, 1975, APPL MICROBIOL, V29, P598, DOI 10.1128/AEM.29.5.598-603.1975; [No title captured]	11	74	81	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					349	350						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728750				2022-12-28	WOS:A1992HA99100027
J	BERMAN, E; LITTLE, C; GEE, T; OREILLY, R; CLARKSON, B				BERMAN, E; LITTLE, C; GEE, T; OREILLY, R; CLARKSON, B			REASONS THAT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA DO NOT UNDERGO ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; 1ST COMPLETE REMISSION; CYTOSINE-ARABINOSIDE; INDUCTION THERAPY; CHEMOTHERAPY; DAUNORUBICIN; ADULTS; TRIAL	Background. Numerous reports suggest that allogeneic bone marrow transplantation prolongs the survival of adult patients with acute myelogenous leukemia (AML) in first remission. However, it is unclear how many such patients actually undergo this procedure. Methods. We reviewed the case records of 350 consecutive adult patients with AML treated with chemotherapy at a single institution from 1979 (when the policy of offering allogeneic transplantation to all such patients in first remission was introduced) through 1990. The criteria for exclusion before transplantation included age greater than 40 and, beginning in 1984, a diagnosis of acute promyelocytic leukemia. Results. One hundred forty-two patients (41 percent of the study population) were 40 years of age or younger. HLA testing was performed for 120 of these patients (85 percent). Sixty-seven patients (47 percent) had an HLA-identical sibling as a potential donor. One hundred three patients (73 percent) entered remission during treatment according to one of five chemotherapy protocols. Of the 52 patients who both entered remission and had an HLA match, 30 underwent transplantation while they were in first remission. These 30 patients constituted 21 percent of all study patients 40 years old or younger, 29 percent of all patients 40 or under who entered remission, 45 percent of all patients with an HLA match, 58 percent of all patients who had both a remission and a match, and 9 percent of all patients treated according to a protocol. Among patients with a match who did not undergo transplantation, those with primary refractory disease were the largest subgroup. Conclusions. These findings suggest that allogeneic bone marrow transplantation is performed in less than 60 percent of adult patients with AML who are potentially eligible for the procedure.	MEM SLOAN KETTERING CANC CTR, BONE MARROW TRANSPLANT SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	BERMAN, E (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, LEUKEMIA SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							APPELBAUM FR, 1988, BLOOD, V72, P179; ARLIN Z, 1990, LEUKEMIA, V4, P177; BERMAN E, 1991, BLOOD, V77, P1666; BISHOP JF, 1990, BLOOD, V75, P27; BRINCKER H, 1985, CANCER TREAT REP, V69, P5; CASSILETH PA, 1984, BLOOD, V63, P843; CHAMPLIN RE, 1985, ANN INTERN MED, V102, P285, DOI 10.7326/0003-4819-102-3-285; CHAN KW, 1982, TRANSPLANTATION, V33, P613, DOI 10.1097/00007890-198206000-00009; CLARKSON B, 1990, UCLA SYM BI, V108, P231; CUNNINGHAM I, 1989, BLOOD, V73, P1116; FORMAN SJ, 1987, TRANSPLANTATION, V43, P650, DOI 10.1097/00007890-198705000-00009; GELLER RB, 1989, BLOOD, V73, P2209; GRATWOHL A, 1988, LANCET, V1, P1379; HERMANS J, 1989, EUR J CANCER CLIN ON, V25, P545, DOI 10.1016/0277-5379(89)90268-X; KANTARJIAN HM, 1987, CANCER-AM CANCER SOC, V59, P1258, DOI 10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MCGLAVE PB, 1988, BLOOD, V72, P1512; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PREISLER HD, 1979, BLOOD, V53, P455; RAI KR, 1981, BLOOD, V58, P1203; STONE RM, 1988, BLOOD, V71, P690; WEINSTEIN HJ, 1980, NEW ENGL J MED, V303, P473, DOI 10.1056/NEJM198008283030901; YATES J, 1982, BLOOD, V60, P454; YOUNG JW, 1990, BLOOD S, V76, pA575; ZANDER AR, 1988, J CLIN ONCOL, V6, P1548, DOI 10.1200/JCO.1988.6.10.1548	25	54	54	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					156	160		10.1056/NEJM199201163260303	http://dx.doi.org/10.1056/NEJM199201163260303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ213	1727546				2022-12-28	WOS:A1992GZ21300003
J	HAHN, RA; MULINARE, J; TEUTSCH, SM				HAHN, RA; MULINARE, J; TEUTSCH, SM			INCONSISTENCIES IN CODING OF RACE AND ETHNICITY BETWEEN BIRTH AND DEATH IN UNITED-STATES INFANTS - A NEW LOOK AT INFANT-MORTALITY, 1983 THROUGH 1985	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To ascertain the consistency of the racial and ethnic classification of US infants between birth and death and its impact on infant mortality rates. Subjects. - All US infants born from 1983 through 1985 who died within a year. Design. - We used the national linked birth/infant-death computer tape, augmented with information on infants' race and ethnicity at death, to compare the coding of race and Hispanic ethnicity at birth and at death. We also assessed infant mortality rates by race and ethnicity as defined (1) by the standard algorithm and (2) by the rule that, beginning in published tabulations for 1989, assigns newborns the race of their mothers. Finally, we estimated infant mortality rates based on consistent coding of race and ethnicity at birth and death. Results. - Inconsistency in the coding of race is low for whites (1.2%), greater for blacks (4.3%), and greatest for races other than white or black (43.2%). Most infants reclassified at death (87.3%) are classified as white at death. Inconsistency in coding is lower for non-Hispanic whites (3.5%) and non-Hispanic blacks (3.3%) than for Hispanic populations (30.3%). Compared with the standard algorithm for calculation of infant mortality, consistent definition at birth and death produces rates 2.1 % lower for whites, and higher for all other groups-3.2% for blacks, 46.9% for American Indians, 33.3% for Chinese, 48.8% for Japanese, 78.7% for Filipinos, and 8.9% for Hispanics. Conclusions. - The coding of race and ethnicity of infants at birth and death is remarkably inconsistent, with substantial impact on the estimation of infant mortality rates. A need exists to reconsider the nature and definition of race and ethnicity in public health.			HAHN, RA (corresponding author), CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV SURVEILLANCE & EPIDEMIOL,ATLANTA,GA 30333, USA.							BECERRA JE, 1991, JAMA-J AM MED ASSOC, V265, P217, DOI 10.1001/jama.265.2.217; FROST F, 1980, AM J PUBLIC HEALTH, V70, P974, DOI 10.2105/AJPH.70.9.974; KENNEDY RD, 1991, PUBLIC HEALTH REP, V106, P97; Kleinman J C, 1990, MMWR CDC Surveill Summ, V39, P31; NORRIS FD, 1971, HSMHA HEALTH REP, V86, P810, DOI 10.2307/4594302; 1987, PHS871113 US DEP HLT, P1; 1989, PUBLIC USE DATA TAPE; 1987, HOSPITALS PHYSICIANS; 1988, PHS881113 US DEP HLT, P1; 1989, PHS881101 US DEP HLT, P2; 1988, PHS881100 US DEP HLT, V1, P7; 1987, PHS871101 US DEP HLT, P2; 1990, HLTH PEOPLE 2000; 1988, PHS881100 US DEP HLT, P2	14	155	156	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					259	263		10.1001/jama.267.2.259	http://dx.doi.org/10.1001/jama.267.2.259			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY046	1727523				2022-12-28	WOS:A1992GY04600030
J	BIKOFF, EK; JAFFE, L; RIBAUDO, RK; OTTEN, GR; GERMAIN, RN; ROBERTSON, EJ				BIKOFF, EK; JAFFE, L; RIBAUDO, RK; OTTEN, GR; GERMAIN, RN; ROBERTSON, EJ			MHC CLASS-I SURFACE EXPRESSION IN EMBRYO-DERIVED CELL-LINES INDUCIBLE WITH PEPTIDE OR INTERFERON	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CARCINOMA-CELLS; GENE-EXPRESSION; MOUSE; ANTIGEN; BETA-2-MICROGLOBULIN; TRANSCRIPTS; MOLECULES; PLACENTA; VECTOR	IT has long been recognized that the absence of expression of products of the major histocompatibility complex (MHC) during early development might allow the fetus to escape recognition by maternal lymphocytes. In addition to the MHC class I heavy chain and beta-2-microglobulin, antigenic peptide is an essential structural component of the class I molecule 1-5. Indeed, there is evidence that MHC-linked genes encoding peptide transporter molecules 6-10 and possibly components of a proteolytic complex 11,12 are necessary for MHC class I assembly and stability at the cell surface. Here we demonstrate that embryonic cells in general show a defect in MHC class I assembly. Surface expression was rescued in the presence of an appropriate antigenic peptide, or by treatment with interferon. Consistent with this, HAM1 (ref. 9) messenger RNA was not constitutively expressed, but was inducible by interferon, and during differentiation in vitro. Thus, tolerance of the fetal allograft may in part be controlled at the level of peptide-dependent MHC class I assembly.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University	BIKOFF, EK (corresponding author), CUNY MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY 10029, USA.		Ribaudo, Randall/AAH-7094-2021; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEDLEY ML, 1989, J IMMUNOL, V142, P4046; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAFFE L, IN PRESS J IMMUN; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MORELLO D, 1982, NATURE, V296, P260, DOI 10.1038/296260a0; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENTHAL A, 1984, NATURE, V310, P415, DOI 10.1038/310415a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SILVERMAN T, 1988, J IMMUNOL, V140, P4378; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0	30	57	60	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1991	354	6350					235	238		10.1038/354235a0	http://dx.doi.org/10.1038/354235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ948	1720508				2022-12-28	WOS:A1991GQ94800051
J	HEITMAN, J; MOVVA, NR; HALL, MN				HEITMAN, J; MOVVA, NR; HALL, MN			TARGETS FOR CELL-CYCLE ARREST BY THE IMMUNOSUPPRESSANT RAPAMYCIN IN YEAST	SCIENCE			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; FK506-BINDING PROTEIN; CYCLOSPORIN-A; SACCHAROMYCES-CEREVISIAE; MACROLIDES FK-506; FK506; CYCLOPHILIN; ACTIVATION	FK506 and rapamycin are related immunosuppressive compounds that block helper T cell activation by interfering with signal transduction. In vitro, both drugs bind and inhibit the FK506-binding protein (FKBP) proline rotamase. Saccharomyces cerevisiae cells treated with rapamycin irreversibly arrested in the G1 phase of the cell cycle. An FKBP-rapamycin complex is concluded to be the toxic agent because (i) strains that lack FKBP proline rotamase, encoded by FPR1, were viable and fully resistant to rapamycin and (ii) FK506 antagonized rapamycin toxicity in vivo. Mutations that conferred rapamycin resistance altered conserved residues in FKBP that are critical for drug binding. Two genes other than FPR1, named TOR1 and TOR2, that participate in rapamycin toxicity were identified. Nonallelic noncomplementation between FPR1, TORI, and TOR2 alleles suggests that the products of these genes may interact as subunits of a protein complex. Such a complex may mediate nuclear entry of signals required for progression through the cell cycle.	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	University of Basel; Novartis; Sandoz			Heitman, Joseph/ABC-6006-2021	Hall, Michael N/0000-0002-2998-0757				ATKINSON KD, 1985, GENETICS, V111, P1; ATKINSON KD, 1988, PLANT MEMBRANES STRU, P65; BAKER H, 1978, J ANTIBIOT, V31, P539, DOI 10.7164/antibiotics.31.539; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BIERER BE, 1990, SCIENCE, V250, P1948; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CIANCIOTTO NP, 1989, INFECT IMMUN, V57, P1255, DOI 10.1128/IAI.57.4.1255-1262.1989; COLLIER J, 1990, CURR OPIN IMMUNOL, V2, P854; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ENGLEBERG NC, 1989, INFECT IMMUN, V57, P1263, DOI 10.1128/IAI.57.4.1263-1270.1989; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, pS35; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, UNPUB; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOMYK T, 1988, GENETICS, V119, P105; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUSCH M, 1986, GENETICS, V113, P621; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; PERRY ACF, 1988, J BACTERIOL, V170, P1691, DOI 10.1128/jb.170.4.1691-1697.1988; ROSE MD, 1988, LABORATORY COURSE MA; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEARNS T, 1988, GENETICS, V119, P249; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STEINMANN B, 1991, J BIOL CHEM, V266, P3630; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1990, IMMUNOL TODAY, V11, P35; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE SGD, 1991, NATURE, V351, P248; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029	47	1451	1517	10	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					905	909		10.1126/science.1715094	http://dx.doi.org/10.1126/science.1715094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1715094				2022-12-28	WOS:A1991GC15200046
J	LEVINE, AM; WERNZ, JC; KAPLAN, L; RODMAN, N; COHEN, P; METROKA, C; BENNETT, JM; RARICK, MU; WALSH, C; KAHN, J; MILES, S; EHMANN, WC; FEINBERG, J; NATHWANI, B; GILL, PS; MITSUYASU, R				LEVINE, AM; WERNZ, JC; KAPLAN, L; RODMAN, N; COHEN, P; METROKA, C; BENNETT, JM; RARICK, MU; WALSH, C; KAHN, J; MILES, S; EHMANN, WC; FEINBERG, J; NATHWANI, B; GILL, PS; MITSUYASU, R			LOW-DOSE CHEMOTHERAPY WITH CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS AND ZIDOVUDINE MAINTENANCE IN AIDS-RELATED LYMPHOMA - A PROSPECTIVE MULTIINSTITUTIONAL TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HODGKINS LYMPHOMA; AGENTS M-BACOD; HOMOSEXUAL MEN; MALIGNANT-LYMPHOMA; UNDIFFERENTIATED LYMPHOMA; IMPROVED PROGNOSIS; CELL LYMPHOMA; EXPERIENCE; NEOPLASIA	Objective. - To ascertain if low-dose multiagent chemotherapy, with central nervous system prophylaxis and antiretroviral therapy, might be associated with increased efficacy and decreased risk of intercurrent infection in patients with malignant lymphoma related to the acquired immunodeficiency syndrome (AIDS). Design. - A phase 11 prospective clinical trial, with median follow-up of 33 months. Setting. - Eight university hospitals, within the context of the AIDS Clinical Trials Units, sponsored by the National institute of Allergy and Infectious Diseases. Patients. - Forty-two patients with AIDS-related malignant lymphoma. All were evaluable for toxicity assessment, and 35 for response. Intervention. - A low-dose modification of the M-BACOD regimen (day 1): cyclophosphamide, 300 mg/m2 intravenously (IV); doxorubicin, 25 mg/m2 IV; vincristine sulfate, 1.4 mg/m2 IV; bleomycin, 4 mg/m2 IV; dexamethasone, 3 mg/m2 orally on days 1 through 5; methotrexate, 500 mg/m2 IV on day 15, with leucovorin rescue. Intrathecal cytosine arabinoside (50 mg) to all on days 1, 8, 21, and 28, with radiation therapy to a helmet field to those with central nervous system involvement. Zidovudine for 12 months after completion of four to six cycles of chemotherapy. Main Outcome Measures. - Response rate and number of opportunistic infections. Results. - Response rate was 51% with a complete response of 46%. Of 16 complete responses, relapse occurred in four, none isolated to the central nervous system. Opportunistic infections occurred in 21% of those receiving treatment. Median duration of survival among all 42 patients is 5.6 months, 6.5 months in 35 patients evaluable for response, and 15 months in patients with complete response. Lower concentration of CD4 cells, history of prior AIDS, bone marrow involvement, and stage IV disease were independently associated with decreased survival. Conclusions. - Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance may be associated with durable remissions in AIDS-related lymphoma with fewer opportunistic infections than noted in prior reports.	UNIV SO CALIF,LOS ANGELES CTY MED CTR,LOS ANGELES,CA 90033; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14627; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; NYU,NEW YORK,NY 10003; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10025; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,HERSHEY,PA 17033; NIAID,DIV AIDS,AIDS CLIN TRIALS UNIT,BETHESDA,MD 20892; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709	University of Southern California; University of California System; University of California San Francisco; George Washington University; University of Rochester; University of California System; University of California Los Angeles; New York University; San Francisco General Hospital Medical Center; Mount Sinai St. Luke's; Mount Sinai West; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Research Triangle Institute	LEVINE, AM (corresponding author), UNIV SO CALIF,SCH MED,1975 ZONAL AVE,KAM 110F,LOS ANGELES,CA 90033, USA.			feinberg, judith/0000-0003-4206-7214				[Anonymous], 1982, CANCER, V49, P2112; BERMUDEZ MA, 1989, AM J MED, V86, P71, DOI 10.1016/0002-9343(89)90232-5; BERNARD EM, 1988, 4TH INT C AIDS STOCK; CARBONE PP, 1971, CANCER RES, V31, P1860; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; GILL PS, 1987, J CLIN ONCOL, V5, P1322, DOI 10.1200/JCO.1987.5.9.1322; GILL PS, 1985, AM J MED, V78, P742, DOI 10.1016/0002-9343(85)90277-3; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; HARDY D, 1985, 1ST INT C AIDS ATL; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KALTER SP, 1985, BLOOD, V66, P655; KAPLAN EL, 1958, AM STAT ASS J, P457; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LAUBENSTEIN LJ, 1984, J CLIN ONCOL, V103, P335; LEVINE AM, 1984, ANN INTERN MED, V100, P7, DOI 10.7326/0003-4819-100-1-7; LEVINE AM, 1985, JAMA-J AM MED ASSOC, V254, P1921, DOI 10.1001/jama.254.14.1921; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; LUKES RJ, 1974, CANCER, V34, P1488, DOI 10.1002/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; SCHEIN PS, 1976, ANN INTERN MED, V85, P415; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; SO YT, 1986, ANN NEUROL, V20, P566, DOI 10.1002/ana.410200503; VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335; WALSH C, 1991, UNPUB PHASE I STUDY; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; SAS USERS GUIDE STAT, P529; 1985, ANN INTERN MED, V103, P402	31	156	158	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					84	88		10.1001/jama.266.1.84	http://dx.doi.org/10.1001/jama.266.1.84			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	1710673				2022-12-28	WOS:A1991FT93400032
J	SHELDON, TA; SIMPSON, J				SHELDON, TA; SIMPSON, J			APPRAISAL OF A NEW SCHEME FOR PRENATAL SCREENING FOR DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							NEURAL-TUBE DEFECTS; DECISION-ANALYSIS; PREGNANCY	Objective - To appraise a new method of prenatal screening for Down's syndrome based on maternal serum concentrations of alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin combined with maternal age - the "triple test". Design - Examination of the cost effectiveness of the triple test relative to screening only by maternal age over a range of population detection rates. Setting - Leicestershire Health Authority. Main outcome measures - Costs per affected fetus detected. Results - The triple test is more cost effective than screening only by maternal age for risk cut off points for amniocentesis, resulting in a detection rate over 45%. The most efficient detection rate is around 60-65%, for which the cost per case detected is around L29 000, though screening with higher detection rates is still likely to be cost beneficial. Conclusions - Prenatal screening for Down's syndrome based on the triple test should replace screening based only on maternal age. Individual women's preferences should be elicited by the use of structured decision analysis in order to maximise utility and so increase the benefits of the screening programme.	LEICESTERSHIRE DIST HLTH AUTHOR,LEICESTER LE1 6TY,ENGLAND		SHELDON, TA (corresponding author), UNIV LEEDS,DEPT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913				CALLAN J, 1988, 42 CTR HLTH EC DISC; CARTMILL RS, 1991, IN PRESS J PERINATAL; DOUBILET P, 1985, MED CARE, V23, P648, DOI 10.1097/00005650-198505000-00021; DOWIE J, 1987, PROFESSIONAL JUDGMEN, P9; Drummond Michael, 1988, Br Med J (Clin Res Ed), V296, P566; FERGUSONSMITH M, 1987, SCREENING FETAL GENE; GILL M, 1987, SOC SCI MED, V24, P725, DOI 10.1016/0277-9536(87)90109-2; HAGARD S, 1976, BRIT MED J, V1, P753, DOI 10.1136/bmj.1.6012.753; HENDERSON JB, 1987, SCREENING FETAL GENE; MCGROTHER CW, 1990, J MENT DEFIC RES, V34, P49; McKeown Thomas, 1968, SCREENING MED CARE R; Pauker S P, 1987, Birth Defects Orig Artic Ser, V23, P151; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; RICHARDS M, 1987, SCREENING FETAL GENE; SADOVNICK AD, 1981, AM J MED GENET, V10, P367, DOI 10.1002/ajmg.1320100409; SCHWARTZ WB, 1979, NEW ENGL J MED, V300, P556, DOI 10.1056/NEJM197903083001011; THORNTON JG, 1990, PRENATAL DIAGNOSIS P; Torrance GW, 1987, METHODS EC EVALUATIO; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1987, BAILLIERE CLIN OB GY, V1, P649, DOI 10.1016/S0950-3552(87)80010-X; Weinstein MC, 1980, CLIN DECISION ANAL; 1987, SCREENING FETAL GENE	22	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1133	1136		10.1136/bmj.302.6785.1133	http://dx.doi.org/10.1136/bmj.302.6785.1133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1710520	Green Published, Bronze			2022-12-28	WOS:A1991FL43900023
J	STAMNES, MA; SHIEH, BH; CHUMAN, L; HARRIS, GL; ZUKER, CS				STAMNES, MA; SHIEH, BH; CHUMAN, L; HARRIS, GL; ZUKER, CS			THE CYCLOPHILIN HOMOLOG NINAA IS A TISSUE-SPECIFIC INTEGRAL MEMBRANE-PROTEIN REQUIRED FOR THE PROPER SYNTHESIS OF A SUBSET OF DROSOPHILA RHODOPSINS	CELL			English	Article								Mutations in the Drosophila ninaA gene cause dramatic reductions in rhodopsin levels, leading to impaired visual function. The ninaA protein is a homolog of peptidyl-prolyl cis-trans isomerases. We find that ninaA is unique among this family of proteins in that it is an integral membrane protein, and it is expressed in a cell type-specific manner. We have used transgenic animals misexpressing different rhodopsins in the major class of photoreceptor cells to demonstrate that ninaA is required for normal function by two homologous rhodopsins, but not by a less conserved member of the Drosophila rhodopsin gene family. This demonstrates in vivo substrate specificity in a cyclophilin-like molecule. We also show that vertebrate retina contains a ninaA-related protein and that ninaA is a member of a gene family in Drosophila. These data offer insights into the in vivo role of this important family of proteins.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	STAMNES, MA (corresponding author), UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA.			Stamnes, Mark/0000-0002-5869-7985				BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; COWMAN AF, 1986, CELL, V44, P705, DOI 10.1016/0092-8674(86)90836-6; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEILER R, 1988, NATURE, V333, P737, DOI 10.1038/333737a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRANCESCHINI N, 1971, KYBERNETIK, V8, P1, DOI 10.1007/BF00270828; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KRENSKY AM, 1990, NEW ENGL J MED, V322, P510, DOI 10.1056/NEJM199002223220805; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MINKE B, 1975, J COMP PHYSIOL, V98, P345, DOI 10.1007/BF00709805; MINKE B, 1979, J GEN PHYSIOL, V73, P517, DOI 10.1085/jgp.73.5.517; MISMER D, 1987, GENETICS, V116, P565; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL C, 1987, J NEUROSCI, V7, P1558; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; Oliver D., 1970, DROS INFORM SERV, V45, P58; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; POLLOCK JA, 1988, NATURE, V333, P779, DOI 10.1038/333779a0; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIGAL NH, 1990, BIOCHEM PHARMACOL, V40, P2201, DOI 10.1016/0006-2952(90)90712-T; SIGAL NH, 1991, IN PRESS J EXP MED; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STEPHENSON RS, 1983, BIOL PHOTORECEPTORS, P471; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Sved J, 1986, DROSOPH INF SERV, V63, P169; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TRENN G, 1989, J IMMUNOL, V142, P3796; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; ZUKER CS, 1987, J NEUROSCI, V7, P1550; ZUKER CS, 1988, CELL, V53, P475, DOI 10.1016/0092-8674(88)90167-5; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	63	245	256	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					219	227		10.1016/0092-8674(91)90156-S	http://dx.doi.org/10.1016/0092-8674(91)90156-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1707759				2022-12-28	WOS:A1991FH09200005
J	PAGE, CP				PAGE, CP			ONE EXPLANATION OF THE ASTHMA PARADOX - INHIBITION OF NATURAL ANTIINFLAMMATORY MECHANISM BY BETA-2-AGONISTS	LANCET			English	Note							MAST-CELL; BRONCHIAL RESPONSIVENESS; TRACHEAL EPITHELIUM; HEPARIN; DRUGS; TERBUTALINE; PROVOCATION; HISTAMINE; PROTEIN; AIRWAY	Our understanding of the mechanisms contributing to the pathogenesis of bronchial asthma has increased substantially over the past decade. This has been accompanied by the introduction of a range of new drugs for the treatment of this disorder, and the usage of anti-asthma drugs is increasing. Despite these changes and an increased awareness of the disease, asthma remains the only "preventable" disease where the morbidity and mortality are still increasing in most parts of the world. This "asthma paradox" requires explanation, and this article is an attempt to provide a plausible scientific one. The hypothesis expresses concern that a long recognised, but little publicised, pharmacological property of the drug class most widely prescribed for the treatment of asthma, the beta-2-adrenoceptor agonists-namely, the inhibition of mast-cell degranulation-may be contributing to the world wide increase in morbidity and mortality from asthma via the inhibition of a natural anti-inflammatory mechanism.			PAGE, CP (corresponding author), UNIV LONDON,KINGS COLL,DEPT PHARMACOL,LONDON SW3 6LX,ENGLAND.							BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BLOCK PE, 1980, BIOCHEM J, V191, P769; BOWLER S, 1988, HEPARIN RELATED POLY; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BUTTERFIELD JH, 1990, LAB INVEST, V62, P72; CARR J, 1979, THROMB RES, V16, P507, DOI 10.1016/0049-3848(79)90097-5; CAUGHEY GH, 1989, AM J PHYSIOL, V257, pL39, DOI 10.1152/ajplung.1989.257.2.L39; CHIHARA J, 1988, AM REV RESPIR DIS, V137, pA421; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COHEN S, 1967, J IMMUNOL, V98, P351; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CRANE J, 1989, LANCET, V1, P917; DAHL S, 1962, Z Tuberk Erkr Thoraxorg, V118, P255; DOLOWITZ DA, 1965, ANN ALLERGY, V23, P309; DOUTREMEPUICH C, 1987, J LEUKOCYTE BIOL, V42, P628, DOI 10.1002/jlb.42.6.628; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; FRIERI M, 1983, J IMMUNOL, V131, P1942; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P78; GRAHAM MF, 1987, GASTROENTEROLOGY, V93, P801, DOI 10.1016/0016-5085(87)90443-4; HALES CA, 1983, AM REV RESPIR DIS, V128, P747; HANSS J G, 1989, American Review of Respiratory Disease, V139, pA134; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JEFFREY PK, 1990, AM REV RESPIR DIS, pA500; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAI CKW, 1987, AM REV RESPIR DIS, V140, P917; LASSER EC, 1987, ALLERGY, V42, P549, DOI 10.1111/j.1398-9995.1987.tb00381.x; LASSER EC, 1987, ALLERGY, V42, P619, DOI 10.1111/j.1398-9995.1987.tb00393.x; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LUNGREN R, 1988, EUR RESPIR J, V1, P883; MATZNER Y, 1984, THROMB HAEMOSTASIS, V52, P134; MCCLAIN E J, 1982, Journal of Allergy and Clinical Immunology, V69, P93; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; RASHAD S, 1989, LANCET, V2, P519; ROCHE WR, 1989, LANCET, V1, P520; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; STOKES TC, 1981, BR J DIS CHEST, V75, P11; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; Van de Carr FR, 1928, J IMMUNOL, V15, P13; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YAMASHITA Y, 1990, American Review of Respiratory Disease, V141, pA912; 1985, J ALLERGY CLIN IMMUN, V75, P443	48	95	99	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					717	720		10.1016/0140-6736(91)90289-2	http://dx.doi.org/10.1016/0140-6736(91)90289-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1706045				2022-12-28	WOS:A1991FD36700019
J	MORRIS, CE; HORN, R				MORRIS, CE; HORN, R			FAILURE TO ELICIT NEURONAL MACROSCOPIC MECHANOSENSITIVE CURRENTS ANTICIPATED BY SINGLE-CHANNEL STUDIES	SCIENCE			English	Article							ACTIVATED ION CHANNELS; MEMBRANE; CELLS; CALCIUM; VOLUME; STRESS; YEAST	Mechanosensitive channels can be observed in most cell types during single-channel recording and have been implicated in many cellular processes. Potassium-selective single-channel currents, both stretch-activated and stretch-inactivated, can be observed in growth cones and cell bodies of Lymnaea stagnalis neurons. Equivalent macroscopic mechanosensitive currents could not, however, be elicited while applying various mechanical stimuli. This discrepancy suggests that single-channel mechanosensitivity is an artifact of patch recording.	UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA; ROCHE INST MOLEC BIOL,DEPT NEUROSCI,NUTLEY,NJ 07110	University of Ottawa				Morris, Catherine/0000-0002-7401-6545				BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BELARDETTI F, 1987, NATURE, V325, P153, DOI 10.1038/325153a0; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; EDWARDS C, 1981, NEUROSCIENCE, V6, P1455, DOI 10.1016/0306-4522(81)90200-1; ERXLEBEN C, 1989, J GEN PHYSIOL, V94, P1071, DOI 10.1085/jgp.94.6.1071; FALKE LC, 1989, P NATL ACAD SCI USA, V86, P3919, DOI 10.1073/pnas.86.10.3919; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; KIMITSUKI T, 1990, AM J PHYSIOL, V258, pH247, DOI 10.1152/ajpheart.1990.258.1.H247; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; MEDINA IR, 1988, PROC R SOC SER B-BIO, V235, P95, DOI 10.1098/rspb.1988.0064; MILLS LR, 1988, NEUR SOC ABSTR, V14, P583; MILTON RL, 1990, PFLUG ARCH EUR J PHY, V416, P758, DOI 10.1007/BF00370626; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SIGURDSON WJ, 1990, THESIS U OTTAWA; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SUGRDSON WJ, 1989, J NEUROSCI, V9, P2801; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; VANDORPE D, UNPUB; [No title captured]	26	157	161	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1246	1249		10.1126/science.1706535	http://dx.doi.org/10.1126/science.1706535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1706535				2022-12-28	WOS:A1991FA69100046
J	LOWE, JB; STOOLMAN, LM; NAIR, RP; LARSEN, RD; BERHEND, TL; MARKS, RM				LOWE, JB; STOOLMAN, LM; NAIR, RP; LARSEN, RD; BERHEND, TL; MARKS, RM			ELAM-1-DEPENDENT CELL-ADHESION TO VASCULAR ENDOTHELIUM DETERMINED BY A TRANSFECTED HUMAN FUCOSYL-TRANSFERASE CDNA	CELL			English	Article									UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	LOWE, JB (corresponding author), UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA049256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038482] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA49256] Funding Source: Medline; NIDDK NIH HHS [DK38482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; Battey, 1986, BASIC METHODS MOL BI; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIA D, 1985, CANCER RES, V45, P435; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUNSTAN RA, 1986, BRIT J HAEMATOL, V62, P301, DOI 10.1111/j.1365-2141.1986.tb02933.x; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FOX N, 1983, CANCER RES, V43, P669; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALTON J, 1985, ANTIBODIES PROTECTIV, P117; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, TRANSPLANTATION, V48, P727, DOI 10.1097/00007890-198911000-00001; KANNAGI R, 1986, CANCER RES, V46, P2619; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PARHAM P, 1979, J IMMUNOL, V123, P342; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1989, J IMMUNOL, V142, P1895; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1987, BLOOD, V70, P1842; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; VANKEUREN ML, 1986, AM J HUM GENET, V38, P793; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WONG CH, 1989, SCIENCE, V244, P1145, DOI 10.1126/science.2658059; YASUYUKI I, 1990, IN PRESS J CELL BIOL; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313	70	754	800	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	1990	63	3					475	484		10.1016/0092-8674(90)90444-J	http://dx.doi.org/10.1016/0092-8674(90)90444-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EG687	1699667	Green Published			2022-12-28	WOS:A1990EG68700006
J	NICOLL, DA; LONGONI, S; PHILIPSON, KD				NICOLL, DA; LONGONI, S; PHILIPSON, KD			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF THE CARDIAC SARCOLEMMAL NA+-CA-2+ EXCHANGER	SCIENCE			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NHLBI NIH HHS [HL27821] Funding Source: Medline; BHP HRSA HHS [AHL07386] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P240; PENNISTON J, UNPUB; PHILIPSON KA, UNPUB; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PHILIPSON KD, 1990, CALCIUM HEART, P85; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; VEMURI R, IN PRESS J MEMBR BIO; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	30	682	699	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 26	1990	250	4980					562	565		10.1126/science.1700476	http://dx.doi.org/10.1126/science.1700476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE660	1700476				2022-12-28	WOS:A1990EE66000039
J	GREEN, JBA; SMITH, JC				GREEN, JBA; SMITH, JC			GRADED CHANGES IN DOSE OF A XENOPUS ACTIVIN-A HOMOLOG ELICIT STEPWISE TRANSITIONS IN EMBRYONIC-CELL FATE	NATURE			English	Article											GREEN, JBA (corresponding author), NATL INST MED RES,EMBRYOGENESIS LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620; Smith, Jim/0000-0003-2413-9392				COOKE J, 1983, J EMBRYOL EXP MORPH, V76, P95; COOKE J, 1989, DEVELOPMENT, V105, P549; DIXON JE, 1989, DEVELOPMENT, V106, P749; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Ruiz i Altaba A, 1989, Nature, V341, P33; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; Smith JC, 1989, CURR OPIN CELL BIOL, V1, P1061, DOI 10.1016/S0955-0674(89)80051-1; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1989, DEVELOPMENT S, P149; SYMES K, 1988, DEVELOPMENT, V104, P609; VANDENEIJNDENVA.AJ, 1990, NATURE, V345, P732; WOLPERT L, 1989, DEVELOPMENT S, P3	23	452	467	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 27	1990	347	6291					391	394		10.1038/347391a0	http://dx.doi.org/10.1038/347391a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA564	1699129				2022-12-28	WOS:A1990EA56400066
J	SHAYWITZ, SE; ESCOBAR, MD; SHAYWITZ, BA; FLETCHER, JM; MAKUCH, R				SHAYWITZ, SE; ESCOBAR, MD; SHAYWITZ, BA; FLETCHER, JM; MAKUCH, R			EVIDENCE THAT DYSLEXIA MAY REPRESENT THE LOWER TAIL OF A NORMAL-DISTRIBUTION OF READING-ABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETARDATION; PREVALENCE; BOYS	Background. Dyslexia is now widely believed to be a biologically based disorder that is distinct from other, less specific reading problems. According to this view, reading ability is considered to follow a bimodal distribution, with dyslexia as the lower mode. We hypothesized that, instead, reading ability follows a normal distribution, with dyslexia at the lower end of the continuum. Methods and Results. We used data from the Connecticut Longitudinal Study, a sample survey of 414 Connecticut children who entered kindergarten in 1983 and were followed as a longitudinal cohort. Dyslexia was defined in terms of a discrepancy score, which represents the difference between actual reading achievement and achievement predicted on the basis of measures of intelligence. Data were available from intelligence tests administered in grades 1, 3, and 5 and achievement tests administered yearly in grades 1 through 6. For each child there were 108 possible discrepancy scores ([3 x 3 years] x [2 x 6 years]) based on combinations of the ability scores (full-scale, verbal, and performance 10) in each of three years and two achievement scores (reading and mathematics) in each of six years. We demonstrated that each of the discrepancy scores followed a univariate normal distribution and that the interrelation of two different discrepancy scores followed a bivariate normal distribution. At most, only 9 of 108 discrepancy scores (8.3 percent) and 171 of 3402 pairs of discrepancy scores (5-0 percent) were significantly different (at the 5 percent level) from the expected scores - well within the expected values for data with univariate and bivariate normal distributions, respectively. We also examined the stability of dyslexia over time. The normal-distribution model predicted (and the data indicated) that only 7 of the 25 children (28 percent) classified as having dyslexia in grade 1 would also be classified as having dyslexia in grade 3. Conclusions. Reading difficulties, including dyslexia, occur as part of a continuum that also includes normal reading ability. Dyslexia is not an all-or-none phenomenon, but like hypertension, occurs in degrees. The variability inherent in the diagnosis of dyslexia can be both quantified and predicted with use of the normal-distribution model.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR CHILD STUDY,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DIV BIOSTAT,NEW HAVEN,CT 06510; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213; UNIV TEXAS,DEPT PEDIAT,HOUSTON,TX 77025	Yale University; Yale University; Yale University; Carnegie Mellon University; University of Texas System	SHAYWITZ, SE (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,POB 3333,NEW HAVEN,CT 06510, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NICHD NIH HHS [P01 HD21888, P50 HD25802] Funding Source: Medline; NIMH NIH HHS [MH15758] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD021888, P50HD025802] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BADIAN NA, 1982, J SPEC EDUC, V16, P309, DOI 10.1177/002246698201600306; BADIAN NA, 1988, PRESCHOOL PREVENTION, P78; CONE TE, 1981, LEARN DISABILITY Q, V4, P359, DOI 10.2307/1510737; CRITCHLEY M, 1970, DYSLEXIC CHILD; de Hirsch K., 1966, PREDICTING READING F; HOGG R, 1970, INTRO MATH STAT, P166; JANSKY JJ, 1989, ANN DYSLEXIA, V39, P227, DOI 10.1007/BF02656911; MAKUCH RW, 1989, STATISTICIAN, V38, P61; PRENTICE RL, 1986, J AM STAT ASSOC, V81, P321, DOI 10.2307/2289219; REYNOLDS CR, 1984, J SPEC EDUC, V18, P451, DOI 10.1177/002246698401800403; Reynolds CR, 1990, HDB PSYCHOL ED ASSES, P571; RODGERS B, 1983, BRIT J EDUC PSYCHOL, V53, P369, DOI 10.1111/j.2044-8279.1983.tb02570.x; RUTTER M, 1975, J CHILD PSYCHOL PSYC, V16, P181, DOI 10.1111/j.1469-7610.1975.tb01269.x; RUTTER M, 1981, ED HLTH BEHAVIOR; SATTLER JM, 1988, ASSESSMENT CHILDRENS; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SILVA PA, 1985, J CHILD PSYCHOL PSYC, V26, P407, DOI 10.1111/j.1469-7610.1985.tb01942.x; THORNDIKE RL, 1963, CONCEPTS OVER UNDER; VANDERWISSEL A, 1985, BRIT J DEV PSYCHOL, V3, P3; Wechsler DW., 1999, INTELLIGENCE SCALE C; Woodcock R.W., 1977, WOODCOCK JOHNSON PSY; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x; YULE W, 1985, CHILD ADOLESCENT PSY, P444; 1977, FED REGISTER, V42, P62082; 1989, JAMA-J AM MED ASSOC, V261, P2236	25	489	490	1	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					145	150		10.1056/NEJM199201163260301	http://dx.doi.org/10.1056/NEJM199201163260301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727544				2022-12-28	WOS:A1992GZ21300001
J	SACK, JB; KESSELBRENNER, MB; BREGMAN, D				SACK, JB; KESSELBRENNER, MB; BREGMAN, D			SURVIVAL FROM IN-HOSPITAL CARDIAC-ARREST WITH INTERPOSED ABDOMINAL COUNTERPULSATION DURING CARDIOPULMONARY-RESUSCITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPRESSION-CPR; STANDARD CPR; BLOOD-FLOW; CIRCULATION; PERFUSION	Objective. - To determine whether interposed abdominal counterpulsation (IAC) during standard cardiopulmonary resuscitation (CPR) improves outcome in patients experiencing in-hospital cardiac arrest. Design and Setting. - Randomized controlled trial in a university-affiliated hospital. Patients. - Patients experiencing in-hospital cardiac arrest during a 6-month period. Interventions. - Patients were randomized to receive either IAC during CPR or standard CPR in the event of cardiac arrest. Abdominal compressions were performed during the relaxation phase of chest compression, corresponding to CPR diastole, at a rate of 80/min to 1 00/min. Main Outcome Measures. - The three end points studied were (1) return of spontaneous circulation, (2) survival 24 hours after resuscitation, and (3) survival to hospital discharge. In addition, we examined neurological outcome in those patients surviving to hospital discharge. Results. - During the study period there were 135 resuscitation attempts in 103 patients. Return of spontaneous circulation was significantly greater in the group receiving IAC during CPR than in the group receiving standard CPR (51% vs 27%, P = .007). At hospital discharge, a significantly greater proportion of patients was alive in the IAC group than in the control group (25% vs 7%, P = .02). Eight (17%) of 48 patients who received IAC during CPR survived to hospital discharge neurologically intact, compared with only three (6%) of 55 patients from the standard CPR group (not significant). Conclusions. - We conclude that the addition of IAC to standard CPR may improve meaningful survival following in-hospital cardiac arrest. The optimal use of this technique awaits further clinical trials.	ST JOSEPHS HOSP,SETON HALL UNIV SCH GRAD MED EDUC,DEPT MED,PATERSON,NJ 07503; ST JOSEPHS HOSP,SETON HALL UNIV SCH GRAD MED EDUC,DEPT SURG,PATERSON,NJ 07503				Sack, Jeffrey/G-5831-2010					BABBS CF, 1984, ANN EMERG MED, V13, P761, DOI 10.1016/S0196-0644(84)80429-1; BABBS CF, 1985, AM J EMERG MED, V3, P165, DOI 10.1016/0735-6757(85)90043-9; BABBS CF, 1984, ANN EMERG MED, V13, P660, DOI 10.1016/S0196-0644(84)80722-2; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; COLETTI RH, 1983, CIRCULATION S2, V64, P226; EARNEST MP, 1980, NEUROLOGY, V30, P1298, DOI 10.1212/WNL.30.12.1298; EINAGLE V, 1988, CHEST, V93, P1206, DOI 10.1378/chest.93.6.1206; LINDNER KH, 1990, ANESTHESIOLOGY, V72, P675, DOI 10.1097/00000542-199004000-00017; MAIER GW, 1984, CIRCULATION, V70, P86, DOI 10.1161/01.CIR.70.1.86; MATEER JR, 1985, AM J EMERG MED, V3, P143, DOI 10.1016/0735-6757(85)90038-5; Molokhia F A, 1972, Chest, V62, P610; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; RALSTON SH, 1982, ANESTH ANALG, V61, P645; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SAUNDERS AB, 1984, CRIT CARE MED, V12, P871; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TORTOLANI AJ, 1990, RESUSCITATION, V20, P115, DOI 10.1016/0300-9572(90)90047-I; URBERG M, 1987, J FAM PRACTICE, V25, P41; VOORHEES WD, 1983, ANN EMERG MED, V12, P128, DOI 10.1016/S0196-0644(83)80550-2; WALKER JW, 1984, AM J EMERG MED, V2, P391, DOI 10.1016/0735-6757(84)90039-1; WARD KR, 1989, ANN EMERG MED, V18, P831, DOI 10.1016/S0196-0644(89)80206-9; 1986, JAMA-J AM MED ASSOC, V255, P2841	22	105	108	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					379	385						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727961				2022-12-28	WOS:A1992GY43700035
J	VARGA, J; UITTO, J; JIMENEZ, SA				VARGA, J; UITTO, J; JIMENEZ, SA			THE CAUSE AND PATHOGENESIS OF THE EOSINOPHILIA-MYALGIA-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Review						EOSINOPHILIA-MYALGIA SYNDROME; TRYPTOPHAN; EOSINOPHILIA; FIBROBLASTS; FIBROSIS	TOXIC-OIL SYNDROME; L-TRYPTOPHAN INGESTION; FACTOR TYPE-BETA; CLINICAL SPECTRUM; GENE-EXPRESSION; QUINOLINIC ACID; FASCIITIS; SCLERODERMA; MANIFESTATIONS; INTERLEUKIN-5	Objective: To review recent advances in the understanding of the cause and pathogenesis of the eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Data Sources: Studies published from 1989 to 1991 were identified using a MEDLINE literature search. Additional references were selected from the bibliographies of identified articles. Data Synthesis: The eosinophilia-myalgia syndrome was epidemiologically associated with ingestion of L-tryptophan-containing preparations. Analysis of case-associated lots of L-tryptophan has revealed several chemical impurities. One of these, labeled "peak E," is an unusual dimeric form of L-tryptophan (1,1'-ethylidenebis[tryptophan]), and its presence is associated with the eosinophilia-myalgia syndrome (P = 0.022). Evidence of abnormal metabolism of tryptophan has been found in some patients with the syndrome. Eosinophil activation and the release of major basic protein and other eosinophil-derived toxic proteins into the extracellular space is a striking feature in the eosinophilia-myalgia syndrome and implicates eosinophils or their products in the pathogenesis. Mononuclear cell activation and infiltration of various affected tissues as well as fibrosis of the integument and of the connective tissue components of blood vessels, nerves, and muscles are additional frequent findings. Conclusions: Current evidence suggests that the epidemic of the eosinophilia-myalgia syndrome was caused by contaminated L-tryptophan preparations originating from a single manufacturer. Peak E or other, as yet unidentified, contaminants may trigger activation of eosinophils and inflammatory cells and increase biosynthesis of connective tissue components, resulting in the clinical and pathologic manifestations of the eosinophilia-myalgia syndrome. Further studies of the interaction of eosinophils, inflammatory cells, and fibroblasts may increase the understanding of the pathogenesis of the eosinophilia-myalgia syndrome. The insights gained from the epidemic may be applicable to more common idiopathic diseases associated with eosinophilia and fibrosis.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT DERMATOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University	VARGA, J (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL, BLUEMLE LIFE SCI BLDG, ROOM 522, PHILADELPHIA, PA 19107 USA.			Jimenez, Sergio/0000-0001-5213-1203	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616, R01AR041439, K08AR001817] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-01817, AR-19616, AR-41439] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALOH RW, 1982, ANN NEUROL, V11, P95, DOI 10.1002/ana.410110117; BARRHART ER, 1990, LANCET, V336, P742; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BOUCEK RJ, 1972, P SOC EXP BIOL MED, V140, P599; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; CRISWELL LA, 1990, WESTERN J MED, V153, P269; CROFFORD LJ, 1990, J CLIN INVEST, V86, P1757, DOI 10.1172/JCI114902; DURING MJ, 1989, BRAIN RES, V476, P384, DOI 10.1016/0006-8993(89)91265-1; EMSLIESMITH AM, 1991, ANN NEUROL, V29, P524, DOI 10.1002/ana.410290512; FREESE A, 1988, ANN INTERN MED, V108, P312, DOI 10.7326/0003-4819-108-2-312_2; FRIES JF, 1973, ARCH INTERN MED, V131, P550, DOI 10.1001/archinte.1973.00320100078010; GLICKSTEIN SL, 1990, J RHEUMATOL, V17, P1534; GORONZY JJ, 1990, KLIN WOCHENSCHR, V68, P735, DOI 10.1007/BF01647582; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; GUM OB, 1960, ARTHRITIS RHEUM, V3, P447; GUPTA A, 1985, Q J MED, V56, P367; GUSTAFSSON R, 1991, ARTHRITIS RHEUM-US, V34, P414, DOI 10.1002/art.1780340406; HEIMANPATTERSON TD, 1990, ANN NEUROL, V28, P522, DOI 10.1002/ana.410280409; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HERTZMAN PA, 1991, J RHEUMATOL, V18, P867; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; KAUFMAN LD, 1990, MEDICINE, V69, P187, DOI 10.1097/00005792-199007000-00001; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; KILBOURNE EM, 1988, AM J EPIDEMIOL, V127, P1210, DOI 10.1093/oxfordjournals.aje.a114914; LEHRER S, 1988, INT J CANCER, V42, P137, DOI 10.1002/ijc.2910420126; MACDONALD RA, 1958, P SOC EXP BIOL MED, V97, P334; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; NORIEGA AR, 1982, LANCET, V2, P697; OWEN WF, 1991, J CLIN INVEST, V87, P1958, DOI 10.1172/JCI115222; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PELTONEN J, 1991, J INVEST DERMATOL, V96, P20, DOI 10.1111/1523-1747.ep12514683; PINCUS SH, 1987, BLOOD, V70, P572; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROHRBACH MS, 1990, J EXP MED, V172, P1271, DOI 10.1084/jem.172.4.1271; SCHNEIDERHELMERT D, 1986, PSYCHOPHARMACOLOGY, V89, P1; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SEIDMAN RJ, 1991, J NEUROPATH EXP NEUR, V50, P49, DOI 10.1097/00005072-199101000-00004; SIDRANSKY H, 1985, NUTRITIONAL PATHOLOG, P1; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; STACHOW A, 1977, BRIT J DERMATOL, V97, P147, DOI 10.1111/j.1365-2133.1977.tb15060.x; STEINER W, 1986, BIOL PSYCHIAT, V21, P1067, DOI 10.1016/0006-3223(86)90287-8; STRONGWATER SL, 1990, ARCH INTERN MED, V150, P2178, DOI 10.1001/archinte.150.10.2178; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TEN RM, 1990, CLIN EXP IMMUNOL, V82, P313; TODD R, 1991, AM J PATHOL, V138, P1307; UTZ DAVID C., 1965, J AMER MED ASS, V191, P983; VARGA J, 1990, SEMIN ARTHRITIS RHEU, V19, P313, DOI 10.1016/0049-0172(90)90069-R; VARGA J, 1990, ANN INTERN MED, V112, P344, DOI 10.7326/0003-4819-112-5-344; VARGA J, 1992, IN PRESS ARTHRITIS R; VERITY MA, 1991, HUM PATHOL, V22, P3, DOI 10.1016/0046-8177(91)90054-S; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; YOUNG SN, 1989, PROG NEURO-PSYCHOPH, V13, P373, DOI 10.1016/0278-5846(89)90126-7; 1990, MMWR, V39, P789; 1989, MMWR, V38, P785; 1989, MMWR, V38, P765; 1990, MMWR, V39, P587	62	68	70	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					140	147		10.7326/0003-4819-116-2-140	http://dx.doi.org/10.7326/0003-4819-116-2-140			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1727618				2022-12-28	WOS:A1992GZ35600007
J	EAKIN, D				EAKIN, D			JOURNAL REVIEWS IN JAMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											EAKIN, D (corresponding author), TEXAS A&M UNIV SYST,MED SCI LIB,COLLEGE STN,TX 77843, USA.							HAYNES RB, 1990, ANN INTERN MED, V111, P724	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					104	104						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727177				2022-12-28	WOS:A1992GW84800035
J	STEENLAND, K				STEENLAND, K			PASSIVE SMOKING AND THE RISK OF HEART-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ENVIRONMENTAL TOBACCO-SMOKE; CORONARY-ARTERY DISEASE; LUNG-CANCER; UNITED-STATES; CARBON-MONOXIDE; MORTALITY; EXPOSURE; NONSMOKERS; VALIDATION; POPULATION	Objective. - This paper reviews the evidence that exposure to environmental tobacco smoke (ETS) increases the risk of heart disease death among persons who have never smoked (never-smokers). The annual number of heart disease deaths in the United States attributable to ETS is estimated, as is the individual risk of heart disease death for exposed never-smokers. Data Sources. - Nine epidemiologic studies and numerous experimental studies are available to evaluate the association of ETS and heart disease. Data Synthesis. - The relative risk for never-smokers living with current or former smokers, compared with never-smokers living with nonsmokers, has ranged from 0.9 to 3.0 in nine studies. Seven studies were positive, one was positive for women but not men, and one was negative. Several studies have shown a dose-response relationship.and have controlled for other risk factors. Evidence from experimental studies suggests that ETS can damage the cardiovascular system, via both short-term and long-term mechanisms. Assuming that the observed heart disease risk for those exposed to ETS is not an artifact of misclassification or confounding, approximately 35 000 to 40 000 deaths from ischemic heart disease among never-smokers and long-term former smokers are estimated to have occurred annually in the United States as a result of ETS exposure in the early 1980s. An individual male never-smoker living with a current or former smoker is estimated to have an approximately 9.6% chance of dying of ischemic heart disease by the age of 74 years, compared with a 7.4% chance for a male never-smoker living with a nonsmoker. The corresponding lifetime risks for women are 6.1 % and 4.9%. Conclusions. - The public health burden due to ETS exposure is likely to be much greater for heart disease than for lung cancer, which has been the focus of most debate to date. Individual lifetime excess risks of heart disease death due to ETS of one to three per 1 00 can be compared with much lower excess risks of one death per 100 000, which are often used in determining environmental limits for other toxins. Exposure to ETS is not currently regulated at the federal level, except f or domestic air traffic.			STEENLAND, K (corresponding author), NIOSH,MAILSTOP R13,4676 COLUMBIA PKWY,CINCINNATI,OH 45226, USA.							ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; [Anonymous], 1990, HLTH BENEFITS SMOKIN; [Anonymous], 1986, ENV TOBACCO SMOKE ME; Axelson O., 1978, SCAND J WORK ENV HEA, V4, P85; BEESON WL, 1989, CANCER, V64, P570, DOI 10.1002/1097-0142(19890801)64:3<570::AID-CNCR2820640303>3.0.CO;2-4; BRACKBILL R, 1988, AM J IND MED, V13, P5, DOI 10.1002/ajim.4700130103; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; CORREA P, 1983, LANCET, V2, P595; CUMMINGS K, 1990, ARCH ENVIRON HEALTH, V45, P75; DOBSON AJ, 1991, MED J AUSTRALIA, V154, P793, DOI 10.5694/j.1326-5377.1991.tb121366.x; FELDMAN J, 1991, PEDIATRICS, V2, P259; GAIL M, 1975, J CHRON DIS, V28, P135, DOI 10.1016/0021-9681(75)90002-8; GARFINKEL L, 1985, J NATL CANCER I, V75, P463; GARLAND C, 1985, AM J EPIDEMIOL, V121, P645, DOI 10.1093/aje/121.5.645; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HALEY NJ, 1989, ENVIRON RES, V49, P127, DOI 10.1016/S0013-9351(89)80027-1; HAMMOND SK, 1987, ENVIRON SCI TECHNOL, V21, P494, DOI 10.1021/es00159a012; HE Y, 1989, CHIN J PREV MED, V23, P19; HELSING KJ, 1988, AM J EPIDEMIOL, V127, P915, DOI 10.1093/oxfordjournals.aje.a114894; HIRAYAMA T, 1984, LUNG CANCER CAUSES P; HOLE D, 1990, BRIT MED J, V299, P423; HUMBLE C, 1990, AM J PUBLIC HEALTH, V80, P599, DOI 10.2105/AJPH.80.5.599; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; HUSGAFVELPURSIAINEN K, 1987, INT ARCH OCC ENV HEA, V59, P337, DOI 10.1007/BF00405277; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; Kleinbaum DG, 1983, EPIDEMIOLOGIC RES; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; MARCHAND LL, 1991, CANCER CAUSE CONTROL, V2, P11; REPACE J, 1989, ENV TOBACCO SMOKE CO; REPACE JL, 1990, RISK ANAL, V10, P27, DOI 10.1111/j.1539-6924.1990.tb01017.x; RODERICKS JV, 1987, REGUL TOXICOL PHARM, V7, P307; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; SIDNEY S, 1989, AM J EPIDEMIOL, V129, P1305, DOI 10.1093/oxfordjournals.aje.a115250; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; STERN FB, 1988, AM J EPIDEMIOL, V128, P1276, DOI 10.1093/oxfordjournals.aje.a115081; SVENDSEN KH, 1987, AM J EPIDEMIOL, V126, P783, DOI 10.1093/oxfordjournals.aje.a114715; VAINIO H, 1989, MUTAT RES, V222, P137, DOI 10.1016/0165-1218(89)90027-X; WALD N, 1984, LANCET, V1, P1067; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WELLS AJ, 1988, ENVIRON INT, V14, P249; 1983, HLTH CONSEQUENCES SM; 1990, EPA600690006A PUBL; 1986, HLTH CONSEQUENCES IN	44	167	169	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					94	99		10.1001/jama.267.1.94	http://dx.doi.org/10.1001/jama.267.1.94			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1727204				2022-12-28	WOS:A1992GW84800031
J	STEFANOVA, I; HOREJSI, V; ANSOTEGUI, IJ; KNAPP, W; STOCKINGER, H				STEFANOVA, I; HOREJSI, V; ANSOTEGUI, IJ; KNAPP, W; STOCKINGER, H			GPI-ANCHORED CELL-SURFACE MOLECULES COMPLEXED TO PROTEIN TYROSINE KINASES	SCIENCE			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL; CYTOPLASMIC DOMAINS; MEMBRANE; CD4; PHOSPHORYLATION; P56LCK	Binding of ligand or antibody to certain cell-surface proteins that are anchored to the membrane by glycophosphatidylinositol (GPI) can cause activation of leukocytes. However, it is not known how these molecules, which lack intracellular domains, can transduce signals. The GPI-linked human molecules CD59, CD55, CD48, CD24, and CD14 as well as the mouse molecules Thy-1 and Ly-6 were found to associate with protein tyrosine kinases, key regulators of cell activation and signal transduction. A protein tyrosine kinase associated with the GPI-linked proteins CD59, CD55, and CD48 in human T cells, and with Thy-1 in mouse T cells was identified as p56lck, a protein tyrosine kinase related to Src. This interaction of GPI-linked molecules with protein tyrosine kinases suggests a potential mechanism of signal transduction in cells.	CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-14220 PRAGUE 4, CZECHOSLOVAKIA; KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Karolinska Institutet	STEFANOVA, I (corresponding author), UNIV VIENNA, VIENNA INT RES COOPERAT CTR SFI, INST IMMUNOL, BRUNNER STR 59, A-1235 VIENNA, AUSTRIA.		Horejsi, Vaclav/G-3113-2014; Stockinger, Hannes/E-5173-2011	Horejsi, Vaclav/0000-0003-4925-0142; Stockinger, Hannes/0000-0001-6404-4430				ANSOTEGUI IJ, 1991, SCAND J IMMUNOL, V33, P375, DOI 10.1111/j.1365-3083.1991.tb01784.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FISCHER GF, 1990, J IMMUNOL, V144, P638; HOREJSI V, 1991, ADV IMMUNOL, V49, P75; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; STEFANOVA I, UNPUB; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2	17	871	887	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1016	1019		10.1126/science.1719635	http://dx.doi.org/10.1126/science.1719635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1719635				2022-12-28	WOS:A1991GP88300048
J	SOMMER, B; KOHLER, M; SPRENGEL, R; SEEBURG, PH				SOMMER, B; KOHLER, M; SPRENGEL, R; SEEBURG, PH			RNA EDITING IN BRAIN CONTROLS A DETERMINANT OF ION FLOW IN GLUTAMATE-GATED CHANNELS	CELL			English	Article							B MESSENGER-RNA; ACID RECEPTOR CHANNELS; FUNCTIONAL EXPRESSION; NERVOUS-SYSTEM; DNA; CLONING; RAT; MITOCHONDRIA; SUBUNIT; NEURONS	L-glutamate, the principal excitatory transmitter in the brain, gates ion channels mediating fast neurotrans-mission. Subunit components of two related classes of glutamate receptor channels have been characterized by cDNA cloning and shown to carry either an arginine or a glutamine residue in a defined position of their putative channel-forming segment. The arginine residue in this segment profoundly alters, and dominates, the properties of ion flow, as demonstrated for one channel class. We now show that the genomic DNA sequences encoding the particular channel segment of all subunits harbor a glutamine codon (CAG), even though an arginine codon (CGG) is found in mRNAs of three subunits. Multiple genes and alternative exons were excluded as sources for the arginine codon; hence, we propose that transcripts for three subunits are altered by RNA editing. This process apparently edits subunit transcripts of the two glutamate receptor classes with different efficiency and selectivity.			SOMMER, B (corresponding author), UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, NEUENHEIMER FELD 282, W-6900 HEIDELBERG, GERMANY.							BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1991, IN PRESS J PHYSL; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAVARATNAM N, 1991, NUCLEIC ACIDS RES, V19, P1741, DOI 10.1093/nar/19.8.1741; Olney J W, 1986, Adv Exp Med Biol, V203, P631; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; TENG BB, 1990, J BIOL CHEM, V265, P20616; VEWRYVERDOORN TA, 1991, SCIENCE, V252, P1715; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WU JH, 1990, J BIOL CHEM, V265, P12312; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	1189	1225	0	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					11	19		10.1016/0092-8674(91)90568-J	http://dx.doi.org/10.1016/0092-8674(91)90568-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717158				2022-12-28	WOS:A1991GJ32000003
J	CHADWICK, DJ; KEMPLE, T; ASTLEY, JP; MACIVER, AG; GILLATT, DA; ABRAMS, P; GINGELL, JC				CHADWICK, DJ; KEMPLE, T; ASTLEY, JP; MACIVER, AG; GILLATT, DA; ABRAMS, P; GINGELL, JC			PILOT-STUDY OF SCREENING FOR PROSTATE-CANCER IN GENERAL-PRACTICE	LANCET			English	Article							DIGITAL RECTAL EXAMINATION; PSYCHOLOGICAL COSTS; NATURAL-HISTORY; CARCINOMA; HYPERTENSION; POPULATION	The success of a screening programme for cancer depends on the sensitivity of the tests used and on the proportion of the target population that comes forward for screening. To assess the value of digital rectal screening and prostate-specific antigen (PSA) measurement as screening measures, the 814 men in a city general practice aged between 55 and 70 were recruited in one of five different ways. Men with a palpably suspicious prostate or a serum PSA greater than 4 ng/ml were referred for transrectal ultrasonography and, if indicated, biopsy. 472 men (58%) were screened; of these 68 underwent transrectal ultrasonography and 29 biopsy. In 7 the biopsy specimen showed carcinoma. Serum PSA was better than digital examination as a screening test-all men with prostate cancer had raised concentrations of serum PSA, whereas only 1 had a palpably abnormal prostate. All 7 had localised disease, and 5 underwent radical prostatectomy. The best methods of patient recruitment were to send an appointment for screening and to "tag" the patient's notes.	HORFIELD HLTH CTR, BRISTOL, ENGLAND; SOUTHMEAD GEN HOSP, DEPT UROL, BRISTOL BS10 5NB, AVON, ENGLAND; SOUTHMEAD GEN HOSP, DEPT CLIN CHEM, BRISTOL BS10 5NB, AVON, ENGLAND; SOUTHMEAD GEN HOSP, DEPT HISTOPATHOL, BRISTOL BS10 5NB, AVON, ENGLAND	Southmead Hospital; Southmead Hospital; Southmead Hospital				Kemple, Terence/0000-0002-9217-4598				BAUMAH PK, 1988, BR J UROL, V62, P581; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHADWICK D, 1990, BRIT MED J, V301, P119, DOI 10.1136/bmj.301.6743.119-b; CHODAK GW, 1984, JAMA-J AM MED ASSOC, V252, P3261, DOI 10.1001/jama.252.23.3261; COONER W H, 1989, Journal of Endourology, V3, P193, DOI 10.1089/end.1989.3.193; COONER WH, 1988, J UROLOGY, V139, P758, DOI 10.1016/S0022-5347(17)42624-3; GEORGE NJR, 1988, LANCET, V1, P494; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; IMAI K, 1988, PROSTATE, V12, P199, DOI 10.1002/pros.2990120303; JOHANSSON JE, 1989, LANCET, V1, P799; KEMPLE T, 1990, BRIT MED J, V301, P667, DOI 10.1136/bmj.301.6753.667-b; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; Love R R, 1985, Med Decis Making, V5, P263, DOI 10.1177/0272989X8500500303; LOWE BA, 1988, J UROLOGY, V140, P1340, DOI 10.1016/S0022-5347(17)42039-8; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MARTEAU TM, 1990, BRIT MED J, V301, P26, DOI 10.1136/bmj.301.6742.26; MOSSEY JM, 1981, CLIN INVEST MED, V4, P201; NATHOO V, 1988, BRIT MED J, V296, P1041, DOI 10.1136/bmj.296.6628.1041; PEDERSEN KV, 1990, BRIT MED J, V300, P1041, DOI 10.1136/bmj.300.6731.1041; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; THOMPSON IM, 1987, J UROLOGY, V137, P424, DOI 10.1016/S0022-5347(17)44055-9; VIHKO P, 1985, CANCER, V56, P173, DOI 10.1002/1097-0142(19850701)56:1<173::AID-CNCR2820560127>3.0.CO;2-0; WILLIAMS EMI, 1989, BMJ-BRIT MED J, V299, P158, DOI 10.1136/bmj.299.6692.158	26	45	46	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	1991	338	8767					613	616						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1715503				2022-12-28	WOS:A1991GD80900011
J	VERKERK, AJMH; PIERETTI, M; SUTCLIFFE, JS; FU, YH; KUHL, DPA; PIZZUTI, A; REINER, O; RICHARDS, S; VICTORIA, MF; ZHANG, FP; EUSSEN, BE; VANOMMEN, GJB; BLONDEN, LAJ; RIGGINS, GJ; CHASTAIN, JL; KUNST, CB; GALJAARD, H; CASKEY, CT; NELSON, DL; OOSTRA, BA; WARREN, ST				VERKERK, AJMH; PIERETTI, M; SUTCLIFFE, JS; FU, YH; KUHL, DPA; PIZZUTI, A; REINER, O; RICHARDS, S; VICTORIA, MF; ZHANG, FP; EUSSEN, BE; VANOMMEN, GJB; BLONDEN, LAJ; RIGGINS, GJ; CHASTAIN, JL; KUNST, CB; GALJAARD, H; CASKEY, CT; NELSON, DL; OOSTRA, BA; WARREN, ST			IDENTIFICATION OF A GENE (FMR-1) CONTAINING A CGG REPEAT COINCIDENT WITH A BREAKPOINT CLUSTER REGION EXHIBITING LENGTH VARIATION IN FRAGILE-X SYNDROME	CELL			English	Article							SOMATIC-CELL HYBRIDS; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; SITE; DNA; CHROMOSOME; SEQUENCES; FRAGMENTS; CONSTRUCTION; METHYLATION	Fragile X syndrome is the most frequent form of inherited mental retardation and is associated with a fragile site at Xq27.3. We identified human YAC clones that span fragile X site-induced translocation breakpoints coincident with the fragile X site. A gene (FMR-1) was identified within a four cosmid contig of YAC DNA that expresses a 4.8 kb message in human brain. Within a 7.4 kb EcoRl genomic fragment, containing FMR-1 exonic sequences distal to a CpG island previously shown to be hypermethylated in fragile X patients, is a fragile X site-induced breakpoint cluster region that exhibits length variation in fragile X chromosomes. This fragment contains a lengthy CGG repeat that is 250 bp distal of the CpG island and maps within a FMR-1 exon. Localization of the brain-expressed FMR-1 gene to this EcoRl fragment suggests the involvement of this gene in the phenotypic expression of the fragile X syndrome.	BAYLOR UNIV,HOWARD HUGHES MED INST,CTR HUMAN GENOME,INST MOLEC GENET,HOUSTON,TX 77030; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322; SYLVIUS LAB,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS	Baylor College of Medicine; Baylor University; Howard Hughes Medical Institute; Emory University; Emory University; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	VERKERK, AJMH (corresponding author), ERASMUS UNIV,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS.		Warren, Stephen T/A-2498-2012; Sutcliffe, James S/C-1348-2012; Reiner, Orly/E-9455-2010	Sutcliffe, James S/0000-0001-5200-6007; Reiner, Orly/0000-0001-7560-9599; PIZZUTI, Antonio/0000-0003-3245-1925; Verkerk, Annemieke JMH/0000-0002-7523-3656	NHGRI NIH HHS [HG00038] Funding Source: Medline; NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; KRAWCZUN MS, 1985, HUM GENET, V69, P209, DOI 10.1007/BF00293026; LEDBETTER DH, 1986, NATURE, V324, P161, DOI 10.1038/324161a0; LEE CH, 1987, NUCLEIC ACIDS RES, V15, P7639, DOI 10.1093/nar/15.18.7639; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARTINPONTHIEU A, 1991, EUR J BIOCHEM, V195, P611, DOI 10.1111/j.1432-1033.1991.tb15744.x; NELSON DL, 1991, IN PRESS P NATL ACAD; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; NUSSBAUM RL, 1990, METABOLIC BASIS INHE, P327; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; Smith C.L., 1988, P41; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTHERLAND GR, 1985, FRAGILE SITES HUMAN, P53; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VANOMMEN GJB, 1986, HUMAN GENETIC DISEAS, P113; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1988, AM J MED GENET, V30, P613, DOI 10.1002/ajmg.1320300162; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759; YU S, 1991, IN PRESS FRAGILE X G	40	2812	2895	4	152	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					905	914		10.1016/0092-8674(91)90397-H	http://dx.doi.org/10.1016/0092-8674(91)90397-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710175				2022-12-28	WOS:A1991FP51600020
J	CALNAN, BJ; TIDOR, B; BIANCALANA, S; HUDSON, D; FRANKEL, AD				CALNAN, BJ; TIDOR, B; BIANCALANA, S; HUDSON, D; FRANKEL, AD			ARGININE-MEDIATED RNA RECOGNITION - THE ARGININE FORK	SCIENCE			English	Article								Short peptides that contain the basic region of the HIV-1 Tat protein bind specifically to a bulged region in TAR RNA. A peptide that contained nine arginines (R9) also bound specifically to TAR, and a mutant Tat protein that contained R9 was fully active for transactivation. In contrast, a peptide that contained nine lysines (K9) bound TAR poorly and the corresponding protein gave only marginal activity. By starting with the K9 mutant and replacing lysine residues with arginines, a single arginine was identified that is required for specific binding and transactivation. Ethylation interference experiments suggest that this arginine contacts two adjacent phosphates at the RNA bulge. Model building suggests that the arginine eta-nitrogens and the epsilon-nitrogen can form specific networks of hydrogen bonds with adjacent pairs of phosphates and that these arrangements are likely to occur near RNA loops and bulges and not within double-stranded A-form RNA. Thus, arginine side chains may be commonly used to recognize specific RNA structures.	WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA; MILLIGEN BIOSEARCH, NOVATO, CA 94949 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute				/0000-0002-3320-3969	NIAID NIH HHS [AI29135] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CALNAN BJ, UNPUB; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P17; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; VLASSOV VV, 1981, EUR J BIOCHEM, V119, P51, DOI 10.1111/j.1432-1033.1981.tb05575.x; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	32	588	594	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1167	1171		10.1126/science.252.5009.1167	http://dx.doi.org/10.1126/science.252.5009.1167			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	1709522				2022-12-28	WOS:A1991FN05600049
J	DIFRANCESCO, D; TORTORA, P				DIFRANCESCO, D; TORTORA, P			DIRECT ACTIVATION OF CARDIAC-PACEMAKER CHANNELS BY INTRACELLULAR CYCLIC-AMP	NATURE			English	Article							SINO-ATRIAL NODE; DEPENDENT PROTEIN-KINASE; CURRENT IF; PHOSPHORYLATION; MYOCYTES; MODULATION; NEURONS; HEART; ACETYLCHOLINE; CONDUCTANCE	CYCLIC AMP acts as a second messenger in the modulation of several ion channels 1-9 that are typically controlled by a phosphorylation process 10. In cardiac pacemaker cells, adrenaline and acetylcholine regulate the hyperpolarization-activated current (i(f)), but in opposite ways; this current is involved in the generation and modulation of pacemaker activity 11. These actions are mediated by cAMP and underlie control of spontaneous rate by neurotransmitters 12-17. Whether the cAMP modulation of i(f) is mediated by channel phosphorylation is, however, still unknown. Here we investigate the action of cAMP on i(f) in excised patches of cardiac pacemaker cells and find that cAMP activates i(f) by a mechanism independent of phosphorylation, involving a direct interaction with the channels at their cytoplasmic side. Cyclic AMP activates i(f) by shifting its activation curve to more positive voltages, in agreement with whole-cell results. This is the first evidence of an ion channel whose gating is dually regulated by voltage and direct cAMP binding.			DIFRANCESCO, D (corresponding author), UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,VIA CELORIA 26,I-20133 MILAN,ITALY.		DiFrancesco, Dario/G-8408-2017	DiFrancesco, Dario/0000-0002-7322-1790; Tortora, Paolo/0000-0001-5234-601X				BOBKER DH, 1989, NEURON, V2, P1535, DOI 10.1016/0896-6273(89)90041-X; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; CHANG F, 1990, BIOPHYS J, V57, pA141; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P477, DOI 10.1113/jphysiol.1988.sp017343; DIFRANCESCO D, 1989, SCIENCE, V243, P669, DOI 10.1126/science.2916119; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1985, PROG BIOPHYS MOL BIO, V46, P163, DOI 10.1016/0079-6107(85)90008-2; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; JAYNES LW, 1986, NATURE, V317, P61; JOHNSON EC, 1986, NATURE, V324, P468, DOI 10.1038/324468a0; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OSTERRIEDER W, 1982, NATURE, V298, P576, DOI 10.1038/298576a0; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; TERESAKI WL, 1977, J BIOL CHEM, V252, P1041; Tsien R W, 1977, Adv Cyclic Nucleotide Res, V8, P363; TSIEN RW, 1974, J GEN PHYSIOL, V64, P293, DOI 10.1085/jgp.64.3.293; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	30	656	669	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					145	147		10.1038/351145a0	http://dx.doi.org/10.1038/351145a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709448				2022-12-28	WOS:A1991FL03500050
J	GUNTHERT, U; HOFMANN, M; RUDY, W; REBER, S; ZOLLER, M; HAUSSMANN, I; MATZKU, S; WENZEL, A; PONTA, H; HERRLICH, P				GUNTHERT, U; HOFMANN, M; RUDY, W; REBER, S; ZOLLER, M; HAUSSMANN, I; MATZKU, S; WENZEL, A; PONTA, H; HERRLICH, P			A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS	CELL			English	Article							INHIBITS EXPERIMENTAL METASTASIS; LYMPHOCYTE HOMING RECEPTOR; HUMAN-TUMOR CELLS; MONOCLONAL-ANTIBODIES; HIGH ENDOTHELIUM; MELANOMA-CELLS; SURFACE GLYCOPROTEINS; PLASMINOGEN-ACTIVATOR; EXPRESSION; GENE	Using a monoclonal antibody (MAb1.1ASML) raised against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, cDNA clones have been isolated that encode glycoproteins with partial homology to CD44, a presumed adhesion molecule. In one of the clones, pMeta-1, the epitope marks an additional extracellular domain of 162 amino acids inserted into the rat CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). The new variants are expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; they are not expressed in the nonmetastasizing tumor cell lines nor in most normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cells suffices to establish full metastatic behavior.	GERMAN CANC RES CTR,INST RADIOL & PATHOPHYSIOL,W-6900 HEIDELBERG 1,GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,W-7500 KARLSRUHE 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology	GUNTHERT, U (corresponding author), UNIV KARLSRUHE,INST GENET,W-7500 KARLSRUHE 1,GERMANY.		Hofmann-Apitius, Martin/E-6123-2018	Hofmann-Apitius, Martin/0000-0001-9012-6720				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; CARR I, 1981, Invasion and Metastasis, V1, P34; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLARD JG, 1987, CANCER RES, V47, P754; DEAR TN, 1989, CANCER RES, V49, P5323; DENNING SM, 1990, J IMMUNOL, V144, P7; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FRISCH SM, 1990, ONCOGENE, V5, P75; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GARBISA S, 1987, CANCER RES, V47, P1523; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUET S, 1989, J IMMUNOL, V143, P798; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KANSAS GS, 1989, J IMMUNOL, V142, P3050; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MATZKU S, 1984, CANCER IMMUNOL IMMUN, V17, P106, DOI 10.1007/BF00200045; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLSON GL, 1987, CANCER RES, V47, P1473; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAZ A, 1989, CANCER RES, V49, P3489; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; REICH R, 1988, CANCER RES, V48, P3307; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P6863, DOI 10.1073/pnas.80.22.6863; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WONG YC, 1990, BIOCHEM BIOPH RES CO, V166, P984, DOI 10.1016/0006-291X(90)90908-6; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	65	1626	1716	1	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					13	24		10.1016/0092-8674(91)90403-L	http://dx.doi.org/10.1016/0092-8674(91)90403-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707342	Bronze			2022-12-28	WOS:A1991FF77300004
J	BALLOU, LM; LUTHER, H; THOMAS, G				BALLOU, LM; LUTHER, H; THOMAS, G			MAP2 KINASE AND 70K-S6 KINASE LIE ON DISTINCT SIGNALING PATHWAYS	NATURE			English	Article							RIBOSOMAL-PROTEIN S6; SERINE-THREONINE KINASE; SWISS MOUSE 3T3-CELLS; 3T3 CELLS; INSULIN; ACTIVATION; SERUM; PHOSPHORYLATION; PURIFICATION; IDENTIFICATION	ACTIVATION of protein synthesis is required for quiescent cells to transit the cell cycle1, and seems to be mediated in part by phosphorylation of the 40S ribosomal protein, S6 (ref. 2). A mitogen-activated S6 kinase of relative molecular mass 70,000 (70K) has been isolated from mouse fibroblasts3,4 as well as from avian, rat and rabbit tissues5-9. Comparison of complementary DNA sequences shows that this enzyme10 is distinct from S6 kinase II (92K)11 found in Xenopus eggs12 and fibroblasts13,14. Both kinases are activated by serine/threonine phosphorylation3,15-18, suggesting that at least one serine/threonine kinase links receptor tyrosine kinases with S6 kinases. A candidate for this link is MAP2 kinase, which is rapidly activated by tyrosine/threonine phosphorylation following mitogenic stimulation19-23. Incubation of MAP2 kinase from insulin-treated 3T3-L1 adipocytes with phosphatase-inactivated S6 kinase II from Xenopus leads to partial reactivation and phosphorylation of the enzyme17. These and other findings8 have led to the suggestion that MAP2 kinase also activates the 70K S6 kinase. Here we refute this idea by showing that the two kinases lie on distinct signalling pathways.	FRIEDRICH MIESCHER INST,POSTFACH 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BLENIS J, 1984, P NATL ACAD SCI-BIOL, V81, P6408, DOI 10.1073/pnas.81.20.6408; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOSHI M, 1988, J BIOL CHEM, V263, P5396; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANE HA, IN PRESS METH ENZYM; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, ARCH BIOCHEM BIOPHYS, V262, P307, DOI 10.1016/0003-9861(88)90193-2; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	28	204	204	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					348	350		10.1038/349348a0	http://dx.doi.org/10.1038/349348a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702881				2022-12-28	WOS:A1991EU50100059
J	KASAI, H; AUGUSTINE, GJ				KASAI, H; AUGUSTINE, GJ			CYTOSOLIC CA-2+ GRADIENTS TRIGGERING UNIDIRECTIONAL FLUID SECRETION FROM EXOCRINE PANCREAS	NATURE			English	Article									MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	Max Planck Society			Augustine, George James/J-9228-2013	Kasai, Haruo/0000-0003-2327-9027				AMSTERDAM A, 1972, P NATL ACAD SCI USA, V69, P3028, DOI 10.1073/pnas.69.10.3028; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRUZZONE R, 1986, BIOCHEM J, V235, P139, DOI 10.1042/bj2350139; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; HABARA Y, 1980, JPN J PHYSIOL, V30, P561; KANNO T, 1989, BIOMED RES-TOKYO, V10, P475; LAUGIER R, 1980, PFLUG ARCH EUR J PHY, V386, P147, DOI 10.1007/BF00584202; MARTY A, 1984, J PHYSIOL-LONDON, V357, P293, DOI 10.1113/jphysiol.1984.sp015501; MARTY A, 1987, TRENDS NEUROSCI, V10, P373, DOI 10.1016/0166-2236(87)90074-9; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MARUYAMA Y, 1982, NATURE, V299, P159, DOI 10.1038/299159a0; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MERRITT JE, 1985, BIOCHEM J, V230, P151, DOI 10.1042/bj2300151; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; OSCIPCHUK YV, 1990, EMBO J, V9, P697; PETERSEN OH, 1970, EXPERIENTIA, V26, P1103, DOI 10.1007/BF02112700; PETERSEN OH, 1977, J PHYSIOL-LONDON, V264, P819, DOI 10.1113/jphysiol.1977.sp011696; PETERSEN OH, 1988, ANNU REV PHYSIOL, V50, P65; PETERSEN OH, 1980, ELECTROPHYSIOLOGY GL; RANDRIAMAMPITA C, 1988, PFLUG ARCH EUR J PHY, V411, P53, DOI 10.1007/BF00581646; RAPP PE, 1981, J EXP BIOL, V93, P119; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0	26	364	365	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 20	1990	348	6303					735	738		10.1038/348735a0	http://dx.doi.org/10.1038/348735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP049	1701852				2022-12-28	WOS:A1990EP04900061
J	HORAK, ID; POPOVIC, M; HORAK, EM; LUCAS, PJ; GRESS, RE; JUNE, CH; BOLEN, JB				HORAK, ID; POPOVIC, M; HORAK, EM; LUCAS, PJ; GRESS, RE; JUNE, CH; BOLEN, JB			NO T-CELL TYROSINE PROTEIN-KINASE SIGNALING OR CALCIUM MOBILIZATION AFTER CD4 ASSOCIATION WITH HIV-1 OR HIV-1 GP120	NATURE			English	Article									NCI,TUMOR VIRUS BIOL LAB,BLDG 41 ROOM D824,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; USN,MED RES INST,BETHESDA,MD 20814; NEW MEXICO STATE UNIV,DEPT VIROL,PRIMATE RES INST,HOLLOMAN AFB,NM 88330	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; New Mexico State University								BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; FOLKS T, 1986, J IMMUNOL, V136, P4049; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; NEUDORF SML, 1990, CELL IMMUNOL, V125, P301, DOI 10.1016/0008-8749(90)90086-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; ULLRICH A, 1990, CELL, V61, P212; VEILETTE A, 1989, J EXP MED, V170, P16710; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	19	92	93	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 6	1990	348	6301					557	560		10.1038/348557a0	http://dx.doi.org/10.1038/348557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL760	1701034				2022-12-28	WOS:A1990EL76000070
J	WANG, JH; YAN, YW; GARRETT, TPJ; LIU, JH; RODGERS, DW; GARLICK, RL; TARR, GE; HUSAIN, Y; REINHERZ, EL; HARRISON, SC				WANG, JH; YAN, YW; GARRETT, TPJ; LIU, JH; RODGERS, DW; GARLICK, RL; TARR, GE; HUSAIN, Y; REINHERZ, EL; HARRISON, SC			ATOMIC-STRUCTURE OF A FRAGMENT OF HUMAN CD4 CONTAINING 2 IMMUNOGLOBULIN-LIKE DOMAINS	NATURE			English	Article									UPJOHN CO, KALAMAZOO, MI 49007 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOL LAB, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Pfizer; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	WANG, JH (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.							ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BRUNGER A, XPLOR MANUAL VERSION; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIS SJ, 1990, J MOL BIOL, V213, P7, DOI 10.1016/S0022-2836(05)80116-0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GARLICK RL, 1990, AIDS RES HUM RETROV, V6, P465, DOI 10.1089/aid.1990.6.465; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HARRISON SC, UNPUB; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HUBER R, 1985, MOL REPLACEMENT, P58; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KRENSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P2365, DOI 10.1073/pnas.79.7.2365; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; Richardson JS., 1989, PREDICT PROTEIN STRU; RICHARDSON NE, 1988, P NATL ACAD SCI USA, V85, P6102, DOI 10.1073/pnas.85.16.6102; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SAYRE PH, 1985, EUR J IMMUNOL, V15, P291, DOI 10.1002/eji.1830150315; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; STUART D, 1984, ACTA CRYSTALLOGR A, V40, P713, DOI 10.1107/S0108767384001471; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637	68	563	577	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	1990	348	6300					411	418		10.1038/348411a0	http://dx.doi.org/10.1038/348411a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK697	1701030				2022-12-28	WOS:A1990EK69700052
J	SOMMER, B; KEINANEN, K; VERDOORN, TA; WISDEN, W; BURNASHEV, N; HERB, A; KOHLER, M; TAKAGI, T; SAKMANN, B; SEEBURG, PH				SOMMER, B; KEINANEN, K; VERDOORN, TA; WISDEN, W; BURNASHEV, N; HERB, A; KOHLER, M; TAKAGI, T; SAKMANN, B; SEEBURG, PH			FLIP AND FLOP - A CELL-SPECIFIC FUNCTIONAL SWITCH IN GLUTAMATE-OPERATED CHANNELS OF THE CNS	SCIENCE			English	Article									UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC ENDOCRINOL LAB, W-6900 HEIDELBERG, GERMANY; MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, W-6900 HEIDELBERG 1, GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society			Burnashev, Nail/G-4056-2013; Wisden, William/A-4071-2011; Keinanen, Kari/E-9122-2010	Wisden, William/0000-0003-4743-0334; 				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; Bayer S.A, 1985, RAT NERVOUS SYSTEM, V1, P335; BEESON D, 1990, EMBO J, V9, P2101, DOI 10.1002/j.1460-2075.1990.tb07378.x; BLAKE JF, 1989, BRIT J PHARMACOL, V97, P71, DOI 10.1111/j.1476-5381.1989.tb11925.x; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KISKIN NI, 1990, EUR J NEUROSCI, V2, P464; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1969, SCIENCE, V166, P386, DOI 10.1126/science.166.3903.386; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRIESTLEY T, 1989, BRIT J PHARMACOL, V97, P1315, DOI 10.1111/j.1476-5381.1989.tb12594.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WISDEN W, IN PRESS MOL NEUROBI, V2	43	1061	1087	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 28	1990	249	4976					1580	1585		10.1126/science.1699275	http://dx.doi.org/10.1126/science.1699275			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA463	1699275				2022-12-28	WOS:A1990EA46300042
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LICENSING OF G-CSF AND GM-CSF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-28	WOS:A1991FJ95500009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NUTRITION LABELING AND EDUCATION ACT OF 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V263, P2995	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-28	WOS:A1991FJ95500007
